<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As filed with the U.S. Securities and Exchange Commission on August 10, 2022.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>FORM S-1<BR>
</B></FONT><B><FONT STYLE="font-size: 10pt">REGISTRATION STATEMENT UNDER<BR>
THE SECURITIES ACT OF 1933</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Felicitex Therapeutics Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>80-0815393</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
    incorporation or organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Primary Standard Industrial<BR>
    Classification Code Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer<BR>
    Identification Number)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>27 Strathmore Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Natick, MA 01760</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(919) 213-0025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone number,
including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maria Vilenchik</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>27 Strathmore Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Natick, MA 01760</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(919) 213-0025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Names, address, including zip code, and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><I>Copies
    to:</I></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Louis
                                            A. Bevilacqua, Esq.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Bevilacqua PLLC</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">1050 Connecticut
    Avenue, NW, Suite 500</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Washington, DC 20036</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(202) 869-0888</P></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Matthew
                                            W. Mamak, Esq.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Alston &amp; Bird LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">90 Park Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, NY 10016</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(212) 210-1256</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approximate date of commencement of proposed
sale to the public:</B> As soon as practicable after this Registration Statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
box. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Accelerated filer &#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Smaller reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"></TD>
    <TD STYLE="text-align: justify">Emerging growth company &#9746;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of Securities Act.&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to such Section&nbsp;8(a),
may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information in
this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers
to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: Red"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase; color: Red"><B>Subject
    to completion, dated AUGUST 10, 2022</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Felicitex Therapeutics Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$15,500,000<BR>
[2,480,000] Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Each Unit Consisting of One Share of Common
Stock and One Warrant to Purchase One Share of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is our initial public offering. We are offering
<FONT STYLE="background-color: white">$15,500,000 of units, each unit consisting of one share of common stock, par value $0.0001 </FONT>&nbsp;&nbsp;<FONT STYLE="background-color: white">per
share, and a warrant to purchase one share of common stock</FONT>. We currently estimate that the initial public offering price will
be between $<FONT STYLE="background-color: white">5.25</FONT> and $<FONT STYLE="background-color: white">7.25 </FONT>per unit. Each share
of common stock is being sold together with one warrant to purchase one share of common stock. Each whole share exercisable pursuant
to the warrants will have an exercise price per share equal to the initial public offering price. The warrants will be immediately exercisable
and will expire on the fifth anniversary of the original issuance date. The units will not be certificated. The shares of common stock
and related warrants are immediately separable and will be issued separately but must be purchased together as a unit in this offering.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, there is no public market for our
common stock. We intend to apply to list our common stock on the Nasdaq Capital Market, under the symbol &ldquo;FLCT&rdquo; and our warrants
under the symbol &ldquo;FLCTW.&rdquo; We believe that upon the completion of this offering, we will meet the standards for listing on
Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our key officers and directors will own approximately
[&nbsp;&nbsp;]% of our outstanding common stock following this offering, or approximately [&nbsp;&nbsp;]% if the underwriters exercise
the over-allotment&nbsp;option in full. As a result, they may have the ability to approve all matters submitted to our shareholders for
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are an &ldquo;emerging growth company&rdquo;
under applicable federal securities laws and as such, we have elected to comply with certain reduced public company reporting requirements
for this prospectus and future filings. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our shares of common stock and
the warrants (collectively, &ldquo;securities&rdquo;) involves a high degree of risk. See the section of this prospectus entitled &ldquo;Risk
Factors&rdquo; beginning on page 10 for a discussion of information that should be considered in connection with an investment in our
securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the SEC nor any state securities commission
has approved or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Unit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%"><FONT STYLE="font-size: 10pt">Initial public offering price</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to Felicitex Therapeutics Inc. <SUP>(2)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Does not include
                                            the following additional compensation payable to the underwriters: we have agreed to pay
                                            the representative of the underwriters Aegis Capital Corp. (&ldquo;Aegis&rdquo; or the &ldquo;representative&rdquo;)
                                            a non-accountable expense allowance equal to one percent (1%) of the total proceeds raised
                                            and to reimburse the underwriters for certain expenses incurred relating to this offering.
                                            In addition, we will issue to Aegis warrants to purchase in the aggregate the number of shares
                                            of our common stock equal to eight percent (8%) of the number of shares sold in this offering
                                            (excluding shares that may be issued under the over-allotment option). The registration statement
                                            of which this prospectus forms a part also registers the issuance of the shares of common
                                            stock issuable upon exercise of the representative&rsquo;s warrants. See also &ldquo;Underwriting&rdquo;
                                            for a description of compensation and other items of value payable to the underwriters.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The amount of
                                            offering proceeds to us presented in this table does not give effect to any exercise of the:
                                            (i)&nbsp;underwriters&rsquo; over-allotment&nbsp;option (if any) we have granted to the underwriters
                                            as described below; (ii)&nbsp;warrants to be issued to the representative of the underwriters,
                                            or the representative&rsquo;s warrants; (iii) warrants that are included in the units; or
                                            (iv) warrants, or the Additional Warrants, issuable to certain Qualified Buyers (as defined
                                            below) in connection with certain dilutive issuances (as defined in the warrants) or adjustment
                                            to the exercise price of the warrants on the date that is 90 calendar days immediately following
                                            the initial issuance date of the warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted a 45-day-option to the underwriters
to purchase up to an additional <FONT STYLE="background-color: white">[372,000]</FONT> shares of our common stock and/or up to [372,000]
over-allotment warrants (equal to 15% of the shares of common stock and warrants underlying the units sold in the offering) in any combination
thereof, solely to cover over-allotments, if any, at the public offering price less the underwriting discounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, in the event of certain future
dilutive issuances of securities by us that result in a reduction of the exercise price of the warrant, as provided therein, in aggregate,
to 50%, or the floor price, of $6.25 per share, or the Initial Exercise Price, then in connection with such adjustment, each holder of
warrants that purchases at least $500,000 of units in this offering, or a Qualified Buyer, shall receive two Additional Warrants for
each one warrant held by such holder on the date of adjustment. The maximum number of warrants subject to such adjustment by a given
Qualified Buyer will be limited to the number of warrants purchased by such Qualified Buyer in this offering. See &ldquo;Description
of Securities - Warrants Included in the Units&rdquo; for more information. Alternatively, in the event that the exercise price
of the warrants on the date that is 90 calendar days immediately following the initial issuance date of the warrants is adjusted to the
reset floor price, Qualified Buyers will receive Additional Warrants (as described further below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the date that is 90 calendar days immediately
following the initial issuance date of the warrants, the exercise price of all warrants purchased in this offering will adjust to be
equal to the greater of (a) 50% of the Initial Exercise Price of the Warrants on the issuance date, that is, the reset floor price or
(b) 100% of the lowest volume weighted average price per share occurring during the 90 calendar days following the issuance date of the
warrants, or the Reset Price, provided that such value is less than the exercise price in effect on that date. The lowest Reset Price
is $3.125, which is the same as the reset floor price, or $3.125, based on an assumed public offering price of $6.25 per unit, the midpoint
of the price range of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also choose to lower the exercise
price of the warrants at its option at any time during the life of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters are offering the units for sale
on a firm commitment basis. The underwriters expect to deliver the units to the purchasers on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 90%"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Cautionary Statement Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="text-align: center">54</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="text-align: center">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results
    of Operations</FONT></A></TD>
    <TD STYLE="text-align: center">57</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="text-align: center">68</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_021"><FONT STYLE="font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="text-align: center">96</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Executive Compensation</FONT></A></TD>
    <TD STYLE="text-align: center">101</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Certain Relationships and Related Party Transactions</FONT></A></TD>
    <TD STYLE="text-align: center">108</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Principal Shareholders</FONT></A></TD>
    <TD STYLE="text-align: center">109</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Description of Securities</FONT></A></TD>
    <TD STYLE="text-align: center">111</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Shares Eligible for Future Sale</FONT></A></TD>
    <TD STYLE="text-align: center">115</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Underwriting</FONT></A></TD>
    <TD STYLE="text-align: center">116</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center">121</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center">121</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_019"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: center">121</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_020"><FONT STYLE="font-size: 10pt">Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center">F-1</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Please read this prospectus carefully. It
describes our business, financial condition, results of operations and prospects, among other things. We are responsible for the information
contained in this prospectus and in any free-writing prospectus we have authorized. Neither we nor the underwriter have authorized anyone
to provide you with different information, and neither we nor the underwriter take responsibility for any other information others may
give you. Neither we nor the underwriter are making an offer to sell these securities in any jurisdiction where the offer or sale is
not permitted. The information contained in this prospectus is accurate only as of the date on the front of this prospectus, regardless
of the time of delivery of this prospectus or any sale of our units. You should not assume that the information contained in this prospectus
is accurate as of any date other than its date. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For investors outside the United States: Neither
we nor the underwriters have done anything that would permit this offering, or the possession or distribution of this prospectus, in
any jurisdiction where action for those purposes is required, other than in the United States. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of common
stock and the distribution of this prospectus outside the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2022 (25 days after the commencement of this offering), all dealers that buy, sell or trade shares of our common stock, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&rsquo;
obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Industry and&nbsp;Market&nbsp;Data</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are responsible for the information contained
in this prospectus. This prospectus includes industry and market data that we obtained from periodic industry publications, third-party
studies and surveys, filings of public companies in our industry and internal company surveys. These sources generally state that the
information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of the information
are not guaranteed. The forecasts and projections are based on historical market data, and there is no assurance that any of the forecasts
or projected amounts will be achieved. Industry and market data could be wrong because of the method by which sources obtained their
data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability
of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. The market and industry data
used in this prospectus involve risks and uncertainties that are subject to change based on various factors, including the COVID-19 pandemic
and those discussed in the section titled &ldquo;<I>Risk Factors</I>.&rdquo; These and other factors could cause results to differ materially
from those expressed in, or implied by, the estimates made by independent parties and by us. Furthermore, we cannot assure you that a
third party using different methods to assemble, analyze or compute industry and market data would obtain the same results.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Trademarks and&nbsp;Tradenames</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We own certain U.S. federal and/or unregistered
trademarks. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for
convenience, the trademarks and trade names in this prospectus are referred to without the symbols &ldquo;&reg;&rdquo; and &ldquo;&trade;&rdquo;,
but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under
applicable law, their right thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>About this&nbsp;Prospectus</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this prospectus, unless the context suggests
otherwise, references to &ldquo;Felicitex Therapeutics,&rdquo; &ldquo;Felicitex,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
&ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Felicitex Therapeutics Inc., and its subsidiary UAB Felicitex Therapeutics, which is
a variable interest entity, or VIE, organized as a Lithuanian limited liability company, and the term &ldquo;common stock&rdquo; refers
to the common stock, par value $0.0001 per share, of Felicitex Therapeutics Inc., a Delaware corporation. The financial information included
herein is presented in United States dollars, or U.S. Dollars, the functional currency of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus describes the specific details
regarding this offering, the terms and conditions of the securities being offered hereby, and the risks of investing in our securities.
You should read this prospectus, any free writing prospectus and the additional information about us described in the section entitled
&ldquo;<I>Where You Can Find More Information</I>&rdquo; before making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we, nor any of our officers, directors,
agents or representatives or underwriters, make any representation to you about the legality of an investment in our securities. You
should not interpret the contents of this prospectus or any free writing prospectus to be legal, business, investment or tax advice.
You should consult with your own advisors for that type of advice and consult with them about the legal, tax, business, financial and
other issues that you should consider before investing in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_022"></A>GLOSSARY OF PHARMACEUTICAL
TERMS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a glossary of certain pharmaceutical terms that are
used in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; padding-bottom: 8pt"><FONT STYLE="font-size: 10pt"><B>acquired resistance mechanisms</B></FONT></TD>
    <TD STYLE="padding-bottom: 8pt; text-align: justify; width: 76%; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Acquired resistance
    mechanisms occur&nbsp;when a particular microorganism obtains the ability to resist the activity of an antimicrobial agent, to which
    it was previously susceptible.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>ALL</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 4.5pt"><FONT STYLE="font-size: 10pt"><I>Acute lymphocytic leukemia</I>&nbsp;is
    a type of cancer of the blood and bone marrow.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>ADMET properties</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The absorption, distribution,
    metabolism, excretion, and toxicity&nbsp;(ADMET) properties of chemicals.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Affordable Care Act</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Patient Protection and
    Affordable Care Act, as amended.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>AKS</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The federal Anti-Kickback
    Statute, a criminal law that prohibits the knowing and willful payment of &ldquo;remuneration,&rdquo; directly or indirectly, in
    cash or in kind, to induce or reward patient referrals or the generation of business involving any item or service payable by the
    Federal health care programs (e.g., drugs, supplies, or health care services for Medicare or Medicaid patients).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>animal xenograft model</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">One of the most widely used
    models; these are mouse models involving&nbsp;the direct transfer of fresh human tumor samples into immunodeficient mice following
    surgical resection or other medical operations. <I>Mouse xenograft animal models</I>&nbsp;are used to assess the efficacy of medicines
    before they are tested in clinical trials.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>anti-angiogenesis therapy</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Therapy drugs that are&nbsp;treatments
    that stop tumors from growing their own blood vessels.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>antibody drugs</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Antibody drugs, as well as
    other biologicals, are usually designed to minimize undesired responses, by the immune system of the patient, against the drug.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><B>bioavailable</B></TD>
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt; text-align: justify">The ability of a drug to be absorbed and used by the body.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>biologic</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Biologics, or biological
    medications, are developed from blood, proteins, viruses, and living organisms and are used to prevent, treat, and cure human disease.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>biopharmaceutical</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Any pharmaceutical drug product
    manufactured in, extracted from, or semi-synthesized from biological sources.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>blood-brain-barrier</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A semipermeable barrier formed
    by cells lining the blood capillaries that supply the brain and other parts of the central nervous system.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>breakthrough therapy</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Breakthrough Therapy designation
    is a process, granted by the FDA, designed to expedite the development and review of drugs that are intended to treat a serious condition
    and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically
    significant endpoint(s).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>cancer</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A disease in which abnormal
    cells divide uncontrollably and destroy body tissue.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>cancer cell quiescence</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Cellular quiescence (G0)
    is a sleep-like cellular state that allows cells to maintain the ability to re-enter and exit the proliferative cycle.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>carcinogenicity</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Ability or tendency to produce
    cancer.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>cellular dormancy&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Occurs when tumor cells reversibly
    exit the cell cycle but remain capable of re-initiating tumor growth.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>cGMP</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Current Good Manufacturing
    Processes, which are the standards mandated by the FDA to assure the proper design, monitoring and control of manufacturing processes
    and facilities in connection with the production of pharmaceuticals.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>chemotherapy</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The treatment of disease by the use of chemical
    substances, especially the treatment of cancer by cytotoxic and other drugs.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt; width: 24%"><FONT STYLE="font-size: 10pt"><B>clinical trials</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt; width: 76%"><FONT STYLE="font-size: 10pt">Clinical trials
    are a type of research that studies new tests and treatments and evaluates their effects on human health outcomes.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>CMC</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Chemistry, Manufacturing
    and Control, refers to the&nbsp;various procedures used to assess the physical and chemical characteristics of drug products, and
    to ensure their quality and consistency during manufacturing.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>colorectal</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Relating to or affecting
    the colon and the rectum.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>compound</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A chemical compound is a
    chemical substance composed of many identical molecules composed of atoms from more than one element held together by chemical bonds.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>CROs</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt">Contract Research Organizations, are organizations contracted
    by another company to take the lead in managing that company&rsquo;s clinical trials and complex medical testing responsibilities.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>deregulation of the cell cycle</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The deregulation of the cell
    cycle is one of the hallmarks of cancer, where cell cycle proteins are mostly unregulated.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>dormant cancer cells</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Dormancy is a&nbsp;stage
    in cancer progression where the cells cease dividing but survive while&nbsp;waiting for appropriate environmental conditions to begin
    proliferation again.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>DYRK</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A dual specificity protein
    kinase. There are variations of DYRK: DYRK1A and DYRK1B.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>EC</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Ethics committees, or similar
    institutional mechanisms, assist in addressing ethical issues that arise in patient care and facilitate sound decision making that
    respects participants&rsquo; values, concerns, and interests.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Efficacy</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The ability to produce a
    desired or intended result.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>EGFR</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">An Epidermal Growth Factor
    Receptor, a receptor protein which spans the cell membrane so that one end of the protein remains inside the cell and the other end
    projects from the outer surface of the cell.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>EMA</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The European Medicines Agency
    is an agency of the European Union in charge of the evaluation and supervision of medicinal products.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>FDA</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The U.S. Food and Drug Administration.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><B>First line therapies</B></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    therapeutic approach that is often part of a standard set of treatments, such as surgery followed by chemotherapy and radiation.
    When used by itself, first-line therapy is the treatment accepted as the best therapy.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Generics</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Generic medicines work in
    the same way and provide the same clinical benefit and risks as their brand-name counterparts.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Glioblastoma</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A malignant tumor affecting
    the brain or spine.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>GBM</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Glioblastoma multiforme is
    the most aggressive of the gliomas, a collection of tumors arising from glia or their precursors within the central nervous system.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>GCP</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Good clinical practice (GCP)
    is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve
    human subjects which governments can transpose into regulations for clinical trials involving human subjects.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>GLP</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Good Laboratory Practices
    (GLP)&nbsp;refer to a set of principles intended to ensure quality and integrity of non-clinical studies and the conditions under
    which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Hematological</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The&nbsp;branch&nbsp;of&nbsp;medicine&nbsp;that&nbsp;deals&nbsp;with&nbsp;the&nbsp;diagnosis&nbsp;and&nbsp;treatment&nbsp;of&nbsp;diseases&nbsp;of&nbsp;the&nbsp;blood
    and&nbsp;bone&nbsp;marrow.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Hematopoietic</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Relating to or involved in
    the formation of blood cells.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Heterogeneous</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Consisting of dissimilar
    or diverse ingredients or constituents.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; width: 24%; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>HHS</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 76%; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The U.S. Department
    of Health and Human Services.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>HIPAA</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The Health Insurance Portability
    and Accountability Act of 1996, as amended.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>HITECH</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The Health Information Technology
    for Economic and Clinical Health Act of 2009.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Hormone therapy</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><I>Hormone therapy</I>&nbsp;is
    a treatment that slows or stops the growth of breast and prostate cancers that use hormones to grow.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Hypoxia/hypoxic </B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A deficiency in the amount
    of oxygen reaching the tissues.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>IMM</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Referring to irreversible
    morbidity or mortality.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Immune-mediated diseases</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Immune mediated diseases
    (IMIDs) are&nbsp;a group of autoimmune inflammatory disorders characterized by an alteration in cellular homeostasis.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Immune-oncology </B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><I>Immuno</I>-<I>oncology</I>&nbsp;is
    the study and development of treatments that take advantage of the body&rsquo;s&nbsp;<I>immune</I>&nbsp;system to fight&nbsp;<I>cancer</I>.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B><I>In vitro</I></B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A process performed or taking
    place in a test tube, culture dish, or elsewhere outside a living organism.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B><I>In vivo</I></B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A process performed or taking
    place in a living organism.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>IND</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">An Investigational New Drug
    Application (IND) is a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA)
    to administer an investigational drug or biological product to humans.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Inhibitor(s)</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A substance which slows down
    or prevents a particular chemical reaction or other process, or which reduces the activity of a particular reactant, catalyst, or
    enzyme.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>IRB</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt; background-color: white">The
    Institutional Review Board is an administrative body established to protect the rights and welfare of human research subjects recruited
    to participate in research activities conducted under the auspices of the institution with which it is affiliated. The IRB is tasked
    with reviewing clinical trial protocols</FONT> <FONT STYLE="font-size: 10pt">and informed consent information for patients in clinical
    trials for the FDA.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>IMM</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Referring to irreversible
    morbidity or mortality.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Kinases</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Any of the various enzymes
    that catalyze the transfer of phosphate groups from a high-energy phosphate-containing molecule (such as ATP) to a substrate.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>KRAS</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The Kirsten rat sarcoma virus.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Liquid tumors</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Cancers present in body fluids&nbsp;(the
    blood and bone marrow), that are detectable by blood laboratory tests.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>MAPK pathway</B></FONT></TD>
    <TD STYLE="padding-bottom: 6pt; text-align: justify; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The mitogen-activated protein
    kinase (MAPK) pathway plays a role in the regulation of gene expression, cellular growth, and survival.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Mechanistic diversity</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Relating to cellular signaling&nbsp;pathways
    that may be extremely different in normal healthy cells&nbsp;compared to cancerous&nbsp;cells.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Medicare</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Medicare</FONT><FONT STYLE="font-size: 10pt">&nbsp;is
    a federal health insurance program for people 65 or older, as well as some younger people with disabilities or end-stage renal disease
    (ESRD).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Medicaid</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Medicaid is a federal and
    state program that provides health coverage to millions of Americans, including eligible low-income adults, children, pregnant women,
    elderly adults, and people with disabilities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>MEK</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Mitogen-activated protein
    kinase, or MEK, is a kinase enzyme that adds a phosphate group to mitogen (cells that a small bioactive protein or peptide that induces
    a cell to begin cell division) activated protein kinases.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Metabolic state</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The metabolic state of a
    cell includes a balance between its energetic demands and its biosynthetic requirements to support cellular function.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Metabolism</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The chemical processes that
    occur within a living organism to maintain life.</FONT></TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; width: 24%; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Metastasis</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; width: 76%; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The development
    of secondary malignant growths at a distance from a primary site of cancer.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Microanatomical structure</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Microanatomy, also called
    histology, is&nbsp;the microscopic study of tissue structure.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Mitosis</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A type of cell division that
    results in two daughter cells each having the same number and kind of chromosomes as the parent nucleus, typical of ordinary tissue
    growth.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Mutant</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A mutant is&nbsp;an organism
    or a new genetic character arising or resulting from an alteration of the DNA sequence of the genome or chromosome of an organism.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>NDA</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A new drug application to
    permit the sale and marketing of a new drug in the United States.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Neurological</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Relating to the anatomy,
    functions, and organic disorders of nerves and the nervous system, including the brain, nerves found throughout the human body and
    the spinal cord.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Neuroscience</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Any or all of the sciences,
    such as neurochemistry and experimental psychology, which deal with the structure or function of the nervous system and brain.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>NHP</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A non-human primate means
    any nonhuman member of the highest order of mammals including prosimians, monkeys, and apes.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>NSCLC</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-small
                                            cell lung cancer is a group of lung cancers that behave similarly, such as squamous cell
                                            carcinoma and adenocarcinoma. Symptoms of this cancer include a cough, shortness of breath,
                                            weight loss, or coughing up blood.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>oncology</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Oncology is&nbsp;the study
    of cancer.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>orally</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">By means of or through the
    mouth.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>orphan drug</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A pharmaceutical intended
    for the treatment, prevention or diagnosis of a rare disease or condition, which is one that (1) affects less than 200,000 persons
    in the U.S; or (2) affects more than 200,000 persons in the United States for which there is no reasonable expectation that the cost
    of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the
    United States of such drug.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>osteosarcoma</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A type of bone cancer that
    begins in the cells that form bones.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>ovarian</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Relating to an ovary or the
    ovaries, a part of the female reproductive system.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>pancreatic</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Relating to the pancreas,
    the organ in the body that produces insulin.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>PDUFA</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The Prescription Drug User
    Fee Act.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>PPACA</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The Patient Protection and
    Affordable Health Care Act.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>pharmacological quiescence</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">This relates to drugs keeping
    cells in a reversible state of non-dividing (G0) or temporarily preventing the cells from entering a state of cellular division.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Phase 1/2 development</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phase
                                            1 studies are the initial introduction of an investigational drug in humans. Phase 1 studies
                                            are closely monitored and are used to gather information about how a drug interacts with
                                            the human body. In Phase 2 studies,&nbsp;researchers administer the drug to a group of patients,
                                            up to several hundred people, with the disease or condition for which the&nbsp;drug is being
                                            developed. Phase 2 studies are also used to determine the common short-term side effects
                                            and risks associated with the drug.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><B>Phase 1b/2a trial</B></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Phase
                                            1b/2a trial means a human clinical trial of a product for any indication that (a) is intended
                                            for dose exploration, examination of pharmacological or clinical activity (including dose
                                            response, dose escalation, duration of effect or kinetic/dynamic relationship assessments)
                                            and preliminary determination of efficacy and safety in the target patient population, and
                                            (b) contains a sufficient number of well characterized and clinically uniform subjects for
                                            the applicable indication using a pre-specified and uniform dose.</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Phase 3 clinical trial</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Phase 3 trials are expanded
    controlled and uncontrolled trials in which researchers administer the drug to a group of patients, from several hundred to several
    thousand individuals, with the disease or condition for which the&nbsp;drug is being developed to evaluate the overall benefit-risk
    relationship of the drug and to provide an adequate basis for physician labeling. The study may last for multiple years.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>phenotype</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    set of observable characteristics of an individual resulting from the interaction of its genotype with the environment.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Physician Payments Sunshine Act</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The Physician Payments Sunshine
    Act is a 2010 United States healthcare law that requires the disclosure of financial relationships between health care providers
    and pharmaceutical manufacturers.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>PK</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The physicochemical properties,
    the physical and chemical properties of a substance.</FONT></TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; width: 24%; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>placebo effect</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; width: 76%; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A beneficial
    effect produced by a placebo drug or treatment, which cannot be attributed to the properties of the placebo, itself, and must therefore
    be due to the patient&rsquo;s belief in that treatment.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>PLK1</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">Polo-like kinase 1, an enzyme
    that in humans is encoded by the PLK1 gene.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>preclinical</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A stage of research that
    begins before clinical trials.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>proliferating cancer cell</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">A quickly dividing cancer
    cell that copies its DNA and divides into 2 cells.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>prostate</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The&nbsp;prostate&nbsp;is
    a walnut-sized&nbsp;gland&nbsp;in the male reproductive system.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>radiation therapy</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A cancer treatment that uses
    high doses of radiation to kill cancer cells and shrink tumors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>REMS</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A Risk Evaluation and Mitigation
    Strategy (REMS) is a drug safety program that the FDA can require for certain medications with serious safety concerns to help ensure
    the benefits of the medication outweigh its risks.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>second line therapies</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Treatment for a disease or
    condition after the initial treatment (first-line treatment) has failed, stopped working, or has side effects that aren&rsquo;t tolerated.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>small molecules</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Low molecular weight molecules&nbsp;that
    include lipids, monosaccharides, second messengers, other natural products and metabolites, as well as drugs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>solid tumors</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">Solid tumors contain abnormal
    and heterotypic cells that communicate through tight and gap junctions. Unlike liquid tumors, as the cells multiply, they form a
    &ldquo;mass&rdquo; called a solid tumor and usually do not contain pockets of fluid, pus, air, or other substances.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>targeted drug therapy</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><I>A</I> type of cancer&nbsp;<I>treatment</I>&nbsp;that
    uses&nbsp;<I>drugs</I>&nbsp;or other substances to precisely identify and attack certain types of cancer cells.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>taxane family</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><I>Taxanes</I>&nbsp;comprise
    some of the most widely used cancer chemotherapeutic agents. This drug&nbsp;<I>family</I>&nbsp;is commonly used to treat breast,
    prostate, and lung cancers.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>third line therapies</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A therapeutic approach adopted
    after the failure of the first- and second- line therapies.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>third-party clinical investigators</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A clinical investigator conducts
    research that contributes to generalizable knowledge while protecting the rights and welfare of human participants, but not related
    to the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>tissue</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A
group of cells that have similar structure and that function together as a unit.&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>toxicity</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt">The degree to which a substance
    (a toxin or poison) can harm humans or animals.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><B>toxicology</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">The branch of science concerned
    with the nature, effects, and detection of poisons.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><B>transcription</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><I>Transcription</I>&nbsp;is
    the process by which the information in a strand of&nbsp;<I>DNA</I>&nbsp;is copied into a new molecule of messenger RNA (mRNA).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><B>translation</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><I>Translation</I>&nbsp;refers
    to the process of creating proteins from an&nbsp;<I>mRNA</I>&nbsp;template.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><B>tumor hypoxia</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A&nbsp;situation where tumor
    cells have been deprived of oxygen.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><B>tumor-targeted small molecules</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A drug or series of drugs
    that target tumors. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><B>Type I Diabetes</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A chronic condition in which
    the pancreas produces little or no insulin.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.5pt"><FONT STYLE="font-size: 10pt"><B>vinca alkaloids</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 5.5pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">A set of anti-mitotic and
    anti-microtubule alkaloid agents originally derived from the periwinkle plant and other vinca plants.&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A>PROSPECTUS SUMMARY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights selected information
contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information that you should consider
before deciding whether to invest in our securities. You should carefully read the entire prospectus, including the risks associated
with an investment in our company discussed in the &ldquo;Risk Factors&rdquo; section of this prospectus, before making an investment
decision. Some of the statements in this prospectus are forward-looking statements. See the section titled &ldquo;Cautionary Statement
Regarding Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Unless
otherwise indicated, all share amounts and per share amounts in this prospectus have been presented on a retroactive basis to reflect
a reverse stock split of our outstanding common stock at a ratio of one-for-9.08 (1 for 9.08) which was implemented on [ ], 2022.</I></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a preclinical oncology drug development
company focused on developing therapies targeting dormant and active cancer cells. We have designed and patented small molecules and
related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. This approach
is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal of acquired
resistance mechanisms. Our drug candidates are intended to be effective across a broad range of solid tumors and hematological cancers.
We target a high unmet need in large oncology markets including non-small cell lung cancer, or NSCLC, glioblastoma multiforme, or GBM,
ovarian, prostate, colorectal, pancreatic cancers, and acute lymphoblastic leukemia, or ALL.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established what we believe to be a unique
drug discovery platform, utilizing simultaneous identification of novel targets and corresponding specific small molecule inhibitors,
that, we hope, will enable us to expand our drug candidate pipeline in a way that will be faster than possible with other current methodologies.
We cannot guarantee, of course, that we will be successful in discovering or advancing new product candidates in a rapid manner, if at
all. We have a strong IP position that is continuously growing, and we have a cost-effective development strategy drawing on a network
of top-notch U.S.-based and international collaborators, each a recognized leader in their respective areas of expertise.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an oncology drug development company, we are
at the forefront of one of the most promising areas - dormant cancers. These cancers are responsible for resistance, metastasis,
and recurrence. We are developing treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term
outcomes of treatments for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal,
osteosarcoma, glioblastoma, and lung.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A challenge for durable cancer treatment is the
extreme mechanistic diversity and adaptive capacity of tumors within and among cancer patients. For any given drug, the benefit is increasingly
limited by the subtype of disease and by the rapid emergence of drug resistance. Our goal is to deliver a broadly active and durable
therapy by targeting vulnerabilities in dormant cancer cells. The therapeutic strategy is to use our molecules alone or in combinations
with either marketed or clinical stage drugs, each combination representing a potential opportunity for partnering or licensing. The
goal is to increase the patient response rate, quality of life and overall survival rate towards 100% and minimize the side effects and
cost of treatments by reducing the overall amount of drug required and sequential rounds of treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current internal pipeline development activities
are focused on the small molecules inhibitors of the dual specificity tyrosine phosphorylation-regulated protein kinase, or DYRK, family
of kinases. Our molecules pre-clinically have shown a high level of synergy with a spectrum of approved oncology therapeutics, including
both drugs with significant patent protection (such as epidermal growth factor receptor, or EGFR, inhibitors, Kirsten rat sarcoma virus,
or KRAS, inhibitors, mitogen-activated protein kinase, or MEK, inhibitors, and polo-like kinase 1, or PLK1, inhibitors), and drugs with
expiring patent protection, specifically the taxane family and vinca alkaloids.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our mechanism of action is unique. We believe
that acquired resistance is a major issue for targeted therapies (mutant KRAS, MEK, EGFR inhibitors) including immuno-oncology agents,
and that cancer cell dormancy is a key driver of developing acquired resistance and a pro-survival mechanism of cancer. In addition,
DYRK1 kinase plays a major role in dormancy specific to cancer cells. Accordingly, we are developing small molecule inhibitors specific
and selective for DYRK1 kinase. Our FX-9847 and FX-1610 product candidates inhibit tumor growth and metastasis in animal models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Products and Services </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, our business development efforts have
consisted of working to discover and identify new therapeutic compounds through our own proprietary drug discovery platform and in collaboration
with third parties, and in advancing what we believe to be the most promising of these compounds through preliminary characterization,
validation and efficacy studies, both in vitro and in vivo. We have not obtained regulatory approval for any of our drug candidates and
none has yet entered Phase I clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0pt 0">We have created a pipeline of therapeutic compounds focused primarily on oncology indications
of high unmet medical need. Our three most advanced product candidates are listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><I>FX-1610,</I> a small molecule
                                            inhibitor of DYRK1A and DYRK1B kinases (not orally bioavailable), is our compound being developed
                                            for pediatric leukemia - Acute Lymphoblastic Leukemia (ALL), an orphan drug indication of
                                            high unmet medical need. We expect to file an Investigational New Drug, or IND, application
                                            for FX-1610 during the first half of 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><I>FX-7742</I> is our compound
                                            being developed for solid tumor indications including NSCLC and colorectal cancer with mutations
                                            in EGFR (such as T790M) and KRAS (such as G12C). We are targeting an IND submission for FX-7742
                                            for NSCLC and/or other solid tumors with EGFR and KRAS mutations in the first half of 2023.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><I>FX-9847 is</I> our compound
                                            being developed for solid tumor indications as a back-up to FX-7742, if FX-7742 fails safety
                                            testing. We expect to file an IND for FX-9847 in the second half of 2023, if we replace FX-7742
                                            with FX-9847, or otherwise in the first half of 2024 assuming the required funds are available
                                            for this IND at that time.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We are currently developing the chemistry,
manufacturing and control (CMC) and formulation and qualifying the safety profiles of FX-1610, FX-7742 and FX-9847 to comply with current
regulatory requirements. We are undertaking the characterization and validation of these product candidates prior to entering non-human
primate (NHP) preclinical toxicology studies for further refining safety, formulation, dosing and scheduling regimen parameters in advance
of a Phase 1b/2a trials in humans. Assuming completion of the work described immediately above and following the completion of pre-IND
enabling studies which we would undertake assuming the successful completion of this offering (which we cannot guarantee), we expect
to file INDs for FX-1610 and FX-7742 in the first half of 2023. If we need to substitute FX-9847 for FX-7742, if FX-7742 fails safety
studies, we would expect to be ready to file an IND for FX-9847 in the fourth quarter of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In addition, we are working
to expand our pipeline through the identification and development of new dormancy targets.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The biotechnology and pharmaceutical industries
are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. Our unique knowledge,
experience, and scientific resources focuses on a strategy that provides us with competitive advantages. Nevertheless, the market for
oncology products is very competitive, changes rapidly, and welcomes the advent of new technology quickly.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that we can be a leader in the discovery,
development, and commercialization of cancer dormancy targeted drugs due to the following key strengths:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Therapies against dormant
                                            cancer cells</I>. </B>Our patented small molecules and related methods selectively disrupt
                                            cancer cells once they enter the dormant state in a manner that is specific to the disease
                                            and tissue context. Our drug candidates are intended to be effective across a broad range
                                            of solid tumors and liquid hematological cancers. We believe we can develop multiple profitable
                                            therapies based on the significant demand for such treatments.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Cost-effective and
                                            professional research, development and manufacturing strategy</I></B>. Our network of top-notch
                                            U.S.-based and international collaborators, each a recognized leader in their respective
                                            areas of expertise, helps us reduce the initial costs related to, and accelerate the timeline
                                            towards, the development and deployment of medical breakthrough therapies.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Seasoned and accomplished
                                            management</I></B>. Our management team members are leaders in drug discovery. Our officers
                                            have led drug discovery programs at Hoffman-La Roche and Memorial Sloan Kettering Cancer
                                            Center, authored more than 20 publications in peer reviewed journals, developed eight patents,
                                            have many years of pharmaceutical industry experience, and have experience collaborating
                                            with a broad array of biopharmaceutical companies. We also have more than two decades of
                                            business management experience in the pharmaceutical and biotechnology fields. Our board
                                            of directors and scientific advisors includes the Head of Developmental Therapeutics at Memorial
                                            Sloan-Kettering Cancer Center and Professor of Pharmacology, Cell Biology and Medicine at
                                            Cornell University Medical School, and all of our directors have more than 20 years of experience
                                            in the biotechnology/pharmaceutical industries. Our officers and directors have advanced
                                            medical and business degrees from leading world universities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Growth Strategies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our mission is to develop novel treatments for dormant cancers: targeting
cancer resistance, metastasis, and relapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary objective is to advance our pipeline
and leverage our therapeutic platform to become a leader in the discovery, development, and commercialization of cancer dormancy targeted
drugs. We intend to seek approval of our product candidates as first line cancer therapies to be used in combination with other first
line cancer therapy drugs. The strategies of the Company to achieve this objective, while increasing value for our shareholders, will
include the following steps:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Execute DYRK program
                                            advancement. </I></B>Preparation is underway to submit an Investigational New Drug application,
                                            or IND, for FX-1610, for liquid tumor ALL indications, followed by FX-7742, for solid tumor
                                            oncology indications, both in 2023. If FX-7742 fails safety studies in animals, we intend
                                            to substitute FX-7742 with FX-9847, an advanced small molecule compound being developed for
                                            solid tumors indications although not orally bioavailable.</TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">Our goal is to advance two discovery assets per year into
                                            preclinical development. Assuming we raise the maximum amount in this offering (an assumption
                                            which we cannot guarantee), we expect to have sufficient funds for approximately the next
                                            20 to 24 months to advance two product candidates, FX-1610 and FX-7742 (or FX-9847), through
                                            the IND enabling stage and filing process up to Phase 1b/2a clinical studies. We expect that
                                            we will need additional funds to begin Phase 1b/2a clinical studies for FX-1610 and FX-7742
                                            (or FX-9847), to advance our additional pipeline prospective product candidates into the
                                            pre-IND enabling stage in 2023 or 2024, and to begin to disclose additional discovery assets
                                            on an annual basis. There can be no assurances, however, that we will be able to raise these
                                            needed additional funds on terms acceptable to us, if at all.</TD></TR>
                                                                                                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Implement accelerated
                                            breakthrough therapy regulatory strategy</I></B>. We believe that our assets are differentiated
                                            and represent potential breakthroughs in biopharmaceutical drug development. We will endeavor
                                            to seek breakthrough therapy designation (discussed below) for each of our drug candidates
                                            with regulatory agencies, which could potentially lead to accelerated clinical development
                                            timelines. In addition, we will be seeking orphan drug designation for our FX-1610 drug candidate
                                            for pediatric ALL, which is identified as an orphan disease by the FDA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Pursue pipeline licensing
                                            opportunities</I></B>. We are pursuing opportunities with leading biopharmaceutical companies
                                            for the development and commercialization of our pipeline assets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Leverage research,
                                            collaboration and IP licensing agreements with leading institutions</I></B>. We have, or
                                            have had, research and collaboration programs with several biotechnology companies. These
                                            collaborations allow us to accelerate our research program toward the discovery and development
                                            of breakthrough therapies based on the combined data and research resources of our program
                                            collaborators and our patented and potentially patentable cancer therapies. These companies
                                            include Ryvu, a Polish integrated drug research services company, and &Eacute;quilibre Biopharmaceuticals,
                                            a New York-based breakthrough neurological therapeutics company. Our collaboration partners
                                            also include Memorial Sloan Kettering Cancer Center, one of the world&rsquo;s premier cancer
                                            centers, and Whitehead Institute for Biomedical Research.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The success of our growth strategy will be contingent,
among other things, on the successful completion of this offering and on our ability to raise additional funds in the future for the
further advancement of the two product candidates, whose pre-IND enabling studies we expect to fund with the proceeds of this offering,
and our other pipeline candidates. Considering our history of net losses, our accumulated deficit as of March 31, 2022 of $7,070,505,
the fact that we have not, and will not in the foreseeable future, generate any revenues or operational cash flow and the fact that we
will have to rely on our ability to raise additional capital to further the development of our product candidates and continue our business
operations, we can provide no assurance that we will be successful in executing any of our growth strategies as listed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COVID-19 Pandemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Starting in late 2019, a novel strain of&nbsp;the
coronavirus, or COVID-19, began to rapidly spread around the world and every state in the United&nbsp;States. At this time, there continues
to be significant volatility and uncertainty relating to the full extent to which the COVID-19&nbsp;pandemic and the various responses
to it will impact our business, operations and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Most states and cities have at various times
instituted quarantines, restrictions on travel, &ldquo;stay at home&rdquo; rules, social distancing measures and restrictions on the
types of businesses that could continue to operate, as well as guidance in response to the pandemic and the need to contain it. As a
result, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, including such authorities in Europe,
which could result in delays of reviews and approvals. While there have been no specific notices of delay from federal or foreign government
authorities, potential interruptions, delays, or changes to the operations of the FDA, or of any foreign authority with which we might
interact, might impact the approval of any applications we plan and will need to file in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As in many other industries, we believe that
the COVID-19 pandemic has weakened many oncology drug development companies and their suppliers. We believe that we have fully complied
with all state and local requirements relating to COVID-19. We have undertaken various measures in an effort to mitigate the spread of
COVID-19, including encouraging employees to work remotely if possible. However, we have not developed any further COVID-19 contingency
plans to address the potential challenges and risks presented by this pandemic. If we were to prepare such plans, there could be no assurance
that they would be effective in mitigating the effects of the COVID-19 virus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, w<FONT STYLE="font-family: Times New Roman, Times, Serif">e
are dependent upon certain contract manufacturers and suppliers and their ability to reliably and efficiently fulfill our orders is critical
to our business success. The COVID-19&nbsp;pandemic has impacted and may continue to impact certain of our manufacturers and suppliers.
As a result, we have faced and may continue to face delays or difficulty sourcing certain products, which could negatively affect our
business and financial results.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The spread of COVID-19&nbsp;has also adversely
impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets.&nbsp;The
pandemic has resulted, and may continue to result, in a significant disruption of global financial markets, which may reduce our ability
to access capital in the future, which could negatively affect our liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the COVID-19&nbsp;pandemic does not continue to slow and the spread of COVID-19&nbsp;is not contained, our business operations, including
those of contract manufacturers, could be further delayed or interrupted. We expect that government and health authorities may announce
new or extend existing restrictions, which could require us or our subcontractors to make further adjustments to our operations in order
to comply with any such restrictions. We or our subcontractors may also experience limitations in employee resources. In addition, our
operations could be disrupted if any of our employees or employees of our subcontractors were to be tested positive for having&nbsp;COVID-19,
which could require quarantine of some or all such employees or closure of our or their facilities for disinfection. The duration of
any business disruption cannot be reasonably estimated at this time but may materially affect our ability to operate our business and
result in additional costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent to which the&nbsp;COVID-19&nbsp;pandemic&nbsp;may impact our results will depend on future developments, which are highly uncertain
and cannot be predicted as of the date of this prospectus, including the effectiveness of vaccines and other treatments for COVID-19,
the emergence of new strains of the virus and other new information that may emerge concerning the severity of the&nbsp;pandemic&nbsp;and
steps taken to contain the&nbsp;pandemic&nbsp;or treat its impact. Nevertheless, the pandemic and the current financial, economic and
capital markets environment, and future developments in the global supply chain and other areas present material uncertainty and risk
with respect to our performance, financial condition, results of operations and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a further discussion of the impact of the COVID-19 pandemic on our business, please see &ldquo;<I>Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations - Impact of COVID-19 Pandemic</I>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the completion of this offering, we will qualify as an &ldquo;emerging growth company&rdquo; under the Jumpstart Our Business Startups
Act of 2012 (the &ldquo;JOBS Act&rdquo;). As a result, we will be permitted to, and intend to, rely on exemptions from certain disclosure
requirements. For so long as we are an emerging growth company, we will not be required to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
                                            an auditor report on our internal controls over financial reporting pursuant to Section 404(b)
                                            of the Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
                                            with any requirement that may be adopted by the Public Company Accounting Oversight Board
                                            regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing
                                            additional information about the audit and the financial statements (i.e., an auditor discussion
                                            and analysis);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submit
                                            certain executive compensation matters to shareholder advisory votes, such as &ldquo;say-on-pay&rdquo;
                                            and &ldquo;say-on-frequency;&rdquo; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
                                            certain executive compensation related items such as the correlation between executive compensation
                                            and performance and comparisons of the chief executive officer&rsquo;s compensation to median
                                            employee compensation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period
provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) for complying with new or
revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition
period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting
standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an emerging growth company for up to five years, or until the earliest of (i) the last day of the first fiscal year in which
our total annual gross revenues exceed $1.07 billion, (ii) the date that we become a &ldquo;large accelerated filer&rdquo; as defined
in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act,&rdquo;) which would occur if the market
value of our securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed
second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three
year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in the State of Delaware on May 4, 2012<B>. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 27 Strathmore Road, Natick, MA 01760 and our telephone number is (919) 213-0025. We maintain
a website at https://www.felicitex.com/. Information available on our website is not incorporated by reference in and is not deemed a
part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 26%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            being offered:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,500,000
    of units (or $17,825,000 of units if the underwriters exercise the over-allotment option to purchase additional units in full), each
    unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price equal to the
    initial public offering price, which will be immediately exercisable and will expire on the fifth anniversary of the original issuance
    date. The shares and warrants that are part of the units are immediately separable and will be issued separately in this offering.</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
    price:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently estimate that the initial public offering price will be between $5.25 and $7.25 per share.</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered by us:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 2,480,000 shares of common stock (assumed a public offering price of $6.25 per unit, the midpoint of the range set forth on the
    cover page of this prospectus).</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    offered by us:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Up
                                            to 2,480,000 warrants to purchase up to 2,480,000 shares of common stock. Each share of common
                                            stock is being sold together with one warrant to purchase one share of common stock. Each
                                            whole share exercisable pursuant to the warrants will have an initial exercise price per
                                            share equal to the initial public offering price, will be immediately exercisable and will
                                            expire on the fifth anniversary of the original issuance date. Warrants may be exercised
                                            only for a whole number of shares. The shares of common stock and warrants are immediately
                                            separable and will be issued separately but must be purchased together in this offering as
                                            units. This prospectus also relates to the offering of the shares issuable upon exercise
                                            of the warrants.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain exemptions outlined in the
warrants, for a period until the later of: (i) two years from the date of issuance of the warrants, or (ii) on the date no Qualified
Buyer holds any warrants, if the Company shall sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter
into an agreement to sell, or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any
option to purchase or other disposition) any shares of its common stock or convertible security, at an effective price per share less
than the exercise price of the warrants then in effect, or a dilutive issuance, the exercise price of the warrants shall be reduced to
equal the effective price per share in such dilutive issuance;&nbsp;provided, however, that in no event shall the exercise price of the
warrants be reduced to an exercise price lower than 50% of the public offering price per unit in this offering, or the floor price.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the date that is 90 calendar days immediately
following the initial issuance date of the warrants, the exercise price of the warrants will adjust to be equal to the Reset Price, provided
that such value is less than the exercise price in effect on that date. The Reset Price is equal to the greater of (a) the floor price
and (b) 100% of the lowest volume weighted average price per share of our common stock occurring during the 90 calendar days following
the issuance date of the warrants. The lowest Reset Price is the same as the floor price, or $3.125, which is 50% of the offering price,
based on an assumed public offering price of $6.25 per unit, the midpoint of the price range of the units.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also choose to lower the exercise
price of the warrants at its option at any time during the life of the warrants.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of warrants and Additional Warrants will
have the right to participate in certain subsequent offerings available to our stockholders, subject to certain limits as described in
the warrants and Additional Warrants.</P>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, until the later of (a) two years
after the date the warrants are issued or (b) the date no Qualified Buyer holds any warrants, in the event of any adjustment under the
dilutive issuance provision of the warrants that results in a reduction of the exercise price, in aggregate, to the floor price, then
in connection with such adjustment, each Qualified Buyer shall receive two Additional Warrants for each one warrant held by such holder
on the date of adjustment. The maximum number of warrants subject to such adjustment by a given Qualified Buyer will be limited to the
number of warrants purchased by such Qualified Buyer in this offering. Qualified Buyers would also receive Additional Warrants as a result
of the Reset Price being set at the floor price.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such Additional Warrants shall be on substantially
the same terms as the warrants; provided, however, that the term of the Additional Warrants shall be five (5) years from the issuance
date and such Additional Warrants will not be tradable warrants.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants (including the Additional Warrants)
will be subject to forced exercise commencing six months from issuance subject to the condition that the volume weighted average price
of our common stock exceeds 200% of the initial exercise price of the warrants for ten consecutive trading days and subject to certain
other conditions set forth in the warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P></TD></TR>
</TABLE>

</div>
<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    outstanding after the offering:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[6,935,999]
    shares of common stock (or [7,307,999] shares if the underwriters exercise the over-allotment option in full). </FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
    option:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted to the underwriters a 45-day option to purchase from us up to an additional 15% of the shares of common stock and/or
    warrants sold in the offering in any combination thereof, solely to cover over-allotments, if any, at the initial public offering
    price, less the underwriting discounts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative&rsquo;s
    warrants:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have agreed to issue to the representative warrants to purchase
a number of shares of common stock equal in the aggregate to 8% of the total number of shares issued in this offering (excluding shares
that may be issued under the over-allotment option). The representative&rsquo;s warrant will be exercisable at a per share exercise price
equal to 125% of the public offering price per share of common stock sold in this offering. The representative&rsquo;s warrant is exercisable
at any time and from time to time, in whole or in part, during the four years and six months commencing six months after the closing of
this offering and terminating on the fifth anniversary of the commencement date of sales in this offering. The registration statement
of which this prospectus forms a part also registers the issuance of the shares of common stock issuable upon exercise of the representative&rsquo;s
warrant. See &ldquo;<I>Underwriting</I>&rdquo; for more information.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to receive net proceeds of approximately $13,327,000 from this offering (or approximately $15,442,750 if the underwriters
    exercise their over-allotment option in full), assuming an initial public offering price of $6.25 per unit (which is the midpoint
    of the estimated range of the initial public offering price shown on the cover page of this prospectus) and no exercise of the underwriters&rsquo;
    over-allotment option, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
    by us. We plan to use the net proceeds of this offering for research, product development, general and administrative expenses, and
    working capital and other corporate purposes. See &ldquo;<I>Use of Proceeds</I>&rdquo; for more information on the use of proceeds.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our securities involves a high degree of risk. As an investor, you should be able to bear a complete loss of your investment.
    You should carefully consider the information set forth in the &ldquo;<I>Risk Factors</I>&rdquo; section beginning on page 10 before
    deciding to invest in our common stock and warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; width: 26%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-up</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify; width: 72%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
    all of our directors and officers and our shareholders holding at least 10% of the outstanding shares of our common stock have agreed
    with the underwriters, subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our common
    stock or securities convertible into or exercisable or exchangeable for our common stock for a period of six months after the closing
    of this offering. See &ldquo;<I>Underwriting</I>&rdquo; for more information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
    trading market and symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we intend to file an application to list our shares of common stock under the symbol &ldquo;FLCT&rdquo;
and our warrants, but not the Additional Warrants, under the symbol &ldquo;FLCTW,&rdquo; both on the Nasdaq Capital Market. We do not
intend that the units trade and we will not apply for listing of the units on any securities exchange or other nationally recognized
trading system. Without an active trading market, the liquidity of the units will be limited. The closing of this offering is contingent
upon the successful listing of our common stock and warrants on the Nasdaq Capital Market.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The number of shares of common stock outstanding
immediately following this offering is based on 4,455,999 shares outstanding as of March 31, 2022, after giving effect to a reverse share
split effected on [&nbsp;&nbsp; ], 2022 at a ratio of 1-for-9.08 and excludes:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,018,146
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2012 Plan (as defined below).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,117
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2022 Plan (as defined below).</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,519
                                            total shares of common stock issuable upon the conversion of a convertible promissory note
                                            which we issued to our Chairman;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">729,874
                                            additional shares of common stock that are reserved for issuance under the 2022 Plan;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123,735
                                            shares of common stock issuable upon exercise of warrants issued to our Chairman;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">up
                                            to [2,480,000] shares of common stock issuable upon exercise of warrants included in the
                                            units being offered in this offering;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                            to [372,000] shares of common stock issuable upon the exercise of warrants that may be issued
                                            as a result of exercise of the representative&rsquo;s over-allotment option;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</DIV>
<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                            to [4,960,000] shares of common stock issuable upon exercise of Additional Warrants issuable
                                            to Qualified Buyers pursuant to any adjustment in the dilutive issuance provision of the
                                            warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                            to [372,000] shares of common stock issuable upon the exercise of warrants and/or [372,000]
                                            shares of common stock that may be issued as a result of exercise of the representative&rsquo;s
                                            over-allotment option; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                            to [198,400] shares of common stock issuable upon exercise of the representative&rsquo;s
                                            warrants issued in connection with this offering.</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Summary
Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize certain financial data regarding our business and should be read in conjunction with our financial statements
and related notes contained elsewhere in this prospectus and the information under &ldquo;<I>Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our summary financial data as of quarters ended
March 31, 2022 and 2021 and fiscal years ended December 31, 2020 and 2021, are derived from our reviewed financial statements and our
audited financial statements included elsewhere in this prospectus, respectively. All financial statements included in this prospectus
are prepared and presented in accordance with generally accepted accounting principles in the United States (&ldquo;GAAP&rdquo;). The
summary financial information is only a summary and should be read in conjunction with the historical financial statements and related
notes contained elsewhere herein. The financial statements contained elsewhere fully represent our financial condition and operations;
however, they are not indicative of our future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><B>Quarters Ended March 31</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><B>Years Ended December 31,</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Statement of Operations Data</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Operating expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">684,682</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">286,904</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,409,691</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,136,267</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(684,682</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(286,904</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,409,691</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,136,267</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,939</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(78,275</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(219,348</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(117,901</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss before provision for income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(707,621</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,629,039</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,254,168</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Income tax expense (benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss and comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(707,621</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,629,039</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,254,168</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share attributable to the Company -
    basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.16</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.09</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.39</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.22</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average common shares outstanding - basic
    and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,295,189</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,283,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,457,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,198,555</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Balance Sheet Data</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31, <BR> 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>March 31<BR> 2022,<BR> Pro Forma<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>March 31,<BR> 2022 <BR> Pro Forma as<BR> Adjusted<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">32,023</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right">32,023</TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,359,023</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10,362</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,370,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,362</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,375,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,822</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">919,309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">811,553</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">919,309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">811,553</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(870,735</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(739,469</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,587,531</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(795,731</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total liabilities and deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,375,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,822</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">on
                                            a pro forma basis to give effect to issuance of 42,519 shares of our common stock upon the
                                            conversion of outstanding loans provided by our Chairman.</P></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">on
                                            a pro forma as adjusted basis to reflect the pro forma adjustments as described above and
                                            the sale of 2,480,000 shares by us in this offering at an assumed price to the public of
                                            $6.25 per share, which is the midpoint of the estimated offering range set forth on the cover
                                            page of this prospectus, resulting in net proceeds to us of $13,327,000 after deducting (i)
                                            underwriter commissions of $1,520,000 and (ii) our estimated other offering expenses of $653,000
                                            (assuming no exercise of the over-allotment option).</P></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Reverse Stock Split</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On [ ], 2022, we implemented a one-for-nine and
eight one-hundredths (1 for 9.08) reverse stock split of our outstanding common stock under Delaware law. As a result of the reverse
stock split, the total of 40,460,420 issued and outstanding shares of our common stock prior to the reverse stock split was reduced to
a total of 4,455,999, after rounding, issued and outstanding shares of our common stock. The purpose of the reverse stock split was to
enhance our ability to achieve a share price for our shares of common stock consistent with the listing requirements of the Nasdaq Capital
Market. The reverse stock split maintained our existing shareholders&rsquo; percentage ownership interests in our company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
</DIV>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Summary
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<FONT STYLE="font-variant: small-caps"><B>of
Risk Factors</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our securities involves a high degree of risk. You should carefully consider the risks summarized below. These risks are
discussed more fully in the &ldquo;<I>Risk Factors</I>&rdquo; section immediately following this Prospectus Summary. These risks include,
but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Risks
Related to Our Limited Operating History and Our Financial Position </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are a preclinical oncology drug development company with a limited operating history. We
                                            have never generated any revenue from product sales and may never be profitable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            recurring losses from operations have raised substantial doubt regarding our ability to continue
                                            as a going concern.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will require substantial funding to finance our operations, complete the development and
                                            any commercialization of our drug candidates and evaluate future drug candidates. If we are
                                            unable to raise funding when needed, we may be forced to delay, reduce or eliminate our product
                                            development programs or other operations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Risks
Related to Clinical Development and Commercialization of Our Product Candidates</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            product candidates and those of any collaborators will need to undergo preclinical and clinical
                                            trials that are time-consuming and expensive, the outcomes of which are unpredictable, and
                                            for which there is a high risk of failure. If preclinical or clinical trials of our or their
                                            product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA, the
                                            EMA and any other comparable regulatory authority, additional costs may be incurred or delays
                                            experienced in completing, the development of these product candidates, or their development
                                            may be abandoned.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We are
                                            very early in our development efforts and are substantially dependent on our lead, most advanced
                                            product candidates, FX-1610, a small molecule inhibitor in development for pediatric ALL,
                                            an orphan indication of high unmet medical need, and FX-7742, an orally bioavailable compound
                                            being developed for solid tumor indications, including non-small cell lung cancer, or NSCLC.
                                            If we are unable to advance our lead product candidates or any of our other product candidates
                                            through clinical development, obtain regulatory approval and ultimately commercialize our
                                            lead product candidates or any of our other product candidates, or experience significant
                                            delays in doing so, our business will be materially harmed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            drug development is a lengthy, expensive and uncertain process. The results of preclinical
                                            studies and early clinical trials are not always predictive of future results. Any drug candidate
                                            that we advance into clinical trials may not achieve favorable results in later clinical
                                            trials, if any, or receive marketing approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have no experience as a company in conducting clinical trials.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction
                                            of the FDA or similar regulatory authorities outside the United States or do not otherwise
                                            produce positive results, we may incur additional costs or experience delays in completing,
                                            or ultimately be unable to complete, the development and commercialization of our drug candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Difficulty
                                            in enrolling patients could delay or prevent clinical trials of our product candidates. We
                                            may find it difficult to enroll patients in our clinical trials for FX-1610 and FX-7742 with
                                            pediatric leukemia - Acute Lymphoblastic Leukemia or non-small cell lung cancer and colorectal
                                            cancer, respectively, the types of cancers that FX-1610 and FX-7742 are designed to target.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serious
                                            adverse events, undesirable side effects or toxicities, or other unexpected properties of
                                            our drug candidates could limit the commercial potential of such drug candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            market opportunities for our product candidates may be relatively small as it will be limited
                                            to those patients who are ineligible for or have failed prior treatments and our estimates
                                            of the prevalence of our target patient populations may be inaccurate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Risks
Related to Manufacturing, Supply, and Our Relationships with Third Parties</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            expect to depend on collaborations with third parties for certain research, development and
                                            commercialization activities, and if any such collaborations are not successful, it may harm
                                            our business and prospects.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            expect to rely on third parties to conduct, supervise and monitor our clinical trials and
                                            some aspects of our research and preclinical testing, and if those third parties do not successfully
                                            carry out their contractual duties, comply with regulatory requirements, or otherwise perform
                                            in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize
                                            product candidates, or such approval or commercialization may be delayed, and our business
                                            may be substantially harmed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
                                            our product candidates is complex and we may encounter difficulties in production. If we
                                            encounter such difficulties, our ability to provide supply of our product candidates for
                                            preclinical studies and clinical trials or for commercial purposes could be delayed or stopped.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
                                            or our third-party manufacturers, may be unable to successfully scale-up the manufacturing
                                            process for our drug candidates to provide sufficient quality and quantity, which would delay
                                            or prevent us from conducting clinical trials, developing our drug candidates and commercializing
                                            our drugs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Risk
Related to Sales, Marketing, and Competition</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            currently have no marketing and sales organization and have no experience in marketing products.
                                            If we are unable to establish marketing and sales capabilities or enter into agreements with
                                            third parties to market and sell our product candidates, if approved, we may not be able
                                            to generate product revenue.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
                                            if we obtain FDA approval of any of our drug candidates, we may never obtain approval or
                                            commercialize such products outside of the United States, which would limit our ability to
                                            realize their full market potential.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            face substantial competition, which may result in others discovering, developing or commercializing
                                            products before or more successfully than we do.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Risks
Related to Our Business Operations</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may expend our limited resources to pursue a particular product candidate or indication and
                                            fail to capitalize on product candidates or indications that may be more profitable or for
                                            which there is a greater likelihood of success.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            expect to expand our development, regulatory and operational capabilities and, as a result,
                                            we may encounter difficulties in managing our growth, which could disrupt our operations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            future success depends on our ability to retain key employees, consultants and advisors and
                                            to attract, retain and motivate qualified personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Risks
Related to Our Intellectual Property</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we are unable to obtain and maintain sufficient intellectual property protection for our
                                            drug candidates, or if the scope of the intellectual property protection is not sufficiently
                                            broad, our competitors could develop and commercialize products similar or identical to ours,
                                            and our ability to successfully commercialize our products may be adversely affected.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
                                            patents covering our products and product candidates could be found invalid or unenforceable
                                            if challenged in court or in administrative proceedings. We may not be able to protect our
                                            trade secrets in court.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may be subject to claims challenging the inventorship or ownership of our patents and other
                                            intellectual property.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            reliance on third parties requires us to share our trade secrets, which increases the possibility
                                            that a competitor will discover them or that our trade secrets will be misappropriated or
                                            disclosed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
                                            and maintaining patent protection depends on compliance with various procedural, document
                                            submission, fee payment and other requirements imposed by governmental patent agencies, and
                                            our patent protection could be reduced or eliminated for non-compliance with these requirements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our securities involves a high degree of risk. You should carefully consider the risks described below, as well as the other information
in this prospectus, including our financial statements and the related notes thereto and the section of this prospectus titled &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; before you make an investment decision. The occurrence
of any of the events or developments described below could harm our business, financial condition, results of operations and prospects.
As a result, the market price of our securities could decline, and you may lose all or part of your investment in our securities.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
related to Our Limited Operating History and Our Financial Position </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a preclinical oncology drug development company with a limited operating history. We have never generated any revenue from product
sales and may never be profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing small molecule drugs for the treatment of unmet medical needs in immune-mediated diseases. We are developing therapies
targeting dormant and active cancer cells. We have a limited operating history that may make it difficult to evaluate the success of
our business to date and to assess our future viability. In addition, oncology drug development is a highly speculative undertaking and
involves a substantial degree of risk. Our operations have been limited to organizing and staffing our company, business planning, raising
capital, identifying potential drug candidates, establishing licensing and partnering arrangements, undertaking various research and
conducting preclinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not generated any revenue from product
sales and have incurred cumulative net losses since we commenced operations. For the fiscal quarters ended March 31, 2022 and March 31,
2021, we recorded net losses of $707,621 and $295,031, respectively. As of March 31, 2022, we had an accumulated deficit of $7,070,505.
We expect that it will be several years, if ever, before we have a drug candidate ready for commercialization. We expect to incur increasing
levels of operating expenses, and continue to incur net operating losses, for the foreseeable future as we seek to advance our drug candidates.
The net operating losses that we incur may fluctuate significantly from quarter to quarter and year to year.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
become and remain profitable, we must develop and eventually commercialize a product with significant product revenue. This will require
us to be successful in a range of challenging activities, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continuing
                                            our research and development efforts and submit investigational new drug applications, or
                                            INDs, for our lead product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiating
                                            and conducting the required preclinical studies and clinical trials of our current and future
                                            drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submitting
                                            applications for and obtaining marketing approval for these drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">researching
                                            and discovering new drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            a new sales and marketing presence for, or entering into a collaboration with respect to
                                            the sales and marketing of, these drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            effective pricing, third-party coverage and reimbursement programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing,
                                            marketing and selling products for which we may obtain marketing approval and satisfying
                                            any post-marketing regulatory requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entering
                                            into and maintaining successful collaborations with our strategic partners or future partners;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining,
                                            protecting and expanding our portfolio of intellectual property rights, including patents,
                                            trade secrets and know-how;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
                                            operational, financial and management systems and appropriate controls; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting,
                                            hiring and retaining additional administrative, clinical, regulatory and scientific personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
challenging activities will increase our operating expenses substantially. We may never succeed in these activities and, even if we succeed
in commercializing one or more of our drug candidates, we may never generate revenues that are significant or large enough to achieve
profitability. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges.
Because of these numerous risks and uncertainties, we are unable to accurately predict the timing or amount of increased expenses or
when, or if, we will be able to generate product revenues or achieve profitability. If we do achieve profitability, we may not be able
to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development
and other expenditures to develop and market additional drug candidates. Our failure to become and remain profitable could decrease the
value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business
or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred recurring losses and negative
cash flows from operations activities since inception and we expect to generate losses and negative cash flows from operations for the
foreseeable future primarily due to research and development costs for our potential product candidates. As of March 31, 2022, we had
cash of $32,023 and stockholders&rsquo; deficit of $(870,735). We believe our cash on March 31, 2022 is insufficient to fund our projected
operations, but we have received a commitment to fund from our principal investor through December 31, 2022, or until such time the Company
successfully raises capital from other investors, whichever occurs first. Substantial additional financing will be needed by us to fund
our operations. These factors raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated
and combined financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction
of liabilities in the normal course of business. The consolidated and combined financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will require additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources to carry
out our planned development activities. If additional capital is not secured when required, we may need to delay or curtail our operations
until such funding is received. Various internal and external factors will affect whether and when our product candidates become approved
for marketing and successful commercialization. The regulatory approval and market acceptance of our products candidates, length of time
and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will
materially affect our financial condition and future operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
since inception have consisted primarily of organizing our company, securing financing, developing our technologies through performing
research and development and conducting preclinical studies. We face risks associated with companies whose products are in development.
These risks include the need for additional financing to complete our research and development, achieving our research and development
objectives, defending our intellectual property rights, recruiting, and retaining skilled personnel, and dependence on key members of
management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to continue as a going concern is dependent on our ability to raise additional equity or debt capital. Should we be unable to
raise sufficient additional capital, we may be required to undertake cost-cutting measures including delaying or discontinuing certain
preclinical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the
progress of our preclinical and future clinical development programs. Funding may not be available when needed, at all, or on terms acceptable
to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate some or all of our planned clinical
trials. These factors among others create a substantial doubt about our ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the potential economic impact brought by, and the duration of, COVID-19, discussed further below, may be difficult to assess or predict,
a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which
could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19
could materially affect our business and the value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will require substantial funding to finance our operations, complete the development and any commercialization of our drug candidates
and evaluate future drug candidates. If we are unable to raise funding when needed, we may be forced to delay, reduce or eliminate our
product development programs or other operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase in parallel with our ongoing activities, particularly as we continue our discovery and preclinical development
activities to identify new product candidates and initiate clinical trials of, and seek marketing approval for, our product candidates.
In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses
related to product sales, marketing, manufacturing and distribution. Furthermore, upon the closing of this offering, we expect to incur
significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional
funding in connection with our continuing operations. However, we have estimated our current additional funding needs based on assumptions
that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently
anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We cannot be certain
that additional funding will be available on acceptable terms, or at all. Until such time, if ever, as we can generate substantial product
revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, governmental
funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties.
If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our discovery
and preclinical development programs or any future commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, our cash, cash equivalents
and marketable securities totaled $32,023. We believe that, based upon our current operating plan, our existing capital resources, together
with the net proceeds from this offering will be sufficient to fund our anticipated operations for the next 20 to 24 months, including
the Phase 1/2 development of FX-1610 and FX-7742. Our future capital requirements will depend on many factors, including:</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope, progress, results and costs of discovery, preclinical development and clinical trials
                                            for our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extent to which we enter into collaboration arrangements with regard to product discovery
                                            or acquire or in-license products or technologies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to establish discovery collaborations on favorable terms, if at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs, timing and outcome of regulatory review of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of future commercialization activities, including product sales, marketing, manufacturing
                                            and distribution, for any of our product candidates for which we receive marketing approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenue,
                                            if any, received from commercial sales of our product candidates, should any of our product
                                            candidates receive marketing approval; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, enforcing
                                            and protecting our intellectual property rights and defending intellectual property-related
                                            claims.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve
product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any,
will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we
will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available
to us on acceptable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising
additional capital may cause dilution to our existing shareholders, restrict our operations or cause us to relinquish valuable rights.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and
alliances, licensing arrangements or monetization transactions. To the extent that we raise additional capital through the sale of equity,
convertible debt securities or other equity-based derivative securities, your ownership interest will be diluted, and the terms may include
liquidation or other preferences that adversely affect your rights as a shareholder. Any indebtedness we incur would result in increased
fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such
issuance, may cause the market price of our common stock to decline and existing shareholders may not agree with our financing plans
or the terms of such financings. If we raise additional funds through strategic partnerships and alliances, licensing arrangements or
monetization transactions with third parties, we may have to relinquish valuable rights to our technologies, or our product candidates,
or grant licenses on terms unfavorable to us. Adequate additional financing may not be available to us on acceptable terms, or at all.
If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development
or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop
and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to achieve and maintain effective internal controls could adversely affect our business and price of our securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Effective internal controls
are necessary for us to provide reliable financial reports. All internal control systems, no matter how well designed, have inherent
limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to the consolidated
and combined financial statement preparation and presentation. While we continue to evaluate our internal controls, we cannot be certain
that these measures will ensure that we implement and maintain adequate internal control&nbsp;over financial&nbsp;reporting in the future.
If we fail to maintain the adequacy of our internal controls or if we or our independent registered public accounting firm were to discover
material weaknesses in our internal controls, as such standards are modified, supplemented or amended, we may not be able to ensure that
we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 of
the Sarbanes-Oxley Act. Failure to achieve and maintain an effective internal control environment could cause us to be unable to produce
reliable financial reports or prevent fraud. This may cause investors to lose confidence in our reported financial information, which
could have a material adverse effect on the price of our securities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Clinical Development and Commercialization of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates and those of any collaborators will need to undergo preclinical and clinical trials that are time-consuming and expensive,
the outcomes of which are unpredictable, and for which there is a high risk of failure. If preclinical or clinical trials of our or their
product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA, the EMA and any other comparable regulatory authority,
additional costs may be incurred or delays experienced in completing the development of these product candidates, or their development
may be abandoned.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA in the United States, the EMA in the European Union and the European Economic Area, and other comparable regulatory authorities in
other jurisdictions must approve new product candidates before they can be marketed, promoted or sold in those territories. We have not
previously submitted an IND to the FDA or similar drug approval filings to comparable foreign regulatory authorities for any of our product
candidates. We must provide these regulatory authorities with data from preclinical studies and clinical trials that demonstrate that
our product candidates are safe and effective for a specific indication before they can be approved for commercial distribution. We cannot
be certain that our clinical trials for our product candidates will be successful or that any of our product candidates will receive
approval from the FDA, the EMA or any other comparable regulatory authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
studies and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee
that any clinical trials will be conducted as planned or completed on schedule, if at all. It may take several years and require significant
expenditures to complete the preclinical studies and clinical trials necessary to commercialize a product candidate, and delays or failure
are inherently unpredictable and can occur at any stage. We may also be required to conduct additional clinical trials or other testing
of our product candidates beyond the trials and testing that we contemplate, which may lead to us incurring additional unplanned costs
or result in delays in clinical development. In addition, we may be required to redesign or otherwise modify our plans with respect to
an ongoing or planned clinical trial and changing the design of a clinical trial can be expensive and time consuming. An unfavorable
outcome in one or more trials would be a major setback for our product candidates and for us. An unfavorable outcome in one or more trials
may require us to delay, reduce the scope of or eliminate one or more product development programs, which could have a material adverse
effect on our business, financial position, results of operations and future growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial
of marketing approval for our product candidates. The FDA, EMA or any other comparable regulatory authority may disagree with our clinical
trial design and our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed
and commented on the design for our clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with clinical trials of our product candidates, we face a number of risks, including risks that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            product candidate is ineffective or inferior to existing approved products for the same indications;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            product candidate causes or is associated with unacceptable toxicity or has unacceptable
                                            side effects;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
                                            may die or suffer adverse effects for reasons that may or may not be related to the product
                                            candidate being tested;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results may not confirm the positive results of earlier trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results may not meet the level of statistical significance required by the FDA, the EMA or
                                            other relevant regulatory agencies to establish the safety and efficacy of our product candidates
                                            for continued trial or marketing approval; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            collaborators may be unable or unwilling to perform under their contracts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory and other product
development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies,
clinical trials, the submission of regulatory filings or commercialization objectives. From time to time, we may publicly announce the
expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs,
the receipt of marketing approval or a commercial launch of a product. The achievement of many of these milestones may be outside of
our control. All of these milestones are based on a variety of assumptions, which may cause the timing of achievement of the milestones
to vary considerably from our estimates. If we fail to achieve milestones in the timeframes we expect, the commercialization of our product
candidates may be delayed, we may not be entitled to receive certain contractual payments, which could have a material adverse effect
on our business, financial position, results of operations and future growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are very early in our development efforts
and are substantially dependent on our most advanced, lead product candidates, FX-1610, our non-orally bioavailable small molecule inhibitor
in development for pediatric ALL, and FX-7742, our orally bioavailable compound being developed for solid tumor indications, including
non-small tumors. If we are unable to advance our lead product candidates or any of our other product candidates through clinical development,
obtain regulatory approval and ultimately commercialize our lead product candidates or any of our other product candidates, or experience
significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are very early in our development efforts. All of our product candidates are still in preclinical development and have never been tested
in human subjects. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily
on the successful clinical development and eventual commercialization of our FX-1610 and FX-7742 product candidates and one or more of
our other product candidates. In addition, our drug development programs contemplate the development of companion diagnostics, which
are assays or tests to identify an appropriate patient population. The success of our product candidates will depend on several factors,
including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            completion of preclinical studies (specifically non-rodent animal toxicity);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            of INDs for our planned clinical trials or future clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            initiation of clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            patient enrollment in and completion of clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety,
                                            tolerability and efficacy profiles for our product candidates that are satisfactory to the
                                            FDA or any foreign regulatory authority for marketing approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
                                            of marketing approvals for our product candidates and any companion diagnostics from applicable
                                            regulatory authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extent of any required post-marketing approval commitments to applicable regulatory authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining patent and trade secret protection and regulatory exclusivity for our product
                                            candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
                                            arrangements with third-party manufacturers, or establishing manufacturing capabilities,
                                            for both clinical and commercial supplies of our product candidates, if any product candidates
                                            are approved;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            sales, marketing and distribution capabilities and launching commercial sales of our products,
                                            if and when approved, whether alone or in collaboration with others;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            of our products, if and when approved, by patients, the medical community and third-party
                                            payors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
                                            competing with other cancer therapies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining third-party coverage and adequate reimbursement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
                                            a continued acceptable safety profile of our products following approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that the results obtained in current preclinical studies of FX-1610 and FX-7742 will be sufficient to obtain regulatory
approval or marketing authorization for such product candidates. Negative results in the development of our lead product candidates may
also impact our ability to obtain regulatory approval for our other product candidates, either at all or within anticipated timeframes
because, although other product candidates may target different indications, there are certain similarities in the underlying technology
platform for all of our product candidates. Accordingly, a failure in any one program may affect the ability to obtain regulatory approval
to continue or conduct clinical programs for other product candidates</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, because we have limited financial and personnel resources and are placing significant focus on the development of our lead
product candidates, we may forgo or delay pursuit of opportunities with other future product candidates that later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. Our spending on current and future research and development programs and other future product candidates for specific
indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential
or target market for a particular future product candidate, we may relinquish valuable rights to those future product candidates through
collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development
and commercialization rights to such future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
drug development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not
always predictive of future results. Any drug candidate that we advance into clinical trials may not achieve favorable results in later
clinical trials, if any, or receive marketing approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research and development of drugs is an extremely risky industry. Only a small percentage of drug candidates that enter the development
process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate,
we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug
candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of preclinical studies and completed
clinical trials are not necessarily predictive of future results, and our current drug candidates may not be further developed or have
favorable results in later studies or trials. Clinical trial failure may result from a multitude of factors including, but not limited
to, flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or
efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical
industry have suffered setbacks in the advancement of their drug candidates into later stage clinical trials due to lack of efficacy
or adverse safety profiles, notwithstanding results in earlier preclinical studies or clinical trials. Based upon negative or inconclusive
results, we may decide, or regulatory authorities may require us, to conduct additional clinical trials or preclinical studies. In addition,
data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may
not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials or marketing
approval. Furthermore, as more competing drug candidates within a particular class of drugs proceed through clinical development to regulatory
review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have two lead drug candidates in preclinical development, and their risk of failure is high. We are unable to predict if these
drug candidates or any of our future drug candidates that advance into clinical trials will prove safe or effective in humans or will
obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to complete preclinical studies or clinical trials of current or future drug candidates, due to safety concerns, or if
the results of these trials are not sufficient to convince regulatory authorities of their safety or efficacy, we will not be able to
obtain marketing approval for commercialization. Even if we are able to obtain marketing approval for any of our drug candidates, those
approvals may be for indications or dose levels that deviate from our desired approach or may contain other limitations that would adversely
affect our ability to generate revenue from sales of those products. Additionally, patent rights are of limited duration, and patents
protecting such drug candidates might expire before, or soon after, we obtain marketing approval leaving us open to competition from
biosimilar or generic products. Moreover, if we are not able to differentiate our product against other approved products within the
same class of drugs, or if any of the other circumstances described above occur, our business would be harmed and our ability to generate
revenue from that class of drugs would be severely impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Difficulty
in enrolling patients could delay or prevent clinical trials of our product candidates. We may find it difficult to enroll patients in
our clinical trials for FX-1610 and FX-7742 with pediatric leukemia - Acute Lymphoblastic Leukemia or non-small cell lung cancer and
colorectal cancer, respectively, the types of cancers that FX-1610 and FX-7742 are designed to target.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of completion
of our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our product candidates,
and we may experience delays in our clinical trials if we encounter difficulties in enrollment. We may not be able to initiate or continue
clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate
in these trials as required by the FDA or similar regulatory authorities outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the potentially small populations, the eligibility criteria of our planned clinical trials will further limit the pool of
available study participants as we will require that patients have specific characteristics that we can measure to assure their disease
is either severe enough or not too advanced to include them in a study. Additionally, the process of finding and diagnosing patients
may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical studies
because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies
and clinical trials, the proximity and availability of clinical study sites for prospective patients, and the patient referral practices
of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting
studies and obtaining regulatory approval of potential products may be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
enrollment of patients further depends on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            proximity of patients to clinical trial sites;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            design of the clinical trial;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain patient consents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting
                                            of the preliminary results of any of our clinical trials; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk that patients enrolled in clinical trials will drop out of the clinical trials before
                                            clinical trial completion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as
our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might
have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial being conducted by one of our competitors.
Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical
trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such
clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment
and because most of our product candidates have not been tested in humans before, potential patients and their doctors may be inclined
to use conventional therapies, rather than enroll patients in any future clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects
of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed
or prevented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have no experience as a company in conducting clinical trials. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no experience as a company in conducting clinical trials. In part because of this lack of experience, we cannot be certain that
our ongoing preclinical studies will be completed on time or if the planned preclinical studies and clinical trials will begin or be
completed on time, if at all. Large-scale clinical trials would require significant additional financial and management resources and
reliance on third-party clinical investigators, contract research organizations, or CROs, and consultants. Relying on third-party clinical
investigators, CROs and consultants may force us to encounter delays that are outside of our control. We may be unable to identify and
contract with sufficient investigators, CROs and consultants on a timely basis or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities
outside the United States or do not otherwise produce positive results, we may incur additional costs or experience delays in completing,
or ultimately be unable to complete, the development and commercialization of our drug candidates. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of our product candidates, including FX-1610 and FX-7742, we must demonstrate
through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective
for use in each target indication. Preclinical and clinical testing is expensive and can take many years to complete, and its outcome
is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our product
candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage
clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they
may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing
in humans and therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high
rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates
in later stages of clinical trials may fail to show the desired safety, potency, purity and efficacy profile despite having progressed
through preclinical studies and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual
safety or effectiveness in large-scale pivotal clinical trials. A number of companies in the biopharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or
unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies
and clinical trials are never approved as products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency, purity and efficacy necessary to
obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical
trials are inconclusive with respect to the safety, potency, purity and efficacy of our product candidates, if we do not meet the clinical
endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates,
we may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant
variability in safety, potency, purity or efficacy results between different preclinical studies and clinical trials of the same product
candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of
the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants.
As is the case with all oncology drugs, it is likely that there may be side effects associated with their use. Results of our trials
could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended
or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval
of our product candidates for any or all targeted indications. Drug-related side effects could also affect patient recruitment or the
ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm
our business, financial condition and prospects significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
design or our execution of clinical trials may not support regulatory approval. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
design or execution of a clinical trial can determine whether its results will support regulatory approval and flaws in the design or
execution of a clinical trial may not become apparent until the clinical trial is well advanced or completed. In some instances, there
can be significant variability in safety or efficacy results between different trials of the same drug candidate due to numerous factors,
including changes or variations in trial protocols, differences in size and type of the patient populations, adherence to the dosing
regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials
we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, the FDA and comparable foreign regulatory
authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be obtained
for any of our drug candidates. Our drug candidates may not be approved even if they achieve their primary endpoints in current or future
Phase 3 clinical trials or registration trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and
our interpretation of data from preclinical studies and clinical trials or may have divergent requirements for our trials or approval.
In addition, any of these regulatory authorities may change requirements for the approval of a drug candidate even after reviewing and
providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential to result in FDA or other regulatory
authorities&rsquo; approvals. In addition, any of these regulatory authorities may also approve a drug candidate for fewer or more limited
dose levels or indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials.
The FDA or other non-U.S. regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable
for the successful commercialization of our drug candidates, if approved. Failure to successfully obtain regulatory approval could have
a material adverse impact on our business and financial performance.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Serious
adverse events, undesirable side effects or toxicities, or other unexpected properties of our drug candidates could limit the commercial
potential of such drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. If any serious adverse
events, unacceptable levels of toxicity, undesirable side effects or unexpected characteristics may emerge, it could cause us to abandon
these drug candidates or limit their development to more narrow uses, lower dose levels or subpopulations in which the serious adverse
events, unacceptable levels of toxicity, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable
from a risk/benefit perspective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our drug candidates initially show promise in early clinical trials, the side effects of drugs are frequently only detectable after
they are tested in large Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after
approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the drug candidate
or another factor, especially in subjects who may suffer from other medical conditions and may be taking other medications. Regulatory
authorities may draw different conclusions or require additional testing to confirm any such determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
serious adverse or unexpected side effects are identified during development and are determined to be attributable to or result from
our drug candidates, we may be required to discontinue the development program, or the regulatory authorities may refuse to approve the
drug candidates. Drug-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the
trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if one or more of our drug candidates receives marketing approval, and we or others later identify undesirable side effects
caused by such products, a number of potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            authorities may withdraw approvals of such product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            authorities may require additional warnings on the label;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be required to create a medication guide outlining the risks of such side effects for
                                            distribution to patients, to enter into a risk evaluation and mitigation strategy, or REMS,
                                            or to compile a patient database;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            could face litigation and be held liable for harm caused to patients; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            reputation may suffer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the drug candidate, if approved, and could harm our
business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may announce preliminary, interim or&nbsp;top-line&nbsp;data&nbsp;from&nbsp;our clinical&nbsp;trials that&nbsp;may change as more patient
data become available, and as the data is&nbsp;subject to&nbsp;typical&nbsp;audit procedures that could result in material changes in
the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may announce preliminary, interim or top-line data from our clinical trials. Preliminary, interim and top-line data
from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change from the preliminary data
as patient enrollment continues, enrolled patients continue to progress through the trial, and more patient data become available. Preliminary,
interim&nbsp;and&nbsp;top-line&nbsp;data also remain subject to typical audit procedures that may result in the final audited data being
materially different from the preliminary data we previously announced. As a result,&nbsp;preliminary, interim and&nbsp;top-line&nbsp;data&nbsp;should
be viewed with caution until the final data are available. Adverse differences between preliminary, interim or&nbsp;top-line&nbsp;data
and final data could impact the regulatory approval of, and significantly harm the prospects of,&nbsp;any drug candidate that is impacted
by the applicable data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market opportunities for our product
candidates may be relatively small as it may be limited to those patients who are ineligible for or have failed prior treatments and
our estimates of the prevalence of our target patient populations may be inaccurate. </I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Cancer therapies are sometimes characterized
as first line, second line, or third line, and the FDA often approves new therapies initially only for a particular line of use. When
cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever
first line therapy, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery,
or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more
chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include
chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We intend
to seek approval of our product candidates that prove to be sufficiently safe and beneficial, if any, in most instances as a first line
therapy for use in patients with one of the types of cancers that our several product candidates address, including acute lymphoblastic
leukemia, non-small cell lung cancer, GBM, ovarian, prostate, colorectal, and pancreatic cancers. There is no guarantee that any of our
product candidates would be approved for a first line of therapy.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Our projections of both the number of
people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive a particular
line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates.
These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations
or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers
that we are targeting. Consequently, even if our product candidates are approved for a first line of therapy, the number of patients
that may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not
yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple
tumor types if there are different lines of approved therapies for each such tumor type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B><I>Industry and other market data
that may be used in our prospectus or in periodic reports that we may in the future file with the SEC and our other materials, including
those undertaken by us or our engaged consultants, may not prove to be representative of current and future market conditions or future
results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">This prospectus, and periodic reports
that we may in the future file with the SEC, includes or may include or refer to statistical and other industry and market data that
we obtained from industry publications and research, surveys and studies conducted by third parties and surveys and studies that we may
have undertaken ourselves regarding the market potential for our product candidates. Although we believe that such information has been,
and will be, obtained from reliable sources, the sources of such data do not guarantee the accuracy or completeness of such information.
While we believe these industry publications and third-party research, surveys and studies are reliable, we do not independently verify
such data. The results of this data represent various methodologies, assumptions, research, analysis, projections, estimates, composition
of respondent pool, presentation of data and adjustments, each of which may ultimately prove to be incorrect or inaccurate and may cause
actual results and market viability information to differ materially from that presented in this prospectus or any such report or other
materials that we may prepare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization
of our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive
marketing approval or commercialize our drug candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            authorities or institutional review boards or ethics committees, or IRBs or ECs, may not
                                            authorize us or our investigators to commence a clinical trial or conduct a clinical trial
                                            at a prospective trial site or we may fail to reach a consensus with regulatory authorities
                                            on trial design;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            authorities in jurisdictions in which we seek to conduct clinical trials may differ from
                                            each other on our trial design, and it may be difficult or impossible to satisfy all such
                                            authorities with one approach;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts
                                            or clinical trial protocols with prospective trial sites, the terms of which can be subject
                                            to extensive negotiation and may vary significantly among different contract research organizations,
                                            or CROs, and trial sites;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trials of our drug candidates may produce negative or inconclusive results, and we may decide,
                                            or regulatory authorities may require us, to conduct additional clinical trials or abandon
                                            product development programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">number
                                            of patients required for clinical trials of our drug candidates may be larger than we anticipate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enrollment
                                            in our clinical trials may be slower than we anticipate, or participants may drop out of
                                            these clinical trials at a higher rate than we anticipate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may need to effect changes
                                            to clinical trial protocols based on feedback from regulatory authorities, ECs, IRBs, or
                                            clinical site requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            third-party contractors may fail to comply with regulatory requirements or meet their contractual
                                            obligations to us in a timely manner, or at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            might have to suspend or terminate clinical trials of our drug candidates for various reasons,
                                            including a finding that the participants are being exposed to unacceptable health risks;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            authorities or IRBs may require that we or our investigators suspend or terminate clinical
                                            research for various reasons, including noncompliance with regulatory requirements or a finding
                                            that the participants are being exposed to unacceptable health risks;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            cost of clinical trials of our drug candidates may be greater than we anticipate, and we
                                            may lack adequate funding to continue one or more clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            supply or quality of our drug candidates or other materials necessary to conduct clinical
                                            trials of our drug candidates may be insufficient or inadequate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            clinical investigators may lose the licenses or permits necessary to perform our clinical
                                            trials, or not perform our clinical trials on our anticipated schedule or consistent with
                                            the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            contract manufacturing organizations may lose licenses due to their failure to comply with
                                            good manufacturing practices, or GMP, or failing to satisfy inspection requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            vendors, such as laboratories, used by us, may fail to follow quality guidelines or otherwise
                                            lose their ability to perform functions for which we rely on them;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            drug candidates may have undesirable side effects or other unexpected characteristics, causing
                                            us or our investigators, regulatory authorities or institutional review boards to suspend
                                            or terminate the trials; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
                                            of serious adverse events in trials of the same class of agents conducted by other companies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delays in the regulatory process are part of
drug discovery, and the FDA may issue clinical holds. We have experienced delays in the past and may experience such delays in the future.
In the event of a delay, we work closely and collaboratively with the regulatory authority to address their concerns.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate,
if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or
tests are not positive or are only modestly positive or if there are safety concerns, we may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            delayed in obtaining marketing approval for our drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            obtain marketing approval at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            approval for indications, dosages or patient populations that are not as broad as intended
                                            or desired;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            approval with labeling that includes significant use or distribution restrictions or safety
                                            warnings, including boxed warnings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            subject to additional post-marketing testing requirements; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
                                            the medicine removed from the market after obtaining marketing approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials
will begin as planned, will need to be amended or will be completed on schedule, or at all. Significant clinical trial delays also could
shorten any periods during which we may have the exclusive right to commercialize our drug candidates, could allow our competitors to
bring products to market before we do, and could impair our ability to successfully commercialize our drug candidates, if approved, any
of which may harm our business and results of operations. In addition, many of the factors that cause, or lead to a delay in the commencement
or completion of, clinical trials may also ultimately lead to termination or suspension of a clinical trial. Any of these occurrences
may harm our business, financial condition and prospects significantly. Any termination of any clinical trial of our drug candidates
will harm our commercial prospects and our ability to generate revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we receive marketing approval, we may not be able to successfully commercialize our drug candidates due to unfavorable pricing regulations
or third-party coverage and reimbursement policies, which could make it difficult for us to sell our drug candidates profitably.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement approval for a product from a third-party payor, including governmental healthcare programs such as Medicare
and Medicaid, private health insurers, managed care organizations, and other third-party payors, is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of such product to the payor.
There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited
than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for
coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including
research, development, intellectual property, manufacture, sale and distribution expenses, and in some countries, we may lose eligibility
for coverage even after obtaining it. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover
our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in
which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments
for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs
or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product
from countries where they may be sold at lower prices than in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage
and reimbursement for drug products among third party payors in the United States. While third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own reimbursement rates, they also have their own methods and approval process
apart from Medicare determinations. There may be significant delays in obtaining coverage and reimbursement as the process of determining
coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the
use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult
to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for
our drug products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">We cannot be sure that reimbursement
will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement
will be. Obtaining &nbsp;favorable reimbursement from payors of our products may be particularly challenging because of the higher prices
often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Our inability to promptly
obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop
could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our
overall financial condition.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain or maintain orphan drug designations or exclusivity for our drug candidates, which could limit the potential
profitability of our drug candidates, if approved. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan
drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease
or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or if it affects
more than 200,000, there is no reasonable expectation that sales of the drug in the United States will be sufficient to offset the costs
of developing and making the drug available in the United States. Generally, if a drug with an orphan drug designation subsequently receives
the first marketing approval for an indication for which it receives the designation, then the drug is eligible for a seven-year period
of marketing exclusivity during which the FDA may not approve another marketing application for the same drug for the same indication,
except in limited circumstances, such as if a subsequent application demonstrates that its product is clinically superior. During an
orphan drug&rsquo;s exclusivity period, however, competitors may receive approval for drugs with different active moieties for the same
indication as the approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different indications.
Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for a drug with
the same active moiety intended for the same indication before we do, unless we are able to demonstrate that grounds for withdrawal of
the orphan drug exclusivity exist or that our product is clinically superior. Further, if a designated orphan drug receives marketing
approval for an indication broader than the rare disease or condition for which it received orphan drug designation, it may not be entitled
to exclusivity. For purposes of small molecule drugs, the FDA defines &ldquo;same drug&rdquo; as a drug that contains the same active
moiety and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if
it is approved for a use that is broader than the indication for which it received orphan drug designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
orphan drug designations is important to our business strategy; however, obtaining an orphan drug designation can be difficult, and we
may not be successful in doing so. Even if we were to obtain orphan drug designation for a drug candidate, we may not obtain orphan exclusivity,
and any such exclusivity, if attained, may not effectively protect the drug from the competition of different drugs for the same condition,
which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve
another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective
or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA
later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity
of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any
drug candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability
to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable drug candidate to balance
our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Manufacturing, Supply, and Our Relationships with Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any
such collaborations are not successful, it may harm our business and prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
with collaborators poses several significant risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
                                            availability of resource allocation and other developmental decisions made by our collaborators
                                            about the product candidates or technologies that we seek to develop with them may result
                                            in the delay or termination of research programs, studies or trials, repetition of or initiation
                                            of new studies or trials or provision of insufficient funding or resources for the completion
                                            of studies or trials or the successful marketing and distribution of any product candidates
                                            that may receive approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            could independently develop, or develop with third parties, product candidates or technologies
                                            that compete directly or indirectly with our product candidates or technologies if the collaborators
                                            believe that competitive products or technologies are more likely to be successfully developed
                                            or can be commercialized under terms that are more economically attractive than ours;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may not properly obtain, maintain, enforce or defend our intellectual property or proprietary
                                            rights or may use our proprietary information in such a way that could jeopardize or invalidate
                                            our proprietary information or expose us to potential litigation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                            may arise between us and our collaborators that result in the delay or termination of the
                                            research, development or commercialization activities or that result in costly litigation
                                            or arbitration that diverts management attention and resources.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate revenues from these arrangements will depend on our collaborators&rsquo; abilities to successfully perform the functions
assigned to them in these arrangements. If our collaborations do not result in the successful development and commercialization of product
candidates or technologies, or if one of our collaborators terminates its agreement with us, we may not receive any future funding or
milestone or royalty payments under the collaboration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not receive the funding we expect under these agreements, our development of product candidates or technologies could be delayed,
and we may need additional resources to develop such product candidates or technologies. In addition, if one of our collaborators terminates
its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and may
need to raise additional capital to pursue further development or commercialization of the applicable product candidates or technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
events could delay development programs and negatively impact the perception of our company in business and financial communities. Failure
to develop or maintain relationships with any current collaborators could result in the loss of opportunity to work with that collaborator
or reputational damage that could impact our relationships with other collaborators in the relatively small industry communities in which
we operate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
all of the risks relating to product development, regulatory approval and commercialization described in this prospectus apply to the
activities of our collaborators. If our existing collaboration agreements or any collaborative or strategic relationships we may establish
in the future are not effective and successful, it may damage our reputation and business prospects, delay or prevent the development
and commercialization of product candidates and inhibit or preclude our ability to realize any revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical
testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or otherwise
perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval
or commercialization may be delayed, and our business may be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research
organizations, or CROs, to conduct preclinical studies and future clinical trials for our product candidates. Nevertheless, we will be
responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory
requirements and scientific standards, and our reliance on such third parties will not relieve us of our regulatory responsibilities.
For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational
plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as good clinical practices,
or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to assure that data and reported results
are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we intend to design the trials for our product candidates either alone or with collaborators, third parties may conduct all of the trials.
As a result, many important aspects of our research and development programs, including their conduct and timing, will be outside of
our direct control. Our reliance on third parties to conduct future studies and trials will also result in less direct control over the
management of data developed through studies and trials than would be the case if we were relying entirely upon our own staff. Communicating
with outside parties can also be challenging, potentially leading to mistakes and difficulties in coordinating activities. Such third
parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo
changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs or other third parties,
which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. For
any violations of laws and regulations during the conduct of our preclinical studies and future clinical trials, we could be subject
to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, our collaborators, our CROs or other third parties fail to comply with applicable GCPs, the clinical data generated in our clinical
trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical
trials before approving our marketing applications. We also are required to register certain ongoing clinical trials and post the results
of such completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so
can result in fines, adverse publicity and civil and criminal sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our CROs or other third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines,
or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols
or regulatory requirements or for any other reasons, trials for product candidates may be extended, delayed or terminated, and we or
our collaborators may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop.
If we are required to repeat, extend the duration of or increase the size of any trials we conduct, it could significantly delay commercialization
and require significantly greater expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of any of these factors, our financial results and the commercial prospects for any product candidate that we or our collaborators
may develop would be harmed, our costs could increase and our ability to generate revenues could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain sufficient quantities of raw materials and supplies, at acceptable prices and on a timely basis, it could harm
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on third parties for the supply of various materials and the manufacture of product supplies that are necessary to produce
our product candidates. The supply of these materials could be reduced or interrupted at any time. In such case, identifying and engaging
an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers
on acceptable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changing
suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.
If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional
studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we or
our collaborators may not be able to develop, manufacture and market product candidates in a timely and competitive manner, or at all.
If any of our product candidates receives approval, we will likely need to seek alternative sources of supply of raw materials or manufactured
product supplies and there can be no assurance that we will be able to establish such relationships to provide such supplies on commercially
reasonable terms or at acceptable quality levels, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to identify and procure additional sources of supply that fit our required needs, we could face substantial delays or incur
additional costs in procuring such materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will rely on third parties to manufacture our clinical product supplies, and we may rely on third parties to produce and process our
product candidates, if approved. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own any facility that may be used as our clinical scale manufacturing facility and expect to rely on outside vendors
to manufacture supplies of our product candidates. We will need to negotiate and maintain contractual arrangements with these outside
vendors for the supply of our product candidates and we may not be able to do so on favorable terms. We have not yet caused any product
candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or other foreign regulatory
authorities following inspections that will be conducted after we submit an application to the FDA or other foreign regulatory authorities.
We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance
with cGMPs and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates.
Beyond periodic audits, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality
assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the
manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities,
which would require the incurrence of significant additional costs and significantly impact our ability to develop, obtain regulatory
approval for or market our product candidates, if approved. Similarly, if any third-party manufacturers on which we will rely fail to
manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient
to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be
materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Manufacturing
our product candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability to
provide supply of our product candidates for preclinical studies and clinical trials or for commercial purposes could be delayed or stopped.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of manufacturing of our product candidates is complex and highly regulated. We rely on third parties for the manufacture of our
product candidates. These third-party manufacturers may incorporate their own proprietary processes into our product candidate manufacturing
processes. We have limited control and oversight of a third party&rsquo;s proprietary process, and a third party may elect to modify
its process without our consent or knowledge. These modifications could negatively impact our manufacturing, including product loss or
failure that requires additional manufacturing runs or a change in manufacturer, both of which could significantly increase the cost
of and significantly delay the manufacture of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our product candidates progress through preclinical studies and clinical trials towards approval and commercialization, it is expected
that various aspects of the manufacturing process will be altered in an effort to optimize processes and results. Such changes may require
amendments to be made to regulatory applications which may further delay the timeframes under which modified manufacturing processes
can be used for any of our product candidates and additional bridging studies or trials may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have our own clinical-scale manufacturing facility and are currently reliant on a limited number of manufacturers for our product
candidates. These third-party manufacturing providers may not be able to provide adequate resources or capacity to meet our needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We or our contract manufacturers must supply
all necessary documentation in support of an NDA on a timely basis and must adhere to the FDA&rsquo;s cGMP regulations enforced by the
FDA through its facility evaluation and inspection program. Comparable foreign regulatory authorities may require compliance with similar
requirements. The facilities and quality systems of our third-party manufacturers must pass a pre-approval inspection for compliance
with the applicable regulations as a condition of marketing approval of our drug candidates. We do not control the manufacturing process
of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality,
timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced
to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement
with another third party, which we may not be able to do on a timely basis or on acceptable terms, if at all. In particular, any replacement
of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.
In some cases, the technical skills or technology required to manufacture our drug candidates may be unique or proprietary to the original
manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may
not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in
order to have another third party manufacture our drug candidates. If we are required to change manufacturers for any reason, we will
be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable
regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to
develop drug candidates in a timely manner or within budget.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our,
or a third party&rsquo;s, failure to execute on our manufacturing requirements, or to do so on commercially reasonable terms and comply
with cGMP could adversely affect our business in a number of ways, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            inability to initiate or continue clinical trials of our drug candidates under development;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
                                            in submitting regulatory applications, or receiving marketing approvals, for our drug candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
                                            of the cooperation of an existing or future collaborator;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
                                            third-party manufacturing facilities or our manufacturing facilities to additional inspections
                                            by regulatory authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
                                            loss and additional costs resulting from starting materials, intermediates, API or drug product
                                            that cannot be used in clinical trials or for other purposes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
                                            to cease development or to recall batches of our drug candidates; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the event of approval to market and commercialize our drug candidates, an inability to meet
                                            commercial demands for our product or any other future drug candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We,
or our third-party manufacturers, may be unable to successfully scale-up the manufacturing process for our drug candidates to provide
sufficient quality and quantity, which would delay or prevent us from conducting clinical trials, developing our drug candidates and
commercializing our drugs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to conduct clinical trials of our drug candidates or commercialize our drugs, we will need to manufacture them in large quantities.
We, or our third-party manufacturers, may be unable to successfully increase the manufacturing capacity for any of our drug candidates
in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we or our third-party
manufacturers are unable to successfully scale up the manufacture of our drug candidates in sufficient quality and quantity, the development,
testing and clinical trials of that drug candidate may be delayed or become infeasible, and marketing approval or commercial launch of
any resulting product may be delayed or not obtained, which could significantly harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Existing
or changes in methods of drug candidate manufacturing or formulation may result in additional costs or delays.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
drug candidates progress through preclinical to clinical-stage trials to marketing approval and commercialization, it is common that
various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to
optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that
they will not achieve these intended objectives. Any of these changes could cause our drug candidates to perform differently and affect
the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion
of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical
trial costs, delay approval of our drug candidates or jeopardize our ability to commercialize our drug candidates and generate any revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization
plans.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and product development programs and the potential commercialization of our product candidates will require substantial additional
cash to fund expenses, and we expect that we will continue to seek collaborative arrangements for the development and potential commercialization
of current and future product candidates or the development of ancillary technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant
number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future
collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the
collaborator&rsquo;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&rsquo;s
evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product
or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood
of approval, if necessary, by the USDA, the FDA or similar regulatory authorities outside the United States, the potential market for
the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential
of competing products and technologies and industry and market conditions generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable
terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that
diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable
to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology
for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines,
reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners may engage in misconduct or
other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors and potential
commercial partners. Misconduct by these parties could include failures to comply with (i) FDA laws and regulations or those of comparable
foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing
standards, (iii) laws and regulations in the United States and abroad relating to data privacy and security, fraud and abuse, government
price reporting, transparency reporting requirements, and healthcare laws and regulations in the United States and abroad, (iv) laws
that require the true, complete and accurate reporting of financial information or data, or (v) insider trading laws. Such misconduct
could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions
and cause serious harm to our reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of conduct applicable to all of our employees, as well as an insider trading policy, disclosure program and other
applicable policies and procedures, but it is not always possible to identify and deter employee misconduct. Although we take measures
to protect against misconduct, the precautions we take to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure
to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant adverse impact on our business, including the imposition of significant
civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare,
Medicaid and other federal healthcare programs, imprisonment, integrity oversight and reporting requirements, contractual damages, reputational
harm, diminished profits and future earnings, and curtailment or restructuring of our operations. In addition, our employees, consultants,
vendors and other third parties involved in our business could engage in conduct or activities that could generate negative publicity
or social media attention or have other adverse consequences to our business. As a result of the rapid spread of information online,
even activities that are unrelated to our business operations could have a negative impact on our reputation by virtue of our association
with such individuals or entities, which could further harm our reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Sales, Marketing, and Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing
and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not
be able to generate product revenue. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We may determine to develop
an in-house marketing organization and sales force for at least one of our product candidates, which would require significant capital
expenditures, management resources and time. In order to establish our own sales and marketing capabilities, we would have to compete
with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any case, for at least two of our product candidates, we intend to pursue arrangements with third-party sales, marketing, and distribution
collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able
to establish or maintain such arrangements on favorable terms or at all, or if we are able to do so, that these third-party arrangements
will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of
such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third
parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face
competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships
with third-party collaborators to commercialize any product in the United States or overseas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
there are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties
to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product
launch. If the commercial launch of a drug candidate for which we recruit a sales force and establish marketing capabilities is delayed
or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly,
and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain FDA approval of any of our drug candidates, we may never obtain approval or commercialize such products outside of the United
States, which would limit our ability to realize their full market potential.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country.
Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review
periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional
preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country
to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements
is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any
country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any drug candidates
approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining commercial approval
in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required
approvals, our ability to realize the full market potential of our products will be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals,
cancer treatment centers and others in the medical community. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
factors will influence whether our product candidates are accepted in the market, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            clinical indications for which our product candidates are licensed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians,
                                            hospitals, cancer treatment centers and patients considering our product candidates as a
                                            safe and effective treatment;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential and perceived advantages of our product candidates over alternative treatments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to demonstrate the advantages of our product candidates over other cancer medicines;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any side effects;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            labeling or product insert requirements of the FDA or other regulatory authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            or warnings contained in the labeling approved by the FDA;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing of market introduction of our product candidates as well as competitive products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            cost of treatment in relation to alternative treatments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of adequate coverage, reimbursement and pricing by third-party payors and government
                                            authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors
                                            and government authorities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
                                            convenience and ease of administration, including as compared to alternative treatments and
                                            competitive therapies; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effectiveness of our sales and marketing efforts.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers
or others in the medical community, we will not be able to generate significant revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies
are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than we do. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
oncology drug and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. While
we believe that our scientific knowledge, platform technology and development expertise provide us with competitive advantages, we face
potential competition from many different sources, including major pharmaceuticals, specialty pharmaceuticals and biotechnology companies,
academic institutions and government agencies, and public and private research institutes that conduct research, development, manufacturing
and commercialization. Many of our competitors have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, regulatory approvals and product marketing than we do. Our competitors may compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover,
develop, license or commercialize products before or more successfully than we do.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available
in the future. Specifically with respect to FX-1610 and FX-7742, we expect competition from at least one other early-stage pharmaceutical
company similarly targeting dormant cancer cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our candidates, including FX-1610 and FX-7742, are approved for the indications for which we are currently planning clinical trials,
they will likely compete with the competitor drugs mentioned above and with other drugs that are currently in development. Key product
features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of
our products. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or
commercialize our product candidates. The availability of reimbursement from government and other third-party payors will also significantly
affect the pricing and competitiveness of our products. Our competitors may also obtain FDA or other regulatory approval for their products
more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before
we are able to enter the market. . If we are not successful in developing, commercializing and achieving higher levels of reimbursement
than our competitors, we will not be able to compete against them and our business would be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Market
disruptions, supply-chain disruptions, geopolitical conflicts, including acts of war, macroeconomic events, and inflation, could create
market volatility that negatively impact our business and operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
social and political tensions in the United States and around the world may contribute to increased market volatility, may have long-term
effects on the U.S. and worldwide markets and may cause further economic uncertainties in the United States and worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of events similar to those in recent years, such as localized wars, instability, new and ongoing pandemics (such as COVID-19),
epidemics or outbreaks of infectious diseases in certain parts of the world, natural/environmental disasters, supply-chain disruptions,
terrorist attacks in the United States and around the world, social and political discord, increasingly strained relations between the
United States and a number of foreign countries, new and continued political unrest in various countries, continued changes in the balance
of political power among and within the branches of the U.S. Government, government shutdowns, among others, may result in market volatility,
may have long term effects on the U.S. and worldwide financial markets, and may cause further economic uncertainties in the United States
and worldwide, all of which could make it more difficult for us to raise capital in this offering or otherwise and to continue our product
candidate development efforts in an efficient and timely fashion.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we must focus on a limited number of research programs and product candidates and
on specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications
that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable
commercial products or profitable market opportunities. Our spending on current and future discovery and preclinical development programs
and product candidates for specific indications may not yield any commercially viable products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing
our growth, which could disrupt our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, we had 2 full-time employees
and 1 part-time employee. As we advance our research and development programs and begin to operate as a public company, we expect to
experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development,
quality, regulatory affairs and, if any of our drug candidates receives marketing approval, sales, marketing and distribution. To manage
our anticipated future growth, we must:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify,
                                            recruit, integrate, maintain and motivate additional qualified personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
                                            our development efforts effectively, including the initiation and conduct of clinical trials
                                            for our drug candidates, both as monotherapy and in combination with other intra-portfolio
                                            drug candidates; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">improve
                                            our operational, financial and management controls, reporting systems and procedures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to develop, manufacture and commercialize our drug candidates will depend, in part, on our
ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate
amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified
personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the services of Dr. Maria Vilenchik, who serves as our Chief Executive Officer, Dr. Michael Frid, who serves
as our Head of Preclinical Pharmacology, and Marc Duey, who serves as our Chairman of the Board. We have entered into an employment agreement
only with Dr. Vilenchik, although it is not for a specific term and she may terminate her employment with us at any time, though we are
not aware of any present intention of Dr. Vilenchik to leave us<B>. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive biopharmaceuticals
industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical,
regulatory, manufacturing and management skills and experience. We conduct our operations in the Boston Area, a region that is home to
many other pharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified
personnel. We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number
of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have
greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide
higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors
may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully
develop and commercialize our drug candidates and to grow our business and operations as currently contemplated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory requirements
and other risks and uncertainties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future profitability may depend, in part, on our ability to commercialize our drug candidates in foreign markets for which we may rely
on collaboration with third parties. We are not permitted to market or promote any of our drug candidates before we receive marketing
approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of
our drug candidates. To obtain marketing approval in many foreign countries, we must comply with numerous and varying regulatory requirements
of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and
distribution of our drug candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our drug candidates
and ultimately commercialize our drug candidates in foreign markets, we would be subject to additional risks and uncertainties, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            customers&rsquo; ability to obtain reimbursement for our drug candidates in foreign markets;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to directly control commercial activities because we are relying on third parties;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            burden of complying with complex and changing foreign regulatory, tax, accounting and legal
                                            requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">different
                                            medical practices and customs in foreign countries affecting acceptance in the marketplace;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">import
                                            or export licensing requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer
                                            accounts receivable collection times;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer
                                            lead times for shipping;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">language
                                            or cultural barriers for technical training;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
                                            protection of intellectual property rights in some foreign countries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            existence of additional potentially relevant third-party intellectual property rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
                                            currency exchange rate fluctuations; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            interpretation of contractual provisions governed by foreign laws in the event of a contract
                                            dispute.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
internal information technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security
breaches, loss or leakage of data, and other disruptions, which could potentially expose us to liability or otherwise adversely affecting
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course
of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary
business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality, integrity
and availability of such confidential information. We also have outsourced elements of our operations to third parties, and as a result
we manage a number of third-party contractors who have access to our confidential information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that
they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are
potentially vulnerable to breakdown or other damage or service interruptions, system malfunctions, natural disasters, terrorism, war
and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees,
contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including
the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability
and threaten the confidentiality, integrity, privacy and availability of information), which may compromise our system infrastructure
or lead to unauthorized or inappropriate use or disclosure of our confidential information. In addition, as our trials advance in locations
across the world, our employees or other parties we work with may be required to travel or send data across international borders with
increasing frequency, which may increase our exposure to cyberattacks and other information security incidents or interruptions. To the
extent that any of these incidents were to result in a loss of, or damage to, our data or applications, or inappropriate use or disclosure
of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization
of our drug candidates could be delayed. Even the perception that such an incident has occurred could harm our reputation and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
to our knowledge we have not experienced any such system failure, accident or security breach to date, we cannot assure you that our
data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in
our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial
condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our programs and the development of our drug candidates could be delayed. In addition, the loss of clinical trial data for our drug
candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the
data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss,
misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including
trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial,
legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal
information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel
us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action,
and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which
could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage
and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability
to generate revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the cost of our product candidates to be substantial, when and if they achieve market approval. The availability and extent of
reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of our
product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates
will be paid by private payors, such as private health coverage insurers, health maintenance, managed care, pharmacy benefit and similar
healthcare management organizations, or reimbursed by government health care programs, such as Medicare and Medicaid. We may not be able
to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement is not available, or is available
only at limited levels, we may not be able to successfully commercialize our product candidates, even if approved. Even if coverage is
provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize
a sufficient return on our investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about coverage and reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid
Services, or CMS, an agency within the U.S. Department of Health and Human Services, as the CMS decides whether and to what extent a
new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult
to predict what CMS will decide with respect to coverage and reimbursement for novel products such as ours, as there is no body of established
practices and precedents for these new products. Coverage and reimbursement by a third-party payor may depend upon a number of factors,
including the third-party payor&rsquo;s determination that use of a product is: (1) a covered benefit under its health plan; (2) safe,
effective and medically necessary; (3) appropriate for the specific patient; (4) cost-effective; and (5) neither experimental nor investigational.
In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, the
coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support
for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently
or obtained in the first instance. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not
be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Third-party payors
may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the approved
drugs for a particular indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of
product candidates. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to
cover a significant portion of the cost of our product candidates. Because our product candidates may have a higher cost of goods than
conventional therapies, and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate
for us to achieve profitability may be greater. There is significant uncertainty related to insurance coverage and reimbursement of newly
approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement
for our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause
such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover
or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United
States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and
proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to
the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional
legislative changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical
products, or medicinal products, as they are commonly referred to in the European Union. These countries have broad discretion in setting
prices, and we cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities
in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues
from sales by us or our collaborators, and the potential profitability of our drug products, in those countries would be negatively affected.
An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts
on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the
world but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product
before it can be lawfully marketed. In many countries, the pricing review period begins after marketing or product licensing approval
is granted. To obtain reimbursement or pricing approval in some countries, we, or any collaborators, may be required to conduct a clinical
trial that compares the cost-effectiveness of our product to other available therapies. As a result, we might obtain marketing approval
for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price
regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the
revenues we are able to generate from the sale of the product in that particular country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The downward pressure on healthcare costs in
general, particularly prescription drugs and other treatments, has become very intense. As a result, increasingly high barriers are being
erected to the entry of new products. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is
set at unsatisfactory levels, our business could be harmed.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include
general liability, property and workers&rsquo; compensation, and we are in the process of acquiring directors&rsquo; and officers&rsquo;
insurance. Our insurance is expensive, and we do not know if we will be able to maintain existing insurance with adequate levels of coverage.
Our insurance policies contain exclusions that may apply to our risks. Some risks may not be insurable on commercially reasonable terms,
or at all. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Business
or economic disruptions or global health concerns could seriously harm our development efforts and increase our costs and expenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broad-based
business or economic disruptions could adversely affect our ongoing or planned research and development activities. For example, in December
2019, an outbreak of a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which
causes coronavirus disease (COVID-19) was reported to have surfaced in Wuhan, China, and has since spread to other regions and countries
worldwide. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Almost all U.S. states and many local
jurisdictions issued &ldquo;shelter-in-place&rdquo; orders, quarantines, executive orders and similar government orders, restrictions,
and recommendations for their residents to control the spread of COVID-19. Such orders, restrictions and recommendations, and the perception
that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed &ldquo;essential,&rdquo;
work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events, as well as volatility
in stock prices, among other effects. There is a risk that government actions will not be effective at containing COVID-19 or other infectious
diseases, and that government actions, including the orders and restrictions described above, that are intended to contain the spread
of COVID-19 will have a devastating negative impact on the world economy at large, in which case the risks to our operating results and
financial condition described herein would be elevated significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continued spread of COVID-19 or other global health matters, has impacted and may continue to impact our target patient populations as
well as the hospitals and clinical sites in which we conduct any of our clinical trials, which could lead to delays in completing enrollment
of our clinical trials. For instance, the COVID-19 outbreak may continue to impair our ability to recruit and retain patients and engage
principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in
their geography or due to prioritization of hospital resources toward the outbreak and restrictions on travel. Furthermore, some patients
may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede
patient movement or interrupt healthcare services. COVID-19 already has affected and may further negatively affect the operations of
third-party contract research organizations that we rely upon to carry out our discovery work, clinical trials or the operations of our
third-party manufacturers, which could result in delays or disruptions in the supply of our product candidates and the conduct of experiments
and studies. Any negative impact COVID-19 has to patient enrollment or treatment or the timing and execution of our preclinical studies
or clinical trials could cause costly delays to our development programs, which could adversely affect our ability to obtain regulatory
approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our business
and financial results. COVID-19 has also caused, and may continue to cause for an extended period, volatility in the global financial
markets and threatened a slowdown in the global economy, which would reduce our ability to access capital and could negatively affect
our liquidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our lab-based employees have returned to our labs with enhanced safety measures, our office-based employees continue to work primarily
from home, and we expect this to continue for an extended period. Furthermore, there has been a resurgence of COVID-19 cases, which could
prompt a reinstatement of &ldquo;shelter-in-place&rdquo; orders and restrictions at the state and local levels impacting our reentry
to the workplace and causing hospital and clinical sites to suspend our clinical trials or could deter patients from continuing to participate
in our trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Three vaccines for COVID-19 were granted Emergency
Use Authorization by the FDA in late 2020 and early 2021, and two were granted full authorization as of early January 2022. More are
likely to be authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials
to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain
materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global outbreak of COVID-19 continues to
rapidly evolve. The extent to which COVID-19 impacts our business, results of operations and financial condition will depend on future
developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions,
new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken in the United States and other
countries to contain COVID-19 or treat its impact, among others. We cannot presently predict the scope and severity of any potential
business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including the suppliers, clinical trial
sites, service providers, regulators and other third parties with whom we conduct business, were to experience prolonged business shutdowns
or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially
and negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to obtain and maintain
sufficient intellectual property protection for our drug candidates, or if the scope of the intellectual property protection is not sufficiently
broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize
our products may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in large part on our ability
to obtain and maintain patent protection in the United States and other countries with respect to our drug candidates and research programs.
We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries
and technologies that are important to our business. We own, or have licensed exclusive rights in, numerous patents, we have certain
patent applications pending, and we may seek additional patents in the future, in the United States and in other countries. Our pending
and future patent applications may not result in patents being issued which protect our drug candidates or their intended uses or which
effectively prevent others from commercializing competitive technologies, products or drug candidates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining and enforcing patents is expensive
and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce
patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will
fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although
we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development
output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers,
consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent
application is filed, thereby jeopardizing our ability to seek patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent position of pharmaceutical companies
generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation,
resulting in court decisions, including Supreme Court decisions, which increase uncertainties as to the ability to enforce patent rights
in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States,
or vice versa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, we may not be aware of all third-party
intellectual property rights potentially relating to our drug candidates or their intended uses, and as a result the impact of such third-party
intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party
intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions
are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether
we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for
patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights
are highly uncertain. Our patents or pending patent applications may be challenged in the courts or patent offices in the United States
and abroad. For example, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office,
or become involved in post-grant review procedures, oppositions, derivations, reexaminations or inter partes review proceedings, in the
United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges
may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration
of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing
and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates
are commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Issued patents covering our products and
product candidates could be found invalid or unenforceable if challenged in court or in administrative proceedings. We may not be able
to protect our trade secrets in court.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we initiate legal proceedings against a third-party
to enforce a patent covering one of our products or product candidates, should such a patent issue, the defendant could counterclaim
that the patent covering our product or product candidate is invalid or unenforceable. In patent litigation in the United States, defendant
counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to
meet any of several statutory requirements, including lack of novelty, obviousness, written description or non- enablement. Grounds for
an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material
to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination,
post-grant review, inter partes review and equivalent proceedings in foreign jurisdictions. An adverse determination in any of the foregoing
proceedings could result in the revocation or cancellation of, or amendment to, our patents in such a way that they no longer cover our
products or product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect
to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and
we were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability,
we could lose at least part, and perhaps all, of the patent protection on one or more of our products and product candidates. Such a
loss of patent protection could have a material adverse impact on our business.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, our trade secrets may otherwise
become known or be independently discovered by competitors. Competitors and other third parties could purchase our products and product
candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe,
misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop their own competitive
technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently
developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using
that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage
over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to
maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade
secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims challenging
the inventorship or ownership of the patents and other intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be subject to claims that former employees,
collaborators or other third parties have an ownership interest in the patents and intellectual property that we own or that we may own
or license in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who in fact develops intellectual property that we regard as our own or such assignments may not be self-executing or may
be breached. We could be subject to ownership disputes arising, for example, from conflicting obligations of employees, consultants or
others who are involved in developing our products or product candidates. Litigation may be necessary to defend against any claims challenging
inventorship or ownership. If we fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our reliance on third parties requires
us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be
misappropriated or disclosed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because we rely on third parties to manufacture
our product candidates, and because we collaborate with various organizations and academic institutions on the development of our product
candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into
confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements
or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary
information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as
trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the contractual provisions employed when
working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&rsquo;s discovery
of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect
on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, these agreements typically restrict
the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our
academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for
a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights
are controlled exclusively by us, although in some cases we may share these rights with other parties. Despite our efforts to protect
our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development
or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at
the time of publication. A competitor&rsquo;s discovery of our trade secrets would impair our competitive position and have an adverse
impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periodic maintenance fees, renewal fees, annuity
fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent
agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S.
governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during
the patent application process and after a patent has issued. There are situations in which non- compliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. The
terms of one or more licenses that we enter into the future may not provide us with the ability to maintain or prosecute patents in the
portfolio and must therefore rely on third parties to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with our obligations
in our intellectual property licenses from third parties, we could lose license rights that are important to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a party to intellectual property license
agreements, and we may enter into additional license agreements in the future. Our existing license agreements impose, and we expect
that our future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us.
If we fail to comply with these obligations, our current and future licensors may have the right to reduce the scope of our rights or
terminate these agreements, in which event we may not be able to develop and market any product that is covered by these agreements and
would adversely impact our existing collaboration agreements under which we have sublicensed such rights. Termination of this license
for failure to comply with such obligations or for other reasons, or reduction or elimination of our licensed rights under it or any
other license, may result in our having to negotiate new or reinstated licenses on less favorable terms or our not having sufficient
intellectual property rights to operate our business. The occurrence of such events could materially harm our business and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risks described elsewhere pertaining to our
intellectual property rights also apply to the intellectual property rights that we in-license, and any failure by us or our licensors
to obtain, maintain, defend and enforce these rights could have a material adverse effect on our business. In some cases, we do not have
control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide
input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the
steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may rely on trade secret and proprietary
know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business
and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to seeking patents for some of our
technology and drug candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information,
to maintain our competitive position. Elements of our drug candidates, including processes for their preparation and manufacture, may
involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade
secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees,
the employees of third parties with whom we share our facilities or third party consultants and vendors that we engage to perform research,
clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade
secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our
competitive position in our market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade secrets and know-how can be difficult to
protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations
to assign to us any inventions generated in the course of their employment. We and any third parties with whom we may, in the future,
share facilities with, will enter into written agreements that include confidentiality and intellectual property obligations to protect
each party&rsquo;s property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential
trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties
who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations,
contract manufacturers, consultants, advisors and other third parties. Despite these efforts, we cannot ensure that these agreements
will provide adequate protection for our trade secrets, know-how or other proprietary information, and any of these parties may breach
the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect
trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other
third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade
secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that consultants, contractors,
collaborators or employees apply technological information independently developed by them or by others to our drug candidates, disputes
may arise as to the proprietary rights in such information, which may not be resolved in our favor. With our consultants, contractors,
outside scientific collaborators, and employees who work with our confidential and proprietary technologies, we enter into agreements
that typically include invention assignment obligations. However, these consultants, contractors, collaborators, and employees may terminate
their relationship with us, and we cannot preclude them indefinitely from dealing with our competitors. If our trade secrets become known
to competitors with greater experience and financial resources, the competitors may copy or use our trade secrets and other proprietary
information in the advancement of their products, methods or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>In the future, we may need to obtain additional
licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which
may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may be required to license
technology from additional third parties to further develop or commercialize our drug candidates. Should we be required to obtain licenses
to any third-party technology, including any such patents required to manufacture, use or sell our drug candidates, such licenses may
not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop
or commercialize any of our drug candidates could cause us to abandon any related efforts, which could seriously harm our business and
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not identify relevant third-party
patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability
to develop and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot guarantee that any of our patent searches
or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are
complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the
United States and abroad that is relevant to or necessary for the commercialization of our drug candidates in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The scope of a patent claim is determined by
an interpretation of the law, the written disclosure in a patent and the patent&rsquo;s prosecution history. Our interpretation of the
relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products.
We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&rsquo;s
pending application will issue with claims of relevant scope. In addition, because patent applications can take many years to issue,
there may be currently pending applications unknown to us that may later result in issued patents upon which our drug candidates may
infringe. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect,
which may negatively impact our ability to develop and market our drug candidates. Our failure to identify and correctly interpret relevant
patents may negatively impact our ability to develop and market our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual property rights do not necessarily
address all potential threats to our competitive advantage.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The degree of future protection afforded by our
intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business
or permit us to maintain our competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">others
                                            may be able to make drug candidates that are similar to ours but that are not covered by
                                            the claims of the patents that we own or have exclusively licensed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">we
                                            or our licensors or future collaborators might not have been the first to make the inventions
                                            covered by the issued patent or pending patent application that we own or have exclusively
                                            licensed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">we
                                            or our licensors or future collaborators might not have been the first to file patent applications
                                            covering certain of our inventions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">others
                                            may independently develop similar or alternative technologies or duplicate any of our technologies
                                            without infringing our intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">it
                                            is possible that our pending patent applications will not lead to issued patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">issued
                                            patents that we own or have exclusively licensed may be held invalid or unenforceable, as
                                            a result of legal challenges by our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                            competitors might conduct research and development activities in countries where we do not
                                            have patent rights and then use the information learned from such activities to develop competitive
                                            products for sale in our major commercial markets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">we
                                            may not develop additional proprietary technologies that are patentable; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            patents of others may have an adverse effect on our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should any of these events occur, they could
significantly harm our business, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are sued for infringing intellectual
property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or
commercializing our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success depends, in part, on our
ability to develop, manufacture, market and sell our drug candidates without infringing the intellectual property and other proprietary
rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or
other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and
time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially
increase our operating expenses and reduce the resources available for development activities or any future sales, marketing or distribution
activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater
financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation
of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is a substantial amount of intellectual
property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or
other adversarial proceedings regarding intellectual property rights with respect to our drug candidates. Third parties may assert infringement
claims against us based on existing or future intellectual property rights. The pharmaceutical and biotechnology industries have produced
a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types
of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always
uniform. If we were sued for patent infringement, we would need to demonstrate that our drug candidates, products or methods either do
not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able
to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of
clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings,
we may incur substantial costs and the time and attention of our management, legal and scientific personnel could be diverted in pursuing
these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient
resources to bring these actions to a successful conclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are found to infringe a third party&rsquo;s
intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the
infringing drug candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the
infringing technology and continue developing, manufacturing or marketing the infringing drug candidate. However, we may not be able
to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be non-exclusive,
thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages,
including treble damages and attorneys&rsquo; fees if we are found to have willfully infringed a patent. A finding of infringement could
prevent us from commercializing our drug candidates, force us to cease some of our business operations, or require substantial investment
and/or time to alter our products, processes, methods, or other technologies, all of which could materially harm our business. Claims
that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may become involved in lawsuits to defend
or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competitors may infringe our patents, trademarks,
copyrights or other intellectual property. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation
of our intellectual property rights. Even if we detect such infringement or misappropriation, to counter infringement or unauthorized
use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our
management, legal and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims
against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable,
or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable,
in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk
that, even if the validity of such patents is upheld, the court will construe the patent claims narrowly or decide that we do not have
the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention.
An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties
or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive
products. Any of these occurrences could materially adversely affect our competitive business position, business prospects and financial
condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or
unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In
this case, we could ultimately be forced to cease use of such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we establish infringement, the court
may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not
be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could
also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock.
Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims,
which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation
and the diversion of the attention of our management, legal and scientific personnel could outweigh any benefit we receive as a result
of the proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because of the expense and uncertainty
of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the expense and uncertainty of litigation,
we may conclude that even if a third party is infringing our issued patents, any patents that may be issued as a result of our pending
or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or
action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent
course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to protect our intellectual
property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents are of national or regional effect, and
filing, prosecuting and defending patents on all of our drug candidates throughout the world would be prohibitively expensive. As such,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling
or importing products made using our inventions in and into the United States or other jurisdictions. Further, the legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing
of competing products in violation of our proprietary rights generally. In addition, certain developing countries, including China and
India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries,
we and our licensors and licensees may have limited remedies if patents are infringed or if we or our licensors or licensees are compelled
to grant a license to a third party, which could diminish the value of those patents. This could limit our potential revenue opportunities.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in patent law in the United States
and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As is the case with other pharmaceutical companies,
our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical
industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in
either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs. Patent reform
legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into
law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These
include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective
avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO
during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings,
including post-grant review, inter partes review, and derivation proceedings. After March 2013, under the Leahy-Smith Act, the United
States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor
to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse
effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. Supreme Court has ruled on several patent
cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of
patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making
bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability
to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent terms may be inadequate to protect
our competitive position on our drug candidates for an adequate amount of time.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent rights are of limited duration. Given
the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates
might expire before or shortly after such drug candidates are commercialized. Even if patents covering our drug candidates are obtained,
once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent term extension
based on a delay in obtaining FDA approval may be available in the United States. However, only a single patent can be extended for each
marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period
of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved.
Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple
patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail
to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent
term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right
to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent
expiration, and our revenue could be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Other Regulatory Matters
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if
we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any regulatory approvals that we receive for
our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require
a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication
guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates,
the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export
and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include
submissions of safety and other post-marketing information and reports, facility registration, as well as continued compliance with cGMPs
for manufacturing and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be
subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing
application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend
time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the
FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply
with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on
promoting products for uses or in patient populations that are not described in the product&rsquo;s approved uses (known as &ldquo;off-label
use&rdquo;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving
the internet and social media. Later discovery of previously unknown problems with our product candidates, including adverse events of
unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory
requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical
studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a risk evaluation and mitigation
strategy program. Other potential consequences include, among other things:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">restrictions
                                            on the marketing or manufacturing of our product candidates, withdrawal of the product from
                                            the market or voluntary or mandatory product recalls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">fines,
                                            warning letters or holds on clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">refusal
                                            by the FDA to approve pending applications or supplements to approved applications filed
                                            by us or suspension or revocation of license approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">product
                                            seizure or detention, or refusal to permit the import or export of our product candidates;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">injunctions
                                            or the imposition of civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA&rsquo;s and other regulatory authorities&rsquo;
policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our
product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
marketing approval that we may have obtained and we may not achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining regulatory approval
of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product
candidates in other jurisdictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining and maintaining regulatory approval
of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any
other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory
approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities
in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate prior to marketing in
those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different
from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted
in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States,
a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price
that we intend to charge for our products is also subject to approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also submit marketing applications in
other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates
with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign
regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction
of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable
marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates
will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with existing or future
health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal fines
or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws and
regulations could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively
affect our operating results and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulation of data processing is evolving as
federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security,
and the collection, use, disclosure and cross-border transfer of data. We and any collaborators may be subject to current, new, or modified
federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security).
In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data
breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the
Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information
could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties
(including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under
the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for
Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to significant civil,
criminal, and administrative liabilities or penalties if we knowingly obtain, use, or disclose individually identifiable health information
maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in June 2018, California enacted
the California Consumer Privacy Act of 2018, or CCPA, which went into effect on January 1, 2020. The CCPA gives California residents
the right to access and require deletion of their personal information, the right to opt out of certain personal information sharing,
and the right to detailed information about how their personal information is collected, used and shared. The CCPA provides civil penalties
for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although
the CCPA includes exemptions for certain clinical trials data, the law may increase our compliance costs and potential liability with
respect to other personal information we collect about California residents. The CCPA has prompted a wave of proposals for new federal
and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect
our business. Several foreign jurisdictions, including the European Union (EU), its member states, the United Kingdom, Japan and Australia,
among others, have adopted legislation and regulations that increase or change the requirements governing the collection, use, disclosure
and transfer of the personal information of individuals in these jurisdictions. These laws and regulations are complex and change frequently,
at times due to changes in political climate, and existing laws and regulations are subject to different and conflicting interpretations,
which adds to the complexity of processing personal data from these jurisdictions. Additionally, certain countries have passed or are
considering passing laws that require local data residency and/or restrict the international transfer of data. These laws have the potential
to increase costs of compliance, risks of noncompliance and penalties for noncompliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain international data protection laws, including
the EU&rsquo;s General Data Protection Regulation (GDPR) and EU member state implementing legislation, apply to health-related and other
personal information of individuals in the EU. These laws impose strict obligations on the ability to process health-related and other
personal information of individuals in the EU, including in relation to collection, use, disclosure and cross-border transfer of that
information. These include several requirements relating to the consent of the individuals to whom the personal information relates,
the information that companies must provide to individuals about how they collect, use and disclose personal information, individual
rights to access and delete their personal information, notification of data breaches to authorities and affected individuals, and the
security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European
Economic Area (EEA) such as the United States, which are not considered by the European Commission to provide an adequate level of data
protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data
from the EEA and Switzerland to other countries, including the United States, they are subject to legal challenges and uncertainty about
compliance with EU data protection laws remains. Such mechanisms may not be available or applicable with respect to the personal data
processing activities necessary to research, develop, and market our products and services. For example, ongoing legal challenges in
Europe to the mechanisms allowing companies to transfer personal data across national borders could result in further limitations on
the ability to engage in cross-border data transfers, particularly if governments are unable or unwilling to reach new or maintain existing
agreements that support such transfers. The GDPR allows EU member states to make additional laws and regulations further limiting the
processing of genetic, biometric, health data, or other personal data. Failure to comply with these laws, where applicable, can result
in the imposition of significant regulatory fines and penalties of up to the greater of &euro;20 million or 4% of annual global turnover
(revenue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compliance with U.S. and international data protection
laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and
disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations
could result in government enforcement actions (which could include significant civil, criminal or administrative penalties, fines or
sanctions), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical
trial subjects, employees and other individuals about whom we or our collaborators obtain personal information, as well as the providers
who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated
individuals&rsquo; privacy rights, failed to comply with data protection laws, or breached our contractual obligations related to security
or data privacy, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity
that could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be subject, directly or indirectly, to
federal and state healthcare fraud and abuse laws, false claims laws health information privacy and security laws, and other health care
laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we obtain FDA approval for any of our product
candidates and begin commercializing those products in the United States, our operations will be directly, or indirectly through our
prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without
limitation, the federal Anti-Kickback Statute, or Anti-Kickback Statute (AKS), the federal civil and criminal False Claims Act and Physician
Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs.
In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business.
The laws that will affect our operations include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            federal AKS, which prohibits, among other things, persons or entities from knowingly and
                                            willfully soliciting, receiving, offering or paying any remuneration (including any kickback,
                                            bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce,
                                            or in return for, either the referral of an individual, or the purchase, lease, order, arrangement,
                                            or recommendation of any good, facility, item or service for which payment may be made, in
                                            whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs.
                                            &ldquo;Remuneration&rdquo; has been interpreted broadly to include anything of value. A person
                                            or entity does not need to have actual knowledge of the AKS or specific intent to violate
                                            it to have committed a violation. In addition, the government may assert that a claim including
                                            items or services resulting from a violation of the AKS constitutes a false or fraudulent
                                            claim for purposes of the federal False Claims Act, or FCA, or federal civil money penalties.
                                            The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers
                                            on the one hand and prescribers, purchasers, and formulary managers on the other. There are
                                            a number of statutory exceptions and regulatory safe harbors protecting some common activities
                                            from prosecution The Health and Human Services Office of Inspector General (OIG) continues
                                            to make modifications to existing AKS safe harbors which may increase liability and risk
                                            as well as adversely impact sales relationships. On November 20, 2020, OIG issued the final
                                            rule for Safe Harbors under the Federal AKS. This new final rule creates additional safe
                                            harbors including ones pertaining to patient incentives. The final rule also removed safe
                                            harbor protections for rebates and other reductions in price paid by manufacturers to plan
                                            sponsors under Medicare Part D, either directly or through pharmacy benefit managers acting
                                            under contract with plan sponsors, unless the reduction in price is required by law. OIG
                                            is able to modify safe harbors as well as regulatory compliance requirements, which could
                                            impact our business adversely. If the removal of safe harbors for rebates takes effect, our
                                            ability to negotiate coverage and formulary placement for Part D plans may be affected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            federal civil and criminal false claims laws and civil monetary penalty laws, or CMP, including
                                            the FCA, which impose criminal and civil penalties against individuals or entities for, among
                                            other things: knowingly presenting, or causing to be presented, to the federal government,
                                            claims for payment that are false or fraudulent; knowingly making, using or causing to be
                                            made or used, a false statement of record material to a false or fraudulent claim or obligation
                                            to pay or transmit money or property to the federal government. Manufacturers can be held
                                            liable under the FCA even when they do not submit claims directly to government payors if
                                            they are deemed to &ldquo;cause&rdquo; the submission of false or fraudulent claims. The
                                            FCA also permits a private individual acting as a &ldquo;whistleblower&rdquo; to bring actions
                                            on behalf of the federal government alleging violations of the FCA and to share in any monetary
                                            recovery;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            beneficiary inducement provisions of the CMP Law, which prohibits, among other things, the
                                            offering or giving of remuneration, which includes, without limitation, any transfer of items
                                            or services for free or for less than fair market value (with limited exceptions), to a Medicare
                                            or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&rsquo;s
                                            selection of a particular supplier of items or services reimbursable by a federal or state
                                            governmental program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created
                                            new federal criminal statutes that prohibit a person from knowingly and willfully executing,
                                            or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by
                                            means of false or fraudulent pretenses, representations or promises, any of the money or
                                            property owned by, or under the custody or control of, any healthcare benefit program, regardless
                                            of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing
                                            or covering up by any trick or device a material fact or making any materially false, fictitious,
                                            or fraudulent statements or representations in connection with the delivery of, or payment
                                            for, healthcare benefits, items or services relating to healthcare matters; similar to the
                                            Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute
                                            or specific intent to violate it in order to have committed a violation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act of 2009,
                                            and their respective implementing regulations, which impose requirements on certain healthcare
                                            providers, health plans, and healthcare clearinghouses, known as covered entities, as well
                                            as their respective business associates, individuals and entities that perform services on
                                            their behalf that involve the use or disclosure of individually identifiable health information,
                                            relating to the privacy, security and transmission of individually identifiable health information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            U.S. federal transparency requirements under the Patient Protection and Affordable Care Act,
                                            as amended by the Health Care and Education Reconciliation Act, or collectively, ACA, including
                                            the provision commonly referred to as the Physician Payments Sunshine Act, which requires
                                            applicable manufacturers of drugs, devices, biologics and medical supplies for which payment
                                            is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with
                                            certain exceptions) to report annually to CMS information related to payments or other transfers
                                            of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists
                                            and chiropractors) and teaching hospitals, as well as ownership and investment interests
                                            held by the physicians described above and their immediate family members. Beginning in 2022,
                                            applicable manufacturers also will be required to report information regarding payments and
                                            transfers of value provided to physician assistants, nurse practitioners, clinical nurse
                                            specialists, certified nurse anesthetists, and certified nurse-midwives;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">federal
                                            government price reporting laws, which require us to calculate and report complex pricing
                                            metrics in an accurate and timely manner to government programs; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">federal
                                            consumer protection and unfair competition laws, which broadly regulate marketplace activities
                                            and activities that potentially harm consumers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, we are subject to state and foreign
equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may
apply regardless of the payer. Many U.S. states have adopted laws similar to the Anti-Kickback Statute and False Claims Act, and may
apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving
healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed
laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for
Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&rsquo;s Code on Interactions with Healthcare
Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price
disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply
with an applicable state law requirement, we could be subject to penalties. Finally, there are state and foreign laws governing the privacy
and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the breadth of these laws and the
narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could
be subject to challenge under one or more of such laws. Law enforcement authorities are increasingly focused on enforcing fraud and abuse
laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future
business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will
involve substantial costs. If our operations, including our arrangements with physicians and other healthcare providers, some of whom
may receive stock options as compensation for services provided, are found to be in violation of any of such laws or any other governmental
regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties,
damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring
of our operations, exclusion from participation in federal and state healthcare programs (such as Medicare and Medicaid), additional
reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations
of non-compliance with these laws, and individual imprisonment, any of which could adversely affect our ability to operate our business
and our financial results. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer
to incur significant legal expenses and divert management&rsquo;s attention from the operation of the business. Prohibitions or restrictions
on sales or withdrawal of future marketed products could materially affect business in an adverse way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to the U.S. Foreign Corrupt
Practices Act of 1977, as amended, or the FCPA, and other anti-corruption laws, as well as export control laws, import and customs laws,
trade and economic sanctions laws and other laws governing our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations are subject to anti-corruption
laws, including the FCPA, the U.S. domestic bribery statute contained in 18 &sect;201, the U.S. Travel Act, and other anti-corruption
laws that apply in countries where we may do business in the future. The Bribery Act, the FCPA and these other laws generally prohibit
us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited
payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business
advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery
offense. We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations,
and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject
us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge
of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international
operations might be subject or the manner in which existing laws might be administered or interpreted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will also be subject to other laws and regulations
governing our potential future international operations, including regulations administered by the governments of the United Kingdom
and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and
embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations,
collectively referred to as the Trade Control laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that we will be completely
effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements,
including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control
laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses,
which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation
of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by United Kingdom, United
States or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse
effect on the success of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to numerous environmental, health
and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal
of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological
materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials
and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting
from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.
We also could incur significant costs associated with civil or criminal fines and penalties. Furthermore, environmental laws and regulations
are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain
of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health
and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts.
Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we maintain workers&rsquo; compensation
insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials
or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future
laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also
may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial
condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Product liability lawsuits against us could
cause us to incur substantial liabilities and could limit our commercialization of any drug candidates that we may develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face an inherent risk of product liability
exposure related to the testing of our drug candidates in human clinical trials and will face an even greater risk if we commercially
sell any products that we may develop. If we cannot successfully defend ourselves against claims that our drug candidates or products
caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result
in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">delay
                                            or termination of clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">decreased
                                            demand for any drug candidates or products that we may develop;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">injury
                                            to our reputation and significant negative media attention;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">withdrawal
                                            of clinical trial subjects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">initiation
                                            of investigations by regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">significant
                                            costs to defend the related litigation and diversion of management&rsquo;s time and our resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">substantial
                                            monetary awards to study subjects or patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">product
                                            recalls, withdrawals or labeling, marketing or promotional restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">loss
                                            of revenue; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            inability to commercialize any products that we may develop.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, manufacturing defects, errors in
product distribution or storage processes, improper administration or application and known or unknown side effects of product usage
may result in liability claims against us or third parties with which we have relationships. These actions could include claims resulting
from acts by our collaborators, licensees and subcontractors over which we have little or no control. For example, our liability could
be sought by patients participating in clinical trials for potential therapeutic product candidates as a result of unexpected side effects,
improper product administration or the deterioration of a patient&rsquo;s condition, patient injury or even death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Criminal or civil proceedings might be filed
against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing any product
candidates or products that we develop alone or with collaborators. On occasion, large judgments have been awarded in class action lawsuits
based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that product candidates
or products we develop alone or with collaborators caused harm, we could incur substantial liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical development does not always fully characterize
the safety and efficacy profile of a new medicine, and it is always possible that a drug or biologic, even after regulatory approval,
may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval,
we may be exposed to substantial liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we will maintain product liability insurance
coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance
coverage as our drug candidates advance through clinical trials and if we successfully commercialize any products. Insurance coverage
is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy
any liability that may arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering and Ownership
of Our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There has been no public market for our
common stock and warrants prior to this offering, and an active market in which investors can resell their shares of our common stock
and warrants may not develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there has been no public
market for our common stock and warrants. We intend to file an application to list our shares of common stock under the symbol &ldquo;FLCT&rdquo;
and our warrants under the symbol &ldquo;FLCTW,&rdquo; both on the Nasdaq Capital Market. The closing of this offering is contingent
upon the successful listing of our common stock and warrants on the Nasdaq Capital Market. There is no guarantee that Nasdaq, or any
other exchange or quotation system, will permit our common stock and warrants to be listed and traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if our common stock and warrants are approved
for listing on Nasdaq, a liquid public market for our common stock and warrants may not develop. The initial public offering price for
our securities has been determined by negotiation between us and the underwriters based upon several factors, including prevailing market
conditions, our historical performance, estimates of our business potential and earnings prospects, and the market valuations of similar
companies. The price at which our securities are traded after this offering may decline below the initial public offering price, meaning
that you may experience a decrease in the value of your common stock and warrants regardless of our operating performance or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market price of our securities may
fluctuate, and you could lose all or part of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After this offering, the market price for our
securities is likely to be volatile, in part because our shares and warrants have not been traded publicly. In addition, the market price
of our securities may fluctuate significantly in response to several factors, most of which we cannot control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">actual
                                            or anticipated variations in our periodic operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">increases
                                            in market interest rates that lead investors of our common stock and warrants to demand a
                                            higher investment return;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">changes
                                            in earnings estimates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">changes
                                            in market valuations of similar companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">actions
                                            or announcements by our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">adverse
                                            market reaction to any increased indebtedness we may incur in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">additions
                                            or departures of key personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">actions
                                            by shareholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">speculation
                                            in the media, online forums, or investment community; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                            intentions and ability to maintain the listing of our common stock and warrants on Nasdaq.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The public offering price of our securities has
been determined by negotiations between us and the underwriters based upon many factors and may not be indicative of prices that will
prevail following the closing of this offering. Volatility in the market price of our securities may prevent investors from being able
to sell their securities at or above the initial public offering price. As a result, you may suffer a loss on your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to maintain a listing
of our common stock and warrants on Nasdaq.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming that our common stock and warrants are
listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&rsquo;s listing
requirements, or if we fail to meet any of Nasdaq&rsquo;s listing standards, our common stock and warrants may be delisted. In addition,
our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits
of such listing. A delisting of our common stock and warrants from Nasdaq may materially impair our shareholders&rsquo; ability to buy
and sell our common stock and warrants and could have an adverse effect on the market price of, and the efficiency of the trading market
for, our common stock and warrants. The delisting of our common stock and warrants could significantly impair our ability to raise capital
and the value of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have considerable discretion as to the
use of the net proceeds from this offering and we may use these proceeds in ways with which you may not agree. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the proceeds from this offering
for research, product development, general and administrative expenses and working capital, and general working capital and other corporate
purposes. However, we have considerable discretion in the application of the proceeds. Because of the number and variability of factors
that will determine our use of our net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
You must rely on the judgment of our management regarding the application of the net proceeds of this offering. The net proceeds may
be used for corporate or other purposes with which you do not agree or that do not improve our profitability or increase our share price.
The net proceeds from this offering may also be placed in investments that do not produce income or that lose value. Please see &ldquo;<I>Use
of Proceeds</I>&rdquo; below for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants may not have any value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants will be exercisable for five years
from the date of initial issuance at an initial exercise price equal to 100% of the public offering price per unit set forth on the cover
page of this prospectus. There can be no assurance that the market price of our shares of common stock will ever equal or exceed the
exercise price of the warrants. In the event that the stock price of our shares of common stock does not exceed the exercise price of
the warrants during the period when the warrants are exercisable, the warrants may not have any value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of warrants purchased in this offering
will have no rights as shareholders until such holders exercise their warrants and acquire our shares of common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until holders of the warrants purchased in this
offering acquire shares of common stock upon exercise thereof, such holders will have no rights with respect to the shares of common
stock underlying the warrants. Upon exercise of the warrants, the holders will be entitled to exercise the rights of a shareholder only
as to matters for which the record date occurs after the date they were entered in the register of members of the Company as a shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and substantial
dilution as a result of this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, our net tangible book value
was approximately $(870,735), or approximately $(0.20) per share. Since the effective price per share of our common stock being offered
in this offering is substantially higher than the net tangible book value per share of our common stock, you will suffer substantial
dilution with respect to the net tangible book value of the common stock included in the units that you purchase in this offering. Based
on the assumed public offering price of $6.25 per unit being sold in this offering, which is the midpoint of the estimated offering range
set forth on the cover page of this prospectus, and our net tangible book value per share as of March 31, 2022, and assuming no exercise
of the warrants being offered in this offering, if you purchase units in this offering, you will suffer immediate and substantial dilution
of $4.45 per share (or $4.26 per share if the underwriters exercise the over-allotment option to purchase additional shares of common
stock and warrants in full) with respect to the net tangible book value of the common stock included in the units. See the section titled
&ldquo;<I>Dilution</I>&rdquo; for a more detailed discussion of the dilution you will incur if you purchase securities in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A recent independent&nbsp;valuation&nbsp;of
our&nbsp;stock and recent stock purchase prices and stock option grant exercise prices are lower than the purchase price in this offering,
which means that our securities may be worth less than the purchase price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The per unit purchase price of our units in this
offering has been arbitrarily determined by us and the representative without regard to an independent&nbsp;valuation&nbsp;of the common&nbsp;stock
or warrants included in the units being offered in this offering. Although we have an independent valuation of our common stock as of
November 5, 2021, we have not obtained an independent appraisal opinion on the&nbsp;valuation&nbsp;of our units as of the date of this
offering. Accordingly, our units may have a value significantly less than the offering price, and our common stock and warrants included
in the units may never obtain a value equal to or greater than the offering price.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not expect to declare or pay dividends
in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not expect to declare or pay dividends
in the foreseeable future, as we anticipate that we will invest future earnings in the development and growth of our business. Therefore,
holders of our common stock included in the units being offered in this offering will not receive any return on their investment unless
they sell their securities, and holders may be unable to sell their securities on favorable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities industry analysts do not
publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our securities
could be negatively affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any trading market for our common stock and warrants
may be influenced in part by any research reports that securities industry analysts publish about us. We do not currently have and may
never obtain research coverage by securities industry analysts. If no securities industry analysts commence coverage of us, the market
price and market trading volume of our securities could be negatively affected. In the event we are covered by analysts, and one or more
of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues coverage of us, the market price and
market trading volume of our securities could be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future issuances of our common stock or
securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration of lock-up agreements that restrict
the issuance of new common stock or the trading of outstanding common stock, could cause the market price of our securities to decline
and would result in the dilution of your holdings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future issuances of our common stock or securities
convertible into, or exercisable or exchangeable for, our common stock, or the expiration of lock-up agreements that restrict the issuance
of new common stock or the trading of outstanding common stock, could cause the market price of our common stock to decline. We cannot
predict the effect, if any, of future issuances of our securities, or the future expirations of lock-up agreements, on the price of our
securities. In all events, future issuances of our securities would result in the dilution of your holdings. In addition, the perception
that new issuances of our securities could occur, or the perception that locked-up parties will sell their securities when the lock-ups
expire, could adversely affect the market price of our securities. In connection with this offering, we will enter into a lock-up agreement
that prevents us, subject to certain exceptions, from offering additional shares of capital stock for up to 180 days after the closing
of this offering, as further described in the section titled &ldquo;<I>Underwriting</I>.&rdquo; In addition to any adverse effects that
may arise upon the expiration of these lock-up agreements, the lock-up provisions in these agreements may be waived, at any time and
without notice. If the restrictions under the lock-up agreements are waived, our securities may become available for resale, subject
to applicable law, including without notice, which could reduce the market price for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future issuances of debt securities, which
would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of preferred stock, which could rank senior
to our common stock for the purposes of dividends and liquidating distributions, may adversely affect the level of return you may be
able to achieve from an investment in our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the future, we may attempt to increase our
capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of our debt securities, and lenders with respect
to other borrowings we may make, would receive distributions of our available assets prior to any distributions being made to holders
of our common stock. Moreover, if we issue preferred stock, the holders of such preferred stock could be entitled to preferences over
holders of common stock in respect of the payment of dividends and the payment of liquidating distributions. Because our decision to
issue debt or preferred stock in any future offering, or borrow money from lenders, will depend in part on market conditions and other
factors beyond our control, we cannot predict or estimate the amount, timing or nature of any such future offerings or borrowings. Holders
of our securities must bear the risk that any future offerings we conduct or borrowings we make may adversely affect the level of return,
if any, they may be able to achieve from an investment in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our securities become subject to the
penny stock rules, it would become more difficult to trade our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC has adopted rules that regulate broker-dealer
practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00,
other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation
systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange
or system. If we do not retain a listing on Nasdaq or another national securities exchange and if the price of our securities is less
than $5.00, our securities could be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny
stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In
addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules,
a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive
(i) the purchaser&rsquo;s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions
involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have
the effect of reducing the trading activity in the secondary market for our securities, and therefore shareholders may have difficulty
selling their securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will be subject to ongoing public reporting
requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, and our shareholders
could receive less information than they might expect to receive from more mature public companies. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the completion of this offering, we will
be required to publicly report on an ongoing basis as an &ldquo;emerging growth company&rdquo; (as defined in the JOBS Act) under the
reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth company, we may take advantage of certain
exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not emerging growth
companies, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">not
                                            being required to comply with the auditor attestation requirements of Section 404 of the
                                            Sarbanes-Oxley Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">being
                                            permitted to comply with reduced disclosure obligations regarding executive compensation
                                            in our periodic reports and proxy statements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">being
                                            exempt from the requirement to hold a non-binding advisory vote on executive compensation
                                            and shareholder approval of any golden parachute payments not previously approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Section 107 of the JOBS Act also
provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits
of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such
new or revised accounting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to take advantage of these reporting
exemptions until we are no longer an emerging growth company. We would remain an emerging growth company for up to five years, although
if the market value of our securities that is held by non-affiliates exceeds $700 million as of any June 30 before that time, we would
cease to be an emerging growth company as of the following December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because we will be subject to ongoing public
reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, our shareholders
could receive less information than they might expect to receive from more mature public companies. We cannot predict if investors will
find our securities less attractive if we elect to rely on these exemptions, or if taking advantage of these exemptions would result
in less active trading or more volatility in the price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A>CAUTIONARY STATEMENT
REGARDING FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains forward-looking statements
that are based on our management&rsquo;s beliefs and assumptions and on information currently available to us. All statements other than
statements of historical facts are forward-looking statements. The forward-looking statements are contained principally in, but not limited
to, the sections entitled &ldquo;<I>Prospectus Summary</I>,&rdquo; &ldquo;<I>Risk Factors</I>,&rdquo; &ldquo;<I>Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations</I>&rdquo; and &ldquo;<I>Business</I>.&rdquo; These statements relate to
future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity,
performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not
limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                            goals and strategies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                            future business development, financial condition and results of operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">expected
                                            changes in our revenue, costs or expenditures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">growth
                                            of and competition trends in our industry;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                            expectations regarding demand for, and market acceptance of, our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                            expectations regarding our relationships with investors, institutional funding partners and
                                            other parties with whom we collaborate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">our
                                            expectation regarding the use of proceeds from this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">fluctuations
                                            in general economic and business conditions in the markets in which we operate;&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">relevant
                                            government policies and regulations relating to our industry.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In some cases, you can identify forward-looking
statements by terms such as &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;intend,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
&ldquo;potential,&rdquo; &ldquo;project&rdquo; or &ldquo;continue&rdquo; or the negative of these terms or other comparable terminology.
These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.
Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under
the heading &ldquo;<I>Risk Factors</I>&rdquo; and elsewhere in this prospectus. If one or more of these risks or uncertainties occur,
or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected
by the forward-looking statements. No forward-looking statement is a guarantee of future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements made in this prospectus
relate only to events or information as of the date on which the statements are made in this prospectus. Although we will become a public
company after this offering and have ongoing disclosure obligations under United&nbsp;States federal securities laws, we do not intend
to update or otherwise revise the forward-looking statements in this prospectus, whether as a result of new information, future events
or&nbsp;otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A>USE OF PROCEEDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After deducting the estimated underwriters&rsquo;
discounts and commissions and offering expenses payable by us, we expect to receive net proceeds of approximately $[13,327,000] from
this offering (or approximately $[15,442,750] if the underwriters exercise the over-allotment option in full), based on an assumed public
offering price of $6.25 per unit, which is the midpoint of the estimated offering range set forth on the cover page of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to use the net proceeds of this offering
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">60%
                                            of the net proceeds (approximately $8.0&nbsp;million) for research and product development;
                                            and</P> </TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">40% of the net proceeds (approximately
                                            $5.3&nbsp;million) for general and administrative, working capital and other corporate purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of the 60% of the net proceeds we expect to dedicate
to research and product development, these expenditures will be split approximately equally between our two product candidates, FX-1610
and FX-7742 (or FX-9847 if FX-7742 fails safety studies), and will be used for pre-IND enabling studies and the preparation and filing
of the IND applications for these two product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing represents our current intentions
to use and allocate the net proceeds of this offering based upon our present plans and business conditions. Our management, however,
will have broad discretion in the way that we use the net proceeds of this offering. Pending the final application of the net proceeds
of this offering, we intend to invest the net proceeds of this offering in short-term, interest-bearing, investment-grade securities.
See &ldquo;<I>Risk Factors-Risks Related to This Offering and Ownership of Our Securities-We have considerable discretion
as to the use of the net proceeds from this offering and we may use these proceeds in ways with which you may not agree</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A>DIVIDEND POLICY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid cash dividends
on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business
and do not anticipate paying any cash dividends on our common stock in the near future. We may also enter into credit agreements or other
borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any future
determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition,
operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors
may deem relevant. See also &ldquo;<I>Risk Factors-Risks Related to This Offering and Ownership of Our Securities-We do not
expect to declare or pay dividends in the foreseeable future</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A>CAPITALIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our capitalization
as of March 31, 2022:&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">on an actual
                                            basis;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">on a pro forma basis to give effect
                                            to issuance of 42,519 shares of our common stock upon the conversion of outstanding loans
                                            provided by our Chairman;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">on a pro forma
                                            basis to give effect to the 9.08:1 reverse split that will be completed immediately prior
                                            the effective date of the registration statement of which this prospectus forms a part; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">on a pro forma
                                            as adjusted basis to reflect the pro forma adjustments as described above and the sale of
                                            [2,480,000] shares by us in this offering at an assumed price to the public of $6.25 per
                                            share, which is the midpoint of the estimated offering range set forth on the cover page
                                            of this prospectus, resulting in net proceeds to us of $13,327,000 after deducting (i) underwriter
                                            commissions of $1,520,000 and (ii) our estimated other offering expenses of $653,000 (assuming
                                            no exercise of the over-allotment option); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The pro forma information
below is illustrative only and our capitalization following the completion of this offering is subject to adjustment based on the initial
public offering price of our units and other terms of this offering determined at pricing. You should read this table together with our
financial statements and the related notes included elsewhere in this prospectus and the information under &ldquo;<I>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31, 2022:</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Actual</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Pro Forma As Adjusted</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; padding-bottom: 4pt; padding-left: 0.7pt">Cash</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">32,023</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">32,023</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">13,359,023</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.7pt">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.4pt">Due to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,203</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,203</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,203</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.4pt">Accrued Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-left: 0.125in; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt">&nbsp;&nbsp;&nbsp;Convertible Notes payable related party</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">128,224</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.7pt">Total debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">251,469</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">120,203</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">120,203</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.7pt">Stockholders&rsquo; equity (deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.4pt">Common stock, $0.0001 par value, 100,000,000 shares authorized, 4,455,999 shares
    issued and outstanding, actual, 4,498,518 shares issued and outstanding, pro forma, 6,978,518 shares issued and outstanding, pro
    forma as adjusted.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">698</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.4pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,199,324</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,330,586</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,657,338</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 8.4pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,070,505</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,070,505</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,070,505</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt">Total deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(870,735</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(739,469</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,587,531</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.7pt">Total capitalization</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(619,266</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(619,266</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12,707,734</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table above excludes the following shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,018,146
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2012 Plan (as defined below);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,117
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2022 Plan (as defined below);</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">729,874
                                            additional shares of common stock that are reserved for issuance under the 2022 Plan;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123,735
                                            shares of common stock issuable upon exercise of warrants issued to our Chairman;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">up
                                            to [2,480,000] shares of common stock issuable upon exercise of warrants included in the
                                            units being offered in this offering;</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">up
                                            to [4,960,000] shares of common stock issuable upon exercise of Additional Warrants issuable
                                            to Qualified Buyers pursuant to any adjustment in the dilutive issuance provision of the
                                            warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">up
                                            to [372,000] shares of common stock issuable upon the exercise of the representative&rsquo;s
                                            over-allotment option, including 372,000 shares of common stock issuable upon the exercise
                                            of warrants that may be issued as a result of exercise of the representative&rsquo;s over-allotment
                                            option;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">up
                                            to [372,000] shares of common stock issuable upon the exercise of warrants and/or [372,000]
                                            shares of common stock that may be issued as a result of exercise of the representative&rsquo;s
                                            over-allotment option; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">up
                                            to [198,400] shares of common stock issuable upon exercise of the representative&rsquo;s
                                            warrants issued in connection with this offering.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A>DILUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>As
described elsewhere in this prospectus, all share amounts and per share amounts set forth below have been presented on a retroactive
basis to reflect the reverse stock split of our outstanding shares of common stock at a ratio of one-for-nine and eight hundredths (1
for 9.08) which was implemented on [ &#8239;], 2022.</I></FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dilution in net tangible book value per share
to new investors in our securities, assuming no value is attributed to the related warrants, is the amount by which the offering price
paid by the purchasers of the shares of our common stock included in the units sold in this offering exceeds the pro forma net tangible
book value per share of common stock after this offering. Net tangible book value per share is determined at any date by subtracting
our total liabilities from the total book value of our tangible assets and dividing the difference by the number of shares of common
stock deemed to be outstanding at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net tangible book value of our common stock
as of March 31, 2022 was $(870,735), or approximately $(0.20) per share.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pro forma as adjusted net tangible book value
dilution per share included in each unit to new investors represents the difference between the amount per share included in each unit
paid by purchasers of our units in this offering and the pro forma as adjusted net tangible book value per share of our common stock
immediately after completion of this offering. Investors participating in this offering will incur immediate, substantial dilution. After
giving effect to our sale of [2,480,000] units of our common stock in this offering at an assumed initial public offering price of $6.25
per unit, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and after deducting
the estimated underwriting discounts and commissions and estimated offering expenses, and assuming no exercise of the warrants contained
in the units to be sold in this offering, our pro forma as adjusted net tangible book value as of March 31, 2022 would have been approximately
$[12,587,531], or approximately $[1.80] per share. This amount represents an immediate increase in pro forma as adjusted net tangible
book value of $[2.00] per share to existing shareholders and an immediate dilution in pro forma as adjusted net tangible book value of
$[4.45] per share to purchasers of our common stock in this offering, as illustrated in the following table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assumed public offering price per unit</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.25</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Historical net tangible book value per share as of March 31, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[(0.20</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase in pro forma as adjusted net tangible book value per share to existing stockholders</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[2.00</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro forma as-adjusted net tangible book value per share after this offering</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[1.80</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dilution per share to new investors purchasing shares in this offering</FONT></TD>
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;$</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[4.45</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the underwriters exercise their over-allotment
option in full, the pro forma as adjusted net tangible book value per share of our common stock, as adjusted to give effect to this offering,
would be $[1.99] per share, and the dilution in pro forma net tangible book value per share to new investors purchasing units in this
offering would be $[4.26] per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth, assuming the
sale of [2,480,000] shares of our common stock in this offering, as of March 31, 2022, after giving effect to a reverse share split effected
on [ ], 2022, at a ratio of 1 for 9.08, the total number of shares of common stock previously issued and sold by us to existing investors,
the total consideration paid for the foregoing and the average price per unit, before deducting estimated underwriter commissions and
offering expenses (assuming no exercise of the over-allotment option to purchase additional shares of common stock and warrants and assuming
no exercise of the representative&rsquo;s warrants), in each case payable by us. As the table shows, new investors purchasing shares
of our common stock in this offering may in certain circumstances pay an average price per share substantially higher than the average
price per share paid by our existing shareholders.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Average&nbsp;</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Per Share</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Existing shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,498,518</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">64.5</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,393,945</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">25.8</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">New investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,480,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,978,518</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,893,945</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.99</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table above excludes the following shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,018,146
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2012 Plan; &nbsp;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">96,117
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2022 Plan; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">42,519 total shares of common
                                            stock issuable upon the conversion of a convertible promissory note which we issued to our
                                            Chairman;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">729,874
                                            additional shares of common stock that are reserved for issuance under the 2022 Plan;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">123,735
                                            shares of common stock issuable upon exercise of warrants issued to our Chairman;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                            to [2,480,000] shares of common stock issuable upon exercise of warrants included in the
                                            units being offered in this offering; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">up
                                            to [4,960,000] shares of common stock issuable upon exercise of Additional Warrants issuable
                                            to Qualified Buyers pursuant to any adjustment in the dilutive issuance provision of the
                                            warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">up
                                            to[ 372,000] shares of common stock issuable upon the exercise of warrants and/or [372,000]
                                            shares of common stock that may be issued as a result of exercise of the representative&rsquo;s
                                            over-allotment option; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">up
                                            to [198,400] shares of common stock issuable upon exercise of the representative&rsquo;s
                                            warrants issued in connection with this offering.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that any outstanding options or
warrants are exercised, new options, restricted stock units or other securities are issued under our stock-based compensation plans,
or new shares of preferred stock are issued, or we issue additional shares of common stock or warrants in the future, there will be further
dilution to investors participating in this offering.</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_009"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL <BR>
CONDITION AND RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion and analysis summarizes
the significant factors affecting our operating results, financial condition, liquidity and cash flows of our company as of and for the
periods presented below. The following discussion and analysis should be read in conjunction with our financial statements and the related
notes thereto included elsewhere in this prospectus. The discussion contains forward-looking statements that are based on the beliefs
of management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially
from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and
elsewhere in this prospectus, particularly in the sections titled &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Statement Regarding
Forward-Looking Statements&rdquo;.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a preclinical oncology drug development
company focused on developing therapies targeting dormant and active cancer cells. During the financial reporting periods presented in
this prospectus, we have operated our business in two segments, as discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Our Felicitex Business Segment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Through
                                            our Felicitex business, we have designed and patented small molecules and related methods
                                            to selectively disrupt dormant cancer cells in a manner that is specific to the disease and
                                            tissue context. This approach is lethal to cancer cells that rely on deregulation of the
                                            cell cycle for survival and has been shown to lead to the reversal of acquired resistance
                                            mechanisms. Our drug candidates are intended to be effective across a broad range of solid
                                            tumors and hematological cancers. We are designing our drug candidates to work synergistically
                                            with most chemotherapy and targeted therapies to improve the overall efficacy of cancer treatment
                                            programs, the survival of patients and quality of life. We target a high unmet need in large
                                            oncology markets including such solid tumors as non-small cell lung cancer, or NSCLC, glioblastoma
                                            multiforme, or GBM, ovarian, prostate, colorectal, pancreatic cancers, and liquid tumors
                                            such as acute lymphoblastic leukemia, or ALL.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1pt"><I>Our TarMeta Segment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">TarMeta
                                            Biosciences, LLC was formed in 2016 by Dr. Felix Chapovsky and our Chairman, Marc Duey, to
                                            build a rapid and cost-effective drug discovery platform for small molecule inhibitors targeting
                                            cancer. TarMeta developed drug candidates for its own account and also entertained collaborative
                                            agreements to discover assets in association with other biotechnology firms. Both Felicitex
                                            and TarMeta were under the common control of our Chairman, Marc Duey. Felicitex expects that
                                            the establishment of a proprietary drug discovery platform will enable the expansion of its
                                            drug candidate pipeline, via simultaneous identification of novel targets and corresponding
                                            specific small molecule inhibitors, in a way that is faster than possible through other currently
                                            available methodologies.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1pt">In June 2019, Felicitex
entered into a collaboration with TarMeta pursuant to which Felicitex provided a library of small molecules for screening and TarMeta
utilized its platform to screen those molecules for specific oncology targets. Felicitex acquired TarMeta on December 30, 2021, to internalize
and secure the platform developed by TarMeta along with its technical and human resources. See &ldquo;<I>TarMeta Biosciences&rsquo; Drug
Development Platform - Combining Target With Phenotypic-Based Drug Discovery&rdquo; </I>for more information regarding the TarMeta discovery
platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1pt">We have a strong IP position
that is continuously growing. We have what we believe to be an efficient and cost-effective development strategy drawing on a network
of top-notch U.S.-based and international collaborators, each a recognized leader in their respective areas of expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date we have been reliant on our Chairman,
Marc Duey, to finance our operations. We expect to continue to incur operating losses and negative cash flows for the foreseeable future.
Until we are successful in our capital infusion efforts, and because the completion of such capital raising efforts, including a successful
conclusion to this offering, is not within our control, a substantial doubt exists about our ability to continue as a going concern for
a period of one year after the date of filing of the registration statement of which this prospectus is a part. Management continues
to address our liquidity position and will adjust spending as needed in order to preserve liquidity. Our future liquidity needs will
be determined primarily by the success of our operations with respect to the progression of our product candidates and key development
and regulatory events in the future. Potential sources of additional funding include: (1) pursuing collaboration, out-licensing and/or
partnering opportunities for our portfolio programs and product candidates with one or more third parties, (2) renegotiating third party
agreements, (3) securing additional debt financing and/or (4) selling equity securities. We cannot be sure that we will be successful
in any of these capital-raising efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also noted that companies in the pharmaceutical
industry have indicated that a greater number of their employees now work from home than was the case in past periods. We believe this
increase may be partially a result of the relatively new risk to office work from the COVID-19 pandemic, and that this trend may continue
due to the growing spread of the more contagious Omicron variant of the COVID-19 virus. In addition, the Company faces the ongoing risk
that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company&rsquo;s research and pre-clinical studies.
The effects of the ongoing coronavirus pandemic may also increase non-research related costs such as insurance premiums, increase the
demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key pre-clinical trial vendors
and suppliers of our pharmaceutical ingredients. The full extent to which the COVID-19 pandemic could impact drug development and research,
or impact the Company&rsquo;s suppliers and other commercial partners, will depend on future developments that cannot be predicted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional discussion, see &ldquo;<I>Impact
of COVID-19 Pandemic</I>&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. We have
incurred losses since our inception. As of March 31, 2022, we had an accumulated deficit of $7,070,505. As of March 31, 2022, we had
$48,574 in total assets with $870,735 of total deficit.&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July 23, 2021, we organized </FONT>UAB Felicitex Therapeutics, or UAB, a Lithuanian limited liability company. We organized UAB for the
purpose of applying for grants in Lithuania to pursue pre-clinical studies in Europe relating to our non-cancer therapies. To comply
with funding requirements under the government grant programs in Lithuania, our Chief Executive officer, Maria Vilenchik, is the sole
owner of UAB and, as such, we account for UAB as a variable interest entity, and we include UAB in our consolidated and combined financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2021, we acquired 100% of the
ownership interests in TarMeta Biosciences, LLC, or TarMeta, in exchange for 635,378 shares of our common stock. Our Chairman, Marc Duey,
had a controlling interest in both TarMeta and us prior to the acquisition. As a result of this ownership structure, we determined that
the TarMeta acquisition was a common control transaction under ASC Topic 805, <I>Business Combinations</I>, and we accounted for this
transaction at the carrying amount of the net assets acquired. As a result of our acquisition of TarMeta, our financial statements as
of and for the years ended December 31, 2021 and 2020 have been adjusted to include the financial information of TarMeta as both entities,
TarMeta and our company, were under common control during the presented time period. As a result of the business combination, TarMeta
ceased to exist as a separate legal entity.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Impact of COVID-19 Pandemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Starting in late 2019, a novel strain of&nbsp;the
coronavirus, or COVID-19, began to rapidly spread around the world and every state in the United&nbsp;States. At this time, there continues
to be significant volatility and uncertainty relating to the full extent to which the COVID-19&nbsp;pandemic and the various responses
to it will impact our business, operations and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Most states and cities have at various times
instituted quarantines, restrictions on travel, &ldquo;stay at home&rdquo; rules, social distancing measures and restrictions on the
types of businesses that could continue to operate, as well as guidance in response to the pandemic and the need to contain it. As a
result, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, including such authorities in Europe,
which could result in delays of reviews and approvals. While there have been no specific notices of delay from federal or foreign government
authorities, potential interruptions, delays, or changes to the operations of the FDA, or of any foreign authority with which we might
interact, might impact the approval of any applications we plan and will need to file in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As in many other industries, we believe that
the COVID-19 pandemic has weakened many oncology drug development companies and their suppliers. We believe that we have fully complied
with all state and local requirements relating to COVID-19. We have undertaken various measures in an effort to mitigate the spread of
COVID-19, including encouraging employees to work remotely if possible. However, we have not developed any further COVID-19 contingency
plans to address the potential challenges and risks presented by this pandemic. If we were to prepare such plans, there could be no assurance
that they would be effective in mitigating the effects of the COVID-19 virus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, w<FONT STYLE="font-family: Times New Roman, Times, Serif">e
are dependent upon certain contract manufacturers and suppliers and their ability to reliably and efficiently fulfill our orders is critical
to our business success. The COVID-19&nbsp;pandemic has impacted and may continue to impact certain of our manufacturers and suppliers.
As a result, we have faced and may continue to face delays or difficulty sourcing certain products, which could negatively affect our
business and financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The spread of COVID-19&nbsp;has also adversely
impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets.&nbsp;The
pandemic has resulted, and may continue to result, in a significant disruption of global financial markets, which may reduce our ability
to access capital in the future, which could negatively affect our liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the COVID-19&nbsp;pandemic does not continue
to slow and the spread of COVID-19&nbsp;is not contained, our business operations, including those of contract manufacturers, could be
further delayed or interrupted. We expect that government and health authorities may announce new or extend existing restrictions, which
could require us or our subcontractors to make further adjustments to our operations in order to comply with any such restrictions. We
or our subcontractors may also experience limitations in employee resources. In addition, our operations could be disrupted if any of
our employees or employees of our subcontractors were to be tested positive for having&nbsp;COVID-19, which could require quarantine
of some or all such employees or closure of our or their facilities for disinfection. The duration of any business disruption cannot
be reasonably estimated at this time but may materially affect our ability to operate our business and result in additional costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
extent to which the&nbsp;COVID-19&nbsp;pandemic&nbsp;may impact our results will depend on future developments, which are highly uncertain
and cannot be predicted as of the date of this prospectus, including the effectiveness of vaccines and other treatments for COVID-19,
the emergence of new strains of the virus and other new information that may emerge concerning the severity of the&nbsp;pandemic&nbsp;and
steps taken to contain the&nbsp;pandemic&nbsp;or treat its impact. Nevertheless, the pandemic and the current financial, economic and
capital markets environment, and future developments in the global supply chain and other areas present material uncertainty and risk
with respect to our performance, financial condition, results of operations and cash flows. </FONT>See also &ldquo;<I>Risk Factors</I>&rdquo;
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Principal Factors Affecting Our Financial
Performance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating results are primarily affected
by the following factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            ability to obtain regulatory approval to market product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">slow
                                            or delayed IND applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            timing, costs and results of clinical trials and other development activities versus expectations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            ability to manufacture products successfully;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">competition
                                            from products sold or being developed by other companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            price of, and demand for, Company products once approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">the
                                            ability to negotiate favorable licensing or other manufacturing and marketing agreements
                                            for its products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">patent
                                            reinforcement and prosecution; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">changes
                                            in laws or the regulatory environment affecting our company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Emerging Growth Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We qualify as an &ldquo;emerging growth company&rdquo;
under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so
long as we are an emerging growth company, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">have
                                            an auditor report on our internal controls over financial reporting pursuant to Section 404(b)
                                            of the Sarbanes-Oxley Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">comply
                                            with any requirement that may be adopted by the Public Company Accounting Oversight Board
                                            regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing
                                            additional information about the audit and the financial statements (i.e., an auditor discussion
                                            and analysis);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">submit
                                            certain executive compensation matters to shareholder advisory votes, such as &ldquo;say-on-pay&rdquo;
                                            and &ldquo;say-on-frequency;&rdquo; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">disclose
                                            certain executive compensation related items such as the correlation between executive compensation
                                            and performance and comparisons of the chief executive officer&rsquo;s compensation to median
                                            employee compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Section 107 of the JOBS Act also
provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits
of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such
new or revised accounting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will remain an emerging growth company for
up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed
$1.07 billion, (ii) the date that we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the Exchange Act,
which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business
day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible
debt during the preceding three year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Comparison of Three Months Ended March 31, 2022 and 2021</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our results of
operations for the three months ended March 31, 2022 and 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended<BR>
    March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; width: 52%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">164,935</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">133,846</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">31,089</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">23</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">519,747</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">153,058</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">366,689</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">240</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">684,682</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">286,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">397,778</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(684,682</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(286,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(397,778</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">PPP loan forgiveness</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,939</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,601</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,338</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">202</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Inducement loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(80,972</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,972</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-100</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total other expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,939</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(78,275</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55,338</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-71</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss before provision for income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(707,621</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(342,442</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Income tax expense (benefit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss and comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(707,621</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(342,442</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Less: Net loss of TarMeta Biosciences,
    LLC prior to acquisition by Felicitex Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(70,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">70,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net loss attributable to Felicitex
    Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(707,621</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(295,031</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(412,590</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">140</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>Revenues</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>Research and Development
Expenses</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Research and development
program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions. Our product
candidates are in various stages of development and significant additional expenditures will be required if we start clinical trials,
encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations and/or
bring our product candidates to market. The total cost of any particular clinical trial is dependent on a number of factors such as trial
design, length of the trial, number of clinical sites, number of patients and trial sponsorship. The process of obtaining and maintaining
regulatory approvals for new products is lengthy, expensive and uncertain. Because of the current stage of our product candidates, among
other factors, we are unable to reliably estimate the cost of completing our research and development programs or the timing for bringing
such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash
inflows are likely to commence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Research and development
activities are central to our business model. We expect that our research and development expenses will continue to increase substantially
for the foreseeable future and will comprise a larger percentage of our total expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table
sets forth the breakdown of research and development costs for each of our two segments for the years ending March 31, 2022 and 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Felicitex Therapeutics, Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">164,935</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">78,165</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">58.40</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">86,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">111.01</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">TarMeta Biosciences, LLC</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55,681</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">56.44</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(55,681</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">164,935</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">133,846</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">31,089</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23.23</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Research and development
expenses for the two segments increased 23%, or $31,089, to $164,935 for the three months ended March 31, 2022 compared to $133,846 for
the same period of the prior year. This increase was primarily due to increases in compensation, pre-clinical studies, and materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>General and Administrative
Expenses</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table
sets forth the breakdown of general and administrative expenses for each of our two segments for the years ending March 31, 2022 and
2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Felicitex Therapeutics, Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">519,747</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">138,591</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">90.50</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">381,156</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">275.02</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">TarMeta Biosciences, LLC</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.45</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(14,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-100.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">519,747</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">153,058</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">366,689</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">239.57</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">General and administrative
expenses consist of compensation, professional fees, patent licensing fee and the cost of filing patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">General and administrative
expenses for the two segments increased 239%, or $366,689 to $519,747 for the three months ended March 31, 2022 compared to approximately
$153,000 for the same period of the prior year. This increase was primarily due to increases in compensation expense and professional
fees for the filing of patents and conducting a financial statement audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>Other Income and
Expense</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Other income and expenses
decreased by approximately $55,000 primarily due to the inducement loss of $80,972 in the first quarter of 2021, which was partially
offset by interest expense of $23,000 in the first quarter of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>Net Earnings and
Losses</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net loss increased 140% from $295,031 for
the three months ended March 31, 2021 to&nbsp;net losses of $707,621 for the three months ended March 31, 2022. This increase was due
primarily to increases in both operating expenses and other expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Comparison of Years Ended December 31, 2021 and 2020</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our results of
operations for the years ended December 31, 2021 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended
    December 31,</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: 10pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">631,751</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">487,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">144,034</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">30</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">777,940</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">648,550</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">129,390</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0.375in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,409,691</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,136,267</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">273,424</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0.375in">Operating loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,409,691</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,136,267</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(273,424</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">137</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">PPP loan forgiveness</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,064</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,064</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(44,007</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,123</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,884</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Inducement loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(151,497</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(83,510</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67,987</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Gain on change in fair value of warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(46,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,687</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(51,075</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-1090</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0.375in">Total other expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219,348</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(117,901</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(101,447</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss before provision for income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,629,039</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,254,168</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(374,871</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax expense (benefit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss and comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,629,039</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,254,168</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(374,871</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: Net loss of TarMeta Biosciences,
    LLC prior to acquisition by Felicitex Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(277,526</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(535,725</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">258,199</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-48</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss attributable to Felicitex Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,351,513</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(718,443</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(633,070</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">88</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>Revenues</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>Research and Development
Expenses</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Research and development
program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions. Our product
candidates are in various stages of development and significant additional expenditures will be required if we start clinical trials,
encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations and/or
bring our product candidates to market. The total cost of any particular clinical trial is dependent on a number of factors such as trial
design, length of the trial, number of clinical sites, number of patients and trial sponsorship. The process of obtaining and maintaining
regulatory approvals for new products is lengthy, expensive and uncertain. Because of the current stage of our product candidates, among
other factors, we are unable to reliably estimate the cost of completing our research and development programs or the timing for bringing
such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash
inflows are likely to commence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Research and development
activities are central to our business model. We expect that our research and development expenses will continue to increase substantially
for the foreseeable future and will comprise a larger percentage of our total expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table
sets forth the breakdown of research and development costs for each of our two segments for the years ending December 31, 2021 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Felicitex Therapeutics, Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">402,382</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">63.69</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">212,440</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">43.56</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">189,942</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">89.41</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">TarMeta Biosciences, LLC</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">229,369</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36.31</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">275,277</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">56.44</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(45,908</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-16.68</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">631,751</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">487,717</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">144,034</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">29.53</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Research and development
expenses for Felicitex increased 89%, or $190,000, to $402,000 for the year ended December 31, 2021 compared to $212,000 for the year
ended December 31, 2020. This increase was primarily due to increases in compensation, pre-clinical studies, and materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Research and development
expenses for TarMeta decreased 17%, or $46,000, to $229,000 for the year ended December 31, 2021 compared to approximately $275,000 for
the year ended December 31, 2020. This decrease was primarily due to reduction in consulting fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>General and Administrative
Expenses</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table
sets forth the breakdown of general and administrative expenses for each of our two segments for the years ending December 31, 2021 and
2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Felicitex Therapeutics, Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">717,720</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">92.26</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">398,022</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">61.37</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">319,698</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">80.32</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">TarMeta Biosciences, LLC</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60,220</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.74</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">250,528</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38.63</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(190,308</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-75.96</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">777,940</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">648,550</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">129,390</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">19.95</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">General and administrative
expenses consist of compensation, professional fees, patent licensing fee and the cost of filing patent applications. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">General and administrative
expenses for Felicitex increased 80%, or $320,000, to $718,000 for the year ended December 31, 2021 compared to approximately $398,000
for the year ended December 31, 2020. This increase was primarily due to increases in compensation expense and professional fees for
the filing of patents and conducting a financial statement audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">General and administrative
expenses for TarMeta decreased 76%, or $190,000, to $60,000 for the year ended December 31, 2021 compared to approximately $251,000 for
the year ended December 31, 2020. This decrease was primarily due to reduction in management fee and depreciation expense related to
equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>Other Income and
Expense</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Other income and expense
consist of PPP loan forgiveness, other income from equipment rental, interest expense, inducement loss and loss on fair value of warrants.
Our other expenses increased $102,000 from approximately $118,000 in the year ended December 31, 2020 to $220,000 in the year ended December
31, 2021, or 105%. This increase was primarily due to inducement loss to convert debt into equity and loss on the change in fair value
of warrants. Our other income increased $22,000 from approximately $0 in the year ended December 31, 2020 to $22,000 in the year ended
December 31, 2021, or 500%. This increase/decrease was primarily due to forgiveness of PPP loan payable and increase in equipment rental
income.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I><U>Net Earnings and
Losses</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net loss increased 30%&nbsp;from approximately
$1.3 million for the year ended December 31, 2020 to&nbsp;net losses of approximately $1.6M for the year ended December 31, 2021. This
increase/decrease was due primarily to increases in both operating expenses and other expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, we had cash of $32,023.
To date, we have financed our operations primarily from loans and investments from our principal shareholder and Chairman, Mr. Marc Duey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is in the development stage and has
incurred losses and negative cash flows from operations. For the three months ended March 31, 2022 and 2021, the Company had a net loss
of approximately $700,000 and $300,000, respectively, and negative cash flows from operations of approximately $442,000 and $200,000,
respectively. Further, the Company had an accumulated deficit of $7,070,505 as of March 31, 2022, and $6,362,884 as of December 31, 2021.
Based on the current development plans for the Company&rsquo;s drug candidates and other operating requirements, existing cash and equivalents
are not sufficient to fund operations for the twelve months following the date of the registration statement of which this prospectus
is a part. We expect to incur losses over the next several years as we continue development of our technologies and product candidates,
manage our regulatory processes, initiate and continue clinical trials, and prepare for potential commercialization of products. To date,
we have been reliant on our Chairman, Marc Duey, and a small number of investors to finance our operations. From our inception through
March 31, 2022, we received funding of $5.0 million. This amount does not include a $200,000 grant received from the Massachusetts Life
Sciences Center in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until we are successful in our efforts for capital
infusion, which is not entirely within our control, a substantial doubt exists about our ability to continue as a going concern for a
period of one year after the date of filing of these financial statements. In addition, the ability of our principal shareholder to continue
to provide financial support is dependent on our ability to secure additional funding. Management continues to address our liquidity
position and will adjust spending as needed in order to preserve liquidity. Our future liquidity needs will be determined primarily by
the success of our operations with respect to the progression of our product candidates and key development and regulatory events in
the future. Potential sources of additional funding include: (1) pursuing collaboration, out-licensing and/or partnering opportunities
for our portfolio programs and product candidates with one or more third parties, (2) renegotiating third party agreements, (3) securing
additional debt financing and/or (4) selling equity securities. There can be no assurances that we will be successful in these efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to raise additional capital from various
potential sources, including equity and/or debt financings, grant funding, and strategic relationships. In addition, we have an engagement
with the representative to sell up to $15 million of our common stock and common stock warrants in this initial public offering, which
amount, if fully raised, would be sufficient to fund our operations for approximately 24 months. However, there can be no guarantee that
we will be able to successfully complete this initial public offering or otherwise raise the necessary capital on terms acceptable to
us, if at all. Should such financings be unsuccessful, we would be required to delay, scale back or eliminate some or all of our research
and development programs, which would likely have a material adverse effect on us and our consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the above factors, a substantial doubt
exists as to our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Loans to the Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 16, 2018, Marc Duey, our Chairman,
agreed to lend up to $550,000 to the Company on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey&rsquo;s option at a price per share of $ 2.29. On March 17, 2020, we issued 238,612 shares
of our common stock on Mr. Duey&rsquo;s conversion of approximately $502,000 in principal and $45,000 of accrued interest on loans under
the January 16, 2018 agreement. Mr. Duey also received warrants to purchase 47,722 additional shares of common stock as an incentive
to convert these loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2020, Mr. Duey entered into an additional
on-demand agreement to lend us up to $550,000 on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey&rsquo;s option at a price per share of $2.29. On March 17, 2021, we issued 232,473 shares
of common stock to Mr. Duey on conversion of $521,000 in principal and $27,823 of accrued interest on loans under the March 31, 2020
agreement. Additionally, the Company issued warrants that are exercisable into 46,495 shares of common stock within five years at an
exercise price of $2.36 per share as an incentive to convert these loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2021, Mr. Duey entered into an additional
on-demand agreement to lend us up to $550,000 on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey&rsquo;s option at a price per share of $2.29. On November 2, 2021, we issued 147,586 shares
of our common stock to Mr. Duey on conversion of $348,420 in principal on loans under the March 31, 2021 agreement. Additionally, the
Company issued warrants that are exercisable into 29,518 shares of common stock within five years at an exercise price of $2.36 per share
as an incentive to convert these loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2022, the total liability owed to
our Chairman, Marc Duey, for loans Mr. Duey made to us was $541,180 in principle plus $54,564 in accrued interest.&nbsp; On March 16,
2022, our board of directors authorized the conversion of the combined liability&nbsp;in the amount of $595,744 into 192,977 shares of
our common stock, effective as of March 16, 2022.&nbsp; The conversion price valuation was determined using&nbsp;an independent 409A
valuation. The Company has also entered into a convertible grid note with the Chairman with respect to additional advances that the Chairman
expects to make to the Company for general working capital purposes from now until additional funds are raised from investors. This grid
note carries interest at 12% per year, payable in one lump sum on the maturity date, matures on the one-year anniversary of the issuance
date and may be prepaid at any time, in whole or in part, without penalty. It may also be converted at any time, in the sum of any advances
and accrued interest at a price per share of $3.09.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, Mr. Duey had loaned to
us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has loaned to us an additional $408,000 under the grid note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, we received
loan proceeds in the amount of approximately $10 thousand under the Paycheck Protection Program, or PPP, which was established as part
of the Coronavirus Aid, Relief and Economic Security Act administered through the Small Business Administration, or SBA. The PPP provides
loans to qualifying businesses in amounts up to 2.5 times their average monthly payroll expenses and was designed to provide a direct
financial incentive for qualifying businesses to keep their workforce employed during the Coronavirus crisis. PPP loans are uncollateralized
and guaranteed by the SBA and are forgivable after a &ldquo;covered period&rdquo; (eight or twenty-four weeks) as long as the borrower
maintains its payroll levels and uses the loan proceeds for eligible expenses, including payroll, benefits, mortgage interest, rent and
utilities. The forgiveness amount will be reduced if the borrower terminates employees or reduces salaries and wages more than 25% during
the covered period. Any unforgiven portion is payable over two years if issued before, or 5 years if issued after, June 5, 2020 at an
interest rate of 1% with payments deferred until the SBA remits the borrower&rsquo;s loan forgiveness amount to the lender, or, if the
borrower does not apply for forgiveness, ten months after the end of the covered period. PPP loan terms provide for customary events
of default, including payment defaults, breaches of representations and warranties, and insolvency events and may be accelerated upon
the occurrence of one or more of these events of default. Additionally, PPP loan terms do not include prepayment penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We used all proceeds for purposes consistent
with the PPP requirements and met the conditions for forgiveness of the loan. On February 24, 2021, our loan was forgiven in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Summary of Cash Flow</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides detailed information
about our net cash flow for all financial statement periods presented in this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cash Flow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<BR>
    March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash flows used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(441,563</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(184,102</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash flows used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash flows provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">463,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,643</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,459</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cash, beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cash, end of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,896</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended
    December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash flows used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(888,237</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(978,481</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash flows used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(957</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash flows provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">860,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,010,267</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,993</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,829</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash, beginning of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,526</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash, end of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities was approximately
$442,000 for the three months ended March 31, 2022, as compared to net cash used in operating activities of $184,000 for the three months
ended March 31, 2021 which represents an approximate $257,000 increase in net cash used in operating activities&nbsp;including preparation
for the company&rsquo;s initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities was approximately
$888,000 for the year ended December 31, 2021, as compared to net cash used in operating activities of $978,000 for the year ended December
31, 2021 which represents an approximate $90,000 decrease in net cash used in operating activities&nbsp;which resulted from an increase
in accounts payable during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No cash was used investing activities for the
three months ended March 31, 2022 and 2021 respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in investing activities was approximately
$0 and $1,000 for the years ended December 31, 2021 and 2020 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities was
approximately $463,000 and $154,000 for the three months ended March 31, 2022 and 2021 respectively. For both these periods, net cash
provided by financing activities primarily consisted of loans made by our principal investor and chairman which were substantially converted
subsequently into common stock plus warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities was
approximately $860,000 and $1 million for the years ended December 31, 2021 and 2020, respectively. For both the years ended December
31, 2021 and 2020, net cash provided by financing activities consisted of loans made by our principal investor and chairman which were
substantially converted subsequently into common stock plus warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contractual Obligations</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On December 31, 2018, the Company entered
into an exclusive license Agreement with Ryvu Therapeutics S.A. (formerly &ldquo;Selvita S.A.&rdquo;), a Polish corporation for sole
responsibility and discretion of developing and commercializing certain compounds and products. The milestone payments to be paid to
Ryvu under the agreement were amended by agreement dated April 16, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the agreement, the Company
is obligated to make certain milestone and royalty payments to Ryvu. There were no royalty or milestone payments made to Ryvu during
the three months ended March 31, 2022 and 2021, or the years ended December 31, 2021 and 2020.</P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2014, the Company entered into a collaboration
and license agreement with Eurobio Scientific SA (formerly &ldquo;Diaxonhit&rdquo;), a French company, for the development and commercialization
of certain compounds developed and owned by Eurobio. The terms were amended by agreement on July 23, 2014 and on February 14, 2022. Under
the agreement, the Company must pay Eurobio an annual license fee for a certain number of years, certain milestone payments, and certain
royalties and sub-license payments on net sales of licensed compounds.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no royalty or sub-license payments
made to Eurobio during the three month periods ended March 31, 2022 and 2021 and the years ended December 31, 2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion relates to critical accounting policies for our company. The preparation of financial statements in conformity with
GAAP requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto,
and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant
to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition
and results of operation. Critical accounting policies are those that are most important to the portrayal of our financial condition
and results of operations and require management&rsquo;s difficult, subjective, or complex judgment, often as a result of the need to
make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates
are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting
the estimate may differ significantly from management&rsquo;s current judgments. We believe the following critical accounting policies
involve the most significant estimates and judgments used in the preparation of our financial statements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated and combined
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the consolidated and combined financial
statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors
including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic
conditions and trends and the assessment of the probable future outcome. Subjective and significant estimates include, but are not limited
to, the valuation of stock-based compensation,&nbsp;the valuation of warrant liability, expense recognition and accruals associated with
third party providers supporting pre-clinical studies and other research and development, and income tax asset realization. Actual results
could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of changes, if any, are reflected
in the consolidated and combined statements of operations in the period that they are determined.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Collaborative
Arrangements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope
of FASB ASC Topic 808, <I>Collaborative Arrangements</I> (&ldquo;ASC 808&rdquo;). For collaborative arrangements that contain multiple
elements, the Company determines which units of account are deemed to be within the scope of ASC 808 and which units of account are more
reflective of a vendor-customer relationship, and therefore are within the scope of ASC 606. For units of account that are accounted
for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting
literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of ASC 808,
the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated
with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are
the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities,
are recorded as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate. Milestone
payments are considered contingent liabilities and are recognized when the Company deems the milestone event to be probable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value Measurements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB
ASC Topic 820, <I>Fair Value Measurements and Disclosures</I>, defines fair value, establishes a framework for measuring fair value,
and expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair
value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that
market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
inputs reflect the Company&rsquo;s assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 - Valuations based on quoted prices for identical instruments in active markets.
                                            Since valuations are based on quoted prices that are readily and regularly available in an
                                            active market, valuation of these instruments does not entail a significant degree of judgment.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 - Valuations based on observable inputs other than quoted prices included in Level
                                            1, such as quoted prices for either similar instruments in active markets, identical or similar
                                            instruments in markets that are not active, or model-derived valuations whose inputs or significant
                                            value drivers are observable or can be corroborated by observable market data.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 - Valuations based on inputs that are unobservable. These valuations require significant
                                            judgment.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability of valuation techniques and observable inputs can vary and is affected by a wide variety of factors, including the type
of asset or liability, whether the asset or liability is new and not yet established in the marketplace, and other characteristics particular
to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market,
the determination of fair value requires more judgment. Those estimated values do not necessarily represent the amounts that may be ultimately
realized due to the occurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of valuations,
those estimated values may be materially higher or lower than the values that would have been used had a ready market for the assets
or liabilities existed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC
730-10. Research and development costs are charged to expense as incurred and include the cost of wages, equipment, materials, and laboratory
fees paid in conducting scientific research on potential drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of FASB ASC Topic 718<I>,
Compensation - Stock Based Compensation</I>. The Company expenses stock-based compensation to employees and non-employees over the requisite
service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of options granted using
the Black Scholes Merton model. The Company estimates when and if performance-based awards will be earned. If an award is not considered
probable of being earned, no amount of equity-based compensation expense is recognized. If the award is deemed probable of being earned,
related equity-based compensation expense is recorded. The fair value of an award ultimately expected to vest is recognized as an expense,
net of forfeitures, over the requisite service, which is generally the vesting period of the award. Options forfeitures are recorded
as they occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black Scholes Merton model requires the input of certain subjective assumptions and the application of judgment in determining the fair
value of the awards. The most significant assumptions and judgments include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            volatility - The expected price volatility is based on the historical volatilities
                                            of peer group companies as the Company does not have a sufficient trading history. Industry
                                            peers consist of several public companies in the bio-tech industry similar in size, stage
                                            of life cycle, and capital structure. The Company also blends in historical data on the volatility
                                            of its own equity, increasing in proportion as the period of historical data on the Company&rsquo;s
                                            data becomes more representative.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
                                            interest rate - The risk-free rate was determined based on yields of U.S. Treasury
                                            Bonds of comparable terms.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            dividend yield - The Company has not previously issued dividends and do not anticipate
                                            paying dividends in the foreseeable future. Therefore, we used a dividend rate of zero based
                                            on our expectation of additional dividends.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            term -The expected term of the options was estimated using the simplified method.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
shares issued to third parties for services provided are valued at fair value of the Company&rsquo;s shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrant
Liability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 0in">Warrants are accounted for
in accordance with the guidance contained in ASC 815-40-15-7D and 7F, under which the warrants do not meet the criteria for equity treatment
and must be recorded as liabilities. Accordingly, the Company classifies warrants as liabilities at their fair value and adjusts the
warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised,
and any change in fair value is recognized in the consolidated and combined statement of operations and comprehensive loss. The warrants
are valued using a Black Scholes model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recently
Adopted Accounting Pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2018, the FASB issued Accounting
Standard Update (&ldquo;ASU&rdquo;) No. 2018-18, <I>Collaborative Arrangements (Topic 808) </I>(&ldquo;ASU No. 2018-18&rdquo;). This
update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including
the alignment of unit of account guidance between the two topics. The Company early adopted ASU No. 2018-18 as of January 1, 2020. The
adoption of this update did not have a material effect on the Company&rsquo;s consolidated and combined financial statements, as there
were no collaborative arrangements that had identified performance obligations to customers.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04, <I>Earnings
Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives
and Hedging-Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40): Issuer&rsquo;s Accounting for Certain Modifications or Exchanges
of Freestanding Equity-Classified Written Call Options </I>(&ldquo;ASU 2021-04&rdquo;). The amendments in ASU 2021-04 provide guidance
to clarify and reduce diversity in an issuer&rsquo;s accounting for modifications or exchanges of freestanding equity-classified written
call options (for example, warrants) that remain equity classified after modification or exchange. The update is effective for all entities
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company does not believe
that the adoption of ASU No. 2021-04 has had a material effect on its consolidated and combined financial statements.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04, <I>Earnings
Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives
and Hedging-Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40): Issuer&rsquo;s Accounting for Certain Modifications or Exchanges
of Freestanding Equity-Classified Written Call Options </I>(&ldquo;ASU 2021-04&rdquo;). The amendments in ASU 2021-04 provide guidance
to clarify and reduce diversity in an issuer&rsquo;s accounting for modifications or exchanges of freestanding equity-classified written
call options (for example, warrants) that remain equity classified after modification or exchange. The update is effective for all entities
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has adopted the
amendment which did not have a material effect on its consolidated and combined financial statements.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU No. 2020-06,
<I>Debt - Debt with Conversion and Other Options</I> (Subtopic 470-20) and <I>Derivatives and Hedging - Contracts in Entity&rsquo;s
Own Equity</I> (Subtopic 815-40) (&ldquo;ASU No. 2020-06&rdquo;). ASU No. 2020-06 was issued to address issues identified as a result
of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics
of liabilities and equity. For convertible instruments, the FASB decided to reduce the number of accounting models for convertible debt
instruments and convertible preferred stock. In addition to eliminating certain accounting models, the FASB also decided to enhance information
transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. This update
is effective for public business entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal
year. For all other entities, this update is effective for fiscal years beginning after December 15, 2023, and interim periods within
those fiscal years. The Company adopted ASU No. 2021-04 which did not have a material effect on its consolidated and combined financial
statements.&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Accounting Pronouncements Not Yet Adopted</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02,
<I>Leases (Topic 842) as subsequently amended</I> (&ldquo;ASU No. 2016-02&rdquo;). ASU No. 2016-02 was issued to increase transparency
and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information
about leasing arrangements. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including
interim periods within those fiscal years, for public business entities, not-for-profit entities that has issued securities that are
traded, listed or quoted on an exchange or an over-the-counter market, and employee benefit plans that file financial statements with
the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2021, and
interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that the adoption of ASU No. 2021-04
will have a material effect on its consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,
<I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I> (&ldquo;ASU 2019-12&rdquo;), as part as part of its overall
simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness
of the information provided to users of financial statements. Amendments include removal of certain exceptions to the general principles
of ASC 740 and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based
on income. The update is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and
interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that the adoption of ASU No. 2021-04
will have a material effect on its consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Mission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
novel treatments for dormant cancers: targeting cancer resistance, metastasis, and relapse.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a preclinical oncology drug development company focused on developing treatments that target both dormant and proliferating cancers
to improve treatment effectiveness and long-term outcomes for the deadliest and most therapy resistant liquid and solid tumors - hematopoietic,
ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have designed and patented small molecules
and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. This
approach is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal
of acquired resistance mechanisms. Our drug candidates are intended to be effective across a broad range of solid tumors and hematological
cancers. We target a high unmet need in large oncology markets for liquid and solid tumors including, but not limited to, non-small cell
lung cancer, or NSCLC, glioblastoma multiforme, or GBM, ovarian, prostate, colorectal, pancreatic cancers, and acute lymphoblastic leukemia,
or ALL.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We
                                            have established a drug discovery platform that, we expect, will enable the expansion of
                                            our product candidate pipeline, via simultaneous identification of novel targets and corresponding
                                            specific small molecule inhibitors, in a way that is faster than through other currently
                                            available methodologies. We have a strong IP position that is continuously growing. We have
                                            a cost-effective development strategy drawing on a network of top-notch U.S.-based and international
                                            collaborators, each a recognized leader in their respective areas of expertise.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Developing
Novel Treatments for Dormant Cancers - Targeting Resistance, Metastasis, and Relapse</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an oncology drug development company, we are
at the forefront of one of the most promising areas&nbsp;- dormant&nbsp;cancers. These cancers are responsible for resistance,
metastasis, and recurrence. We are developing treatments that target both dormant and proliferating cancers and seek to improve the effectiveness
and long-term outcomes of treatments for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic,
colorectal, osteosarcoma, glioblastoma, and&nbsp;lung.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is well established that most tumors are heterogeneous.&nbsp;While some of the cancer cells divide rapidly others do not.&nbsp;They are
staying in the dormant state using this as a survival niche (or microanatomical structure in which dormant cancer cells are maintained
and protected from therapy).&nbsp;This is especially true of solid tumors in which the cells in the outer layers are proliferating, but
the inner volume comprises a large proportion of dormant&nbsp;cells, frequently as a result of inadequate nutrient supply and oxygen
deprivation (hypoxia).&nbsp;Hypoxic regions have long been known to be resistant to chemotherapy and radiation treatment. Tumor hypoxia,
as a target for chemotherapy, is currently an active area of research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
when cancer cells are under stress from either chemotherapy, anti-angiogenesis therapy, specific targeted treatment, or radiation, cancer
cells often go into dormant state, or G0, using&nbsp;it as a niche to hide. After the completion of treatment, these cells can mutate
and acquire resistance to the current treatment, begin growing and cause cancer recurrence. This process is called pharmacological quiescence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancer
cell dormancy is a major and as yet unaddressed mechanism of cancer survival and resistance. Until&nbsp;recently, the research efforts
have been focused on combating the inherently resistant cancer cells and the acquired resistance, which develops over time on exposure
to chemotherapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Felicitex
is developing new therapies that specifically target and kill cancer cells that use the dormancy state for their survival niche.&nbsp;Our
therapies&nbsp;are designed to target cancer cells that are either in the active growing or dormant states. While in the dormant state,
cancer cells are non-responsive to any existing treatments. Our treatment approach is designed to exhibit three therapeutically beneficial
outcomes: </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">first,
                                            kill dormant cancer cells depriving them of the ability to remain in their &ldquo;survival
                                            niche&rdquo; and thereby eliminating their ability to develop resistant phenotype;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">second,
                                            decrease their metastatic potential;&nbsp;and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">third,
                                            eliminate cancer recurrence.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Cellular
dormancy&nbsp;is a resting or &ldquo;sleeping&rdquo; state, denoted as the G0 state of the cell cycle. While being dormant,&nbsp;a cell
is in a reversible low metabolic state.&nbsp;As a consequence, both transcription and translation processes are slowed down and, therefore,
these cells&nbsp;are&nbsp;resistant to treatments by chemotherapeutics and targeted therapies, as well as immunotherapies.&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
challenge for durable cancer treatment is the extreme mechanistic diversity and adaptive capacity of tumors within and among cancer patients.
For any given drug, the benefit is increasingly limited by the subtype of disease and by the rapid emergence of drug resistance. Our
goal is to deliver a broadly active and durable therapy by targeting vulnerabilities in dormant cancer cells. The therapeutic strategy
is to use our molecules alone or in combinations with either marketed or clinical stage drugs, each combination representing a potential
opportunity for partnering or licensing. The goal is to increase the patient response rate, quality of life and overall survival rate
toward 100% and minimize the side effects and cost of treatments by reducing the overall amount of drug required and sequential rounds
of treatments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current internal pipeline
development activities are focused on the small molecules inhibitors of the dual specificity protein kinase, or DYRK, family of kinases.
Our molecules pre-clinically have shown a high level of synergy in combination with a spectrum of approved oncology therapeutics, including
drugs with significant patent protection (such as epidermal growth factor receptor inhibitors, or EGFR, inhibitors, Kirsten rat sarcoma
virus, or KRAS, inhibitors, mitogen-activated protein kinase, or MEK, inhibitors, and polo-like kinase 1, or PLK1, inhibitors), and drugs
with expiring patent protection, specifically the taxane family and vinca alkaloids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center; width: 50%"><IMG SRC="image_004.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: center; width: 50%"><IMG SRC="image_005.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our mechanism of action is unique. Our molecules
inhibit the activity of DYRK1 kinase and, therefore, deprive cancer cells of the ability to enter and stay in &ldquo;sleeping&rdquo;
or G0 state. Acquired resistance is a major issue for targeted therapies (mutant KRAS, MEK, EGFR inhibitors) including immuno-oncology
agents, and such resistance is being developed while cancer cells stay in G0 (dormancy) state. DYRK1 kinase maintains the ability of
cancer cells to stay in dormant, G0 state and this is a key driver of developing acquired resistance. Accordingly, we are developing
small molecule inhibitors specific and selective for DYRK1 kinase. Our FX-1610, FX-7742, and FX-9847 product candidates inhibit tumor
growth and metastasis in animal models.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TarMeta
Biosciences&rsquo; Drug Development Platform - Combining Target With Phenotypic-Based Drug Discovery</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our collaboration with TarMeta Biosciences, LLC, which we subsequently acquired in December 2021, we have been utilizing TarMeta&rsquo;s
drug discovery platform technology for the identification of target-specific small molecules for difficult to treat cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TarMeta&rsquo;s high throughput platform is based
on a combination of <FONT STYLE="background-color: white">an<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>affinity
selection mass spectrometry&nbsp;screening technique, a phenotypic based drug discovery technique, and a </FONT>cellular thermal shift
assay (CETSA)<FONT STYLE="background-color: white">. This unique combination </FONT>offers an approach to the drug discovery process
that is geared towards efficient and cost-effective pre-clinical drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TarMeta&rsquo;s drug discovery platform allows
not only for the assessment and quantification of target engagement under physiological conditions - without the need to modify
the compound or protein, but also for the investigation of a molecule&rsquo;s direct effects in a physiologic environment, providing
important information about the complex biological mechanisms that may be impacted upon treatment.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improving
R&amp;D productivity is among the greatest issues faced by the pharmaceutical industry. The ability to reduce the attrition rate of drug
candidates in clinical development not only addresses one of the greatest challenges in the pharmaceutical industry but also the greatest
opportunity. Given the extremely high costs of clinical development, an efficient and economical strategy for drug discovery would involve
a process that has the ability to reduce late-stage development failures. In addition, any cost-effective approach that could predict
toxicological liability or undesirable pharmacokinetic properties pre-clinically will also reduce downstream attrition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Target-Based
Drug Discovery</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
target-based drug discovery, the goal is to identify molecules that interact with a specific drug target known to be involved in a disease
process. This is typically done with high throughput screening, or HTS, which allows for the automated screening of large compound libraries
to determine if any molecules in the library bind the target of interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This &ldquo;hit&rdquo; molecule would then undergo
modification through medicinal chemistry which requires extensive time and resources in an effort to optimize the potency, selectivity,
and solubility properties of the compound.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant limitation of target-based approaches is that certain chemical properties critical to the development of a new drug can&rsquo;t
be assessed by compound library screening. For example, HTS cannot evaluate cytotoxicity, mechanisms of action, or solubility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phenotypic
Based Drug Discovery</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phenotypic
Based Drug Discovery is a more direct translational model of disease pathophysiology and is used to identify molecules that have the
ability to alter a cell&rsquo;s phenotype in a pre-specified manner, such as a specific mechanism of action of identified small molecules
culminating in cancer cell death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
contrast to target-based drug discovery, phenotypic screening does not rely on knowing the identity of the specific drug target or its
hypothetical role in the disease. This method allows for the investigation of a molecule&rsquo;s effects in a physiologic environment
and provides important information about the complex biological mechanisms that may be impacted upon treatment, thus allowing for elucidation
of a drug&rsquo;s mechanism of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
the understanding of cell signaling pathways affected by a drug could potentially decrease the number of clinical failures by identifying
factors contributing to unexpected activity, toxicities, and lack of efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
offering a robust methodology for identification of novel targets in a physiologic environment, the identification of a specific target,
i.e., the target deconvolution process, is considered to be a major limitation in the phenotypic based approach as it requires a &ldquo;reverse
engineering&rdquo; approach to identify the affected pathway and kinase target that can deliver false - positive results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Felicitex&rsquo;s
and TarMeta&rsquo;s Combined Approach for Drug Discovery</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TarMeta&rsquo;s novel, proprietary drug discovery
platform is able to generate high-quality drug candidates which are not only validated against specific therapeutic targets of high clinical
and commercial interest but also demonstrate mechanisms of action.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This coordinated platform combines a target,
phenotypic, and CETSA based approach in a cellular context to the drug discovery process, which offers distinct advantages to any of
these methods alone by providing information about the physicochemical, biochemical, and mechanistic properties of a molecule (solubility,
stability, cell permeability, mode of action).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TarMeta&rsquo;s platform methodology provides
the opportunity to advance drug discovery for Felicitex more quickly and efficiently with less upfront investment in medicinal chemistry
resources.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
this platform, we and TarMeta have identified to date eight small molecules (composed of two unique scaffolds) which have demonstrated
significant anti-tumor activity in non-small cell lung cancer. The molecules of interest are currently undergoing further testing by
Felicitex in additional cell-based assays. The acquisition of TarMeta by Felicitex Therapeutics permits Felicitex to pursue commercialization
of any discovered assets in a fashion that is not encumbered by licensing obligations including one-time payments and milestone payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>Acquisition of TarMeta Biosciences,
LLC and its Proprietary Drug Discovery Platform</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We closed our acquisition of TarMeta Biosciences,
LLC on December 30, 2021. Upon closing this acquisition, we acquired all of the intellectual property owned by TarMeta and all rights
of TarMeta in and to all third-party intellectual property. Through this acquisition, the proprietary platform developed by TarMeta enables
us to potentially identify novel cancer dormancy targets and, at the same time, identify and develop small molecule inhibitors that,
we believe, are potent and selective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Product Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a pipeline of therapeutic compounds focused primarily on oncology indications of high unmet medical need. The following chart summarizes
the status of the drug candidates in our current pipeline:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_007.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">Notes:
1. The column heading &ldquo;Preclinical&rdquo; refers to the Pre-IND enabling studies phase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;2.
FX 7742 and FX-9847 are both being developed for solid tumor indications including NSCLC and colorectal cancer.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>FX-1610</I>,
                                            a small molecule inhibitor of DYRK1A and DYRK1B kinases (not orally bioavailable), is our
                                            compound in development for pediatric leukemia - Acute Lymphoblastic Leukemia (ALL), an orphan
                                            drug indication of high unmet medical need. We expect to file an Investigational New Drug,
                                            or IND, application for FX-1610 during the first half of 2023.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>FX-7742
                                            </I>is our orally bioavailable compound being developed for solid tumor indications including
                                            NSCLC and colorectal cancer with mutations in EGFR (such as T790M) and KRAS (such as G12C).
                                            We are targeting an IND submission for FX-7742 for NSCLC and/or other solid tumors with EGFR
                                            and KRAS mutations in the first half of 2023.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>FX-9847
                                            is</I> our non-orally available small molecule compound being developed for solid tumor indications
                                            as a back-up to FX-7742, if FX-7742 fails safety testing. We expect to file an IND for FX-9847
                                            in the second half of 2023, if we replace FX-7742 with FX-9847, or otherwise in the first
                                            half of 2024 assuming the required funds are available for this IND at that time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We are currently developing the chemistry,
manufacturing and control (CMC) and formulation and qualifying the safety profiles of FX-1610, FX-7742 and FX-9847 to comply with current
regulatory requirements. We are undertaking the characterization and validation of these product candidates prior to entering non-human
primate (NHP) preclinical toxicology studies for further refining safety, formulation, dosing and scheduling regimen parameters in advance
of a Phase 1b/2a trials in humans. Assuming completion of the work described immediately above and following the completion of pre-IND
enabling studies which we would undertake assuming the successful completion of this offering (which we cannot guarantee), we expect
to file INDs for FX-1610 and FX-7742 in the first half of 2023. If we need to substitute FX-9847 for FX-7742, if FX-7742 fails safety
studies, we would expect to be ready to file an IND for FX-9847 in the fourth quarter of 2023.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In addition, we
are working to expand our pipeline through the identification and development of new dormancy targets.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Drug Development Timetable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to initiate IND enabling studies in the second quarter of 2022 with our two advanced drug candidates which are still in preclinical
development, FX-1610 and FX-7742, each of which has demonstrated significant anti-cancer efficacy in animal models with no toxicity.
Initial target indications for these candidates include ALL, NSCLC (EGFR and KRAS mutations).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our first-in-human
clinical trials (for FX-1610) are expected in the second quarter of 2023. We are executing our development strategy as rapidly and cost-effectively
as we can, drawing on a network of top-notch U.S.-based and international collaborators, each a recognized leader in their respective
areas of expertise. Current indications include liquid (e.g., ALL) and solid tumors such as non-small cell lung focusing on EGFR and
KRAS mutants. We plan to advance an additional program targeting solid tumors with our molecule FX-9847, in case FX-7742 fails further
safety studies and a back-up becomes necessary for that product candidate. We retain full, worldwide rights to our most advanced programs.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have expertise in targeting cancer pro-survival mechanisms and our drugs are synergistic with chemotherapy and targeted therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The example of
the synergistic mechanism of action of DYRK1 inhibitors when combined with G12C mutant KRAS targeted inhibitors is illustrated as follows:</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_008.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Results of our
animal preclinical efficacy study of our product candidate FX-1610 with respect to the treatment of Acute Lymphoblastic Leukemia is discussed
immediately below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_009.jpg" ALT="">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 1: FX-1610 was demonstrated to have efficacy
in B-ALL mice model (NSG mice with human B-ALL cells). Animals were treated with 40 mg/kg/day FX-1610, IP, for 2 weeks (yellow boxes).
Kaplan-Meier analysis of mice treated with FX-1610 was performed.&nbsp;Data were statistically significant as determined by log-rank
(Mantel-Cox) test <I>P</I>&nbsp;&lt; 0.01. Treatment of B-ALL with FX-1610 was well tolerated and had on-target effects in vivo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">100% survival of mice was observed 80 days after
termination of the treatment with our molecule FX-1610.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional descriptions of animal efficacy studies
conducted to demonstrate the efficacy of FX-7742 in synergy with KRAS G12C inhibitors are provided in the figure below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FX-7742 / NSCLC KRAS G12C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_010.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 2: To demonstrate efficacious combination
of FX-7742 and KRAS G12C inhibitor <I>in vivo</I>, xenograft H2122 model was performed. Mice were treated with daily oral dosing 20 mg/kg
FX-7742, AMG510, oral dosing 10mg/kg, combination of FX-7742 and AMG510 (KRAS G12C inhibitor) or vehicle solution the day after tumors
reached 200 mm<SUP>3</SUP>. AMG510 is a specific G12C KRAS inhibitor approved for lung cancer treatment. Importantly, there was clear
evidence of synergistic effect of the combination on the tumor growth compared to either agent alone. The results were statistically
significant, calculated P-values, P&lt;0.001. No toxicity was observed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional descriptions of animal efficacy studies
conducted to demonstrate the efficacy of FX-9847 in synergy with T790M EFGR inhibitors are provided in the figure below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FX-9847 / <FONT STYLE="font-family: Times New Roman, Times, Serif">NSCLC
EGFR T790M </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 46%"><IMG SRC="image_011.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="width: 10%"></TD>
  <TD STYLE="text-align: left; width: 44%; vertical-align: middle"><P STYLE="text-align: justify; font: italic 8pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"></P>

<P STYLE="font: italic 8pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify">Figure 3: In vivo efficacy of combination therapy
of FX-9847 and osimertinib (Tagrisso) in NSCLC H1975 xenograft model: (1) vehicle control (black line); (2) FX-9847 100 mg/kg IP BID (green
line); (3) Osimertinib IV, 2.5 mg/kg BIW (blue line); (4) FX-9847 100 mg/kg IP and Osimertinib 2.5 mg/kg IV (red line); tumors initial
volume was 200 mm<SUP>3</SUP>, n=10. Treatment continued for 3 weeks; no weight loss was observed. From day 21 to day 34 mice were monitored
for tumor re-growth.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt">&nbsp;</P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 3: A proof of concept, animal efficacy
experiment in NSCLC EGFR T790M mice xenograft model (H1975) was performed. The goal was to demonstrate the efficacy of the combination
therapy of osimertinib (Tagrisso) and FX-9847. The treatment resulted not only in significantly improved anti-tumor efficacy compared
with osimertinib monotherapy and complete disappearance of the tumors but also 12 days delays in tumor re-growth (<B>Figure 3</B>). Animals
were separated into 4 groups, 10 in each and were treated with either vehicle, FX-9847, osimertinib, or the combinations of osimertinib
and FX-9847. Animals were dosed for 21 days. On day 22, the treatment was stopped and tumors were continuously monitored for the following
12 days until the tumor size limit of 2000 mm<SUP>3</SUP> was reached and mice were sacrificed. Strikingly, there was a significant reduction
on the rate of tumor re-growth in the group treated with the combination of osimertinib and FX-9847. Only after 12 days tumors started
to increase in size indicating the significant reduction of the dormant cancer cell population as a consequence of the combination treatment.
The results were statistically significant, calculated P-values. No toxicity was observed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this preclinical animal study, we demonstrated
the eradication of the resistant dormant population of cancer cells via treatment with FX-9847.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional descriptions of animal efficacy studies
conducted to demonstrate the efficacy of FX-9847 in synergy with KRAS G12C inhibitors are provided in the figure below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FX-9847 / NSCLC KRAS G12C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center; width: 40%"><IMG SRC="image_012.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 32%; vertical-align: top"><P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt">&nbsp;</P>
                                                                <P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt"></P>

<P STYLE="font: italic 8pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify">Figure 4: In vivo efficacy of combination therapy
of FX-9847 and AZD8037 in PDX NSCLC xenograft model: (1) vehicle control (red line); (2) FX-9847 100 mg/kg IP BID (grey line); (3) AZD8037
(blue line); (4) FX-9847 100 mg/kg IP and AZD8037 (green line); tumors initial volume was 200 mm<SUP>3</SUP>, n=10.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt">&nbsp;</P>

</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 4: To demonstrate efficacious combination
of FX-9847 and KRAS G12C inhibitor <I>in vivo</I>, xenograft H358 model was performed. Mice were treated with daily intraperitoneal injections
of 80 mg/kg FX-9847, AZD8037 (KRAS G12C inhibitor), combination of FX-9847 and AZD8037 or PBS the day after tumors reached 200 mm<SUP>3</SUP>,
n=10. Importantly, there was clear evidence of synergistic effect of the combination on the tumor growth compared to either agent alone.
The results of this animal study were statistically significant, calculated P-values, P&lt;0.01. No toxicity was observed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">An example of the single agent efficacy of FX-9847
<I>in vivo</I> is demonstrated below, illustrating almost complete elimination of metastasis in prostate cancer model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_013.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 5: Demonstration of the efficacy of FX-9847 in reducing primary
and metastatic cancer growth and increasing overall survival in multiple animal models. Treatment with FX-9847 prevented metastasis in
70% of mice compared with the control. The data were statistically significant, n=12, P&lt;0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competitive
Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we can be a leader in the discovery, development, and commercialization of cancer dormancy targeted drugs due to the following
key strengths:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Therapies
                                            targeting dormant cancer cells</I>. </B>Our patented small molecules and related methods
                                            selectively disrupt cancer cells in the dormant state in a manner that is specific to the
                                            disease and tissue context. Our drug candidates are intended to be effective across a broad
                                            range of solid tumors and hematological cancers. We believe we can develop multiple profitable
                                            therapies based on the significant demand for such treatments.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 8pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Cost-effective
                                            and professional research, development and manufacturing strategy</I></B>. We have a network
                                            of top-notch U.S.-based and international collaborators, each a recognized leader in their
                                            respective areas of expertise. With our network, we are reducing the initial costs and accelerating
                                            the timeline toward the development and deployment of medical breakthrough therapies.</FONT></TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Seasoned
                                            and accomplished management</I></B>. Our management team members are leaders in drug discovery.
                                            Our officers have led drug discovery programs at Hoffman-La Roche and Memorial Sloan Kettering
                                            Cancer Center, authored 20 publications in peer reviewed journals, obtained several patents,
                                            have many years of pharmaceutical industry experience, and have experience collaborating
                                            with a broad array of biopharmaceutical companies. We also have more than two decades of
                                            business management experience in the pharmaceutical and biotechnology fields. Our board
                                            of directors includes the Head of Developmental Therapeutics at Memorial Sloan-Kettering
                                            Cancer Center and Professor of Pharmacology, Cell Biology and Medicine at Cornell University
                                            Medical School, and all of our directors have more than 20 years of experience in the biotechnology/pharmaceutical
                                            industries. Our officers and directors have advanced medical and business degrees from leading
                                            world universities.</FONT></TD>
</TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Growth
Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our
                                            mission is to rapidly advance our drug candidate pipeline and leverage our therapeutic platform
                                            to become a leader in the discovery, development, and commercialization of cancer dormancy
                                            targeted drugs. We intend to seek approval of our product candidates as first line cancer
                                            therapies to be used in combination with other first line cancer therapy drugs. The strategies
                                            of the Company to achieve this mission, while increasing value for our shareholders, will
                                            include the following steps:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B><I>Execute
                                            DYRK program advancement.</I></B> Preparation is underway to submit an Investigational New
                                            Drug application, or IND, for FX-1610, for ALL indications, followed by FX-7742, for solid
                                            tumor oncology indications, both in 2023. If FX-7742 fails safety studies, we intend to substitute
                                            FX-7742 with FX-9847, an advanced small molecule compound being developed for solid tumors
                                            indications although not orally bioavailable.</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><B><I>Implement
                                            accelerated breakthrough therapy regulatory strategy</I></B>. We believe that our assets
                                            are differentiated and represent potential breakthroughs in biopharmaceutical drug development.
                                            We will endeavor to seek breakthrough therapy designation (discussed below) with regulatory
                                            agencies, which could potentially lead to accelerated clinical development timelines. In
                                            addition, we will be seeking orphan drug indication for our FX-1610 drug candidate for pediatric
                                            leukemia - Acute Lymphoblastic Leukemia, which is identified as an orphan disease by the
                                            FDA.</TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pursue
                                            pipeline licensing opportunities</I></B>. We are pursuing opportunities with leading biopharmaceutical
                                            companies for the development and commercialization of our pipeline assets.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B><I>Leverage
                                            research, collaboration and IP licensing agreements with leading institutions</I></B>. We
                                            have, or have had, research and collaboration programs with several biotechnology companies.
                                            These collaborations allow us to accelerate our research program toward the discovery and
                                            development of breakthrough therapies based on the combined data and research resources of
                                            our program collaborators and our patented and potentially patentable cancer therapies. These
                                            companies include Ryvu, a Polish integrated drug research services company, and &Eacute;quilibre
                                            Biopharmaceuticals, a New York-based breakthrough neurological therapeutics company. Our
                                            collaboration partners also include Memorial Sloan Kettering Cancer Center, one of the world&rsquo;s
                                            premier cancer centers, and Whitehead Institute for Biomedical Research.</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to advance two discovery assets per
year into preclinical development. Assuming we raise the maximum amount in this offering (an assumption which we cannot guarantee), we
expect to have from the offering sufficient funds for approximately the next 20 to 24 months to advance two product candidates, FX-1610
and FX-7742 (or FX-9847), through the IND enabling stage and filing process up to Phase 1b/2a clinical studies. We expect that we will
need additional funds to begin Phase 1b/2a clinical studies for FX-1610 and FX-7742 (or FX-9847), to advance our prospective additional
pipeline product candidates into the pre-IND enabling stage in 2023 or 2024, and to begin to disclose additional discovery assets on
an annual basis. These additional funds will have to come from either additional securities offerings, whether public or private, debt
or equity, or loans or other financing mechanisms provided by third parties or existing investors. There can be no assurances, however,
that we will be successful in any future fund-raising efforts or that we will be able to raise these needed additional funds on terms
acceptable to us, if at all. Considering our history of net losses, our accumulated deficit as of March 31, 2022 of $7,070,505, the fact
that we have not, and will not in the foreseeable future, generate any revenues or operational cash flow and that we will need to raise
substantial amounts of additional funds to advance our development programs, and the substantial doubt about our ability to continue
as a going concern, we can provide no assurance that we will be successful in executing any of our growth strategies as listed above.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a strong IP position that is continuously
growing. Our patent portfolio includes licensed patents covering, <I>inter alia</I>, fundamental compositions of matter. In addition,
our portfolio includes three patent families covering combination treatments with major other types of inhibitors used as cancer therapeutics
(i.e., inhibitors of mitosis, EGFR inhibitors and MAPK pathway inhibitors), more specifically described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our team of scientific and pharmaceutical development
experts work with researchers at leading academic centers to advance breakthroughs to address the unmet need for effective and feasible
cancer treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in part on our ability to
obtain and maintain proprietary protection for our product candidates, as well as novel discoveries, product development technologies,
and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success also depends in part on our ability
to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy
is to conduct surveillance of third-party patents and patent application publications periodically while developing and maintaining protection
of our proprietary position by, among other methods, filing or in-licensing US and foreign patents and applications related to our technology,
inventions, and improvements that are important to the development and implementation of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on trademarks, trade secrets, know-how,
continuing technological innovation, confidentiality agreements, and invention assignment agreements to develop and maintain our proprietary
position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements
are designed to grant us ownership of technologies that are developed for us by our employees, consultants, or other third parties. We
seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and
physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures,
either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently
discovered by competitors.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Besides
the specific patents mentioned below under the section &ldquo;-<I>Patents</I>&rdquo; immediately below, we cannot be sure that
patents will be granted with respect to any of our pending patent applications pending now or filed by us in the future, nor can we be
absolutely certain to what degree, if any, our existing patents or any patents that may be granted to us in the future will be commercially
useful in protecting our commercial products and methods of using and manufacturing the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates FX-1610, FX-9847 and FX-5372
are protected by U.S. Patent No. 9,446,044 and its foreign counterparts (in major European counties, and Australia, Brazil, Canada, China,
Iceland, Israel, India, Japan, Hong Kong, Kazakhstan, Russia, and South Korea), which were licensed by us from EuroBio Scientific, as
described below. This patent family is projected to expire in August of 2032, except for certain European jurisdictions where it will
expire in August 2031.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidate FX-7742 is protected by
our U.S. Patent No. 10,577,365 and its foreign counterpart pending patent applications. This patent family is co-owned by us with Ryvu
Therapeutics S.A., (formerly, Selvita S.A.), and is subject to a world-wide exclusive license, granted to us by Ryvu Therapeutics S.A.,
as described below. This U.S. patent and its counterparts pending applications pending in Europe and Japan, if granted, are projected
to expire in December 2037.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our patent portfolio further includes three additional
patent families related to &ldquo;method of use&rdquo; cancer treatment of certain DYRK1 inhibitors in combination with major other classes
cancer therapeutics as listed in the table below:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: left"><FONT STYLE="font-size: 10pt"><B>Granted
    U.S. Patent No(s). or Pending U.S. Application No.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Primary
    Treatment</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Pending
    Foreign Counterparts or Pending PCT Application No.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">US Patent Nos. 10,322,128; 11,202,779 </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Combination of DYRK and EGFR inhibitors </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Australia, Canada, China, European Patent Office, Israel, Japan, Mexico,
    South Korea,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">US Patent No. 10,314,843</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Combination of DYRK and Mitosis inhibitors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Australia, Canada, China, European Patent Office, Israel, Japan, Mexico,
    South Korea</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">US App. No. 17/081,863 (unpublished)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Combination of DYRK and MAPK pathway inhibitors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">PCT/US22/13081<BR>
    (unpublished)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the above-referenced patents and
applications, our patent portfolio includes additional pending continuing US applications and their foreign counterpart applications
owned solely by Felicitex, with projected expiration dates in 2037 or later. We continuously file additional patent applications as needs
arise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our IP position includes two fundamental composition
of matter patents families and three methods of use patent families, as referenced below:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Composition
                                            of matter (several leads): &ldquo;DYRK1 Inhibitors and Uses Thereof&rdquo; WO2013/026806
                                            A1 (Exclusive license from EuroBio Scientific);</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Composition
                                            of matter (several leads): &ldquo;Derivatives of Quinoline as inhibitors of DYRK1A and/or
                                            DYRK1B kinases&rdquo; WO2018/119039 (Co-owned with, and exclusively licensed from, Selvita/Ryvu);</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Methods
                                            of use: &ldquo;Combinations for the treatment of cancer using quiescent cell targeting and
                                            inhibitors of mitosis&rdquo; WO2017/181087;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Methods
                                            of use: &ldquo;Combinations for the treatment of neoplasms using quiescent cell targeting
                                            with EGFR inhibitors&rdquo; WO2017/181075; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Methods
                                            of use: &ldquo;Combination cancer therapy with DYRK1 inhibitors and inhibitors of the RAS-RAF-MEK-ERK
                                            (MAPK) pathway&rdquo; PCT/US22/13081, unpublished, filed January 20, 2022.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Patent Term Extension and Patent Term Adjustment
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of a patent in most countries, including
the United States, is 20 years from the effective filing date of the patent assuming maintenance fees are paid, the patent has not been
terminally disclaimed, and the patent has not been invalidated through administrative and/or court proceedings. For pharmaceutical products,
however, the patent term covering the approved product, can be extended beyond the 20-year term if certain statutory and regulatory requirements
are satisfied. In the United States one way the patent term of a patent covering the approved pharmaceutical product can be extended
is under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit a patent term extension, or PTE, of up to five years, but not to exceed fourteen years from the date of receipt of
marketing approval, for a patent covering an approved product as compensation for effective patent term lost during product development
and the FDA regulatory review process. In the future, if and when our drug candidates are approved by the FDA or foreign regulatory authorities,
we will apply for patent term extensions on patents covering the approved products if the patents are eligible for such extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in the United States a patent term
may be extended by patent term adjustment, or PTA, which compensates a patent for administrative delays by the USPTO in examining and
granting a patent unless the patent is terminally disclaimed over an earlier filed patent. PTE and PTA extensions are not mutually exclusive;
however, extension under the PTA does not have any extension limits. We cannot, however, provide any assurance that any of our present
or future patents will be eligible for patent term adjustment or patent term extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Trademarks and Domain Names</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently own one pending U.S. trademark registration
application for the mark, FELICITEX, which will serve as a priority filing in other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We own the internet domain name, www.felicitex.com,
which is our primary operating website. The information contained in our websites is not incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Licensing and Research and Collaboration Agreements</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Eurobio Scientific (formerly Diaxonhit)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 16, 2014, we entered a license and collaboration
agreement with Diaxonhit. Under Amendment No. 1 to the agreement, dated July 21, 2014, we extended the agreement to October 31, 2014,
and increased our access to Diaxonhit&rsquo;s research materials. Under an Amendment No. 2 to the agreement, dated February 14, 2022,
the term of this agreement is perpetual, subject to continued payment of required annual license fee and milestone payments. Either party
may terminate the agreement upon 60 days&rsquo; notice if the other party is in material breach of the agreement, except that a shortened
period of 30 days shall apply in the event such a breach is solely due to a party&rsquo;s failure to pay an uncontested amount due under
the agreement. Below are the material terms and conditions of the agreement, as amended.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below are the material terms and conditions of
the agreement, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rights under DYRK 1B Eurobio Scientific Program
License and Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">We have been granted
an exclusive, royalty-bearing, sublicensable, and perpetual license for research, development, marketing and commercialization of oncology-treatment,
prevention and diagnostic products using Eurobio Scientific&rsquo;s DYRK 1B inhibitors covered by Eurobio Scientific patents and know-how,
as well as certain materials from Eurobio Scientific. It is our expectation that the patent which covers the intellectual property relating
to the DYRK1 1B inhibitors will expire in August 2032 worldwide, except Europe where the patents will expire in August 2031.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Obligations under DYRK 1B Eurobio Scientific
Program License and Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Down payment</U>: The Eurobio Scientific license
and collaboration agreement became effective upon the Company&rsquo;s completion of a proof of concept (POC) study using compound EHT
5372, subject to our providing evidence to Eurobio Scientific of an investment into our company of at least $1,000,000 and then making
a license investment payment to Eurobio Scientific of $300,000, within 30 days of the completion of the POC study, that is, by October
31, 2014. We completed and provided the POC to Eurobio Scientific as of October 31, 2014 and also completed the payment of the required
investment amount as of October 31, 2014. We have satisfied the Eurobio Scientific licensing terms to date.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>License maintenance fee</U>: We agreed to
pay Eurobio Scientific an annual license maintenance fee of $100,000, due within 30 days from the end of each 12 months period following
the effective date of the Eurobio Scientific license and collaboration agreement, which will be credited against the milestone payment
due during the years which a milestone is achieved by us. We have made these payments in a timely manner since the date of this agreement.
To date, we have paid Eurobio Scientific a total of $700,000 in annual license fee payments. Except for this amount and the initial $300,000
license investment payment, we have not made any other payments to Eurobio Scientific in connection with our agreement with them.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Milestone payments - Independent and
direct development and commercialization:</U> We agreed to pay a total of $11,500,000 milestone payments to Eurobio Scientific.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Milestone payments - Third-Party Sub-License
Payments:</U> We agreed to pay Eurobio Scientific between 5% and 10% of payments provided by third parties sub-licensees.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our obligation to pay royalties begins on the
date of the first commercial sale of a product in any country and territories in the world and shall remain in effect for at least ten
years or until the expiration of the last to expire valid claim of any patent rights covering the Product, whichever is longer. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Termination of DYRK 1B Eurobio Scientific
Program License and Collaboration Agreement.</U> The Eurobio Scientific license and collaboration agreement and Eurobio Scientific&rsquo;s
obligations may be terminated 90 days following POC study completion if the investment payment requirement described above is not fully
satisfied, or due to a material breach by either party, including failure by us to obtain a timely investment payment commitment, make
timely investment payments, meet product development and product commercialization timelines as specified in this agreement, make timely
payment of any amounts properly due and payable to Eurobio Scientific, provide Eurobio Scientific with timely prior notice if we do not
intend to undertake development of a product or do not obtain marketing authorizations and/or do not commercialize products in any country
in the world, or commit any other material breach of this agreement. If the license agreement is not previously terminated, the license
agreement will automatically terminate after the fifth anniversary of the expiration of the last patent covered under this agreement.
Upon termination of this agreement by Eurobio Scientific, the licenses and rights granted to us will terminate and revert to Eurobio
Scientific. Upon termination of this agreement by us, the collaboration shall terminate and we will complete an orderly wind-down, in
accordance with accepted pharmaceutical industry norms and ethical practices, of any then on-going studies for the product and other
activities for which we have responsibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Ryvu Therapeutics (formerly Selvita S.A.)
</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2014, we entered into a research
collaboration and licensing option agreement with Selvita S.A., a Polish corporation now known Ryvu Therapeutics S.A., or Ryvu, for a
co-discovery research collaboration to validate a certain kinase target of interest, &ldquo;DYRK1A/B&rdquo;, and to generate new kinase
inhibitor drug candidates with high selectivity towards such selected kinase target with defined activity in certain cancer subtypes,
with an initial focus, but not limited to, on pancreatic, colon, ovarian, lung and hematopoietic cancers based on targeting cancer cell
quiescence. The parties agreed to collaborate together during the research collaboration term, which means the period commencing upon
the effective date of this agreement and continuing through 27 consecutive months, comprised of (i) Collaboration Period I commencing
on the effective date of this agreement and continuing until December 31, 2015 and (ii) Collaboration Period II commencing on January
1, 2016 and continuing until December 31, 2016, to conduct a research collaboration in accordance with the applicable research plans
as outlined in the agreement to development one or more clinical candidates for filing of an IND to initiate clinical trials. The parties
further agreed to collaborate on one kinase research program, defined by the joint steering committee, or JSC, to be established by the
parties, which shall have the overall management of the research collaboration and the implementation of the research plan and review,
oversight, and decision-making responsibilities and authority, based on the expected target activity profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The collaboration aspect of our agreement with
Ryvu terminated with the end of Collaboration Period I on December 31, 2015 and we did not continue with Collaboration Period II.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Rights Under the Ryvu Research Collaboration
and Option Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been granted an exclusive option to obtain
certain intellectual property rights in and to certain program compounds resulting from the research program as selected by us upon option
exercise. The option(s) are exercisable during the period which we may exercise the option(s) and shall be perfected by the parties by
a separate exclusive license agreement as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On August 30, 2018, as a result of our activities
under our Period I research collaboration with Ryvu which focused on the program compound FX-7742, we exercised our option under this
research collaboration and option agreement for the Ryvu-owned program compound FX-7742.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ryvu has the right to assume all of our company&rsquo;s
rights for any clinical candidate for the one-time milestone payment to us at any time after the selection of a clinical candidate by
the JSC and prior to the initiation of GLP toxicology studies. In such case, Ryvu shall be free of all further obligations to us. &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obligations Under the Ryvu Research Collaboration
and Option Agreement</I></B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research Plan</U>. The parties agreed to establish
a joint project team (Project Team) made up of 3 members nominated by us and 3 members nominated by Ryvu to execute the research plan
to be developed by the Project Team describing the scientific hypothesis, identifying key scientific questions and target profiles and
outlining the experimental approach for the research program and to submit the research plan to the JSC for approval. Upon the JSC&rsquo;s
approval, the research plan will define the research program under the research collaboration. The goal of the research plan shall be
the validation of the DYRK1A kinase and DYRK1B kinase, which we refer to collectively, as the Target, and the identification and progression
of program compounds. Each party shall appoint an individual to act as project manager to oversee the activities and tasks allocated
to such party for the overall research collaboration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Initial scientific contributions</U>. We agreed
to contribute into the research collaboration its lead candidate compound (FX-1) and DYRK1B library (FX-2) for screening of compounds,
and to share structural data on the compounds within FX-2 and FX-1. Ryvu agreed to contribute into the research collaboration its library
of compounds (SEL141 Library) to be screened for the purpose of identifying a DYRK1A/DYRK1B inhibitor, and to share structural data on
the compounds within its SEL 141 Program. Ryvu agreed to disclose two chemical scaffolds around which Ryvu has built a library of DYRK1A/B
kinase inhibitors. The parties further agreed that all medicinal and general chemistry work and analysis will be conducted in accordance
with the research pan by Ryvu in its laboratories in Krakow, Poland, including the determination of physicochemical properties, PK, and
appropriate <I>in vitro</I> and <I>in vivo</I> ADMET properties, and all of the biology work and analysis will be conducted in accordance
with the research plan by us in our laboratories in Cambridge or Watertown, Massachusetts or as otherwise located by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Funding</U>. We agreed to the following allocation
of funding obligations during the research collaboration term. All required payments by the Company under this agreement have been made
in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">During
                                            Collaboration Period I, we must cover a certain percentage of our own internal and external
                                            costs and expenses incurred in connection with our activities under the research collaboration
                                            and a certain percentage of Ryvu&rsquo;s internal and external costs and expenses incurred
                                            in connection with its activities under the research collaboration. Ryvu must cover a certain
                                            percentage of its internal and external costs and expenses incurred in connection with its
                                            activities under the research collaboration. We agreed to pay Ryvu collectively up to a certain
                                            amount during Collaboration Period I to cover Ryvu&rsquo;s costs.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During
                                            Collaboration Period II, we were to cover a certain percentage of our own internal and external
                                            costs and expenses incurred in connection with our activities under the research collaboration
                                            and a certain percentage of Ryvu&rsquo;s internal and external costs and expenses incurred
                                            in connection with its activities under the research collaboration. Ryvu would not cover
                                            any costs of the research collaboration, unless Ryvu or both parties secured additional grant
                                            financing and mutually agreed to apply such funding to the research collaboration. We agreed
                                            to pay Ryvu up to a respective amount based on the actual cost and expenses of Ryvu during
                                            this period as evidenced and demonstrated by Ryvu. Because we terminated our collaboration
                                            with Ryvu at the end of Collaboration Period I and did not enter into Collaboration Period
                                            II, neither we nor Ryvu incurred any liabilities or obligations with respect to Collaboration
                                            Period II.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">While
                                            covering its own internal and external costs and expenses incurred in connection with its
                                            activities under the research collaboration during this period, Ryvu will spend collectively
                                            up to a certain amount during Collaboration Period I.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>License grants</U>. Both parties agreed to
grant each other for the research collaboration term a non-exclusive, royalty-free, fully-paid license in the treatment and remediation
of any human or veterinary oncologic disease, disorder or condition, or the Field, in the entire world, with the right to grant sublicenses
to affiliates and engaged persons solely as necessary or useful to conduct the activities under the research program. In addition, Ryvu
agreed to grant to us, for a period commencing upon the end of the research collaboration term and ending upon expiration of the option
period, a non-exclusive, royalty-free, fully-paid license in the Field in the entire world, with the right to grant sublicenses to its
affiliates and engaged persons solely as necessary or useful to undertake research and development of program compounds for the purpose
of evaluating such program compounds for a potential Option exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Exclusivity</U>. Upon the effective date of
the agreement and for a further period of 25 years after the expiration (but not early termination) of the term of this agreement, Ryvu
shall not pursue, neither alone nor in collaboration with or through third parties, the research, development, manufacturing (for development
or commercialization), or commercialization of any compounds or therapeutic products selective against the target. In case of early termination
of this agreement by either party without the exercise of an option by Felicitex, Ryvu&rsquo;s exclusivity obligation shall also terminate
upon the effective date of any such early termination without any further applicable restrictions and limitations for Ryvu. During the
term of this agreement, Felicitex shall not undertake, neither alone nor in collaboration with or through third parties, any work on
medicinal chemistry for compounds selective against the target outside the scope of this agreement. In the event that we exercise our
option, our company shall be entitled to continue its work on medicinal chemistry for compounds selective against the target either by
itself or through an affiliate, engaged person, other sublicensee or other third party, in each case in accordance with the provisions
of this agreement, and such continuing work of our company shall not be considered a breach of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Termination of the Ryvu research collaboration
and option agreement</U>. The Ryvu research collaboration and option agreement may be terminated (i) upon 60 days prior written notice
from us to Ryvu, (ii) upon 60 days prior written notice by either party is it deems that the research and development activities under
the research program are not progressing pursuant to the research plan and, in case that an adequate amendment of the research plan excess
the decision making authority of the JSC, the parties are unable to agree on an amendment of the research plan within 30 days following
the first notification of such assessment by the respective party to the JSC, (iii) by other material breaches of material obligations;
and (iv) by written notice immediately if the party becomes insolvent, bankrupt, or liquidated. Upon expiration or termination of the
agreement, the option period and all mutual licenses granted under this agreement shall terminate. A termination terminates all license
rights under this agreement, parties must wind down the research program, return materials owned by other party, and provide certain
other required information, documentation and materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exclusive License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On December 31, 2018, we entered into an exclusive
license agreement with Ryvu, or Exclusive License Agreement. Pursuant to the Exclusive License Agreement, Ryvu agreed to grant us exclusive,
worldwide licenses for the purpose of facilitating our research, development, manufacturing, and commercialization activities on all
optioned compounds (FX-7742) and products against the target in the Field in the entire world. In consideration of the license grants,
we agreed to pay Ryvu certain milestones, royalties, and/or participation payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The one issued U.S. patent and pending patent applications
in certain other jurisdictions included in this license are based on WO2018/119039 and are expected to expire in December of 2037 worldwide,
except in Europe, where they are expected to expire in December 2036. The patent WO2018/119039 relates to our product candidate FX-7742.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><U>Milestone, Participation and Royalty Payments</U>.
We agreed to make non-refundable, non-creditable development milestone payments and royalty payments to Ryvu in the course of internal
development, subject to adjustments in case that the Decreased Value Share (as defined in the agreement) or Adjusted Value Share (as
defined in the agreement) applies. We also agreed to make participation payments and royalty payments in course of external development.
Our agreement with Ryvu provides that milestone payments are to be made to Ryvu&nbsp;upon the achievement of certain liabilities the
first of which is participation in Phase II clinical trials.&nbsp; To date, we have not achieved any of the milestones obligated by our
agreement and no milestone payments have been made to Ryvu.&nbsp; The agreement with Ryvu does not provide for any payments to be received&nbsp;by
us from Ryvu. With respect to participation payments made to Ryvu, from inception in November 2014 through November 2017, we paid Ryvu
$461,727.16 in expense reimbursements. No other payments were made to Ryvu and no other contingent liability for payment exists as of
today.&nbsp; Ryvu has not paid us any participation payments nor does it owe us any. Royalty rates under our agreement with Ryvu are
in the low single digits and will be payable only with respect to product sales in the countries where the patents are issued.&nbsp;
As of the date hereof, patent applications in certain foreign jurisdictions are still pending and we have not paid, nor do we expect
to pay in the near future, any royalties to Ryvu. In the future, we may have milestone payments owed to Ryvu in an aggregate amount of
up to $11 million. The expiration date of these patents should they issue will vary by jurisdiction, and as indicated above, are expected
to expire in 2036 and 2037.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Term and Termination Provisions.</U> The term
of our license agreement with Ryvu continues in full force and effect until the expiration of all of our payment obligations under the
agreement. The agreement can be terminated earlier by either party if there is a material breach of the agreement by the other party
that has not been cured within 90 days after receipt by the breaching party of a notice of breach. Additionally, either party may terminate
the agreement immediately upon the insolvency of the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Amendment No.1 to Exclusive Licensing Agreement</U>.
On April 19, 2019, we entered into the Amendment No.1 to Exclusive Licensing Agreement with Ryvu, pursuant to which the milestone payment
terms were amended. Under this amendment, development stage milestones payment amounts were increased for second and subsequent indications
by between forty and fifty percent and sales milestone payments were increased by forty percent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Material Transfer Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our material transfer agreement with Whitehead
Institute for Biomedical Research, or Whitehead, dated January 29, 2020, until the agreement is terminated, all results of research using
our materials are Whitehead&rsquo;s property. However, for inventions that represent a new use of our materials, such inventions will
become the property of Whitehead and we will receive a free non-exclusive license to use the materials for research, development, manufacturing
and commercialization. In addition, we may exercise an option for an exclusive license to inventions that represent new uses of our material
if we agree to pay the royalty option rates of $10,000 for initial exercise of the option, a $500,000 milestone payment upon NDA approval
of a covered invention, and 0.25% royalties on sales of the invention. During the option period and negotiation period, Felicitex will
reimburse Whitehead for costs of prosecuting patents per requests of Felicitex. Under this agreement, we have agreed to provide Whitehead
with an amount of our product candidate FX-9847. Whitehead is under no specific performance obligations under this agreement. This agreement
does not include specific agreement term and termination provisions however, it allows us to terminate Whitehead&rsquo;s right to use
our materials at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our material transfer and royalty agreement
with Memorial Sloan Kettering Cancer Center, or MSK, dated December 4, 2020, MSK will own, and grant us a first option to license, inventions
or discoveries that are conceived and reduced to practice by MSK using our materials on the agreed-to research until the agreement is
terminated. Under this agreement, we have agreed to provide MSK with an amount of our product candidate FX 9847. MSK is under no specific
performance obligations under this agreement, but it has granted us the first right to negotiate any licenses to any MSK inventions utilizing
our material. This agreement terminates on December 4, 2022 unless earlier terminated by a party on 30 days prior written notice. This
agreement does not provide for any payments to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our material transfer agreement with &Eacute;quilibre
Biopharmaceuticals, or &Eacute;quilibre, dated February 15, 2021, &Eacute;quilibre agreed to assign us its entire right and interest
in the inventions or discoveries that are conceived and reduced to practice by &Eacute;quilibre using our materials on the agreed-to
research until the agreement is terminated. Under this agreement, we have agreed to provide Equilibre with amounts of our product candidates
FX-1610 and FX-9847. Equilibre is under no specific performance obligations under this agreement. This agreement does not include specific
agreement term and termination provisions, however, it allows us to terminate Equilibre&rsquo;s right to use our materials at any time.
This agreement does not provide for any payments to us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our material transfer agreement with UAB
DolceRx Baltika, or DolceRx, dated May 15, 2021, DolceRx agreed to assign us its entire right and interest in the inventions or discoveries
that are conceived and reduced to practice by DolceRx using our materials on the agreed-to research until the agreement is terminated.
Under this agreement, we have agreed to provide DolceRx with amounts of our product candidates FX-1610 and FX-7742. DolceRx is under
no specific performance obligations under this agreement. This agreement does not include specific agreement term and termination provisions,
however, it allows us to terminate DolceRx&rsquo;s right to use our materials at any time. This agreement does not provide for any payments
to us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our material transfer agreement with Barbara
Ann Karmanos Cancer Institute, or KCI, dated July 18, 2022, KCI agreed to assign us its entire right and interest in the inventions or
discoveries that are conceived and reduced to practice by KCI using our materials on the agreed-to research until the agreement is terminated.
Under this agreement, we have agreed to provide KCI with amounts of our product candidates to be specified by mutual agreement at a future
date. KCI is under no specific performance obligations under this agreement. This agreement does not include specific agreement term
and termination provisions, however, it allows us to terminate KCI&rsquo;s right to use our materials at any time. This agreement does
not provide for any payments to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are headquartered at 27 Strathmore Road, Natick,
MA 01760, with lab and office space of approximately 1,600 square feet. We lease this facility pursuant to a lease agreement entered
into with Kaufman Nir LLC and TarMeta Inc., dated March 15, 2017. Under the lease, we pay $10,500 basic monthly rent. The lease has a
24-month term and renews automatically for an additional 12-month term unless we give 90 days&rsquo; notice of termination or terminate
immediately with three months&rsquo; rent payments.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into a sublease agreement with
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quateris LLC, dated March 15, 2017, providing partial access
to our lab facilities for $2,500 per month. Felicitex does not receive or recognize any income from this sublease; it only reduces its
net monthly lease obligation by $2,500 dollars each month. Both the lease and sublease have a 24-month initial term and renew automatically
for additional 12-month terms unless we give 90 days&rsquo; notice of termination, or we terminate immediately with three months&rsquo;
rent payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into several collaboration agreements
with certain international pharmaceutical firms to assist in the continued development of our therapeutic assets. Subject to successfully
filing Investigational New Drug Applications (INDs), business development efforts will focus on further fostering such collaborations
and positive relations with candidate collaborators who typically pay upfront fees, milestone payments, and a significant fraction of
the ongoing development costs as product candidates move through the regulatory process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to receiving marketing approvals, we
expect to embark, alongside our partners, with development and commercialization activities by selecting and training focused sales and
marketing organizations in each geography of interest. We expect collaborators will manage most of the marketing tasks in geographies
outside of the United States, while we expect to play a role in the marketing of our products in the United States alongside our selected
partner. The marketing partner in the United States will be chosen in part on its proven ability to communicate and serve the needs of
the leading cancer centers and our target community-oncologists who are the most critical decision-makers in treating the patients for
which our dormancy/acquired resistance product candidates are being developed. We expect to enter into distribution and other marketing
arrangements with third parties for any of our product candidates that obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, for those products that obtain marketing
approval and are highly focused on a limited number of specific patients, we plan to build a limited mission-driven marketing and sales
management organization to create and implement marketing strategies for these selected products in the United States. We will oversee
and support our focused salesforce and assume marketing responsibilities with the assistance of contracted service organizations, including
developing educational initiatives concerning approved products and establishing relationships with key opinion leaders, researchers,
and practitioners in the relevant sub-specialties within oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The area of negotiating
collaboration and licensing deals in the pharmaceutical industry and in oncology, in particular, is very competitive. We expect to encounter
substantial competition from many firms vying for the attention of established pharmaceutical firms active in the cancer therapeutics
market. Other forms of competition are discussed immediately below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The biotechnology and pharmaceutical industries
are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. Our unique knowledge,
experience, and scientific resources provide us with competitive advantages. Nevertheless, the market for oncology products is very competitive,
changes rapidly, and welcomes the advent of new technology quickly.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are many companies with ambitions to address
the unmet needs in cancer. Many of these potential and current competitors enjoy significantly greater financial, technical and human
resources to bring to their business implementations to market. Also, selected early-stage companies may prove to be significant competitors
in the future as they may be successful in establishing collaborative arrangements with large and established companies and pursuing
activities that permit them to discover, develop, license, or commercialize products that address the same unmet needs we are pursuing.
Competition also presents itself in the form of cost-effective generics and non-drug-based treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, we are aware of several other drug
candidates developing potential treatments for some of the indications that we are targeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically, our competitors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD STYLE="text-align: justify"><U>HiberCell, Inc.:</U> This
                                            company is developing oncology drug candidates targeting the same mechanism of action that
                                            we are targeting, dormant cancer cells;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD STYLE="text-align: justify"><U>Biosplice Therapeutics, Inc.</U>:
                                            This company also has an oncology drug candidate, Cirtuvivint (SM08502), which is DYRK1A
                                            inhibitor in Phase I clinical trials; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt">&#9679;</TD><TD STYLE="text-align: justify">Brickell Biotech, Inc.: This
                                            company has a diabetes drug candidate, BBI-02, which is a DYRK1A inhibitor ready for Phase
                                            I clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial opportunity could be reduced or
eliminated if our competitors develop and commercialize drugs that are safer, more effective, more convenient, less expensive or with
a more favorable label than our current drug candidates or any other drug candidates that we may develop. Our competitors also may obtain
FDA or other regulatory approvals for their drug candidates more rapidly than we may obtain approval for our drug candidates, which could
result in our competitors establishing a strong market position before we are able to enter the market. Many of the companies against
which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Primary methods of treating
cancer patients include surgery, radiation, and drug therapy, including chemotherapy and hormone therapy. More recently, targeted drug
therapy has emerged as an important contributor to improved outcomes. Typically, a combination of approaches is deployed on a cancer
patient. If our product candidates are approved for marketing, they may compete with these approaches. To the extent our products, if
approved for marketing, work in combination, providing synergy with other products and creating opportunities for improved outcomes,
our products may be considered competitive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not own or operate, and currently have
no plans to establish, any manufacturing facilities. We expect to rely on third parties for the manufacture of our drug candidates undergoing
preclinical and clinical testing, as well as for manufacture of any drugs that we may commercialize.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should our product candidates receive marketing
approval, we expect to rely on contracted commercial manufacturers with established track records for quality and compliance. All of
our drug candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry
appears amenable to scale up and does not currently require unusual equipment in the manufacturing process. We expect to continue to
develop product candidates that can be produced cost-effectively at contract manufacturing facilities. We generally expect to rely on
third parties to manufacture companion diagnostics for our products, which are assays or tests to identify an appropriate patient population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, we have two
full-time employees and one part-time employee. &nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of our employees is represented by labor
unions, and we believe that we have an excellent relationship with our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may become involved in
various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties,
and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of
any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Government authorities in the United States at
the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture,
quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring
and reporting, marketing and export and import of drug products. Generally, before a new drug can be marketed, considerable data demonstrating
its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review,
and approved by the regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In the United States,
the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. Drugs also are
subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent
compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and
financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval
process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions,
the FDA&rsquo;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product
recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals
of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have
a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Any of our future drug
candidates must be approved by the FDA through an NDA process before they may be legally marketed in the United States. The process generally
involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Completion
                                            of extensive preclinical studies in accordance with applicable regulations, including studies
                                            conducted in accordance with good laboratory practice, or GLP, requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Submission
                                            to the FDA of an IND, which must become effective before human clinical trials may begin;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Approval
                                            by an independent institutional review board, or IRB, or ethics committee at each clinical
                                            trial site before each trial may be initiated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Performance
                                            of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
                                            good clinical practice, or GCP, requirements and other clinical trial-related regulations
                                            to establish the safety and efficacy of the investigational product for each proposed indication;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Submission
                                            to the FDA of an NDA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">A
                                            determination by the FDA within 60 days of its receipt of an NDA to accept the filing for
                                            review;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Satisfactory
                                            completion of a FDA pre-approval inspection of the manufacturing facility or facilities where
                                            the drug will be produced to assess compliance with current good manufacturing practices,
                                            or cGMP, requirements to assure that the facilities, methods and controls are adequate to
                                            preserve the drug&rsquo;s identity, strength, quality and purity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Potential
                                            FDA audit of the preclinical and/or clinical trial sites that generated the data in support
                                            of the NDA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Payment
                                            of user fees and FDA review and approval of the NDA, including consideration of the views
                                            of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the
                                            United States; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Compliance
                                            with any post-approval requirements, including the potential requirement to implement a Risk
                                            Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval
                                            studies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The data required to
support an NDA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and
approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future
drug candidates will be granted on a timely basis, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Preclinical Studies
and IND</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The preclinical developmental
stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity
in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with
manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as
part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become
effective before human clinical trials may begin. Preclinical studies include laboratory evaluation of product chemistry and formulation,
as well as&nbsp;<I>in vitro&nbsp;</I>and animal studies to assess the potential for adverse events and in some cases to establish a rationale
for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations
for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information,
analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of
an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after
the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises
concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may
not result in the FDA allowing clinical trials to commence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Clinical Trials</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The clinical stage of
development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified
investigators, generally physicians not employed by or under the trial sponsor&rsquo;s control, in accordance with GCP requirements,
which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial.
Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures,
subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol,
and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must
be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the
informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical
trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results
to public registries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A sponsor who wishes
to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under
an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in
support of an NDA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial
was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Clinical trials generally
are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap. In some cases, drug approvals may also
require a post-approval clinical study, referred to as a Phase 4 study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Phase
                                            1 clinical trials generally involve a small number of healthy volunteers or disease-affected
                                            patients who are initially exposed to a single dose and then multiple doses of the drug candidate.
                                            The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action,
                                            side effect tolerability and safety of the drug candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Phase
                                            2 clinical trials involve studies in disease-affected patients to determine the dose required
                                            to produce the desired benefits. At the same time, safety and further PK and PD information
                                            is collected, possible adverse effects and safety risks are identified, and a preliminary
                                            evaluation of efficacy is conducted.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Phase
                                            3 clinical trials generally involve a large number of patients at multiple sites and are
                                            designed to provide the data necessary to demonstrate the effectiveness of the product for
                                            its intended use, its safety in use and to establish the overall benefit/risk relationship
                                            of the product and provide an adequate basis for product approval. These trials may include
                                            comparisons with placebo and/or other comparator treatments. The duration of treatment is
                                            often extended to mimic the actual use of a product during marketing. Post-approval trials,
                                            sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing
                                            approval. These trials are used to gain additional experience from the treatment of patients
                                            in the intended therapeutic indication. In certain instances, the FDA may mandate the performance
                                            of Phase 4 clinical trials as a condition of approval of an NDA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Progress reports detailing
the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports
must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting
a significant risk to humans exposed to the drug, findings from animal or&nbsp;<I>in vitro&nbsp;</I>testing that suggest a significant
risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in
the protocol or investigator brochure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Clinical trials may
not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial
at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted
in accordance with the IRB&rsquo;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally,
some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data
safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points
based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies
and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process
for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable
of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity,
strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies
must be conducted to demonstrate that our drug candidates do not undergo unacceptable deterioration over their shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Breakthrough Therapy
Designation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Breakthrough therapy
designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and
for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically
significant endpoint(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">To determine whether
the improvement over available therapy is substantial is a matter of judgment and depends on both the magnitude of the treatment effect,
which could include duration of the effect, and the importance of the observed clinical outcome. In general, the preliminary clinical
evidence should show a clear advantage over available therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For purposes of breakthrough
therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible morbidity
or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can also refer
to findings that suggest an effect on IMM or serious symptoms, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
                                            effect on an established surrogate endpoint;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
                                            effect on a surrogate endpoint or intermediate clinical endpoint considered reasonably likely
                                            to predict a clinical benefit (i.e., the accelerated approval standard);</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
                                            effect on a pharmacodynamic biomarker(s) that does not meet criteria for an acceptable surrogate
                                            endpoint, but strongly suggests the potential for a clinically meaningful effect on the underlying
                                            disease; or</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
                                            significantly improved safety profile compared to available therapy (e.g., less dose-limiting
                                            toxicity for an oncology agent), with evidence of similar efficacy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
drug that receives breakthrough therapy designation is eligible for the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">More
                                            frequent meetings with FDA to discuss the drug&rsquo;s development plan and ensure collection
                                            of appropriate data needed to support drug approval;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">More
                                            frequent written communication from FDA about such things as the design of the proposed clinical
                                            trials and use of biomarkers;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Eligibility
                                            for&nbsp;Accelerated Approval and Priority Review, if relevant criteria are met;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rolling
                                            Review, which means that a drug company can submit completed sections of its Biologic License
                                            Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until
                                            every section of the NDA is completed before the entire application can be reviewed. BLA
                                            or NDA review usually does not begin until the drug company has submitted the entire application
                                            to the FDA;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intensive
                                            guidance on an efficient drug development program, beginning as early as Phase 1; or</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Organizational
                                            commitment involving senior managers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We intend to request
breakthrough therapy designation for our drug candidates. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Ideally,
we would submit a breakthrough therapy designation request to the FDA no later than the end-of-phase-2 meetings if any of the features
of the designation are to be obtained. We expect that the FDA would respond to our breakthrough therapy designation requests within sixty
days of receipt of a request.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>NDA Review Process</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Following completion
of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated
use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed
labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA is a request for
approval to market the drug for one or more specified indications and must contain proof of safety and efficacy for a drug. The application
must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come
from company-sponsored clinical trials intended to test the safety and efficacy of a product&rsquo;s use or from a number of alternative
sources, including studies initiated by unaffiliated investigators. To support marketing approval, the data submitted must be sufficient
in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval
of an NDA must be obtained before a drug may be marketed in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under the Prescription
Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a significant user fee. Fee waivers or reductions are available
in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally,
no user fees are assessed on NDAs for drug candidates designated as orphan drugs, unless the drug candidate also includes&nbsp;a&nbsp;non-orphan
drug&nbsp;indication.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, under the
Pediatric Research Equity Act, an NDA or supplement to an NDA must contain data that are adequate to assess the safety and effectiveness
of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant
deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers
from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products
with orphan drug designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The FDA also may require
submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The
REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such
as restricted distribution methods, patient registries, or other risk minimization tools.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The FDA reviews all
submitted NDAs before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The
FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA
begins an&nbsp;in-depth&nbsp;review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months,
from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six months
from the filing date of a new molecular entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates
for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Before approving an
NDA, the FDA will conduct a&nbsp;pre-approval&nbsp;inspection of the manufacturing facilities for the new product to determine whether
they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities
are in compliance with cGMP requirements and adequate to ensure consistent production of the product within required specifications.
The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications
for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should
be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such
recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive
discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA, it will issue an approval letter
or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the drug with specific prescribing information
for specific indications. A CRL indicates that the review cycle of the application is complete, and the application will not be approved
in its present form. A CRL usually describes all of the specific deficiencies in the NDA identified by the FDA. The CRL may require additional
clinical data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical
trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies
identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA
does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data
differently than we interpret the same data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Even if the FDA approves
a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included
in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&rsquo;s
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential
market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing
studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing
changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Orphan Drugs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under the Orphan Drug
Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease
or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States
and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for
this type of disease or condition will be recovered from sales of the product.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Orphan drug designation
must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its
potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration
of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives the first FDA approval
for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that
the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such
approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means
of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors,
however, may receive approval of either a different product for the same indication or the same product for a different indication but
that could be used&nbsp;off-label&nbsp;in the orphan drug indication. Orphan drug exclusivity also could block the approval of one of
our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same
indication we are seeking approval, or if a drug candidate is determined to be contained within the scope of the competitor&rsquo;s product
for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication
broader than that which is designated, it may not be entitled to orphan drug exclusivity.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In the European Union,
the European Medicines Agency&rsquo;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development
of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition
affecting not more than five in 10,000&nbsp;persons in the European Union. Additionally, designation is granted for products intended
for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating, or serious and chronic condition when, without
incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing
the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method
exists, the medicine must be of significant benefit to those affected by the condition. In the European Union, orphan drug designation
entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following approval
for the approved therapeutic indication. This period may be reduced to six years if, at the end of the fifth year, the orphan drug designation
criteria are no longer met, including where it is shown that the drug is sufficiently profitable not to justify maintenance of market
exclusivity. In the European Union, a marketing authorization for an orphan drug designated product will not be granted if a similar
drug has been approved in the European Union for the same therapeutic indication, unless the applicant can establish that its product
is safer, more effective or otherwise clinically superior. A similar drug is a product containing a similar active substance or substances
as those contained in an already authorized product. Similar active substance is defined as an identical active substance, or an active
substance with the same principal molecular structural features (but not necessarily all of the same molecular features) and which acts
via the same mechanism.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Post-Approval
Requirements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among
other things, monitoring and record-keeping requirements, requirements to report adverse experiences, and comply with promotion and advertising
requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (known as&nbsp;&ldquo;off-label&nbsp;use&rdquo;)
and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs
for&nbsp;off-label&nbsp;uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted
to the FDA in conjunction with their first use. Further, if there are any modifications to the drug, including changes in indications,
labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or supplemental
NDA, or sNDA, which may require the development of additional data or preclinical studies and clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to
assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe
use, such as restricted distribution methods, patient registries and other risk minimization tools.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products.
Product approvals may be withdrawn for&nbsp;non-compliance&nbsp;with regulatory standards or if problems occur following initial marketing.
The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to
the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks;
or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other
things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictions
                                            on the marketing or manufacturing of the product, complete withdrawal of the product from
                                            the market or product recalls;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fines,
                                            warning letters or holds on post-approval clinical studies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refusal
                                            of the FDA to approve pending applications or supplements to approved applications;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applications,
                                            or suspension or revocation of product license approvals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
                                            seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Injunctions
                                            or the imposition of civil or criminal penalties. The FDA strictly regulates marketing, labeling,
                                            advertising, and promotion of products that are placed on the market. Drugs may be promoted
                                            only for the approved indications and in accordance with the provisions of the approved label.
                                            The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion
                                            of&nbsp;off-label&nbsp;uses, and a company that is found to have improperly promoted&nbsp;off-label&nbsp;uses
                                            may be subject to significant liability.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Coverage,
Pricing and Reimbursement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In
the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale
will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such
products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health
insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be
separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for
the product. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might
not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price,
examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning
their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and
cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be
considered medically necessary or cost-effective. A payor&rsquo;s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be approved. Further, one payor&rsquo;s determination to provide coverage for a product does not assure that
other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain
price levels sufficient to realize an appropriate return on our investment in product development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Different
pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through
their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products
to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement
price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials
that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies
to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become
very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries,
cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has
increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement
rates may change at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable
coverage policies and reimbursement rates may be implemented in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Healthcare
Reform</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate
post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among
policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers.
Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise
described above, are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">created
                                            an annual, nondeductible fee on any entity that manufactures or imports certain specified
                                            branded prescription drugs and biologic agents apportioned among these entities according
                                            to their market share in some government healthcare programs that began in 2011;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
                                            the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program,
                                            retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most
                                            branded and generic drugs, respectively, and capped the total rebate amount for innovator
                                            drugs at 100% of the Average Manufacturer Price, or AMP;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">created
                                            a new Medicare Part D coverage gap discount program, in which manufacturers must now agree
                                            to offer 70% point-of-sale discounts, off negotiated prices of applicable brand drugs to
                                            eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&rsquo;
                                            outpatient drugs to be covered under Medicare Part D;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extended
                                            manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals
                                            who are enrolled in Medicaid managed care organizations; expanded eligibility criteria for
                                            Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional
                                            individuals and added new mandatory eligibility categories for individuals with income at
                                            or below 133% of the federal poverty level, thereby potentially increasing manufacturers&rsquo;
                                            Medicaid rebate liability;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanded
                                            of the list of entities eligible for discounts under the 340B Drug Discount Program;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">created
                                            a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
                                            comparative clinical effectiveness research, along with funding for such research;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanded
                                            healthcare fraud and abuse laws, including the Foreign Corrupt Practices Act, or the FCPA,
                                            and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties
                                            for noncompliance;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">created
                                            a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
                                            are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">required
                                            reporting of certain financial arrangements with physicians and teaching hospitals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">required
                                            annual reporting of certain information regarding drug samples that manufacturers and distributors
                                            provide to physicians;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">established
                                            a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service
                                            delivery models to lower Medicare and Medicaid spending; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">created
                                            a licensure framework for follow on biologic products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and we expect there will
be additional challenges and amendments to the ACA in the future. Former President Trump signed several Executive Orders and other directives
designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance
mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA.
While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the
ACA have been enacted. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the tax-based shared responsibility
payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, a process
that is commonly referred to as the &ldquo;individual mandate.&rdquo; In addition, the Further Consolidated Appropriations Act, 2020
permanently eliminated, effective January 1, 2020, the ACA-mandated &ldquo;Cadillac&rdquo; tax on high-cost employer-sponsored health
coverage and medical device tax; and, effective January 1, 2021, it also eliminated the health insurance tax. On December 14, 2018, the
U.S. District Court for the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the
ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December
18, 2019, the U.S. Court of Appeals for the Fifth Circuit ruled that the individual mandate was unconstitutional and remanded the case
back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On June 17, 2021, the U.S. Supreme
Court reversed the ruling of the Fifth Circuit, holding that the challengers lacked standing to sue and otherwise abstaining from reaching
the merits of the case. Notwithstanding the resolution of this legal challenge, there may be other efforts to challenge, repeal, or replace
the ACA which may impact our business in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President Joseph R. Biden, Jr. signed an Executive
Order on Strengthening Medicaid and the Affordable Care Act, stating his administration&rsquo;s intentions to reverse the actions of
his predecessor and strengthen the ACA. As part of this Executive Order, the Department of Health and Human Services, United States Treasury,
and the Department of Labor were directed to review all existing regulations, orders, guidance documents, policies, and agency actions
and to consider if they are consistent with ensuring coverage under the ACA making high-quality healthcare affordable and accessible
to Americans. We are unable to predict the likelihood of changes to the ACA or other healthcare laws which may negatively impact our
profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President Biden intends, as his predecessor did,
to take action against drug prices which are considered &ldquo;high.&rdquo; Such measures could be addressed in a legislative package
in 2022, including with the reauthorization of the Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;), or in the future. Drug pricing
continues to be a subject of debate at the executive and legislative levels of U.S. government, and we expect to see legislation focusing
on this in the coming years. The American Rescue Plan Act of 2021, signed into law by President Biden on March 14, 2021, included a provision
that will eliminate the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. With the elimination of
the rebate cap, manufacturers may be required to compensate states in an amount greater than what the state Medicaid programs pay for
the drug.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further legislation or regulation could be passed
that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted
since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year,
effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030 with the exception of a temporary
suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2022, unless additional congressional
action is taken.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, there has recently been heightened
governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional
inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, to review
the relationship between pricing and manufacturer patient assistance programs, and to reform government program reimbursement methodologies
for pharmaceutical products. The Prescription Drug Pricing Reduction Act, or PDPRA, which was introduced in Congress in 2019, and again
in 2020, proposed to, among other things, penalize pharmaceutical manufacturers for raising prices on drugs covered by Medicare Parts
B and D faster than the rate of inflation, cap out-of-pocket expenses for Medicare Part D beneficiaries, and several changes to how drugs
are reimbursed in Medicare Part B. A similar drug pricing bill, the Elijah E. Cummings Lower Drug Costs Now Act, proposed to enable direct
price negotiations by the federal government for certain drugs (with the maximum price paid by Medicare capped based on an international
index), would require manufacturers to offer these negotiated prices to other payers, and would restrict manufacturers from raising prices
on drugs covered by Medicare Parts B and D. This Act passed in the House of Representatives when it was introduced in 2019, and it has
been introduced again in the 2021 term. A modified version of this Act was included in the Build Back Better proposed legislation in
late 2021, which also included a provision enabling government price negotiations. We cannot predict whether any proposed legislation
will become law and the effect of these possible changes on our business cannot be predicted at this time.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, the Centers for Medicare &amp; Medicaid
Services (&ldquo;CMS&rdquo;) has significant regulatory authority to promulgate regulations and impose other compliance requirements
that may increase our compliance costs and impact our ability to attain profitability and market our product candidates. CMS sets coverage
and reimbursement rates for Medicare and oversees the implementation of Medicaid at the state level. CMS could modify or impose coverage
restrictions or modify reimbursement rates on any of our product candidates in a manner that could adversely impact our business. For
example, on January 8, 2021, CMS approved Tennessee&rsquo;s Medicaid section 1115 demonstration application, granting the state the unprecedented
ability to implement a closed drug formulary without foregoing the state&rsquo;s entitlement to rebates under the Medicaid Drug Rebate
Program. Implementation of a closed formulary could mean that our products could be excluded from coverage under Medicaid. It is unclear
whether the Biden Administration will reverse or modify Tennessee&rsquo;s section 1115 demonstration approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within CMS, the Center for Medicare and Medicaid
Innovation (&ldquo;CMMI&rdquo;), as established by the ACA, has broad authority to design, implement, and test new health care payment
models that could potentially lower health care spending while maintaining quality or increase quality without increasing spending. CMMI
has considered implementing models that could have a significant adverse effect on our business. For example, on November 27, 2020, CMMI
finalized a mandatory Medicare Part B drug payment model that would have aligned payment for drugs with international reference prices,
entitled the Most Favored Nation (MFN) Model. The MFN Model was enjoined by a Federal court on December 28, 2020 for failure to comply
with rulemaking procedural requirements and was ultimately withdrawn by the Biden Administration on December 29, 2021. It is unclear
whether the Biden Administration will propose and implement the same or a similar model in future rulemaking, and we cannot predict how
future regulatory actions by CMMI or any other component of CMS may impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any reduction in reimbursement from Medicare
and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which
we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
Foreign Corrupt Practices Act</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FCPA prohibits any United States individual or business from paying, offering, or authorizing payment or offering of anything of value,
directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the
foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose
securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that
accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an
adequate system of internal accounting controls for international operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Environmental
Regulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use certain plastic, glass, fabric, metal and other products in our business which may be harmful if released into the environment. In
view of the nature of our business, compliance with federal, state, and local laws regulating the discharge of materials into the environment,
or otherwise relating to the protection of the environment, has had no material effect upon our operations or earnings, and we do not
expect it to have a material impact in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Tax
Laws and Regulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in tax laws or regulations in the jurisdictions in which we do business, including the United States, or changes in how the&nbsp;tax
laws are interpreted, could further impact our effective tax rate, further restrict our ability to repatriate undistributed offshore
earnings, or impose new restrictions, costs or prohibitions on our current practices and reduce our net income and adversely affect our
cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to tax audits in the United States and other jurisdictions and our tax positions may be challenged by tax authorities.
Although we believe that our current tax provisions are reasonable and appropriate, there can be no assurance that these items will be
settled for the amounts accrued, that additional tax exposures will not be identified in the future or that additional tax reserves will
not be necessary for any such exposures. Any increase in the amount of taxation incurred as a result of challenges to our tax filing
positions could result in a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Regulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to international, federal, national, regional, state, local and other laws and regulations affecting our business, including
those promulgated under the Occupational Safety and Health Act, the Consumer Product Safety Act, the Flammable Fabrics Act, the Textile
Fiber Product Identification Act, the rules and regulations of the Consumer Products Safety Commission, the Food, Drug, and Cosmetic
Act, the Foreign Corrupt Practices Act of 1977 (FCPA), various securities laws and regulations including but not limited to the Securities
Exchange Act of 1934, the Securities Exchange Act of 1933, and the Nasdaq Stock Market LLC Rules, various labor, workplace and related
laws, and environmental laws and regulations. Failure to comply with such laws and regulations may expose us to potential liability and
have an adverse effect on our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
U.S. Regulatory Matters</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities prior to product approval and manufacturing, sales, promotion and other activities following product approval
are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers
for Medicare&nbsp;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, or HHS, the Department of
Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational
Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and local governments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, in the United States, prescription drug manufacturers must comply with federal fraud and abuse, data privacy, transparency,
and other healthcare laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription
drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that
is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which
payment may be made under a federal healthcare program, such as Medicare or Medicaid. Moreover, the government may assert that a claim
including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the civil False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
civil and criminal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower
and qui tam actions, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false
or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false
record or statement material to a false or fraudulent claim to the federal government. Pharmaceutical companies have been prosecuted
under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would
bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&rsquo;
marketing of the product for unapproved, and thus&nbsp;non-covered,&nbsp;uses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
civil and criminal statutes prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact
or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, healthcare benefits,
items or services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and more recent
requirements in the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010,
or collectively the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration,
additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention
Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection
and unfair competition laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made to institutions, physicians and other healthcare providers are subject to federal and state regulations, including the Physician
Payments Sunshine Act, or the Sunshine Act. The Sunshine Act requires certain manufacturers of drugs, devices, biologicals and medical
supplies, with certain exceptions, to report annually to CMS information related to payments and other transfers of value to physicians
and teaching hospitals and ownership and investment interests held by physicians and their immediate family members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personally
identifiable information, under certain conditions, is also subject to data privacy and security regulation by both federal and state
governments. The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) as amended by the Health Information Technology
for Economic and Clinical Health Act (HITECH), and their implementing regulations, imposes certain requirements relating to the privacy,
security and transmission of individually identifiable health information on covered entities and business associates that perform services
for covered entities that involve individually identifiable health information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing,
storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have similar healthcare statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs,
or, in several states, apply regardless of the payor. Certain states require the posting of information relating to clinical studies,
pharmaceutical companies to implement a comprehensive compliance program that includes a limit on expenditures for, or payments to, individual
medical or health professionals and track and report gifts and other payments made to physicians and other healthcare providers, and
certain state and local jurisdictions require the registration of pharmaceutical sales representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with any of these laws or regulatory requirements may subject a pharmaceutical manufacturer to possible legal or regulatory
action. Depending on the circumstances, failure to comply with these laws can result in significant civil, criminal and administrative
penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare
and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, integrity oversight and reporting obligations,
and the curtailment or restructuring of operations. Any action against us for violation of these laws, even if we successfully defend
against it, could cause us to incur significant legal expenses and divert our management&rsquo;s attention from the operation of our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prohibitions
or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. Changes
in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:
(i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or
discontinuation of our products; or (iv)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could
adversely affect the operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and
other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated
by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could
be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that
continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these
laws may affect our future operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Overseas
Government Regulation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among
other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product,
we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials
or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the
submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example,
a clinical trial application must be submitted to each country&rsquo;s national health authority and an independent ethics committee,
much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&rsquo;s requirements,
clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use
may be restricted in some countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to
country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the
ethical principles that have their origin in the Declaration of Helsinki.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain regulatory approval of an investigational drug under EU regulatory systems, we must submit a marketing authorization application.
The application used to file the NDA in the United States is similar to that required in the EU, with the exception of, among other things,
country-specific document requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials
must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin
in the Declaration of Helsinki.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>European
Union General Data Protection Regulation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&rsquo;s General
Data Protection Regulation, or the GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data of persons
in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened
timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories
of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing
of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States
and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting
the processing of personal data, including genetic, biometric or health data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal
data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements
of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &euro;20,000,000 or
up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties.
GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process, and we may be required
to put in place additional mechanisms to ensure compliance with the new data protection rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 286.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_021"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
and Executive Officers </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is information regarding our directors and executive officers as of the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Marc Duey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chairman and Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Maria Vilenchik</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Arthur Healey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer and Secretary</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Alex Shlyankevich</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Yuriy Gankin </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Michael Frid</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Michael Kody</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director Nominee<SUP>(1)</SUP>&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Douglas T. Moore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director Nominee<SUP>(1)</SUP>&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Appointed to our
                                            board of directors effective automatically upon the effectiveness of the registration statement
                                            of which this prospectus forms a part.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Marc Duey </I></B>has served as Executive
Chairman and Chairman of the Board of the Company since 2014. Mr. Duey has also served as the managing partner of Duce Management, LLC
since September 2012, and was Chairman of TarMeta from 2016 until we acquired it in December 2021. Mr. Duey brings more than two decades
of experience in the Pharmaceutical and Biotechnology fields to our Company. Mr. Duey has managed an investment portfolio of technology
companies, including Atrin Pharmaceuticals, Felicitex, and TarMeta. From March 1994 to March 2020, Mr. Duey was the founder and Chief
Executive Officer of ProMetrics, Inc., a healthcare advisory firm dedicated to serving the biopharmaceutical industry, where Mr. Duey
managed more than 100 consultants serving the patient-level data needs of dynamic pharmaceutical firms, including many oncology firms,
in their quest to launch and grow successful brands. Mr. Duey is also a director of Atrin Pharmaceuticals and Trustee of International
House Philadelphia. Since 2007, Mr. Duey has also taught as an adjunct professor at West Chester University in Pennsylvania for undergraduates
and graduates in its marketing and MBA programs, specializing in its Pharmaceutical Product Development Program. Mr. Duey&rsquo;s educational
background includes Bachelor and Master of Science degrees in Science, with a specialization in Toxicology from the University of Ottawa,
an MBA from The University of Western Ontario&rsquo;s Richard Ivey School of Business, and a Master&rsquo;s Degree in International Business
from University of Li&egrave;ge. Our board of directors believes that Mr. Duey is qualified to serve as a member of the board due to
his record of service as chairman of Felicitex&rsquo;s board for eight years and TarMeta&rsquo;s board for six years, as well as his
more than 20 years of experience in the pharmaceutical and biotechnology fields.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Maria Vilenchik </I></B>founded our company
and has served as our Chief Executive Officer since May 2012. Dr Vilenchik leads the Company and is responsible for all management functions,
including business development, fundraising, and intellectual property. Prior to her tenure at the Company, Dr. Vilenchik was a consultant
at Advanced Bio Design Inc. in the Oncology Drug Development Department. From 2004 to 2012, Dr. Vilenchik worked at Hoffman-La Roche
Inc. as a Principal Scientist in the Discovery Oncology division. At Hoffman-La Roche, Dr. Vilenchik was a project leader for all phases
of pre-clinical drug discovery, led multi-functional teams through discovery, led identification and optimization phases, and independently
planned and managed aggressive research and product development timelines. From 2004 to 2005, Dr. Vilenchik was a Business Development
Consultant with Keryx Biopharmaceuticals in New York. Dr. Vilenchik participated in post-doctoral training at Memorial Sloan Kettering
Cancer Center, Dr. Rosen lab, from 2001 to 2004. Dr. Vilenchik&rsquo;s education includes a Bachelor of Science from St. Petersburg Polytechnic
University in St. Petersburg, Russia, a Master of Science from Brandeis University in Waltham, Massachusetts, and a Master of Philosophy
and a PhD in Molecular Pharmacology from Columbia University in New York. Our board of directors believes that Dr. Vilenchik is qualified
to serve as a member of the board due to her experience as our chief executive officer since our founding in 2012, and her expertise
in oncology and drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Arthur Healey</I></B> has been our Chief
Financial Officer and Secretary since April 2021. Mr. Healey had previously provided consulting services to the Company from November
2017. Since January 2017, Mr. Healey has been the owner and Chief Executive Officer of A.T. Healey, LLC, an outsourced finance and accounting
company. Mr. Healey has also been Chief Financial Officer of Viihealth, Inc. since January 2017; Chief Financial Officer to New View
Surgical, Inc. since October 2016 and advisor of other private companies. Mr. Healey provides finance, accounting, and tax services,
including CFO services, to early-stage technology companies and those in the venture capital industry. Mr. Healey&rsquo;s experience
also includes consulting companies on corporate reorganizations, mergers and acquisitions, and contract negotiations. Mr. Healey previously
served as a Senior Manager at EY (formerly Ernst &amp; Young LLP), Manager at PWC (formerly Coopers &amp; Lybrand) and Manager at KPMG.
Mr. Healey has a BS in Accounting from Villanova University and a JD from Villanova University School of Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Alex Shlyankevich </I></B>has been our
director since January 2017. In April 2015, Dr. Shylankevich became President and owner of MH Biomedical Investments, LLC, or MH, a healthcare
investment company. At MH, Dr. Shlyankevich creates portfolios of healthcare investment projects and manages their deal sourcing, due
diligence, negotiations, and corporate governance. Dr. Shlyankevich has also served as a director at NuPulseCV, Inc., GiveVision, and
Constant Therapeutics LLC. Dr. Shlyankevich has more than 25 years of experience in the pharmaceutical industry in a variety of both
technical and managerial capacities, along with more than six years of experience specifically in healthcare investments. Dr. Shlyankevich
has a thorough understanding of compliance, business and budgetary aspects of CMC operations. Additionally, Dr. Shlyankevich has a background
in brand and generic pharmaceutical, biotech, drug delivery, medical devices, services, contract pharmaceuticals, and startup companies.
Dr. Shlyankevich has experience at all stages of the biomedical startup process: cross-functional and international facilitation of product
development, program leadership, collaboration management, business presentation, and start up organization growth. Further, in the drug
pharmaceutical process, Dr. Shylankevich has worked with matters involving the submission, approval, and commercial stages of the regulatory
review process of the FDA and the Federal Institute for Drugs and Medical Devices, the medical regulatory body in Germany. His educational
background includes a Master of Science degree in Pharmacy from the Moscow Medical School and a PhD. in Pharmaceutical Analysis. Our
board of directors believes that Dr. Shlyankevich is qualified to serve as a member of the board due to his business and investment management
background and experience in the pharmaceutical industry in a variety of technical and managerial capacities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Yuriy Gankin </I></B>has been our director
since 2012. Dr. Gankin contributes his experience in business development and operations, as well as life science expertise to the Company.
Dr. Gankin is a life sciences researcher, entrepreneur, and inventor with more than two decades of experience. Dr. Gankin&rsquo;s research
has been published in multiple scientific journals and Dr. Gankin holds several patents in the areas of mass spectrometry and cancer
therapy. Dr. Gankin&rsquo;s expertise is in research, database development, and modeling in chemistry and biology. Since December 2019,
Dr. Gankin has been founder and Chief Scientific Officer at Quantori, LLC, a developer of intelligent IT and data science solutions for
life science and healthcare organizations. From June 2014 to December 2019, Mr. Gankin served as the Chief Life Science Officer at EPAM
Systems. At EPAM Systems, a software development services company, Dr. Gankin developed and managed scientific strategy, client management,
and pre-sales support. Dr. Gankin holds a PhD in Analytical Chemistry from Tufts University and an MBA from MIT Sloan School of Management.
Our board of directors believes that Dr. Gankin is qualified to serve as a member of the board due to his experience in business development
and operations and his life science expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Michael
Frid</I></B> has been our director since May 2012. Dr. Frid served as our Vice President for preclinical operations from May 2012 to
June 2018. Prior to that, Dr. Frid worked at Wolfe Laboratories leading drug discovery and development and CMC processes. Since January
2016, Dr. Frid has been Chief Scientific Officer for Manna Molecular Science LLC, a research and development company that focused on
the manufacturing of cannabis-infused products such as hemp-derived cannabidiol (CBD). In this position, Dr. Frid leads the research,
development and manufacturing process scale up for the dosage forms for different administration routes. Since June 2019, Dr. Frid has
also been Chief Product Officer at Vella Bioscience, Inc., a cosmetics company. At Vella Bioscience, Dr. Frid develops and tests new
products, selection of manufacturing sites and oversight, and intellectual property strategy and execution. Dr. Frid holds a PhD in Organic
Chemistry from Massachusetts Institute of Technology (Dr. Buchwald lab) and he graduated cum laude with a BS from New York University.
Dr. Frid is a member of the honor societies Phi Beta Kappa, Phi Lambda Upsilon and Sigma Xi. Our board of directors believes that Dr.
Frid is qualified to serve as a member of the board due to his long experience as our board member and former officer, and knowledge
of our research and development programs, intellectual property portfolio, and business strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Michael Kody</I></B> will be a member of
our board of directors immediately upon the effectiveness of the registration statement of which this prospectus forms a part. Mr. Kody
is a certified public accountant excelling in financial planning, accounting and risk management, and business process administration.
Mr. Kody is heavily involved in the pharmaceutical drug industry. From 2021 to the present day, Mr. Kody was the Chief Financial Officer
of Pharmaceutical Associates, Inc., where he revises financial reporting processes and provides guidance to the company for strategic
initiatives that included mergers and acquisitions, investments, and new market opportunities. From 2019 to 2021, Mr. Kody worked for
Prasco Laboratories, LLC in Healthcare Service as the Divisional President. During his tenure, Mr. Kody developed a business plan for
Prasco to achieve its target valuation within five years. Further, Mr. Kody also has executive experience from his time at G&amp;W Laboratories
Inc. from 2017 to 2019, he was the Lead Executive that managed the operations and sale of the generic drug division valued at $100 million.
From 2007 to 2017, Mr. Kody worked as the SVP at AmerisourceBergen Corp. (NYSE: ABC). Mr. Kody&rsquo;s financial and audit experience
comes from his 16 years, from 1991 to 2007, as a public accountant at PricewaterhouseCoopers LLP in the Detroit, Chicago, Dallas, and
Philadelphia offices. At PwC Mr. Kody was a Senior Director who performed financial audits, Sarbanes Oxley Compliance review, and prepared
financial statements. Mr. Kody holds a Bachelor of Arts in Economics from the University of Michigan and is currently a Certified Public
Accountant in the states of Michigan and Pennsylvania. Our board of directors believes Mr. Kody is qualified to serve on the board due
to his financial experience in accounting and his business development background with pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Douglas T. Moore</I></B> will be a member
of our board of directors immediately upon the effectiveness of the registration statement of which this prospectus forms a part. Through
his more than 25 years of retail experience, Mr. Moore has developed an understanding of strategic and tactical business issues that
include store operations, merchandising, supply chain, sourcing, and human resource planning. He also possesses senior management, marketing,
risk assessment and retail knowledge. Mr. Moore has served on multiple company boards, including his present position as a director on
the Board of LL Flooring Holdings Inc., formerly Lumber Liquidators Flooring (NYSE: LL), one of the leading specialty retailers of hard-surface
flooring in North America, since April 2006. From August 2019 to September 2021, Mr. Moore was the Chief Executive Officer of 1847 Goedeker
Inc., (NYSE American: GOED) (&ldquo;Goedeker&rsquo;s&rdquo;) a publicly traded company, where he spearheaded a $222 million dollar acquisition
of Appliance Connection, Inc. and grew the company&rsquo;s market cap over seven times its previous amount during the company&rsquo;s
2020 initial public offering. Prior to his tenure at Goedeker&rsquo;s, Mr. Moore was a Senior Vice President of in the division of Aging
in the Home Remodelers, which is a part of FirstSTREET for Boomers and Beyond, Inc., a leading direct marketer of products for baby boomers,
from August 2017 to August 2019. Further, Mr. Moore has experience organically growing sales, as Mr. Moore was also the President and
Chief Executive Officer of Med-Air Homecare, a home healthcare equipment and service provider, from November 2013 to May 2019. Additionally,
Mr. Moore has extensive experience with consumer facing retail businesses, as he was the Chief Merchandising and Marketing Officer of
H. H. Gregg, Inc., a consumer electronics retail chain, from February 2012 to June 2012; the Vice President of Operations for Safelite
Group, Inc., a provider of vehicle glass repairs and replacements and insurance claims management company, from 2011 to 2012; the Senior
Vice President of Merchandising at Sears Holdings Corporation from 2007 to 2010; and the EVP Chief Merchandising Officer at Circuit City
Stores, Inc. from 2004 to 2007. Mr. Moore received his undergraduate degree and M.B.A. from the University of Virginia. We believe Mr.
Moore is qualified to serve on our board of directors due to his extensive experience in the retail industry and public company board
experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.
                                            Kody and Mr. Moore will be members of our board of directors automatically upon the effectiveness
                                            of the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors currently have terms which will end at our next annual meeting of the shareholders or until their successors are elected and
qualify, subject to their prior death, resignation or removal. Officers serve at the discretion of the board of directors. There is no
arrangement or understanding between any director or executive officer and any other person pursuant to which he was or is to be selected
as a director, nominee or officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our officers or directors.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Involvement
in Certain Legal Proceedings </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the best of our knowledge, except as described below, none of our directors or executive officers has, during the past ten years:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding
                                            traffic violations and other minor offences);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">had
                                            any bankruptcy petition filed by or against the business or property of the person, or of
                                            any partnership, corporation or business association of which he was a general partner or
                                            executive officer, either at the time of the bankruptcy filing or within two years prior
                                            to that time;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
                                            of any court of competent jurisdiction or federal or state authority, permanently or temporarily
                                            enjoining, barring, suspending or otherwise limiting, his involvement in any type of business,
                                            securities, futures, commodities, investment, banking, savings and loan, or insurance activities,
                                            or to be associated with persons engaged in any such activity;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            found by a court of competent jurisdiction in a civil action or by the Securities and Exchange
                                            Commission or the Commodity Futures Trading Commission to have violated a federal or state
                                            securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            the subject of, or a party to, any federal or state judicial or administrative order, judgment,
                                            decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement
                                            of a civil proceeding among private litigants), relating to an alleged violation of any federal
                                            or state securities or commodities law or regulation, any law or regulation respecting financial
                                            institutions or insurance companies including, but not limited to, a temporary or permanent
                                            injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent
                                            cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
                                            mail or wire fraud or fraud in connection with any business entity; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            the subject of, or a party to, any sanction or order, not subsequently reversed, suspended
                                            or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange
                                            Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the
                                            Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity
                                            or organization that has disciplinary authority over its members or persons associated with
                                            a member.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Governance
Structure </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
chose to appoint a separate Chairman of the Board who is not our Chief Executive Officer. Our board of directors has made this decision
based on their belief that an independent Chairman of the Board can act as a balance to the Chief Executive Officer, who also serves
as a non-independent director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Board&rsquo;s Role in Risk Oversight </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors oversees that the assets of our company are properly safeguarded, that the appropriate financial and other controls
are maintained, and that our business is conducted wisely and in compliance with applicable laws and regulations and proper governance.
Included in these responsibilities is the board&rsquo;s oversight of the various risks facing our company. In this regard, our board
seeks to understand and oversee critical business risks. Our board does not view risk in isolation. Risks are considered in virtually
every business decision and as part of our business strategy. Our board recognizes that it is neither possible nor prudent to eliminate
all risk. Indeed, purposeful and appropriate risk-taking is essential for our company to be competitive on a global basis and to achieve
its objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the board oversees risk management, company management is charged with managing risk. Management communicates routinely with the board
and individual directors on the significant risks identified and how they are being managed. Directors are free to, and indeed often
do, communicate directly with senior management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board administers its risk oversight function as a whole by making risk oversight a matter of collective consideration. Much of this
work has been delegated to committees, which will meet regularly and report back to the full board. The audit committee oversees risks
related to our financial statements, the financial reporting process, accounting and legal matters, the compensation committee evaluates
the risks and rewards associated with our compensation philosophy and programs, and the nominating and corporate governance committee
evaluates risk associated with management decisions and strategic direction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Independent
Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Nasdaq&rsquo;s rules generally require that a majority
of an issuer&rsquo;s board of directors must consist of independent directors. Our board of directors currently consists of five (5)
directors, Maria Vilenchik, Marc Duey, Alex Shlyankevich, Yuriy Gankin, and Michael Frid. There are two (2) director nominees, Michael
Kody, and Douglas Moore, who will also be members of our board of directors immediately upon the effectiveness of the registration statement
of which this prospectus forms a part. Including the director nominees, there will be five (5) directors who will meet the definition
of &ldquo;Independent Director&rdquo; within the meaning of Nasdaq&rsquo;s listing rules. We will also enter into independent director
agreements with our current independent directors and the director nominees, the terms of which are described under &ldquo;<I>Executive
Compensation - Director Agreements</I>&rdquo;. As a result of these board changes, our board of directors will consist of seven
(7) directors, five (5) of whom will be independent within the meaning of Nasdaq&rsquo;s rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Committees
of the Board of Directors </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board has established an audit committee, a compensation committee, and a nominating and corporate governance committee, each with its
own charter approved by the board. The committee charters have been filed as exhibits to the registration statement of which this prospectus
is a part. Upon completion of this offering, we intend to make each committee&rsquo;s charter available on our website at https://www.felicitex.com/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our board of directors may, from time to time, designate one or more additional committees, which shall have the duties and
powers granted to it by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Audit
Committee </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Michael Kody, Douglas Moore and Yuriy Gankin,
each of whom satisfies the &ldquo;independence&rdquo; requirements of Rule&nbsp;10A-3 under the Exchange Act and Nasdaq&rsquo;s rules,
will serve on our audit committee upon Michael Kody&rsquo;s and Douglas Moore&rsquo;s appointment to the board, with Mr. Kody serving
as the chairman. Our board has determined that Mr. Kody qualifies as an &ldquo;audit committee financial expert.&rdquo; The audit committee
oversees our accounting and financial reporting processes and the audits of the financial statements of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee is responsible for, among other things: (i) retaining and overseeing our independent accountants; (ii) assisting the
board in its oversight of the integrity of our financial statements, the qualifications, independence and performance of our independent
auditors and our compliance with legal and regulatory requirements; (iii) reviewing and approving the plan and scope of the internal
and external audit; (iv) pre-approving any audit and non-audit services provided by our independent auditors; (v) approving the fees
to be paid to our independent auditors; (vi) reviewing with our chief executive officer and principal financial officer and independent
auditors the adequacy and effectiveness of our internal controls; (vii) reviewing hedging transactions; and (viii) reviewing and assessing
annually the audit committee&rsquo;s performance and the adequacy of its charter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Compensation
Committee </U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Alex Shlyankevich, Yuriy Gankin,
and Michael Frid, each of whom satisfies the &ldquo;independence&rdquo; requirements of Rule&nbsp;10C-1 under the Exchange Act and Nasdaq&rsquo;s
rules, will serve on our compensation committee, with Dr. Gankin serving as the chairman. The members of the compensation committee are
also &ldquo;outside directors&rdquo; as defined in Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code, and
&ldquo;non-employee directors&rdquo; within the meaning of Section 16 of the Exchange Act. The compensation committee assists the board
in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee is responsible for, among other things: (i) reviewing and approving the remuneration of our executive officers;
(ii) making recommendations to the board regarding the compensation of our independent directors; (iii) making recommendations to the
board regarding equity-based and incentive compensation plans, policies and programs; and (iv) reviewing and assessing annually the compensation
committee&rsquo;s performance and the adequacy of its charter.</FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Nominating
and Corporate Governance Committee </U></I></FONT></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Alex Shlyankevich, Douglas Moore,
and Michael Frid, each of whom satisfies the &ldquo;independence&rdquo; requirements of Nasdaq&rsquo;s rules, will serve on our nominating
and corporate governance committee upon Douglas Moore&rsquo;s appointment to the board, with Dr. Frid serving as the chairman. The nominating
and corporate governance committee assists the board of directors in selecting individuals qualified to become our directors and in determining
the composition of the board and its committees.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee will be responsible for, among other things: (i) identifying and evaluating individuals
qualified to become members of the board by reviewing nominees for election to the board submitted by shareholders and recommending to
the board director nominees for each annual meeting of shareholders and for election to fill any vacancies on the board; (ii) advising
the board with respect to board organization, desired qualifications of board members, the membership, function, operation, structure
and composition of committees (including any committee authority to delegate to subcommittees), and self-evaluation and policies; (iii)
advising on matters relating to corporate governance and monitoring developments in the law and practice of corporate governance; (iv)
overseeing compliance with the our code of ethics; and (v) approving any related party transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee&rsquo;s methods for identifying candidates for election to our board of directors (other
than those proposed by our shareholders, as discussed below) will include the solicitation of ideas for possible candidates from a number
of sources - members of our board of directors, our executives, individuals personally known to the members of our board of directors,
and other research. The nominating and corporate governance committee may also, from time-to-time, retain one or more third-party search
firms to identify suitable candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
making director recommendations, the nominating and corporate governance committee may consider some or all of the following factors:
(i) the candidate&rsquo;s judgment, skill, experience with other organizations of comparable purpose, complexity and size, and subject
to similar legal restrictions and oversight; (ii) the interplay of the candidate&rsquo;s experience with the experience of other board
members; (iii) the extent to which the candidate would be a desirable addition to the board and any committee thereof; (iv) whether or
not the person has any relationships that might impair his or her independence; and (v) the candidate&rsquo;s ability to contribute to
the effective management of our company, taking into account the needs of our company and such factors as the individual&rsquo;s experience,
perspective, skills and knowledge of the industry in which we operate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder may nominate one or more persons for election as a director at an annual meeting of shareholders if the shareholder complies
with the notice and information provisions contained in our bylaws. Such notice must be in writing to our Company not later than the
close of business on the ninetieth (90th) day nor earlier than the close of business on the one-hundred-twentieth (120th) day prior to
the first anniversary of the preceding year&rsquo;s annual meeting; provided, however, that in the event that the date of the annual
meeting is advanced more than thirty (30) days prior to or delayed by more than thirty (30) days after the anniversary of the preceding
year&rsquo;s annual meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the
one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of the ninetieth
(90th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting
is first made or as otherwise required by the Exchange Act. In addition, shareholders furnishing such notice must be a holder of record
on both (i)&nbsp;the date of delivering such notice and (ii)&nbsp;the record date for the determination of shareholders entitled to vote
at such meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Ethics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of ethics that applies to all of our directors, officers and employees, including our principal executive officer,
principal financial officer and principal accounting officer. Such code of ethics addresses, among other things, honesty and ethical
conduct, conflicts of interest, compliance with laws, regulations and policies, including disclosure requirements under the federal securities
laws, and reporting of violations of the code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the code of ethics has been filed as an exhibit to the registration statement of which this prospectus is a part. We are required
to disclose any amendment to, or waiver from, a provision of our code of ethics applicable to our principal executive officer, principal
financial officer, principal accounting officer, controller, or persons performing similar functions. We intend to use our website as
a method of disseminating this disclosure as well as by SEC filings, as permitted or required by applicable SEC rules. Any such disclosure
will be posted to our website within four (4) business days following the date of any such amendment to, or waiver from, a provision
of our code of ethics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE
COMPENSATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Compensation Table - Years Ended December 31, 2021 and 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to all individuals
who served as the Company&rsquo;s principal executive officer or acting in similar capacity during the last two completed fiscal years,
regardless of compensation level, and other individuals as required by Item 402(m)(2) of Regulation S-K, during the noted periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-left: 0pt"><P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><B>Name
                                            and Principal Position</B></P></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salary<BR>
                                            ($)</B></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Bonus<BR>
                                            ($)</B></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stock<BR>
                                            Awards<BR>
                                            ($)</B></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option<BR>
                                            Awards<BR>
                                            ($)</B></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>All
                                            Other<BR>
                                            Compensation<BR>
                                            ($)</B></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total<BR>
                                            ($)&nbsp;&nbsp;</B></P></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 24%; text-align: left">Maria Vilenchik,</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center">2021</TD><TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">160,000</TD><TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;-</TD><TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">308,610</TD><TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">468,610</TD><TD STYLE="width: 1%; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">President, Chief Executive Officer and Director</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">2020</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">38,316</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: right">198,316</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Information for
                                            Arthur Healey, the Company&rsquo;s Chief Financial Officer, is not required to be presented
                                            in this table pursuant to the instructions to Item 402(m)(2) of Regulation S-K.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Employment Agreements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Maria Vilenchik, Chief Executive Officer </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We entered into an employment agreement with our
Chief Executive Officer, Dr. Maria Vilenchik, dated December 30, 2022 and effective as of January 1, 2022. This agreement was amended
and ratified by our board of directors on March 10, 2022. Dr. Vilenchik&rsquo;s employment is at will and may be terminated by either
party at any time, with or without cause or reason. Although Dr. Vilenchik will initially serve as our Chief Executive Officer, we may
appoint a new Chief Executive Officer during Dr. Vilenchik&rsquo;s term. In that case, she would report to the Chief Executive Officer
and have the duties and responsibilities commensurate with her new position as our board of directors may determine. Dr. Vilenchik&rsquo;s
compensation will not be reduced in that circumstance.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will pay Dr. Vilenchik an base annual salary of
$160,000, payable in monthly installments, until the Company raises a minimum of $10,000,000 in an equity capital raise, at which time
her base salary will increase to $250,000. Dr. Vilenchik&rsquo;s base salary will begin to accrue on January 1, 2022 and will be subject
to annual review and adjustment, but not reduction, pursuant to the Company&rsquo;s employee compensation policies in effect from time
to time. Dr. Vilenchik will be eligible for the following bonus cash compensation: (i) an annual bonus for the achievement of milestones
established by the Compensation Committee of the Board of Directors of up to 30% of her base salary; and (ii) a cash bonus equal to 2%
of any &ldquo;upfront payment&rdquo; on any collaboration agreement reached with a pharmaceutical company, so long as the negotiations
were initiated during her employment with the Company.&nbsp; Additionally, Dr. Vilenchik will receive the following equity compensation:
(i) a grant of nonqualified stock options exercisable for 220,265 shares of common stock that will vest quarterly at a rate 1/16 per
quarter over a period of four years; and (i) a grant of nonqualified stock options exercisable for 330,397 shares of common stock that
will vest upon the achievement of milestones including: (a) 16.67% upon each of the first, second and third FDA approval of a new drug
indication pursuant to a successful IND application by the Company; (b) 16.67% upon the first dosing of a patient in each of the Company&rsquo;s
first, second and third Phase IIb trials; and (c) nonqualified stock options exercisable for 22,027 shares of common stock upon a non-dilutive
research funding from any U.S agency. The options will have an exercise price no higher than the fair market value on the date of grant
and shall be exercisable on a cashless basis, at Dr. Vilenchik&rsquo;s option, in the event of an exit. Dr. Vilenchik will be provided
with any standard executive officer benefits, reimbursement for all reasonable business-related expenses, 25 days of paid time off per
year, and a monthly phone allowance of up to $100 per month.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we terminate Dr. Vilenchik without cause or she resigns for good reason, as provided under her employment agreement, then we must, for
the shorter of 12 months or the period before Dr. Vilenchik obtains gainful employment or self-employment, pay monthly severance payments
of her base salary and any unvested options granted under her employment agreement will continue to vest. Any additional payments or
benefits following termination other than previously accrued obligations will be subject to Dr. Vilenchik&rsquo;s execution of a general
release of claims. Dr. Vilenchik is also subject to standard exclusive employment, confidentiality, non-disparagement, non-solicitation,
assignment of inventions, and non-competition provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Key Employee Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Alexei Belenky, Lead Scientist</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under our employment contract with Alexei Belenky,
dated December 30, 2021, we agreed that Dr. Belenky would begin permanent full-time employment as our Lead Scientist on December 30,
2021. Dr. Belenky&rsquo;s employment is at will and his employment may be terminated by either party at any time and with or without
cause or reason. We may modify Dr. Belenky&rsquo;s job title or duties, provided that such changes would be considered reasonable for
a similar position in our industry or business. His job title or duties may be changed by agreement and with both his and our approval
or after a notice period required under law. We will pay Dr. Belenky an annual salary of $160,000, payable in monthly installments. Dr.
Belenky will receive a grant of nonqualified stock options exercisable for 22,027 shares of common stock that will vest over four years.
We will reimburse Dr. Belenky for all reasonable expenses, in accordance with our lawful policies as in effect from time to time, including
but not limited to, any travel and entertainment expenses incurred by Dr. Belenky in connection with the business of the Company. He
will be entitled to four weeks of paid vacation each year during the term of the agreement, and upon termination of employment, we will
compensate Dr. Belenky for any accrued but unused vacation. Dr. Belenky will be entitled to only those additional benefits that are currently
available as described in the lawful provisions of our employment booklets, manuals, and policy documents or as required by law. Any
discretionary benefits are subject to change, without compensation, upon the Company providing Dr. Belenky with 60 days&rsquo; written
notice of that change and providing that any change to those benefits is taken generally with respect to other employees and does not
single out Dr. Belenky. Dr. Belenky is also subject to standard exclusive employment, confidentiality, non-disparagement, non-solicitation,
non-competition, and assignment of inventions provisions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year-End </B>&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the following named executive officers had the following unexercised options, stock that has not vested, and equity
incentive plan awards:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><B>Name</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Number of Securities Underlying Unexercised Options
    # Exercisable</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B># <BR> Unexercisable</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Incentive Plan Awards: Number of Securities Underlying
    Unexercised Options</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Option Exercise Price</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Option Expiration Date</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Number of Shares or Units of Stock not Vested</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Market Value of Shares or Units not Vested</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Awards: Number of Unearned Shares, Units or Other
    Rights not Vested</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Value of Unearned Shares, Units or Other Rights not
    Vested</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in; width: 9%">Maria Vilenchik, Chief Executive Officer and
    Director</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">87,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.18</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: center">2/28/2023</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">6/14/2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">6/14/2031&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,027</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">6/14/2031&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">3/17/2031&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">11/1/2031&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the compensation paid to our directors during the fiscal year ended December 31, 2021 other than compensation
disclosed above in a director&rsquo;s capacity as an executive officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees <BR> Earned or<BR> Paid in <BR>
    Cash<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stock<BR>
                                            Awards</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>($)</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> Awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>All
                                            Other<BR> Compensation</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>($)</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: justify">Marc Duey</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,784</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,784</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Alexander Shlyankevich</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,784</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Yuriy Gankin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,784</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Michael Frid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,352</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,352</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valeria Povolotsky<B><SUP>(1)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,784</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Resigned from the board of directors effective February 10,
                                         2022.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
other member of our board of directors received any compensation for his or her services as a director during the fiscal year ended December
31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Agreements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 23, 2021, we entered into agreements with
each of the members of our board of directors. Under these agreements, we have agreed to award each director a one-time grant of nonqualified
stock options under our 2012 Plan to purchase 3,304 shares of our common stock at an exercise price equal to the fair market value of
the stock on the option grant date, as determined in good faith by our board of directors.&nbsp; These options will vest over three years
subject to continued service on the board of directors or as a consultant to the Company and will be subject to the terms and conditions
of the 2012 Plan and standard form of 2021 Plan stock option agreement. We will also reimburse each director for reasonable travel and
other business-related expenses incurred in in connection with the performance of the director&rsquo;s duties for us, subject to preapproval
if an expense is more than $300. These agreements have confidentiality, assignment of inventions, and other standard provisions. Separately,
we have entered into our standard form of indemnification agreement for officers and directors of the Company with each of our directors
and director nominees.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current independent directors, Alex Shlyankevich, Yuriy Gankin,
and Michael Frid, and the director nominees, Douglas T. Moore and Michael Kody, will enter into new independent director agreements. These
agreements will supersede the previous director agreements with the current independent directors. Under their independent director agreements
with us, each independent director and director nominee will receive an annual cash fee and an initial award of equity upon either: (i)
the director nominee&rsquo;s appointment to our board of directors immediately upon effectiveness of the registration statement of which
this prospectus forms a part or (ii) the effective date of this registration statement for current directors. We will pay an annual cash
compensation fee and provide an annual equity award to each director and director nominee, both paid in four equal installments no later
than the fifth business day of each calendar quarter commencing in the quarter following the effective date of our registration statement.
The cash fee to be paid to each director nominee will be $[ ]. The annual equity award for each independent director and director nominee
will be [ ] [shares of common stock/options]. Under their agreements, [ ] [shares of common stock] [options] will be awarded to each director
nominee and independent director. The [shares of common stock] [options] will vest in four (4) equal quarterly installments commencing
in the quarter following the effective date of this registration statement. We will also reimburse each independent director and director
nominee for pre-approved reasonable business-related expenses incurred in good faith in connection with the performance of the independent
director or director nominee&rsquo;s duties for us. As also required under the independent director agreements, we have separately entered
into a standard indemnification agreement with each of our current independent directors and director nominees, the term of which for
the director nominees will begin on the date of the director nominee&rsquo;s appointment.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
2012 Stock Option and Restrictive Stock Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 20, 2012, we adopted the Felicitex Therapeutics
Inc. 2012 Stock Option and Restricted Stock Plan, or the 2012 Plan. The purpose of the 2012 Plan is to grant restricted stock and stock
options to our officers, employees, directors, advisors and consultants. The maximum number of shares of common stock that may be issued
pursuant to awards granted under the 2012 Plan after the effect of the reverse stock-split, is 1,101,321 shares. As of the date of this
prospectus, options to purchase 1,018,146 shares of our common stock are outstanding. There were also 83,175 shares of restricted stock
awards granted under the 2012 Plan, all of which are fully vested and included in the number of shares of our common stock currently
outstanding. The 2012 Plan terminates on July 20, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary briefly describes the principal features of the 2012 Plan and is qualified in its entirety by reference to the full
text of the 2012 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards
that may be granted include: (a)&nbsp;Incentive Stock Options, (b)&nbsp;Non-qualified&nbsp;Stock Options, and (c)&nbsp;Restricted Stock.
These awards offer our officers, employees, consultants and directors the possibility of future value, depending on the long-term&nbsp;price
appreciation of our Common Stock and the award holder&rsquo;s continuing service with our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options give the option holder the right to acquire from us a designated number of shares of Common Stock at a purchase price that is
fixed upon the grant of the option. The exercise price will not be less than the market price of the Common Stock on the date of grant.
Stock options granted may be either tax-qualified&nbsp;stock options (so-called&nbsp;&ldquo;incentive stock options&rdquo;) or non-qualified&nbsp;stock
options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
Stock are shares of Common Stock awarded to participants at no cost. Restricted Stock represent issued and outstanding shares of our
Common Stock subject to vesting criteria, or restricted stock units, which represent the right to receive shares of our Common Stock
subject to satisfaction of the vesting criteria. Restricted shares are forfeitable and non-transferable&nbsp;until the shares vest. The
vesting date or dates and other conditions for vesting are established when the shares are awarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the permissible types of awards under the 2012 Plan are described in more detail as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Purposes
of 2012 Plan:</I></B> The purposes of the 2012 Plan are to secure the benefits arising from capital stock ownership by officers, employees,
directors, and advisors or consultants for our company who are expected to contribute to our Company&rsquo;s future growth and success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><BR>
Administration of the 2012 Plan:</I></B> The 2012 Plan is currently administered by our board of directors and will be administered by
our compensation committee once it is established (which we refer to as the administrator). Among other things, the administrator has
the authority to select persons who will receive awards, determine the types of awards and the number of shares to be covered by awards,
and to establish the terms, conditions, performance criteria, restrictions and other provisions of awards. The administrator has authority
to establish, amend and rescind rules and regulations relating to the 2012 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eligible
Recipients:</I></B> Persons eligible to receive awards under the 2012 Plan will be those officers, employees, consultants, and directors
of our company and its subsidiaries who are selected by the administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><B><I>Shares Available Under the 2012 Plan:
</I></B>The maximum number of shares of our Common Stock that may be delivered to participants under the 2012 Plan is 1,101,231 subject
to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to an award under the 2012 Plan
for which the award is canceled, forfeited or expires again become available for grants under the 2012 Plan. Shares subject to an award
that is settled in cash will not again be made available for grants under the 2012 Plan.</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Options:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General.</I>&nbsp;Subject
to the provisions of the 2012 Plan, the administrator has the authority to determine all grants of stock options. That determination
will include: (i)&nbsp;the number of shares subject to any option; (ii)&nbsp;the exercise price per share; (iii)&nbsp;the expiration
date of the option; (iv)&nbsp;the manner, time and date of permitted exercise; (v)&nbsp;other restrictions, if any, on the option or
the shares underlying the option; and (vi)&nbsp;any other terms and conditions as the administrator may determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Option
Price</I>. The exercise price for stock options will be determined at the time of grant. Normally, the exercise price will not be less
than the fair market value on the date of grant. As a matter of tax law, the exercise price for any incentive stock option awarded may
not be less than the fair market value of the shares on the date of grant. However, incentive stock option grants to any person owning
more than 10% of our voting stock must have an exercise price of not less than 110% of the fair market value on the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
of Options.</I> An option may be exercised only in accordance with the terms and conditions for the option agreement as established by
the administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the administrator, by actual or constructive delivery of shares of Common Stock to
the holder of the option based upon the fair market value of the shares on the date of exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expiration
or Termination.</I> Options, if not previously exercised, will expire on the expiration date established by the administrator at the
time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders of more
than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date if the holder&rsquo;s
service with our company or a subsidiary terminates before the expiration date. The option may remain exercisable for specified periods
after certain terminations of employment, including terminations as a result of death, disability or retirement, with the precise period
during which the option may be exercised to be established by the administrator and reflected in the grant evidencing the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Incentive
and Non-Qualified&nbsp;Options.</I>&nbsp;As described elsewhere in this summary, an incentive stock option is an option that is intended
to qualify under certain provisions of the Code, for more favorable tax treatment than applies to non-qualified&nbsp;stock options. Any
option that does not qualify as an incentive stock option will be a non-qualified&nbsp;stock option. Under the Code, certain restrictions
apply to incentive stock options. For example, the exercise price for incentive stock options may not be less than the fair market value
of the shares on the grant date and the term of the option may not exceed ten years. In addition, an incentive stock option may not be
transferred, other than by will or the laws of descent and distribution, and is exercisable during the holder&rsquo;s lifetime only by
the holder. In addition, no incentive stock options may be granted to a holder that is first exercisable in a single year if that option,
together with all incentive stock options previously granted to the holder that also first become exercisable in that year, relate to
shares having an aggregate market value in excess of $100,000, measured at the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock
Awards:</I></B> Stock awards can also be granted under the 2012 Plan. A stock award is a grant of shares of Common Stock or of a right
to receive shares in the future. These awards will be subject to such conditions, restrictions and contingencies as the administrator
shall determine at the date of grant. Those may include requirements for continuous service and/or the achievement of specified performance
goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Section&nbsp;162(m)
of the Code:</I></B> Section&nbsp;162(m) of the Code limits publicly-held&nbsp;companies to an annual deduction for U.S. federal income
tax purposes of $1.0&nbsp;million for compensation paid to each of their principal executive officer or principal financial officer and
their three highest compensated executive officers (other than the principal executive officer or principal financial officer) determined
at the end of each year, referred to as covered employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Material Provisions:</I></B> Awards will be evidenced by a written agreement, in such form as may be approved by the administrator. In
the event of various changes to the capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations,
an appropriate adjustment will be made by the administrator to the number of shares covered by outstanding awards or to the exercise
price of such awards. The administrator is also permitted to include in the written agreement provisions that provide for certain changes
in the award in the event of a change of control of our company, including acceleration of vesting. Except as otherwise determined by
the administrator at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution.
Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.
Our board also has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend
the 2012 Plan or any outstanding award or may terminate the 2012 Plan as to further grants, provided that no amendment will, without
the approval of our stockholders, to the extent that such approval is required by law or the rules of an applicable exchange, increase
the number of shares available under the 2012 Plan, change the persons eligible for awards under the 2012 Plan, extend the time within
which awards may be made, or amend the provisions of the 2012 Plan related to amendments. No amendment that would adversely affect any
outstanding award made under the 2012 Plan can be made without the consent of the holder of such award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The 2022 Equity Incentive Plan </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2022, our Board of Directors approved,
and our majority shareholders ratified, the Felicitex Therapeutics, Inc. 2022 Equity Incentive Plan, or the 2022 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B><I>Purpose of the 2022 Plan</I></B>: The purpose
of the 2022 Plan is to advance our interests and the interests of our shareholders by providing an incentive to attract, retain and reward
persons performing services for us and by motivating such persons to contribute to our growth and profitability. The maximum number of
shares of common stock that may be issued pursuant to awards granted under the 2022 Plan is 825,992 shares. Cancelled and forfeited stock
options and stock awards may again become available for grant under the 2022 Plan. As of the date of this prospectus, we have granted
options to purchase 96,117 shares of our common stock under the 2022 Plan and 729,874 shares remain available for issuance under the
2022 Plan. We intend that awards granted under the 2022 Plan be exempt from or comply with Section&nbsp;409A of the Internal Revenue
Code, or the Code (including any amendments or replacements of such section), and the 2022 Plan shall be so construed.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summary briefly describes the principal
features of the 2022 Plan and is qualified in its entirety by reference to the full text of the 2022 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Awards that may be granted include: (a) Incentive
Stock Options, or ISO, (b) Nonstatutory Stock Options, (c) Stock Appreciation Rights, (d) Restricted Stock, (e) Restricted Stock Units,
or RSUs, (f) Stock granted as a bonus or in lieu of another award, and (g) Performance Awards. These awards offer us and our shareholders
the possibility of future value, depending on the long-term price appreciation of our common stock and the award holder&rsquo;s continuing
service with us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock options give the option holder the right
to acquire from us a designated number of shares of our common stock at a purchase price that is fixed at the time of the grant of the
option. The exercise price will not be less than the market price of the common stock on the date of grant. Stock options granted may
be either incentive stock options or non-statutory stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock appreciation rights, or SARs, which may
be granted alone or in tandem with options, have an economic value similar to that of options. When an SAR for a particular number of
shares is exercised, the holder receives a payment equal to the difference between the market price of the shares on the date of exercise
and the exercise price of the shares under the SAR. Again, the exercise price for SARs normally is the market price of the shares on
the date the SAR is granted. Under the 2022 Plan, holders of SARs may receive this payment - the appreciation value - either
in cash or shares of common stock valued at the fair market value on the date of exercise. The form of payment will be determined by
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted stock are awards of a right to receive
shares of our common stock on a future date. Restricted Stock Unit Awards are evidenced by award agreements in such form as our board
of directors shall from time to time establish. Restricted stock shares can take the form of awards of restricted stock, which represent
issued and outstanding shares of our common stock subject to vesting criteria, or restricted stock units, which represent the right to
receive shares of our common stock subject to satisfaction of the vesting criteria. Restricted shares are forfeitable and non-transferable
until the shares vest. The vesting date or dates and other conditions for vesting are established when the shares are awarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may grant common stock
to any eligible recipient as a bonus, or to grant stock or other awards in lieu of obligations to pay cash or deliver other property
under the 2022 Plan or under other plans or compensatory arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2022 Plan also provides for performance awards,
representing the right to receive a payment, which may be in the form of cash, shares of common stock, or a combination, based on the
attainment of pre-established goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the permissible types of awards under
the 2022 Plan are described in more detail below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Administration of the 2022 Plan:</I></B>&nbsp;The
2022 Plan is currently administered by our board of directors. All questions of interpretation of the 2022 Plan, of any award agreement
or of any other form of agreement or other document employed by us in the administration of the 2022 Plan or of any award shall be determined
by the Board, and such determinations shall be final, binding and conclusive upon all persons having an interest in the 2022 Plan or
such award, unless fraudulent or made in bad faith. Any and all actions, decisions and determinations taken or made by the board of directors.
in the exercise of its discretion pursuant to the 2022 Plan or award agreement or other agreement thereunder (other than determining
questions of interpretation pursuant to the preceding sentence) shall be final, binding and conclusive upon all persons having an interest
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Eligible Recipients:</I></B>&nbsp;Persons
eligible to receive awards under the 2022 Plan will be those employees, consultants and directors of us or of any of our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Shares Available Under the 2022 Plan:</I></B>
The maximum aggregate number of shares of common stock that may be issued under the 2022 Plan shall be 825,992 shares and shall consist
of authorized but unissued or reacquired shares of common stock or any combination thereof, subject to adjustment for certain corporate
changes affecting the shares, such as stock splits, merger, consolidation, reorganization, reincorporation, recapitalization, reclassification,
stock dividend. Shares subject to an award under the 2022 Plan for which the award is canceled, forfeited, or expires again become available
for grants under the 2022 Plan.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock Options and Stock Appreciation Rights:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General.</I>&nbsp;Stock options and SARs shall
be evidenced by award agreements specifying the number of shares of common stock covered thereby, in such form as the board of directors
shall from time to time establish. Each Stock option grant will identify the option as an ISO or Nonstatutory Stock Option. Subject to
the provisions of the 2022 Plan, the administrator has the authority to determine all grants of stock options. That determination will
include: (i) the number of shares subject to any option; (ii) the exercise price per share; (iii) the expiration date of the option;
(iv) the manner, time and date of permitted exercise; (v) other restrictions, if any, on the option or the shares underlying the option;
and (vi) any other terms and conditions as the administrator may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Option Price</I>. The exercise price for each
stock option or SAR shall be established in the discretion of the board of directors; provided, however, that the exercise price per
share for the stock option or SAR shall be not less than the fair market value of a share of common stock on the effective date of grant
of the stock option or SAR. Notwithstanding the foregoing, a stock option or SAR may be granted with an exercise price lower than the
minimum exercise price set forth above if such stock option or SAR is granted pursuant to an assumption or substitution for another option
in a manner qualifying under the provisions of Section&nbsp;424(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercise of Options.</I>&nbsp;Stock options
may be immediately exercisable but subject to repurchase or may be exercisable at such time or times, or upon such event or events, and
subject to such terms, conditions, performance criteria and restrictions as shall be determined by the board of directors and set forth
in the award agreement evidencing such stock option. No stock option or SAR shall be exercisable after the expiration of ten (10) years
after the effective date of grant of such stock option or SAR. Subject to the foregoing, unless otherwise specified by the board of directors
in the grant of a stock option or SAR, any stock option or SAR granted hereunder shall terminate ten (10) years after the effective date
of grant of the stock option or SAR, unless earlier terminated in accordance with its provisions. The board of directors may set a reasonable
minimum number of shares of common stock that may be exercised at any one time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Expiration or Termination.</I>&nbsp;Options,
if not previously exercised, will expire on the expiration date established by the administrator at the time of grant. In the case of
incentive stock options, such term cannot exceed ten years provided that in the case of holders of more than 10% of our total combined
voting stock, such term cannot exceed five years. Options will terminate before their expiration date if the holder&rsquo;s service with
our company or a subsidiary terminates before the expiration date. The option may remain exercisable for specified periods after certain
terminations of employment, including terminations as a result of death, disability or retirement, with the precise period during which
the option may be exercised to be established by the administrator and reflected in the grant evidencing the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Incentive Stock Options.</I>&nbsp;Stock options
intending to qualify as ISOs may only be granted to employees, as determined by the board of directors. No ISO shall be granted to any
person if immediately after the grant of such award, such person would own common stock, including common stock subject to outstanding
awards held by him or her under the 2022 Plan or any other plan established by the Company, amounting to more than ten percent (10%)
of the total combined voting power or value of all classes of stock of the Company. To the extent that the award agreement specifies
that an Option is intended to be treated as an ISO, the Option is intended to qualify to the greatest extent possible as an &ldquo;incentive
stock option&rdquo; within the meaning of Section 422 of the Code, and shall be so construed; provided, however, that any such designation
shall not be interpreted as a representation, guarantee or other undertaking on the part of the Company that the Option is or will be
determined to qualify as an ISO. If and to the extent that any shares of Stock are issued under a portion of any Option that exceeds
the $100,000 limitation of Section 422 of the Code, such shares of common stock shall not be treated as issued under an ISO notwithstanding
any designation otherwise.&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Restricted Stock Awards:</I></B>&nbsp;Stock
awards can also be granted under the 2022 Plan. A stock award is a grant of shares of common stock or of a right to receive shares in
the future. These awards will be subject to such conditions, restrictions and contingencies as the administrator shall determine at the
date of grant. Those may include requirements for continuous service and/or the achievement of specified performance goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Restricted Stock Units</I></B>:&nbsp;RSU
Awards shall be evidenced by award agreements in such form as the board of directors shall from time to time establish. The purchase
price for shares of Stock issuable under each RSU Award shall be established by the board of directors in its discretion. Except as may
be required by Applicable Law or established by the board of directors, no monetary payment (other than applicable tax withholding) shall
be required as a condition of receiving a RSU Award. Shares issued pursuant to any RSU Award may (but need not) be made subject to vesting
conditions based upon the satisfaction of such Service requirements, conditions, restrictions or Performance Criteria, as shall be established
by the Board and set forth in the award agreement evidencing such award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Performance Criteria</I></B><I>:</I>&nbsp;Under
the 2022 Plan, Performance Criteria means business criteria including, but not limited to: revenue; revenue growth; earnings before interest
and taxes; earnings before interest, taxes, depreciation and amortization; earnings per share; operating income; pre-or after-tax income;
net operating profit after taxes; economic value added (or an equivalent metric); ratio of operating earnings to capital spending; cash
flow (before or after dividends); cash-flow per share (before or after dividends); net earnings; net sales; sales growth; share price
performance; return on assets or net assets; return on equity; return on capital (including return on total capital or return on invested
capital); cash flow return on investment; total shareholder return; improvement in or attainment of expense levels; and improvement in
or attainment of working capital levels or Performance Criteria. Any Performance Criteria may be used to measure the Company&rsquo;s
performance as a whole or any of the Company&rsquo;s business units and may be measured relative to a peer group or index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Performance Awards.&nbsp;</I></B>Performance
awards shall be evidenced by award agreements in such form as the board of directors shall from time to time establish. Each performance
sward shall entitle the participant to a payment in cash or common stock upon the attainment of Performance Criteria and other terms
and conditions specified by the board of directors. Notwithstanding the satisfaction of any Performance Criteria, the amount to be paid
under a performance award may be adjusted by the board of directors on the basis of such further consideration as the board of directors
in its sole discretion shall determine. The board of directors may, in its discretion, substitute actual common stock for the cash payment
otherwise required to be made to a participant pursuant to a performance award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Bonus Stock and Awards in Lieu of Obligations.&nbsp;</I></B>The
board of directors may grant common stock to any eligible recipient as a bonus, or to grant common stock or other awards in lieu of obligations
to pay cash or deliver other property under the 2022 Plan or under other plans or compensatory arrangements, provided that, in the case
of participants subject to Section 16 of the Exchange Act, the amount of such grants remains within the discretion of the board of directors
to the extent necessary to ensure that acquisitions of common stock or other awards are exempt from liability under Section 16(b) of
the Exchange Act. common stock or awards granted hereunder shall be subject to such other terms as shall be determined by the board of
directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Material Provisions:</I></B>&nbsp;Awards
will be evidenced by a written agreement, in such form as may be approved by the administrator. In the event of various changes to the
capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate adjustment will be
made by the administrator to the number of shares covered by outstanding awards or to the exercise price of such awards. The administrator
is also permitted to include in the written agreement provisions that provide for certain changes in the award in the event of a change
of control of our company, including acceleration of vesting. Except as otherwise determined by the administrator at the date of grant,
awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution, we are
permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. Our board of directors also
has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend the 2022 Plan
or any outstanding award or may terminate the 2022 Plan as to further grants, provided that no amendment will, without the approval of
our stockholders, to the extent that such approval is required by law or the rules of an applicable exchange, increase the number of
shares available under the 2022 Plan, change the persons eligible for awards under the 2022 Plan, extend the time within which awards
may be made, or amend the provisions of the 2022 Plan related to amendments. No amendment that would adversely affect any outstanding
award made under the 2022 Plan can be made without the consent of the holder of such award.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions
with Related Persons </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following includes a summary of transactions
since the beginning of our 2019 fiscal year, or any currently proposed transaction, in which we were or are to be a participant and the
amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last
three completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation
described under &ldquo;<I>Executive Compensation</I>&rdquo; above). We believe the terms obtained or consideration that we paid or received,
as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid
or received, as applicable, in arm&rsquo;s-length transactions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">On January 16, 2018, Marc
                                            Duey, our Chairman, agreed to lend up to $550,000 to the Company on an unsecured basis, at
                                            an interest rate of 12% per year, payable on demand and convertible into shares of our common
                                            stock at Mr. Duey&rsquo;s option at a price per share of $2.29 On March 17, 2020, we issued
                                            238,612 shares of our common stock on Mr. Duey&rsquo;s conversion of $502,000 in principal
                                            and $45,000 of accrued interest on loans under the January 16, 2018 agreement. Mr. Duey also
                                            received warrants to purchase 47,722 &nbsp;&nbsp;additional shares of common stock as an
                                            incentive to convert these loans.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">On March 31, 2020, Mr. Duey
                                            entered into an additional on-demand agreement to lend us up to $550,000 on an unsecured
                                            basis, at an interest rate of 12% per year, payable on demand and convertible into shares
                                            of our common stock at Mr. Duey&rsquo;s option at a price per share of $2.29. On March 17,
                                            2021, we issued 232,473 shares of common stock to Mr. Duey on conversion of $521,000 in principal
                                            and $27,823 of accrued interest on loans under the March 31, 2020 agreement. Additionally,
                                            the Company issued warrants that are exercisable into 46,495 shares of common stock within
                                            five years at an exercise price of $2.36 per share as an incentive to convert these loans.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Through
                                            December 31, 2020, Duce Consulting, Inc., a company owned by Marc Duey, provided management
                                            consulting services to TarMeta valued at $48,000. This amount was recorded as a capital contribution
                                            by TarMeta.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">An outsourced accounting
                                            and finance firm that is owned by our Chief Financial Officer provided accounting, bookkeeping,
                                            finance and other services to us. For the three months ended March 31, 2022, total fees for
                                            services were $91,083. For the years ended December 31, 2021 and 2020, total fees for these
                                            services were $96,000 and $41,000, respectively. The cost of these services was recorded
                                            as a General and Administrative expense. For the year ended December 31, 2021, $60,000 of
                                            accounts payable owed to our Chief Financial Officer was converted into options to purchase
                                            25,416 shares of our common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">On March 31, 2021, Mr. Duey
                                            entered into an additional on-demand agreement to lend us up to $550,000 on an unsecured
                                            basis, at an interest rate of 12% per year, payable on demand and convertible into shares
                                            of our common stock at Mr. Duey&rsquo;s option at a price per share of $2.29. On November
                                            2, 2021, we issued 147,586 shares of our common stock to Mr. Duey on conversion of $348,420
                                            in principal on loans under the March 31, 2021 agreement. Additionally, the Company issued
                                            warrants that are exercisable into 29,518 shares of common stock within five years at an
                                            exercise price of $2.36 per share as an incentive to convert these loans.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">On December 30, 2021, we
                                            completed the acquisition of TarMeta Biosciences, LLC pursuant to an Agreement and Plan of
                                            Merger with TarMeta. In consideration of the acquisition of TarMeta, we issued a total of
                                            635,378 shares of our common stock to the members of TarMeta in exchange for their TarMeta
                                            membership interests. We issued 607,845 of these shares to Mr. Duey, who was a member of
                                            TarMeta and one of the designees of its shares.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                            the year ended December 31, 2020, our Chief Executive Officer provided scientific advisory
                                            services to TarMeta totaling $30,000.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
                                            of March 15, 2022, the total liability owed to our Chairman, Marc Duey, for loans Mr. Duey
                                            made to us was $541,180 in principle plus $54,564 in accrued interest.&nbsp; On March 16,
                                            2022, our board of directors authorized the conversion of the combined liability&nbsp;in
                                            the amount of $595,744 into 192,977 shares of our common stock, effective as of March 16,
                                            2022.&nbsp; The conversion price valuation was determined using&nbsp;an independent 409A
                                            valuation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
                                            January 1, 2022 through March 15, 2022, our Chairman and principal investor made additional
                                            advances to the Company in the amount of $335,000.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On March 16, 2022, we entered into a convertible grid note with the
Chairman with respect to additional advances that the Chairman has made and expects to make to us for general working capital purposes
from now until additional funds are raised from investors. The grid note carries interest at the rate of 12% per year payable in one lump
sum on the maturity date, matures on the one-year anniversary of the issuance date and may be prepaid at any time, in whole or in part,
without penalty. As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has loaned
to us an additional $408,000 under the grid note.</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Anna
                                            Vilenchik, the mother of our CEO, was compensated $10,000 for research services rendered
                                            during the year ended December 31, 2021, and $8,300 during the three months ended March 31,
                                            2022, as an independent contractor.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Promoters
and Certain Control Persons </B>&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of Maria Vilenchik, our co-founder and Chief
Executive Officer, and Michael Frid, Valeria Povolotsky, and Yuriy Gankin, each co-founders, may be deemed a &ldquo;promoter&rdquo; as
defined by Rule 405 of the Securities Act. For information regarding compensation, including items of value, that have been provided
or that may be provided to these individuals, please refer to &ldquo;<I>Executive Compensation</I>&rdquo; above.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRINCIPAL
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth certain information
with respect to the beneficial ownership of our common stock as of the date of this prospectus for (i) each of our named executive officers,
directors, and director nominees; (ii) all of our named executive officers and directors as a group; and (iii) each other shareholder
known by us to be the beneficial owner of more than 5% of our outstanding common stock. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table assumes that the underwriters have not exercised the over-allotment option. </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. For
purposes of this table, a person or group of persons is deemed to have &ldquo;beneficial ownership&rdquo; of any shares of common stock
that such person or any member of such group has the right to acquire within sixty (60) days of the date of this prospectus. For purposes
of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares
that such person or persons has the right to acquire within sixty (60) days of the date of this prospectus are deemed to be outstanding
for such person, but not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion
herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership by any person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address of each beneficial owner listed in the table below is c/o our company, Felicitex Therapeutics Inc.,
27 Strathmore Road, Natick, MA 01760.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Common
Stock <BR>
Beneficially</B>&nbsp;<B>Owned Prior <BR>
to this Offering<SUP>(1)(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Common
    Stock <BR>
    Beneficially Owned After <BR>
    this Offering<SUP>(2)(3)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name of Beneficial Owner</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify"><FONT STYLE="font-size: 10pt">Marc Duey<B><SUP>&nbsp;&nbsp;(5) (6)</SUP></B></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,167,447</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">66.0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,167,447</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">43.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Maria Vilenchik<B><SUP>(4) (5) (7)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,124,625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,124,625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.2</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Alex Shlyankevich <B><SUP>(5) (8)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Yuriy Gankin <B><SUP>(5) (9)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.5</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Michael Frid <B><SUP>(5) (10)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,706</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,706</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.5</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Michael Kody, Director Nominee <B><SUP>(11)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Douglas T. Moore, Director Nominee <B><SUP>(12)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">All executive officers and directors** (7 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,556,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,556,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59.4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Norma Investments Limited <B><SUP>(14)&nbsp;&nbsp;</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">436,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">436,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.3</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
                                            than 1%</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">**</TD><TD STYLE="text-align: justify">Arthur Healey is
                                            not a named executive officer and is therefore not included.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify">Based on 4,455,999 shares of common stock issued and outstanding as
of August 10, 2022.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
                                            ownership is determined in accordance with the rules of the SEC and generally includes voting
                                            or investment power with respect to securities. Except as disclosed in the following footnotes,
                                            each of the beneficial owners listed above has direct ownership of and sole voting and investment
                                            power to the shares of the Company&rsquo;s common stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on 6,978,518 shares of common stock issued and outstanding after this offering.</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Named
                                            Executive Officer.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Consists of (i) 2,864,975 shares of common stock held directly, (ii)
fully vested nonqualified stock options exercisable into 1,468 shares, (iii) nonqualified stock options exercisable into 184 shares within
60 days of the date of this prospectus, (iv) 177,086 shares of common stock issuable upon the conversion of a convertible promissory note
as of the date of this prospectus, and (v) warrants to purchase 123,734 shares of common stock. Does not include 1,652 shares issuable
upon the exercise of options not vesting within 60 days.</P></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(7)</TD><TD STYLE="text-align: justify">Consists of (i) 694,264 shares of common stock, (ii) nonqualified stock
options exercisable into 13,950 shares within 60 days of the date of this prospectus, and (iii) fully vested non-qualified stock options
to purchase 416,411 shares of common stock. Does not include (iv) 192,730 shares of common stock issuable upon the exercise of nonqualified
options, subject to vesting, (v) 1,652 shares issuable upon the exercise of options not vesting within 60 days, and (vi) 330,397 shares
of common stock issuable upon the exercise of nonqualified options, subject to certain milestones.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(8)</TD><TD STYLE="text-align: justify">Consists of (i) fully vested non-qualified stock options exercisable
into 1,468 shares and (ii) non-qualified stock options exercisable into 184 shares within 60 days of the date of this prospectus. Does
not include 1,652 shares issuable upon the exercise of options not vesting within 60 days of the date of this prospectus.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(9)</TD><TD STYLE="text-align: justify">Consists of (i) 164,887 shares of common stock, (ii) fully vested non-qualified
stock option to purchase 8,778 shares of common stock, and (iii) non-qualified stock options exercisable into 184 shares within 60 days
of the date of this prospectus. Does not include 1,652 shares issuable upon the exercise of options not vesting within 60 days.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(10)</TD><TD STYLE="text-align: justify">Consists of (i) 133,639 shares of common stock, (ii) a fully vested
non-qualified stock option to purchase 44,699 shares of common stock, and (iii) non-qualified stock options exercisable into 184 shares
within 60 days of the date of this prospectus. Does not include 1,652 shares issuable upon the exercise of options not vesting within
60 days.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(11)</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under
                                            the independent director agreement between Michael Kody and the Company, Mr. Kody will receive
                                            (i) an initial award of [ ] shares of common stock, which will vest in four (4) equal quarterly
                                            installments commencing in the quarter following the date of his appointment immediately
                                            upon the effectiveness of the registration statement of which this prospectus forms a part
                                            and (ii) an annual amount of equity compensation of [ ] shares of common stock.</P>


</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(12)</TD><TD STYLE="text-align: justify">Under the independent
                                            director agreement between Douglas T. Moore and the Company, Mr. Moore will receive (i) an
                                            initial award of [ ] shares of common stock, which will vest in four (4) equal quarterly
                                            installments commencing in the quarter following the date of his appointment immediately
                                            upon the effectiveness of the registration statement of which this prospectus forms a part
                                            and (ii) an annual amount of equity compensation of [ ] shares of common stock.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(13)</TD><TD STYLE="text-align: justify">Includes the
                                            shares of common stock beneficially owned by Arthur Healey, our Chief Financial Officer.
                                            Mr. Healey owns a fully vested non-qualified stock option to purchase 25,416 shares of common
                                            stock.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">(14)</TD><TD STYLE="text-align: justify">[&nbsp;&nbsp;]
                                            has voting and dispositive control over Norma Investments Limited. Norma Investments Limited&rsquo;s
                                            business address is Coastal Building, Wickham&rsquo;s Cay II, P.O. Box 2221, Road Town, Tortola,
                                            British Virgin Islands.</TD>
</TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any arrangements which if consummated may result in a change of control of our company.</FONT></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION
OF SECURITIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock currently consists of 100,000,000 shares, consisting of 100,000,000 shares of common stock, par value $0.0001
per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description summarizes important terms of the classes of our capital stock following the filing of our articles of incorporation.
This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of incorporation and
our bylaws which have been filed as exhibits to the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, there were
4,455,999 shares of common stock issued and outstanding held by eleven (11) stockholders of record.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B><I>. </I>The holders of common stock are entitled to one vote for each share held of record on all matters submitted to
a vote of the shareholders. Under our articles of incorporation and bylaws, any corporate action to be taken by vote of shareholders
other than for election of directors shall be authorized by the affirmative vote of the majority of votes cast. Directors are elected
by a plurality of votes. Shareholders do not have cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B>. Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled
to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation
Rights</I></B>. In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably
in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities and
the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Rights</I></B>. Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking
fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to,
and may be adversely affected by, the rights of the holders of shares of any series of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
unit being offered in this offering consists of one share of common stock and a warrant to purchase one share of common stock. The share
of common stock and warrant that are part of the units are immediately separable and will be issued separately in this offering, although
they will have been purchased together in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants
Included in the Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Form</I></B>.
The warrants will be issued under a warrant agent agreement between us and [&nbsp;&nbsp;], as warrant agent. The material terms and provisions
of the warrants offered hereby are summarized below. The following description is subject to, and qualified in its entirety by, the form
of warrant agent agreement and accompanying form of warrant, which is filed as an exhibit to the registration statement of which this
prospectus is a part. You should review a copy of the form of warrant agent agreement and accompanying form of warrant for a complete
description of the terms and conditions applicable to the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exercisability</I></B>.
The warrants are exercisable immediately upon issuance and will thereafter remain exercisable at any time up to five (5) years from the
date of original issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a
duly executed exercise notice accompanied by payment in full for the number of shares purchased upon such exercise (except in the case
of a cashless exercise as discussed below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exercise
Price</I></B>. Each warrant represents the right to purchase one share of common stock at an exercise price of $[&nbsp;&nbsp;] per share
(equal to 100% of the public offering price). The exercise price is subject to appropriate adjustment in the event of certain share dividends
and distributions, stock splits, stock combinations, reclassifications or similar events affecting our shares of common stock and also
upon any distributions of assets, including cash, stock or other property to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrant exercise price is also subject to
the following anti-dilution adjustments: Subject to certain exemptions outlined in the warrants, for a period until the later of: (i)
two years from the date of issuance of the warrants, or (ii) on the date no Qualified Buyer holds any warrants, if the Company shall
sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter into an agreement to sell, or grant any right
to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any
shares of its common stock or convertible security, at an effective price per share less than the exercise price of the warrant then
in effect, or a dilutive issuance, the exercise price of the warrant shall be reduced to equal the effective price per share in such
dilutive issuance;&nbsp;provided, however, that in no event shall the exercise price of the warrant be reduced to an exercise price lower
than 50% of the public offering price per unit in this offering, or the floor price. On the date that is 90 calendar days immediately
following the initial issuance date of the warrants, the exercise price of the warrants will adjust to be equal to the Reset Price, provided
that such value is less than the exercise price in effect on that date. The Reset Price is equal to the greater of (a) the floor price
and (b) 100% of the lowest volume weighted average price per share of our common stock occurring during the 90 calendar days following
the issuance date of the warrants. The lowest Reset Price is the same as the floor price, or $3.125, which is 50% of the offering price,
based on an assumed public offering price of $6.25 per unit, the midpoint of the price range of the units, per share. Separately, the
Company may choose to lower the exercise price of the warrants at its option at any time during the life of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cashless
Exercise</I></B>. If, at any time during the term of the warrants, the issuance of shares of common stock upon exercise of the warrants
is not covered by an effective registration statement, the holder is permitted to effect a cashless exercise of the warrants (in whole
or in part) by having the holder deliver to us a duly executed exercise notice, canceling a portion of the warrant in payment of the
purchase price payable in respect of the number of shares of common stock purchased upon such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Additional Warrants</I></B>. Additionally,
in the event of any adjustment under the dilutive issuance provision of the warrants that results in a reduction of the exercise price,
in aggregate, to 50% of the Initial Exercise Price, then in connection with such adjustment, each Qualified Buyer shall receive two Additional
Warrants for each one warrant held by such holder on the date of adjustment. The maximum number of warrants subject to such adjustment
by a given Qualified Buyer will be limited to the number of warrants purchased by such Qualified Buyer in this offering. Qualified Buyers
will also receive Additional Warrants as a result of the Reset Price being set at the floor price. Such Additional Warrants shall be
on substantially the same terms as the warrant; provided, however, that the term of the Additional Warrants shall be five (5) years from
the issuance date and such Additional Warrants will not be tradable warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to Timely Deliver Shares</I></B>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">If we fail for any reason to deliver to the holder the shares subject to an
exercise within the timeframe specified in the warrant, we will be required pay to the holder cash liquidated damages. In addition, if
the holder or its broker has to purchase shares to deliver in satisfaction of a sale by the holder, then we shall be required to pay
to the holder a certain cash amount as specified in the warrant. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercise Limitation.</I></B> A holder will
not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially own in excess
of&nbsp;4.99% (or, upon election by the holder prior to the issuance of any warrants, 9.99%)&nbsp;of the number of shares of our common
stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the
terms of the warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided
that any increase in such percentage shall not be effective until 61 days following notice from the holder to us.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Forced Exercise</I></B>. The warrants (including
the Additional Warrants) will be subject to forced exercise commencing six months from issuance subject to the condition that the volume
weighted average price of our common stock exceeds 200% of the Initial Exercise Price for ten consecutive trading days and subject to
certain other conditions set forth in the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Rights
as a Shareholder</I></B>. Except as otherwise provided in the warrants or by virtue of such holder&rsquo;s ownership of our shares of
common stock, the holder of a warrant does not have the rights or privileges of a holder of our shares of common stock, including any
voting rights, until the holder exercises the warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrant Agent; Global Certificate</I></B><I>.&nbsp;</I>The
warrants&#8239;will be issued in registered form under the warrant agent agreement between the warrant
agent and us. The warrants shall initially be represented only by one or more global warrants deposited with the warrant agent, as custodian
on behalf of The Depository Trust Company (DTC) and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed
by DTC. Our transfer agent, VStock Transfer, LLC, will serve as the warrant agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Governing
Law and Jurisdiction</I></B>. The warrant agent agreement and warrant provide that the validity, interpretation, and performance of the
warrant agent agreement and the warrants will be governed by the laws of the State of New York, without giving effect to conflicts of
law principles that would result in the application of the substantive laws of another jurisdiction. In addition, the warrant agent agreement
and warrant provide that any action, proceeding or claim against any party arising out of or relating to the warrant agent agreement
or the warrants must be brought and enforced in the state and federal courts sitting in the Borough of Manhattan in the State of New
York. Investors in this offering will be bound by these provisions. However, we do not intend that the foregoing provisions would apply
to actions arising under the Securities Act or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, there will be up to [198,400] shares of common stock issuable upon exercise of the representative&rsquo;s
warrants. See &ldquo;<I>Underwriting-Representative&rsquo;s Warrants</I>&rdquo; below for a description of the representative&rsquo;s
warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants
Issued to Marc Duey</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2020, March 17, 2021 and November
2, 2021, we issued warrants to purchase 47,722, 46,495 and 29,518 shares of our common stock, respectively, to Marc Duey, our Chairman.
These warrants are exercisable at $2.36 per share. The March 2020 warrants have a term of six years while the March 2021 and the November
2021 warrants each have five-year terms.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On July 20, 2012, we adopted the Felicitex Therapeutics
Inc. 2012 Stock Option and Restricted Stock Plan, or the 2012 Plan. The purpose of the 2012 Plan is to grant restricted stock and stock
options to our officers, employees, directors, advisors and consultants. The maximum number of shares of common stock that may be issued
pursuant to awards granted under the 2012 Plan is 1,101,321 shares. Cancelled and forfeited stock options and stock awards may again
become available for grant under the Plan. As of the date of this prospectus, unexercised options to purchase 1,018,146 shares of our
common stock are outstanding under the 2012 Plan. There were also 83,175 shares of restricted stock awards granted under the 2012 Plan,
all of which are fully vested and are included in number of shares of our common stock currently outstanding. The 2012 Plan expires on
July 20, 2022.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 15, 2022, we adopted the Felicitex Therapeutics
Inc. 2022 Equity Incentive Stock Plan, or the 2022 Plan. The purpose of the 2022 Plan is to grant restricted stock and stock options
to our officers, employees, directors, advisors and consultants. The maximum number of shares of common stock that may be issued pursuant
to awards granted under the 2022 Plan is 825,992 shares. Cancelled and forfeited stock options and stock awards may again become available
for grant under the Plan. As of the date of this prospectus, unexercised options to purchase 96,117 shares of our common stock are outstanding
under the 2022 Plan. The 2022 Plan expires on March 15, 2032.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of the&nbsp;Delaware&nbsp;Revised Statutes, our articles of incorporation and our bylaws could have the effect of delaying or preventing
a third-party from acquiring us, even if the acquisition would benefit our stockholders. Such provisions of the&nbsp;Delaware&nbsp;Revised
Statutes, our articles of incorporation and our bylaws are intended to enhance the likelihood of continuity and stability in the composition
of our board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that
may involve an actual or threatened change of control of our company. These provisions are designed to reduce our vulnerability to an
unsolicited proposal for a takeover that does not contemplate the acquisition of all of our outstanding shares, or an unsolicited proposal
for the restructuring or sale of all or part of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bylaws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, various provisions of our bylaws may have an anti-takeover effect. These provisions may delay, defer or prevent a tender offer
or takeover attempt of the company that a stockholder might consider in his or her best interest, including attempts that might result
in a premium over the market price for the shares held by our stockholders. Our bylaws may be adopted, amended or repealed by the affirmative
vote of the holders of at least a majority of our outstanding shares of capital stock entitled to vote for the election of directors,
and except as provided by&nbsp;Delaware&nbsp;law, our board of directors shall have the power to adopt, amend or repeal the bylaws by
a vote of not less than a majority of our directors. Any bylaw provision adopted by the board of directors may be amended or repealed
by the holders of a majority of the outstanding shares of capital stock entitled to vote for the election of directors. Our bylaws also
contain limitations as to who may call special meetings as well as require advance notice of stockholder matters to be brought at a meeting.
Additionally, our bylaws also provide that no director may be removed by less than a two-thirds vote of the issued and outstanding shares
entitled to vote on the removal. Our bylaws also permit the board of directors to establish the number of directors and fill any vacancies
and newly created directorships. These provisions will prevent a shareholder from increasing the size of our board of directors and gaining
control of our board of directors by filling the resulting vacancies with its own nominees.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws establish an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including
proposed nominations of persons for election to the board of directors. Shareholders at an annual meeting will only be able to consider
proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors
or by a shareholder who was a shareholder of record on the record date for the meeting, who is entitled to vote at the meeting and who
has given us timely written notice, in proper form, of the shareholder&rsquo;s intention to bring that business before the meeting. Although
our bylaws do not give the board of directors the power to approve or disapprove shareholder nominations of candidates or proposals regarding
other business to be conducted at a special or annual meeting, our bylaws may have the effect of precluding the conduct of certain business
at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation
of proxies to elect its own slate of directors or otherwise attempting to obtain control of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Authorized
but Unissued Shares</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized but unissued shares of common stock are available for our board of directors to issue without stockholder approval. We may
use these additional shares for a variety of corporate purposes, including raising additional capital, corporate acquisitions and employee
stock plans. The existence of our authorized but unissued shares of common stock could render it more difficult or discourage an attempt
to obtain control of the company by means of a proxy context, tender offer, merger or other transaction since our board of directors
can issue large amounts of capital stock as part of a defense to a take-over challenge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Supermajority
Voting Provisions</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware&nbsp;Law
provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&rsquo;s
articles of incorporation or bylaws, unless a corporation&rsquo;s articles of incorporation or bylaws, as the case may be, require a
greater percentage. Although our articles of incorporation and bylaws do not currently provide for such a supermajority vote on any matters,
our board of directors can amend our bylaws and we can, with the approval of our stockholders, amend our articles of incorporation to
provide for such a super-majority voting provision.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cumulative
Voting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the holders of our common stock do not have cumulative voting rights in the election of our directors. The combination of the present
ownership by a few shareholders of a significant portion of our issued and outstanding common stock and lack of cumulative voting makes
it more difficult for other shareholders to replace our board of directors or for a third party to obtain control of our company by replacing
its board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exchange
Listing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to file an application to list our shares of common stock on the Nasdaq Capital Market under the symbol &ldquo;FLCT&rdquo; and
the warrants offered in this offering on the Nasdaq Capital Market under the symbol &ldquo;FLCTW.&rdquo; We will not consummate and close
this offering without a listing approval letter from the Nasdaq Capital Market. Our receipt of a listing approval letter is not the same
as an actual listing on the Nasdaq Capital Market. The listing approval letter will serve only to confirm that, if we sell a number of
units in this firm commitment offering sufficient to satisfy applicable listing criteria, our common stock and warrants will in fact
be listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our shares of common stock and warrants are
listed on the Nasdaq Capital Market, we will be subject to continued listing requirements and corporate governance standards of the Nasdaq
Capital Market. We expect these new rules and regulations to significantly increase our legal, accounting and financial compliance costs.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have appointed VStock Transfer, LLC, 18 Lafayette
Place, Woodmere, NY 1159, (212) 828-8436, as the transfer agent for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHARES
ELIGIBLE FOR FUTURE SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
this offering, there has not been a public market for shares of our common stock. Future sales of substantial amounts of shares of our
common stock, including shares issued upon the conversion of convertible notes, the exercise of outstanding options and warrants, in
the public market after this offering, or the possibility of these sales occurring, could cause the prevailing market price for our common
stock to fall or impair our ability to raise equity capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the closing of this offering, we will have [&nbsp;&nbsp;&nbsp;] shares of common stock issued and outstanding, assuming no
exercise of the warrants being offered in this offering. In the event the underwriters exercise the over-allotment option to purchase
additional shares of common stock and/or warrants in full, we will have [&nbsp;&nbsp;&nbsp;] shares of common stock issued and outstanding.
The common stock sold in this offering will be freely tradable without restriction or further registration or qualification under the
Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
issued shares of common stock that were not offered and sold in this offering, as well as shares issuable upon the exercise of warrants
and subject to employee stock options, are or will be upon issuance, &ldquo;restricted securities,&rdquo; as that term is defined in
Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if such public resale is registered
under the Securities Act or if the resale qualifies for an exemption from registration under Rule 144 or Rule 701 under the Securities
Act, which are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a person who has beneficially owned restricted shares of our common stock for at least twelve months, or at least six months
in the event we have been a reporting company under the Exchange Act for at least ninety (90) days before the sale, would be entitled
to sell such securities, provided that such person is not deemed to be an affiliate of ours at the time of sale or to have been an affiliate
of ours at any time during the ninety (90) days preceding the sale. A person who is an affiliate of ours at such time would be subject
to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of shares that
does not exceed the greater of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
                                            of the number of shares of our common stock then outstanding; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
                                            of the average weekly trading volume of our common stock during the four calendar weeks preceding
                                            the filing by such person of a notice on Form 144 with respect to the sale;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that, in each case, we are subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule
144 trades must also comply with the manner of sale, notice and other provisions of Rule 144, to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Rule 701 allows a shareholder who purchased shares of our capital stock pursuant to a written compensatory plan or contract
and who is not deemed to have been an affiliate of ours during the immediately preceding 90 days to sell those shares in reliance upon
Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of
Rule 144. All holders of Rule 701 shares, however, are required to wait until ninety (90) days after the date of this prospectus before
selling shares pursuant to Rule 701.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
all of our directors and officers and our shareholders holding at least 10% of the outstanding shares of our common stock have agreed
with the underwriters, subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our common
stock or securities convertible into or exercisable or exchangeable for our common stock for a period of six months after the closing
of this offering. See &ldquo;<I>Underwriting-Lock-Up - No Sales of Securities</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_016"></A>UNDERWRITING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering the shares of common stock and
warrants described in this prospectus through&nbsp;Aegis Capital Corp., who is&nbsp;acting as the representative of the underwriters
of this offering (the &ldquo;Representative&rdquo;). The underwriting agreement that we intend to enter into with the Representative
(the &ldquo;Underwriting Agreement&rdquo;) will provide that the obligations of the underwriters are subject to representations, warranties
and conditions contained therein. The underwriters will agree to buy, subject to the terms of the Underwriting Agreement, the number
of shares of common stock and warrants listed opposite their names below. Pursuant to the Underwriting Agreement, the underwriters will
be committed to purchase and pay for all of the shares and warrants if any are purchased, other than those shares and accompanying warrants
covered by the over-allotment option described below.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Underwriters</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of<BR>
                                            Accompanying<BR>
                                            Warrants </B>&nbsp;</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Aegis Capital Corp.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock and warrants sold
by the underwriters to the public will initially be offered at the initial public offering price range set forth on the cover page of
this prospectus. The per unit purchase price of our common stock and warrants in this offering has been arbitrarily determined by us
and the Representative without regard to an independent&nbsp;valuation&nbsp;of the common&nbsp;stock or warrants included in the units
being offered in this offering. Although we completed an independent valuation of our common stock as of a November 5, 2021 valuation
date, we have not obtained an independent appraisal opinion on the&nbsp;valuation&nbsp;of our units as of the date of this offering and
we did not rely on the November 5, 2021 valuation in determining the pricing for this offering. Accordingly, our units may have a value
significantly less than the offering price, and our common stock and warrants included in the units may never obtain a value equal to
or greater than the offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any shares of common stock sold by the underwriters to securities dealers
may be sold at a discount from the initial public offering price not to exceed $[ &nbsp;] per share. If all of the shares are not sold at the
initial offering price, the representative may change the offering price and the other selling terms. The representative has advised us
that the underwriters do not intend to make sales to discretionary accounts.</P>


<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted to the representative an
option, exercisable for 45 days from the date of this prospectus, to purchase up to [&nbsp;&nbsp;&nbsp;] additional shares of common stock and/or
warrants at the public offering price less the underwriting discount, constituting 15% of the total number of shares of common stock
to be offered in this offering (excluding shares and/or warrants subject to this option). This offering is being conducted on a firm
commitment basis.&nbsp; Any shares of common stock and/or warrants issued or sold under the option will be issued and sold on the
same terms and conditions as the other shares of common stock and warrants that are the subject of this offering.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the offering, the underwriters may purchase and sell shares in the open market. Purchases and sales in the open market
may include short sales, purchases to cover short positions, which may include purchases pursuant to the over-allotment option, and stabilizing
purchases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
                                            sales involve secondary market sales by an underwriter of a greater number of shares than
                                            they are required to purchase in the offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Covered&rdquo;
                                            short sales are sales of shares in an amount up to the number of shares represented by the
                                            over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Naked&rdquo;
                                            short sales are sales of shares in an amount in excess of the number of shares represented
                                            by the over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covering
                                            transactions involve purchases of shares either pursuant to the over-allotment option or
                                            in the open market after the distribution has been completed in order to cover short positions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            close a naked short position, an underwriter must purchase shares in the open market after
                                            the distribution has been completed.&nbsp;&nbsp;A naked short position is more likely to
                                            be created if an underwriter is concerned that there may be downward pressure on the price
                                            of the shares in the open market after pricing that could adversely affect investors who
                                            purchase in the offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            close a covered short position, an underwriter must purchase shares in the open market after
                                            the distribution has been completed or must exercise the over-allotment option. In determining
                                            the source of shares to close the covered short position, the underwriters will consider,
                                            among other things, the price of shares available for purchase in the open market as compared
                                            to the price at which they may purchase shares through the over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
                                            transactions involve bids to purchase shares so long as the stabilizing bids do not exceed
                                            a specified maximum.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases
to cover short positions and stabilizing purchases, as well as other purchases by an underwriter for its own account, may have the effect
of preventing or retarding a decline in the market price of the shares of common stock. They may also cause the price of the shares of
common stock to be higher than the price that would otherwise exist in the open market in the absence of these transactions. The underwriters
may conduct these transactions in the over-the-counter market or otherwise. If the underwriters commence any of these transactions, they
may discontinue them at any time.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discounts
and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the underwriting discounts
payable to the underwriters by us in connection with this offering (assuming both the exercise and non-exercise of the over-allotment
option that we have granted to the representative), based on the assumed initial public offering price of $6.25 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Per<BR>
    Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Without Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">With<BR>
    Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Underwriting discounts and commissions (8%)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Proceeds, before expenses, to us</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay the underwriters a cash fee equal to eight percent (8%) of the aggregate gross proceeds of received by the Company
from the securities sold in this offering (excluding shares that may be issued under the over-allotment option). We have further agreed
to pay a non-accountable expense allowance to the representative of the underwriters equal to 1.0% of the gross proceeds received by
the Company at the closing of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to issue warrants to the representative to purchase
a number of shares of common stock equal to 8% of the total number of shares sold in this offering (excluding shares that may be issued
under the over-allotment option) at an exercise price equal to 125% of the public offering price of the shares sold in this offering (excluding
shares that may be issued under the over-allotment option). The underwriters&rsquo; warrants will be exercisable commencing six months
from the closing of this initial public offering and terminating on the fifth anniversary of the commencement date of sales in this offering,
and will have a cashless exercise provision. The underwriters&rsquo; warrants are not exercisable or convertible for more than five years
from the commencement date of sales in this offering. The underwriters&rsquo; warrants also provide for customary anti-dilution provisions,
a one-time demand registration right and immediate &ldquo;piggyback&rdquo; registration rights with respect to the registration of the
shares of common stock underlying the warrants. We have registered the underwriters&rsquo; warrants and the shares underlying the underwriters&rsquo;
warrants in this offering.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters&rsquo; warrant and the underlying shares may be deemed to be compensation by FINRA, and therefore will be subject to FINRA
Rule 5110(e)(1). In accordance with FINRA Rule 5110(e)(1), neither the underwriters&rsquo; warrant nor any of our shares of common stock
issued upon exercise of the underwriters&rsquo; warrants may be sold, transferred, assigned, pledged or hypothecated, or be the subject
of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities
by any person, for a period of 180 days immediately following the commencement date of sales in this offering, subject to certain exceptions.
The underwriters&rsquo; warrant to be received by the Representative and related persons in connection with this offering: (i) fully
comply with lock-up restrictions pursuant to FINRA Rule 5110(e)(1); and (ii) fully comply with transfer restrictions pursuant to FINRA
Rule 5110(e)(2). In the event of written notice of a registration trigger event, as defined in the underwriter&rsquo;s warrant, the parties
shall negotiate in good faith a single demand registration right as outlined in the underwriter&rsquo;s warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have agreed to issue to the underwriters warrants to
purchase a number of shares of common stock and warrants equal to 8.0% of the aggregate number of shares of common stock sold in the offering
(including shares of common stock sold upon exercise of the over-allotment option), excluding shares underlying the Warrants. The underwriters&rsquo;
warrants will be exercisable at any time and from time to time, in whole or in part, during the five-year period commencing six months
from the date of commencement of the sales of the shares of common stock and warrants in connection with this offering, at a price per
share equal to $[7.8125] which is 125% of the initial public offering price per share and accompanying Warrant. Such underwriter&rsquo;s
warrants are exercisable on a cash basis. The warrants will provide for registration rights (including a one-time demand registration
right and unlimited piggyback rights).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that our total expenses of this offering, excluding underwriting
discounts, will be approximately $653,000 which includes a maximum of $125,000 of out of pocket expenses for &ldquo;road show,&rdquo;
diligence, and reasonable legal fees and disbursements for underwriters&rsquo; counsel, subject to a maximum of $62,500 in the event that
this offering is not consummated. We have also agreed to reimburse the underwriters, subject to compliance with FINRA Rule 5110(g).&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Underwriting Agreement, we also intend to agree to indemnify the underwriters against certain liabilities, including civil liabilities
under the Securities Act, or to contribute to payments that the underwriters may be required to make in respect of those liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Determination
of Offering Price</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the initial public offering price, we and the representative have considered a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            information set forth in this prospectus and otherwise available to the representative;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            prospects and the history and prospects for the industry in which we compete;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            assessment of our management;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            prospects for future revenue and earnings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            general condition of the securities markets at the time of this offering;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            recent market prices of, and demand for, publicly traded securities of generally comparable
                                            companies; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            factors deemed relevant by the Representative and us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated initial public offering price set forth on the cover page of this preliminary prospectus is subject to change as a result of
market conditions and other factors. Neither we nor the representative can assure investors that an active trading market will develop
for our shares of common stock, or that the shares will trade in the public market at or above the initial public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the representative and the other underwriters against certain liabilities, including liabilities under the Securities
Act. If we are unable to provide this indemnification, we will contribute to payments that the representative and the other underwriters
may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the Representative a right of first refusal, for a period of twelve (12) months from the closing of the offering, to act
as sole investment banker, sole book-runner, and/or sole placement agent, at the Representative&rsquo;s sole discretion, for each and
every future public and private equity and debt offering, including all equity linked financings, subject to certain exceptions (each,
a &ldquo;subject transaction&rdquo;), during such twelve (12) month period, of the Company, or any successor to or subsidiary of the
Company, on terms and conditions customary to the Representative for such subject transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tail
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Representative does not consummate the offering, the Representative shall be entitled to a cash fee equal to eight
percent (8.0%) of the gross proceeds received by the Company from the sale of the securities to any investor actually introduced by the
Representative to the Company during the engagement period (the &ldquo;Tail Financing&rdquo;), and such Tail Financing is consummated
at any time during the engagement period or within the twelve (12) month period following the expiration of the engagement period, provided
that such financing is by a party actually introduced to the Company in an offering in which the Company has direct knowledge of such
party&rsquo;s participation and not a party that the Company can demonstrate was already known to the Company. In addition, unless (x)
the Company terminates the&nbsp;underwriting&nbsp;agreement for cause, or (y) the Representative fails to provide the underwriting services
provided in the underwriting agreement, upon termination of such agreement, if the Company subsequently completes a public or private
financing with any investors introduced to the Company by the Representative during the twelve (12) month period following such termination,
the Representative shall be entitled to receive the same compensation to be paid to the Representative in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
- No Sales of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, on behalf of itself and any successor
entity, will agree in the Underwriting Agreement that, without the prior written consent of the Representative or unless excluded from
Lock-Up restrictions in the Underwriting Agreement, it will not, for a period of 180 days after the date of the Underwriting Agreement
(the &ldquo;Lock-Up Period&rdquo;), offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or
file with the Commission a registration statement under the Securities Act relating to, any Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock, or publicly disclose the intention to make any offer, sale, pledge, disposition
or filing, or (y) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of the Common Stock or any such other securities, whether any such transaction described in clause (x) or (y) above is to be settled
by delivery of Common Stock or such other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, each of our directors, officers and stockholders holding at least ten percent (10%) of the outstanding shares of common stock
of the Company has agreed that for a period of 180 days after the date of this prospectus, without the prior written consent of the Representative,
and subject to certain exceptions, they will not, directly or indirectly,&nbsp;(i)&nbsp;offer, pledge, sell, contract to sell, grant,
lend, or otherwise transfer or dispose of, directly or indirectly, any common stock of the Company or any securities convertible into
or exercisable or exchangeable for the common stock of the Company, whether now owned or hereafter acquired by such person or with respect
to which such person has or hereafter acquires the power of disposition; (ii)&nbsp;enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of such securities; (iii)&nbsp;make any demand for or
exercise any right with respect to the registration of any such securities; or (iv)&nbsp;publicly disclose the intention to make any
offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any such securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price
Stabilization, Short Positions and Penalty Bids</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
facilitate this offering, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of our securities
during and after the offering. Specifically, the underwriters may over-allot or otherwise create a short position in our securities for
their own account by selling more securities than we have sold to the underwriters. The underwriters may close out any short position
by either exercising its option to purchase additional securities or purchasing securities in the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the underwriters may stabilize or maintain the price of our securities by bidding for or purchasing securities in the open
market and may impose penalty bids. If penalty bids are imposed, selling concessions allowed to broker-dealers participating in this
offering are reclaimed if securities previously distributed in this offering are repurchased, whether in connection with stabilization
transactions or otherwise. The effect of these transactions may be to stabilize or maintain the market price of our securities at a level
above that which might otherwise prevail in the open market. The imposition of a penalty bid may also affect the price of our securities
to the extent that it discourages resales of our securities. The magnitude or effect of any stabilization or other transactions is uncertain.
These transactions may be effected on the Nasdaq Capital Market or otherwise and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters and selling group members, if any, may also engage in passive market making transactions
in our securities on the Nasdaq Capital Market. Passive market making consists of displaying bids on the Nasdaq Capital Market by the
prices of independent market makers and effecting purchases limited by those prices in response to order flow. Rule 103 of Regulation
M promulgated by the SEC limits the amount of net purchases that each passive market maker may make and the displayed size of each bid.
Passive market making may stabilize the market price of our securities at a level above that which might otherwise prevail in the open
market and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described
above may have on the price of our securities. In addition, neither we nor the underwriters make any representation that the underwriters
will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Affiliations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
underwriter and its respective affiliates are full-service financial institutions engaged in various activities, which may include securities
trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. The underwriters may in the future engage in investment banking and other commercial dealings in
the ordinary course of business with us or our affiliates. The underwriters may in the future receive customary fees and commissions
for these transactions. We have not engaged the underwriters to perform any services for us in the previous 180 days, nor do we have
any agreement to engage the underwriters to perform any services for us in the future, subject to the right to act as an advisor as described
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of its various business activities, each underwriter and its respective affiliates may make or hold a broad array
of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including
bank loans) for its own account and for the accounts of its customers, and such investment and securities activities may involve securities
and/or instruments of the issuer. Each underwriter and its respective affiliates may also make investment recommendations and/or publish
or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients
that they acquire, long and/or short positions in such securities and instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters or certain of the securities dealers may distribute prospectuses by electronic means,
such as e-mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the shares of common stock,
or the possession, circulation or distribution of this prospectus or any other material relating to us or the shares of common stock,
where action for that purpose is required. Accordingly, the shares of common stock may not be offered or sold, directly or indirectly,
and neither this prospectus nor any other offering material or advertisements in connection with the shares of common stock may be distributed
or published, in or from any country or jurisdiction except in compliance with any applicable rules and regulations of any such country
or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_017"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL
MATTERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bevilacqua
PLLC and IP Supra, PLLC have acted as our counsel in connection with the preparation of this prospectus. The underwriters have been represented
in connection with this offering by Alston &amp; Bird LLP.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_018"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated and combined financial statements
of Felicitex Therapeutics Inc. as of December 31, 2021 and 2020 and for the years then ended included in the registration statement of
which this prospectus forms a part have been so included in reliance on the report of Friedman LLP, an independent registered public
accounting firm (the report on the financial statements contains an explanatory paragraph regarding the Company&rsquo;s ability to continue
as a going concern) appearing elsewhere herein, given on the authority of said firm as experts in auditing and accounting.</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_019"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
YOU CAN FIND MORE INFORMATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities we are offering
by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information
about us and our securities, you should refer to the registration statement and the exhibits and schedules filed with the registration
statement. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are materially
complete but may not include a description of all aspects of such contracts, agreements or other documents, and you should refer to the
exhibits attached to the registration statement for copies of the actual contract, agreement or other document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, we will be subject to the information requirements of the Exchange Act and will file annual, quarterly and
current event reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration
statement, over the Internet at the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL
STATEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; background-color: White; text-align: center">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; background-color: White; text-align: center">Page</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; background-color: White; width: 87%"><FONT STYLE="font-size: 10pt">Reviewed
    Condensed Consolidated and Combined Financial Statements (unaudited)</FONT></TD>
    <TD STYLE="background-color: White; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 12%; background-color: White">&nbsp;</TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="#f_002">Condensed
    Consolidated Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">F-2</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><A HREF="#f_003"><FONT STYLE="font-size: 10pt">Condensed
    Consolidated and Combined Statements of Operations and Comprehensive Loss (unaudited) for the three months ended March 31, 2022 and
    2021</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">F-3</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><A HREF="#f_004"><FONT STYLE="font-size: 10pt">Condensed
    Consolidated and Combined Statements of Stockholders&rsquo; Deficit (unaudited) for the three months ended March 31, 2022 and 2021</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">F-4</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom"><A HREF="#f_005"><FONT STYLE="font-size: 10pt">Condensed
    Consolidated and Combined Statements of Cash Flows (unaudited) for the three months ended March 31, 2022 and 2021</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">F-5</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom"><A HREF="#f_006"><FONT STYLE="font-size: 10pt">Notes
    to Condensed Consolidated and Combined Financial Statements (unaudited) </FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">F-6-F-18</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 87%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audited
    Consolidated and Combined &nbsp;Financial Statements for the Years Ended December 31, 2021 and 2020</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#fin_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of Independent Registered Public Accounting Firm (PCAOB Firm ID 711)</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#fin_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    and Combined &nbsp;Balance Sheets as of December 31, 2021 and 2020</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#fin_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    and Combined &nbsp;Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021 and 2020</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#fin_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    and Combined &nbsp;Statements of Stockholders&rsquo; Deficit for the Years Ended December 31, 2021 and 2020</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom"><A HREF="#fin_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    and Combined &nbsp;Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-23</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom"><A HREF="#fin_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated and Combined Financial Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 132; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="f_002"></A><B>FELICITEX THERAPEUTICS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">March&nbsp;31,<BR>
    2022</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(unaudited)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: -0.125in; padding-left: 0.25in">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">32,023</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10,362</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Prepaid Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,362</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,801</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,960</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.5in">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">48,574</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,822</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Liabilities and Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">353,393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">232,842</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,781</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,171</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Due to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,203</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,652</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Convertible note payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206,180</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">276,708</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">276,708</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">919,309</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">811,553</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.375in">Total liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">919,309</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">811,553</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Common Stock: Par value of $0.0001 per share, 100,000,000 shares authorized;
    4,455,999 and 4,263,022 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">426</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,199,324</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,566,727</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,070,505</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,362,884</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Total deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(870,735</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(795,731</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.5in">Total liabilities and deficit</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">48,574</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,822</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are
an integral part of these unaudited condensed consolidated financial statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="f_003"></A><B>FELICITEX
THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED
AND COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<BR>
    March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">164,935</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">133,846</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">519,747</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">153,058</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">684,682</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">286,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Operating loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(684,682</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(286,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,298</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,939</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,601</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left">Inducement loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(80,972</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total other expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,939</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(78,275</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss before provision for income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(707,621</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,179</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax expense (benefit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(707,621</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(365,179</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: Net loss of TarMeta Biosciences, LLC prior to acquisition by Felicitex
    Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(70,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss attributable to Felicitex Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(707,621</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(295,031</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss per share attributable to Felicitex Therapeutics, Inc.-basic and
    diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding attributable to Felicitex Therapeutics,
    Inc.-basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,295,189</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,283,747</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are
an integral part of these unaudited condensed consolidated and combined financial statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="f_004"></A><B>FELICITEX
THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED
AND COMBINED STATEMENTS OF CHANGES IN DEFICIT (UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Paid-In</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Balances at January 1, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,247,585</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">325</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,881,728</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(6,640,657</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(758,604</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock options issued for settlement of deferred compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock options issued for settlement of accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,246</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued in connection with settlement of convertible
    note payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">232,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">548,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">548,823</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Contributions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,643</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,643</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(365,179</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(365,179</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balances at March 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,480,058</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">348</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,614,439</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(7,005,836</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(391,049</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Balances at January 1, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,263,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,566,727</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,362,884</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(795,731</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued in connection with settlement of convertible
    note payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">595,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">595,744</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,873</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,873</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(707,621</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(707,621</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balances at March 31, 2022</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,455,999</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">446</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,199,324</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(7,070,505</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(870,735</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The accompanying notes are an integral
part of these unaudited condensed consolidated and combined financial statements.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_005"></A>FELICITEX THERAPEUTICS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED AND COMBINED STATEMENTS
OF CASH FLOWS (UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<BR>
    March 31,</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(707,621</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(365,179</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Adjustments to reconcile net loss to net cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">768</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,972</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,873</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">Forgiveness of PPP loan Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,298</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">186,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,577</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,703</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,250</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash flows used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(441,563</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(184,102</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Proceeds from convertible note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">463,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left">Equity contributions - related party</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">49,643</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash flows provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">463,224</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">154,643</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.375in; text-align: left">Net change in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,459</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><B>Cash, beginning of period-</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,362</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38,355</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Cash, end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">32,023</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,896</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplementary cash flows information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Cash paid during the year for interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Cash paid during the year for taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Non-cash investing and financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Conversion of convertible note payable into common stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">595,744</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">548,823</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Conversion of deferred compensation into stock options</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">36,667</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Conversion of accounts payable into stock options</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22,246</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The accompanying notes are an integral
part of these unaudited condensed consolidated and combined financial statements.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="f_006"></A>FELICITEX
THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED
AND COMBINED FINANCIAL STATEMENTS (UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Nature
                                            of the Business and Basis of Presentation</B></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 0.5in">Felicitex Therapeutics,
Inc. (&ldquo;Felicitex&rdquo;) was incorporated in Delaware on May 4, 2012. Felicitex is an early-stage drug development company developing
treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term outcomes for the deadliest and
most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established a drug discovery platform focused on cellular dormancy to identify novel targets and corresponding small molecule
inhibitors and has developed seven advanced clinical drug candidates thus far. It has an expanding IP position that includes two fundamental
composition of matter patents, three methods of use patents, and a companion diagnostics patent. The research and development activities
of the Company are currently in the pre-clinical phase of development. The company has retroactively applied impacts for the reverse
stock split of 1 to 9.08, which was approved by the Board of Directors on May 23, 2022. All references to the number of shares in the
footnotes have been retroactively updated.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Basis
of Presentation and Principles of Consolidation and Combination</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
accompanying unaudited condensed consolidated and combined financial statements have been prepared in accordance with accounting principles
generally accepted in the United States of America (&ldquo;GAAP&rdquo;) for interim financial information and with the instructions for
Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed financial statements reflect
all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results. Interim
operating results are not necessarily indicative of results that may be expected for the full year ending December 31, 2022 or for any
subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements
and notes thereto of the Company which are included in the accompanying Form S-1/A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
July 23, 2021, the Company incorporated Felicitex Therapeutics UAB (&ldquo;UAB&rdquo;), a Lithuania Corporation, for the purpose of applying
for grants. The Company intends to use the grant proceeds, if awarded, in pre-clinical studies to be conducted in Europe to assess the
potential of conducting clinical trials on its molecule in the future. The Company&rsquo;s CEO is necessarily the sole owner of UAB in
order to comply with the funding requirements of the government grant programs in Lithuania and the European Union. As discussed in Note
14, UAB is deemed to be a Variable Interest Entity (&ldquo;VIE&rdquo;), and is therefore required to be included in the consolidated
and combined financial statements of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
discussed in Note 11, on December 30, 2021, the Company acquired TarMeta BioSciences, LLC (&ldquo;TarMeta&rdquo;), an early-stage drug
discovery platform company with deep expertise in analytical chemistry whose mission is to identify and commercialize novel small molecule
therapeutics for difficult to treat cancers. The Company determined the TarMeta acquisition to be a common control transaction under
ASC Topic 805, Business Combinations, and accounted for this transaction at the carrying amount of the net assets acquired. As a result
of the TarMeta acquisition, the financial statements for the three months ended March 31, 2021 has been adjusted to include the financial
information of TarMeta for the period. TarMeta ceased to exist as a separate legal entity on December 31, 2021 and is therefore not included
in the financial statements for the three months ended March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
consolidated and combined financial statements include the accounts of Felicitex, UAB and TarMeta (collectively, the &ldquo;Company&rdquo;).
All intercompany transactions and balances have been eliminated in consolidation and combination. There is no difference between net
loss and comprehensive loss in these consolidated and combined financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Liquidity
and Going Concern</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company is in the development stage and has incurred losses and negative cash flows from operations. The Company had a net loss of approximately
$0.7 million and negative cash flows from operations of approximately $0.4 million for the three months ended March 31, 2022. Further,
the Company has an accumulated deficit of $7.0 million, as of March 31, 2022. Based on the current development plans for the Company&rsquo;s
drug candidates and other operating requirements, existing cash is not sufficient to fund operations for the twelve months following
the financial statement filing date. These factors raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">A
significant amount of additional capital will be necessary to advance the development of our products to the point at which they may
become commercially viable. The Company plans to raise additional capital from various potential sources, including equity and/or debt
financings, grant funding, and strategic relationships. In addition, the Company has an active equity purchase agreement with Aegis Capital
to sell $15 million of Company common stock in an initial public offering, which amount, if fully accessible, would be sufficient to
fund the Company&rsquo;s operations beyond one year from the filing date of these statements. However, there can be no guarantee that
the Company will be able to close on the financing. Should such financing be unsuccessful, the Company would be required to delay, scale
back or eliminate some or all of its research and development programs, which would likely have a material adverse effect on the Company
and its consolidated and combined financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
accompanying consolidated and combined financial statements do not include any adjustments relating to the recoverability and classification
of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Other
Uncertainties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Generally,
the industry in which the Company operates subjects the Company to a number of other risks and uncertainties that can affect its operating
results and financial condition. Such factors include, but are not limited to: the timing, costs and results of clinical trials and other
development activities versus expectations; the ability to obtain regulatory approval to market product candidates; the ability to manufacture
products successfully; competition from products sold or being developed by other companies; the price of, and demand for, Company products
once approved; the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company&rsquo;s
research and pre-clinical studies. The effects of the ongoing coronavirus pandemic may also increase non-research related costs such
as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact
our key pre-clinical trial vendors and suppliers of our pharmaceutical ingredients. The full extent to which the COVID-19 pandemic could
impact drug development and research, or impact the Company&rsquo;s suppliers and other commercial partners, will depend on future developments
that cannot be predicted. We assessed certain accounting matters that generally require consideration of forecasted financial information
in context with the information reasonably available to us and the unknown future impacts COVID-19 as of March 31, 2022, and through
the date of this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Summary
                                            of Significant Accounting Policies</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Cash
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company
had no cash equivalents at March 31, 2022 and year ended December 31, 2021, respectively. At times, the Company&rsquo;s cash balances
may exceed the current insured amounts under the Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;). On March 31, 2022 and December
31, 2021, the Company did not exceed FDIC insurance limits. Unrealized gain or loss are included in the interest income and are immaterial
to the consolidated and combined financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
preparation of consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at
the date of the consolidated and combined financial statements as well as the reported amounts of revenues and expenses during the reporting
period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical
experience, risk of loss, general economic conditions and trends and the assessment of the probable future outcome. Subjective and significant
estimates include, but are not limited to, the valuation of stock-based compensation, valuation of issued warrants, expense recognition
and accruals associated with third party providers supporting pre-clinical studies and other research and development, and income tax
asset realization. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects
of changes, if any, are reflected in the consolidated and combined statements of operations in the period that they are determined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Segment
Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company determined its operating segment after considering the Company&rsquo;s organizational structure and the information regularly
reviewed and evaluated by the Company&rsquo;s chief operating decision maker (&ldquo;CODM&rdquo;) in deciding how to allocate resources
and assess performance. The Company has determined that its CODM is its Chief Executive Officer. Effective January 1, 2022, the financial
accounts of both TarMeta and Felicitex are integrated into a single report to be reviewed by the CODM. Previously, the CODM reviewed
the financial information of Felicitex and TarMeta independently for the purpose of evaluating financial performance and allocating resources.
On the basis of these factors, the Company has determined that it operates and manages its business as one segment for the three months
ended March 31, 2022, and two operating segments for the three months ended March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Substantially
all the Company&rsquo;s long-lived assets are held in the United States. Segment considerations are further discussed in Note 12.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Property
and Equipment, Net</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation and amortization. Expenditures for repairs and maintenance are expensed
as incurred. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 12pt; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated Useful Life</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%">Equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center">3 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Shorter of remaining life of lease or useful life</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Patent Costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">All
patent-related costs are expensed as incurred due to uncertainty with respect to the Company&rsquo;s ability to commercialize the patents.
Amounts incurred are classified as general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Leases</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Lease
agreements are evaluated to determine whether they are capital or operating leases in accordance with Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 840, Leases (&ldquo;ASC 840&rdquo;). When any
one of the four test criteria in ASC 840 is met, the lease then qualifies as a capital lease. Capital leases are capitalized at the lower
of the net present value of the total amount payable under the leasing agreement (excluding finance charges) or the fair market value
of the leased asset. Capital lease assets are depreciated on a straight-line basis, over a period consistent with the Company&rsquo;s
normal depreciation policy for tangible fixed assets. The Company allocates each lease payment between a reduction of the lease obligation
and interest expense using the effective interest method. Rent expense for operating leases, which may include free rent or fixed escalation
amounts in addition to minimum lease payments, is recognized on a straight-line basis over the duration of the lease term. The Company
had no capital leases related to equipment as of March 31, 2022 and December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Collaborative
Arrangements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope
of FASB ASC Topic 808, Collaborative Arrangements (&ldquo;ASC 808&rdquo;). For collaborative arrangements that contain multiple elements,
the Company determines which units of account are deemed to be within the scope of ASC 808 and which units of account are more reflective
of a vendor-customer relationship, and therefore are within the scope of ASC 606. For units of account that are accounted for pursuant
to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature
or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of ASC 808, the Company
evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple
units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result
of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded
as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate. Milestone payments
are considered contingent liabilities and are recognized when the Company deems the milestone event to be probable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Fair
Value Measurements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">FASB
ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value, and expands
disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset
or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly
transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy
has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable
inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would
use in pricing the asset or liability based on market data obtained from sources independent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Unobservable
inputs reflect the Company&rsquo;s assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 - Valuations based on quoted prices for identical instruments in active markets.
                                            Since valuations are based on quoted prices that are readily and regularly available in an
                                            active market, valuation of these instruments does not entail a significant degree of judgment.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 - Valuations based on observable inputs other than quoted prices included in Level
                                            1, such as quoted prices for either similar instruments in active markets, identical or similar
                                            instruments in markets that are not active, or model-derived valuations whose inputs or significant
                                            value drivers are observable or can be corroborated by observable market data.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 - Valuations based on inputs that are unobservable. These valuations require significant
                                            judgment.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
availability of valuation techniques and observable inputs can vary and is affected by a wide variety of factors, including the type
of asset or liability, whether the asset or liability is new and not yet established in the marketplace, and other characteristics particular
to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market,
the determination of fair value requires more judgment. Those estimated values do not necessarily represent the amounts that may be ultimately
realized due to the occurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of valuations,
those estimated values may be materially higher or lower than the values that would have been used had a ready market for the assets
or liabilities existed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
of March 31, 2022, the Company&rsquo;s assets and liabilities measured at fair value on a recurring basis were categorized as follows
within the fair value hierarchy:</FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Level
    1</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Level
    2</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Level
    3</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Total</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">Liabilities</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Warrant liability</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">Total liabilities</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As of December 31,
2021, the Company&rsquo;s assets and liabilities measured at fair value on a recurring basis were categorized as follows within the fair
value hierarchy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Level
    1</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Level
    2</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Level
    3</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Total</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt">Liabilities</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Warrant liability</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">Total liabilities</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
value of cash, prepaid expenses, accounts payable, accrued expenses, PPP loan payable, amounts due to related parties and convertible
notes payable - related party approximate fair value to due to the short-term nature of these assets and liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company estimated the fair value of the warrant liability classified as Level 3 liabilities using the Black-Scholes option pricing model
utilizing certain weighted average assumptions such as expected stock price volatility, expected term of the warrants, and risk-free
interest rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
following table summarizes the activity for the Company&rsquo;s Level 3 liabilities measured at fair value on a recurring basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">Amount</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%"><FONT STYLE="font-size: 10pt">Balance as of January 1, 2021</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">78,823</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Issuance</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">151,497</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Changes in fair value</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">46,388</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Balance as of December 31, 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Issuance</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Changes in fair value</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">Balance as of March 31, 2022</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">276,708</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the three months ended March 31, 2022 and the year ended December 31, 2021, there were no transfers between Level 1 and Level 2, nor
into and out of Level 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Costs
and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC
730-10. Research and development costs are charged to expense as incurred and include the cost of wages, equipment, materials, and laboratory
fees paid in conducting scientific research on potential drug candidates. Research and development costs were $0.2 million and $0.1 million
for the three months ended March 31, 2022, and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of FASB ASC Topic 718,
Compensation - Stock Based Compensation. The Company expenses stock-based compensation to employees and non-employees over the requisite
service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of options granted using
the Black Scholes Merton model. The Company estimates when and if performance-based awards will be earned. If an award is not considered
probable of being earned, no amount of equity-based compensation expense is recognized. If the award is deemed probable of being earned,
related equity-based compensation expense is recorded. The fair value of an award ultimately expected to vest is recognized as an expense,
net of forfeitures, over the requisite service, which is generally the vesting period of the award. Options forfeitures are recorded
as they occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Black Scholes Merton model requires the input of certain subjective assumptions and the application of judgment in dete<FONT STYLE="font-family: Times New Roman, Times, Serif">rmining
the fair value of the awards. The most significant assumptions and judgments include the following:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            volatility - The expected price volatility is based on the historical volatilities
                                            of peer group companies as the Company does not have a sufficient trading history. Industry
                                            peers consist of several public companies in the bio-tech industry similar in size, stage
                                            of life cycle, and capital structure. The Company also blends in historical data on the volatility
                                            of its own equity, increasing in proportion as the period of historical data on the Company&rsquo;s
                                            data becomes more representative.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
                                            interest rate - The risk-free rate was determined based on yields of U.S. Treasury
                                            Bonds of comparable terms.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            dividend yield - The Company has not previously issued dividends and do not anticipate
                                            paying dividends in the foreseeable future. Therefore, we used a dividend rate of zero based
                                            on our expectation of additional dividends.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            term -The expected term of the options was estimated using the simplified method.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Common shares issued
to third parties for services provided are valued at fair value of the Company&rsquo;s shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Warrant
Liability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Warrants
are accounted for in accordance with the guidance contained in ASC 815-40-15-7D and 7F, under which the warrants do not meet the criteria
for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies warrants as liabilities at their fair value
and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date
until exercised, and any change in fair value is recognized in the consolidated and combined statement of operations and comprehensive
loss. The warrants are valued using a Black Scholes model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ASC&nbsp;Topic
740, Income Taxes (&ldquo;ASC 740&rdquo;) sets forth standards for financial presentation and disclosure of income tax liabilities and
expense. The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">A
valuation allowance is established to reduce net deferred tax assets to the amount expected to be realized. The Company recognizes the
effect of income tax positions only if those positions are more likely than not of being sustained. Changes in recognition and measurement
are reflected in the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included
in income tax expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company provides reserves for potential payments of taxes to various tax authorities related to uncertain tax positions. Amounts recognized
are based on a determination of whether a tax benefit previously taken by the Company on filed tax returns or a position expected to
be taken on future tax returns is more likely than not sustaining a challenge from the local tax authorities. The tax benefit recognized
is equal to the largest amount that is more than 50% likely to be sustained. Interest and penalties associated with uncertain tax positions
are recorded as a component of income tax expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Prior
to its acquisition by the Company on December 30, 2021, TarMeta was a limited liability company. As a limited liability company, the
Company elected to treat TarMeta as a partnership for federal and state income tax reporting purposes. Accordingly, for federal and certain
state income tax purposes, TarMeta&rsquo;s income was included in the income tax returns of its members. In most jurisdictions, income
tax liabilities and/or tax benefits are passed through to the individual members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Basic
and Diluted Loss per Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Basic
and diluted loss per share is computed based on the weighted-average outstanding shares of common stock, which are all voting shares.
Diluted net loss per share is computed giving effect to all proportional shares of common stock, including stock options and warrants
to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three months ended March 31, 2022
and 2021, respectively, as the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following
potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,<BR>
    2022</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31,<BR>
    2021</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options
    excluded</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,114,264</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">409,926</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock warrants excluded</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123,735</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94,217</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    convertible under outstanding notes payable excluded</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,519</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,044&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    potentially dilutive securities</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,280,518</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">532,187</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Emerging
Growth Company Status</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company anticipates that it will qualify as an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012
(the &ldquo;JOBS Act&rdquo;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued
subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company will elect to
use this extended transition period for complying with new or revised accounting standards that have different effective dates for public
and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably
opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated and combined financial statements
may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Recently
Adopted Accounting Pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
November 2018, the FASB issued Accounting Standard Update (&ldquo;ASU&rdquo;) No. 2018-18, Collaborative Arrangements (Topic 808) (&ldquo;ASU
No. 2018-18&rdquo;). This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative
Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. The Company early adopted ASU No.
2018-18 as of January 1, 2020. The adoption of this update did not have a material effect on the Company&rsquo;s consolidated and combined
financial statements, as there were no collaborative arrangements that had identified performance obligations to customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <FONT STYLE="font-weight: normal">Debt - Debt with Conversion and Other Options</FONT>
(Subtopic 470-20) and <FONT STYLE="font-weight: normal">Derivatives and Hedging - Contracts in Entity&rsquo;s Own Equity</FONT>
(Subtopic 815-40) (&ldquo;ASU No. 2020-06&rdquo;). ASU No. 2020-06 was issued to address issues identified as a result of the complexity
associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities
and equity. For convertible instruments, the FASB decided to reduce the number of accounting models for convertible debt instruments
and convertible preferred stock. In addition to eliminating certain accounting models, the FASB also decided to enhance information transparency
by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. This update is effective
for public business entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal year. For all
other entities, this update is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal
years. Early adoption is permitted, but no earlier than fiscal years beginning after December 31, 2020. The Company has adopted ASU No.
2021-04 and believes it will have no material effect on its consolidated and combined financial statements.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40): Issuer&rsquo;s Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&ldquo;ASU 2021-04&rdquo;). The amendments
in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&rsquo;s accounting for modifications or exchanges of freestanding
equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The update
is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
The adoption of ASU No. 2021-04 did not have a material effect on the condensed consolidated and combined financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Recent
Accounting Pronouncements Not Yet Adopted</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) as subsequently amended (&ldquo;ASU No. 2016-02&rdquo;). ASU No. 2016-02
was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance
sheet and disclosing key information about leasing arrangements. The amendments in this update are effective for fiscal years beginning
after December 15, 2018, including interim periods within those fiscal years, for public business entities, not-for-profit entities that
has issued securities that are traded, listed or quoted on an exchange or an over-the-counter market, and employee benefit plans that
file financial statements with the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that
the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (&ldquo;ASU 2019-12&rdquo;),
as part as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining
or improving the usefulness of the information provided to users of financial statements. Amendments include removal of certain exceptions
to the general principles of ASC 740 and simplification in several other areas such as accounting for a franchise tax (or similar tax)
that is partially based on income. The update is effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that
the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Property
                                            and Equipment, Net</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Property and equipment,
net consisted of the following as of March 31, 2022 and the year ended December 31, 2021, respectively:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">March
    31,<BR>
    2022</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;31,
    <BR>
    2021</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%"><FONT STYLE="font-size: 10pt">Equipment</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">21,525</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">21,525</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Less: Accumulated depreciation</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(19,724</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(19,565</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">Property and equipment, net</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,801</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,960</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Paycheck
                                            Protection Program Loan</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the year ended December 31, 2020, the Company received loan proceeds in the amount of $10 thousand under the Paycheck Protection Program
(&ldquo;PPP&rdquo;) which was established as part of the Coronavirus Aid, Relief and Economic Security Act (&ldquo;CARES Act&rdquo;)
administered through the Small Business Administration (&ldquo;SBA&rdquo;). The PPP provides loans to qualifying businesses in amounts
up to 2.5 times their average monthly payroll expenses and was designed to provide a direct financial incentive for qualifying businesses
to keep their workforce employed during the Coronavirus crisis. PPP loans are uncollateralized and guaranteed by the SBA and are forgivable
after a &ldquo;covered period&rdquo; (eight or twenty-four weeks) as long as the borrower maintains its payroll levels and uses the loan
proceeds for eligible expenses, including payroll, benefits, mortgage interest, rent and utilities. The forgiveness amount will be reduced
if the borrower terminates employees or reduces salaries and wages more than 25% during the covered period. Any unforgiven portion is
payable over 2 years if issued before, or 5 years if issued after, June 5, 2020 at an interest rate of 1% with payments deferred until
the SBA remits the borrower&rsquo;s loan forgiveness amount to the lender, or, if the borrower does not apply for forgiveness, ten months
after the end of the covered period. PPP loan terms provide for customary events of default, including payment defaults, breaches of
representations and warranties, and insolvency events and may be accelerated upon the occurrence of one or more of these events of default.
Additionally, PPP loan terms do not include prepayment penalties. On February 24, 2021, the Company&rsquo;s PPP loan in the amount of
$10 thousand was forgiven.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Convertible
                                            Note Payable - Related Party</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Chairman of the Board (&ldquo;Principal Investor&rdquo;) has substantial control of the voting power of the Company. During the three
months ended March 31, 2022 and 2021, the Company issued convertible notes payable to the Principal Investor for cash advances made to
the Company. The notes payable outstanding as of March 31, 2022 are convertible to common stock at a price of $3.09 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2021, the Company issued 232,473 shares of common stock to the Principal Investor as consideration for the conversion of a
$521 thousand shareholder loan and $27 thousand in accrued interest. In addition, the Company issued warrants exercisable into 46,495
shares of common stock within five years at an exercise price of $2.36&nbsp; per share as an incentive for converting the loan receivable
into shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2021, the Company entered into a loan agreement with principal investor to lend up to $550 thousand. The note is convertible
at $2.29 per share and accrues interest at 12% with no maturity date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 2, 2021, the Company issued 147,586 shares of common stock to its principal investor as consideration for the conversion of
a $348 thousand convertible note payable. In addition, the Company issued warrants exercisable into 29,518 shares of common stock within
five years at an exercise price of $2.36 per share to the shareholder as an incentive for converting the loan receivable into shares
of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2022, the Company issued 192,977 shares of common stock to its principal investor as consideration for the conversion of $596
thousand loan payable pursuant to a debt cancellation and exchange agreement,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 16, 2022, we entered into a convertible grid note with Mr. Duey with respect to additional advances that Mr. Duey has made and
expects to make to us for general working capital purposes until additional funds are raised from investors. The grid note carries interest
at the rate of 12% per year payable in one lump sum on the maturity date, matures on the one-year anniversary of the issuance date and
may be prepaid at any time, in whole or in part, without penalty. It may also be converted at any time, in the sum of any advances and
accrued interest at a price per share of $3.09. As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since
April 1, 2022, Mr. Duey has loaned to us an additional $408,000 under the grid note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
warrants above do not meet criteria for equity treatment and are recorded as liabilities based on the guidance in ASC 815-40-15-7D and
7F. Refer to Note 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of March 31, 2022 and December 31, 2021, the Company had $128 thousand and $206 thousand,
                                            respectively, in outstanding convertible note payables related to the Principal Investor.
                                            The notes bear an interest rate of 12% with no maturity date. Accrued interest related to
                                            the advances from the Principal Investor was $3 thousand and $36 thousand at the three months
                                            ended March 31, 2022 and December 31, 2021, respectively. Interest expense related to the
                                            advances from the Principal Investor was $23 thousand and $8 thousand for the three months
                                            ended March 31, 2022 and March 31, 2021, respectively.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Deficit</B></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of Company common
stock is entitled to one vote for each share thereof held by such holder at all meetings of stockholders (and written action in lieu
of meetings). Common stockholders are not entitled to receive dividends, unless declared by the board of directors. In the event of the
liquidation, dissolution, or winding-up of the Company, holders of Company common stock will be entitled to receive all assets of the
Company available for distribution to its stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2021, the Company
issued 232,473 shares of common stock to the Principal Investor as consideration for the conversion of a $548 thousand convertible note.
See Note 5 for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2021, the
Company issued 147,586 shares of common stock to the Principal Investor as consideration for the conversion of a $348 thousand convertible
note. See Note 5 for further details.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2021, the
Company issued 635,378 shares of common stock as consideration for the acquisition of the assets owned by TarMeta BioSciences, LLC. See
Note 11 for further details.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 16, 2022, the Company
issued 192,977 shares of common stock to the principal investor for the consideration of $596 thousand convertible note. See Note 5 for
further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2021, the Company
issued warrants exercisable into 46,495 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the Principal
Investor as an incentive to convert a convertible note payable into shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2021, the
Company issued warrants exercisable into 29,518 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the
Principal Investor as an incentive to convert a convertible note payable into shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrants were exercised
or expired during the three months ended March 31, 2022 and the year ended December 31, 2021. The following table provides the activity
in warrants for the three months ended March 31, 2022 and the year ended December 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<BR>
    Warrants</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<BR>
    Average<BR>
    Remaining<BR>
    Term&nbsp;(Years)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<BR>
    Average<BR>
    Exercise&nbsp;Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average<BR>
    Intrinsic<BR>
    Value</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding January 1, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">47,722</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Issued</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">76,013</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.45</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.73</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">123,735</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.73</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Issued</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt">Outstanding March 31, 2022</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">123,735</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3.72</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.36</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.73</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants issued in 2021
had a total fair value of $151 thousand at the time of issue, calculated using the Black Scholes model assuming an underlying security
value of $2.36 per share and volatility rate of 99.97%, a risk-free rate of .60%, and a term of 5.0 years. The fair value at issuance
was recorded in Inducement loss and changes in the fair value are recorded as Gain/(loss) on fair value of warrant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Stock-Based
                                            Compensation</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>Stock Options</I></B></P>








<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
July 20, 2012, the Company adopted the 2012 Stock Option and Restricted Stock Plan, and the shareholders authorized the Board to make
grants restricted shares or options to purchase shares up to 242,291 shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2021, the Board
of Directors authorized the Company to grant 37,558 options to its CEO, of which 15,532 was payment in exchange for deferred compensation,
and 22,027 was payment for bonus. The Company issued 12,708 options to its CFO in exchange for its account payable. The Company also
issued 6,608 options to a Director for consulting services, and 19,824 options to Directors for services as Directors. All options granted
are exercisable at a price of $2.36 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2021, the
Board authorized the Company to grant 110,133 options to its CEO as a discretionary bonus for achieving significant milestones during
the year and also granted 12,708 options exercisable at a price of $2.36 per share to the CFO as payment in full of $30,000 accounts
payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 21, 2021, the
shareholders approved an increase in the size of the stock option plan to 1,101,321 shares, which no shares remained available to grant
as of March 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 15, 2022, the Company
adopted the 2022 Equity Incentive Plan and authorized the Company to issue options which may be exercised for up to 825,992 shares of
the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 15, 2022, the Company
granted options exercisable into 220,265 shares of common stock that vest over a four year period and 330,397 shares of common stock
that vest upon the achievement of milestones, awarded to its CEO, and 30,837 options excisable into 30,837 shares of common stock that
vest over four years to employees and consultants. As of March 31, 2022, 729,874 shares remained available to grant.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">No
options were exercised or expired during the three months ended March 31, 2022, and the year ended December 31, 2021. The following tables
provide the stock option activity for the three months ended March 31, 2022, and the year ended December 31, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total&nbsp;Options<BR>
    Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<BR>
    Average<BR>
    Remaining<BR>
    Term (Years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<BR>
    Average<BR>
    Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<BR>
    Average Fair<BR>
    Value at Issue</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding January 1, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">333,229</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6.61</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.18</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Granted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">199,537</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.54</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding December 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">532,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.73</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Granted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">581,498</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3.09</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.45</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding March 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,114,264</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Vested Options March 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">531,940</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.45</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The intrinsic value of the
options at March 31, 2022 and December 31, 2021 was $734,000 and $734,000, respectively. The total fair value of instruments issued for
the three months ended March 31, 2022 and the three months ended March 31, 2021 was $1.3 million and $0.4 million, respectively.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
of March 31, 2022 and December 31, 2021, unrecorded compensation expense was $1.3 million and $0, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company used the Black Scholes valuation model to determine the fair value of the options issued, using the following key assumptions
for the three months ended March 31, 2022 and 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<BR>
    2022</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<BR>
    2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Fair Value per Share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.09</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected Term (Years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected Dividend</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102.48</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99.97</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.70</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.86</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; text-decoration: none"><B>Commitments
                                            and Contingencies</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Commitments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
October 1, 2014 the Company entered into a Research Collaboration and Option Agreement with Ryvu Therapeutics S.A. (&ldquo;Ryvu&rdquo;
and formerly &ldquo;Selvita S.A.&rdquo;) for sole responsibility and discretion of developing and commercializing certain compounds and
products. On December 31, 2018, the Company entered into an Exclusive License Agreement with Ryvu. The milestone payments to be paid
to Ryvu under the agreement were amended by agreements dated December 31, 2018 and April 16, 2019. Under the terms of the agreement,
the Company is obligated to make contingent milestone payments to Ryvu up to $11 million on a product-by-product basis upon the achievement
of certain development and regulatory approval milestones related to a product. The Company has also agreed to pay Ryvu low single-digit
royalties on net sales of products sold by the Company up to $3 million per year. Royalties on each product are payable on a country-by-country
basis until the later of (i) a specified period of time after the first commercial sale, and (ii) the date of expiration of the last
valid claim in the last-to-expire of the issued patents covered by the license agreement with Ryvu. At any time during the term, the
Company has the right to terminate its royalty payment obligation by providing written notice to Ryvu and paying Ryvu a royalty termination
fee. There were no royalty or milestone payments due to Ryvu at March 31, 2022 and December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
May 5, 2014, the Company entered into a Collaboration and License Agreement with Eurobio Scientific, SA (&ldquo;Eurobio&rdquo; and formerly
&ldquo;Diaxonhit&rdquo;) for the development and commercialization of certain compounds developed and owned by Eurobio. The terms were
amended by agreement on July 23, 2014. Under the agreement, the Company shall pay Eurobio a license fee of $100,000 per year for 12 years
plus contingent milestone payments to Eurobio up to $11.5 million on a product-by-product basis upon the achievement of certain development
and approval milestones related to a product. The Company has also agreed to pay Eurobio low single-digit royalties on net sales of products
sold by the Company. In addition, the Company is obligated to pay Eurobio a percentage of payments received from third parties under
sub-licensing agreements ranging from 5% to 10% as well as royalties ranging from 5% to 14% on net sales of products sold by third parties
under sub-licensing agreements. Royalties on each product are payable on a country-by-country basis until the later of (i) a specified
period of time after the first commercial sale, and (ii) the date of expiration of the last valid claim in the last-to-expire of the
issued patents covered by the license agreement with Eurobio. There were no royalty, milestone, or sub-license payments due to Eurobio
at March 31, 2022, and December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Contingencies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company believes that it has adequately accrued for the potential impact of loss contingencies that are probable and reasonably estimable.
The Company does not believe that the ultimate resolution of any matters to which it is presently a party will have a material effect
on the Company&rsquo;s results of operations, financial condition, or cash flows. However, the ultimate outcome is not known, and an
unfavorable resolution of one or more of these matters could have a material effect on the Company&rsquo;s financial condition, results
of operations or cash flows. There are no known claims or pending litigations against the company as of March 31, 2022, or December 31,
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Employment
Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2021, the
company entered into an employment agreement with its CEO subject to Board approval. Pursuant to the agreement, the CEO will receive
tiered compensation which increases in the event the Company raises a minimum of $10,000,000 in an equity capital raise. The compensation
will be payable in accordance with the Company&rsquo;s standard payroll practices for salaried employees. The CEO is also eligible for
an annual bonus for the achievement of milestones established by the Compensation Committee of the Board and is eligible to receive a
cash bonus equal to a percentage of any upfront payment on any collaboration agreement reached with a pharmaceutical company. The CEO
will also receive a grant of nonqualified stock options exercisable into 220,265 common shares that shall vest quarterly over a period
of four years, nonqualified stock options exercisable into 330,397 common shares that shall vest upon achievement of milestones and nonqualified
stock options exercisable for 22,027 shares of common stock upon a non-dilutive research funding from any U.S agency. &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Collaborative
Arrangements</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company assessed the
Ryvu and Eurobio agreements summarized in Note 8 under Topic 808 to determine whether the license agreements or units of account within
the license agreements represent a collaborative arrangement based on the risk, rewards, and activities of the parties. The Company concluded
that neither Ryvu nor Eurobio represent a customer, as Ryvu and Eurobio are the entities that have performance conditions to the Company
and the Company records no revenue related to the transactions within the Ryvu and Eurobio agreements. There were no cash payments or
transactions in the Consolidated and Combined Statements of Operations and Comprehensive Loss related to the Ryvu agreement for the three
months ended March 31, 2022 and the three months ended March 31, 2021.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Related-Party
                                            Transactions </B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Debt</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed in Note 5, during
the three months ended March 31, 2022, and the year ended December 31, 2021, the Company issued convertible notes payable to the Principal
Investor bearing an interest rate of 12%. The convertible note payable carries interest at the rate of 12% per year payable in one lump
sum on the maturity date, matures on the one year anniversary of the issuance date and may be prepaid at any time, in whole or in part,
without penalty. It may also be converted at any time, in the sum of any advances and accrued interest at a price per share of $3.09.
As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has loaned to us an additional
$408,000 under the grid note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Consulting
and Management Services</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Chief Financial Officer (&ldquo;CFO&rdquo;) of the Company is the owner of an outsourced accounting and finance company that also employs
other accountants and bookkeepers. Total fees for accounting and finance services rendered during the three months ended March 31, 2022,
and 2021 were $91 thousand and $13 thousand, respectively. The cost of these services was recorded as a General and Administrative expense
and are reflected as a related party liability on the accompanying consolidated and combined balance sheet. As of March 31, 2022 and
December 31, 2021 the balance due to related party was $120 thousand and $49 thousand, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Anna
Vilenchik, the mother of our CEO, was compensated as an independent contractor $8,300 and $0 for research services rendered during the
three months ended March 31,2021 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Segment
                                            information</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
the three months ended March 31, 2022, the Company operated its business as one segment. For the three months ended March 31, 2021, the
Company managed its business activities in&nbsp;two&nbsp;reportable segments: Felicitex and TarMeta. The Company evaluated the performance
of its reportable segments based on Research and Development and General and Administrative expenses, which comprises the net operating
loss of each segment. Both Felicitex and TarMeta&rsquo;s operations are primarily within the United States. For the three months ended
March 31, 2021, TarMeta recognized $0 revenue. There are no inter-segment sales included in the amounts disclosed. Beginning January
1, 2022, the Company combined the activities of the segments into one operating segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>Felicitex</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
reporting segment includes the development of treatments that target both dormant and proliferating cancers to improve the effectiveness
and long-term outcomes for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal,
osteosarcoma, glioblastoma, and lung. The Felicitex reporting segment consists of one operating segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 10pt"><B><I>TarMeta</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
reporting segment includes the identification and commercialization of novel, small molecule therapeutics for difficult to treat cancers.
The TarMeta reporting segment consists of&nbsp;one&nbsp;operating segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Summarized
financial information concerning the Company&rsquo;s reportable segments is shown in the following tables:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Month Ended March 31, 2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Felicitex</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">TarMeta</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">78,165</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">55,681</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">133,846</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">138,591</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">153,058</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">216,756</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">70,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">286,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Operating loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(216,756</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(70,148</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(286,904</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Felicitex</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">TarMeta</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; padding-bottom: 1.5pt">Cash</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,511</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,851</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">10,362</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,511</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,851</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,362</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">610</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,350</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,960</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,121</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,701</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,822</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Business
                                            Combination</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
December 30, 2021, Felicitex acquired 100% of the ownership interests in the development stage drug discovery company TarMeta Biosciences,
LLC (&ldquo;TarMeta&rdquo;) in exchange for 5,769,231 common shares of Felicitex (&ldquo;TarMeta acquisition&rdquo;). One individual
investor had a controlling interest in both Felicitex and TarMeta prior to the acquisition. The Company determined the TarMeta acquisition
to be a common control transaction under ASC Topic 805, Business Combinations, and accounted for this transaction at the carrying amount
of the net assets acquired. As a result of the TarMeta acquisition, the financial statement as of and for the year ended December 31,
2021 have been adjusted to include the financial information of TarMeta.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Variable
                                            Interest Entity</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 23, 2021, the Company&rsquo;s
CEO incorporated UAB Felicitex Therapeutics (&ldquo;UAB&rdquo;), a Lithuania Corporation, for the purpose of applying for research and
development grants in the European Union. The Company&rsquo;s CEO is the sole owner of UAB in order to comply with the funding requirements
of the targeted grant programs. Due to the Company&rsquo;s control over the operations of UAB, its power to direct activities that most
significantly impact its economic performance, and the fact that the Company has the obligation to absorb losses or the right to receive
benefits from UAB, UAB is considered a VIE in accordance with applicable GAAP. A company with an interest in a VIE must consolidate the
entity in its financial statements if it has both (1) the power to direct the economically significant activities of the entity and (2)
the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to the VIE.
As of March 31, 2022, no grants have been awarded to UAB, nor have any contracts to fund UAB or utilize UAB grant proceeds been finalized,
and its balances and the activity were de minimis. In accordance with applicable GAAP, UAB has been consolidated from its inception in
the consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>13.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Subsequent
                                            Events</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company has executed a reverse stock-split whereby each shareholder received one (1) share of Common Stock for every nine and eight hundredths
(9.08) shares of Common Stock held as of that date, and as such, all share numbers were retroactively adjusted to account for the reverse
split.</FONT></P>

<P STYLE="margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="fin_001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">To the Board of Directors and<BR>
Stockholders of Felicitex Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Consolidated and Combined Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
and combined balance sheets of Felicitex Therapeutics, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2021 and 2020, and the related
consolidated and combined statement of operations, changes in deficit, and cash flows for the years ended December 31, 2021 and 2020,
and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of
its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United
States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Substantial Doubt about the Company&rsquo;s
Ability to Continue as a Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
has an accumulated deficit of approximately $6.4 million, and recurring losses since inception, which raise substantial doubt about its
ability to continue as a going concern. Management&rsquo;s evaluation of the events and conditions and management&rsquo;s plans regarding
those matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty. Our opinion is not modified with respect to that matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards
require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material
misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial
reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial
reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Friedman LLP</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have served as the Company&rsquo;s
    auditor since 2021.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Marlton, New Jersey</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt"><P STYLE="margin: 0pt 0">March 22, 2022, except for Note 1 and Note 15, as to which the date is June
                                2, 2022</P></TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_002"></A>FELICITEX THERAPEUTICS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED AND COMBINED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 76%; padding-bottom: 1.5pt">Cash</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">10,362</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">38,355</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,960</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,822</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">46,807</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Liabilities and Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">232,842</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">133,260</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,348</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Due to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,652</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,915</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">PPP loan payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,298</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Convertible note payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">481,100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">276,708</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">78,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">811,553</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">805,411</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">811,553</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">805,411</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Commitments and contingencies (Note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><B>Deficit</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Common Stock: Par value of $0.0001 per share, 100,000,000
    shares authorized; 4,263,022 and 3,247,585 shares issued and outstanding at December 31, 2021 and 2020, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,566,727</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,881,728</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,362,884</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,640,657</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(795,731</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(758,604</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 4pt">Total liabilities and deficit</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,822</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">46,807</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_003"></A>FELICITEX THERAPEUTICS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">631,751</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">487,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">777,940</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">648,550</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,409,691</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,136,267</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Operating loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,409,691</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,136,267</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">PPP Loan Forgiveness</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,064</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(44,007</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,123</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Inducement loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(151,497</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(83,510</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Gain (Loss) on change in fair value
    of warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(46,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,687</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in">Total other expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219,348</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(117,901</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net loss before provision for income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,629,039</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,254,168</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Income tax expense (benefit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net loss and comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,629,039</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,254,168</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Less: Net loss of TarMeta Biosciences,
    LLC prior to acquisition by Felicitex Therapeutics, Inc. (Note 13)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(277,526</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(535,725</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Net loss attributable to Felicitex
    Therapeutics, Inc.</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,351,513</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(718,443</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Net loss per share attributable to
    Felicitex Therapeutics, Inc.-basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.39</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average common shares outstanding
    attributable to Felicitex Therapeutics, Inc. basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,457,249</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,198,555</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_004"></A>FELICITEX THERAPEUTICS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED AND COMBINED STATEMENTS OF CHANGES
IN DEFICIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Paid-In</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Balance at January 1, 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,008,973</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">301</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,305,148</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,386,489</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,081,040</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock options issued for settlement of deferred compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">399,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">399,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued in connection with settlement of convertible
    note payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">546,780</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">546,804</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Contributions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,254,168</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,254,168</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance at December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,247,585</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">325</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,881,728</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6,640,657</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(758,604</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock options issued for settlement of deferred compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock options issued for settlement of accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,739</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,739</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stock compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339,620</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339,620</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued in connection with settlement of convertible
    note payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">380,059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">897,206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">897,243</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common stock issued in connection with acquisition of
    TarMeta</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">635,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,906,876</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,906,812</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Contributions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,643</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,643</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,629,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,629,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance at December 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,263,022</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">426</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,566,727</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6,362,884</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(795,731</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_005"></A>FELICITEX THERAPEUTICS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED AND COMBINED STATEMENTS OF CASH
FLOWS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,629,039</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,254,168</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Adjustments to reconcile net loss to net cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,559</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151,497</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Gain on change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,687</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339,620</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Forgiveness of paycheck protection loan payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,298</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.375in">Increase (decrease) in liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">170,660</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(81,907</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.5in">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,609</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.5in">Deferred compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,334</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in">Other current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,961</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">487</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.375in">Net cash flows used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(888,238</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(978,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(957</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.375in">Net cash flows used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(957</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Payments of capital leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(142,181</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Proceeds from convertible note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">594,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">511,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Equity contributions - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,643</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Proceeds from PPP loan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,298</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.375in">Net cash flows provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">860,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,010,267</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Net change in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,993</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,829</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash, beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38,355</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,526</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash, end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,362</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">38,355</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Supplementary cash flows information</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Cash paid during the year for interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Cash paid during the year for taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Non-cash investing and financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.375in">Conversion of convertible note payable into common stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">897,243</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">546,804</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.375in">Conversion of deferred compensation into stock options</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">36,667</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">399,250</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.375in">Conversion of accounts payable into stock options</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">52,739</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.375in">Acquisition of Tarmeta Biosciences</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,907,389</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="fin_006"></A>FELICITEX
THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED
AND COMBINED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>1.</B></TD><TD><B>Nature of the Business and Basis of Presentation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Felicitex Therapeutics, Inc.
(&ldquo;Felicitex&rdquo;) was incorporated in Delaware on Mary 4, 2012. Felicitex is an early-stage drug development company developing
treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term outcomes for the deadliest and
most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has established
a drug discovery platform focused on cellular dormancy to identify novel targets and corresponding small molecule inhibitors and has
developed two advanced drug candidates thus far that are all in the preclinical development stage. It has an expanding IP position that
includes two fundamental composition of matter patents and three methods of use patents. The research and development activities of the
Company are currently in the pre-clinical phase of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The company has retroactively
applied the impacts for the reverse stock split of 1 to 9.08, which was approved by the Board of Directors on May 23, 2022. All references
to the number of shares in the footnotes have been retroactively adjusted.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Basis of Presentation
and Principles of Consolidation and Combination</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
and combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&ldquo;U.S. GAAP&rdquo;) and the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;). On
July 23, 2021, the Company incorporated Felicitex Therapeutics UAB (&ldquo;UAB&rdquo;), a Lithuania Corporation, for the purpose of applying
for grants. The Company intends to use the grant proceeds, if awarded, in pre-clinical studies to be conducted in Europe to assess the
potential of conducting clinical trials on its molecule in the future. The Company&rsquo;s CEO is necessarily the sole owner of UAB in
order to comply with the funding requirements of the government grant programs in Lithuania and the European Union. As discussed in Note
14, UAB is deemed to be a Variable Interest Entity (&ldquo;VIE&rdquo;), and is therefore required to be included in the consolidated
and combined financial statements of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed in Note 13,
on December 30, 2021, the Company acquired TarMeta BioSciences, LLC (&ldquo;TarMeta&rdquo;), an early-stage drug discovery platform company
with deep expertise in analytical chemistry whose mission is to identify and commercialize novel small molecule therapeutics for difficult
to treat cancers. The Company determined the TarMeta acquisition to be a common control transaction under ASC Topic 805, Business Combinations,
and accounted for this transaction at the carrying amount of the net assets acquired. As a result of the TarMeta acquisition, the financial
statements as of and for the years ended December 31, 2021 and 2020 have been adjusted to include the financial information of TarMeta
for the period. As a result of the business combination, TarMeta ceased to exist as a separate legal entity. The consolidated and combined
financial statements include the accounts of Felicitex, UAB and TarMeta (collectively, the &ldquo;Company&rdquo;). All intercompany transactions
and balances have been eliminated in combination. There is no difference between net loss and comprehensive loss in these consolidated
and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Liquidity and Going
Concern</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is in the development stage and has incurred losses and negative cash flows from operations. The Company had a net loss of approximately
$1.6 million and $1.3 million, and negative cash flows from operations of approximately $900 thousand and $1.0 million for the years
ended December 31, 2021, and 2020, respectively. Further, the Company has an accumulated deficit of $6,362,884</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">as
of December 31, 2021. Based on the current development plans for the Company&rsquo;s drug candidates and other operating requirements,
existing cash is not sufficient to fund operations for the twelve months following the financial statement filing date. These factors
raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A significant amount of additional
capital will be necessary to advance the development of our products to the point at which they may become commercially viable. The Company
plans to raise additional capital from various potential sources, including equity and/or debt financings, grant funding, and strategic
relationships. In addition, the Company has an active equity purchase agreement with Aegis Capital to sell up to $15 million of Company
common stock in an initial public offering, which amount, if fully accessible, would be sufficient to fund the Company&rsquo;s operations
beyond one year from the filing date of these statements. However, there can be no guarantee that the Company will be able to close on
the financing. Should such financing be unsuccessful, the Company would be required to delay, scale back or eliminate some or all of
its research and development programs, which would likely have a material adverse effect on the Company and its consolidated and combined
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
and combined financial statements do not include any adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Other Uncertainties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, the industry in
which the Company operates subjects the Company to a number of other risks and uncertainties that can affect its operating results and
financial condition. Such factors include, but are not limited to: the timing, costs and results of clinical trials and other development
activities versus expectations; the ability to obtain regulatory approval to market product candidates; the ability to manufacture products
successfully; competition from products sold or being developed by other companies; the price of, and demand for, Company products once
approved; the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company faces the ongoing
risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company&rsquo;s research and pre-clinical
studies. The effects of the ongoing coronavirus pandemic may also increase non-research related costs such as insurance premiums, increase
the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key pre-clinical trial vendors
and suppliers of our pharmaceutical ingredients. The full extent to which the COVID-19 pandemic could impact drug development and research,
or impact the Company&rsquo;s suppliers and other commercial partners, will depend on future developments that cannot be predicted. We
assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information
reasonably available to us and the unknown future impacts COVID-19 as of December 31, 2021, and through the date of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>2.</B></TD><TD><B>Summary of Significant Accounting Policies</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Cash </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers all
highly liquid investments with original maturities of three months or less to be cash equivalents. The Company had no cash equivalents
at December 31, 2021 and 2020. At times, the Company&rsquo;s cash balances may exceed the current insured amounts under the Federal Deposit
Insurance Corporation (&ldquo;FDIC&rdquo;). On December 31, 2021 and 2020, the Company did not exceed FDIC insurance limits. Unrealized
gain or loss are included in the interest income and are immaterial to the consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">The
preparation of consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at
the date of the consolidated and combined financial statements as well as the reported amounts of revenues and expenses during the reporting
period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical
experience, risk of loss, general economic conditions and trends and the assessment of the probable future outcome. Subjective and significant
estimates include, but are not limited to, the valuation of stock-based compensation, valuation of issued warrants, expense recognition
and accruals associated with third party providers supporting pre-clinical studies and other research and development, and income tax
asset realization. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects
of changes, if any, are reflected in the consolidated and combined statements of operations in the period that they are determined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Segment Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determined its
operating segment after considering the Company&rsquo;s organizational structure and the information regularly reviewed and evaluated
by the Company&rsquo;s chief operating decision maker (&ldquo;CODM&rdquo;) in deciding how to allocate resources and assess performance.
The Company has determined that its CODM is its Chief Executive Officer. The CODM reviews the financial information of Felicitex and
TarMeta independently for the purpose of evaluating financial performance and allocating resources. On the basis of these factors, the
Company determined that it operates and manages its business as two operating segments and accordingly has two reportable segments for
financial reporting purposes. Substantially all the Company&rsquo;s long-lived assets are held in the United States. Segment considerations
are further discussed in Note 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Property and Equipment,
Net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost less accumulated depreciation and amortization. Expenditures for repairs and maintenance are expensed as incurred. Depreciation
and amortization are computed using the straight-line method over the estimated useful lives of the assets as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Estimated
                                            Useful Life</B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%">Equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: center"><FONT STYLE="font-size: 10pt">3
                                            years</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Shorter of remaining
                                            life of lease or useful life</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Patent Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All patent-related costs
are expensed as incurred due to uncertainty with respect to the Company&rsquo;s ability to commercialize the patents. Amounts incurred
are classified as general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lease agreements are evaluated
to determine whether they are capital or operating leases in accordance with Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 840, <I>Leases </I>(&ldquo;ASC 840&rdquo;). When any one of the four test
criteria in ASC 840 is met, the lease then qualifies as a capital lease. Capital leases are capitalized at the lower of the net present
value of the total amount payable under the leasing agreement (excluding finance charges) or the fair market value of the leased asset.
Capital lease assets are depreciated on a straight-line basis, over a period consistent with the Company&rsquo;s normal depreciation
policy for tangible fixed assets. The Company allocates each lease payment between a reduction of the lease obligation and interest expense
using the effective interest method. Rent expense for operating leases, which may include free rent or fixed escalation amounts in addition
to minimum lease payments, is recognized on a straight-line basis over the duration of the lease term. The Company had one capital lease
related to equipment as of January 1, 2020, that was fully paid off prior to December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Collaborative Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company analyzes its
collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both
active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB ASC Topic
808, <I>Collaborative Arrangements</I> (&ldquo;ASC 808&rdquo;). For collaborative arrangements that contain multiple elements, the Company
determines which units of account are deemed to be within the scope of ASC 808 and which units of account are more reflective of a vendor-customer
relationship, and therefore are within the scope of ASC 606. For units of account that are accounted for pursuant to ASC 808, an appropriate
recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable
accounting policy election. For collaborative arrangements that are within the scope of ASC 808, the Company evaluates the income statement
classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative
arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead
of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to Research
and Development Expense or General and Administrative Expense, as appropriate. Milestone payments are considered contingent liabilities
and are recognized when the Company deems the milestone event to be probable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Fair Value Measurements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FASB ASC Topic 820, <I>Fair
Value Measurements and Disclosures</I>, defines fair value, establishes a framework for measuring fair value, and expands disclosures
about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset or paid
to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy has been
established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable
inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would
use in pricing the asset or liability based on market data obtained from sources independent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unobservable inputs reflect
the Company&rsquo;s assumption about the inputs that market participants would use in pricing the asset or liability developed based
on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the inputs,
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Level 1 - Valuations
                                            based on quoted prices for identical instruments in active markets. Since valuations are
                                            based on quoted prices that are readily and regularly available in an active market, valuation
                                            of these instruments does not entail a significant degree of judgment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Level 2 - Valuations
                                            based on observable inputs other than quoted prices included in Level 1, such as quoted prices
                                            for either similar instruments in active markets, identical or similar instruments in markets
                                            that are not active, or model-derived valuations whose inputs or significant value drivers
                                            are observable or can be corroborated by observable market data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Level 3 - Valuations
                                            based on inputs that are unobservable. These valuations require significant judgment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The availability of valuation
techniques and observable inputs can vary and is affected by a wide variety of factors, including the type of asset or liability, whether
the asset or liability is new and not yet established in the marketplace, and other characteristics particular to the transaction. To
the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair
value requires more judgment. Those estimated values do not necessarily represent the amounts that may be ultimately realized due to
the occurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of valuations, those
estimated values may be materially higher or lower than the values that would have been used had a ready market for the assets or liabilities
existed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2021, the Company&rsquo;s assets
and liabilities measured at fair value on a recurring basis were categorized as follows within the fair value hierarchy:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Liabilities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 1.5pt">Warrant liability</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">276,708</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">276,708</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,708</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,708</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2020, the Company&rsquo;s assets
and liabilities measured at fair value on a recurring basis were categorized as follows within the fair value hierarchy:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Liabilities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 1.5pt">Warrant liability</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">78,823</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">78,823</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">78,823</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">78,823</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The value of cash, prepaid expenses, accounts
payable, accrued expenses, PPP loan payable, amounts due to related parties and convertible notes payable - related party approximate
fair value to due to the short-term nature of these assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company estimated the
fair value of the warrant liability classified as Level 3 liabilities using the Black-Scholes option pricing model utilizing certain
weighted average assumptions such as expected stock price volatility, expected term of the warrants, and risk-free interest rates. The
following table summarizes the activity for the Company&rsquo;s Level 3 liabilities measured at fair value on a recurring basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance as of January 1, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%">Issuance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">83,510</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Changes in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,687</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Balance as of January 1, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">78,823</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151,497</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Changes in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">46,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0pt">Balance as of December 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,708</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2021, and 2020 there were no transfers between Level 1 and Level 2, nor into and out of Level 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></P>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Costs and expenses that can
be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. Research and
development costs are charged to expense as incurred and include the cost of wages, equipment, materials, and laboratory fees paid in
conducting scientific research on potential drug candidates. Research and development costs were $632 thousand and $488 thousand for
the years ended December 31, 2021, and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for
stock-based compensation to employees and non-employees in conformity with the provisions of FASB ASC Topic 718<I>, Compensation - Stock
Based Compensation</I>. The Company expenses stock-based compensation to employees and non-employees over the requisite service period
based on the estimated grant-date fair value of the awards. The Company estimates the fair value of options granted using the Black Scholes
Merton model. The Company estimates when and if performance-based awards will be earned. If an award is not considered probable of being
earned, no amount of equity-based compensation expense is recognized. If the award is deemed probable of being earned, related equity-based
compensation expense is recorded. The fair value of an award ultimately expected to vest is recognized as an expense, net of forfeitures,
over the requisite service, which is generally the vesting period of the award. Options forfeitures are recorded as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black Scholes Merton
model requires the input of certain subjective assumptions and the application of judgment in determining the fair value of the awards.
The most significant assumptions and judgments include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Expected volatility -
                                            The expected price volatility is based on the historical volatilities of peer group companies
                                            as the Company does not have a sufficient trading history. Industry peers consist of several
                                            public companies in the bio-tech industry similar in size, stage of life cycle, and capital
                                            structure. The Company also blends in historical data on the volatility of its own equity,
                                            increasing in proportion as the period of historical data on the Company&rsquo;s data becomes
                                            more representative.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Risk-free interest rate -
                                            The risk-free rate was determined based on yields of U.S. Treasury Bonds of comparable terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Expected dividend yield -
                                            The Company has not previously issued dividends and do not anticipate paying dividends in
                                            the foreseeable future. Therefore, we used a dividend rate of zero based on our expectation
                                            of additional dividends.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Expected term -The expected
                                            term of the options was estimated using the simplified method.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Common shares issued to third
parties for services provided are valued at fair value of the Company&rsquo;s shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Warrant Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants are accounted for
in accordance with the guidance contained in ASC 815-40-15-7D and 7F, under which the warrants do not meet the criteria for equity treatment
and must be recorded as liabilities. Accordingly, the Company classifies warrants as liabilities at their fair value and adjusts the
warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised,
and any change in fair value is recognized in the consolidated and combined statement of operations and comprehensive loss. The warrants
are valued using a Black Scholes model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC&nbsp;Topic 740, <I>Income
Taxes</I> (&ldquo;ASC 740&rdquo;) sets forth standards for financial presentation and disclosure of income tax liabilities and expense.
The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A valuation allowance is
established to reduce net deferred tax assets to the amount expected to be realized. The Company recognizes the effect of income tax
positions only if those positions are more likely than not of being sustained. Changes in recognition and measurement are reflected in
the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included in income
tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company provides reserves
for potential payments of taxes to various tax authorities related to uncertain tax positions. Amounts recognized are based on a determination
of whether a tax benefit previously taken by the Company on filed tax returns or a position expected to be taken on future tax returns
is more likely than not sustaining a challenge from the local tax authorities. The tax benefit recognized is equal to the largest amount
that is more than 50% likely to be sustained. Interest and penalties associated with uncertain tax positions are recorded as a component
of income tax expense.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to its acquisition
by the Company on December 30, 2021, TarMeta was a limited liability company. As a limited liability company, the Company elected to
treat TarMeta as a partnership for federal and state income tax reporting purposes. Accordingly, for federal and certain state income
tax purposes, TarMeta&rsquo;s income was included in the income tax returns of its members. In most jurisdictions, income tax liabilities
and/or tax benefits are passed through to the individual members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Basic and Diluted Loss
per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic and diluted loss per
share is computed based on the weighted-average outstanding shares of common stock, which are all voting shares. Diluted net loss per
share is computed giving effect to all proportional shares of common stock, including stock options and warrants to the extent dilutive.
Basic net loss per share was the same as diluted net loss per share for the year ended December 31, 2021, and 2020, respectively, as
the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following potentially dilutive securities
were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<BR>
    2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<BR>
    2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Stock options excluded</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">532,766</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">333,229</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock warrants excluded</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">722</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Stock convertible under outstanding notes payable excluded</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">105,529</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">218,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total potentially dilutive securities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">762,030</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">599,351</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Emerging Growth Company
Status</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company anticipates that
it will qualify as an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;).
Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS Act until such time as those standards apply to private companies. The Company will elect to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies until
the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended
transition period provided in the JOBS Act. As a result, these consolidated and combined financial statements may not be comparable to
companies that comply with the new or revised accounting pronouncements as of public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Recently Adopted Accounting
Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, the FASB
issued Accounting Standard Update (&ldquo;ASU&rdquo;) No. 2018-18, <I>Collaborative Arrangements (Topic 808) </I>(&ldquo;ASU No. 2018-18&rdquo;).
This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808)
including the alignment of unit of account guidance between the two topics. The Company early adopted ASU No. 2018-18 as of January 1,
2020. The adoption of this update did not have a material effect on the Company&rsquo;s consolidated and combined financial statements,
as there were no collaborative arrangements that had identified performance obligations to customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Recent Accounting Pronouncements
Not Yet Adopted</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2016, the FASB
issued ASU No. 2016-02, <I>Leases (Topic 842) as subsequently amended</I> (&ldquo;ASU No. 2016-02&rdquo;). ASU No. 2016-02 was issued
to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet
and disclosing key information about leasing arrangements. The amendments in this update are effective for fiscal years beginning after
December 15, 2018, including interim periods within those fiscal years, for public business entities, not-for-profit entities that has
issued securities that are traded, listed or quoted on an exchange or an over-the-counter market, and employee benefit plans that file
financial statements with the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after
December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that the adoption
of ASU No. 2021-04 will have a material effect on its consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, the FASB
issued ASU 2019-12, <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I> (&ldquo;ASU 2019-12&rdquo;), as part
as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or
improving the usefulness of the information provided to users of financial statements. Amendments include removal of certain exceptions
to the general principles of ASC 740 and simplification in several other areas such as accounting for a franchise tax (or similar tax)
that is partially based on income. The update is effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that
the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, the FASB issued
ASU 2021-04, <I>Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation
(Topic 718), and Derivatives and Hedging-Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40): Issuer&rsquo;s Accounting for Certain
Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </I>(&ldquo;ASU 2021-04&rdquo;). The amendments in
ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&rsquo;s accounting for modifications or exchanges of freestanding
equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The update
is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
The Company does not believe that the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the FASB
issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts
in Entity&rsquo;s Own Equity (Subtopic 815-40) (&ldquo;ASU No. 2020-06&rdquo;). ASU No. 2020-06 was issued to address issues identified
as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with
characteristics of liabilities and equity. For convertible instruments, the FASB decided to reduce the number of accounting models for
convertible debt instruments and convertible preferred stock. In addition to eliminating certain accounting models, the FASB also decided
to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share
guidance. This update is effective for public business entities for fiscal years beginning after December 15, 2021, and interim periods
within those fiscal year. For all other entities, this update is effective for fiscal years beginning after December 15, 2023, and interim
periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 31, 2020. The
Company does not believe that the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><B>3.</B></TD><TD><B>Property and Equipment, Net</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment, net
consisted of the following as of December 31, 2021 and 2020, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&nbsp;31,<BR>
    2021</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&nbsp;31,
    <BR>
    2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">21,525</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">21,525</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(19,565</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,573</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,960</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,952</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><B>4.</B></TD><TD><B>Paycheck Protection Program Loan</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2020, the Company received loan proceeds in the amount of $10 thousand under the Paycheck Protection Program (&ldquo;PPP&rdquo;)
which was established as part of the Coronavirus Aid, Relief and Economic Security Act (&ldquo;CARES Act&rdquo;) administered through
the Small Business Administration (&ldquo;SBA&rdquo;). The PPP provides loans to qualifying businesses in amounts up to 2.5 times their
average monthly payroll expenses and was designed to provide a direct financial incentive for qualifying businesses to keep their workforce
employed during the Coronavirus crisis. PPP loans are uncollateralized and guaranteed by the SBA and are forgivable after a &ldquo;covered
period&rdquo; (eight or twenty-four weeks) as long as the borrower maintains its payroll levels and uses the loan proceeds for eligible
expenses, including payroll, benefits, mortgage interest, rent and utilities. The forgiveness amount will be reduced if the borrower
terminates employees or reduces salaries and wages more than 25% during the covered period. Any unforgiven portion is payable over 2
years if issued before, or 5 years if issued after, June 5, 2020 at an interest rate of 1% with payments deferred until the SBA remits
the borrower&rsquo;s loan forgiveness amount to the lender, or, if the borrower does not apply for forgiveness, ten months after the
end of the covered period. PPP loan terms provide for customary events of default, including payment defaults, breaches of representations
and warranties, and insolvency events and may be accelerated upon the occurrence of one or more of these events of default. Additionally,
PPP loan terms do not include prepayment penalties. On February 24, 2021, the Company&rsquo;s PPP loan in the amount of $10 thousand
was forgiven.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"></P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>5.</B></TD><TD><B>Convertible Note Payable - Related Party</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chairman of the Board
(&ldquo;Principal Investor&rdquo;) has substantial control of the voting power of the Company. During the years ended December 31, 2021
and 2020, the Company issued convertible notes payable to the Principal Investor in lieu of paying cash compensation. The notes payable
are convertible to common stock at a price of $2.27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2020, the Principal
Investor agreed to accept 238,612 shares of common stock at a price of $2.36 per share as payment in full of $502 thousand of principal
and $45 thousand of accrued interest on outstanding loans. In addition, the Principal Investor received warrants to purchase 47,722 additional
shares of common stock as an incentive to convert the note. The conversion was accounted for as a general conversion with the fair value
of the warrants recognized as an expense in Inducement loss and included as an adjustment to reconcile net loss to net cash provided
by (used in) operating activities in our consolidated and combined statements of cash flows. Inducement expense recorded for the year
ended December 31, 2020 was $84 thousand. The common stock consideration issued under the original terms of the notes payable was accounted
for under general conversion accounting guidance, with a net carrying amount of $547 thousand recorded in additional paid in capital
and as a non-cash transaction excluded from cash activities on the consolidated and combined statements of cash flows.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020,
the Company had $481 thousand in outstanding convertible note payables related to the Principal Investor. The notes bear an interest
rate of 12% with no maturity date. Interest expense related to the advances from the Principal Investor was $29 thousand for the year
ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2021, the Company
issued 232,473 shares of common stock to the Principal Investor as consideration for the conversion of a $521 thousand shareholder loan
and $27 thousand in accrued interest. In addition, the Company issued warrants exercisable into 46,495 shares of common stock within
five years at an exercise price of $2.36 per share &nbsp;&nbsp;as an incentive for converting the loan receivable into shares of common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2021, the Company
entered into a loan agreement with principal investor to lend up to $550 thousand. The note is convertible at $2.29 per share and accrues
interest at 12% with no maturity date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2021, the
Company issued 147,586 shares of common stock to an existing shareholder as consideration for the conversion of a $348 thousand convertible
note payable. In addition, the Company issued warrants exercisable into 29,518 shares of common stock within five years at an exercise
price of $2.36 per share &nbsp;&nbsp;to the shareholder as an incentive for converting the loan receivable into shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 16, 2022, we entered
into a convertible grid note with Mr. Duey with respect to additional advances that Mr. Duey has made and expects to make to us for general
working capital purposes until additional funds are raised from investors. The grid note carries interest at the rate of 12% per year
payable in one lump sum on the maturity date, matures on the one-year anniversary of the issuance date and may be prepaid at any time,
in whole or in part, without penalty. It may also be converted at any time, in the sum of any advances and accrued interest at a price
per share of $3.09. As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has
loaned to us an additional $408,000 under the grid note.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants above do not
meet criteria for equity treatment and are recorded as liabilities based on the guidance in ASC 815-40-15-7D and 7F. Refer to Note 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2021,
the Company had $206 thousand in outstanding convertible note payables related to the Principal Investor. The notes bear an interest
rate of 12% with no maturity date. Accrued interest related to the advances from the Principal Investor was $36 thousand for the year
ended December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>6.</B></TD><TD><B>Deficit</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of Company common
stock is entitled to one vote for each share thereof held by such holder at all meetings of stockholders (and written action in lieu
of meetings). Common stockholders are not entitled to receive dividends, unless declared by the board of directors. In the event of the
liquidation, dissolution, or winding-up of the Company, holders of Company common stock will be entitled to receive all assets of the
Company available for distribution to its stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2020, the Company
issued 238,612 shares of common stock to the Principal Investor as consideration for the conversion of a $502 thousand convertible note
plus $45 thousand in accrued interest. See Note 5 for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2021, the Company
issued 232,473 shares of common stock to the Principal Investor as consideration for the conversion of a $548 thousand convertible note.
See Note 5 for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2021, the
Company issued 147,586 shares of common stock to the Principal Investor as consideration for the conversion of a $348 thousand convertible
note. See Note 5 for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2021, the
Company issued 635,378 shares of common stock as consideration for the acquisition of the assets owned by TarMeta BioSciences, LLC. See
Note 13 for further details.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2020, the Company
issued warrants exercisable into 47,722 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the Principal
Investor as an incentive to convert a convertible note payable into shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2021, the Company
issued warrants exercisable into 46,495 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the Principal
Investor as an incentive to convert a convertible note payable into shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2021, the
Company issued warrants exercisable into 29,518 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the
Principal Investor as an incentive to convert a convertible note payable into shares of common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrants were exercised
or expired during the year ended December 31, 2021 or December 31, 2020. The following table provides the activity in warrants for the
year ended December 31, 2021 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Term (Years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Intrinsic Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding January 1, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; padding-bottom: 1.5pt">Issued</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">47,722</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">5.00</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2.36</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding January 1, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,722</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Issued</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">76,013</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.08</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding December 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">123,735</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.40</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.36</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.08</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants issued in 2020
had a total fair value of $84 thousand at time of issue, calculated using the Black Scholes model assuming an underlying security value
of $2.36 per share and volatility rate of 99.90%, a risk-free rate of 1.21%, and a term of 5.0 years. The warrants issued in 2021 had
a total fair value of $151 thousand at the time of issue, calculated using the Black Scholes model 6assuming an underlying security value
of 2.36 per share and volatility rate of 99.97%, a risk-free rate of .60%, and a term of 5.0 years. The fair value at issuance was recorded
in Inducement loss and changes in the fair value are recorded as Gain/(loss) on fair value of warrant liability.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>7.</B></TD><TD><B>Stock-Based Compensation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in">On July 20, 2012, the Company
adopted the 2012 Stock Option and Restricted Stock Plan and the shareholders authorized the Board to make grants restricted shares or
options to purchase shares up to 242,291 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 8pt; color: windowtext">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in">On March 17, 2020, the
Board authorized the Company to grant 174,114 options exercisable at a price of $2.36 per share to employees as payment in full of the
$334 thousand deferred compensation payable plus $65 thousand bonus.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2021, the Board
of Directors authorized the Company to grant 37,558 options to its CEO, of which 15,532 was payment in exchange for deferred compensation,
and 22,027 was payment for bonus. The Company issued 12,708 options to its CFO in exchange for its account payable. The Company also
issued 6,608 options to a Director for consulting services, and 19,824 options to Directors for services as Directors. All options granted
are exercisable at a price of $2.36 per share.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in">On November 2, 2021, the
Board authorized the Company to grant 110,133 options to its CEO as a discretionary bonus for achieving significant milestones during
the year and also granted 12,708 options exercisable at a price of $2.36 per share to the CFO as payment in full of $30,000 accounts
payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in">On December 21, 2021, the
shareholders approved an increase in the size of the stock option plan to 1,101,321 shares, which 568,556 shares remained available to
grant as of December 31, 2021.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No options were exercised
or expired during the years ended December 31, 2021 and 2020. The following tables provide the stock option activity for the year ended
December 31, 2021 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Options Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Term (Years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<BR>
    Exercise<BR>
    Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR>
    Average Fair<BR>
    Value at<BR>
    Issue</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Outstanding January 1, 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">159,115</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.40</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8.26</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Granted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">174,114</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.69</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.98</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333,229</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Granted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">199,537</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.54</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Outstanding December 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">532,766</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7.10</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.73</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.82</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All options were fully vested
on grant date. The intrinsic value of the options as of December 31, 2021 and 2020 was $734 thousand and $347 thousand, respectively.
The total compensation for instruments issued for the years ended December 31, 2021 and 2020 was $376 thousand and $-0-, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was no unrecognized
compensation expense as of December 31, 2021 or 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company used the Black
Scholes valuation model to determine the fair value of the options issued, using the following key assumptions for the year ended December
31, 2021 and December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Fair Value per Share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected Term (Years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected Dividend</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99.97</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99.90</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.86</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.42</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>8.</B></TD><TD><B>Income Taxes</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The difference between the
income tax provision and income taxes computed using the U. S. federal income tax rate of 21% consisted of the following for the year
ended December 31, 2021 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<BR>
    December&nbsp;31,<BR>
    2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<BR>
    December&nbsp;31,<BR>
    2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Provision at statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State taxes, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.43</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.98</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Permanent differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-11.31</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-8.21</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-16.12</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-16.76</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></P>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Deferred Tax Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred income taxes reflect
the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and
amounts used for income tax purposes. Significant components of the Company&rsquo;s deferred taxes as of December 31, 2021 and 2020 are
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<BR>
    December 31,<BR>
    2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<BR>
    December 31, <BR>
    2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left">Fixed assets and intangibles</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">113,552</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">110,608</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Stock compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,189</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,699</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net operating loss carryforwards</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">824,326</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">602,379</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,168,067</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">844,687</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,168,067</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(844,687</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Net deferred tax assets (liability)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December
31, 2021 and 2020 the Company recorded a valuation allowance equal to its net deferred tax assets. The Company determined that due to
a recent history of net losses, that at this time, sufficient uncertainty exists regarding the future realization of these deferred tax
assets through future taxable income. If, in the future, the Company believes that it is more likely than not that these deferred tax
benefits will be realized, the valuation allowances will be reduced or eliminated. With a full valuation allowance, any change in the
deferred tax asset or liability is fully offset by a corresponding change in the valuation allowance. For the years ended December 31,
2021 and 2020, the valuation allowance on the Company&rsquo;s net deferred tax assets increased by $191 thousand and $287 thousand, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
Company has federal net operating losses (&ldquo;NOLs&rdquo;) of approximately $3.0 million, of which $600 thousand begin to expire in
2037 and $2.4 million may be carried forward indefinitely. The Company has state net operating losses of $2.4 million which begin to
expire in 2038. Pursuant to Section 382 of the Internal Revenue Code, use of the Company&rsquo;s NOLs and credit carry forwards may be
limited if the Company experiences a cumulative change in ownership of greater than 50% in a moving three-year period.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company also has federal
credits that begin to expire 2031 and state tax credits that may be carried forward indefinitely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has not recorded
any liabilities related to uncertain tax positions in its consolidated and combined financial statements as of December 31, 2021 or 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent the Company
has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal
Revenue Service and state and local tax authorities to the extent utilized in a future period. As of December 31, 2021, the tax years
from 2018 to present remain open to examination by relevant taxing jurisdictions to which the Company is subject. However, to the extent
the Company utilizes net operating losses from years prior to 2018, the statute remains open to the extent of the net operating losses
or other credits that are utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>9.</B></TD><TD><B>Commitments and Contingencies</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Commitments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 1, 2014 the Company
entered into a Research Collaboration and Option Agreement with Ryvu Therapeutics S.A. (&ldquo;Ryvu&rdquo; and formerly &ldquo;Selvita
S.A.&rdquo;) for sole responsibility and discretion of developing and commercializing certain compounds and products. On December 31,
2018, the Company entered into an Exclusive License Agreement with Ryvu. The milestone payments to be paid to Ryvu under the agreement
were amended by agreements dated December 31, 2018 and April 16, 2019. Under the terms of the agreement, the Company is obligated to
make contingent milestone payments to Ryvu up to $11 million on a product-by-product basis upon the achievement of certain development
and regulatory approval milestones related to a product. The Company has also agreed to pay Ryvu low single-digit royalties on net sales
of products sold by the Company up to $3 million per year. Royalties on each product are payable on a country-by-country basis until
the later of (i) a specified period of time after the first commercial sale, and (ii) the date of expiration of the last valid claim
in the last-to-expire of the issued patents covered by the license agreement with Ryvu. At any time during the term, the Company has
the right to terminate its royalty payment obligation by providing written notice to Ryvu and paying Ryvu a royalty termination fee.
There were no royalty or milestone payments made to Ryvu during the years ended December 31, 2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 5, 2014, the Company
entered into a Collaboration and License Agreement with Eurobio Scientific, SA (&ldquo;Eurobio&rdquo; and formerly &ldquo;Diaxonhit&rdquo;)
for the development and commercialization of certain compounds developed and owned by Eurobio. The terms were amended by agreement on
July 23, 2014. Under the agreement, the Company shall pay Eurobio a license fee of $100,000 per year for 12 years plus contingent milestone
payments to Eurobio up to $11.5 million on a product-by-product basis upon the achievement of certain development and approval milestones
related to a product. The Company has also agreed to pay Eurobio low single-digit royalties on net sales of products sold by the Company.
In addition, the Company is obligated to pay Eurobio a percentage of payments received from third parties under sub-licensing agreements
ranging from 5% to 10% as well as royalties ranging from 5% to 14% on net sales of products sold by third parties under sub-licensing
agreements. Royalties on each product are payable on a country-by-country basis until the later of (i) a specified period of time after
the first commercial sale, and (ii) the date of expiration of the last valid claim in the last-to-expire of the issued patents covered
by the license agreement with Eurobio. There were no royalty, milestone, or sub-license payments made to Diaxonhit during the years ended
December 31, 2021 or 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Contingencies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company believes that
it has adequately accrued for the potential impact of loss contingencies that are probable and reasonably estimable. The Company does
not believe that the ultimate resolution of any matters to which it is presently a party will have a material effect on the Company&rsquo;s
results of operations, financial condition, or cash flows. However, the ultimate outcome is not known, and an unfavorable resolution
of one or more of these matters could have a material effect on the Company&rsquo;s financial condition, results of operations or cash
flows. There are no known claims or pending litigations against the company as of December 31, 2021 or 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>Employment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2021 the
company entered into an employment agreement with its CEO subject to Board approval. Pursuant to the agreement, the CEO will receive
tiered compensation which increases in the event the Company raises a minimum of $10,000,000 in an equity capital raise. The compensation
will be payable in accordance with the Company&rsquo;s standard payroll practices for salaried employees. The CEO is also eligible for
an annual bonus for the achievement of milestones established by the Compensation Committee of the Board and is eligible to receive a
cash bonus equal to a percentage of any upfront payment on any collaboration agreement reached with a pharmaceutical company. The CEO
will also receive a grant of nonqualified stock options exercisable into 220,265 common shares that shall vest quarterly over a period
of four years, nonqualified stock options exercisable into 330,397 common shares that shall vest upon achievement of milestones and nonqualified
stock options exercisable for 22,027 shares of common stock upon a non-dilutive research funding from any U.S agency</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>10.</B></TD><TD><B>Collaborative Arrangements</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company assessed the
Ryvu and Eurobio agreements summarized in Note 9 under Topic 808 to determine whether the license agreements or units of account within
the license agreements represent a collaborative arrangement based on the risk, rewards, and activities of the parties. The Company concluded
that neither Ryvu nor Eurobio represent a customer, as Ryvu and Eurobio are the entities that have performance conditions to the Company
and the Company records no revenue related to the transactions within the Ryvu and Eurobio agreements. There were no cash payments or
transactions in the Consolidated and Combined Statements of Operations and Comprehensive Loss related to the Ryvu agreement for the years
ended December 31, 2021 or 2020. The $100 thousand annual license fee payable to Eurobio in 2021 and 2020 was recorded as general and
administrative expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>11.</B></TD><TD><B>Related-Party Transactions</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Debt</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed in Note 5, during
the years ended December 31, 2021 and 2021, the Company issued convertible notes payable to the Principal Investor bearing an interest
rate of 12%. It may also be converted at any time, in the sum of any advances and accrued interest at a price per share of $3.09. As
of March 31, 2022, Mr. Duey had loaned to us $128,224 under the grid note entered into on March 16, 2022. Since April 1, 2022, Mr. Duey
has loaned to us an additional $408,000 under the grid note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"></P>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Consulting and Management
Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The family office of the
Principal Investor provided management services to TarMeta during the years ended December 31, 2021 and 2020 totaling $0 and $48 thousand
respectively, which represents the fair value of the services provided. The cost of these services was recorded as a capital contribution
on the books of TarMeta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Chief Financial
Officer (&ldquo;CFO&rdquo;) of the Company is the owner of an outsourced accounting and finance company that also employs other accountants
and bookkeepers. Total fees for accounting and finance services rendered during the years ended December 31, 2021 and 2020 were $49 thousand
and $36 thousand, respectively. The cost of these services was recorded as a General and Administrative expense and are reflected as
a related party liability on the accompanying consolidated and combined balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chief Executive Officer
(&ldquo;CEO&rdquo;) of the Company provided scientific advisory services to TarMeta during the years ended December 31, 2021 and 2020,
totaling $0 thousand and $30 thousand, respectively. The cost of these services was recorded as research and development expense on the
accompanying consolidated and combined statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anna Vilenchik, the mother
of our CEO, was compensated $10,000 for research services rendered during the year ended December 31, 2021, as an independent contractor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>12.</B></TD><TD><B>Segment information</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company manages its business
activities in&nbsp;two&nbsp;reportable segments: Felicitex and TarMeta. The Company evaluates the performance of its reportable segments
based on Research and Development and General and Administrative expenses, which comprises the net operating loss of each segment. Both
Felicitex and TarMeta&rsquo;s operations are primarily within the United States. For the years ended December 31, 2021 or 2020 TarMeta
recognized $12 thousand and $0 revenue, respectively, which was recorded as Other Revenue on the Statement of Operations. There are no
inter-segment sales included in the amounts disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>Felicitex</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This reporting segment includes
the development of treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term outcomes
for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma,
and lung. The Felicitex reporting segment consists of one operating segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><B><I>TarMeta</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This reporting segment includes
the identification and commercialization of novel, small molecule therapeutics for difficult to treat cancers. The TarMeta reporting
segment consists of&nbsp;one&nbsp;operating segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">Summarized financial information
concerning the Company&rsquo;s reportable segments is shown in the following tables:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Felicitex</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">TarMeta</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">212,440</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">275,277</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">487,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">398,022</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">250,528</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">648,550</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">610,462</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">525,805</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,136,267</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Operating loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(610,462</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(525,805</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,136,267</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Felicitex</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">TarMeta</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; padding-bottom: 1.5pt; padding-left: 0.125in">Cash</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">11,282</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">27,073</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">38,355</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,073</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">849</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,103</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12,131</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">34,676</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">46,807</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD COLSPAN="9" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>Year
                                            Ended December 31, 2020</B>&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 64%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Felicitex</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>TarMeta</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Depreciation expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">106</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">135,453</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">135,559</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD COLSPAN="9" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year
                                            Ended December 31, 2021</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 64%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Felicitex</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>TarMeta</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">402,382</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">229,369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">631,751</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">717,720</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60,220</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">777,940</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,120,102</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">289,589</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,409,691</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Operating loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,120,102</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(289,589</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,409,691</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Felicitex</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">TarMeta</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; padding-bottom: 1.5pt; padding-left: 0.125in">Cash</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,511</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,851</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">10,362</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,511</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,851</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,362</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">610</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,350</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,960</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,121</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,701</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,822</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD COLSPAN="9" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year
                                            Ended December 31, 2021</B>&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; width: 64%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Felicitex</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>TarMeta</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Depreciation expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">239</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,753</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,992</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>13.</B></TD><TD><B>Business Combination</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify; text-indent: 0.5in">On December 30, 2021, Felicitex
acquired 100% of the ownership interests in the development stage drug discovery company TarMeta Biosciences, LLC (&ldquo;TarMeta&rdquo;)
in exchange for 635,378 common shares of Felicitex (&ldquo;TarMeta acquisition&rdquo;). One individual investor had a controlling interest
in both Felicitex and TarMeta prior to the acquisition. The Company determined the TarMeta acquisition to be a common control transaction
under ASC Topic 805, <I>Business Combinations</I>, and accounted for this transaction at the carrying amount of the net assets acquired.
As a result of the TarMeta acquisition, the financial statements as of and for the years ended December 31, 2021 and 2020 have been adjusted
to include the financial information of TarMeta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"></P>

<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.3in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><B>14.</B></TD><TD><B>Variable Interest Entity</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 23, 2021, the Company&rsquo;s
CEO incorporated UAB Felicitex Therapeutics (&ldquo;UAB&rdquo;), a Lithuania Corporation, for the purpose of applying for research and
development grants in the European Union. The Company&rsquo;s CEO is the sole owner of UAB in order to comply with the funding requirements
of the targeted grant programs. Due to the Company&rsquo;s control over the operations of UAB, its power to direct activities that most
significantly impact its economic performance, and the fact that the Company has the obligation to absorb losses or the right to receive
benefits from UAB, UAB is considered a VIE in accordance with applicable GAAP. A company with an interest in a VIE must consolidate the
entity in its financial statements if it has both (1) the power to direct the economically significant activities of the entity and (2)
the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to the VIE.
As of December 31, 2021, no grants have been awarded to UAB, nor have any contracts to fund UAB or utilize UAB grant proceeds been finalized,
and its balances and the activity were de minimis. In accordance with applicable GAAP, UAB has been consolidated and combined from its
inception in the consolidated and combined financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -22.5pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt"><B>15.</B></TD><TD STYLE="text-align: justify"><B>Subsequent Events </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 10, 2022, the Company
modified its employment agreement with its CEO. Under the modified agreement, The CEO will receive tiered compensation which increases
in the event the Company raises a minimum of $10,000,000 in an equity capital raise. The compensation will be payable in accordance with
the Company&rsquo;s standard payroll practices for salaried employees. The CEO is also eligible for an annual bonus for the achievement
of milestones established by the Compensation Committee of the Board and is eligible to receive a cash bonus equal to a percentage of
any upfront payment on any collaboration agreement reached with a pharmaceutical company. The CEO will also receive a grant of nonqualified
stock options exercisable into 220,265 shares of common stock that will vest quarterly over a period of four years, and nonqualified
stock options exercisable into 330,397 shares of common stock that will vest upon achievement of milestones. The CEO is also eligible
for a grant of 22,027 options in the event the Company secures grant funding from a U.S. Agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 15, 2022, the Board
of Directors ratified the modified employment agreement with the Company&rsquo;s CEO, and ratified the employment agreement of its lead
scientist, and a consulting agreement with a key scientific advisor. The board also authorized the grant of options exercisable into
220,265 shares of common stock that will vest quarterly over a period of four years, and nonqualified stock options exercisable into
330,397 shares of common stock that will vest upon achievement of milestones and the grant of options exercisable into 22,027 shares
of common stock to the lead scientist and 8,811 shares of common stock to the scientific advisor. Of the 550,662 options awarded to the
CEO, 454,545 options were awarded from the 2012 Stock Option and Restricted Stock Plan and 96,117 options were awarded from the 2022
Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From January 1, 2022 through
March 15, 2022, our Chairman and principal investor made additional advances to the Company in the amount of $335,000. The total liability
due to the Chairman as of March 15, 2022 was $541,180 in principle plus $54,564 in accrued interest. On March 16, 2022, the Board of
Directors of the Company authorized the conversion of the combined liability&nbsp;in the amount of $595,744 into 192,977 shares of common
stock, to be effective March 16, 2022. The conversion price valuation was determined using&nbsp;an independent 409A valuation. The Company
has also entered into a convertible grid note with the Chairman with respect to additional advances that the Chairman expects to make
to the Company for general working capital purposes from now until additional funds are raised from investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 15, 2022, the majority
shareholders of the Company approved the 2022 Equity Incentive Plan and authorized the Company to issue options which may be exercised
for up to 825,992 shares of the Company&rsquo;s common stock. On March 16, 2022, we entered into a convertible grid note with Mr. Duey
with respect to additional advances that Mr. Duey has made and expects to make to us for general working capital purposes until additional
funds are raised from investors. The grid note carries interest at the rate of 12% per year payable in one lump sum on the maturity date,
matures on the one-year anniversary of the issuance date and may be prepaid at any time, in whole or in part, without penalty. It may
also be converted at any time, in the sum of any advances and accrued interest at a price per share of $3.09. As of March 31, 2022, Mr.
Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has loaned to us an additional $408,000 under the
grid note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The company has retroactively
applied the impacts for the reverse stock split of 1 to 9.08, which was approved by the Board of Directors on May 23, 2022. All references
to the number of shares in the footnotes have been retroactively adjusted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>[&nbsp;&nbsp;&nbsp; ]
Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Felicitex Therapeutics Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 50%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<FONT STYLE="font-size: 12pt"><B>PRELIMINARY PROSPECTUS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 50%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>______________, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2022 (25 days after the date of this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not participating
in this offering, may be required to deliver a&nbsp;prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus
when acting as underwriters and with respect to their unsold allotments or subscriptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 170 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>PART&nbsp;II<BR>
INFORMATION NOT REQUIRED IN THE PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 13. Other Expenses of Issuance and Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the costs and
expenses, other than underwriting discounts and commissions, payable by us in connection with the sale of common stock being registered.
All amounts, other than the SEC registration fee, Nasdaq listing fee and FINRA filing fee, are estimates. We will pay all these expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Amount</B></FONT></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">[&nbsp;&nbsp;]</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Nasdaq listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;[&nbsp;&nbsp;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Transfer agent fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Printing and related fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Miscellaneous</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: justify">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">*</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">To be filed by amendment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Indemnification of Directors and Officers </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a&nbsp;Delaware&nbsp;corporation. The&nbsp;Delaware&nbsp;Revised
Statutes and certain provisions of our bylaws under certain circumstances provide for indemnification of our officers, directors and
controlling persons against liabilities which they may incur in such capacities. A summary of the circumstances in which such indemnification
is provided for is contained herein, but this description is qualified in its entirety by reference to our bylaws and to the statutory
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, any officer, director, employee or
agent may be indemnified against expenses, fines, settlements or judgments arising in connection with a legal proceeding to which such
person is a party, if that person&rsquo;s actions were in good faith, were believed to be in our best interest, and were not unlawful.
Unless such person is successful upon the merits in such an action, indemnification may be awarded only after a determination by independent
decision of our board of directors, by legal counsel, or by a vote of our stockholders, that the applicable standard of conduct was met
by the person to be indemnified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The circumstances under which indemnification
is granted in connection with an action brought on our behalf is generally the same as those set forth above; however, with respect to
such actions, indemnification is granted only with respect to expenses actually incurred in connection with the defense or settlement
of the action. In such actions, the person to be indemnified must have acted in good faith and in a manner believed to have been in our
best interest, and have not been adjudged liable for negligence or misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indemnification may also be granted pursuant
to the terms of agreements which may be entered in the future or pursuant to a vote of stockholders or directors. The&nbsp;Delaware&nbsp;Revised
Statutes also grant us the power to purchase and maintain insurance which protects our officers and directors against any liabilities
incurred in connection with their service in such a position, and such a policy may be obtained by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the maximum extent permitted by law, our articles
of incorporation eliminate or limit the liability of our directors to us or our shareholders for monetary damages for breach of a director&rsquo;s
fiduciary duty as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to enter into separate indemnification
agreements with our directors and officers. Each indemnification agreement will provide, among other things, for indemnification to the
fullest extent permitted by law and our articles of incorporation and bylaws against any and all expenses, judgments, fines, penalties
and amounts paid in settlement of any claim. The indemnification agreements will provide for the advancement or payment of all expenses
to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable
law and our articles of incorporation and bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are in the process of obtaining standard policies
of insurance under which coverage is provided (a)&nbsp;to our directors and officers against loss rising from claims made by reason of
breach of duty or other wrongful act, and (b)&nbsp;to us with respect to payments which we may make to such officers and directors pursuant
to the above indemnification provision or otherwise as a matter of&nbsp;law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriting agreement, filed as Exhibit&nbsp;1.1
to&nbsp;this registration statement, will provide for indemnification, under certain circumstances, by the underwriter of us and our
officers and directors for certain liabilities arising under the Securities Act or&nbsp;otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us under the foregoing provisions, we have been
informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore
unenforceable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 171; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered Securities
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the past three years, we issued the following
securities, which were not registered under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 16, 2018, Marc Duey, our Chairman,
agreed to lend up to $550,000 to the Company on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey&rsquo;s option at a price per share of $2.29. On March 17, 2020, we issued 238,612 shares
of our common stock on Mr. Duey&rsquo;s conversion of $502,000 in principal and $45,000 of accrued interest on loans under the January
16, 2018 agreement. Mr. Duey also received warrants to purchase 47,722 additional shares of common stock as an incentive to convert these
loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2020, we granted an option to purchase
152,295 shares of our common stock to Dr. Vilenchik under the 2012 Plan, at an exercise price of $2.36 per share, as payment of the discretionary
bonus that we awarded to Dr. Vilenchik for achieving significant milestones, in the amount of $50,000, and deferred compensation owed
to Dr. Vilenchik, in the amount of $299,000, for Dr. Vilenchik&rsquo;s services to the Company since May 20, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2020, we granted an option to purchase
21,819 shares of our common stock to Dr. Frid under the 2012 Plan, at an exercise price of $2.36 per share, as payment of the discretionary
bonus that we awarded to Dr. Frid for achieving significant milestones, in the amount of $15,000, and deferred compensation owed to Dr.
Frid, in the amount of $35,000, for Dr. Frid&rsquo;s services to the Company in 2018<B>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2020, Mr. Duey entered into an additional
on-demand agreement to lend us up to $550,000 on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey&rsquo;s option at a price per share of $2.29. On March 17, 2021, we issued 232,473 shares
of common stock to Mr. Duey on conversion of $521,000 in principal and $27,823 of accrued interest on loans under the March 31, 2020
agreement. Additionally, the Company issued warrants that are exercisable into 46,495 shares of common stock within five years at an
exercise price of $2.36 per share as an incentive to convert these loans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2021, we granted (i) an option to
purchase 15,532 shares of our common stock to Dr. Vilenchik under the 2012 Plan, at an exercise price of $2.36 per share, as payment
of the deferred compensation owed in the amount of $36,667, and (ii) an option to purchase 22,027 shares of our common stock under the
2012 Plan, at an exercise price of $2.36 per share, as payment of the discretionary bonus that we awarded to her for achieving significant
milestones in 2020, in the approximate fair value amount of $50,000<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2021, we granted an option to purchase
6,608 shares of our common stock to Dr. Frid under the 2012 Plan, at an exercise price of $2.36 per share, as payment of his support
to the Company without compensation during 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2021, we granted an option to purchase
12,708 shares of our common stock to Arthur Healey under the 2012 Plan, as payment of $30,000 of accounts payable due to him for services
rendered since May 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2021, we granted an option to purchase
3,304 shares of our common stock to each of our directors under the 2012 Plan, which vests in three equal installments over three years,
at an exercise price equal to the fair market value of that stock on the option grant date, as compensation for the directors&rsquo;
services on the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2021, Mr. Duey entered into an additional
on-demand agreement to lend us up to $550,000 on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey&rsquo;s option at a price per share of $2.29. On November 2, 2021, we issued 147,586 shares
of our common stock to Mr. Duey on conversion of $348,420 in principal on loans under the March 31, 2021 agreement. Additionally, the
Company issued warrants that are exercisable into 29,518 shares of common stock within five years at an exercise price of $2.36 per share
as an incentive to convert these loans<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2021, we granted an option to
purchase 110,133 shares of our common stock to Dr. Vilenchik under the 2012 Plan, at an exercise price of $2.36 per share, as a bonus
for achieving significant milestones in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2021, we granted an option to purchase
12,708 shares of our common stock to Arthur Healey under the 2012 Plan, at an exercise price of $2.36 per share, as payment of $30,000
of accounts payable due to him for services rendered since May 1, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 30, 2021, we completed the acquisition
of TarMeta Biosciences, LLC by entering into an Agreement and Plan of Merger with TarMeta. In consideration of the acquisition of TarMeta,
we issued a total of 635,378 shares of our common stock to the members of TarMeta, including the issuance of 607,845 shares of our common
stock to our Chairman, Marc Duey, (i) 22,027 shares of our common stock to Felix Chapovsky, and (iii) 5,507 shares to Alexei Belenky.
We also issued a non-qualified stock option to purchase 8,811 shares of our common stock to Felix Chapovsky. We have entered an employment
agreement with Alexei Belenky on December 30, 2021 granting him a nonqualified stock option to purchase 22,027 shares in our common stock,
vesting over four years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 10, 2022, we entered into an employment
agreement with our CEO, Maria Vilenchik. Under the agreement, we agreed to grant Dr. Vilenchik nonqualified stock options exercisable
for 220,265 shares of common stock that will vest quarterly at a rate 1/16 per quarter over a period of four years. In addition, Dr.
Vilenchik will receive a grant of nonqualified stock options exercisable into 352,423 shares of common stock upon the achievement of
milestones related to approval of drug research, patient trials and non-dilutive research funding. The exercise price of such options,
once vested, shall be at a price per share that does not exceed the fair market value of such shares of Company common stock on the date
of the grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2022, our board of directors ratified
the granting of options to purchase 22,027 shares of our common stock to our lead scientist and 8,811 shares of our common stock to our
scientific advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From January 1, 2022 through March 15, 2022,
our Chairman and principal investor made additional advances to the Company in the amount of $335,000. The total liability due to the
Chairman as of March 15, 2022 was $541,180 in principle plus $54,564 in accrued interest.&nbsp; On March 16, 2022, the Board of Directors
of the Company authorized the conversion of the combined liability&nbsp;in the amount of $595,744 into 192,977 shares of common stock,
effective March 16, 2022.&nbsp; The conversion price valuation was determined using&nbsp;an independent 409A valuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2022, the Company has also entered
into a convertible grid note with the Chairman with respect to additional advances that the Chairman expects to make to the Company for
general working capital purposes from now until additional funds are raised from investors. The grid note carries interest at the rate
of 12% per year payable in one lump sum on the maturity date, matures on the one-year anniversary of the issuance date and may be prepaid
at any time, in whole or in part, without penalty. It may also be converted at any time, in the sum of any advances and accrued interest
at a price per share of $3.09. As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr.
Duey has loaned to us an additional $408,000 under the grid note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of these securities was made in
reliance upon the exemption from the registration requirements of Section 5 of the Securities Act provided by Section 4(a)(2) of the
Securities Act. The Company has reason to believe that all of the foregoing purchasers were familiar with or had access to information
concerning the operations and financial conditions of the Company, and all of those individuals&rsquo; purchasing securities represented
that they were accredited investors, acquiring the shares for investment and without a view to the distribution thereof. At the time
of issuance, all of the foregoing securities were deemed to be restricted securities for purposes of the Securities Act and the certificates
representing such securities bore legends to that effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">1.1**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">3.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex3-1_felicitex.htm"><FONT STYLE="font-size: 10pt">Certificate of Incorporation of Felicitex Therapeutics Inc. </FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.2*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex3-2_felicitex.htm"><FONT STYLE="font-size: 10pt">Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">3.3*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex3-3_felicitex.htm"><FONT STYLE="font-size: 10pt">Second Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.4*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex3-4_felicitex.htm"><FONT STYLE="font-size: 10pt">Certificate of Amendment of Felicitex Therapeutics Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">3.5*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex3-5_felicitex.htm"><FONT STYLE="font-size: 10pt">Second Certificate of Amendment of Felicitex Therapeutics Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.6*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex3-6_felicitex.htm"><FONT STYLE="font-size: 10pt">Third Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc.</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">3.7**</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Amendment to Third Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc. </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.8*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex3-8_felicitex.htm"><FONT STYLE="font-size: 10pt">Bylaws of Felicitex Therapeutics Inc.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">3.9*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex3-9_felicitex.htm"><FONT STYLE="font-size: 10pt">Certificate of Merger of TarMeta Biosciences, LLC and Felicitex Therapeutics Inc., dated December 30, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.1**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Representative&rsquo;s Warrant (included in Exhibit 1.1)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.2**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Warrant Agent Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.3**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Investor Warrant</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.4**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Investor Additional Warrant</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.5*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex4-5_felicitex.htm"><FONT STYLE="font-size: 10pt">Warrant to Purchase Common Shares between Felicitex Therapeutics Inc. and Marc Duey, dated March 17, 2020</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">4.6*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex4-6_felicitex.htm"><FONT STYLE="font-size: 10pt">Warrant to Purchase Common Shares between Felicitex Therapeutics Inc. and Marc Duey, dated March 17, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">4.7*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex4-7_felicitex.htm"><FONT STYLE="font-size: 10pt">Warrant to Purchase Common Shares between Felicitex Therapeutics, Inc and Marc Duey, dated November 2, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">5.1**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Opinion of <FONT STYLE="font-family: Times New Roman, Times, Serif">Bevilacqua PLLC</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-1_felicitex.htm"><FONT STYLE="font-size: 10pt">Agreement and Plan of Merger between Felicitex Therapeutics Inc. and TarMeta Biosciences, LLC, dated December 30, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.2*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-2_felicitex.htm"><FONT STYLE="font-size: 10pt">License and Collaboration Agreement between Felicitex Therapeutics Inc. and Diaxonhit, dated April 16, 2014***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.3*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-3_felicitex.htm"><FONT STYLE="font-size: 10pt">Amendment No. 1 to License and Collaboration Agreement between Felicitex Therapeutics Inc. and Diaxonhit, dated July 21, 2014***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.4*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-4_felicitex.htm"><FONT STYLE="font-size: 10pt">Amendment No. 2 to License and Collaboration Agreement between Felicitex Therapeutics Inc. and Eurobio Scientific SA (formerly Diaxonhit), dated February 14, 2022***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.5*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><A HREF="ea164009ex10-5_felicitex.htm"><FONT STYLE="font-size: 10pt">Research Collaboration and Licensing Option Agreement between Felicitex Therapeutics Inc. and Selvita S.A., dated November 6, 2014***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.6*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea164009ex10-6_felicitex.htm">Notice of Option Exercise under the Research Collaboration and Option Agreement dated October 1, 2014, dated August 30, 2018***</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.7*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-7_felicitex.htm"><FONT STYLE="font-size: 10pt">Exclusive License Agreement between Felicitex Therapeutics Inc. and Selvita S.A., dated December 31, 2018***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.8*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ea164009ex10-8_felicitex.htm">Amendment No. 1 to Exclusive Licensing Agreement between Felicitex Therapeutics Inc. and Selvita S.A., dated April 16, 2019***</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.9*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea164009ex10-9_felicitex.htm">Material Transfer and Royalty Agreement between Felicitex Therapeutics Inc. and Memorial Sloan Kettering Cancer Center, dated December 4, 2020***</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.10*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-10_felicitex.htm"><FONT STYLE="font-size: 10pt">Material Transfer Agreement between Felicitex Therapeutics Inc. and &Eacute;quilibre Biopharmaceuticals, dated February 15, 2021***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.11*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><A HREF="ea164009ex10-11_felicitex.htm"><FONT STYLE="font-size: 10pt">Material Transfer Agreement between Felicitex Therapeutics Inc. and Whitehead Institute for Biomedical Research, dated January 29, 2020***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.12&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><A HREF="ea164009ex10-12_felicitex.htm"><FONT STYLE="font-size: 10pt">Employment Agreement between Felicitex Therapeutics Inc. and Maria Vilenchik dated March 10, 2022</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.13&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-13_felicitex.htm"><FONT STYLE="font-size: 10pt">Employment Contract between Felicitex Therapeutics and Alexei Belenky dated December 30, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.14&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-14_felicitex.htm"><FONT STYLE="font-size: 10pt">Form of Independent Director Agreement between Felicitex Therapeutics Inc. and each independent director and each director nominee</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-size: 10pt">10.15&dagger;*</FONT></TD>
    <TD STYLE="text-align: right; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt"><A HREF="ea164009ex10-15_felicitex.htm">Form of Indemnification Agreement between Felicitex Therapeutics Inc. and each independent director and each director nominee</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.16&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-16_felicitex.htm"><FONT STYLE="font-size: 10pt">Felicitex Therapeutics Inc. 2012 Stock Option and Restricted Stock Plan</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.17&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-17_felicitex.htm"><FONT STYLE="font-size: 10pt">Felicitex Therapeutics Non-Statutory Stock Option Agreement with Valeria Povolotsky, dated March 1, 2013</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.18&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-18_felicitex.htm"><FONT STYLE="font-size: 10pt">Felicitex Therapeutics Non-Statutory Stock Option Agreement with Yuriy Gankin dated March 1, 2013</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.19&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-19_felicitex.htm"><FONT STYLE="font-size: 10pt">Felicitex Therapeutics Non-Statutory Stock Option Agreement with Michael Frid dated March 1, 2013</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.20&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="ea164009ex10-20_felicitex.htm">Felicitex Therapeutics Non-Statutory Stock Option Agreement with Maria Vilenchik dated March 1, 2013</A></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.21&dagger;*</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-21_felicitex.htm"><FONT STYLE="font-size: 10pt">Felicitex Therapeutics Inc. 2022 Equity Incentive Plan</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.22&dagger;*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-22_felicitex.htm"><FONT STYLE="font-size: 10pt">Shareholder Loan Agreement between Marc Duey and Felicitex Therapeutics Inc., dated January 16, 2018</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.23&dagger;*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-23_felicitex.htm"><FONT STYLE="font-size: 10pt">Shareholder Loan Agreement between Marc Duey and Felicitex Therapeutics Inc., dated March 31, 2020</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.24*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-24_felicitex.htm"><FONT STYLE="font-size: 10pt">Grid Note between Marc Duey and Felicitex Therapeutics dated March 16, 2022</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.25*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-25_felicitex.htm"><FONT STYLE="font-size: 10pt">Grant Agreement from Massachusetts Life Sciences Center dated July 15, 2015</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.26&dagger;*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-26_felicitex.htm"><FONT STYLE="font-size: 10pt">Consulting Agreement between Felicitex Therapeutics Inc. and Michael Frid, dated July 20, 2012***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.27*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-27_felicitex.htm"><FONT STYLE="font-size: 10pt">Consulting Agreement between Felicitex Therapeutics Inc. and Valeria Povolotsky, Ph.D., dated July 20, 2012***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.28*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-28_felicitex.htm"><FONT STYLE="font-size: 10pt">Lease between Felicitex Therapeutics Inc., TarMeta Biosciences, LLC and Kaufman Nir LLC, dated March 15, 2017</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.29**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sublease between Felicitex Therapeutics Inc. and Quateris, LLC, dated March 15, 2017</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.30&dagger;*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-30_felicitex.htm"><FONT STYLE="font-size: 10pt">Board of Directors Agreement between Felicitex Therapeutics Inc. and Yuriy Gankin, dated July 23, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.31&dagger;*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-31_felicitex.htm"><FONT STYLE="font-size: 10pt">Board of Directors Agreement between Felicitex Therapeutics Inc. and Valeria Povolotsky, dated July 23, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.32&dagger;*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea164009ex10-32_felicitex.htm">Board of Directors Agreement between Felicitex Therapeutics Inc. and Michael Frid, dated July 23, 2021</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.33&dagger;*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-33_felicitex.htm"><FONT STYLE="font-size: 10pt">Board of Directors Agreement between Felicitex Therapeutics Inc. and Alex Shlyankevich, dated July 23, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.34&dagger;*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-34_felicitex.htm"><FONT STYLE="font-size: 10pt">Board of Directors Agreement between Felicitex Therapeutics Inc. and Marc Duey, dated July 23, 2021</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.35&dagger;*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-35_felicitex.htm">Board of Directors Agreement between Felicitex Therapeutics Inc. and Maria Vilenchik, dated July 23, 2021</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.36*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><A HREF="ea164009ex10-36_felicitex.htm"><FONT STYLE="font-size: 10pt">Material Transfer and Agreement between Felicitex Therapeutics Inc. and UAB DolceRx Baltika, dated May 15, 2021*** </FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.37*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex10-37_felicitex.htm"><FONT STYLE="font-size: 10pt">Material Transfer and Agreement between Felicitex Therapeutics Inc. and Barbara Ann Karmanos Cancer Institute, dated July 18, 2022***</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">14.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex14-1_felicitex.htm"><FONT STYLE="font-size: 10pt">Code of Ethics and Business Conduct</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">21.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex21-1_felicitex.htm"><FONT STYLE="font-size: 10pt">List of Subsidiaries</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex23-1_felicitex.htm"><FONT STYLE="font-size: 10pt">Consent of Friedman LLP</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">23.2**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consent of <FONT STYLE="font-family: Times New Roman, Times, Serif">Bevilacqua PLLC</FONT> (included in Exhibit 5.1)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">24.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#poa_001">Power of Attorney (included on the signature page of this registration statement)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex99-1_felicitex.htm"><FONT STYLE="font-size: 10pt">Audit Committee Charter</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">99.2*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex99-2_felicitex.htm"><FONT STYLE="font-size: 10pt">Compensation Committee Charter</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.3*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex99-3_felicitex.htm"><FONT STYLE="font-size: 10pt">Nominating and Corporate Governance Committee Charter</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">99.4**</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consent of Michael Kody to be named as a director nominee</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.5*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex99-5_felicitex.htm"><FONT STYLE="font-size: 10pt">Consent of Douglas T. Moore to be named as a director nominee</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">107*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea164009ex-fee_felicitex.htm"><FONT STYLE="font-size: 10pt">Filing Fees Table</FONT></A></TD></TR>
  </TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
herewith.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: justify">To be filed by amendment.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.25in">***</TD><TD STYLE="text-align: justify">Portions of this exhibit have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv)
                                                    because the Registrant has determined that the information is not material and is the type that the Registrant treats as private or
                                                    confidential.</TD>
</TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">&dagger;</TD><TD STYLE="text-align: justify">Executive compensation plan or arrangement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Financial Statement Schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">All financial statement schedules are omitted
because the information called for is not required or is shown either in the financial statements or in the notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant hereby undertakes
to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered
in such names as required by the underwriters to permit prompt delivery to each purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">To file, during
                                            any period in which offers or sales are being made, a post-effective amendment to this registration
                                            statement:</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To include any prospectus required by Section 10(a)(3) of the Securities
    Act of 1933 (the &ldquo;Act&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To reflect in the prospectus any facts or events arising after the
    effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the
    aggregate, represent a fundamental change in the information set forth in this registration statement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To include any material information with respect to the plan of distribution
    not previously disclosed in this registration statement or any material change to such information in this registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">That, for the purpose of determining any liability under the Act, each
    such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the
    offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To remove from registration by means of a post-effective amendment
    any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">(4)</TD><TD STYLE="text-align: justify">That,
                                            for the purpose of determining liability under the Securities Act of 1933 to any purchaser,
                                            each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
                                            to an offering, other than registration statements relying on Rule 430B or other than prospectuses
                                            filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
                                            statement as of the date it is first used after effectiveness. Provided, however, that no
                                            statement made in a registration statement or prospectus that is part of the registration
                                            statement or made in a document incorporated or deemed incorporated by reference into the
                                            registration statement or prospectus that is part of the registration statement will, as
                                            to a purchaser with a time of contract of sale prior to such first use, supersede or modify
                                            any statement that was made in the registration statement or prospectus that was part of
                                            the registration statement or made in any such document immediately prior to such date of
                                            first use.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">(5)</TD><TD STYLE="text-align: justify">That,
                                            for the purpose of determining liability of the&nbsp;registrant&nbsp;under the&nbsp;Securities
                                            Act of 1933&nbsp;to any purchaser in the initial&nbsp;distribution&nbsp;of the securities,
                                            the undersigned&nbsp;registrant&nbsp;undertakes that in a primary offering of securities
                                            of the undersigned&nbsp;registrant&nbsp;pursuant to this registration statement, regardless
                                            of the&nbsp;underwriting&nbsp;method used to sell the securities to the purchaser, if the
                                            securities are offered or sold to such purchaser by means of any of the following communications,
                                            the undersigned&nbsp;registrant&nbsp;will be a seller to the purchaser and will be considered
                                            to offer or sell such securities to such purchaser:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify">(i)</TD><TD STYLE="text-align: justify">Any
                                            preliminary prospectus or prospectus of the undersigned&nbsp;registrant&nbsp;relating to
                                            the offering required to be filed pursuant to Rule 424;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: justify">(ii)</TD><TD STYLE="text-align: justify">Any
                                            free writing prospectus relating to the offering prepared by or on behalf of the undersigned&nbsp;registrant&nbsp;or
                                            used or referred to by the undersigned&nbsp;registrant;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">The portion
                                            of any other free writing prospectus relating to the offering containing&nbsp;material&nbsp;information
                                            about the undersigned&nbsp;registrant&nbsp;or its securities provided by or on behalf of
                                            the undersigned&nbsp;registrant; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">Any other communication
                                            that is an offer in the offering made by the undersigned&nbsp;registrant&nbsp;to the purchaser.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(b) Insofar as indemnification
for liabilities arising under the&nbsp;Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the&nbsp;Securities
and Exchange Commission&nbsp;such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) The undersigned registrant hereby undertakes
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">For purposes
                                            of determining any liability under the Securities Act, the information omitted from the form
                                            of prospectus filed as part of this registration statement in reliance upon Rule 430A and
                                            contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)
                                            or 497(h) under the Securities Act shall be deemed to be part of this registration statement
                                            as of the time it was declared effective.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">For purposes
                                            of determining any liability under the Securities Act, each post-effective amendment that
                                            contains a form of prospectus shall be deemed to be a new registration statement relating
                                            to the securities offered therein, and the offering of such securities at that time shall
                                            be deemed to be the initial bona fide offering thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Act of 1933, the registrant
has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Natick,
State of Massachusetts, on August 10, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>Felicitex Therapeutics Inc.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Maria Vilenchik</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Maria Vilenchik</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">Chief Executive Officer</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="poa_001"></A><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each person whose signature appears below constitutes and appoints
each of Maria Vilenchik and Marc Duey as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution,
for him and his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments)
to this registration statement and to file a new registration statement under Rule 461, and to file the same, with all exhibits thereto,
and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents
full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the foregoing,
as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR><TD STYLE="padding: 0in; vertical-align: bottom; width: 30%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></TD>
    <TD STYLE="padding: 0in; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: bottom; width: 48%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TITLE</B></FONT></TD>
    <TD STYLE="padding: 0in; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0in; vertical-align: bottom; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in; border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mar&iacute;a Vilenchik &nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer and Director </FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    10, 2022</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria Vilenchik</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(principal executive officer)</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Arthur Healey</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial
    Officer </FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    10, 2022</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arthur Healey</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">(principal financial and accounting
    officer)</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Marc Duey &nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    10, 2022</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc Duey</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in; border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Alex Shlyankevich &nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    10, 2022</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex Shlyankevich</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in; border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    <FONT STYLE="font-size: 10pt">Yuriy Gankin</FONT></FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    10, 2022</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuriy Gankin</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in; border-bottom: Black 1.5pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Michael Frid</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    10, 2022</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Frid</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="text-align: center; border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



</BODY>
</HTML>
[{"type": "S-1", "sequence": "1", "filename": "ea164009-s1_felicitex.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 2121382}]
{"company-data": {"conformed-name": "Felicitex Therapeutics Inc.", "cik": "0001912287", "assigned-sic": "2834", "irs-number": "811036062", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-266742", "film-number": "221152522"}, "business-address": {"street1": "27 STRATHMORE RD", "city": "NATICK", "state": "MA", "zip": "01760", "phone": "917-361-8514"}, "mail-address": {"street1": "27 STRATHMORE RD", "city": "NATICK", "state": "MA", "zip": "01760"}}
As filed with the U.S. Securities and Exchange Commission on August 10, 2022.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
Felicitex Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
Delaware
2834
80-0815393
(State or other jurisdiction of
incorporation or organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification Number)
27 Strathmore Road
Natick, MA 01760
(919) 213-0025
(Address, including zip code, and telephone number,
including area code, of registrant's principal executive offices)
Maria Vilenchik
Chief Executive Officer
27 Strathmore Road
Natick, MA 01760
(919) 213-0025
(Names, address, including zip code, and telephone
number, including area code, of agent for service)
Copies
    to:
Louis
                                            A. Bevilacqua, Esq.
Bevilacqua PLLC
1050 Connecticut
    Avenue, NW, Suite 500
Washington, DC 20036
(202) 869-0888
Matthew
                                            W. Mamak, Esq.
Alston & Bird LLP
90 Park Avenue
New York, NY 10016
(212) 210-1256
Approximate date of commencement of proposed
sale to the public:
As soon as practicable after this Registration Statement becomes effective.
If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
box. ☐
If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a),
may determine.
The information in
this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers
to buy these securities in any state where the offer or sale is not permitted.
PRELIMINARY PROSPECTUS
Subject
    to completion, dated AUGUST 10, 2022
Felicitex Therapeutics Inc.
$15,500,000
[2,480,000] Units
Each Unit Consisting of One Share of Common
Stock and One Warrant to Purchase One Share of Common Stock
This is our initial public offering. We are offering
$15,500,000 of units, each unit consisting of one share of common stock, par value $0.0001
per
share, and a warrant to purchase one share of common stock
. We currently estimate that the initial public offering price will
be between $
5.25
and $
7.25
per unit. Each share
of common stock is being sold together with one warrant to purchase one share of common stock. Each whole share exercisable pursuant
to the warrants will have an exercise price per share equal to the initial public offering price. The warrants will be immediately exercisable
and will expire on the fifth anniversary of the original issuance date. The units will not be certificated. The shares of common stock
and related warrants are immediately separable and will be issued separately but must be purchased together as a unit in this offering.
Currently, there is no public market for our
common stock. We intend to apply to list our common stock on the Nasdaq Capital Market, under the symbol "FLCT" and our warrants
under the symbol "FLCTW." We believe that upon the completion of this offering, we will meet the standards for listing on
Nasdaq.
Our key officers and directors will own approximately
[  ]% of our outstanding common stock following this offering, or approximately [  ]% if the underwriters exercise
the over-allotment option in full. As a result, they may have the ability to approve all matters submitted to our shareholders for
approval.
We are an "emerging growth company"
under applicable federal securities laws and as such, we have elected to comply with certain reduced public company reporting requirements
for this prospectus and future filings.
Investing in our shares of common stock and
the warrants (collectively, "securities") involves a high degree of risk. See the section of this prospectus entitled "Risk
Factors" beginning on page 10 for a discussion of information that should be considered in connection with an investment in our
securities.
Neither the SEC nor any state securities commission
has approved or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
Per Unit
Total
Initial public offering price
$
$
Underwriting discounts and commissions
(1)
$
$
Proceeds, before expenses, to Felicitex Therapeutics Inc.
(2)
$
$
(1)
Does not include
                                            the following additional compensation payable to the underwriters: we have agreed to pay
                                            the representative of the underwriters Aegis Capital Corp. ("Aegis" or the "representative")
                                            a non-accountable expense allowance equal to one percent (1%) of the total proceeds raised
                                            and to reimburse the underwriters for certain expenses incurred relating to this offering.
                                            In addition, we will issue to Aegis warrants to purchase in the aggregate the number of shares
                                            of our common stock equal to eight percent (8%) of the number of shares sold in this offering
                                            (excluding shares that may be issued under the over-allotment option). The registration statement
                                            of which this prospectus forms a part also registers the issuance of the shares of common
                                            stock issuable upon exercise of the representative's warrants. See also "Underwriting"
                                            for a description of compensation and other items of value payable to the underwriters.
(2)
The amount of
                                            offering proceeds to us presented in this table does not give effect to any exercise of the:
                                            (i) underwriters' over-allotment option (if any) we have granted to the underwriters
                                            as described below; (ii) warrants to be issued to the representative of the underwriters,
                                            or the representative's warrants; (iii) warrants that are included in the units; or
                                            (iv) warrants, or the Additional Warrants, issuable to certain Qualified Buyers (as defined
                                            below) in connection with certain dilutive issuances (as defined in the warrants) or adjustment
                                            to the exercise price of the warrants on the date that is 90 calendar days immediately following
                                            the initial issuance date of the warrants.
We have granted a 45-day-option to the underwriters
to purchase up to an additional
[372,000]
shares of our common stock and/or up to [372,000]
over-allotment warrants (equal to 15% of the shares of common stock and warrants underlying the units sold in the offering) in any combination
thereof, solely to cover over-allotments, if any, at the public offering price less the underwriting discounts.
Additionally, in the event of certain future
dilutive issuances of securities by us that result in a reduction of the exercise price of the warrant, as provided therein, in aggregate,
to 50%, or the floor price, of $6.25 per share, or the Initial Exercise Price, then in connection with such adjustment, each holder of
warrants that purchases at least $500,000 of units in this offering, or a Qualified Buyer, shall receive two Additional Warrants for
each one warrant held by such holder on the date of adjustment. The maximum number of warrants subject to such adjustment by a given
Qualified Buyer will be limited to the number of warrants purchased by such Qualified Buyer in this offering. See "Description
of Securities - Warrants Included in the Units" for more information. Alternatively, in the event that the exercise price
of the warrants on the date that is 90 calendar days immediately following the initial issuance date of the warrants is adjusted to the
reset floor price, Qualified Buyers will receive Additional Warrants (as described further below).
On the date that is 90 calendar days immediately
following the initial issuance date of the warrants, the exercise price of all warrants purchased in this offering will adjust to be
equal to the greater of (a) 50% of the Initial Exercise Price of the Warrants on the issuance date, that is, the reset floor price or
(b) 100% of the lowest volume weighted average price per share occurring during the 90 calendar days following the issuance date of the
warrants, or the Reset Price, provided that such value is less than the exercise price in effect on that date. The lowest Reset Price
is $3.125, which is the same as the reset floor price, or $3.125, based on an assumed public offering price of $6.25 per unit, the midpoint
of the price range of the units.
The Company may also choose to lower the exercise
price of the warrants at its option at any time during the life of the warrants.
The underwriters are offering the units for sale
on a firm commitment basis. The underwriters expect to deliver the units to the purchasers on or about             ,
2022.
, 2022
TABLE OF CONTENTS
Page
Prospectus Summary
1
Risk Factors
10
Cautionary Statement Regarding Forward-Looking Statements
51
Use of Proceeds
52
Dividend Policy
53
Capitalization
54
Dilution
55
Management's Discussion and Analysis of Financial Condition and Results
    of Operations
57
Business
68
Management
96
Executive Compensation
101
Certain Relationships and Related Party Transactions
108
Principal Shareholders
109
Description of Securities
111
Shares Eligible for Future Sale
115
Underwriting
116
Legal Matters
121
Experts
121
Where You Can Find More Information
121
Financial Statements
F-1
Please read this prospectus carefully. It
describes our business, financial condition, results of operations and prospects, among other things. We are responsible for the information
contained in this prospectus and in any free-writing prospectus we have authorized. Neither we nor the underwriter have authorized anyone
to provide you with different information, and neither we nor the underwriter take responsibility for any other information others may
give you. Neither we nor the underwriter are making an offer to sell these securities in any jurisdiction where the offer or sale is
not permitted. The information contained in this prospectus is accurate only as of the date on the front of this prospectus, regardless
of the time of delivery of this prospectus or any sale of our units. You should not assume that the information contained in this prospectus
is accurate as of any date other than its date.
For investors outside the United States: Neither
we nor the underwriters have done anything that would permit this offering, or the possession or distribution of this prospectus, in
any jurisdiction where action for those purposes is required, other than in the United States. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of common
stock and the distribution of this prospectus outside the United States.
Through and including               ,
2022 (25 days after the commencement of this offering), all dealers that buy, sell or trade shares of our common stock, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers'
obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.
i
Industry and Market Data
We are responsible for the information contained
in this prospectus. This prospectus includes industry and market data that we obtained from periodic industry publications, third-party
studies and surveys, filings of public companies in our industry and internal company surveys. These sources generally state that the
information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of the information
are not guaranteed. The forecasts and projections are based on historical market data, and there is no assurance that any of the forecasts
or projected amounts will be achieved. Industry and market data could be wrong because of the method by which sources obtained their
data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability
of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. The market and industry data
used in this prospectus involve risks and uncertainties that are subject to change based on various factors, including the COVID-19 pandemic
and those discussed in the section titled "
Risk Factors
." These and other factors could cause results to differ materially
from those expressed in, or implied by, the estimates made by independent parties and by us. Furthermore, we cannot assure you that a
third party using different methods to assemble, analyze or compute industry and market data would obtain the same results.
Trademarks and Tradenames
We own certain U.S. federal and/or unregistered
trademarks. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for
convenience, the trademarks and trade names in this prospectus are referred to without the symbols "®" and "™",
but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under
applicable law, their right thereto.
About this Prospectus
In this prospectus, unless the context suggests
otherwise, references to "Felicitex Therapeutics," "Felicitex," the "Company," "we,"
"us" and "our" refer to Felicitex Therapeutics Inc., and its subsidiary UAB Felicitex Therapeutics, which is
a variable interest entity, or VIE, organized as a Lithuanian limited liability company, and the term "common stock" refers
to the common stock, par value $0.0001 per share, of Felicitex Therapeutics Inc., a Delaware corporation. The financial information included
herein is presented in United States dollars, or U.S. Dollars, the functional currency of our company.
This prospectus describes the specific details
regarding this offering, the terms and conditions of the securities being offered hereby, and the risks of investing in our securities.
You should read this prospectus, any free writing prospectus and the additional information about us described in the section entitled
"
Where You Can Find More Information
" before making your investment decision.
Neither we, nor any of our officers, directors,
agents or representatives or underwriters, make any representation to you about the legality of an investment in our securities. You
should not interpret the contents of this prospectus or any free writing prospectus to be legal, business, investment or tax advice.
You should consult with your own advisors for that type of advice and consult with them about the legal, tax, business, financial and
other issues that you should consider before investing in our securities.
ii
GLOSSARY OF PHARMACEUTICAL
TERMS
The following is a glossary of certain pharmaceutical terms that are
used in this prospectus.
acquired resistance mechanisms
Acquired resistance
    mechanisms occur when a particular microorganism obtains the ability to resist the activity of an antimicrobial agent, to which
    it was previously susceptible.
ALL
Acute lymphocytic leukemia
is
    a type of cancer of the blood and bone marrow.
ADMET properties
The absorption, distribution,
    metabolism, excretion, and toxicity (ADMET) properties of chemicals.
Affordable Care Act
The Patient Protection and
    Affordable Care Act, as amended.
AKS
The federal Anti-Kickback
    Statute, a criminal law that prohibits the knowing and willful payment of "remuneration," directly or indirectly, in
    cash or in kind, to induce or reward patient referrals or the generation of business involving any item or service payable by the
    Federal health care programs (e.g., drugs, supplies, or health care services for Medicare or Medicaid patients).
animal xenograft model
One of the most widely used
    models; these are mouse models involving the direct transfer of fresh human tumor samples into immunodeficient mice following
    surgical resection or other medical operations.
Mouse xenograft animal models
are used to assess the efficacy of medicines
    before they are tested in clinical trials.
anti-angiogenesis therapy
Therapy drugs that are treatments
    that stop tumors from growing their own blood vessels.
antibody drugs
Antibody drugs, as well as
    other biologicals, are usually designed to minimize undesired responses, by the immune system of the patient, against the drug.
bioavailable
The ability of a drug to be absorbed and used by the body.
biologic
Biologics, or biological
    medications, are developed from blood, proteins, viruses, and living organisms and are used to prevent, treat, and cure human disease.
biopharmaceutical
Any pharmaceutical drug product
    manufactured in, extracted from, or semi-synthesized from biological sources.
blood-brain-barrier
A semipermeable barrier formed
    by cells lining the blood capillaries that supply the brain and other parts of the central nervous system.
breakthrough therapy
Breakthrough Therapy designation
    is a process, granted by the FDA, designed to expedite the development and review of drugs that are intended to treat a serious condition
    and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically
    significant endpoint(s).
cancer
A disease in which abnormal
    cells divide uncontrollably and destroy body tissue.
cancer cell quiescence
Cellular quiescence (G0)
    is a sleep-like cellular state that allows cells to maintain the ability to re-enter and exit the proliferative cycle.
carcinogenicity
Ability or tendency to produce
    cancer.
cellular dormancy
Occurs when tumor cells reversibly
    exit the cell cycle but remain capable of re-initiating tumor growth.
cGMP
Current Good Manufacturing
    Processes, which are the standards mandated by the FDA to assure the proper design, monitoring and control of manufacturing processes
    and facilities in connection with the production of pharmaceuticals.
chemotherapy
The treatment of disease by the use of chemical
    substances, especially the treatment of cancer by cytotoxic and other drugs.
iii
clinical trials
Clinical trials
    are a type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
CMC
Chemistry, Manufacturing
    and Control, refers to the various procedures used to assess the physical and chemical characteristics of drug products, and
    to ensure their quality and consistency during manufacturing.
colorectal
Relating to or affecting
    the colon and the rectum.
compound
A chemical compound is a
    chemical substance composed of many identical molecules composed of atoms from more than one element held together by chemical bonds.
CROs
Contract Research Organizations, are organizations contracted
    by another company to take the lead in managing that company's clinical trials and complex medical testing responsibilities.
deregulation of the cell cycle
The deregulation of the cell
    cycle is one of the hallmarks of cancer, where cell cycle proteins are mostly unregulated.
dormant cancer cells
Dormancy is a stage
    in cancer progression where the cells cease dividing but survive while waiting for appropriate environmental conditions to begin
    proliferation again.
DYRK
A dual specificity protein
    kinase. There are variations of DYRK: DYRK1A and DYRK1B.
EC
Ethics committees, or similar
    institutional mechanisms, assist in addressing ethical issues that arise in patient care and facilitate sound decision making that
    respects participants' values, concerns, and interests.
Efficacy
The ability to produce a
    desired or intended result.
EGFR
An Epidermal Growth Factor
    Receptor, a receptor protein which spans the cell membrane so that one end of the protein remains inside the cell and the other end
    projects from the outer surface of the cell.
EMA
The European Medicines Agency
    is an agency of the European Union in charge of the evaluation and supervision of medicinal products.
FDA
The U.S. Food and Drug Administration.
First line therapies
A
    therapeutic approach that is often part of a standard set of treatments, such as surgery followed by chemotherapy and radiation.
    When used by itself, first-line therapy is the treatment accepted as the best therapy.
Generics
Generic medicines work in
    the same way and provide the same clinical benefit and risks as their brand-name counterparts.
Glioblastoma
A malignant tumor affecting
    the brain or spine.
GBM
Glioblastoma multiforme is
    the most aggressive of the gliomas, a collection of tumors arising from glia or their precursors within the central nervous system.
GCP
Good clinical practice (GCP)
    is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve
    human subjects which governments can transpose into regulations for clinical trials involving human subjects.
GLP
Good Laboratory Practices
    (GLP) refer to a set of principles intended to ensure quality and integrity of non-clinical studies and the conditions under
    which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported.
Hematological
The branch of medicine that deals with the diagnosis and treatment of diseases of the blood
    and bone marrow.
Hematopoietic
Relating to or involved in
    the formation of blood cells.
Heterogeneous
Consisting of dissimilar
    or diverse ingredients or constituents.
iv
HHS
The U.S. Department
    of Health and Human Services.
HIPAA
The Health Insurance Portability
    and Accountability Act of 1996, as amended.
HITECH
The Health Information Technology
    for Economic and Clinical Health Act of 2009.
Hormone therapy
Hormone therapy
is
    a treatment that slows or stops the growth of breast and prostate cancers that use hormones to grow.
Hypoxia/hypoxic
A deficiency in the amount
    of oxygen reaching the tissues.
IMM
Referring to irreversible
    morbidity or mortality.
Immune-mediated diseases
Immune mediated diseases
    (IMIDs) are a group of autoimmune inflammatory disorders characterized by an alteration in cellular homeostasis.
Immune-oncology
Immuno
-
oncology
is
    the study and development of treatments that take advantage of the body's
immune
system to fight
cancer
.
In vitro
A process performed or taking
    place in a test tube, culture dish, or elsewhere outside a living organism.
In vivo
A process performed or taking
    place in a living organism.
IND
An Investigational New Drug
    Application (IND) is a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA)
    to administer an investigational drug or biological product to humans.
Inhibitor(s)
A substance which slows down
    or prevents a particular chemical reaction or other process, or which reduces the activity of a particular reactant, catalyst, or
    enzyme.
IRB
The
    Institutional Review Board is an administrative body established to protect the rights and welfare of human research subjects recruited
    to participate in research activities conducted under the auspices of the institution with which it is affiliated. The IRB is tasked
    with reviewing clinical trial protocols
and informed consent information for patients in clinical
    trials for the FDA.
IMM
Referring to irreversible
    morbidity or mortality.
Kinases
Any of the various enzymes
    that catalyze the transfer of phosphate groups from a high-energy phosphate-containing molecule (such as ATP) to a substrate.
KRAS
The Kirsten rat sarcoma virus.
Liquid tumors
Cancers present in body fluids (the
    blood and bone marrow), that are detectable by blood laboratory tests.
MAPK pathway
The mitogen-activated protein
    kinase (MAPK) pathway plays a role in the regulation of gene expression, cellular growth, and survival.
Mechanistic diversity
Relating to cellular signaling pathways
    that may be extremely different in normal healthy cells compared to cancerous cells.
Medicare
Medicare
is
    a federal health insurance program for people 65 or older, as well as some younger people with disabilities or end-stage renal disease
    (ESRD).
Medicaid
Medicaid is a federal and
    state program that provides health coverage to millions of Americans, including eligible low-income adults, children, pregnant women,
    elderly adults, and people with disabilities.
MEK
Mitogen-activated protein
    kinase, or MEK, is a kinase enzyme that adds a phosphate group to mitogen (cells that a small bioactive protein or peptide that induces
    a cell to begin cell division) activated protein kinases.
Metabolic state
The metabolic state of a
    cell includes a balance between its energetic demands and its biosynthetic requirements to support cellular function.
Metabolism
The chemical processes that
    occur within a living organism to maintain life.
v
Metastasis
The development
    of secondary malignant growths at a distance from a primary site of cancer.
Microanatomical structure
Microanatomy, also called
    histology, is the microscopic study of tissue structure.
Mitosis
A type of cell division that
    results in two daughter cells each having the same number and kind of chromosomes as the parent nucleus, typical of ordinary tissue
    growth.
Mutant
A mutant is an organism
    or a new genetic character arising or resulting from an alteration of the DNA sequence of the genome or chromosome of an organism.
NDA
A new drug application to
    permit the sale and marketing of a new drug in the United States.
Neurological
Relating to the anatomy,
    functions, and organic disorders of nerves and the nervous system, including the brain, nerves found throughout the human body and
    the spinal cord.
Neuroscience
Any or all of the sciences,
    such as neurochemistry and experimental psychology, which deal with the structure or function of the nervous system and brain.
NHP
A non-human primate means
    any nonhuman member of the highest order of mammals including prosimians, monkeys, and apes.
NSCLC
Non-small
                                            cell lung cancer is a group of lung cancers that behave similarly, such as squamous cell
                                            carcinoma and adenocarcinoma. Symptoms of this cancer include a cough, shortness of breath,
                                            weight loss, or coughing up blood.
oncology
Oncology is the study
    of cancer.
orally
By means of or through the
    mouth.
orphan drug
A pharmaceutical intended
    for the treatment, prevention or diagnosis of a rare disease or condition, which is one that (1) affects less than 200,000 persons
    in the U.S; or (2) affects more than 200,000 persons in the United States for which there is no reasonable expectation that the cost
    of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the
    United States of such drug.
osteosarcoma
A type of bone cancer that
    begins in the cells that form bones.
ovarian
Relating to an ovary or the
    ovaries, a part of the female reproductive system.
pancreatic
Relating to the pancreas,
    the organ in the body that produces insulin.
PDUFA
The Prescription Drug User
    Fee Act.
PPACA
The Patient Protection and
    Affordable Health Care Act.
pharmacological quiescence
This relates to drugs keeping
    cells in a reversible state of non-dividing (G0) or temporarily preventing the cells from entering a state of cellular division.
Phase 1/2 development
Phase
                                            1 studies are the initial introduction of an investigational drug in humans. Phase 1 studies
                                            are closely monitored and are used to gather information about how a drug interacts with
                                            the human body. In Phase 2 studies, researchers administer the drug to a group of patients,
                                            up to several hundred people, with the disease or condition for which the drug is being
                                            developed. Phase 2 studies are also used to determine the common short-term side effects
                                            and risks associated with the drug.
Phase 1b/2a trial
Phase
                                            1b/2a trial means a human clinical trial of a product for any indication that (a) is intended
                                            for dose exploration, examination of pharmacological or clinical activity (including dose
                                            response, dose escalation, duration of effect or kinetic/dynamic relationship assessments)
                                            and preliminary determination of efficacy and safety in the target patient population, and
                                            (b) contains a sufficient number of well characterized and clinically uniform subjects for
                                            the applicable indication using a pre-specified and uniform dose.
Phase 3 clinical trial
Phase 3 trials are expanded
    controlled and uncontrolled trials in which researchers administer the drug to a group of patients, from several hundred to several
    thousand individuals, with the disease or condition for which the drug is being developed to evaluate the overall benefit-risk
    relationship of the drug and to provide an adequate basis for physician labeling. The study may last for multiple years.
phenotype
The
    set of observable characteristics of an individual resulting from the interaction of its genotype with the environment.
Physician Payments Sunshine Act
The Physician Payments Sunshine
    Act is a 2010 United States healthcare law that requires the disclosure of financial relationships between health care providers
    and pharmaceutical manufacturers.
PK
The physicochemical properties,
    the physical and chemical properties of a substance.
vi
placebo effect
A beneficial
    effect produced by a placebo drug or treatment, which cannot be attributed to the properties of the placebo, itself, and must therefore
    be due to the patient's belief in that treatment.
PLK1
Polo-like kinase 1, an enzyme
    that in humans is encoded by the PLK1 gene.
preclinical
A stage of research that
    begins before clinical trials.
proliferating cancer cell
A quickly dividing cancer
    cell that copies its DNA and divides into 2 cells.
prostate
The prostate is
    a walnut-sized gland in the male reproductive system.
radiation therapy
A cancer treatment that uses
    high doses of radiation to kill cancer cells and shrink tumors.
REMS
A Risk Evaluation and Mitigation
    Strategy (REMS) is a drug safety program that the FDA can require for certain medications with serious safety concerns to help ensure
    the benefits of the medication outweigh its risks.
second line therapies
Treatment for a disease or
    condition after the initial treatment (first-line treatment) has failed, stopped working, or has side effects that aren't tolerated.
small molecules
Low molecular weight molecules that
    include lipids, monosaccharides, second messengers, other natural products and metabolites, as well as drugs.
solid tumors
Solid tumors contain abnormal
    and heterotypic cells that communicate through tight and gap junctions. Unlike liquid tumors, as the cells multiply, they form a
    "mass" called a solid tumor and usually do not contain pockets of fluid, pus, air, or other substances.
targeted drug therapy
A
type of cancer
treatment
that
    uses
drugs
or other substances to precisely identify and attack certain types of cancer cells.
taxane family
Taxanes
comprise
    some of the most widely used cancer chemotherapeutic agents. This drug
family
is commonly used to treat breast,
    prostate, and lung cancers.
third line therapies
A therapeutic approach adopted
    after the failure of the first- and second- line therapies.
third-party clinical investigators
A clinical investigator conducts
    research that contributes to generalizable knowledge while protecting the rights and welfare of human participants, but not related
    to the Company.
tissue
A
group of cells that have similar structure and that function together as a unit.
toxicity
The degree to which a substance
    (a toxin or poison) can harm humans or animals.
toxicology
The branch of science concerned
    with the nature, effects, and detection of poisons.
transcription
Transcription
is
    the process by which the information in a strand of
DNA
is copied into a new molecule of messenger RNA (mRNA).
translation
Translation
refers
    to the process of creating proteins from an
mRNA
template.
tumor hypoxia
A situation where tumor
    cells have been deprived of oxygen.
tumor-targeted small molecules
A drug or series of drugs
    that target tumors.
Type I Diabetes
A chronic condition in which
    the pancreas produces little or no insulin.
vinca alkaloids
A set of anti-mitotic and
    anti-microtubule alkaloid agents originally derived from the periwinkle plant and other vinca plants.
vii
PROSPECTUS SUMMARY
This summary highlights selected information
contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information that you should consider
before deciding whether to invest in our securities. You should carefully read the entire prospectus, including the risks associated
with an investment in our company discussed in the "Risk Factors" section of this prospectus, before making an investment
decision. Some of the statements in this prospectus are forward-looking statements. See the section titled "Cautionary Statement
Regarding Forward-Looking Statements."
Unless
otherwise indicated, all share amounts and per share amounts in this prospectus have been presented on a retroactive basis to reflect
a reverse stock split of our outstanding common stock at a ratio of one-for-9.08 (1 for 9.08) which was implemented on [ ], 2022.
Our
Company
Overview
We are a preclinical oncology drug development
company focused on developing therapies targeting dormant and active cancer cells. We have designed and patented small molecules and
related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. This approach
is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal of acquired
resistance mechanisms. Our drug candidates are intended to be effective across a broad range of solid tumors and hematological cancers.
We target a high unmet need in large oncology markets including non-small cell lung cancer, or NSCLC, glioblastoma multiforme, or GBM,
ovarian, prostate, colorectal, pancreatic cancers, and acute lymphoblastic leukemia, or ALL.
We have established what we believe to be a unique
drug discovery platform, utilizing simultaneous identification of novel targets and corresponding specific small molecule inhibitors,
that, we hope, will enable us to expand our drug candidate pipeline in a way that will be faster than possible with other current methodologies.
We cannot guarantee, of course, that we will be successful in discovering or advancing new product candidates in a rapid manner, if at
all. We have a strong IP position that is continuously growing, and we have a cost-effective development strategy drawing on a network
of top-notch U.S.-based and international collaborators, each a recognized leader in their respective areas of expertise.
Our Opportunity
As an oncology drug development company, we are
at the forefront of one of the most promising areas - dormant cancers. These cancers are responsible for resistance, metastasis,
and recurrence. We are developing treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term
outcomes of treatments for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal,
osteosarcoma, glioblastoma, and lung.
A challenge for durable cancer treatment is the
extreme mechanistic diversity and adaptive capacity of tumors within and among cancer patients. For any given drug, the benefit is increasingly
limited by the subtype of disease and by the rapid emergence of drug resistance. Our goal is to deliver a broadly active and durable
therapy by targeting vulnerabilities in dormant cancer cells. The therapeutic strategy is to use our molecules alone or in combinations
with either marketed or clinical stage drugs, each combination representing a potential opportunity for partnering or licensing. The
goal is to increase the patient response rate, quality of life and overall survival rate towards 100% and minimize the side effects and
cost of treatments by reducing the overall amount of drug required and sequential rounds of treatments.
Our current internal pipeline development activities
are focused on the small molecules inhibitors of the dual specificity tyrosine phosphorylation-regulated protein kinase, or DYRK, family
of kinases. Our molecules pre-clinically have shown a high level of synergy with a spectrum of approved oncology therapeutics, including
both drugs with significant patent protection (such as epidermal growth factor receptor, or EGFR, inhibitors, Kirsten rat sarcoma virus,
or KRAS, inhibitors, mitogen-activated protein kinase, or MEK, inhibitors, and polo-like kinase 1, or PLK1, inhibitors), and drugs with
expiring patent protection, specifically the taxane family and vinca alkaloids.
Our mechanism of action is unique. We believe
that acquired resistance is a major issue for targeted therapies (mutant KRAS, MEK, EGFR inhibitors) including immuno-oncology agents,
and that cancer cell dormancy is a key driver of developing acquired resistance and a pro-survival mechanism of cancer. In addition,
DYRK1 kinase plays a major role in dormancy specific to cancer cells. Accordingly, we are developing small molecule inhibitors specific
and selective for DYRK1 kinase. Our FX-9847 and FX-1610 product candidates inhibit tumor growth and metastasis in animal models.
Our Products and Services
To date, our business development efforts have
consisted of working to discover and identify new therapeutic compounds through our own proprietary drug discovery platform and in collaboration
with third parties, and in advancing what we believe to be the most promising of these compounds through preliminary characterization,
validation and efficacy studies, both in vitro and in vivo. We have not obtained regulatory approval for any of our drug candidates and
none has yet entered Phase I clinical trials.
We have created a pipeline of therapeutic compounds focused primarily on oncology indications
of high unmet medical need. Our three most advanced product candidates are listed below:
●
FX-1610,
a small molecule
                                            inhibitor of DYRK1A and DYRK1B kinases (not orally bioavailable), is our compound being developed
                                            for pediatric leukemia - Acute Lymphoblastic Leukemia (ALL), an orphan drug indication of
                                            high unmet medical need. We expect to file an Investigational New Drug, or IND, application
                                            for FX-1610 during the first half of 2023.
1
●
FX-7742
is our compound
                                            being developed for solid tumor indications including NSCLC and colorectal cancer with mutations
                                            in EGFR (such as T790M) and KRAS (such as G12C). We are targeting an IND submission for FX-7742
                                            for NSCLC and/or other solid tumors with EGFR and KRAS mutations in the first half of 2023.
●
FX-9847 is
our compound
                                            being developed for solid tumor indications as a back-up to FX-7742, if FX-7742 fails safety
                                            testing. We expect to file an IND for FX-9847 in the second half of 2023, if we replace FX-7742
                                            with FX-9847, or otherwise in the first half of 2024 assuming the required funds are available
                                            for this IND at that time.
We are currently developing the chemistry,
manufacturing and control (CMC) and formulation and qualifying the safety profiles of FX-1610, FX-7742 and FX-9847 to comply with current
regulatory requirements. We are undertaking the characterization and validation of these product candidates prior to entering non-human
primate (NHP) preclinical toxicology studies for further refining safety, formulation, dosing and scheduling regimen parameters in advance
of a Phase 1b/2a trials in humans. Assuming completion of the work described immediately above and following the completion of pre-IND
enabling studies which we would undertake assuming the successful completion of this offering (which we cannot guarantee), we expect
to file INDs for FX-1610 and FX-7742 in the first half of 2023. If we need to substitute FX-9847 for FX-7742, if FX-7742 fails safety
studies, we would expect to be ready to file an IND for FX-9847 in the fourth quarter of 2023.
In addition, we are working
to expand our pipeline through the identification and development of new dormancy targets.
Our Competitive Strengths
The biotechnology and pharmaceutical industries
are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. Our unique knowledge,
experience, and scientific resources focuses on a strategy that provides us with competitive advantages. Nevertheless, the market for
oncology products is very competitive, changes rapidly, and welcomes the advent of new technology quickly.
We believe that we can be a leader in the discovery,
development, and commercialization of cancer dormancy targeted drugs due to the following key strengths:
●
Therapies against dormant
                                            cancer cells
.
Our patented small molecules and related methods selectively disrupt
                                            cancer cells once they enter the dormant state in a manner that is specific to the disease
                                            and tissue context. Our drug candidates are intended to be effective across a broad range
                                            of solid tumors and liquid hematological cancers. We believe we can develop multiple profitable
                                            therapies based on the significant demand for such treatments.
●
Cost-effective and
                                            professional research, development and manufacturing strategy
. Our network of top-notch
                                            U.S.-based and international collaborators, each a recognized leader in their respective
                                            areas of expertise, helps us reduce the initial costs related to, and accelerate the timeline
                                            towards, the development and deployment of medical breakthrough therapies.
●
Seasoned and accomplished
                                            management
. Our management team members are leaders in drug discovery. Our officers
                                            have led drug discovery programs at Hoffman-La Roche and Memorial Sloan Kettering Cancer
                                            Center, authored more than 20 publications in peer reviewed journals, developed eight patents,
                                            have many years of pharmaceutical industry experience, and have experience collaborating
                                            with a broad array of biopharmaceutical companies. We also have more than two decades of
                                            business management experience in the pharmaceutical and biotechnology fields. Our board
                                            of directors and scientific advisors includes the Head of Developmental Therapeutics at Memorial
                                            Sloan-Kettering Cancer Center and Professor of Pharmacology, Cell Biology and Medicine at
                                            Cornell University Medical School, and all of our directors have more than 20 years of experience
                                            in the biotechnology/pharmaceutical industries. Our officers and directors have advanced
                                            medical and business degrees from leading world universities.
2
Our Growth Strategies
Our mission is to develop novel treatments for dormant cancers: targeting
cancer resistance, metastasis, and relapse.
Our primary objective is to advance our pipeline
and leverage our therapeutic platform to become a leader in the discovery, development, and commercialization of cancer dormancy targeted
drugs. We intend to seek approval of our product candidates as first line cancer therapies to be used in combination with other first
line cancer therapy drugs. The strategies of the Company to achieve this objective, while increasing value for our shareholders, will
include the following steps:
●
Execute DYRK program
                                            advancement.
Preparation is underway to submit an Investigational New Drug application,
                                            or IND, for FX-1610, for liquid tumor ALL indications, followed by FX-7742, for solid tumor
                                            oncology indications, both in 2023. If FX-7742 fails safety studies in animals, we intend
                                            to substitute FX-7742 with FX-9847, an advanced small molecule compound being developed for
                                            solid tumors indications although not orally bioavailable.
Our goal is to advance two discovery assets per year into
                                            preclinical development. Assuming we raise the maximum amount in this offering (an assumption
                                            which we cannot guarantee), we expect to have sufficient funds for approximately the next
                                            20 to 24 months to advance two product candidates, FX-1610 and FX-7742 (or FX-9847), through
                                            the IND enabling stage and filing process up to Phase 1b/2a clinical studies. We expect that
                                            we will need additional funds to begin Phase 1b/2a clinical studies for FX-1610 and FX-7742
                                            (or FX-9847), to advance our additional pipeline prospective product candidates into the
                                            pre-IND enabling stage in 2023 or 2024, and to begin to disclose additional discovery assets
                                            on an annual basis. There can be no assurances, however, that we will be able to raise these
                                            needed additional funds on terms acceptable to us, if at all.
●
Implement accelerated
                                            breakthrough therapy regulatory strategy
. We believe that our assets are differentiated
                                            and represent potential breakthroughs in biopharmaceutical drug development. We will endeavor
                                            to seek breakthrough therapy designation (discussed below) for each of our drug candidates
                                            with regulatory agencies, which could potentially lead to accelerated clinical development
                                            timelines. In addition, we will be seeking orphan drug designation for our FX-1610 drug candidate
                                            for pediatric ALL, which is identified as an orphan disease by the FDA.
●
Pursue pipeline licensing
                                            opportunities
. We are pursuing opportunities with leading biopharmaceutical companies
                                            for the development and commercialization of our pipeline assets.
●
Leverage research,
                                            collaboration and IP licensing agreements with leading institutions
. We have, or
                                            have had, research and collaboration programs with several biotechnology companies. These
                                            collaborations allow us to accelerate our research program toward the discovery and development
                                            of breakthrough therapies based on the combined data and research resources of our program
                                            collaborators and our patented and potentially patentable cancer therapies. These companies
                                            include Ryvu, a Polish integrated drug research services company, and Équilibre Biopharmaceuticals,
                                            a New York-based breakthrough neurological therapeutics company. Our collaboration partners
                                            also include Memorial Sloan Kettering Cancer Center, one of the world's premier cancer
                                            centers, and Whitehead Institute for Biomedical Research.
The success of our growth strategy will be contingent,
among other things, on the successful completion of this offering and on our ability to raise additional funds in the future for the
further advancement of the two product candidates, whose pre-IND enabling studies we expect to fund with the proceeds of this offering,
and our other pipeline candidates. Considering our history of net losses, our accumulated deficit as of March 31, 2022 of $7,070,505,
the fact that we have not, and will not in the foreseeable future, generate any revenues or operational cash flow and the fact that we
will have to rely on our ability to raise additional capital to further the development of our product candidates and continue our business
operations, we can provide no assurance that we will be successful in executing any of our growth strategies as listed above.
COVID-19 Pandemic
Starting in late 2019, a novel strain of the
coronavirus, or COVID-19, began to rapidly spread around the world and every state in the United States. At this time, there continues
to be significant volatility and uncertainty relating to the full extent to which the COVID-19 pandemic and the various responses
to it will impact our business, operations and financial results.
Most states and cities have at various times
instituted quarantines, restrictions on travel, "stay at home" rules, social distancing measures and restrictions on the
types of businesses that could continue to operate, as well as guidance in response to the pandemic and the need to contain it. As a
result, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, including such authorities in Europe,
which could result in delays of reviews and approvals. While there have been no specific notices of delay from federal or foreign government
authorities, potential interruptions, delays, or changes to the operations of the FDA, or of any foreign authority with which we might
interact, might impact the approval of any applications we plan and will need to file in the future.
As in many other industries, we believe that
the COVID-19 pandemic has weakened many oncology drug development companies and their suppliers. We believe that we have fully complied
with all state and local requirements relating to COVID-19. We have undertaken various measures in an effort to mitigate the spread of
COVID-19, including encouraging employees to work remotely if possible. However, we have not developed any further COVID-19 contingency
plans to address the potential challenges and risks presented by this pandemic. If we were to prepare such plans, there could be no assurance
that they would be effective in mitigating the effects of the COVID-19 virus.
In addition, w
e
are dependent upon certain contract manufacturers and suppliers and their ability to reliably and efficiently fulfill our orders is critical
to our business success. The COVID-19 pandemic has impacted and may continue to impact certain of our manufacturers and suppliers.
As a result, we have faced and may continue to face delays or difficulty sourcing certain products, which could negatively affect our
business and financial results.
3
The spread of COVID-19 has also adversely
impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The
pandemic has resulted, and may continue to result, in a significant disruption of global financial markets, which may reduce our ability
to access capital in the future, which could negatively affect our liquidity.
If
the COVID-19 pandemic does not continue to slow and the spread of COVID-19 is not contained, our business operations, including
those of contract manufacturers, could be further delayed or interrupted. We expect that government and health authorities may announce
new or extend existing restrictions, which could require us or our subcontractors to make further adjustments to our operations in order
to comply with any such restrictions. We or our subcontractors may also experience limitations in employee resources. In addition, our
operations could be disrupted if any of our employees or employees of our subcontractors were to be tested positive for having COVID-19,
which could require quarantine of some or all such employees or closure of our or their facilities for disinfection. The duration of
any business disruption cannot be reasonably estimated at this time but may materially affect our ability to operate our business and
result in additional costs.
The
extent to which the COVID-19 pandemic may impact our results will depend on future developments, which are highly uncertain
and cannot be predicted as of the date of this prospectus, including the effectiveness of vaccines and other treatments for COVID-19,
the emergence of new strains of the virus and other new information that may emerge concerning the severity of the pandemic and
steps taken to contain the pandemic or treat its impact. Nevertheless, the pandemic and the current financial, economic and
capital markets environment, and future developments in the global supply chain and other areas present material uncertainty and risk
with respect to our performance, financial condition, results of operations and cash flows.
For
a further discussion of the impact of the COVID-19 pandemic on our business, please see "
Management's Discussion and Analysis
of Financial Condition and Results of Operations - Impact of COVID-19 Pandemic
".
Implications
of Being an Emerging Growth Company
Upon
the completion of this offering, we will qualify as an "emerging growth company" under the Jumpstart Our Business Startups
Act of 2012 (the "JOBS Act"). As a result, we will be permitted to, and intend to, rely on exemptions from certain disclosure
requirements. For so long as we are an emerging growth company, we will not be required to:
●
have
                                            an auditor report on our internal controls over financial reporting pursuant to Section 404(b)
                                            of the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act");
●
comply
                                            with any requirement that may be adopted by the Public Company Accounting Oversight Board
                                            regarding mandatory audit firm rotation or a supplement to the auditor's report providing
                                            additional information about the audit and the financial statements (i.e., an auditor discussion
                                            and analysis);
●
submit
                                            certain executive compensation matters to shareholder advisory votes, such as "say-on-pay"
                                            and "say-on-frequency;" and
●
disclose
                                            certain executive compensation related items such as the correlation between executive compensation
                                            and performance and comparisons of the chief executive officer's compensation to median
                                            employee compensation.
In
addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period
provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the "Securities Act") for complying with new or
revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition
period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting
standards.
We
will remain an emerging growth company for up to five years, or until the earliest of (i) the last day of the first fiscal year in which
our total annual gross revenues exceed $1.07 billion, (ii) the date that we become a "large accelerated filer" as defined
in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the "Exchange Act,") which would occur if the market
value of our securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed
second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three
year period.
Corporate
Information
The
Company was incorporated in the State of Delaware on May 4, 2012
.
Our
principal executive offices are located at 27 Strathmore Road, Natick, MA 01760 and our telephone number is (919) 213-0025. We maintain
a website at https://www.felicitex.com/. Information available on our website is not incorporated by reference in and is not deemed a
part of this prospectus.
4
The
Offering
Shares
                                            being offered:
$15,500,000
    of units (or $17,825,000 of units if the underwriters exercise the over-allotment option to purchase additional units in full), each
    unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price equal to the
    initial public offering price, which will be immediately exercisable and will expire on the fifth anniversary of the original issuance
    date. The shares and warrants that are part of the units are immediately separable and will be issued separately in this offering.
Offering
    price:
We
    currently estimate that the initial public offering price will be between $5.25 and $7.25 per share.
Common
    stock offered by us:
Up
    to 2,480,000 shares of common stock (assumed a public offering price of $6.25 per unit, the midpoint of the range set forth on the
    cover page of this prospectus).
Warrants
    offered by us:
Up
                                            to 2,480,000 warrants to purchase up to 2,480,000 shares of common stock. Each share of common
                                            stock is being sold together with one warrant to purchase one share of common stock. Each
                                            whole share exercisable pursuant to the warrants will have an initial exercise price per
                                            share equal to the initial public offering price, will be immediately exercisable and will
                                            expire on the fifth anniversary of the original issuance date. Warrants may be exercised
                                            only for a whole number of shares. The shares of common stock and warrants are immediately
                                            separable and will be issued separately but must be purchased together in this offering as
                                            units. This prospectus also relates to the offering of the shares issuable upon exercise
                                            of the warrants.
Subject to certain exemptions outlined in the
warrants, for a period until the later of: (i) two years from the date of issuance of the warrants, or (ii) on the date no Qualified
Buyer holds any warrants, if the Company shall sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter
into an agreement to sell, or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any
option to purchase or other disposition) any shares of its common stock or convertible security, at an effective price per share less
than the exercise price of the warrants then in effect, or a dilutive issuance, the exercise price of the warrants shall be reduced to
equal the effective price per share in such dilutive issuance; provided, however, that in no event shall the exercise price of the
warrants be reduced to an exercise price lower than 50% of the public offering price per unit in this offering, or the floor price.
On the date that is 90 calendar days immediately
following the initial issuance date of the warrants, the exercise price of the warrants will adjust to be equal to the Reset Price, provided
that such value is less than the exercise price in effect on that date. The Reset Price is equal to the greater of (a) the floor price
and (b) 100% of the lowest volume weighted average price per share of our common stock occurring during the 90 calendar days following
the issuance date of the warrants. The lowest Reset Price is the same as the floor price, or $3.125, which is 50% of the offering price,
based on an assumed public offering price of $6.25 per unit, the midpoint of the price range of the units.
The Company may also choose to lower the exercise
price of the warrants at its option at any time during the life of the warrants.
Holders of warrants and Additional Warrants will
have the right to participate in certain subsequent offerings available to our stockholders, subject to certain limits as described in
the warrants and Additional Warrants.
Additionally, until the later of (a) two years
after the date the warrants are issued or (b) the date no Qualified Buyer holds any warrants, in the event of any adjustment under the
dilutive issuance provision of the warrants that results in a reduction of the exercise price, in aggregate, to the floor price, then
in connection with such adjustment, each Qualified Buyer shall receive two Additional Warrants for each one warrant held by such holder
on the date of adjustment. The maximum number of warrants subject to such adjustment by a given Qualified Buyer will be limited to the
number of warrants purchased by such Qualified Buyer in this offering. Qualified Buyers would also receive Additional Warrants as a result
of the Reset Price being set at the floor price.
Such Additional Warrants shall be on substantially
the same terms as the warrants; provided, however, that the term of the Additional Warrants shall be five (5) years from the issuance
date and such Additional Warrants will not be tradable warrants.
The warrants (including the Additional Warrants)
will be subject to forced exercise commencing six months from issuance subject to the condition that the volume weighted average price
of our common stock exceeds 200% of the initial exercise price of the warrants for ten consecutive trading days and subject to certain
other conditions set forth in the warrants.
5
Shares
    outstanding after the offering:
[6,935,999]
    shares of common stock (or [7,307,999] shares if the underwriters exercise the over-allotment option in full).
Over-allotment
    option:
We
    have granted to the underwriters a 45-day option to purchase from us up to an additional 15% of the shares of common stock and/or
    warrants sold in the offering in any combination thereof, solely to cover over-allotments, if any, at the initial public offering
    price, less the underwriting discounts.
Representative's
    warrants:
We have agreed to issue to the representative warrants to purchase
a number of shares of common stock equal in the aggregate to 8% of the total number of shares issued in this offering (excluding shares
that may be issued under the over-allotment option). The representative's warrant will be exercisable at a per share exercise price
equal to 125% of the public offering price per share of common stock sold in this offering. The representative's warrant is exercisable
at any time and from time to time, in whole or in part, during the four years and six months commencing six months after the closing of
this offering and terminating on the fifth anniversary of the commencement date of sales in this offering. The registration statement
of which this prospectus forms a part also registers the issuance of the shares of common stock issuable upon exercise of the representative's
warrant. See "
Underwriting
" for more information.
Use
    of proceeds:
We
    expect to receive net proceeds of approximately $13,327,000 from this offering (or approximately $15,442,750 if the underwriters
    exercise their over-allotment option in full), assuming an initial public offering price of $6.25 per unit (which is the midpoint
    of the estimated range of the initial public offering price shown on the cover page of this prospectus) and no exercise of the underwriters'
    over-allotment option, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
    by us. We plan to use the net proceeds of this offering for research, product development, general and administrative expenses, and
    working capital and other corporate purposes. See "
Use of Proceeds
" for more information on the use of proceeds.
Risk
    factors:
Investing
    in our securities involves a high degree of risk. As an investor, you should be able to bear a complete loss of your investment.
    You should carefully consider the information set forth in the "
Risk Factors
" section beginning on page 10 before
    deciding to invest in our common stock and warrants.
Lock-up
We,
    all of our directors and officers and our shareholders holding at least 10% of the outstanding shares of our common stock have agreed
    with the underwriters, subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our common
    stock or securities convertible into or exercisable or exchangeable for our common stock for a period of six months after the closing
    of this offering. See "
Underwriting
" for more information.
Proposed
    trading market and symbol
In
connection with this offering, we intend to file an application to list our shares of common stock under the symbol "FLCT"
and our warrants, but not the Additional Warrants, under the symbol "FLCTW," both on the Nasdaq Capital Market. We do not
intend that the units trade and we will not apply for listing of the units on any securities exchange or other nationally recognized
trading system. Without an active trading market, the liquidity of the units will be limited. The closing of this offering is contingent
upon the successful listing of our common stock and warrants on the Nasdaq Capital Market.
The number of shares of common stock outstanding
immediately following this offering is based on 4,455,999 shares outstanding as of March 31, 2022, after giving effect to a reverse share
split effected on [   ], 2022 at a ratio of 1-for-9.08 and excludes:
●
1,018,146
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2012 Plan (as defined below).
●
96,117
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2022 Plan (as defined below).
●
42,519
                                            total shares of common stock issuable upon the conversion of a convertible promissory note
                                            which we issued to our Chairman;
●
729,874
                                            additional shares of common stock that are reserved for issuance under the 2022 Plan;
●
123,735
                                            shares of common stock issuable upon exercise of warrants issued to our Chairman;
●
up
                                            to [2,480,000] shares of common stock issuable upon exercise of warrants included in the
                                            units being offered in this offering;
●
up
                                            to [372,000] shares of common stock issuable upon the exercise of warrants that may be issued
                                            as a result of exercise of the representative's over-allotment option;
6
●
up
                                            to [4,960,000] shares of common stock issuable upon exercise of Additional Warrants issuable
                                            to Qualified Buyers pursuant to any adjustment in the dilutive issuance provision of the
                                            warrants;
●
up
                                            to [372,000] shares of common stock issuable upon the exercise of warrants and/or [372,000]
                                            shares of common stock that may be issued as a result of exercise of the representative's
                                            over-allotment option; and
●
up
                                            to [198,400] shares of common stock issuable upon exercise of the representative's
                                            warrants issued in connection with this offering.
Summary
Financial Information
The
following tables summarize certain financial data regarding our business and should be read in conjunction with our financial statements
and related notes contained elsewhere in this prospectus and the information under "
Management's Discussion and Analysis
of Financial Condition and Results of Operations
."
Our summary financial data as of quarters ended
March 31, 2022 and 2021 and fiscal years ended December 31, 2020 and 2021, are derived from our reviewed financial statements and our
audited financial statements included elsewhere in this prospectus, respectively. All financial statements included in this prospectus
are prepared and presented in accordance with generally accepted accounting principles in the United States ("GAAP"). The
summary financial information is only a summary and should be read in conjunction with the historical financial statements and related
notes contained elsewhere herein. The financial statements contained elsewhere fully represent our financial condition and operations;
however, they are not indicative of our future performance.
Quarters Ended March 31
Years Ended December 31,
Statement of Operations Data
2022
2021
2021
2020
Operating expenses
$
684,682
$
286,904
$
1,409,691
$
1,136,267
Operating loss
(684,682
)
(286,904
)
(1,409,691
)
(1,136,267
)
Other income (expense)
(22,939
)
(78,275
)
(219,348
)
(117,901
)
Net loss before provision for income tax
(707,621
)
(365,179
)
(1,629,039
)
(1,254,168
)
Income tax expense (benefit)
-
-
-
-
Net loss and comprehensive loss
(707,621
)
(365,179
)
(1,629,039
)
(1,254,168
)
Net loss per share attributable to the Company -
    basic and diluted
(0.16
)
(0.09
)
(0.39
)
(0.22
)
Weighted average common shares outstanding - basic
    and diluted
4,295,189
3,283,747
3,457,249
3,198,555
Balance Sheet Data
March 31,
2022
March 31
2022,
Pro Forma
(1)
March 31,
2022
Pro Forma as
Adjusted
(2)
December 31,
2021
Cash
$
32,023
$
32,023
$
13,359,023
$
10,362
Total current assets
43,273
43,273
13,370,273
10,362
Total assets
48,574
48,574
13,375,574
15,822
Total current liabilities
919,309
788,043
788,043
811,553
Total liabilities
919,309
788,043
788,043
811,553
Total deficit
(870,735
)
(739,469
)
12,587,531
(795,731
)
Total liabilities and deficit
48,574
48,574
13,375,574
15,822
1.
on
                                            a pro forma basis to give effect to issuance of 42,519 shares of our common stock upon the
                                            conversion of outstanding loans provided by our Chairman.
2.
on
                                            a pro forma as adjusted basis to reflect the pro forma adjustments as described above and
                                            the sale of 2,480,000 shares by us in this offering at an assumed price to the public of
                                            $6.25 per share, which is the midpoint of the estimated offering range set forth on the cover
                                            page of this prospectus, resulting in net proceeds to us of $13,327,000 after deducting (i)
                                            underwriter commissions of $1,520,000 and (ii) our estimated other offering expenses of $653,000
                                            (assuming no exercise of the over-allotment option).
Reverse Stock Split
On [ ], 2022, we implemented a one-for-nine and
eight one-hundredths (1 for 9.08) reverse stock split of our outstanding common stock under Delaware law. As a result of the reverse
stock split, the total of 40,460,420 issued and outstanding shares of our common stock prior to the reverse stock split was reduced to
a total of 4,455,999, after rounding, issued and outstanding shares of our common stock. The purpose of the reverse stock split was to
enhance our ability to achieve a share price for our shares of common stock consistent with the listing requirements of the Nasdaq Capital
Market. The reverse stock split maintained our existing shareholders' percentage ownership interests in our company.
7
Summary
of
Risk Factors
An
investment in our securities involves a high degree of risk. You should carefully consider the risks summarized below. These risks are
discussed more fully in the "
Risk Factors
" section immediately following this Prospectus Summary. These risks include,
but are not limited to, the following:
Risks
Related to Our Limited Operating History and Our Financial Position
●
We
                                            are a preclinical oncology drug development company with a limited operating history. We
                                            have never generated any revenue from product sales and may never be profitable.
●
Our
                                            recurring losses from operations have raised substantial doubt regarding our ability to continue
                                            as a going concern.
●
We
                                            will require substantial funding to finance our operations, complete the development and
                                            any commercialization of our drug candidates and evaluate future drug candidates. If we are
                                            unable to raise funding when needed, we may be forced to delay, reduce or eliminate our product
                                            development programs or other operations.
Risks
Related to Clinical Development and Commercialization of Our Product Candidates
●
Our
                                            product candidates and those of any collaborators will need to undergo preclinical and clinical
                                            trials that are time-consuming and expensive, the outcomes of which are unpredictable, and
                                            for which there is a high risk of failure. If preclinical or clinical trials of our or their
                                            product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA, the
                                            EMA and any other comparable regulatory authority, additional costs may be incurred or delays
                                            experienced in completing, the development of these product candidates, or their development
                                            may be abandoned.
●
We are
                                            very early in our development efforts and are substantially dependent on our lead, most advanced
                                            product candidates, FX-1610, a small molecule inhibitor in development for pediatric ALL,
                                            an orphan indication of high unmet medical need, and FX-7742, an orally bioavailable compound
                                            being developed for solid tumor indications, including non-small cell lung cancer, or NSCLC.
                                            If we are unable to advance our lead product candidates or any of our other product candidates
                                            through clinical development, obtain regulatory approval and ultimately commercialize our
                                            lead product candidates or any of our other product candidates, or experience significant
                                            delays in doing so, our business will be materially harmed.
●
Clinical
                                            drug development is a lengthy, expensive and uncertain process. The results of preclinical
                                            studies and early clinical trials are not always predictive of future results. Any drug candidate
                                            that we advance into clinical trials may not achieve favorable results in later clinical
                                            trials, if any, or receive marketing approval.
●
We
                                            have no experience as a company in conducting clinical trials.
●
If
                                            clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction
                                            of the FDA or similar regulatory authorities outside the United States or do not otherwise
                                            produce positive results, we may incur additional costs or experience delays in completing,
                                            or ultimately be unable to complete, the development and commercialization of our drug candidates.
●
Difficulty
                                            in enrolling patients could delay or prevent clinical trials of our product candidates. We
                                            may find it difficult to enroll patients in our clinical trials for FX-1610 and FX-7742 with
                                            pediatric leukemia - Acute Lymphoblastic Leukemia or non-small cell lung cancer and colorectal
                                            cancer, respectively, the types of cancers that FX-1610 and FX-7742 are designed to target.
●
Serious
                                            adverse events, undesirable side effects or toxicities, or other unexpected properties of
                                            our drug candidates could limit the commercial potential of such drug candidates.
●
The
                                            market opportunities for our product candidates may be relatively small as it will be limited
                                            to those patients who are ineligible for or have failed prior treatments and our estimates
                                            of the prevalence of our target patient populations may be inaccurate.
8
Risks
Related to Manufacturing, Supply, and Our Relationships with Third Parties
●
We
                                            expect to depend on collaborations with third parties for certain research, development and
                                            commercialization activities, and if any such collaborations are not successful, it may harm
                                            our business and prospects.
●
We
                                            expect to rely on third parties to conduct, supervise and monitor our clinical trials and
                                            some aspects of our research and preclinical testing, and if those third parties do not successfully
                                            carry out their contractual duties, comply with regulatory requirements, or otherwise perform
                                            in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize
                                            product candidates, or such approval or commercialization may be delayed, and our business
                                            may be substantially harmed.
●
Manufacturing
                                            our product candidates is complex and we may encounter difficulties in production. If we
                                            encounter such difficulties, our ability to provide supply of our product candidates for
                                            preclinical studies and clinical trials or for commercial purposes could be delayed or stopped.
●
We,
                                            or our third-party manufacturers, may be unable to successfully scale-up the manufacturing
                                            process for our drug candidates to provide sufficient quality and quantity, which would delay
                                            or prevent us from conducting clinical trials, developing our drug candidates and commercializing
                                            our drugs.
Risk
Related to Sales, Marketing, and Competition
●
We
                                            currently have no marketing and sales organization and have no experience in marketing products.
                                            If we are unable to establish marketing and sales capabilities or enter into agreements with
                                            third parties to market and sell our product candidates, if approved, we may not be able
                                            to generate product revenue.
●
Even
                                            if we obtain FDA approval of any of our drug candidates, we may never obtain approval or
                                            commercialize such products outside of the United States, which would limit our ability to
                                            realize their full market potential.
●
We
                                            face substantial competition, which may result in others discovering, developing or commercializing
                                            products before or more successfully than we do.
Risks
Related to Our Business Operations
●
We
                                            may expend our limited resources to pursue a particular product candidate or indication and
                                            fail to capitalize on product candidates or indications that may be more profitable or for
                                            which there is a greater likelihood of success.
●
We
                                            expect to expand our development, regulatory and operational capabilities and, as a result,
                                            we may encounter difficulties in managing our growth, which could disrupt our operations.
●
Our
                                            future success depends on our ability to retain key employees, consultants and advisors and
                                            to attract, retain and motivate qualified personnel.
Risks
Related to Our Intellectual Property
●
If
                                            we are unable to obtain and maintain sufficient intellectual property protection for our
                                            drug candidates, or if the scope of the intellectual property protection is not sufficiently
                                            broad, our competitors could develop and commercialize products similar or identical to ours,
                                            and our ability to successfully commercialize our products may be adversely affected.
●
Issued
                                            patents covering our products and product candidates could be found invalid or unenforceable
                                            if challenged in court or in administrative proceedings. We may not be able to protect our
                                            trade secrets in court.
●
We
                                            may be subject to claims challenging the inventorship or ownership of our patents and other
                                            intellectual property.
●
Our
                                            reliance on third parties requires us to share our trade secrets, which increases the possibility
                                            that a competitor will discover them or that our trade secrets will be misappropriated or
                                            disclosed.
●
Obtaining
                                            and maintaining patent protection depends on compliance with various procedural, document
                                            submission, fee payment and other requirements imposed by governmental patent agencies, and
                                            our patent protection could be reduced or eliminated for non-compliance with these requirements.
9
RISK
FACTORS
Investing
in our securities involves a high degree of risk. You should carefully consider the risks described below, as well as the other information
in this prospectus, including our financial statements and the related notes thereto and the section of this prospectus titled "Management's
Discussion and Analysis of Financial Condition and Results of Operations" before you make an investment decision. The occurrence
of any of the events or developments described below could harm our business, financial condition, results of operations and prospects.
As a result, the market price of our securities could decline, and you may lose all or part of your investment in our securities.
Risks
related to Our Limited Operating History and Our Financial Position
We
are a preclinical oncology drug development company with a limited operating history. We have never generated any revenue from product
sales and may never be profitable.
We
are developing small molecule drugs for the treatment of unmet medical needs in immune-mediated diseases. We are developing therapies
targeting dormant and active cancer cells. We have a limited operating history that may make it difficult to evaluate the success of
our business to date and to assess our future viability. In addition, oncology drug development is a highly speculative undertaking and
involves a substantial degree of risk. Our operations have been limited to organizing and staffing our company, business planning, raising
capital, identifying potential drug candidates, establishing licensing and partnering arrangements, undertaking various research and
conducting preclinical studies.
We have not generated any revenue from product
sales and have incurred cumulative net losses since we commenced operations. For the fiscal quarters ended March 31, 2022 and March 31,
2021, we recorded net losses of $707,621 and $295,031, respectively. As of March 31, 2022, we had an accumulated deficit of $7,070,505.
We expect that it will be several years, if ever, before we have a drug candidate ready for commercialization. We expect to incur increasing
levels of operating expenses, and continue to incur net operating losses, for the foreseeable future as we seek to advance our drug candidates.
The net operating losses that we incur may fluctuate significantly from quarter to quarter and year to year.
To
become and remain profitable, we must develop and eventually commercialize a product with significant product revenue. This will require
us to be successful in a range of challenging activities, including, but not limited to:
●
continuing
                                            our research and development efforts and submit investigational new drug applications, or
                                            INDs, for our lead product candidates;
●
initiating
                                            and conducting the required preclinical studies and clinical trials of our current and future
                                            drug candidates;
●
submitting
                                            applications for and obtaining marketing approval for these drug candidates;
●
researching
                                            and discovering new drug candidates;
●
establishing
                                            a new sales and marketing presence for, or entering into a collaboration with respect to
                                            the sales and marketing of, these drug candidates;
●
establishing
                                            effective pricing, third-party coverage and reimbursement programs;
●
manufacturing,
                                            marketing and selling products for which we may obtain marketing approval and satisfying
                                            any post-marketing regulatory requirements;
●
entering
                                            into and maintaining successful collaborations with our strategic partners or future partners;
●
maintaining,
                                            protecting and expanding our portfolio of intellectual property rights, including patents,
                                            trade secrets and know-how;
●
implementing
                                            operational, financial and management systems and appropriate controls; and
●
attracting,
                                            hiring and retaining additional administrative, clinical, regulatory and scientific personnel.
10
These
challenging activities will increase our operating expenses substantially. We may never succeed in these activities and, even if we succeed
in commercializing one or more of our drug candidates, we may never generate revenues that are significant or large enough to achieve
profitability. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges.
Because of these numerous risks and uncertainties, we are unable to accurately predict the timing or amount of increased expenses or
when, or if, we will be able to generate product revenues or achieve profitability. If we do achieve profitability, we may not be able
to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development
and other expenditures to develop and market additional drug candidates. Our failure to become and remain profitable could decrease the
value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business
or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.
Our
recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern.
We have incurred recurring losses and negative
cash flows from operations activities since inception and we expect to generate losses and negative cash flows from operations for the
foreseeable future primarily due to research and development costs for our potential product candidates. As of March 31, 2022, we had
cash of $32,023 and stockholders' deficit of $(870,735). We believe our cash on March 31, 2022 is insufficient to fund our projected
operations, but we have received a commitment to fund from our principal investor through December 31, 2022, or until such time the Company
successfully raises capital from other investors, whichever occurs first. Substantial additional financing will be needed by us to fund
our operations. These factors raise substantial doubt about our ability to continue as a going concern. The accompanying consolidated
and combined financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction
of liabilities in the normal course of business. The consolidated and combined financial statements do not include any adjustments that
might result from the outcome of this uncertainty.
We
will require additional capital in the future through equity or debt financings, partnerships, collaborations, or other sources to carry
out our planned development activities. If additional capital is not secured when required, we may need to delay or curtail our operations
until such funding is received. Various internal and external factors will affect whether and when our product candidates become approved
for marketing and successful commercialization. The regulatory approval and market acceptance of our products candidates, length of time
and cost of developing and commercializing these product candidates and/or failure of them at any stage of the approval process will
materially affect our financial condition and future operations.
Operations
since inception have consisted primarily of organizing our company, securing financing, developing our technologies through performing
research and development and conducting preclinical studies. We face risks associated with companies whose products are in development.
These risks include the need for additional financing to complete our research and development, achieving our research and development
objectives, defending our intellectual property rights, recruiting, and retaining skilled personnel, and dependence on key members of
management.
Our
ability to continue as a going concern is dependent on our ability to raise additional equity or debt capital. Should we be unable to
raise sufficient additional capital, we may be required to undertake cost-cutting measures including delaying or discontinuing certain
preclinical activities.
The
source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the
progress of our preclinical and future clinical development programs. Funding may not be available when needed, at all, or on terms acceptable
to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate some or all of our planned clinical
trials. These factors among others create a substantial doubt about our ability to continue as a going concern.
While
the potential economic impact brought by, and the duration of, COVID-19, discussed further below, may be difficult to assess or predict,
a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which
could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19
could materially affect our business and the value of our common stock.
We
will require substantial funding to finance our operations, complete the development and any commercialization of our drug candidates
and evaluate future drug candidates. If we are unable to raise funding when needed, we may be forced to delay, reduce or eliminate our
product development programs or other operations.
We
expect our expenses to increase in parallel with our ongoing activities, particularly as we continue our discovery and preclinical development
activities to identify new product candidates and initiate clinical trials of, and seek marketing approval for, our product candidates.
In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses
related to product sales, marketing, manufacturing and distribution. Furthermore, upon the closing of this offering, we expect to incur
significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional
funding in connection with our continuing operations. However, we have estimated our current additional funding needs based on assumptions
that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently
anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We cannot be certain
that additional funding will be available on acceptable terms, or at all. Until such time, if ever, as we can generate substantial product
revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, governmental
funding, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties.
If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our discovery
and preclinical development programs or any future commercialization efforts.
11
As of March 31, 2022, our cash, cash equivalents
and marketable securities totaled $32,023. We believe that, based upon our current operating plan, our existing capital resources, together
with the net proceeds from this offering will be sufficient to fund our anticipated operations for the next 20 to 24 months, including
the Phase 1/2 development of FX-1610 and FX-7742. Our future capital requirements will depend on many factors, including:
●
the
                                            scope, progress, results and costs of discovery, preclinical development and clinical trials
                                            for our product candidates;
●
the
                                            extent to which we enter into collaboration arrangements with regard to product discovery
                                            or acquire or in-license products or technologies;
●
our
                                            ability to establish discovery collaborations on favorable terms, if at all;
●
the
                                            costs, timing and outcome of regulatory review of our product candidates;
●
the
                                            costs of future commercialization activities, including product sales, marketing, manufacturing
                                            and distribution, for any of our product candidates for which we receive marketing approval;
●
revenue,
                                            if any, received from commercial sales of our product candidates, should any of our product
                                            candidates receive marketing approval; and
●
the
                                            costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, enforcing
                                            and protecting our intellectual property rights and defending intellectual property-related
                                            claims.
Identifying
potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve
product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any,
will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we
will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available
to us on acceptable terms, or at all.
Raising
additional capital may cause dilution to our existing shareholders, restrict our operations or cause us to relinquish valuable rights.
We
may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and
alliances, licensing arrangements or monetization transactions. To the extent that we raise additional capital through the sale of equity,
convertible debt securities or other equity-based derivative securities, your ownership interest will be diluted, and the terms may include
liquidation or other preferences that adversely affect your rights as a shareholder. Any indebtedness we incur would result in increased
fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such
issuance, may cause the market price of our common stock to decline and existing shareholders may not agree with our financing plans
or the terms of such financings. If we raise additional funds through strategic partnerships and alliances, licensing arrangements or
monetization transactions with third parties, we may have to relinquish valuable rights to our technologies, or our product candidates,
or grant licenses on terms unfavorable to us. Adequate additional financing may not be available to us on acceptable terms, or at all.
If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development
or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop
and market ourselves.
12
Failure
to achieve and maintain effective internal controls could adversely affect our business and price of our securities.
Effective internal controls
are necessary for us to provide reliable financial reports. All internal control systems, no matter how well designed, have inherent
limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to the consolidated
and combined financial statement preparation and presentation. While we continue to evaluate our internal controls, we cannot be certain
that these measures will ensure that we implement and maintain adequate internal control over financial reporting in the future.
If we fail to maintain the adequacy of our internal controls or if we or our independent registered public accounting firm were to discover
material weaknesses in our internal controls, as such standards are modified, supplemented or amended, we may not be able to ensure that
we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 of
the Sarbanes-Oxley Act. Failure to achieve and maintain an effective internal control environment could cause us to be unable to produce
reliable financial reports or prevent fraud. This may cause investors to lose confidence in our reported financial information, which
could have a material adverse effect on the price of our securities.
Risks
Related to Clinical Development and Commercialization of Our Product Candidates
Our
product candidates and those of any collaborators will need to undergo preclinical and clinical trials that are time-consuming and expensive,
the outcomes of which are unpredictable, and for which there is a high risk of failure. If preclinical or clinical trials of our or their
product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA, the EMA and any other comparable regulatory authority,
additional costs may be incurred or delays experienced in completing the development of these product candidates, or their development
may be abandoned.
The
FDA in the United States, the EMA in the European Union and the European Economic Area, and other comparable regulatory authorities in
other jurisdictions must approve new product candidates before they can be marketed, promoted or sold in those territories. We have not
previously submitted an IND to the FDA or similar drug approval filings to comparable foreign regulatory authorities for any of our product
candidates. We must provide these regulatory authorities with data from preclinical studies and clinical trials that demonstrate that
our product candidates are safe and effective for a specific indication before they can be approved for commercial distribution. We cannot
be certain that our clinical trials for our product candidates will be successful or that any of our product candidates will receive
approval from the FDA, the EMA or any other comparable regulatory authority.
Preclinical
studies and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee
that any clinical trials will be conducted as planned or completed on schedule, if at all. It may take several years and require significant
expenditures to complete the preclinical studies and clinical trials necessary to commercialize a product candidate, and delays or failure
are inherently unpredictable and can occur at any stage. We may also be required to conduct additional clinical trials or other testing
of our product candidates beyond the trials and testing that we contemplate, which may lead to us incurring additional unplanned costs
or result in delays in clinical development. In addition, we may be required to redesign or otherwise modify our plans with respect to
an ongoing or planned clinical trial and changing the design of a clinical trial can be expensive and time consuming. An unfavorable
outcome in one or more trials would be a major setback for our product candidates and for us. An unfavorable outcome in one or more trials
may require us to delay, reduce the scope of or eliminate one or more product development programs, which could have a material adverse
effect on our business, financial position, results of operations and future growth prospects.
Many
of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial
of marketing approval for our product candidates. The FDA, EMA or any other comparable regulatory authority may disagree with our clinical
trial design and our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed
and commented on the design for our clinical trials.
In
connection with clinical trials of our product candidates, we face a number of risks, including risks that:
●
a
                                            product candidate is ineffective or inferior to existing approved products for the same indications;
13
●
a
                                            product candidate causes or is associated with unacceptable toxicity or has unacceptable
                                            side effects;
●
patients
                                            may die or suffer adverse effects for reasons that may or may not be related to the product
                                            candidate being tested;
●
the
                                            results may not confirm the positive results of earlier trials;
●
the
                                            results may not meet the level of statistical significance required by the FDA, the EMA or
                                            other relevant regulatory agencies to establish the safety and efficacy of our product candidates
                                            for continued trial or marketing approval; and
●
our
                                            collaborators may be unable or unwilling to perform under their contracts.
Furthermore,
we sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory and other product
development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies,
clinical trials, the submission of regulatory filings or commercialization objectives. From time to time, we may publicly announce the
expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs,
the receipt of marketing approval or a commercial launch of a product. The achievement of many of these milestones may be outside of
our control. All of these milestones are based on a variety of assumptions, which may cause the timing of achievement of the milestones
to vary considerably from our estimates. If we fail to achieve milestones in the timeframes we expect, the commercialization of our product
candidates may be delayed, we may not be entitled to receive certain contractual payments, which could have a material adverse effect
on our business, financial position, results of operations and future growth prospects.
We are very early in our development efforts
and are substantially dependent on our most advanced, lead product candidates, FX-1610, our non-orally bioavailable small molecule inhibitor
in development for pediatric ALL, and FX-7742, our orally bioavailable compound being developed for solid tumor indications, including
non-small tumors. If we are unable to advance our lead product candidates or any of our other product candidates through clinical development,
obtain regulatory approval and ultimately commercialize our lead product candidates or any of our other product candidates, or experience
significant delays in doing so, our business will be materially harmed.
We
are very early in our development efforts. All of our product candidates are still in preclinical development and have never been tested
in human subjects. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily
on the successful clinical development and eventual commercialization of our FX-1610 and FX-7742 product candidates and one or more of
our other product candidates. In addition, our drug development programs contemplate the development of companion diagnostics, which
are assays or tests to identify an appropriate patient population. The success of our product candidates will depend on several factors,
including the following:
●
successful
                                            completion of preclinical studies (specifically non-rodent animal toxicity);
●
approval
                                            of INDs for our planned clinical trials or future clinical trials;
●
successful
                                            initiation of clinical trials;
●
successful
                                            patient enrollment in and completion of clinical trials;
●
safety,
                                            tolerability and efficacy profiles for our product candidates that are satisfactory to the
                                            FDA or any foreign regulatory authority for marketing approval;
●
receipt
                                            of marketing approvals for our product candidates and any companion diagnostics from applicable
                                            regulatory authorities;
●
the
                                            extent of any required post-marketing approval commitments to applicable regulatory authorities;
●
obtaining
                                            and maintaining patent and trade secret protection and regulatory exclusivity for our product
                                            candidates;
●
making
                                            arrangements with third-party manufacturers, or establishing manufacturing capabilities,
                                            for both clinical and commercial supplies of our product candidates, if any product candidates
                                            are approved;
14
●
establishing
                                            sales, marketing and distribution capabilities and launching commercial sales of our products,
                                            if and when approved, whether alone or in collaboration with others;
●
acceptance
                                            of our products, if and when approved, by patients, the medical community and third-party
                                            payors;
●
effectively
                                            competing with other cancer therapies;
●
obtaining
                                            and maintaining third-party coverage and adequate reimbursement; and
●
maintaining
                                            a continued acceptable safety profile of our products following approval.
There
is no guarantee that the results obtained in current preclinical studies of FX-1610 and FX-7742 will be sufficient to obtain regulatory
approval or marketing authorization for such product candidates. Negative results in the development of our lead product candidates may
also impact our ability to obtain regulatory approval for our other product candidates, either at all or within anticipated timeframes
because, although other product candidates may target different indications, there are certain similarities in the underlying technology
platform for all of our product candidates. Accordingly, a failure in any one program may affect the ability to obtain regulatory approval
to continue or conduct clinical programs for other product candidates
In
addition, because we have limited financial and personnel resources and are placing significant focus on the development of our lead
product candidates, we may forgo or delay pursuit of opportunities with other future product candidates that later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. Our spending on current and future research and development programs and other future product candidates for specific
indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential
or target market for a particular future product candidate, we may relinquish valuable rights to those future product candidates through
collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development
and commercialization rights to such future product candidates.
Clinical
drug development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not
always predictive of future results. Any drug candidate that we advance into clinical trials may not achieve favorable results in later
clinical trials, if any, or receive marketing approval.
The
research and development of drugs is an extremely risky industry. Only a small percentage of drug candidates that enter the development
process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate,
we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug
candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is uncertain.
The results of preclinical studies and completed
clinical trials are not necessarily predictive of future results, and our current drug candidates may not be further developed or have
favorable results in later studies or trials. Clinical trial failure may result from a multitude of factors including, but not limited
to, flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or
efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical
industry have suffered setbacks in the advancement of their drug candidates into later stage clinical trials due to lack of efficacy
or adverse safety profiles, notwithstanding results in earlier preclinical studies or clinical trials. Based upon negative or inconclusive
results, we may decide, or regulatory authorities may require us, to conduct additional clinical trials or preclinical studies. In addition,
data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may
not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials or marketing
approval. Furthermore, as more competing drug candidates within a particular class of drugs proceed through clinical development to regulatory
review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.
We
currently have two lead drug candidates in preclinical development, and their risk of failure is high. We are unable to predict if these
drug candidates or any of our future drug candidates that advance into clinical trials will prove safe or effective in humans or will
obtain marketing approval.
If
we are unable to complete preclinical studies or clinical trials of current or future drug candidates, due to safety concerns, or if
the results of these trials are not sufficient to convince regulatory authorities of their safety or efficacy, we will not be able to
obtain marketing approval for commercialization. Even if we are able to obtain marketing approval for any of our drug candidates, those
approvals may be for indications or dose levels that deviate from our desired approach or may contain other limitations that would adversely
affect our ability to generate revenue from sales of those products. Additionally, patent rights are of limited duration, and patents
protecting such drug candidates might expire before, or soon after, we obtain marketing approval leaving us open to competition from
biosimilar or generic products. Moreover, if we are not able to differentiate our product against other approved products within the
same class of drugs, or if any of the other circumstances described above occur, our business would be harmed and our ability to generate
revenue from that class of drugs would be severely impaired.
15
Difficulty
in enrolling patients could delay or prevent clinical trials of our product candidates. We may find it difficult to enroll patients in
our clinical trials for FX-1610 and FX-7742 with pediatric leukemia - Acute Lymphoblastic Leukemia or non-small cell lung cancer and
colorectal cancer, respectively, the types of cancers that FX-1610 and FX-7742 are designed to target.
Identifying
and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of completion
of our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our product candidates,
and we may experience delays in our clinical trials if we encounter difficulties in enrollment. We may not be able to initiate or continue
clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate
in these trials as required by the FDA or similar regulatory authorities outside the United States.
In
addition to the potentially small populations, the eligibility criteria of our planned clinical trials will further limit the pool of
available study participants as we will require that patients have specific characteristics that we can measure to assure their disease
is either severe enough or not too advanced to include them in a study. Additionally, the process of finding and diagnosing patients
may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical studies
because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies
and clinical trials, the proximity and availability of clinical study sites for prospective patients, and the patient referral practices
of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting
studies and obtaining regulatory approval of potential products may be delayed.
The
enrollment of patients further depends on many factors, including:
●
the
                                            proximity of patients to clinical trial sites;
●
the
                                            design of the clinical trial;
●
our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience;
●
our
                                            ability to obtain and maintain patient consents;
●
reporting
                                            of the preliminary results of any of our clinical trials; and
●
the
                                            risk that patients enrolled in clinical trials will drop out of the clinical trials before
                                            clinical trial completion.
In
addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as
our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might
have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial being conducted by one of our competitors.
Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical
trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such
clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment
and because most of our product candidates have not been tested in humans before, potential patients and their doctors may be inclined
to use conventional therapies, rather than enroll patients in any future clinical trial.
If
we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects
of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed
or prevented.
16
We
have no experience as a company in conducting clinical trials.
We
have no experience as a company in conducting clinical trials. In part because of this lack of experience, we cannot be certain that
our ongoing preclinical studies will be completed on time or if the planned preclinical studies and clinical trials will begin or be
completed on time, if at all. Large-scale clinical trials would require significant additional financial and management resources and
reliance on third-party clinical investigators, contract research organizations, or CROs, and consultants. Relying on third-party clinical
investigators, CROs and consultants may force us to encounter delays that are outside of our control. We may be unable to identify and
contract with sufficient investigators, CROs and consultants on a timely basis or at all.
If
clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities
outside the United States or do not otherwise produce positive results, we may incur additional costs or experience delays in completing,
or ultimately be unable to complete, the development and commercialization of our drug candidates.
Before
obtaining regulatory approvals for the commercial sale of our product candidates, including FX-1610 and FX-7742, we must demonstrate
through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective
for use in each target indication. Preclinical and clinical testing is expensive and can take many years to complete, and its outcome
is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because our product
candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products.
The
results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage
clinical trials. Although product candidates may demonstrate promising results in preclinical studies and early clinical trials, they
may not prove to be effective in subsequent clinical trials. For example, testing on animals occurs under different conditions than testing
in humans and therefore, the results of animal studies may not accurately predict human experience. There is typically an extremely high
rate of attrition from the failure of product candidates proceeding through preclinical studies and clinical trials. Product candidates
in later stages of clinical trials may fail to show the desired safety, potency, purity and efficacy profile despite having progressed
through preclinical studies and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual
safety or effectiveness in large-scale pivotal clinical trials. A number of companies in the biopharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or
unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence preclinical studies
and clinical trials are never approved as products.
Any
preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency, purity and efficacy necessary to
obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical
trials are inconclusive with respect to the safety, potency, purity and efficacy of our product candidates, if we do not meet the clinical
endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates,
we may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant
variability in safety, potency, purity or efficacy results between different preclinical studies and clinical trials of the same product
candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of
the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants.
As is the case with all oncology drugs, it is likely that there may be side effects associated with their use. Results of our trials
could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended
or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval
of our product candidates for any or all targeted indications. Drug-related side effects could also affect patient recruitment or the
ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm
our business, financial condition and prospects significantly.
The
design or our execution of clinical trials may not support regulatory approval.
The
design or execution of a clinical trial can determine whether its results will support regulatory approval and flaws in the design or
execution of a clinical trial may not become apparent until the clinical trial is well advanced or completed. In some instances, there
can be significant variability in safety or efficacy results between different trials of the same drug candidate due to numerous factors,
including changes or variations in trial protocols, differences in size and type of the patient populations, adherence to the dosing
regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials
we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our drug candidates.
17
Further, the FDA and comparable foreign regulatory
authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be obtained
for any of our drug candidates. Our drug candidates may not be approved even if they achieve their primary endpoints in current or future
Phase 3 clinical trials or registration trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and
our interpretation of data from preclinical studies and clinical trials or may have divergent requirements for our trials or approval.
In addition, any of these regulatory authorities may change requirements for the approval of a drug candidate even after reviewing and
providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential to result in FDA or other regulatory
authorities' approvals. In addition, any of these regulatory authorities may also approve a drug candidate for fewer or more limited
dose levels or indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials.
The FDA or other non-U.S. regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable
for the successful commercialization of our drug candidates, if approved. Failure to successfully obtain regulatory approval could have
a material adverse impact on our business and financial performance.
Serious
adverse events, undesirable side effects or toxicities, or other unexpected properties of our drug candidates could limit the commercial
potential of such drug candidates.
Further,
our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. If any serious adverse
events, unacceptable levels of toxicity, undesirable side effects or unexpected characteristics may emerge, it could cause us to abandon
these drug candidates or limit their development to more narrow uses, lower dose levels or subpopulations in which the serious adverse
events, unacceptable levels of toxicity, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable
from a risk/benefit perspective.
Even
if our drug candidates initially show promise in early clinical trials, the side effects of drugs are frequently only detectable after
they are tested in large Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after
approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the drug candidate
or another factor, especially in subjects who may suffer from other medical conditions and may be taking other medications. Regulatory
authorities may draw different conclusions or require additional testing to confirm any such determination.
If
serious adverse or unexpected side effects are identified during development and are determined to be attributable to or result from
our drug candidates, we may be required to discontinue the development program, or the regulatory authorities may refuse to approve the
drug candidates. Drug-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the
trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects.
In
addition, if one or more of our drug candidates receives marketing approval, and we or others later identify undesirable side effects
caused by such products, a number of potentially significant negative consequences could result, including:
●
regulatory
                                            authorities may withdraw approvals of such product;
●
regulatory
                                            authorities may require additional warnings on the label;
●
we
                                            may be required to create a medication guide outlining the risks of such side effects for
                                            distribution to patients, to enter into a risk evaluation and mitigation strategy, or REMS,
                                            or to compile a patient database;
●
we
                                            could face litigation and be held liable for harm caused to patients; and
●
our
                                            reputation may suffer.
Any
of these events could prevent us from achieving or maintaining market acceptance of the drug candidate, if approved, and could harm our
business, results of operations and prospects.
18
We
may announce preliminary, interim or top-line data from our clinical trials that may change as more patient
data become available, and as the data is subject to typical audit procedures that could result in material changes in
the final data.
From
time to time, we may announce preliminary, interim or top-line data from our clinical trials. Preliminary, interim and top-line data
from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change from the preliminary data
as patient enrollment continues, enrolled patients continue to progress through the trial, and more patient data become available. Preliminary,
interim and top-line data also remain subject to typical audit procedures that may result in the final audited data being
materially different from the preliminary data we previously announced. As a result, preliminary, interim and top-line data should
be viewed with caution until the final data are available. Adverse differences between preliminary, interim or top-line data
and final data could impact the regulatory approval of, and significantly harm the prospects of, any drug candidate that is impacted
by the applicable data.
The market opportunities for our product
candidates may be relatively small as it may be limited to those patients who are ineligible for or have failed prior treatments and
our estimates of the prevalence of our target patient populations may be inaccurate.
Cancer therapies are sometimes characterized
as first line, second line, or third line, and the FDA often approves new therapies initially only for a particular line of use. When
cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever
first line therapy, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery,
or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more
chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include
chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We intend
to seek approval of our product candidates that prove to be sufficiently safe and beneficial, if any, in most instances as a first line
therapy for use in patients with one of the types of cancers that our several product candidates address, including acute lymphoblastic
leukemia, non-small cell lung cancer, GBM, ovarian, prostate, colorectal, and pancreatic cancers. There is no guarantee that any of our
product candidates would be approved for a first line of therapy.
Our projections of both the number of
people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive a particular
line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates.
These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations
or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers
that we are targeting. Consequently, even if our product candidates are approved for a first line of therapy, the number of patients
that may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not
yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple
tumor types if there are different lines of approved therapies for each such tumor type.
Industry and other market data
that may be used in our prospectus or in periodic reports that we may in the future file with the SEC and our other materials, including
those undertaken by us or our engaged consultants, may not prove to be representative of current and future market conditions or future
results.
This prospectus, and periodic reports
that we may in the future file with the SEC, includes or may include or refer to statistical and other industry and market data that
we obtained from industry publications and research, surveys and studies conducted by third parties and surveys and studies that we may
have undertaken ourselves regarding the market potential for our product candidates. Although we believe that such information has been,
and will be, obtained from reliable sources, the sources of such data do not guarantee the accuracy or completeness of such information.
While we believe these industry publications and third-party research, surveys and studies are reliable, we do not independently verify
such data. The results of this data represent various methodologies, assumptions, research, analysis, projections, estimates, composition
of respondent pool, presentation of data and adjustments, each of which may ultimately prove to be incorrect or inaccurate and may cause
actual results and market viability information to differ materially from that presented in this prospectus or any such report or other
materials that we may prepare.
We
may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization
of our drug candidates.
We
may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive
marketing approval or commercialize our drug candidates, including:
●
regulatory
                                            authorities or institutional review boards or ethics committees, or IRBs or ECs, may not
                                            authorize us or our investigators to commence a clinical trial or conduct a clinical trial
                                            at a prospective trial site or we may fail to reach a consensus with regulatory authorities
                                            on trial design;
●
regulatory
                                            authorities in jurisdictions in which we seek to conduct clinical trials may differ from
                                            each other on our trial design, and it may be difficult or impossible to satisfy all such
                                            authorities with one approach;
●
we
                                            may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts
                                            or clinical trial protocols with prospective trial sites, the terms of which can be subject
                                            to extensive negotiation and may vary significantly among different contract research organizations,
                                            or CROs, and trial sites;
●
clinical
                                            trials of our drug candidates may produce negative or inconclusive results, and we may decide,
                                            or regulatory authorities may require us, to conduct additional clinical trials or abandon
                                            product development programs;
19
●
number
                                            of patients required for clinical trials of our drug candidates may be larger than we anticipate;
●
enrollment
                                            in our clinical trials may be slower than we anticipate, or participants may drop out of
                                            these clinical trials at a higher rate than we anticipate;
●
we may need to effect changes
                                            to clinical trial protocols based on feedback from regulatory authorities, ECs, IRBs, or
                                            clinical site requirements;
●
our
                                            third-party contractors may fail to comply with regulatory requirements or meet their contractual
                                            obligations to us in a timely manner, or at all;
●
we
                                            might have to suspend or terminate clinical trials of our drug candidates for various reasons,
                                            including a finding that the participants are being exposed to unacceptable health risks;
●
regulatory
                                            authorities or IRBs may require that we or our investigators suspend or terminate clinical
                                            research for various reasons, including noncompliance with regulatory requirements or a finding
                                            that the participants are being exposed to unacceptable health risks;
●
the
                                            cost of clinical trials of our drug candidates may be greater than we anticipate, and we
                                            may lack adequate funding to continue one or more clinical trials;
●
the
                                            supply or quality of our drug candidates or other materials necessary to conduct clinical
                                            trials of our drug candidates may be insufficient or inadequate;
●
third-party
                                            clinical investigators may lose the licenses or permits necessary to perform our clinical
                                            trials, or not perform our clinical trials on our anticipated schedule or consistent with
                                            the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;
●
third-party
                                            contract manufacturing organizations may lose licenses due to their failure to comply with
                                            good manufacturing practices, or GMP, or failing to satisfy inspection requirements;
●
third-party
                                            vendors, such as laboratories, used by us, may fail to follow quality guidelines or otherwise
                                            lose their ability to perform functions for which we rely on them;
●
our
                                            drug candidates may have undesirable side effects or other unexpected characteristics, causing
                                            us or our investigators, regulatory authorities or institutional review boards to suspend
                                            or terminate the trials; and
●
occurrence
                                            of serious adverse events in trials of the same class of agents conducted by other companies.
Delays in the regulatory process are part of
drug discovery, and the FDA may issue clinical holds. We have experienced delays in the past and may experience such delays in the future.
In the event of a delay, we work closely and collaboratively with the regulatory authority to address their concerns.
If
we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate,
if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or
tests are not positive or are only modestly positive or if there are safety concerns, we may:
●
be
                                            delayed in obtaining marketing approval for our drug candidates;
●
not
                                            obtain marketing approval at all;
●
obtain
                                            approval for indications, dosages or patient populations that are not as broad as intended
                                            or desired;
●
obtain
                                            approval with labeling that includes significant use or distribution restrictions or safety
                                            warnings, including boxed warnings;
●
be
                                            subject to additional post-marketing testing requirements; or
●
have
                                            the medicine removed from the market after obtaining marketing approval.
20
Product
development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials
will begin as planned, will need to be amended or will be completed on schedule, or at all. Significant clinical trial delays also could
shorten any periods during which we may have the exclusive right to commercialize our drug candidates, could allow our competitors to
bring products to market before we do, and could impair our ability to successfully commercialize our drug candidates, if approved, any
of which may harm our business and results of operations. In addition, many of the factors that cause, or lead to a delay in the commencement
or completion of, clinical trials may also ultimately lead to termination or suspension of a clinical trial. Any of these occurrences
may harm our business, financial condition and prospects significantly. Any termination of any clinical trial of our drug candidates
will harm our commercial prospects and our ability to generate revenues.
Even
if we receive marketing approval, we may not be able to successfully commercialize our drug candidates due to unfavorable pricing regulations
or third-party coverage and reimbursement policies, which could make it difficult for us to sell our drug candidates profitably.
Obtaining
coverage and reimbursement approval for a product from a third-party payor, including governmental healthcare programs such as Medicare
and Medicaid, private health insurers, managed care organizations, and other third-party payors, is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of such product to the payor.
There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited
than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for
coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including
research, development, intellectual property, manufacture, sale and distribution expenses, and in some countries, we may lose eligibility
for coverage even after obtaining it. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover
our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in
which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments
for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs
or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product
from countries where they may be sold at lower prices than in the United States.
Additionally,
coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage
and reimbursement for drug products among third party payors in the United States. While third-party payors often rely upon Medicare
coverage policy and payment limitations in setting their own reimbursement rates, they also have their own methods and approval process
apart from Medicare determinations. There may be significant delays in obtaining coverage and reimbursement as the process of determining
coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the
use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult
to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for
our drug products.
We cannot be sure that reimbursement
will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement
will be. Obtaining  favorable reimbursement from payors of our products may be particularly challenging because of the higher prices
often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Our inability to promptly
obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop
could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our
overall financial condition.
We
may not be able to obtain or maintain orphan drug designations or exclusivity for our drug candidates, which could limit the potential
profitability of our drug candidates, if approved.
Regulatory
authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan
drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease
or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or if it affects
more than 200,000, there is no reasonable expectation that sales of the drug in the United States will be sufficient to offset the costs
of developing and making the drug available in the United States. Generally, if a drug with an orphan drug designation subsequently receives
the first marketing approval for an indication for which it receives the designation, then the drug is eligible for a seven-year period
of marketing exclusivity during which the FDA may not approve another marketing application for the same drug for the same indication,
except in limited circumstances, such as if a subsequent application demonstrates that its product is clinically superior. During an
orphan drug's exclusivity period, however, competitors may receive approval for drugs with different active moieties for the same
indication as the approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different indications.
Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for a drug with
the same active moiety intended for the same indication before we do, unless we are able to demonstrate that grounds for withdrawal of
the orphan drug exclusivity exist or that our product is clinically superior. Further, if a designated orphan drug receives marketing
approval for an indication broader than the rare disease or condition for which it received orphan drug designation, it may not be entitled
to exclusivity. For purposes of small molecule drugs, the FDA defines "same drug" as a drug that contains the same active
moiety and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if
it is approved for a use that is broader than the indication for which it received orphan drug designation.
21
Obtaining
orphan drug designations is important to our business strategy; however, obtaining an orphan drug designation can be difficult, and we
may not be successful in doing so. Even if we were to obtain orphan drug designation for a drug candidate, we may not obtain orphan exclusivity,
and any such exclusivity, if attained, may not effectively protect the drug from the competition of different drugs for the same condition,
which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve
another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective
or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA
later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity
of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any
drug candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability
to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable drug candidate to balance
our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.
Risks
Related to Manufacturing, Supply, and Our Relationships with Third Parties
We
expect to depend on collaborations with third parties for certain research, development and commercialization activities, and if any
such collaborations are not successful, it may harm our business and prospects.
Working
with collaborators poses several significant risks, including the following:
●
limited
                                            availability of resource allocation and other developmental decisions made by our collaborators
                                            about the product candidates or technologies that we seek to develop with them may result
                                            in the delay or termination of research programs, studies or trials, repetition of or initiation
                                            of new studies or trials or provision of insufficient funding or resources for the completion
                                            of studies or trials or the successful marketing and distribution of any product candidates
                                            that may receive approval;
●
collaborators
                                            could independently develop, or develop with third parties, product candidates or technologies
                                            that compete directly or indirectly with our product candidates or technologies if the collaborators
                                            believe that competitive products or technologies are more likely to be successfully developed
                                            or can be commercialized under terms that are more economically attractive than ours;
●
collaborators
                                            may not properly obtain, maintain, enforce or defend our intellectual property or proprietary
                                            rights or may use our proprietary information in such a way that could jeopardize or invalidate
                                            our proprietary information or expose us to potential litigation; and
●
disputes
                                            may arise between us and our collaborators that result in the delay or termination of the
                                            research, development or commercialization activities or that result in costly litigation
                                            or arbitration that diverts management attention and resources.
Our
ability to generate revenues from these arrangements will depend on our collaborators' abilities to successfully perform the functions
assigned to them in these arrangements. If our collaborations do not result in the successful development and commercialization of product
candidates or technologies, or if one of our collaborators terminates its agreement with us, we may not receive any future funding or
milestone or royalty payments under the collaboration.
22
If
we do not receive the funding we expect under these agreements, our development of product candidates or technologies could be delayed,
and we may need additional resources to develop such product candidates or technologies. In addition, if one of our collaborators terminates
its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators and may
need to raise additional capital to pursue further development or commercialization of the applicable product candidates or technologies.
These
events could delay development programs and negatively impact the perception of our company in business and financial communities. Failure
to develop or maintain relationships with any current collaborators could result in the loss of opportunity to work with that collaborator
or reputational damage that could impact our relationships with other collaborators in the relatively small industry communities in which
we operate.
Moreover,
all of the risks relating to product development, regulatory approval and commercialization described in this prospectus apply to the
activities of our collaborators. If our existing collaboration agreements or any collaborative or strategic relationships we may establish
in the future are not effective and successful, it may damage our reputation and business prospects, delay or prevent the development
and commercialization of product candidates and inhibit or preclude our ability to realize any revenues.
We
expect to rely on third parties to conduct, supervise and monitor our clinical trials and some aspects of our research and preclinical
testing, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or otherwise
perform in a satisfactory manner, we may not be able to obtain regulatory approval or commercialize product candidates, or such approval
or commercialization may be delayed, and our business may be substantially harmed.
We
expect to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research
organizations, or CROs, to conduct preclinical studies and future clinical trials for our product candidates. Nevertheless, we will be
responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal and regulatory
requirements and scientific standards, and our reliance on such third parties will not relieve us of our regulatory responsibilities.
For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational
plan and protocols for the trial. Moreover, the FDA requires us to comply with regulations, commonly referred to as good clinical practices,
or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to assure that data and reported results
are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.
Although
we intend to design the trials for our product candidates either alone or with collaborators, third parties may conduct all of the trials.
As a result, many important aspects of our research and development programs, including their conduct and timing, will be outside of
our direct control. Our reliance on third parties to conduct future studies and trials will also result in less direct control over the
management of data developed through studies and trials than would be the case if we were relying entirely upon our own staff. Communicating
with outside parties can also be challenging, potentially leading to mistakes and difficulties in coordinating activities. Such third
parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo
changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors.
We
also face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs or other third parties,
which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. For
any violations of laws and regulations during the conduct of our preclinical studies and future clinical trials, we could be subject
to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.
If
we, our collaborators, our CROs or other third parties fail to comply with applicable GCPs, the clinical data generated in our clinical
trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical
trials before approving our marketing applications. We also are required to register certain ongoing clinical trials and post the results
of such completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so
can result in fines, adverse publicity and civil and criminal sanctions.
If
our CROs or other third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines,
or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols
or regulatory requirements or for any other reasons, trials for product candidates may be extended, delayed or terminated, and we or
our collaborators may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop.
If we are required to repeat, extend the duration of or increase the size of any trials we conduct, it could significantly delay commercialization
and require significantly greater expenditures.
23
As
a result of any of these factors, our financial results and the commercial prospects for any product candidate that we or our collaborators
may develop would be harmed, our costs could increase and our ability to generate revenues could be delayed.
If
we are unable to obtain sufficient quantities of raw materials and supplies, at acceptable prices and on a timely basis, it could harm
our business.
We
are dependent on third parties for the supply of various materials and the manufacture of product supplies that are necessary to produce
our product candidates. The supply of these materials could be reduced or interrupted at any time. In such case, identifying and engaging
an alternative supplier or manufacturer could result in delay, and we may not be able to find other acceptable suppliers or manufacturers
on acceptable terms, or at all.
Changing
suppliers or manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.
If we change suppliers or manufacturers for commercial production, applicable regulatory agencies may require us to conduct additional
studies or trials. If key suppliers or manufacturers are lost, or if the supply of the materials is diminished or discontinued, we or
our collaborators may not be able to develop, manufacture and market product candidates in a timely and competitive manner, or at all.
If any of our product candidates receives approval, we will likely need to seek alternative sources of supply of raw materials or manufactured
product supplies and there can be no assurance that we will be able to establish such relationships to provide such supplies on commercially
reasonable terms or at acceptable quality levels, if at all.
If
we are unable to identify and procure additional sources of supply that fit our required needs, we could face substantial delays or incur
additional costs in procuring such materials.
We
will rely on third parties to manufacture our clinical product supplies, and we may rely on third parties to produce and process our
product candidates, if approved.
We
do not currently own any facility that may be used as our clinical scale manufacturing facility and expect to rely on outside vendors
to manufacture supplies of our product candidates. We will need to negotiate and maintain contractual arrangements with these outside
vendors for the supply of our product candidates and we may not be able to do so on favorable terms. We have not yet caused any product
candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates.
The
facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or other foreign regulatory
authorities following inspections that will be conducted after we submit an application to the FDA or other foreign regulatory authorities.
We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance
with cGMPs and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates.
Beyond periodic audits, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality
assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the
manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities,
which would require the incurrence of significant additional costs and significantly impact our ability to develop, obtain regulatory
approval for or market our product candidates, if approved. Similarly, if any third-party manufacturers on which we will rely fail to
manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient
to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be
materially and adversely affected.
Manufacturing
our product candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability to
provide supply of our product candidates for preclinical studies and clinical trials or for commercial purposes could be delayed or stopped.
The
process of manufacturing of our product candidates is complex and highly regulated. We rely on third parties for the manufacture of our
product candidates. These third-party manufacturers may incorporate their own proprietary processes into our product candidate manufacturing
processes. We have limited control and oversight of a third party's proprietary process, and a third party may elect to modify
its process without our consent or knowledge. These modifications could negatively impact our manufacturing, including product loss or
failure that requires additional manufacturing runs or a change in manufacturer, both of which could significantly increase the cost
of and significantly delay the manufacture of our product candidates.
24
As
our product candidates progress through preclinical studies and clinical trials towards approval and commercialization, it is expected
that various aspects of the manufacturing process will be altered in an effort to optimize processes and results. Such changes may require
amendments to be made to regulatory applications which may further delay the timeframes under which modified manufacturing processes
can be used for any of our product candidates and additional bridging studies or trials may be required.
We
do not have our own clinical-scale manufacturing facility and are currently reliant on a limited number of manufacturers for our product
candidates. These third-party manufacturing providers may not be able to provide adequate resources or capacity to meet our needs.
We or our contract manufacturers must supply
all necessary documentation in support of an NDA on a timely basis and must adhere to the FDA's cGMP regulations enforced by the
FDA through its facility evaluation and inspection program. Comparable foreign regulatory authorities may require compliance with similar
requirements. The facilities and quality systems of our third-party manufacturers must pass a pre-approval inspection for compliance
with the applicable regulations as a condition of marketing approval of our drug candidates. We do not control the manufacturing process
of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations.
In
the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality,
timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced
to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement
with another third party, which we may not be able to do on a timely basis or on acceptable terms, if at all. In particular, any replacement
of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.
In some cases, the technical skills or technology required to manufacture our drug candidates may be unique or proprietary to the original
manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may
not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in
order to have another third party manufacture our drug candidates. If we are required to change manufacturers for any reason, we will
be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable
regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to
develop drug candidates in a timely manner or within budget.
Our,
or a third party's, failure to execute on our manufacturing requirements, or to do so on commercially reasonable terms and comply
with cGMP could adversely affect our business in a number of ways, including but not limited to:
●
an
                                            inability to initiate or continue clinical trials of our drug candidates under development;
●
delay
                                            in submitting regulatory applications, or receiving marketing approvals, for our drug candidates;
●
loss
                                            of the cooperation of an existing or future collaborator;
●
subjecting
                                            third-party manufacturing facilities or our manufacturing facilities to additional inspections
                                            by regulatory authorities;
●
economic
                                            loss and additional costs resulting from starting materials, intermediates, API or drug product
                                            that cannot be used in clinical trials or for other purposes;
●
requirements
                                            to cease development or to recall batches of our drug candidates; and
●
in
                                            the event of approval to market and commercialize our drug candidates, an inability to meet
                                            commercial demands for our product or any other future drug candidates.
25
We,
or our third-party manufacturers, may be unable to successfully scale-up the manufacturing process for our drug candidates to provide
sufficient quality and quantity, which would delay or prevent us from conducting clinical trials, developing our drug candidates and
commercializing our drugs.
In
order to conduct clinical trials of our drug candidates or commercialize our drugs, we will need to manufacture them in large quantities.
We, or our third-party manufacturers, may be unable to successfully increase the manufacturing capacity for any of our drug candidates
in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we or our third-party
manufacturers are unable to successfully scale up the manufacture of our drug candidates in sufficient quality and quantity, the development,
testing and clinical trials of that drug candidate may be delayed or become infeasible, and marketing approval or commercial launch of
any resulting product may be delayed or not obtained, which could significantly harm our business.
Existing
or changes in methods of drug candidate manufacturing or formulation may result in additional costs or delays.
As
drug candidates progress through preclinical to clinical-stage trials to marketing approval and commercialization, it is common that
various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to
optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that
they will not achieve these intended objectives. Any of these changes could cause our drug candidates to perform differently and affect
the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion
of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical
trial costs, delay approval of our drug candidates or jeopardize our ability to commercialize our drug candidates and generate any revenue.
If
we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization
plans.
Our
research and product development programs and the potential commercialization of our product candidates will require substantial additional
cash to fund expenses, and we expect that we will continue to seek collaborative arrangements for the development and potential commercialization
of current and future product candidates or the development of ancillary technologies.
We
face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant
number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future
collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the
collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's
evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product
or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood
of approval, if necessary, by the USDA, the FDA or similar regulatory authorities outside the United States, the potential market for
the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential
of competing products and technologies and industry and market conditions generally.
Collaborations
are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable
terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that
diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable
to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology
for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines,
reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense.
Our
employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners may engage in misconduct or
other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
We
are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors and potential
commercial partners. Misconduct by these parties could include failures to comply with (i) FDA laws and regulations or those of comparable
foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing
standards, (iii) laws and regulations in the United States and abroad relating to data privacy and security, fraud and abuse, government
price reporting, transparency reporting requirements, and healthcare laws and regulations in the United States and abroad, (iv) laws
that require the true, complete and accurate reporting of financial information or data, or (v) insider trading laws. Such misconduct
could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions
and cause serious harm to our reputation.
26
We
have adopted a code of conduct applicable to all of our employees, as well as an insider trading policy, disclosure program and other
applicable policies and procedures, but it is not always possible to identify and deter employee misconduct. Although we take measures
to protect against misconduct, the precautions we take to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure
to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant adverse impact on our business, including the imposition of significant
civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare,
Medicaid and other federal healthcare programs, imprisonment, integrity oversight and reporting requirements, contractual damages, reputational
harm, diminished profits and future earnings, and curtailment or restructuring of our operations. In addition, our employees, consultants,
vendors and other third parties involved in our business could engage in conduct or activities that could generate negative publicity
or social media attention or have other adverse consequences to our business. As a result of the rapid spread of information online,
even activities that are unrelated to our business operations could have a negative impact on our reputation by virtue of our association
with such individuals or entities, which could further harm our reputation.
Risks
Related to Sales, Marketing, and Competition
We
currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing
and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not
be able to generate product revenue.
We
currently have no sales, marketing or distribution capabilities and have no experience in marketing products. We may determine to develop
an in-house marketing organization and sales force for at least one of our product candidates, which would require significant capital
expenditures, management resources and time. In order to establish our own sales and marketing capabilities, we would have to compete
with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.
In
any case, for at least two of our product candidates, we intend to pursue arrangements with third-party sales, marketing, and distribution
collaborators regarding the sales and marketing of our products, if approved. However, there can be no assurance that we will be able
to establish or maintain such arrangements on favorable terms or at all, or if we are able to do so, that these third-party arrangements
will provide effective sales forces or marketing and distribution capabilities. Any revenue we receive will depend upon the efforts of
such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third
parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face
competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.
There
can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships
with third-party collaborators to commercialize any product in the United States or overseas.
Furthermore,
there are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties
to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product
launch. If the commercial launch of a drug candidate for which we recruit a sales force and establish marketing capabilities is delayed
or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly,
and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.
27
Even
if we obtain FDA approval of any of our drug candidates, we may never obtain approval or commercialize such products outside of the United
States, which would limit our ability to realize their full market potential.
In
order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country.
Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review
periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional
preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country
to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements
is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any
country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any drug candidates
approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining commercial approval
in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required
approvals, our ability to realize the full market potential of our products will be harmed.
Even
if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals,
cancer treatment centers and others in the medical community.
Various
factors will influence whether our product candidates are accepted in the market, including:
●
the
                                            clinical indications for which our product candidates are licensed;
●
physicians,
                                            hospitals, cancer treatment centers and patients considering our product candidates as a
                                            safe and effective treatment;
●
the
                                            potential and perceived advantages of our product candidates over alternative treatments;
●
our
                                            ability to demonstrate the advantages of our product candidates over other cancer medicines;
●
the
                                            prevalence and severity of any side effects;
●
product
                                            labeling or product insert requirements of the FDA or other regulatory authorities;
●
limitations
                                            or warnings contained in the labeling approved by the FDA;
●
the
                                            timing of market introduction of our product candidates as well as competitive products;
●
the
                                            cost of treatment in relation to alternative treatments;
●
the
                                            availability of adequate coverage, reimbursement and pricing by third-party payors and government
                                            authorities;
●
the
                                            willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors
                                            and government authorities;
●
relative
                                            convenience and ease of administration, including as compared to alternative treatments and
                                            competitive therapies; and
●
the
                                            effectiveness of our sales and marketing efforts.
If
our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers
or others in the medical community, we will not be able to generate significant revenue.
Even
if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies
are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.
28
We
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than we do.
The
oncology drug and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. While
we believe that our scientific knowledge, platform technology and development expertise provide us with competitive advantages, we face
potential competition from many different sources, including major pharmaceuticals, specialty pharmaceuticals and biotechnology companies,
academic institutions and government agencies, and public and private research institutes that conduct research, development, manufacturing
and commercialization. Many of our competitors have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, regulatory approvals and product marketing than we do. Our competitors may compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover,
develop, license or commercialize products before or more successfully than we do.
Product
candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available
in the future. Specifically with respect to FX-1610 and FX-7742, we expect competition from at least one other early-stage pharmaceutical
company similarly targeting dormant cancer cells.
If
our candidates, including FX-1610 and FX-7742, are approved for the indications for which we are currently planning clinical trials,
they will likely compete with the competitor drugs mentioned above and with other drugs that are currently in development. Key product
features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of
our products. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or
commercialize our product candidates. The availability of reimbursement from government and other third-party payors will also significantly
affect the pricing and competitiveness of our products. Our competitors may also obtain FDA or other regulatory approval for their products
more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before
we are able to enter the market. . If we are not successful in developing, commercializing and achieving higher levels of reimbursement
than our competitors, we will not be able to compete against them and our business would be harmed.
Risks
Related to Our Business Operations
Market
disruptions, supply-chain disruptions, geopolitical conflicts, including acts of war, macroeconomic events, and inflation, could create
market volatility that negatively impact our business and operations.
Various
social and political tensions in the United States and around the world may contribute to increased market volatility, may have long-term
effects on the U.S. and worldwide markets and may cause further economic uncertainties in the United States and worldwide.
The
occurrence of events similar to those in recent years, such as localized wars, instability, new and ongoing pandemics (such as COVID-19),
epidemics or outbreaks of infectious diseases in certain parts of the world, natural/environmental disasters, supply-chain disruptions,
terrorist attacks in the United States and around the world, social and political discord, increasingly strained relations between the
United States and a number of foreign countries, new and continued political unrest in various countries, continued changes in the balance
of political power among and within the branches of the U.S. Government, government shutdowns, among others, may result in market volatility,
may have long term effects on the U.S. and worldwide financial markets, and may cause further economic uncertainties in the United States
and worldwide, all of which could make it more difficult for us to raise capital in this offering or otherwise and to continue our product
candidate development efforts in an efficient and timely fashion.
We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success.
Because
we have limited financial and managerial resources, we must focus on a limited number of research programs and product candidates and
on specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications
that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable
commercial products or profitable market opportunities. Our spending on current and future discovery and preclinical development programs
and product candidates for specific indications may not yield any commercially viable products.
We
expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing
our growth, which could disrupt our operations.
As of March 31, 2022, we had 2 full-time employees
and 1 part-time employee. As we advance our research and development programs and begin to operate as a public company, we expect to
experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development,
quality, regulatory affairs and, if any of our drug candidates receives marketing approval, sales, marketing and distribution. To manage
our anticipated future growth, we must:
●
identify,
                                            recruit, integrate, maintain and motivate additional qualified personnel;
●
manage
                                            our development efforts effectively, including the initiation and conduct of clinical trials
                                            for our drug candidates, both as monotherapy and in combination with other intra-portfolio
                                            drug candidates; and
●
improve
                                            our operational, financial and management controls, reporting systems and procedures.
29
Our
future financial performance and our ability to develop, manufacture and commercialize our drug candidates will depend, in part, on our
ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate
amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.
Our
future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified
personnel.
We
are highly dependent on the services of Dr. Maria Vilenchik, who serves as our Chief Executive Officer, Dr. Michael Frid, who serves
as our Head of Preclinical Pharmacology, and Marc Duey, who serves as our Chairman of the Board. We have entered into an employment agreement
only with Dr. Vilenchik, although it is not for a specific term and she may terminate her employment with us at any time, though we are
not aware of any present intention of Dr. Vilenchik to leave us
.
Our
industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive biopharmaceuticals
industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical,
regulatory, manufacturing and management skills and experience. We conduct our operations in the Boston Area, a region that is home to
many other pharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified
personnel. We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number
of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have
greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide
higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors
may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully
develop and commercialize our drug candidates and to grow our business and operations as currently contemplated.
Our
future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory requirements
and other risks and uncertainties.
Our
future profitability may depend, in part, on our ability to commercialize our drug candidates in foreign markets for which we may rely
on collaboration with third parties. We are not permitted to market or promote any of our drug candidates before we receive marketing
approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of
our drug candidates. To obtain marketing approval in many foreign countries, we must comply with numerous and varying regulatory requirements
of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and
distribution of our drug candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our drug candidates
and ultimately commercialize our drug candidates in foreign markets, we would be subject to additional risks and uncertainties, including:
●
our
                                            customers' ability to obtain reimbursement for our drug candidates in foreign markets;
●
our
                                            inability to directly control commercial activities because we are relying on third parties;
●
the
                                            burden of complying with complex and changing foreign regulatory, tax, accounting and legal
                                            requirements;
●
different
                                            medical practices and customs in foreign countries affecting acceptance in the marketplace;
●
import
                                            or export licensing requirements;
●
longer
                                            accounts receivable collection times;
●
longer
                                            lead times for shipping;
●
language
                                            or cultural barriers for technical training;
●
reduced
                                            protection of intellectual property rights in some foreign countries;
●
the
                                            existence of additional potentially relevant third-party intellectual property rights;
●
foreign
                                            currency exchange rate fluctuations; and
●
the
                                            interpretation of contractual provisions governed by foreign laws in the event of a contract
                                            dispute.
30
Our
internal information technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security
breaches, loss or leakage of data, and other disruptions, which could potentially expose us to liability or otherwise adversely affecting
our business.
We
are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course
of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary
business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality, integrity
and availability of such confidential information. We also have outsourced elements of our operations to third parties, and as a result
we manage a number of third-party contractors who have access to our confidential information.
Despite
the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that
they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are
potentially vulnerable to breakdown or other damage or service interruptions, system malfunctions, natural disasters, terrorism, war
and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees,
contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including
the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability
and threaten the confidentiality, integrity, privacy and availability of information), which may compromise our system infrastructure
or lead to unauthorized or inappropriate use or disclosure of our confidential information. In addition, as our trials advance in locations
across the world, our employees or other parties we work with may be required to travel or send data across international borders with
increasing frequency, which may increase our exposure to cyberattacks and other information security incidents or interruptions. To the
extent that any of these incidents were to result in a loss of, or damage to, our data or applications, or inappropriate use or disclosure
of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization
of our drug candidates could be delayed. Even the perception that such an incident has occurred could harm our reputation and our business.
While
to our knowledge we have not experienced any such system failure, accident or security breach to date, we cannot assure you that our
data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in
our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial
condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our programs and the development of our drug candidates could be delayed. In addition, the loss of clinical trial data for our drug
candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the
data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss,
misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including
trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial,
legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal
information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel
us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action,
and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which
could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our
business.
The
insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage
and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability
to generate revenue.
We
expect the cost of our product candidates to be substantial, when and if they achieve market approval. The availability and extent of
reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of our
product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates
will be paid by private payors, such as private health coverage insurers, health maintenance, managed care, pharmacy benefit and similar
healthcare management organizations, or reimbursed by government health care programs, such as Medicare and Medicaid. We may not be able
to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement is not available, or is available
only at limited levels, we may not be able to successfully commercialize our product candidates, even if approved. Even if coverage is
provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize
a sufficient return on our investment.
31
There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about coverage and reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid
Services, or CMS, an agency within the U.S. Department of Health and Human Services, as the CMS decides whether and to what extent a
new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult
to predict what CMS will decide with respect to coverage and reimbursement for novel products such as ours, as there is no body of established
practices and precedents for these new products. Coverage and reimbursement by a third-party payor may depend upon a number of factors,
including the third-party payor's determination that use of a product is: (1) a covered benefit under its health plan; (2) safe,
effective and medically necessary; (3) appropriate for the specific patient; (4) cost-effective; and (5) neither experimental nor investigational.
In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, the
coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support
for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently
or obtained in the first instance. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not
be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Third-party payors
may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the approved
drugs for a particular indication.
Additionally,
third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of
product candidates. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to
cover a significant portion of the cost of our product candidates. Because our product candidates may have a higher cost of goods than
conventional therapies, and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate
for us to achieve profitability may be greater. There is significant uncertainty related to insurance coverage and reimbursement of newly
approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement
for our product candidates.
Moreover,
increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause
such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover
or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United
States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and
proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to
the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional
legislative changes.
Outside
the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical
products, or medicinal products, as they are commonly referred to in the European Union. These countries have broad discretion in setting
prices, and we cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities
in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues
from sales by us or our collaborators, and the potential profitability of our drug products, in those countries would be negatively affected.
An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts
on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the
world but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product
before it can be lawfully marketed. In many countries, the pricing review period begins after marketing or product licensing approval
is granted. To obtain reimbursement or pricing approval in some countries, we, or any collaborators, may be required to conduct a clinical
trial that compares the cost-effectiveness of our product to other available therapies. As a result, we might obtain marketing approval
for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price
regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the
revenues we are able to generate from the sale of the product in that particular country.
32
The downward pressure on healthcare costs in
general, particularly prescription drugs and other treatments, has become very intense. As a result, increasingly high barriers are being
erected to the entry of new products. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is
set at unsatisfactory levels, our business could be harmed.
Our
insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.
We
do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include
general liability, property and workers' compensation, and we are in the process of acquiring directors' and officers'
insurance. Our insurance is expensive, and we do not know if we will be able to maintain existing insurance with adequate levels of coverage.
Our insurance policies contain exclusions that may apply to our risks. Some risks may not be insurable on commercially reasonable terms,
or at all. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position
and results of operations.
Business
or economic disruptions or global health concerns could seriously harm our development efforts and increase our costs and expenses.
Broad-based
business or economic disruptions could adversely affect our ongoing or planned research and development activities. For example, in December
2019, an outbreak of a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which
causes coronavirus disease (COVID-19) was reported to have surfaced in Wuhan, China, and has since spread to other regions and countries
worldwide. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Almost all U.S. states and many local
jurisdictions issued "shelter-in-place" orders, quarantines, executive orders and similar government orders, restrictions,
and recommendations for their residents to control the spread of COVID-19. Such orders, restrictions and recommendations, and the perception
that additional orders, restrictions or recommendations could occur, have resulted in widespread closures of businesses not deemed "essential,"
work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events, as well as volatility
in stock prices, among other effects. There is a risk that government actions will not be effective at containing COVID-19 or other infectious
diseases, and that government actions, including the orders and restrictions described above, that are intended to contain the spread
of COVID-19 will have a devastating negative impact on the world economy at large, in which case the risks to our operating results and
financial condition described herein would be elevated significantly.
The
continued spread of COVID-19 or other global health matters, has impacted and may continue to impact our target patient populations as
well as the hospitals and clinical sites in which we conduct any of our clinical trials, which could lead to delays in completing enrollment
of our clinical trials. For instance, the COVID-19 outbreak may continue to impair our ability to recruit and retain patients and engage
principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in
their geography or due to prioritization of hospital resources toward the outbreak and restrictions on travel. Furthermore, some patients
may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede
patient movement or interrupt healthcare services. COVID-19 already has affected and may further negatively affect the operations of
third-party contract research organizations that we rely upon to carry out our discovery work, clinical trials or the operations of our
third-party manufacturers, which could result in delays or disruptions in the supply of our product candidates and the conduct of experiments
and studies. Any negative impact COVID-19 has to patient enrollment or treatment or the timing and execution of our preclinical studies
or clinical trials could cause costly delays to our development programs, which could adversely affect our ability to obtain regulatory
approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our business
and financial results. COVID-19 has also caused, and may continue to cause for an extended period, volatility in the global financial
markets and threatened a slowdown in the global economy, which would reduce our ability to access capital and could negatively affect
our liquidity.
While
our lab-based employees have returned to our labs with enhanced safety measures, our office-based employees continue to work primarily
from home, and we expect this to continue for an extended period. Furthermore, there has been a resurgence of COVID-19 cases, which could
prompt a reinstatement of "shelter-in-place" orders and restrictions at the state and local levels impacting our reentry
to the workplace and causing hospital and clinical sites to suspend our clinical trials or could deter patients from continuing to participate
in our trials.
33
Three vaccines for COVID-19 were granted Emergency
Use Authorization by the FDA in late 2020 and early 2021, and two were granted full authorization as of early January 2022. More are
likely to be authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials
to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain
materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials.
The global outbreak of COVID-19 continues to
rapidly evolve. The extent to which COVID-19 impacts our business, results of operations and financial condition will depend on future
developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions,
new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken in the United States and other
countries to contain COVID-19 or treat its impact, among others. We cannot presently predict the scope and severity of any potential
business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including the suppliers, clinical trial
sites, service providers, regulators and other third parties with whom we conduct business, were to experience prolonged business shutdowns
or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially
and negatively impacted.
Risks Related to Our Intellectual Property
If we are unable to obtain and maintain
sufficient intellectual property protection for our drug candidates, or if the scope of the intellectual property protection is not sufficiently
broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize
our products may be adversely affected.
Our success depends in large part on our ability
to obtain and maintain patent protection in the United States and other countries with respect to our drug candidates and research programs.
We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries
and technologies that are important to our business. We own, or have licensed exclusive rights in, numerous patents, we have certain
patent applications pending, and we may seek additional patents in the future, in the United States and in other countries. Our pending
and future patent applications may not result in patents being issued which protect our drug candidates or their intended uses or which
effectively prevent others from commercializing competitive technologies, products or drug candidates.
Obtaining and enforcing patents is expensive
and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce
patents that may issue based on our patent applications, at a reasonable cost or in a timely manner. It is also possible that we will
fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although
we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development
output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers,
consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent
application is filed, thereby jeopardizing our ability to seek patent protection.
The patent position of pharmaceutical companies
generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation,
resulting in court decisions, including Supreme Court decisions, which increase uncertainties as to the ability to enforce patent rights
in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States,
or vice versa.
Further, we may not be aware of all third-party
intellectual property rights potentially relating to our drug candidates or their intended uses, and as a result the impact of such third-party
intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party
intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions
are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether
we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for
patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights
are highly uncertain. Our patents or pending patent applications may be challenged in the courts or patent offices in the United States
and abroad. For example, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office,
or become involved in post-grant review procedures, oppositions, derivations, reexaminations or inter partes review proceedings, in the
United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges
may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration
of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing
and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates
are commercialized.
34
Issued patents covering our products and
product candidates could be found invalid or unenforceable if challenged in court or in administrative proceedings. We may not be able
to protect our trade secrets in court.
If we initiate legal proceedings against a third-party
to enforce a patent covering one of our products or product candidates, should such a patent issue, the defendant could counterclaim
that the patent covering our product or product candidate is invalid or unenforceable. In patent litigation in the United States, defendant
counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to
meet any of several statutory requirements, including lack of novelty, obviousness, written description or non- enablement. Grounds for
an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material
to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination,
post-grant review, inter partes review and equivalent proceedings in foreign jurisdictions. An adverse determination in any of the foregoing
proceedings could result in the revocation or cancellation of, or amendment to, our patents in such a way that they no longer cover our
products or product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect
to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and
we were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability,
we could lose at least part, and perhaps all, of the patent protection on one or more of our products and product candidates. Such a
loss of patent protection could have a material adverse impact on our business.
In addition, our trade secrets may otherwise
become known or be independently discovered by competitors. Competitors and other third parties could purchase our products and product
candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe,
misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop their own competitive
technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently
developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using
that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage
over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to
maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade
secrets.
We may be subject to claims challenging
the inventorship or ownership of the patents and other intellectual property.
We may be subject to claims that former employees,
collaborators or other third parties have an ownership interest in the patents and intellectual property that we own or that we may own
or license in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who in fact develops intellectual property that we regard as our own or such assignments may not be self-executing or may
be breached. We could be subject to ownership disputes arising, for example, from conflicting obligations of employees, consultants or
others who are involved in developing our products or product candidates. Litigation may be necessary to defend against any claims challenging
inventorship or ownership. If we fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results
of operations and financial condition.
Our reliance on third parties requires
us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be
misappropriated or disclosed.
Because we rely on third parties to manufacture
our product candidates, and because we collaborate with various organizations and academic institutions on the development of our product
candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into
confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements
or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary
information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as
trade secrets.
35
Despite the contractual provisions employed when
working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor's discovery
of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect
on our business.
In addition, these agreements typically restrict
the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our
academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for
a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights
are controlled exclusively by us, although in some cases we may share these rights with other parties. Despite our efforts to protect
our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development
or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at
the time of publication. A competitor's discovery of our trade secrets would impair our competitive position and have an adverse
impact on our business.
Obtaining and maintaining patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity
fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent
agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S.
governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during
the patent application process and after a patent has issued. There are situations in which non- compliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. The
terms of one or more licenses that we enter into the future may not provide us with the ability to maintain or prosecute patents in the
portfolio and must therefore rely on third parties to do so.
If we fail to comply with our obligations
in our intellectual property licenses from third parties, we could lose license rights that are important to our business.
We are a party to intellectual property license
agreements, and we may enter into additional license agreements in the future. Our existing license agreements impose, and we expect
that our future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us.
If we fail to comply with these obligations, our current and future licensors may have the right to reduce the scope of our rights or
terminate these agreements, in which event we may not be able to develop and market any product that is covered by these agreements and
would adversely impact our existing collaboration agreements under which we have sublicensed such rights. Termination of this license
for failure to comply with such obligations or for other reasons, or reduction or elimination of our licensed rights under it or any
other license, may result in our having to negotiate new or reinstated licenses on less favorable terms or our not having sufficient
intellectual property rights to operate our business. The occurrence of such events could materially harm our business and financial
condition.
The risks described elsewhere pertaining to our
intellectual property rights also apply to the intellectual property rights that we in-license, and any failure by us or our licensors
to obtain, maintain, defend and enforce these rights could have a material adverse effect on our business. In some cases, we do not have
control over the prosecution, maintenance or enforcement of the patents that we license, and may not have sufficient ability to provide
input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the
steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents.
We may rely on trade secret and proprietary
know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business
and competitive position would be harmed.
In addition to seeking patents for some of our
technology and drug candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information,
to maintain our competitive position. Elements of our drug candidates, including processes for their preparation and manufacture, may
involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade
secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees,
the employees of third parties with whom we share our facilities or third party consultants and vendors that we engage to perform research,
clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade
secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our
competitive position in our market.
36
Trade secrets and know-how can be difficult to
protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations
to assign to us any inventions generated in the course of their employment. We and any third parties with whom we may, in the future,
share facilities with, will enter into written agreements that include confidentiality and intellectual property obligations to protect
each party's property, potential trade secrets, proprietary know-how, and information. We further seek to protect our potential
trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties
who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations,
contract manufacturers, consultants, advisors and other third parties. Despite these efforts, we cannot ensure that these agreements
will provide adequate protection for our trade secrets, know-how or other proprietary information, and any of these parties may breach
the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect
trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other
third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade
secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed.
To the extent that consultants, contractors,
collaborators or employees apply technological information independently developed by them or by others to our drug candidates, disputes
may arise as to the proprietary rights in such information, which may not be resolved in our favor. With our consultants, contractors,
outside scientific collaborators, and employees who work with our confidential and proprietary technologies, we enter into agreements
that typically include invention assignment obligations. However, these consultants, contractors, collaborators, and employees may terminate
their relationship with us, and we cannot preclude them indefinitely from dealing with our competitors. If our trade secrets become known
to competitors with greater experience and financial resources, the competitors may copy or use our trade secrets and other proprietary
information in the advancement of their products, methods or technologies.
In the future, we may need to obtain additional
licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which
may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.
From time to time, we may be required to license
technology from additional third parties to further develop or commercialize our drug candidates. Should we be required to obtain licenses
to any third-party technology, including any such patents required to manufacture, use or sell our drug candidates, such licenses may
not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop
or commercialize any of our drug candidates could cause us to abandon any related efforts, which could seriously harm our business and
operations.
We may not identify relevant third-party
patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability
to develop and market our products.
We cannot guarantee that any of our patent searches
or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are
complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the
United States and abroad that is relevant to or necessary for the commercialization of our drug candidates in any jurisdiction.
The scope of a patent claim is determined by
an interpretation of the law, the written disclosure in a patent and the patent's prosecution history. Our interpretation of the
relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products.
We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party's
pending application will issue with claims of relevant scope. In addition, because patent applications can take many years to issue,
there may be currently pending applications unknown to us that may later result in issued patents upon which our drug candidates may
infringe. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect,
which may negatively impact our ability to develop and market our drug candidates. Our failure to identify and correctly interpret relevant
patents may negatively impact our ability to develop and market our products.
37
Intellectual property rights do not necessarily
address all potential threats to our competitive advantage.
The degree of future protection afforded by our
intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business
or permit us to maintain our competitive advantage. For example:
●
others
                                            may be able to make drug candidates that are similar to ours but that are not covered by
                                            the claims of the patents that we own or have exclusively licensed;
●
we
                                            or our licensors or future collaborators might not have been the first to make the inventions
                                            covered by the issued patent or pending patent application that we own or have exclusively
                                            licensed;
●
we
                                            or our licensors or future collaborators might not have been the first to file patent applications
                                            covering certain of our inventions;
●
others
                                            may independently develop similar or alternative technologies or duplicate any of our technologies
                                            without infringing our intellectual property rights;
●
it
                                            is possible that our pending patent applications will not lead to issued patents;
●
issued
                                            patents that we own or have exclusively licensed may be held invalid or unenforceable, as
                                            a result of legal challenges by our competitors;
●
our
                                            competitors might conduct research and development activities in countries where we do not
                                            have patent rights and then use the information learned from such activities to develop competitive
                                            products for sale in our major commercial markets;
●
we
                                            may not develop additional proprietary technologies that are patentable; and
●
the
                                            patents of others may have an adverse effect on our business.
Should any of these events occur, they could
significantly harm our business, results of operations and prospects.
If we are sued for infringing intellectual
property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or
commercializing our drug candidates.
Our commercial success depends, in part, on our
ability to develop, manufacture, market and sell our drug candidates without infringing the intellectual property and other proprietary
rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or
other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and
time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially
increase our operating expenses and reduce the resources available for development activities or any future sales, marketing or distribution
activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater
financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation
of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.
38
There is a substantial amount of intellectual
property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or
other adversarial proceedings regarding intellectual property rights with respect to our drug candidates. Third parties may assert infringement
claims against us based on existing or future intellectual property rights. The pharmaceutical and biotechnology industries have produced
a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types
of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always
uniform. If we were sued for patent infringement, we would need to demonstrate that our drug candidates, products or methods either do
not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able
to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of
clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings,
we may incur substantial costs and the time and attention of our management, legal and scientific personnel could be diverted in pursuing
these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient
resources to bring these actions to a successful conclusion.
If we are found to infringe a third party's
intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the
infringing drug candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the
infringing technology and continue developing, manufacturing or marketing the infringing drug candidate. However, we may not be able
to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be non-exclusive,
thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages,
including treble damages and attorneys' fees if we are found to have willfully infringed a patent. A finding of infringement could
prevent us from commercializing our drug candidates, force us to cease some of our business operations, or require substantial investment
and/or time to alter our products, processes, methods, or other technologies, all of which could materially harm our business. Claims
that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our
business.
We may become involved in lawsuits to defend
or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
Competitors may infringe our patents, trademarks,
copyrights or other intellectual property. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation
of our intellectual property rights. Even if we detect such infringement or misappropriation, to counter infringement or unauthorized
use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our
management, legal and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims
against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable,
or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable,
in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk
that, even if the validity of such patents is upheld, the court will construe the patent claims narrowly or decide that we do not have
the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention.
An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties
or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive
products. Any of these occurrences could materially adversely affect our competitive business position, business prospects and financial
condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or
unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In
this case, we could ultimately be forced to cease use of such trademarks.
Even if we establish infringement, the court
may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not
be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could
also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock.
Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims,
which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation
and the diversion of the attention of our management, legal and scientific personnel could outweigh any benefit we receive as a result
of the proceedings.
Because of the expense and uncertainty
of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
Because of the expense and uncertainty of litigation,
we may conclude that even if a third party is infringing our issued patents, any patents that may be issued as a result of our pending
or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or
action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent
course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.
39
We may not be able to protect our intellectual
property rights throughout the world.
Patents are of national or regional effect, and
filing, prosecuting and defending patents on all of our drug candidates throughout the world would be prohibitively expensive. As such,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling
or importing products made using our inventions in and into the United States or other jurisdictions. Further, the legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing
of competing products in violation of our proprietary rights generally. In addition, certain developing countries, including China and
India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries,
we and our licensors and licensees may have limited remedies if patents are infringed or if we or our licensors or licensees are compelled
to grant a license to a third party, which could diminish the value of those patents. This could limit our potential revenue opportunities.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license.
Changes in patent law in the United States
and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates.
As is the case with other pharmaceutical companies,
our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical
industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in
either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs. Patent reform
legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into
law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These
include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective
avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO
during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings,
including post-grant review, inter partes review, and derivation proceedings. After March 2013, under the Leahy-Smith Act, the United
States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor
to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse
effect on our business, financial condition, results of operations and prospects.
The U.S. Supreme Court has ruled on several patent
cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of
patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making
bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability
to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
Patent terms may be inadequate to protect
our competitive position on our drug candidates for an adequate amount of time.
Patent rights are of limited duration. Given
the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates
might expire before or shortly after such drug candidates are commercialized. Even if patents covering our drug candidates are obtained,
once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent term extension
based on a delay in obtaining FDA approval may be available in the United States. However, only a single patent can be extended for each
marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period
of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved.
Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple
patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail
to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent
term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right
to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent
expiration, and our revenue could be reduced.
40
Risks Related to Other Regulatory Matters
We will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if
we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
Any regulatory approvals that we receive for
our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require
a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication
guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates,
the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export
and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include
submissions of safety and other post-marketing information and reports, facility registration, as well as continued compliance with cGMPs
for manufacturing and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be
subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing
application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend
time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the
FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply
with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on
promoting products for uses or in patient populations that are not described in the product's approved uses (known as "off-label
use"), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving
the internet and social media. Later discovery of previously unknown problems with our product candidates, including adverse events of
unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory
requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical
studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a risk evaluation and mitigation
strategy program. Other potential consequences include, among other things:
●
restrictions
                                            on the marketing or manufacturing of our product candidates, withdrawal of the product from
                                            the market or voluntary or mandatory product recalls;
●
fines,
                                            warning letters or holds on clinical trials;
●
refusal
                                            by the FDA to approve pending applications or supplements to approved applications filed
                                            by us or suspension or revocation of license approvals;
●
product
                                            seizure or detention, or refusal to permit the import or export of our product candidates;
                                            and
●
injunctions
                                            or the imposition of civil or criminal penalties.
The FDA's and other regulatory authorities'
policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our
product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
marketing approval that we may have obtained and we may not achieve or sustain profitability.
Obtaining and maintaining regulatory approval
of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product
candidates in other jurisdictions.
Obtaining and maintaining regulatory approval
of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any
other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory
approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities
in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate prior to marketing in
those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different
from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted
in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States,
a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price
that we intend to charge for our products is also subject to approval.
41
We may also submit marketing applications in
other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates
with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign
regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction
of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable
marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates
will be harmed.
Failure to comply with existing or future
health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal fines
or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws and
regulations could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively
affect our operating results and business.
Regulation of data processing is evolving as
federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security,
and the collection, use, disclosure and cross-border transfer of data. We and any collaborators may be subject to current, new, or modified
federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security).
In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data
breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the
Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information
could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties
(including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under
the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for
Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to significant civil,
criminal, and administrative liabilities or penalties if we knowingly obtain, use, or disclose individually identifiable health information
maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.
In addition, in June 2018, California enacted
the California Consumer Privacy Act of 2018, or CCPA, which went into effect on January 1, 2020. The CCPA gives California residents
the right to access and require deletion of their personal information, the right to opt out of certain personal information sharing,
and the right to detailed information about how their personal information is collected, used and shared. The CCPA provides civil penalties
for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although
the CCPA includes exemptions for certain clinical trials data, the law may increase our compliance costs and potential liability with
respect to other personal information we collect about California residents. The CCPA has prompted a wave of proposals for new federal
and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect
our business. Several foreign jurisdictions, including the European Union (EU), its member states, the United Kingdom, Japan and Australia,
among others, have adopted legislation and regulations that increase or change the requirements governing the collection, use, disclosure
and transfer of the personal information of individuals in these jurisdictions. These laws and regulations are complex and change frequently,
at times due to changes in political climate, and existing laws and regulations are subject to different and conflicting interpretations,
which adds to the complexity of processing personal data from these jurisdictions. Additionally, certain countries have passed or are
considering passing laws that require local data residency and/or restrict the international transfer of data. These laws have the potential
to increase costs of compliance, risks of noncompliance and penalties for noncompliance.
Certain international data protection laws, including
the EU's General Data Protection Regulation (GDPR) and EU member state implementing legislation, apply to health-related and other
personal information of individuals in the EU. These laws impose strict obligations on the ability to process health-related and other
personal information of individuals in the EU, including in relation to collection, use, disclosure and cross-border transfer of that
information. These include several requirements relating to the consent of the individuals to whom the personal information relates,
the information that companies must provide to individuals about how they collect, use and disclose personal information, individual
rights to access and delete their personal information, notification of data breaches to authorities and affected individuals, and the
security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European
Economic Area (EEA) such as the United States, which are not considered by the European Commission to provide an adequate level of data
protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data
from the EEA and Switzerland to other countries, including the United States, they are subject to legal challenges and uncertainty about
compliance with EU data protection laws remains. Such mechanisms may not be available or applicable with respect to the personal data
processing activities necessary to research, develop, and market our products and services. For example, ongoing legal challenges in
Europe to the mechanisms allowing companies to transfer personal data across national borders could result in further limitations on
the ability to engage in cross-border data transfers, particularly if governments are unable or unwilling to reach new or maintain existing
agreements that support such transfers. The GDPR allows EU member states to make additional laws and regulations further limiting the
processing of genetic, biometric, health data, or other personal data. Failure to comply with these laws, where applicable, can result
in the imposition of significant regulatory fines and penalties of up to the greater of €20 million or 4% of annual global turnover
(revenue).
42
Compliance with U.S. and international data protection
laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and
disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations
could result in government enforcement actions (which could include significant civil, criminal or administrative penalties, fines or
sanctions), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical
trial subjects, employees and other individuals about whom we or our collaborators obtain personal information, as well as the providers
who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated
individuals' privacy rights, failed to comply with data protection laws, or breached our contractual obligations related to security
or data privacy, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity
that could harm our business.
We may be subject, directly or indirectly, to
federal and state healthcare fraud and abuse laws, false claims laws health information privacy and security laws, and other health care
laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
If we obtain FDA approval for any of our product
candidates and begin commercializing those products in the United States, our operations will be directly, or indirectly through our
prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without
limitation, the federal Anti-Kickback Statute, or Anti-Kickback Statute (AKS), the federal civil and criminal False Claims Act and Physician
Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs.
In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business.
The laws that will affect our operations include, but are not limited to:
●
the
                                            federal AKS, which prohibits, among other things, persons or entities from knowingly and
                                            willfully soliciting, receiving, offering or paying any remuneration (including any kickback,
                                            bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce,
                                            or in return for, either the referral of an individual, or the purchase, lease, order, arrangement,
                                            or recommendation of any good, facility, item or service for which payment may be made, in
                                            whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs.
                                            "Remuneration" has been interpreted broadly to include anything of value. A person
                                            or entity does not need to have actual knowledge of the AKS or specific intent to violate
                                            it to have committed a violation. In addition, the government may assert that a claim including
                                            items or services resulting from a violation of the AKS constitutes a false or fraudulent
                                            claim for purposes of the federal False Claims Act, or FCA, or federal civil money penalties.
                                            The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers
                                            on the one hand and prescribers, purchasers, and formulary managers on the other. There are
                                            a number of statutory exceptions and regulatory safe harbors protecting some common activities
                                            from prosecution The Health and Human Services Office of Inspector General (OIG) continues
                                            to make modifications to existing AKS safe harbors which may increase liability and risk
                                            as well as adversely impact sales relationships. On November 20, 2020, OIG issued the final
                                            rule for Safe Harbors under the Federal AKS. This new final rule creates additional safe
                                            harbors including ones pertaining to patient incentives. The final rule also removed safe
                                            harbor protections for rebates and other reductions in price paid by manufacturers to plan
                                            sponsors under Medicare Part D, either directly or through pharmacy benefit managers acting
                                            under contract with plan sponsors, unless the reduction in price is required by law. OIG
                                            is able to modify safe harbors as well as regulatory compliance requirements, which could
                                            impact our business adversely. If the removal of safe harbors for rebates takes effect, our
                                            ability to negotiate coverage and formulary placement for Part D plans may be affected;
●
the
                                            federal civil and criminal false claims laws and civil monetary penalty laws, or CMP, including
                                            the FCA, which impose criminal and civil penalties against individuals or entities for, among
                                            other things: knowingly presenting, or causing to be presented, to the federal government,
                                            claims for payment that are false or fraudulent; knowingly making, using or causing to be
                                            made or used, a false statement of record material to a false or fraudulent claim or obligation
                                            to pay or transmit money or property to the federal government. Manufacturers can be held
                                            liable under the FCA even when they do not submit claims directly to government payors if
                                            they are deemed to "cause" the submission of false or fraudulent claims. The
                                            FCA also permits a private individual acting as a "whistleblower" to bring actions
                                            on behalf of the federal government alleging violations of the FCA and to share in any monetary
                                            recovery;
43
●
the
                                            beneficiary inducement provisions of the CMP Law, which prohibits, among other things, the
                                            offering or giving of remuneration, which includes, without limitation, any transfer of items
                                            or services for free or for less than fair market value (with limited exceptions), to a Medicare
                                            or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary's
                                            selection of a particular supplier of items or services reimbursable by a federal or state
                                            governmental program;
●
the
                                            federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created
                                            new federal criminal statutes that prohibit a person from knowingly and willfully executing,
                                            or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by
                                            means of false or fraudulent pretenses, representations or promises, any of the money or
                                            property owned by, or under the custody or control of, any healthcare benefit program, regardless
                                            of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing
                                            or covering up by any trick or device a material fact or making any materially false, fictitious,
                                            or fraudulent statements or representations in connection with the delivery of, or payment
                                            for, healthcare benefits, items or services relating to healthcare matters; similar to the
                                            Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute
                                            or specific intent to violate it in order to have committed a violation;
●
HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act of 2009,
                                            and their respective implementing regulations, which impose requirements on certain healthcare
                                            providers, health plans, and healthcare clearinghouses, known as covered entities, as well
                                            as their respective business associates, individuals and entities that perform services on
                                            their behalf that involve the use or disclosure of individually identifiable health information,
                                            relating to the privacy, security and transmission of individually identifiable health information;
●
the
                                            U.S. federal transparency requirements under the Patient Protection and Affordable Care Act,
                                            as amended by the Health Care and Education Reconciliation Act, or collectively, ACA, including
                                            the provision commonly referred to as the Physician Payments Sunshine Act, which requires
                                            applicable manufacturers of drugs, devices, biologics and medical supplies for which payment
                                            is available under Medicare, Medicaid or the Children's Health Insurance Program (with
                                            certain exceptions) to report annually to CMS information related to payments or other transfers
                                            of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists
                                            and chiropractors) and teaching hospitals, as well as ownership and investment interests
                                            held by the physicians described above and their immediate family members. Beginning in 2022,
                                            applicable manufacturers also will be required to report information regarding payments and
                                            transfers of value provided to physician assistants, nurse practitioners, clinical nurse
                                            specialists, certified nurse anesthetists, and certified nurse-midwives;
●
federal
                                            government price reporting laws, which require us to calculate and report complex pricing
                                            metrics in an accurate and timely manner to government programs; and
●
federal
                                            consumer protection and unfair competition laws, which broadly regulate marketplace activities
                                            and activities that potentially harm consumers.
Additionally, we are subject to state and foreign
equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may
apply regardless of the payer. Many U.S. states have adopted laws similar to the Anti-Kickback Statute and False Claims Act, and may
apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving
healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed
laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for
Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America's Code on Interactions with Healthcare
Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price
disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply
with an applicable state law requirement, we could be subject to penalties. Finally, there are state and foreign laws governing the privacy
and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts.
44
Because of the breadth of these laws and the
narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could
be subject to challenge under one or more of such laws. Law enforcement authorities are increasingly focused on enforcing fraud and abuse
laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future
business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will
involve substantial costs. If our operations, including our arrangements with physicians and other healthcare providers, some of whom
may receive stock options as compensation for services provided, are found to be in violation of any of such laws or any other governmental
regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties,
damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring
of our operations, exclusion from participation in federal and state healthcare programs (such as Medicare and Medicaid), additional
reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations
of non-compliance with these laws, and individual imprisonment, any of which could adversely affect our ability to operate our business
and our financial results. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer
to incur significant legal expenses and divert management's attention from the operation of the business. Prohibitions or restrictions
on sales or withdrawal of future marketed products could materially affect business in an adverse way.
We are subject to the U.S. Foreign Corrupt
Practices Act of 1977, as amended, or the FCPA, and other anti-corruption laws, as well as export control laws, import and customs laws,
trade and economic sanctions laws and other laws governing our operations.
Our operations are subject to anti-corruption
laws, including the FCPA, the U.S. domestic bribery statute contained in 18 §201, the U.S. Travel Act, and other anti-corruption
laws that apply in countries where we may do business in the future. The Bribery Act, the FCPA and these other laws generally prohibit
us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited
payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business
advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery
offense. We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations,
and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject
us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge
of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international
operations might be subject or the manner in which existing laws might be administered or interpreted.
We will also be subject to other laws and regulations
governing our potential future international operations, including regulations administered by the governments of the United Kingdom
and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and
embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations,
collectively referred to as the Trade Control laws.
There is no assurance that we will be completely
effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements,
including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control
laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses,
which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation
of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by United Kingdom, United
States or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.
If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse
effect on the success of our business.
We are subject to numerous environmental, health
and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal
of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological
materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials
and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting
from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.
We also could incur significant costs associated with civil or criminal fines and penalties. Furthermore, environmental laws and regulations
are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain
of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health
and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts.
Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.
45
Although we maintain workers' compensation
insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials
or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future
laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also
may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial
condition, results of operations and prospects.
Product liability lawsuits against us could
cause us to incur substantial liabilities and could limit our commercialization of any drug candidates that we may develop.
We face an inherent risk of product liability
exposure related to the testing of our drug candidates in human clinical trials and will face an even greater risk if we commercially
sell any products that we may develop. If we cannot successfully defend ourselves against claims that our drug candidates or products
caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result
in:
●
delay
                                            or termination of clinical trials;
●
decreased
                                            demand for any drug candidates or products that we may develop;
●
injury
                                            to our reputation and significant negative media attention;
●
withdrawal
                                            of clinical trial subjects;
●
initiation
                                            of investigations by regulatory authorities;
●
significant
                                            costs to defend the related litigation and diversion of management's time and our resources;
●
substantial
                                            monetary awards to study subjects or patients;
●
product
                                            recalls, withdrawals or labeling, marketing or promotional restrictions;
●
loss
                                            of revenue; and
●
the
                                            inability to commercialize any products that we may develop.
Furthermore, manufacturing defects, errors in
product distribution or storage processes, improper administration or application and known or unknown side effects of product usage
may result in liability claims against us or third parties with which we have relationships. These actions could include claims resulting
from acts by our collaborators, licensees and subcontractors over which we have little or no control. For example, our liability could
be sought by patients participating in clinical trials for potential therapeutic product candidates as a result of unexpected side effects,
improper product administration or the deterioration of a patient's condition, patient injury or even death.
Criminal or civil proceedings might be filed
against us by patients, regulatory authorities, biopharmaceutical companies and any other third party using or marketing any product
candidates or products that we develop alone or with collaborators. On occasion, large judgments have been awarded in class action lawsuits
based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that product candidates
or products we develop alone or with collaborators caused harm, we could incur substantial liabilities.
46
Clinical development does not always fully characterize
the safety and efficacy profile of a new medicine, and it is always possible that a drug or biologic, even after regulatory approval,
may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval,
we may be exposed to substantial liabilities.
Although we will maintain product liability insurance
coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance
coverage as our drug candidates advance through clinical trials and if we successfully commercialize any products. Insurance coverage
is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy
any liability that may arise.
Risks Related to this Offering and Ownership
of Our Securities
There has been no public market for our
common stock and warrants prior to this offering, and an active market in which investors can resell their shares of our common stock
and warrants may not develop.
Prior to this offering, there has been no public
market for our common stock and warrants. We intend to file an application to list our shares of common stock under the symbol "FLCT"
and our warrants under the symbol "FLCTW," both on the Nasdaq Capital Market. The closing of this offering is contingent
upon the successful listing of our common stock and warrants on the Nasdaq Capital Market. There is no guarantee that Nasdaq, or any
other exchange or quotation system, will permit our common stock and warrants to be listed and traded.
Even if our common stock and warrants are approved
for listing on Nasdaq, a liquid public market for our common stock and warrants may not develop. The initial public offering price for
our securities has been determined by negotiation between us and the underwriters based upon several factors, including prevailing market
conditions, our historical performance, estimates of our business potential and earnings prospects, and the market valuations of similar
companies. The price at which our securities are traded after this offering may decline below the initial public offering price, meaning
that you may experience a decrease in the value of your common stock and warrants regardless of our operating performance or prospects.
The market price of our securities may
fluctuate, and you could lose all or part of your investment.
After this offering, the market price for our
securities is likely to be volatile, in part because our shares and warrants have not been traded publicly. In addition, the market price
of our securities may fluctuate significantly in response to several factors, most of which we cannot control, including:
●
actual
                                            or anticipated variations in our periodic operating results;
●
increases
                                            in market interest rates that lead investors of our common stock and warrants to demand a
                                            higher investment return;
●
changes
                                            in earnings estimates;
●
changes
                                            in market valuations of similar companies;
●
actions
                                            or announcements by our competitors;
●
adverse
                                            market reaction to any increased indebtedness we may incur in the future;
●
additions
                                            or departures of key personnel;
●
actions
                                            by shareholders;
●
speculation
                                            in the media, online forums, or investment community; and
●
our
                                            intentions and ability to maintain the listing of our common stock and warrants on Nasdaq.
The public offering price of our securities has
been determined by negotiations between us and the underwriters based upon many factors and may not be indicative of prices that will
prevail following the closing of this offering. Volatility in the market price of our securities may prevent investors from being able
to sell their securities at or above the initial public offering price. As a result, you may suffer a loss on your investment.
47
We may not be able to maintain a listing
of our common stock and warrants on Nasdaq.
Assuming that our common stock and warrants are
listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq's listing
requirements, or if we fail to meet any of Nasdaq's listing standards, our common stock and warrants may be delisted. In addition,
our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits
of such listing. A delisting of our common stock and warrants from Nasdaq may materially impair our shareholders' ability to buy
and sell our common stock and warrants and could have an adverse effect on the market price of, and the efficiency of the trading market
for, our common stock and warrants. The delisting of our common stock and warrants could significantly impair our ability to raise capital
and the value of your investment.
We have considerable discretion as to the
use of the net proceeds from this offering and we may use these proceeds in ways with which you may not agree.
We intend to use the proceeds from this offering
for research, product development, general and administrative expenses and working capital, and general working capital and other corporate
purposes. However, we have considerable discretion in the application of the proceeds. Because of the number and variability of factors
that will determine our use of our net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
You must rely on the judgment of our management regarding the application of the net proceeds of this offering. The net proceeds may
be used for corporate or other purposes with which you do not agree or that do not improve our profitability or increase our share price.
The net proceeds from this offering may also be placed in investments that do not produce income or that lose value. Please see "
Use
of Proceeds
" below for more information.
The warrants may not have any value.
The warrants will be exercisable for five years
from the date of initial issuance at an initial exercise price equal to 100% of the public offering price per unit set forth on the cover
page of this prospectus. There can be no assurance that the market price of our shares of common stock will ever equal or exceed the
exercise price of the warrants. In the event that the stock price of our shares of common stock does not exceed the exercise price of
the warrants during the period when the warrants are exercisable, the warrants may not have any value.
Holders of warrants purchased in this offering
will have no rights as shareholders until such holders exercise their warrants and acquire our shares of common stock.
Until holders of the warrants purchased in this
offering acquire shares of common stock upon exercise thereof, such holders will have no rights with respect to the shares of common
stock underlying the warrants. Upon exercise of the warrants, the holders will be entitled to exercise the rights of a shareholder only
as to matters for which the record date occurs after the date they were entered in the register of members of the Company as a shareholder.
You will experience immediate and substantial
dilution as a result of this offering.
As of March 31, 2022, our net tangible book value
was approximately $(870,735), or approximately $(0.20) per share. Since the effective price per share of our common stock being offered
in this offering is substantially higher than the net tangible book value per share of our common stock, you will suffer substantial
dilution with respect to the net tangible book value of the common stock included in the units that you purchase in this offering. Based
on the assumed public offering price of $6.25 per unit being sold in this offering, which is the midpoint of the estimated offering range
set forth on the cover page of this prospectus, and our net tangible book value per share as of March 31, 2022, and assuming no exercise
of the warrants being offered in this offering, if you purchase units in this offering, you will suffer immediate and substantial dilution
of $4.45 per share (or $4.26 per share if the underwriters exercise the over-allotment option to purchase additional shares of common
stock and warrants in full) with respect to the net tangible book value of the common stock included in the units. See the section titled
"
Dilution
" for a more detailed discussion of the dilution you will incur if you purchase securities in this offering.
A recent independent valuation of
our stock and recent stock purchase prices and stock option grant exercise prices are lower than the purchase price in this offering,
which means that our securities may be worth less than the purchase price.
The per unit purchase price of our units in this
offering has been arbitrarily determined by us and the representative without regard to an independent valuation of the common stock
or warrants included in the units being offered in this offering. Although we have an independent valuation of our common stock as of
November 5, 2021, we have not obtained an independent appraisal opinion on the valuation of our units as of the date of this
offering. Accordingly, our units may have a value significantly less than the offering price, and our common stock and warrants included
in the units may never obtain a value equal to or greater than the offering price.
48
We do not expect to declare or pay dividends
in the foreseeable future.
We do not expect to declare or pay dividends
in the foreseeable future, as we anticipate that we will invest future earnings in the development and growth of our business. Therefore,
holders of our common stock included in the units being offered in this offering will not receive any return on their investment unless
they sell their securities, and holders may be unable to sell their securities on favorable terms or at all.
If securities industry analysts do not
publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our securities
could be negatively affected.
Any trading market for our common stock and warrants
may be influenced in part by any research reports that securities industry analysts publish about us. We do not currently have and may
never obtain research coverage by securities industry analysts. If no securities industry analysts commence coverage of us, the market
price and market trading volume of our securities could be negatively affected. In the event we are covered by analysts, and one or more
of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues coverage of us, the market price and
market trading volume of our securities could be negatively affected.
Future issuances of our common stock or
securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration of lock-up agreements that restrict
the issuance of new common stock or the trading of outstanding common stock, could cause the market price of our securities to decline
and would result in the dilution of your holdings.
Future issuances of our common stock or securities
convertible into, or exercisable or exchangeable for, our common stock, or the expiration of lock-up agreements that restrict the issuance
of new common stock or the trading of outstanding common stock, could cause the market price of our common stock to decline. We cannot
predict the effect, if any, of future issuances of our securities, or the future expirations of lock-up agreements, on the price of our
securities. In all events, future issuances of our securities would result in the dilution of your holdings. In addition, the perception
that new issuances of our securities could occur, or the perception that locked-up parties will sell their securities when the lock-ups
expire, could adversely affect the market price of our securities. In connection with this offering, we will enter into a lock-up agreement
that prevents us, subject to certain exceptions, from offering additional shares of capital stock for up to 180 days after the closing
of this offering, as further described in the section titled "
Underwriting
." In addition to any adverse effects that
may arise upon the expiration of these lock-up agreements, the lock-up provisions in these agreements may be waived, at any time and
without notice. If the restrictions under the lock-up agreements are waived, our securities may become available for resale, subject
to applicable law, including without notice, which could reduce the market price for our common stock.
Future issuances of debt securities, which
would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of preferred stock, which could rank senior
to our common stock for the purposes of dividends and liquidating distributions, may adversely affect the level of return you may be
able to achieve from an investment in our securities.
In the future, we may attempt to increase our
capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of our debt securities, and lenders with respect
to other borrowings we may make, would receive distributions of our available assets prior to any distributions being made to holders
of our common stock. Moreover, if we issue preferred stock, the holders of such preferred stock could be entitled to preferences over
holders of common stock in respect of the payment of dividends and the payment of liquidating distributions. Because our decision to
issue debt or preferred stock in any future offering, or borrow money from lenders, will depend in part on market conditions and other
factors beyond our control, we cannot predict or estimate the amount, timing or nature of any such future offerings or borrowings. Holders
of our securities must bear the risk that any future offerings we conduct or borrowings we make may adversely affect the level of return,
if any, they may be able to achieve from an investment in our securities.
49
If our securities become subject to the
penny stock rules, it would become more difficult to trade our shares.
The SEC has adopted rules that regulate broker-dealer
practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00,
other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation
systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange
or system. If we do not retain a listing on Nasdaq or another national securities exchange and if the price of our securities is less
than $5.00, our securities could be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny
stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In
addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules,
a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive
(i) the purchaser's written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions
involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have
the effect of reducing the trading activity in the secondary market for our securities, and therefore shareholders may have difficulty
selling their securities.
We will be subject to ongoing public reporting
requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, and our shareholders
could receive less information than they might expect to receive from more mature public companies.
Upon the completion of this offering, we will
be required to publicly report on an ongoing basis as an "emerging growth company" (as defined in the JOBS Act) under the
reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth company, we may take advantage of certain
exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not emerging growth
companies, including but not limited to:
●
not
                                            being required to comply with the auditor attestation requirements of Section 404 of the
                                            Sarbanes-Oxley Act;
●
being
                                            permitted to comply with reduced disclosure obligations regarding executive compensation
                                            in our periodic reports and proxy statements; and
●
being
                                            exempt from the requirement to hold a non-binding advisory vote on executive compensation
                                            and shareholder approval of any golden parachute payments not previously approved.
In addition, Section 107 of the JOBS Act also
provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits
of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such
new or revised accounting standards.
We expect to take advantage of these reporting
exemptions until we are no longer an emerging growth company. We would remain an emerging growth company for up to five years, although
if the market value of our securities that is held by non-affiliates exceeds $700 million as of any June 30 before that time, we would
cease to be an emerging growth company as of the following December 31.
Because we will be subject to ongoing public
reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies, our shareholders
could receive less information than they might expect to receive from more mature public companies. We cannot predict if investors will
find our securities less attractive if we elect to rely on these exemptions, or if taking advantage of these exemptions would result
in less active trading or more volatility in the price of our securities.
50
CAUTIONARY STATEMENT
REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements
that are based on our management's beliefs and assumptions and on information currently available to us. All statements other than
statements of historical facts are forward-looking statements. The forward-looking statements are contained principally in, but not limited
to, the sections entitled "
Prospectus Summary
," "
Risk Factors
," "
Management's Discussion
and Analysis of Financial Condition and Results of Operations
" and "
Business
." These statements relate to
future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity,
performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not
limited to, statements about:
●
our
                                            goals and strategies;
●
our
                                            future business development, financial condition and results of operations;
●
expected
                                            changes in our revenue, costs or expenditures;
●
growth
                                            of and competition trends in our industry;
●
our
                                            expectations regarding demand for, and market acceptance of, our products;
●
our
                                            expectations regarding our relationships with investors, institutional funding partners and
                                            other parties with whom we collaborate;
●
our
                                            expectation regarding the use of proceeds from this offering;
●
fluctuations
                                            in general economic and business conditions in the markets in which we operate; and
●
relevant
                                            government policies and regulations relating to our industry.
In some cases, you can identify forward-looking
statements by terms such as "may," "could," "will," "should," "would," "expect,"
"plan," "intend," "anticipate," "believe," "estimate," "predict,"
"potential," "project" or "continue" or the negative of these terms or other comparable terminology.
These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.
Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under
the heading "
Risk Factors
" and elsewhere in this prospectus. If one or more of these risks or uncertainties occur,
or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected
by the forward-looking statements. No forward-looking statement is a guarantee of future performance.
The forward-looking statements made in this prospectus
relate only to events or information as of the date on which the statements are made in this prospectus. Although we will become a public
company after this offering and have ongoing disclosure obligations under United States federal securities laws, we do not intend
to update or otherwise revise the forward-looking statements in this prospectus, whether as a result of new information, future events
or otherwise.
51
USE OF PROCEEDS
After deducting the estimated underwriters'
discounts and commissions and offering expenses payable by us, we expect to receive net proceeds of approximately $[13,327,000] from
this offering (or approximately $[15,442,750] if the underwriters exercise the over-allotment option in full), based on an assumed public
offering price of $6.25 per unit, which is the midpoint of the estimated offering range set forth on the cover page of this prospectus.
We plan to use the net proceeds of this offering
as follows:
●
60%
                                            of the net proceeds (approximately $8.0 million) for research and product development;
                                            and
●
40% of the net proceeds (approximately
                                            $5.3 million) for general and administrative, working capital and other corporate purposes.
Of the 60% of the net proceeds we expect to dedicate
to research and product development, these expenditures will be split approximately equally between our two product candidates, FX-1610
and FX-7742 (or FX-9847 if FX-7742 fails safety studies), and will be used for pre-IND enabling studies and the preparation and filing
of the IND applications for these two product candidates.
The foregoing represents our current intentions
to use and allocate the net proceeds of this offering based upon our present plans and business conditions. Our management, however,
will have broad discretion in the way that we use the net proceeds of this offering. Pending the final application of the net proceeds
of this offering, we intend to invest the net proceeds of this offering in short-term, interest-bearing, investment-grade securities.
See "
Risk Factors-Risks Related to This Offering and Ownership of Our Securities-We have considerable discretion
as to the use of the net proceeds from this offering and we may use these proceeds in ways with which you may not agree
."
52
DIVIDEND POLICY
We have never declared or paid cash dividends
on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business
and do not anticipate paying any cash dividends on our common stock in the near future. We may also enter into credit agreements or other
borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any future
determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition,
operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors
may deem relevant. See also "
Risk Factors-Risks Related to This Offering and Ownership of Our Securities-We do not
expect to declare or pay dividends in the foreseeable future
."
53
CAPITALIZATION
The following table sets forth our capitalization
as of March 31, 2022:
1.
on an actual
                                            basis;
2.
on a pro forma basis to give effect
                                            to issuance of 42,519 shares of our common stock upon the conversion of outstanding loans
                                            provided by our Chairman;
3.
on a pro forma
                                            basis to give effect to the 9.08:1 reverse split that will be completed immediately prior
                                            the effective date of the registration statement of which this prospectus forms a part; and
4.
on a pro forma
                                            as adjusted basis to reflect the pro forma adjustments as described above and the sale of
                                            [2,480,000] shares by us in this offering at an assumed price to the public of $6.25 per
                                            share, which is the midpoint of the estimated offering range set forth on the cover page
                                            of this prospectus, resulting in net proceeds to us of $13,327,000 after deducting (i) underwriter
                                            commissions of $1,520,000 and (ii) our estimated other offering expenses of $653,000 (assuming
                                            no exercise of the over-allotment option); and
The pro forma information
below is illustrative only and our capitalization following the completion of this offering is subject to adjustment based on the initial
public offering price of our units and other terms of this offering determined at pricing. You should read this table together with our
financial statements and the related notes included elsewhere in this prospectus and the information under "
Management's
Discussion and Analysis of Financial Condition and Results of Operations
."
As of March 31, 2022:
Actual
Pro Forma
Pro Forma As Adjusted
Cash
$
32,023
$
32,023
$
13,359,023
Liabilities
Due to related party
120,203
120,203
120,203
Accrued Interest
3,042
-
-
Convertible Notes payable related party
128,224
-
-
Total debt
$
251,469
$
120,203
$
120,203
Stockholders' equity (deficit):
Common stock, $0.0001 par value, 100,000,000 shares authorized, 4,455,999 shares
    issued and outstanding, actual, 4,498,518 shares issued and outstanding, pro forma, 6,978,518 shares issued and outstanding, pro
    forma as adjusted.
446
450
698
Additional paid-in capital
6,199,324
6,330,586
19,657,338
Accumulated deficit
(7,070,505
)
(7,070,505
)
(7,070,505
)
Total deficit
(870,735
)
(739,469
)
12,587,531
Total capitalization
$
(619,266
)
$
(619,266
)
$
12,707,734
The table above excludes the following shares:
●
1,018,146
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2012 Plan (as defined below);
●
96,117
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2022 Plan (as defined below);
●
729,874
                                            additional shares of common stock that are reserved for issuance under the 2022 Plan;
●
123,735
                                            shares of common stock issuable upon exercise of warrants issued to our Chairman;
●
up
                                            to [2,480,000] shares of common stock issuable upon exercise of warrants included in the
                                            units being offered in this offering;
●
up
                                            to [4,960,000] shares of common stock issuable upon exercise of Additional Warrants issuable
                                            to Qualified Buyers pursuant to any adjustment in the dilutive issuance provision of the
                                            warrants;
●
up
                                            to [372,000] shares of common stock issuable upon the exercise of the representative's
                                            over-allotment option, including 372,000 shares of common stock issuable upon the exercise
                                            of warrants that may be issued as a result of exercise of the representative's over-allotment
                                            option;
●
up
                                            to [372,000] shares of common stock issuable upon the exercise of warrants and/or [372,000]
                                            shares of common stock that may be issued as a result of exercise of the representative's
                                            over-allotment option; and
●
up
                                            to [198,400] shares of common stock issuable upon exercise of the representative's
                                            warrants issued in connection with this offering.
54
DILUTION
As
described elsewhere in this prospectus, all share amounts and per share amounts set forth below have been presented on a retroactive
basis to reflect the reverse stock split of our outstanding shares of common stock at a ratio of one-for-nine and eight hundredths (1
for 9.08) which was implemented on [  ], 2022.
Dilution in net tangible book value per share
to new investors in our securities, assuming no value is attributed to the related warrants, is the amount by which the offering price
paid by the purchasers of the shares of our common stock included in the units sold in this offering exceeds the pro forma net tangible
book value per share of common stock after this offering. Net tangible book value per share is determined at any date by subtracting
our total liabilities from the total book value of our tangible assets and dividing the difference by the number of shares of common
stock deemed to be outstanding at that date.
The net tangible book value of our common stock
as of March 31, 2022 was $(870,735), or approximately $(0.20) per share.
Pro forma as adjusted net tangible book value
dilution per share included in each unit to new investors represents the difference between the amount per share included in each unit
paid by purchasers of our units in this offering and the pro forma as adjusted net tangible book value per share of our common stock
immediately after completion of this offering. Investors participating in this offering will incur immediate, substantial dilution. After
giving effect to our sale of [2,480,000] units of our common stock in this offering at an assumed initial public offering price of $6.25
per unit, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and after deducting
the estimated underwriting discounts and commissions and estimated offering expenses, and assuming no exercise of the warrants contained
in the units to be sold in this offering, our pro forma as adjusted net tangible book value as of March 31, 2022 would have been approximately
$[12,587,531], or approximately $[1.80] per share. This amount represents an immediate increase in pro forma as adjusted net tangible
book value of $[2.00] per share to existing shareholders and an immediate dilution in pro forma as adjusted net tangible book value of
$[4.45] per share to purchasers of our common stock in this offering, as illustrated in the following table.
Assumed public offering price per unit
$
6.25
Historical net tangible book value per share as of March 31, 2022
$
[(0.20
)]
Increase in pro forma as adjusted net tangible book value per share to existing stockholders
[2.00
]
Pro forma as-adjusted net tangible book value per share after this offering
[1.80
]
Dilution per share to new investors purchasing shares in this offering
$
[4.45
]
If the underwriters exercise their over-allotment
option in full, the pro forma as adjusted net tangible book value per share of our common stock, as adjusted to give effect to this offering,
would be $[1.99] per share, and the dilution in pro forma net tangible book value per share to new investors purchasing units in this
offering would be $[4.26] per share.
55
The following table sets forth, assuming the
sale of [2,480,000] shares of our common stock in this offering, as of March 31, 2022, after giving effect to a reverse share split effected
on [ ], 2022, at a ratio of 1 for 9.08, the total number of shares of common stock previously issued and sold by us to existing investors,
the total consideration paid for the foregoing and the average price per unit, before deducting estimated underwriter commissions and
offering expenses (assuming no exercise of the over-allotment option to purchase additional shares of common stock and warrants and assuming
no exercise of the representative's warrants), in each case payable by us. As the table shows, new investors purchasing shares
of our common stock in this offering may in certain circumstances pay an average price per share substantially higher than the average
price per share paid by our existing shareholders.
Shares Purchased
Total Consideration
Average
Price
Number
Percent
Amount
Percent
Per Share
Existing shareholders
4,498,518
64.5
%
$
5,393,945
25.8
%
$
1.20
New investors
2,480,000
35.5
%
$
15,500,000
74.2
%
$
6.25
Total
6,978,518
100.0
%
$
20,893,945
100.0
%
$
2.99
The table above excludes the following shares:
●
1,018,146
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2012 Plan;
●
96,117
                                            total shares of common stock issuable upon the exercise of options which we granted to our
                                            officers, directors, and employees under the 2022 Plan;
●
42,519 total shares of common
                                            stock issuable upon the conversion of a convertible promissory note which we issued to our
                                            Chairman;
●
729,874
                                            additional shares of common stock that are reserved for issuance under the 2022 Plan;
●
123,735
                                            shares of common stock issuable upon exercise of warrants issued to our Chairman;
●
up
                                            to [2,480,000] shares of common stock issuable upon exercise of warrants included in the
                                            units being offered in this offering;
●
up
                                            to [4,960,000] shares of common stock issuable upon exercise of Additional Warrants issuable
                                            to Qualified Buyers pursuant to any adjustment in the dilutive issuance provision of the
                                            warrants;
●
up
                                            to[ 372,000] shares of common stock issuable upon the exercise of warrants and/or [372,000]
                                            shares of common stock that may be issued as a result of exercise of the representative's
                                            over-allotment option; and
●
up
                                            to [198,400] shares of common stock issuable upon exercise of the representative's
                                            warrants issued in connection with this offering.
To the extent that any outstanding options or
warrants are exercised, new options, restricted stock units or other securities are issued under our stock-based compensation plans,
or new shares of preferred stock are issued, or we issue additional shares of common stock or warrants in the future, there will be further
dilution to investors participating in this offering.
56
MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis summarizes
the significant factors affecting our operating results, financial condition, liquidity and cash flows of our company as of and for the
periods presented below. The following discussion and analysis should be read in conjunction with our financial statements and the related
notes thereto included elsewhere in this prospectus. The discussion contains forward-looking statements that are based on the beliefs
of management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially
from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and
elsewhere in this prospectus, particularly in the sections titled "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements".
Overview
We are a preclinical oncology drug development
company focused on developing therapies targeting dormant and active cancer cells. During the financial reporting periods presented in
this prospectus, we have operated our business in two segments, as discussed below.
Our Felicitex Business Segment
●
Through
                                            our Felicitex business, we have designed and patented small molecules and related methods
                                            to selectively disrupt dormant cancer cells in a manner that is specific to the disease and
                                            tissue context. This approach is lethal to cancer cells that rely on deregulation of the
                                            cell cycle for survival and has been shown to lead to the reversal of acquired resistance
                                            mechanisms. Our drug candidates are intended to be effective across a broad range of solid
                                            tumors and hematological cancers. We are designing our drug candidates to work synergistically
                                            with most chemotherapy and targeted therapies to improve the overall efficacy of cancer treatment
                                            programs, the survival of patients and quality of life. We target a high unmet need in large
                                            oncology markets including such solid tumors as non-small cell lung cancer, or NSCLC, glioblastoma
                                            multiforme, or GBM, ovarian, prostate, colorectal, pancreatic cancers, and liquid tumors
                                            such as acute lymphoblastic leukemia, or ALL.
Our TarMeta Segment
●
TarMeta
                                            Biosciences, LLC was formed in 2016 by Dr. Felix Chapovsky and our Chairman, Marc Duey, to
                                            build a rapid and cost-effective drug discovery platform for small molecule inhibitors targeting
                                            cancer. TarMeta developed drug candidates for its own account and also entertained collaborative
                                            agreements to discover assets in association with other biotechnology firms. Both Felicitex
                                            and TarMeta were under the common control of our Chairman, Marc Duey. Felicitex expects that
                                            the establishment of a proprietary drug discovery platform will enable the expansion of its
                                            drug candidate pipeline, via simultaneous identification of novel targets and corresponding
                                            specific small molecule inhibitors, in a way that is faster than possible through other currently
                                            available methodologies.
In June 2019, Felicitex
entered into a collaboration with TarMeta pursuant to which Felicitex provided a library of small molecules for screening and TarMeta
utilized its platform to screen those molecules for specific oncology targets. Felicitex acquired TarMeta on December 30, 2021, to internalize
and secure the platform developed by TarMeta along with its technical and human resources. See "
TarMeta Biosciences' Drug
Development Platform - Combining Target With Phenotypic-Based Drug Discovery"
for more information regarding the TarMeta discovery
platform.
We have a strong IP position
that is continuously growing. We have what we believe to be an efficient and cost-effective development strategy drawing on a network
of top-notch U.S.-based and international collaborators, each a recognized leader in their respective areas of expertise.
To date we have been reliant on our Chairman,
Marc Duey, to finance our operations. We expect to continue to incur operating losses and negative cash flows for the foreseeable future.
Until we are successful in our capital infusion efforts, and because the completion of such capital raising efforts, including a successful
conclusion to this offering, is not within our control, a substantial doubt exists about our ability to continue as a going concern for
a period of one year after the date of filing of the registration statement of which this prospectus is a part. Management continues
to address our liquidity position and will adjust spending as needed in order to preserve liquidity. Our future liquidity needs will
be determined primarily by the success of our operations with respect to the progression of our product candidates and key development
and regulatory events in the future. Potential sources of additional funding include: (1) pursuing collaboration, out-licensing and/or
partnering opportunities for our portfolio programs and product candidates with one or more third parties, (2) renegotiating third party
agreements, (3) securing additional debt financing and/or (4) selling equity securities. We cannot be sure that we will be successful
in any of these capital-raising efforts.
We have also noted that companies in the pharmaceutical
industry have indicated that a greater number of their employees now work from home than was the case in past periods. We believe this
increase may be partially a result of the relatively new risk to office work from the COVID-19 pandemic, and that this trend may continue
due to the growing spread of the more contagious Omicron variant of the COVID-19 virus. In addition, the Company faces the ongoing risk
that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company's research and pre-clinical studies.
The effects of the ongoing coronavirus pandemic may also increase non-research related costs such as insurance premiums, increase the
demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key pre-clinical trial vendors
and suppliers of our pharmaceutical ingredients. The full extent to which the COVID-19 pandemic could impact drug development and research,
or impact the Company's suppliers and other commercial partners, will depend on future developments that cannot be predicted.
57
For additional discussion, see "
Impact
of COVID-19 Pandemic
" below.
To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future. We have
incurred losses since our inception. As of March 31, 2022, we had an accumulated deficit of $7,070,505. As of March 31, 2022, we had
$48,574 in total assets with $870,735 of total deficit.
Recent Developments
On
July 23, 2021, we organized
UAB Felicitex Therapeutics, or UAB, a Lithuanian limited liability company. We organized UAB for the
purpose of applying for grants in Lithuania to pursue pre-clinical studies in Europe relating to our non-cancer therapies. To comply
with funding requirements under the government grant programs in Lithuania, our Chief Executive officer, Maria Vilenchik, is the sole
owner of UAB and, as such, we account for UAB as a variable interest entity, and we include UAB in our consolidated and combined financial
statements.
On December 30, 2021, we acquired 100% of the
ownership interests in TarMeta Biosciences, LLC, or TarMeta, in exchange for 635,378 shares of our common stock. Our Chairman, Marc Duey,
had a controlling interest in both TarMeta and us prior to the acquisition. As a result of this ownership structure, we determined that
the TarMeta acquisition was a common control transaction under ASC Topic 805,
Business Combinations
, and we accounted for this
transaction at the carrying amount of the net assets acquired. As a result of our acquisition of TarMeta, our financial statements as
of and for the years ended December 31, 2021 and 2020 have been adjusted to include the financial information of TarMeta as both entities,
TarMeta and our company, were under common control during the presented time period. As a result of the business combination, TarMeta
ceased to exist as a separate legal entity.
Impact of COVID-19 Pandemic
Starting in late 2019, a novel strain of the
coronavirus, or COVID-19, began to rapidly spread around the world and every state in the United States. At this time, there continues
to be significant volatility and uncertainty relating to the full extent to which the COVID-19 pandemic and the various responses
to it will impact our business, operations and financial results.
Most states and cities have at various times
instituted quarantines, restrictions on travel, "stay at home" rules, social distancing measures and restrictions on the
types of businesses that could continue to operate, as well as guidance in response to the pandemic and the need to contain it. As a
result, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, including such authorities in Europe,
which could result in delays of reviews and approvals. While there have been no specific notices of delay from federal or foreign government
authorities, potential interruptions, delays, or changes to the operations of the FDA, or of any foreign authority with which we might
interact, might impact the approval of any applications we plan and will need to file in the future.
As in many other industries, we believe that
the COVID-19 pandemic has weakened many oncology drug development companies and their suppliers. We believe that we have fully complied
with all state and local requirements relating to COVID-19. We have undertaken various measures in an effort to mitigate the spread of
COVID-19, including encouraging employees to work remotely if possible. However, we have not developed any further COVID-19 contingency
plans to address the potential challenges and risks presented by this pandemic. If we were to prepare such plans, there could be no assurance
that they would be effective in mitigating the effects of the COVID-19 virus.
In addition, w
e
are dependent upon certain contract manufacturers and suppliers and their ability to reliably and efficiently fulfill our orders is critical
to our business success. The COVID-19 pandemic has impacted and may continue to impact certain of our manufacturers and suppliers.
As a result, we have faced and may continue to face delays or difficulty sourcing certain products, which could negatively affect our
business and financial results.
The spread of COVID-19 has also adversely
impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The
pandemic has resulted, and may continue to result, in a significant disruption of global financial markets, which may reduce our ability
to access capital in the future, which could negatively affect our liquidity.
If the COVID-19 pandemic does not continue
to slow and the spread of COVID-19 is not contained, our business operations, including those of contract manufacturers, could be
further delayed or interrupted. We expect that government and health authorities may announce new or extend existing restrictions, which
could require us or our subcontractors to make further adjustments to our operations in order to comply with any such restrictions. We
or our subcontractors may also experience limitations in employee resources. In addition, our operations could be disrupted if any of
our employees or employees of our subcontractors were to be tested positive for having COVID-19, which could require quarantine
of some or all such employees or closure of our or their facilities for disinfection. The duration of any business disruption cannot
be reasonably estimated at this time but may materially affect our ability to operate our business and result in additional costs.
58
The
extent to which the COVID-19 pandemic may impact our results will depend on future developments, which are highly uncertain
and cannot be predicted as of the date of this prospectus, including the effectiveness of vaccines and other treatments for COVID-19,
the emergence of new strains of the virus and other new information that may emerge concerning the severity of the pandemic and
steps taken to contain the pandemic or treat its impact. Nevertheless, the pandemic and the current financial, economic and
capital markets environment, and future developments in the global supply chain and other areas present material uncertainty and risk
with respect to our performance, financial condition, results of operations and cash flows.
See also "
Risk Factors
"
above.
Principal Factors Affecting Our Financial
Performance
Our operating results are primarily affected
by the following factors:
●
the
                                            ability to obtain regulatory approval to market product candidates;
●
slow
                                            or delayed IND applications;
●
the
                                            timing, costs and results of clinical trials and other development activities versus expectations;
●
the
                                            ability to manufacture products successfully;
●
competition
                                            from products sold or being developed by other companies;
●
the
                                            price of, and demand for, Company products once approved;
●
the
                                            ability to negotiate favorable licensing or other manufacturing and marketing agreements
                                            for its products;
●
patent
                                            reinforcement and prosecution; and
●
changes
                                            in laws or the regulatory environment affecting our company.
Emerging Growth Company
We qualify as an "emerging growth company"
under the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so
long as we are an emerging growth company, we will not be required to:
●
have
                                            an auditor report on our internal controls over financial reporting pursuant to Section 404(b)
                                            of the Sarbanes-Oxley Act;
●
comply
                                            with any requirement that may be adopted by the Public Company Accounting Oversight Board
                                            regarding mandatory audit firm rotation or a supplement to the auditor's report providing
                                            additional information about the audit and the financial statements (i.e., an auditor discussion
                                            and analysis);
●
submit
                                            certain executive compensation matters to shareholder advisory votes, such as "say-on-pay"
                                            and "say-on-frequency;" and
●
disclose
                                            certain executive compensation related items such as the correlation between executive compensation
                                            and performance and comparisons of the chief executive officer's compensation to median
                                            employee compensation.
In addition, Section 107 of the JOBS Act also
provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits
of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such
new or revised accounting standards.
59
We will remain an emerging growth company for
up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed
$1.07 billion, (ii) the date that we become a "large accelerated filer" as defined in Rule 12b-2 under the Exchange Act,
which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business
day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible
debt during the preceding three year period.
Results of Operations
Comparison of Three Months Ended March 31, 2022 and 2021
The following table summarizes our results of
operations for the three months ended March 31, 2022 and 2021:
Three Months Ended
March 31,
Variance
2022
2021
Amount
%
Operating expenses:
Research and development
$
164,935
$
133,846
$
31,089
23
%
General and administrative expenses
519,747
153,058
366,689
240
%
Total operating expenses
684,682
286,904
397,778
139
%
Operating loss
(684,682
)
(286,904
)
(397,778
)
139
%
Other income (expense):
Interest income
PPP loan forgiveness
-
10,298
10,298
-100
%
Interest expense
(22,939
)
(7,601
)
(15,338
)
202
%
Inducement loss
(80,972
)
80,972
-100
%
Total other expense, net
(22,939
)
(78,275
)
55,338
-71
%
Net loss before provision for income tax
(707,621
)
(365,179
)
(342,442
)
94
%
Income tax expense (benefit)
-
-
-
0
%
Net loss and comprehensive loss
(707,621
)
(365,179
)
(342,442
)
94
%
Less: Net loss of TarMeta Biosciences,
    LLC prior to acquisition by Felicitex Therapeutics, Inc.
-
(70,148
)
70,148
-100
%
Net loss attributable to Felicitex
    Therapeutics, Inc.
$
(707,621
)
$
(295,031
)
$
(412,590
)
140
%
Revenues
To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future.
Research and Development
Expenses
Research and development
program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions. Our product
candidates are in various stages of development and significant additional expenditures will be required if we start clinical trials,
encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations and/or
bring our product candidates to market. The total cost of any particular clinical trial is dependent on a number of factors such as trial
design, length of the trial, number of clinical sites, number of patients and trial sponsorship. The process of obtaining and maintaining
regulatory approvals for new products is lengthy, expensive and uncertain. Because of the current stage of our product candidates, among
other factors, we are unable to reliably estimate the cost of completing our research and development programs or the timing for bringing
such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash
inflows are likely to commence.
Research and development
activities are central to our business model. We expect that our research and development expenses will continue to increase substantially
for the foreseeable future and will comprise a larger percentage of our total expenses.
The following table
sets forth the breakdown of research and development costs for each of our two segments for the years ending March 31, 2022 and 2021:
Three Months Ended March 31,
Variance
2022
%
2021
%
Amount
%
Felicitex Therapeutics, Inc.
$
164,935
100.00
%
$
78,165
58.40
%
$
86,770
111.01
%
TarMeta Biosciences, LLC
-
-
55,681
56.44
%
(55,681
)
100.00
%
$
164,935
100.00
%
$
133,846
100.00
%
$
31,089
23.23
%
Research and development
expenses for the two segments increased 23%, or $31,089, to $164,935 for the three months ended March 31, 2022 compared to $133,846 for
the same period of the prior year. This increase was primarily due to increases in compensation, pre-clinical studies, and materials.
60
General and Administrative
Expenses
The following table
sets forth the breakdown of general and administrative expenses for each of our two segments for the years ending March 31, 2022 and
2021:
Three Months Ended December 31,
Variance
2022
%
2021
%
Amount
%
Felicitex Therapeutics, Inc.
$
519,747
100.00
%
$
138,591
90.50
%
$
381,156
275.02
%
TarMeta Biosciences, LLC
-
-
14,467
9.45
%
(14,467
)
-100.00
%
$
519,747
100.00
%
$
153,058
100.00
%
$
366,689
239.57
%
General and administrative
expenses consist of compensation, professional fees, patent licensing fee and the cost of filing patent applications.
General and administrative
expenses for the two segments increased 239%, or $366,689 to $519,747 for the three months ended March 31, 2022 compared to approximately
$153,000 for the same period of the prior year. This increase was primarily due to increases in compensation expense and professional
fees for the filing of patents and conducting a financial statement audit.
Other Income and
Expense
Other income and expenses
decreased by approximately $55,000 primarily due to the inducement loss of $80,972 in the first quarter of 2021, which was partially
offset by interest expense of $23,000 in the first quarter of 2022.
Net Earnings and
Losses
Our net loss increased 140% from $295,031 for
the three months ended March 31, 2021 to net losses of $707,621 for the three months ended March 31, 2022. This increase was due
primarily to increases in both operating expenses and other expenses.
Comparison of Years Ended December 31, 2021 and 2020
The following table summarizes our results of
operations for the years ended December 31, 2021 and 2020:
Years Ended
    December 31,
Variance
2021
2020
Amount
%
Operating expenses:
Research and development
$
631,751
$
487,717
$
144,034
30
%
General and administrative expenses
777,940
648,550
129,390
20
%
Total operating expenses
1,409,691
1,136,267
273,424
24
%
Operating loss
(1,409,691
)
(1,136,267
)
(273,424
)
24
%
Other income (expense):
Interest income
182
45
137
304
%
PPP loan forgiveness
10,298
-
10,298
Other income
12,064
-
12,064
Interest expense
(44,007
)
(39,123
)
(4,884
)
12
%
Inducement loss
(151,497
)
(83,510
)
(67,987
)
81
%
Gain on change in fair value of warrant liability
(46,388
)
4,687
(51,075
)
-1090
%
Total other expense, net
(219,348
)
(117,901
)
(101,447
)
86
%
Net loss before provision for income tax
(1,629,039
)
(1,254,168
)
(374,871
)
30
%
Income tax expense (benefit)
-
-
-
0
%
Net loss and comprehensive loss
(1,629,039
)
(1,254,168
)
(374,871
)
30
%
Less: Net loss of TarMeta Biosciences,
    LLC prior to acquisition by Felicitex Therapeutics, Inc.
(277,526
)
(535,725
)
258,199
-48
%
Net loss attributable to Felicitex Therapeutics, Inc.
$
(1,351,513
)
$
(718,443
)
$
(633,070
)
88
%
Revenues
To date, we have not
generated any revenue from product sales and do not expect to generate any revenue from product sales in the foreseeable future.
Research and Development
Expenses
Research and development
program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions. Our product
candidates are in various stages of development and significant additional expenditures will be required if we start clinical trials,
encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations and/or
bring our product candidates to market. The total cost of any particular clinical trial is dependent on a number of factors such as trial
design, length of the trial, number of clinical sites, number of patients and trial sponsorship. The process of obtaining and maintaining
regulatory approvals for new products is lengthy, expensive and uncertain. Because of the current stage of our product candidates, among
other factors, we are unable to reliably estimate the cost of completing our research and development programs or the timing for bringing
such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash
inflows are likely to commence.
Research and development
activities are central to our business model. We expect that our research and development expenses will continue to increase substantially
for the foreseeable future and will comprise a larger percentage of our total expenses.
61
The following table
sets forth the breakdown of research and development costs for each of our two segments for the years ending December 31, 2021 and 2020:
Years ended December 31,
Variance
2021
%
2020
%
Amount
%
Felicitex Therapeutics, Inc.
$
402,382
63.69
%
$
212,440
43.56
%
$
189,942
89.41
%
TarMeta Biosciences, LLC
229,369
36.31
%
275,277
56.44
%
(45,908
)
-16.68
%
$
631,751
100.00
%
$
487,717
100.00
%
$
144,034
29.53
%
Research and development
expenses for Felicitex increased 89%, or $190,000, to $402,000 for the year ended December 31, 2021 compared to $212,000 for the year
ended December 31, 2020. This increase was primarily due to increases in compensation, pre-clinical studies, and materials.
Research and development
expenses for TarMeta decreased 17%, or $46,000, to $229,000 for the year ended December 31, 2021 compared to approximately $275,000 for
the year ended December 31, 2020. This decrease was primarily due to reduction in consulting fees.
General and Administrative
Expenses
The following table
sets forth the breakdown of general and administrative expenses for each of our two segments for the years ending December 31, 2021 and
2020:
Years ended December 31,
Variance
2021
%
2020
%
Amount
%
Felicitex Therapeutics, Inc.
$
717,720
92.26
%
$
398,022
61.37
%
$
319,698
80.32
%
TarMeta Biosciences, LLC
60,220
7.74
%
250,528
38.63
%
(190,308
)
-75.96
%
$
777,940
100.00
%
$
648,550
100.00
%
$
129,390
19.95
%
General and administrative
expenses consist of compensation, professional fees, patent licensing fee and the cost of filing patent applications.
General and administrative
expenses for Felicitex increased 80%, or $320,000, to $718,000 for the year ended December 31, 2021 compared to approximately $398,000
for the year ended December 31, 2020. This increase was primarily due to increases in compensation expense and professional fees for
the filing of patents and conducting a financial statement audit.
General and administrative
expenses for TarMeta decreased 76%, or $190,000, to $60,000 for the year ended December 31, 2021 compared to approximately $251,000 for
the year ended December 31, 2020. This decrease was primarily due to reduction in management fee and depreciation expense related to
equipment.
Other Income and
Expense
Other income and expense
consist of PPP loan forgiveness, other income from equipment rental, interest expense, inducement loss and loss on fair value of warrants.
Our other expenses increased $102,000 from approximately $118,000 in the year ended December 31, 2020 to $220,000 in the year ended December
31, 2021, or 105%. This increase was primarily due to inducement loss to convert debt into equity and loss on the change in fair value
of warrants. Our other income increased $22,000 from approximately $0 in the year ended December 31, 2020 to $22,000 in the year ended
December 31, 2021, or 500%. This increase/decrease was primarily due to forgiveness of PPP loan payable and increase in equipment rental
income.
62
Net Earnings and
Losses
Our net loss increased 30% from approximately
$1.3 million for the year ended December 31, 2020 to net losses of approximately $1.6M for the year ended December 31, 2021. This
increase/decrease was due primarily to increases in both operating expenses and other expenses.
Liquidity and Capital Resources
As of March 31, 2022, we had cash of $32,023.
To date, we have financed our operations primarily from loans and investments from our principal shareholder and Chairman, Mr. Marc Duey.
The Company is in the development stage and has
incurred losses and negative cash flows from operations. For the three months ended March 31, 2022 and 2021, the Company had a net loss
of approximately $700,000 and $300,000, respectively, and negative cash flows from operations of approximately $442,000 and $200,000,
respectively. Further, the Company had an accumulated deficit of $7,070,505 as of March 31, 2022, and $6,362,884 as of December 31, 2021.
Based on the current development plans for the Company's drug candidates and other operating requirements, existing cash and equivalents
are not sufficient to fund operations for the twelve months following the date of the registration statement of which this prospectus
is a part. We expect to incur losses over the next several years as we continue development of our technologies and product candidates,
manage our regulatory processes, initiate and continue clinical trials, and prepare for potential commercialization of products. To date,
we have been reliant on our Chairman, Marc Duey, and a small number of investors to finance our operations. From our inception through
March 31, 2022, we received funding of $5.0 million. This amount does not include a $200,000 grant received from the Massachusetts Life
Sciences Center in 2015.
Until we are successful in our efforts for capital
infusion, which is not entirely within our control, a substantial doubt exists about our ability to continue as a going concern for a
period of one year after the date of filing of these financial statements. In addition, the ability of our principal shareholder to continue
to provide financial support is dependent on our ability to secure additional funding. Management continues to address our liquidity
position and will adjust spending as needed in order to preserve liquidity. Our future liquidity needs will be determined primarily by
the success of our operations with respect to the progression of our product candidates and key development and regulatory events in
the future. Potential sources of additional funding include: (1) pursuing collaboration, out-licensing and/or partnering opportunities
for our portfolio programs and product candidates with one or more third parties, (2) renegotiating third party agreements, (3) securing
additional debt financing and/or (4) selling equity securities. There can be no assurances that we will be successful in these efforts.
We plan to raise additional capital from various
potential sources, including equity and/or debt financings, grant funding, and strategic relationships. In addition, we have an engagement
with the representative to sell up to $15 million of our common stock and common stock warrants in this initial public offering, which
amount, if fully raised, would be sufficient to fund our operations for approximately 24 months. However, there can be no guarantee that
we will be able to successfully complete this initial public offering or otherwise raise the necessary capital on terms acceptable to
us, if at all. Should such financings be unsuccessful, we would be required to delay, scale back or eliminate some or all of our research
and development programs, which would likely have a material adverse effect on us and our consolidated and combined financial statements.
Due to the above factors, a substantial doubt
exists as to our ability to continue as a going concern.
Loans to the Company
On January 16, 2018, Marc Duey, our Chairman,
agreed to lend up to $550,000 to the Company on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey's option at a price per share of $ 2.29. On March 17, 2020, we issued 238,612 shares
of our common stock on Mr. Duey's conversion of approximately $502,000 in principal and $45,000 of accrued interest on loans under
the January 16, 2018 agreement. Mr. Duey also received warrants to purchase 47,722 additional shares of common stock as an incentive
to convert these loans.
On March 31, 2020, Mr. Duey entered into an additional
on-demand agreement to lend us up to $550,000 on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey's option at a price per share of $2.29. On March 17, 2021, we issued 232,473 shares
of common stock to Mr. Duey on conversion of $521,000 in principal and $27,823 of accrued interest on loans under the March 31, 2020
agreement. Additionally, the Company issued warrants that are exercisable into 46,495 shares of common stock within five years at an
exercise price of $2.36 per share as an incentive to convert these loans.
On March 31, 2021, Mr. Duey entered into an additional
on-demand agreement to lend us up to $550,000 on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey's option at a price per share of $2.29. On November 2, 2021, we issued 147,586 shares
of our common stock to Mr. Duey on conversion of $348,420 in principal on loans under the March 31, 2021 agreement. Additionally, the
Company issued warrants that are exercisable into 29,518 shares of common stock within five years at an exercise price of $2.36 per share
as an incentive to convert these loans.
On March 15, 2022, the total liability owed to
our Chairman, Marc Duey, for loans Mr. Duey made to us was $541,180 in principle plus $54,564 in accrued interest.  On March 16,
2022, our board of directors authorized the conversion of the combined liability in the amount of $595,744 into 192,977 shares of
our common stock, effective as of March 16, 2022.  The conversion price valuation was determined using an independent 409A
valuation. The Company has also entered into a convertible grid note with the Chairman with respect to additional advances that the Chairman
expects to make to the Company for general working capital purposes from now until additional funds are raised from investors. This grid
note carries interest at 12% per year, payable in one lump sum on the maturity date, matures on the one-year anniversary of the issuance
date and may be prepaid at any time, in whole or in part, without penalty. It may also be converted at any time, in the sum of any advances
and accrued interest at a price per share of $3.09.
As of March 31, 2022, Mr. Duey had loaned to
us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has loaned to us an additional $408,000 under the grid note.
63
During the year ended December 31, 2020, we received
loan proceeds in the amount of approximately $10 thousand under the Paycheck Protection Program, or PPP, which was established as part
of the Coronavirus Aid, Relief and Economic Security Act administered through the Small Business Administration, or SBA. The PPP provides
loans to qualifying businesses in amounts up to 2.5 times their average monthly payroll expenses and was designed to provide a direct
financial incentive for qualifying businesses to keep their workforce employed during the Coronavirus crisis. PPP loans are uncollateralized
and guaranteed by the SBA and are forgivable after a "covered period" (eight or twenty-four weeks) as long as the borrower
maintains its payroll levels and uses the loan proceeds for eligible expenses, including payroll, benefits, mortgage interest, rent and
utilities. The forgiveness amount will be reduced if the borrower terminates employees or reduces salaries and wages more than 25% during
the covered period. Any unforgiven portion is payable over two years if issued before, or 5 years if issued after, June 5, 2020 at an
interest rate of 1% with payments deferred until the SBA remits the borrower's loan forgiveness amount to the lender, or, if the
borrower does not apply for forgiveness, ten months after the end of the covered period. PPP loan terms provide for customary events
of default, including payment defaults, breaches of representations and warranties, and insolvency events and may be accelerated upon
the occurrence of one or more of these events of default. Additionally, PPP loan terms do not include prepayment penalties.
We used all proceeds for purposes consistent
with the PPP requirements and met the conditions for forgiveness of the loan. On February 24, 2021, our loan was forgiven in full.
Summary of Cash Flow
The following table provides detailed information
about our net cash flow for all financial statement periods presented in this prospectus:
Cash Flow
Three Months Ended
March 31,
2022
2021
Net cash flows used in operating activities
$
(441,563
)
$
(184,102
)
Net cash flows used in investing activities
-
-
Net cash flows provided by financing activities
463,224
154,643
Net change in cash
21,661
(29,459
)
Cash, beginning of period
10,362
38,355
Cash, end of period
32,023
8,896
Years Ended
    December 31,
2021
2020
Net cash flows used in operating activities
$
(888,237
)
$
(978,481
)
Net cash flows used in investing activities
-
(957
)
Net cash flows provided by financing activities
860,245
1,010,267
Net change in cash
(27,993
)
30,829
Cash, beginning of year
38,355
7,526
Cash, end of year
10,362
38,355
Net cash used in operating activities was approximately
$442,000 for the three months ended March 31, 2022, as compared to net cash used in operating activities of $184,000 for the three months
ended March 31, 2021 which represents an approximate $257,000 increase in net cash used in operating activities including preparation
for the company's initial public offering.
Net cash used in operating activities was approximately
$888,000 for the year ended December 31, 2021, as compared to net cash used in operating activities of $978,000 for the year ended December
31, 2021 which represents an approximate $90,000 decrease in net cash used in operating activities which resulted from an increase
in accounts payable during the period.
No cash was used investing activities for the
three months ended March 31, 2022 and 2021 respectively.
Net cash used in investing activities was approximately
$0 and $1,000 for the years ended December 31, 2021 and 2020 respectively.
Net cash provided by financing activities was
approximately $463,000 and $154,000 for the three months ended March 31, 2022 and 2021 respectively. For both these periods, net cash
provided by financing activities primarily consisted of loans made by our principal investor and chairman which were substantially converted
subsequently into common stock plus warrants.
Net cash provided by financing activities was
approximately $860,000 and $1 million for the years ended December 31, 2021 and 2020, respectively. For both the years ended December
31, 2021 and 2020, net cash provided by financing activities consisted of loans made by our principal investor and chairman which were
substantially converted subsequently into common stock plus warrants.
Contractual Obligations
On December 31, 2018, the Company entered
into an exclusive license Agreement with Ryvu Therapeutics S.A. (formerly "Selvita S.A."), a Polish corporation for sole
responsibility and discretion of developing and commercializing certain compounds and products. The milestone payments to be paid to
Ryvu under the agreement were amended by agreement dated April 16, 2019.
Under the terms of the agreement, the Company
is obligated to make certain milestone and royalty payments to Ryvu. There were no royalty or milestone payments made to Ryvu during
the three months ended March 31, 2022 and 2021, or the years ended December 31, 2021 and 2020.
64
On May 5, 2014, the Company entered into a collaboration
and license agreement with Eurobio Scientific SA (formerly "Diaxonhit"), a French company, for the development and commercialization
of certain compounds developed and owned by Eurobio. The terms were amended by agreement on July 23, 2014 and on February 14, 2022. Under
the agreement, the Company must pay Eurobio an annual license fee for a certain number of years, certain milestone payments, and certain
royalties and sub-license payments on net sales of licensed compounds.
There were no royalty or sub-license payments
made to Eurobio during the three month periods ended March 31, 2022 and 2021 and the years ended December 31, 2021 and 2020.
Off-Balance
Sheet Arrangements
We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Critical
Accounting Policies
The
following discussion relates to critical accounting policies for our company. The preparation of financial statements in conformity with
GAAP requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto,
and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant
to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition
and results of operation. Critical accounting policies are those that are most important to the portrayal of our financial condition
and results of operations and require management's difficult, subjective, or complex judgment, often as a result of the need to
make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates
are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting
the estimate may differ significantly from management's current judgments. We believe the following critical accounting policies
involve the most significant estimates and judgments used in the preparation of our financial statements:
Use
of Estimates
The preparation of consolidated and combined
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the consolidated and combined financial
statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors
including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic
conditions and trends and the assessment of the probable future outcome. Subjective and significant estimates include, but are not limited
to, the valuation of stock-based compensation, the valuation of warrant liability, expense recognition and accruals associated with
third party providers supporting pre-clinical studies and other research and development, and income tax asset realization. Actual results
could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of changes, if any, are reflected
in the consolidated and combined statements of operations in the period that they are determined.
Collaborative
Arrangements
The
Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope
of FASB ASC Topic 808,
Collaborative Arrangements
("ASC 808"). For collaborative arrangements that contain multiple
elements, the Company determines which units of account are deemed to be within the scope of ASC 808 and which units of account are more
reflective of a vendor-customer relationship, and therefore are within the scope of ASC 606. For units of account that are accounted
for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting
literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of ASC 808,
the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated
with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are
the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities,
are recorded as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate. Milestone
payments are considered contingent liabilities and are recognized when the Company deems the milestone event to be probable.
65
Fair
Value Measurements
FASB
ASC Topic 820,
Fair Value Measurements and Disclosures
, defines fair value, establishes a framework for measuring fair value,
and expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair
value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that
market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.
Unobservable
inputs reflect the Company's assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:
●
Level
                                            1 - Valuations based on quoted prices for identical instruments in active markets.
                                            Since valuations are based on quoted prices that are readily and regularly available in an
                                            active market, valuation of these instruments does not entail a significant degree of judgment.
●
Level
                                            2 - Valuations based on observable inputs other than quoted prices included in Level
                                            1, such as quoted prices for either similar instruments in active markets, identical or similar
                                            instruments in markets that are not active, or model-derived valuations whose inputs or significant
                                            value drivers are observable or can be corroborated by observable market data.
●
Level
                                            3 - Valuations based on inputs that are unobservable. These valuations require significant
                                            judgment.
The
availability of valuation techniques and observable inputs can vary and is affected by a wide variety of factors, including the type
of asset or liability, whether the asset or liability is new and not yet established in the marketplace, and other characteristics particular
to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market,
the determination of fair value requires more judgment. Those estimated values do not necessarily represent the amounts that may be ultimately
realized due to the occurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of valuations,
those estimated values may be materially higher or lower than the values that would have been used had a ready market for the assets
or liabilities existed.
Research
and Development
Costs
and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC
730-10. Research and development costs are charged to expense as incurred and include the cost of wages, equipment, materials, and laboratory
fees paid in conducting scientific research on potential drug candidates.
Stock-Based
Compensation
The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of FASB ASC Topic 718
,
Compensation - Stock Based Compensation
. The Company expenses stock-based compensation to employees and non-employees over the requisite
service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of options granted using
the Black Scholes Merton model. The Company estimates when and if performance-based awards will be earned. If an award is not considered
probable of being earned, no amount of equity-based compensation expense is recognized. If the award is deemed probable of being earned,
related equity-based compensation expense is recorded. The fair value of an award ultimately expected to vest is recognized as an expense,
net of forfeitures, over the requisite service, which is generally the vesting period of the award. Options forfeitures are recorded
as they occur.
The
Black Scholes Merton model requires the input of certain subjective assumptions and the application of judgment in determining the fair
value of the awards. The most significant assumptions and judgments include the following:
●
Expected
                                            volatility - The expected price volatility is based on the historical volatilities
                                            of peer group companies as the Company does not have a sufficient trading history. Industry
                                            peers consist of several public companies in the bio-tech industry similar in size, stage
                                            of life cycle, and capital structure. The Company also blends in historical data on the volatility
                                            of its own equity, increasing in proportion as the period of historical data on the Company's
                                            data becomes more representative.
●
Risk-free
                                            interest rate - The risk-free rate was determined based on yields of U.S. Treasury
                                            Bonds of comparable terms.
●
Expected
                                            dividend yield - The Company has not previously issued dividends and do not anticipate
                                            paying dividends in the foreseeable future. Therefore, we used a dividend rate of zero based
                                            on our expectation of additional dividends.
●
Expected
                                            term -The expected term of the options was estimated using the simplified method.
Common
shares issued to third parties for services provided are valued at fair value of the Company's shares.
66
Warrant
Liability
Warrants are accounted for
in accordance with the guidance contained in ASC 815-40-15-7D and 7F, under which the warrants do not meet the criteria for equity treatment
and must be recorded as liabilities. Accordingly, the Company classifies warrants as liabilities at their fair value and adjusts the
warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised,
and any change in fair value is recognized in the consolidated and combined statement of operations and comprehensive loss. The warrants
are valued using a Black Scholes model.
Recently
Adopted Accounting Pronouncements
In November 2018, the FASB issued Accounting
Standard Update ("ASU") No. 2018-18,
Collaborative Arrangements (Topic 808)
("ASU No. 2018-18"). This
update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including
the alignment of unit of account guidance between the two topics. The Company early adopted ASU No. 2018-18 as of January 1, 2020. The
adoption of this update did not have a material effect on the Company's consolidated and combined financial statements, as there
were no collaborative arrangements that had identified performance obligations to customers.
In May 2021, the FASB issued ASU 2021-04,
Earnings
Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives
and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges
of Freestanding Equity-Classified Written Call Options
("ASU 2021-04"). The amendments in ASU 2021-04 provide guidance
to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written
call options (for example, warrants) that remain equity classified after modification or exchange. The update is effective for all entities
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company does not believe
that the adoption of ASU No. 2021-04 has had a material effect on its consolidated and combined financial statements.
In May 2021, the FASB issued ASU 2021-04,
Earnings
Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives
and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges
of Freestanding Equity-Classified Written Call Options
("ASU 2021-04"). The amendments in ASU 2021-04 provide guidance
to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written
call options (for example, warrants) that remain equity classified after modification or exchange. The update is effective for all entities
for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has adopted the
amendment which did not have a material effect on its consolidated and combined financial statements.
In August 2020, the FASB issued ASU No. 2020-06,
Debt - Debt with Conversion and Other Options
(Subtopic 470-20) and
Derivatives and Hedging - Contracts in Entity's
Own Equity
(Subtopic 815-40) ("ASU No. 2020-06"). ASU No. 2020-06 was issued to address issues identified as a result
of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics
of liabilities and equity. For convertible instruments, the FASB decided to reduce the number of accounting models for convertible debt
instruments and convertible preferred stock. In addition to eliminating certain accounting models, the FASB also decided to enhance information
transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. This update
is effective for public business entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal
year. For all other entities, this update is effective for fiscal years beginning after December 15, 2023, and interim periods within
those fiscal years. The Company adopted ASU No. 2021-04 which did not have a material effect on its consolidated and combined financial
statements.
Recent
Accounting Pronouncements Not Yet Adopted
In February 2016, the FASB issued ASU No. 2016-02,
Leases (Topic 842) as subsequently amended
("ASU No. 2016-02"). ASU No. 2016-02 was issued to increase transparency
and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information
about leasing arrangements. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including
interim periods within those fiscal years, for public business entities, not-for-profit entities that has issued securities that are
traded, listed or quoted on an exchange or an over-the-counter market, and employee benefit plans that file financial statements with
the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2021, and
interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that the adoption of ASU No. 2021-04
will have a material effect on its consolidated and combined financial statements.
In December 2019, the FASB issued ASU 2019-12,
Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
("ASU 2019-12"), as part as part of its overall
simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness
of the information provided to users of financial statements. Amendments include removal of certain exceptions to the general principles
of ASC 740 and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based
on income. The update is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and
interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that the adoption of ASU No. 2021-04
will have a material effect on its consolidated and combined financial statements.
67
BUSINESS
Our
Mission
Developing
novel treatments for dormant cancers: targeting cancer resistance, metastasis, and relapse.
Overview
We
are a preclinical oncology drug development company focused on developing treatments that target both dormant and proliferating cancers
to improve treatment effectiveness and long-term outcomes for the deadliest and most therapy resistant liquid and solid tumors - hematopoietic,
ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.
We have designed and patented small molecules
and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. This
approach is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal
of acquired resistance mechanisms. Our drug candidates are intended to be effective across a broad range of solid tumors and hematological
cancers. We target a high unmet need in large oncology markets for liquid and solid tumors including, but not limited to, non-small cell
lung cancer, or NSCLC, glioblastoma multiforme, or GBM, ovarian, prostate, colorectal, pancreatic cancers, and acute lymphoblastic leukemia,
or ALL.
We
                                            have established a drug discovery platform that, we expect, will enable the expansion of
                                            our product candidate pipeline, via simultaneous identification of novel targets and corresponding
                                            specific small molecule inhibitors, in a way that is faster than through other currently
                                            available methodologies. We have a strong IP position that is continuously growing. We have
                                            a cost-effective development strategy drawing on a network of top-notch U.S.-based and international
                                            collaborators, each a recognized leader in their respective areas of expertise.
Developing
Novel Treatments for Dormant Cancers - Targeting Resistance, Metastasis, and Relapse
As an oncology drug development company, we are
at the forefront of one of the most promising areas - dormant cancers. These cancers are responsible for resistance,
metastasis, and recurrence. We are developing treatments that target both dormant and proliferating cancers and seek to improve the effectiveness
and long-term outcomes of treatments for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic,
colorectal, osteosarcoma, glioblastoma, and lung.
It
is well established that most tumors are heterogeneous. While some of the cancer cells divide rapidly others do not. They are
staying in the dormant state using this as a survival niche (or microanatomical structure in which dormant cancer cells are maintained
and protected from therapy). This is especially true of solid tumors in which the cells in the outer layers are proliferating, but
the inner volume comprises a large proportion of dormant cells, frequently as a result of inadequate nutrient supply and oxygen
deprivation (hypoxia). Hypoxic regions have long been known to be resistant to chemotherapy and radiation treatment. Tumor hypoxia,
as a target for chemotherapy, is currently an active area of research.
Moreover,
when cancer cells are under stress from either chemotherapy, anti-angiogenesis therapy, specific targeted treatment, or radiation, cancer
cells often go into dormant state, or G0, using it as a niche to hide. After the completion of treatment, these cells can mutate
and acquire resistance to the current treatment, begin growing and cause cancer recurrence. This process is called pharmacological quiescence.
Cancer
cell dormancy is a major and as yet unaddressed mechanism of cancer survival and resistance. Until recently, the research efforts
have been focused on combating the inherently resistant cancer cells and the acquired resistance, which develops over time on exposure
to chemotherapeutics.
68
Felicitex
is developing new therapies that specifically target and kill cancer cells that use the dormancy state for their survival niche. Our
therapies are designed to target cancer cells that are either in the active growing or dormant states. While in the dormant state,
cancer cells are non-responsive to any existing treatments. Our treatment approach is designed to exhibit three therapeutically beneficial
outcomes:
●
first,
                                            kill dormant cancer cells depriving them of the ability to remain in their "survival
                                            niche" and thereby eliminating their ability to develop resistant phenotype;
●
second,
                                            decrease their metastatic potential; and
●
third,
                                            eliminate cancer recurrence.
Cellular
dormancy is a resting or "sleeping" state, denoted as the G0 state of the cell cycle. While being dormant, a cell
is in a reversible low metabolic state. As a consequence, both transcription and translation processes are slowed down and, therefore,
these cells are resistant to treatments by chemotherapeutics and targeted therapies, as well as immunotherapies.
A
challenge for durable cancer treatment is the extreme mechanistic diversity and adaptive capacity of tumors within and among cancer patients.
For any given drug, the benefit is increasingly limited by the subtype of disease and by the rapid emergence of drug resistance. Our
goal is to deliver a broadly active and durable therapy by targeting vulnerabilities in dormant cancer cells. The therapeutic strategy
is to use our molecules alone or in combinations with either marketed or clinical stage drugs, each combination representing a potential
opportunity for partnering or licensing. The goal is to increase the patient response rate, quality of life and overall survival rate
toward 100% and minimize the side effects and cost of treatments by reducing the overall amount of drug required and sequential rounds
of treatments.
Our current internal pipeline
development activities are focused on the small molecules inhibitors of the dual specificity protein kinase, or DYRK, family of kinases.
Our molecules pre-clinically have shown a high level of synergy in combination with a spectrum of approved oncology therapeutics, including
drugs with significant patent protection (such as epidermal growth factor receptor inhibitors, or EGFR, inhibitors, Kirsten rat sarcoma
virus, or KRAS, inhibitors, mitogen-activated protein kinase, or MEK, inhibitors, and polo-like kinase 1, or PLK1, inhibitors), and drugs
with expiring patent protection, specifically the taxane family and vinca alkaloids.
Our mechanism of action is unique. Our molecules
inhibit the activity of DYRK1 kinase and, therefore, deprive cancer cells of the ability to enter and stay in "sleeping"
or G0 state. Acquired resistance is a major issue for targeted therapies (mutant KRAS, MEK, EGFR inhibitors) including immuno-oncology
agents, and such resistance is being developed while cancer cells stay in G0 (dormancy) state. DYRK1 kinase maintains the ability of
cancer cells to stay in dormant, G0 state and this is a key driver of developing acquired resistance. Accordingly, we are developing
small molecule inhibitors specific and selective for DYRK1 kinase. Our FX-1610, FX-7742, and FX-9847 product candidates inhibit tumor
growth and metastasis in animal models.
TarMeta
Biosciences' Drug Development Platform - Combining Target With Phenotypic-Based Drug Discovery
Through
our collaboration with TarMeta Biosciences, LLC, which we subsequently acquired in December 2021, we have been utilizing TarMeta's
drug discovery platform technology for the identification of target-specific small molecules for difficult to treat cancers.
TarMeta's high throughput platform is based
on a combination of
an
affinity
selection mass spectrometry screening technique, a phenotypic based drug discovery technique, and a
cellular thermal shift
assay (CETSA)
. This unique combination
offers an approach to the drug discovery process
that is geared towards efficient and cost-effective pre-clinical drug development.
TarMeta's drug discovery platform allows
not only for the assessment and quantification of target engagement under physiological conditions - without the need to modify
the compound or protein, but also for the investigation of a molecule's direct effects in a physiologic environment, providing
important information about the complex biological mechanisms that may be impacted upon treatment.
69
Improving
R&D productivity is among the greatest issues faced by the pharmaceutical industry. The ability to reduce the attrition rate of drug
candidates in clinical development not only addresses one of the greatest challenges in the pharmaceutical industry but also the greatest
opportunity. Given the extremely high costs of clinical development, an efficient and economical strategy for drug discovery would involve
a process that has the ability to reduce late-stage development failures. In addition, any cost-effective approach that could predict
toxicological liability or undesirable pharmacokinetic properties pre-clinically will also reduce downstream attrition.
Target-Based
Drug Discovery
In
target-based drug discovery, the goal is to identify molecules that interact with a specific drug target known to be involved in a disease
process. This is typically done with high throughput screening, or HTS, which allows for the automated screening of large compound libraries
to determine if any molecules in the library bind the target of interest.
This "hit" molecule would then undergo
modification through medicinal chemistry which requires extensive time and resources in an effort to optimize the potency, selectivity,
and solubility properties of the compound.
A
significant limitation of target-based approaches is that certain chemical properties critical to the development of a new drug can't
be assessed by compound library screening. For example, HTS cannot evaluate cytotoxicity, mechanisms of action, or solubility.
Phenotypic
Based Drug Discovery
Phenotypic
Based Drug Discovery is a more direct translational model of disease pathophysiology and is used to identify molecules that have the
ability to alter a cell's phenotype in a pre-specified manner, such as a specific mechanism of action of identified small molecules
culminating in cancer cell death.
In
contrast to target-based drug discovery, phenotypic screening does not rely on knowing the identity of the specific drug target or its
hypothetical role in the disease. This method allows for the investigation of a molecule's effects in a physiologic environment
and provides important information about the complex biological mechanisms that may be impacted upon treatment, thus allowing for elucidation
of a drug's mechanism of action.
Increasing
the understanding of cell signaling pathways affected by a drug could potentially decrease the number of clinical failures by identifying
factors contributing to unexpected activity, toxicities, and lack of efficacy.
While
offering a robust methodology for identification of novel targets in a physiologic environment, the identification of a specific target,
i.e., the target deconvolution process, is considered to be a major limitation in the phenotypic based approach as it requires a "reverse
engineering" approach to identify the affected pathway and kinase target that can deliver false - positive results.
Felicitex's
and TarMeta's Combined Approach for Drug Discovery
TarMeta's novel, proprietary drug discovery
platform is able to generate high-quality drug candidates which are not only validated against specific therapeutic targets of high clinical
and commercial interest but also demonstrate mechanisms of action.
This coordinated platform combines a target,
phenotypic, and CETSA based approach in a cellular context to the drug discovery process, which offers distinct advantages to any of
these methods alone by providing information about the physicochemical, biochemical, and mechanistic properties of a molecule (solubility,
stability, cell permeability, mode of action).
TarMeta's platform methodology provides
the opportunity to advance drug discovery for Felicitex more quickly and efficiently with less upfront investment in medicinal chemistry
resources.
Using
this platform, we and TarMeta have identified to date eight small molecules (composed of two unique scaffolds) which have demonstrated
significant anti-tumor activity in non-small cell lung cancer. The molecules of interest are currently undergoing further testing by
Felicitex in additional cell-based assays. The acquisition of TarMeta by Felicitex Therapeutics permits Felicitex to pursue commercialization
of any discovered assets in a fashion that is not encumbered by licensing obligations including one-time payments and milestone payments.
70
Acquisition of TarMeta Biosciences,
LLC and its Proprietary Drug Discovery Platform
We closed our acquisition of TarMeta Biosciences,
LLC on December 30, 2021. Upon closing this acquisition, we acquired all of the intellectual property owned by TarMeta and all rights
of TarMeta in and to all third-party intellectual property. Through this acquisition, the proprietary platform developed by TarMeta enables
us to potentially identify novel cancer dormancy targets and, at the same time, identify and develop small molecule inhibitors that,
we believe, are potent and selective.
Our
Product Pipeline
We
have a pipeline of therapeutic compounds focused primarily on oncology indications of high unmet medical need. The following chart summarizes
the status of the drug candidates in our current pipeline:
Notes:
1. The column heading "Preclinical" refers to the Pre-IND enabling studies phase.
2.
FX 7742 and FX-9847 are both being developed for solid tumor indications including NSCLC and colorectal cancer.
●
FX-1610
,
                                            a small molecule inhibitor of DYRK1A and DYRK1B kinases (not orally bioavailable), is our
                                            compound in development for pediatric leukemia - Acute Lymphoblastic Leukemia (ALL), an orphan
                                            drug indication of high unmet medical need. We expect to file an Investigational New Drug,
                                            or IND, application for FX-1610 during the first half of 2023.
●
FX-7742
is our orally bioavailable compound being developed for solid tumor indications including
                                            NSCLC and colorectal cancer with mutations in EGFR (such as T790M) and KRAS (such as G12C).
                                            We are targeting an IND submission for FX-7742 for NSCLC and/or other solid tumors with EGFR
                                            and KRAS mutations in the first half of 2023.
●
FX-9847
                                            is
our non-orally available small molecule compound being developed for solid tumor indications
                                            as a back-up to FX-7742, if FX-7742 fails safety testing. We expect to file an IND for FX-9847
                                            in the second half of 2023, if we replace FX-7742 with FX-9847, or otherwise in the first
                                            half of 2024 assuming the required funds are available for this IND at that time.
We are currently developing the chemistry,
manufacturing and control (CMC) and formulation and qualifying the safety profiles of FX-1610, FX-7742 and FX-9847 to comply with current
regulatory requirements. We are undertaking the characterization and validation of these product candidates prior to entering non-human
primate (NHP) preclinical toxicology studies for further refining safety, formulation, dosing and scheduling regimen parameters in advance
of a Phase 1b/2a trials in humans. Assuming completion of the work described immediately above and following the completion of pre-IND
enabling studies which we would undertake assuming the successful completion of this offering (which we cannot guarantee), we expect
to file INDs for FX-1610 and FX-7742 in the first half of 2023. If we need to substitute FX-9847 for FX-7742, if FX-7742 fails safety
studies, we would expect to be ready to file an IND for FX-9847 in the fourth quarter of 2023.
71
In addition, we
are working to expand our pipeline through the identification and development of new dormancy targets.
Our
Drug Development Timetable
We
plan to initiate IND enabling studies in the second quarter of 2022 with our two advanced drug candidates which are still in preclinical
development, FX-1610 and FX-7742, each of which has demonstrated significant anti-cancer efficacy in animal models with no toxicity.
Initial target indications for these candidates include ALL, NSCLC (EGFR and KRAS mutations).
Our first-in-human
clinical trials (for FX-1610) are expected in the second quarter of 2023. We are executing our development strategy as rapidly and cost-effectively
as we can, drawing on a network of top-notch U.S.-based and international collaborators, each a recognized leader in their respective
areas of expertise. Current indications include liquid (e.g., ALL) and solid tumors such as non-small cell lung focusing on EGFR and
KRAS mutants. We plan to advance an additional program targeting solid tumors with our molecule FX-9847, in case FX-7742 fails further
safety studies and a back-up becomes necessary for that product candidate. We retain full, worldwide rights to our most advanced programs.
Our
Technology
We
have expertise in targeting cancer pro-survival mechanisms and our drugs are synergistic with chemotherapy and targeted therapies.
The example of
the synergistic mechanism of action of DYRK1 inhibitors when combined with G12C mutant KRAS targeted inhibitors is illustrated as follows:
Results of our
animal preclinical efficacy study of our product candidate FX-1610 with respect to the treatment of Acute Lymphoblastic Leukemia is discussed
immediately below.
72
Figure 1: FX-1610 was demonstrated to have efficacy
in B-ALL mice model (NSG mice with human B-ALL cells). Animals were treated with 40 mg/kg/day FX-1610, IP, for 2 weeks (yellow boxes).
Kaplan-Meier analysis of mice treated with FX-1610 was performed. Data were statistically significant as determined by log-rank
(Mantel-Cox) test
P
< 0.01. Treatment of B-ALL with FX-1610 was well tolerated and had on-target effects in vivo.
100% survival of mice was observed 80 days after
termination of the treatment with our molecule FX-1610.
Additional descriptions of animal efficacy studies
conducted to demonstrate the efficacy of FX-7742 in synergy with KRAS G12C inhibitors are provided in the figure below.
FX-7742 / NSCLC KRAS G12C
Figure 2: To demonstrate efficacious combination
of FX-7742 and KRAS G12C inhibitor
in vivo
, xenograft H2122 model was performed. Mice were treated with daily oral dosing 20 mg/kg
FX-7742, AMG510, oral dosing 10mg/kg, combination of FX-7742 and AMG510 (KRAS G12C inhibitor) or vehicle solution the day after tumors
reached 200 mm
3
. AMG510 is a specific G12C KRAS inhibitor approved for lung cancer treatment. Importantly, there was clear
evidence of synergistic effect of the combination on the tumor growth compared to either agent alone. The results were statistically
significant, calculated P-values, P<0.001. No toxicity was observed.
73
Additional descriptions of animal efficacy studies
conducted to demonstrate the efficacy of FX-9847 in synergy with T790M EFGR inhibitors are provided in the figure below.
FX-9847 /
NSCLC
EGFR T790M
Figure 3: In vivo efficacy of combination therapy
of FX-9847 and osimertinib (Tagrisso) in NSCLC H1975 xenograft model: (1) vehicle control (black line); (2) FX-9847 100 mg/kg IP BID (green
line); (3) Osimertinib IV, 2.5 mg/kg BIW (blue line); (4) FX-9847 100 mg/kg IP and Osimertinib 2.5 mg/kg IV (red line); tumors initial
volume was 200 mm
3
, n=10. Treatment continued for 3 weeks; no weight loss was observed. From day 21 to day 34 mice were monitored
for tumor re-growth.
Figure 3: A proof of concept, animal efficacy
experiment in NSCLC EGFR T790M mice xenograft model (H1975) was performed. The goal was to demonstrate the efficacy of the combination
therapy of osimertinib (Tagrisso) and FX-9847. The treatment resulted not only in significantly improved anti-tumor efficacy compared
with osimertinib monotherapy and complete disappearance of the tumors but also 12 days delays in tumor re-growth (
Figure 3
). Animals
were separated into 4 groups, 10 in each and were treated with either vehicle, FX-9847, osimertinib, or the combinations of osimertinib
and FX-9847. Animals were dosed for 21 days. On day 22, the treatment was stopped and tumors were continuously monitored for the following
12 days until the tumor size limit of 2000 mm
3
was reached and mice were sacrificed. Strikingly, there was a significant reduction
on the rate of tumor re-growth in the group treated with the combination of osimertinib and FX-9847. Only after 12 days tumors started
to increase in size indicating the significant reduction of the dormant cancer cell population as a consequence of the combination treatment.
The results were statistically significant, calculated P-values. No toxicity was observed.
In this preclinical animal study, we demonstrated
the eradication of the resistant dormant population of cancer cells via treatment with FX-9847.
Additional descriptions of animal efficacy studies
conducted to demonstrate the efficacy of FX-9847 in synergy with KRAS G12C inhibitors are provided in the figure below.
FX-9847 / NSCLC KRAS G12C
Figure 4: In vivo efficacy of combination therapy
of FX-9847 and AZD8037 in PDX NSCLC xenograft model: (1) vehicle control (red line); (2) FX-9847 100 mg/kg IP BID (grey line); (3) AZD8037
(blue line); (4) FX-9847 100 mg/kg IP and AZD8037 (green line); tumors initial volume was 200 mm
3
, n=10.
Figure 4: To demonstrate efficacious combination
of FX-9847 and KRAS G12C inhibitor
in vivo
, xenograft H358 model was performed. Mice were treated with daily intraperitoneal injections
of 80 mg/kg FX-9847, AZD8037 (KRAS G12C inhibitor), combination of FX-9847 and AZD8037 or PBS the day after tumors reached 200 mm
3
,
n=10. Importantly, there was clear evidence of synergistic effect of the combination on the tumor growth compared to either agent alone.
The results of this animal study were statistically significant, calculated P-values, P<0.01. No toxicity was observed.
74
An example of the single agent efficacy of FX-9847
in vivo
is demonstrated below, illustrating almost complete elimination of metastasis in prostate cancer model.
Figure 5: Demonstration of the efficacy of FX-9847 in reducing primary
and metastatic cancer growth and increasing overall survival in multiple animal models. Treatment with FX-9847 prevented metastasis in
70% of mice compared with the control. The data were statistically significant, n=12, P<0.001.
Competitive
Strengths
We
believe that we can be a leader in the discovery, development, and commercialization of cancer dormancy targeted drugs due to the following
key strengths:
●
Therapies
                                            targeting dormant cancer cells
.
Our patented small molecules and related methods
                                            selectively disrupt cancer cells in the dormant state in a manner that is specific to the
                                            disease and tissue context. Our drug candidates are intended to be effective across a broad
                                            range of solid tumors and hematological cancers. We believe we can develop multiple profitable
                                            therapies based on the significant demand for such treatments.
●
Cost-effective
                                            and professional research, development and manufacturing strategy
. We have a network
                                            of top-notch U.S.-based and international collaborators, each a recognized leader in their
                                            respective areas of expertise. With our network, we are reducing the initial costs and accelerating
                                            the timeline toward the development and deployment of medical breakthrough therapies.
●
Seasoned
                                            and accomplished management
. Our management team members are leaders in drug discovery.
                                            Our officers have led drug discovery programs at Hoffman-La Roche and Memorial Sloan Kettering
                                            Cancer Center, authored 20 publications in peer reviewed journals, obtained several patents,
                                            have many years of pharmaceutical industry experience, and have experience collaborating
                                            with a broad array of biopharmaceutical companies. We also have more than two decades of
                                            business management experience in the pharmaceutical and biotechnology fields. Our board
                                            of directors includes the Head of Developmental Therapeutics at Memorial Sloan-Kettering
                                            Cancer Center and Professor of Pharmacology, Cell Biology and Medicine at Cornell University
                                            Medical School, and all of our directors have more than 20 years of experience in the biotechnology/pharmaceutical
                                            industries. Our officers and directors have advanced medical and business degrees from leading
                                            world universities.
Growth
Strategies
Our
                                            mission is to rapidly advance our drug candidate pipeline and leverage our therapeutic platform
                                            to become a leader in the discovery, development, and commercialization of cancer dormancy
                                            targeted drugs. We intend to seek approval of our product candidates as first line cancer
                                            therapies to be used in combination with other first line cancer therapy drugs. The strategies
                                            of the Company to achieve this mission, while increasing value for our shareholders, will
                                            include the following steps:
●
Execute
                                            DYRK program advancement.
Preparation is underway to submit an Investigational New
                                            Drug application, or IND, for FX-1610, for ALL indications, followed by FX-7742, for solid
                                            tumor oncology indications, both in 2023. If FX-7742 fails safety studies, we intend to substitute
                                            FX-7742 with FX-9847, an advanced small molecule compound being developed for solid tumors
                                            indications although not orally bioavailable.
●
Implement
                                            accelerated breakthrough therapy regulatory strategy
. We believe that our assets
                                            are differentiated and represent potential breakthroughs in biopharmaceutical drug development.
                                            We will endeavor to seek breakthrough therapy designation (discussed below) with regulatory
                                            agencies, which could potentially lead to accelerated clinical development timelines. In
                                            addition, we will be seeking orphan drug indication for our FX-1610 drug candidate for pediatric
                                            leukemia - Acute Lymphoblastic Leukemia, which is identified as an orphan disease by the
                                            FDA.
75
●
Pursue
                                            pipeline licensing opportunities
. We are pursuing opportunities with leading biopharmaceutical
                                            companies for the development and commercialization of our pipeline assets.
●
Leverage
                                            research, collaboration and IP licensing agreements with leading institutions
. We
                                            have, or have had, research and collaboration programs with several biotechnology companies.
                                            These collaborations allow us to accelerate our research program toward the discovery and
                                            development of breakthrough therapies based on the combined data and research resources of
                                            our program collaborators and our patented and potentially patentable cancer therapies. These
                                            companies include Ryvu, a Polish integrated drug research services company, and Équilibre
                                            Biopharmaceuticals, a New York-based breakthrough neurological therapeutics company. Our
                                            collaboration partners also include Memorial Sloan Kettering Cancer Center, one of the world's
                                            premier cancer centers, and Whitehead Institute for Biomedical Research.
Our goal is to advance two discovery assets per
year into preclinical development. Assuming we raise the maximum amount in this offering (an assumption which we cannot guarantee), we
expect to have from the offering sufficient funds for approximately the next 20 to 24 months to advance two product candidates, FX-1610
and FX-7742 (or FX-9847), through the IND enabling stage and filing process up to Phase 1b/2a clinical studies. We expect that we will
need additional funds to begin Phase 1b/2a clinical studies for FX-1610 and FX-7742 (or FX-9847), to advance our prospective additional
pipeline product candidates into the pre-IND enabling stage in 2023 or 2024, and to begin to disclose additional discovery assets on
an annual basis. These additional funds will have to come from either additional securities offerings, whether public or private, debt
or equity, or loans or other financing mechanisms provided by third parties or existing investors. There can be no assurances, however,
that we will be successful in any future fund-raising efforts or that we will be able to raise these needed additional funds on terms
acceptable to us, if at all. Considering our history of net losses, our accumulated deficit as of March 31, 2022 of $7,070,505, the fact
that we have not, and will not in the foreseeable future, generate any revenues or operational cash flow and that we will need to raise
substantial amounts of additional funds to advance our development programs, and the substantial doubt about our ability to continue
as a going concern, we can provide no assurance that we will be successful in executing any of our growth strategies as listed above.
Our
Intellectual Property
We have a strong IP position that is continuously
growing. Our patent portfolio includes licensed patents covering,
inter alia
, fundamental compositions of matter. In addition,
our portfolio includes three patent families covering combination treatments with major other types of inhibitors used as cancer therapeutics
(i.e., inhibitors of mitosis, EGFR inhibitors and MAPK pathway inhibitors), more specifically described below.
Our team of scientific and pharmaceutical development
experts work with researchers at leading academic centers to advance breakthroughs to address the unmet need for effective and feasible
cancer treatments.
Our success depends in part on our ability to
obtain and maintain proprietary protection for our product candidates, as well as novel discoveries, product development technologies,
and know-how.
Our success also depends in part on our ability
to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy
is to conduct surveillance of third-party patents and patent application publications periodically while developing and maintaining protection
of our proprietary position by, among other methods, filing or in-licensing US and foreign patents and applications related to our technology,
inventions, and improvements that are important to the development and implementation of our business.
We also rely on trademarks, trade secrets, know-how,
continuing technological innovation, confidentiality agreements, and invention assignment agreements to develop and maintain our proprietary
position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements
are designed to grant us ownership of technologies that are developed for us by our employees, consultants, or other third parties. We
seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and
physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures,
either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently
discovered by competitors.
Besides
the specific patents mentioned below under the section "-
Patents
" immediately below, we cannot be sure that
patents will be granted with respect to any of our pending patent applications pending now or filed by us in the future, nor can we be
absolutely certain to what degree, if any, our existing patents or any patents that may be granted to us in the future will be commercially
useful in protecting our commercial products and methods of using and manufacturing the same.
Patents
Our product candidates FX-1610, FX-9847 and FX-5372
are protected by U.S. Patent No. 9,446,044 and its foreign counterparts (in major European counties, and Australia, Brazil, Canada, China,
Iceland, Israel, India, Japan, Hong Kong, Kazakhstan, Russia, and South Korea), which were licensed by us from EuroBio Scientific, as
described below. This patent family is projected to expire in August of 2032, except for certain European jurisdictions where it will
expire in August 2031.
Our product candidate FX-7742 is protected by
our U.S. Patent No. 10,577,365 and its foreign counterpart pending patent applications. This patent family is co-owned by us with Ryvu
Therapeutics S.A., (formerly, Selvita S.A.), and is subject to a world-wide exclusive license, granted to us by Ryvu Therapeutics S.A.,
as described below. This U.S. patent and its counterparts pending applications pending in Europe and Japan, if granted, are projected
to expire in December 2037.
76
Our patent portfolio further includes three additional
patent families related to "method of use" cancer treatment of certain DYRK1 inhibitors in combination with major other classes
cancer therapeutics as listed in the table below:
Granted
    U.S. Patent No(s). or Pending U.S. Application No.
Primary
    Treatment
Pending
    Foreign Counterparts or Pending PCT Application No.
US Patent Nos. 10,322,128; 11,202,779
Combination of DYRK and EGFR inhibitors
Australia, Canada, China, European Patent Office, Israel, Japan, Mexico,
    South Korea,
US Patent No. 10,314,843
Combination of DYRK and Mitosis inhibitors
Australia, Canada, China, European Patent Office, Israel, Japan, Mexico,
    South Korea
US App. No. 17/081,863 (unpublished)
Combination of DYRK and MAPK pathway inhibitors
PCT/US22/13081
(unpublished)
In addition to the above-referenced patents and
applications, our patent portfolio includes additional pending continuing US applications and their foreign counterpart applications
owned solely by Felicitex, with projected expiration dates in 2037 or later. We continuously file additional patent applications as needs
arise.
Our IP position includes two fundamental composition
of matter patents families and three methods of use patent families, as referenced below:
●
Composition
                                            of matter (several leads): "DYRK1 Inhibitors and Uses Thereof" WO2013/026806
                                            A1 (Exclusive license from EuroBio Scientific);
●
Composition
                                            of matter (several leads): "Derivatives of Quinoline as inhibitors of DYRK1A and/or
                                            DYRK1B kinases" WO2018/119039 (Co-owned with, and exclusively licensed from, Selvita/Ryvu);
●
Methods
                                            of use: "Combinations for the treatment of cancer using quiescent cell targeting and
                                            inhibitors of mitosis" WO2017/181087;
●
Methods
                                            of use: "Combinations for the treatment of neoplasms using quiescent cell targeting
                                            with EGFR inhibitors" WO2017/181075; and
●
Methods
                                            of use: "Combination cancer therapy with DYRK1 inhibitors and inhibitors of the RAS-RAF-MEK-ERK
                                            (MAPK) pathway" PCT/US22/13081, unpublished, filed January 20, 2022.
Patent Term Extension and Patent Term Adjustment
The term of a patent in most countries, including
the United States, is 20 years from the effective filing date of the patent assuming maintenance fees are paid, the patent has not been
terminally disclaimed, and the patent has not been invalidated through administrative and/or court proceedings. For pharmaceutical products,
however, the patent term covering the approved product, can be extended beyond the 20-year term if certain statutory and regulatory requirements
are satisfied. In the United States one way the patent term of a patent covering the approved pharmaceutical product can be extended
is under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit a patent term extension, or PTE, of up to five years, but not to exceed fourteen years from the date of receipt of
marketing approval, for a patent covering an approved product as compensation for effective patent term lost during product development
and the FDA regulatory review process. In the future, if and when our drug candidates are approved by the FDA or foreign regulatory authorities,
we will apply for patent term extensions on patents covering the approved products if the patents are eligible for such extension.
In addition, in the United States a patent term
may be extended by patent term adjustment, or PTA, which compensates a patent for administrative delays by the USPTO in examining and
granting a patent unless the patent is terminally disclaimed over an earlier filed patent. PTE and PTA extensions are not mutually exclusive;
however, extension under the PTA does not have any extension limits. We cannot, however, provide any assurance that any of our present
or future patents will be eligible for patent term adjustment or patent term extension.
Trademarks and Domain Names
We currently own one pending U.S. trademark registration
application for the mark, FELICITEX, which will serve as a priority filing in other jurisdictions.
We own the internet domain name, www.felicitex.com,
which is our primary operating website. The information contained in our websites is not incorporated by reference in this prospectus.
77
Licensing and Research and Collaboration Agreements
Eurobio Scientific (formerly Diaxonhit)
On April 16, 2014, we entered a license and collaboration
agreement with Diaxonhit. Under Amendment No. 1 to the agreement, dated July 21, 2014, we extended the agreement to October 31, 2014,
and increased our access to Diaxonhit's research materials. Under an Amendment No. 2 to the agreement, dated February 14, 2022,
the term of this agreement is perpetual, subject to continued payment of required annual license fee and milestone payments. Either party
may terminate the agreement upon 60 days' notice if the other party is in material breach of the agreement, except that a shortened
period of 30 days shall apply in the event such a breach is solely due to a party's failure to pay an uncontested amount due under
the agreement. Below are the material terms and conditions of the agreement, as amended.
Below are the material terms and conditions of
the agreement, as amended.
Rights under DYRK 1B Eurobio Scientific Program
License and Collaboration Agreement
We have been granted
an exclusive, royalty-bearing, sublicensable, and perpetual license for research, development, marketing and commercialization of oncology-treatment,
prevention and diagnostic products using Eurobio Scientific's DYRK 1B inhibitors covered by Eurobio Scientific patents and know-how,
as well as certain materials from Eurobio Scientific. It is our expectation that the patent which covers the intellectual property relating
to the DYRK1 1B inhibitors will expire in August 2032 worldwide, except Europe where the patents will expire in August 2031.
Obligations under DYRK 1B Eurobio Scientific
Program License and Collaboration Agreement
Down payment
: The Eurobio Scientific license
and collaboration agreement became effective upon the Company's completion of a proof of concept (POC) study using compound EHT
5372, subject to our providing evidence to Eurobio Scientific of an investment into our company of at least $1,000,000 and then making
a license investment payment to Eurobio Scientific of $300,000, within 30 days of the completion of the POC study, that is, by October
31, 2014. We completed and provided the POC to Eurobio Scientific as of October 31, 2014 and also completed the payment of the required
investment amount as of October 31, 2014. We have satisfied the Eurobio Scientific licensing terms to date.
License maintenance fee
: We agreed to
pay Eurobio Scientific an annual license maintenance fee of $100,000, due within 30 days from the end of each 12 months period following
the effective date of the Eurobio Scientific license and collaboration agreement, which will be credited against the milestone payment
due during the years which a milestone is achieved by us. We have made these payments in a timely manner since the date of this agreement.
To date, we have paid Eurobio Scientific a total of $700,000 in annual license fee payments. Except for this amount and the initial $300,000
license investment payment, we have not made any other payments to Eurobio Scientific in connection with our agreement with them.
Milestone payments - Independent and
direct development and commercialization:
We agreed to pay a total of $11,500,000 milestone payments to Eurobio Scientific.
Milestone payments - Third-Party Sub-License
Payments:
We agreed to pay Eurobio Scientific between 5% and 10% of payments provided by third parties sub-licensees.
Our obligation to pay royalties begins on the
date of the first commercial sale of a product in any country and territories in the world and shall remain in effect for at least ten
years or until the expiration of the last to expire valid claim of any patent rights covering the Product, whichever is longer.
Termination of DYRK 1B Eurobio Scientific
Program License and Collaboration Agreement.
The Eurobio Scientific license and collaboration agreement and Eurobio Scientific's
obligations may be terminated 90 days following POC study completion if the investment payment requirement described above is not fully
satisfied, or due to a material breach by either party, including failure by us to obtain a timely investment payment commitment, make
timely investment payments, meet product development and product commercialization timelines as specified in this agreement, make timely
payment of any amounts properly due and payable to Eurobio Scientific, provide Eurobio Scientific with timely prior notice if we do not
intend to undertake development of a product or do not obtain marketing authorizations and/or do not commercialize products in any country
in the world, or commit any other material breach of this agreement. If the license agreement is not previously terminated, the license
agreement will automatically terminate after the fifth anniversary of the expiration of the last patent covered under this agreement.
Upon termination of this agreement by Eurobio Scientific, the licenses and rights granted to us will terminate and revert to Eurobio
Scientific. Upon termination of this agreement by us, the collaboration shall terminate and we will complete an orderly wind-down, in
accordance with accepted pharmaceutical industry norms and ethical practices, of any then on-going studies for the product and other
activities for which we have responsibility.
78
Ryvu Therapeutics (formerly Selvita S.A.)
On October 1, 2014, we entered into a research
collaboration and licensing option agreement with Selvita S.A., a Polish corporation now known Ryvu Therapeutics S.A., or Ryvu, for a
co-discovery research collaboration to validate a certain kinase target of interest, "DYRK1A/B", and to generate new kinase
inhibitor drug candidates with high selectivity towards such selected kinase target with defined activity in certain cancer subtypes,
with an initial focus, but not limited to, on pancreatic, colon, ovarian, lung and hematopoietic cancers based on targeting cancer cell
quiescence. The parties agreed to collaborate together during the research collaboration term, which means the period commencing upon
the effective date of this agreement and continuing through 27 consecutive months, comprised of (i) Collaboration Period I commencing
on the effective date of this agreement and continuing until December 31, 2015 and (ii) Collaboration Period II commencing on January
1, 2016 and continuing until December 31, 2016, to conduct a research collaboration in accordance with the applicable research plans
as outlined in the agreement to development one or more clinical candidates for filing of an IND to initiate clinical trials. The parties
further agreed to collaborate on one kinase research program, defined by the joint steering committee, or JSC, to be established by the
parties, which shall have the overall management of the research collaboration and the implementation of the research plan and review,
oversight, and decision-making responsibilities and authority, based on the expected target activity profile.
The collaboration aspect of our agreement with
Ryvu terminated with the end of Collaboration Period I on December 31, 2015 and we did not continue with Collaboration Period II.
Rights Under the Ryvu Research Collaboration
and Option Agreement
We have been granted an exclusive option to obtain
certain intellectual property rights in and to certain program compounds resulting from the research program as selected by us upon option
exercise. The option(s) are exercisable during the period which we may exercise the option(s) and shall be perfected by the parties by
a separate exclusive license agreement as described below.
On August 30, 2018, as a result of our activities
under our Period I research collaboration with Ryvu which focused on the program compound FX-7742, we exercised our option under this
research collaboration and option agreement for the Ryvu-owned program compound FX-7742.
Ryvu has the right to assume all of our company's
rights for any clinical candidate for the one-time milestone payment to us at any time after the selection of a clinical candidate by
the JSC and prior to the initiation of GLP toxicology studies. In such case, Ryvu shall be free of all further obligations to us.
Obligations Under the Ryvu Research Collaboration
and Option Agreement
Research Plan
. The parties agreed to establish
a joint project team (Project Team) made up of 3 members nominated by us and 3 members nominated by Ryvu to execute the research plan
to be developed by the Project Team describing the scientific hypothesis, identifying key scientific questions and target profiles and
outlining the experimental approach for the research program and to submit the research plan to the JSC for approval. Upon the JSC's
approval, the research plan will define the research program under the research collaboration. The goal of the research plan shall be
the validation of the DYRK1A kinase and DYRK1B kinase, which we refer to collectively, as the Target, and the identification and progression
of program compounds. Each party shall appoint an individual to act as project manager to oversee the activities and tasks allocated
to such party for the overall research collaboration.
Initial scientific contributions
. We agreed
to contribute into the research collaboration its lead candidate compound (FX-1) and DYRK1B library (FX-2) for screening of compounds,
and to share structural data on the compounds within FX-2 and FX-1. Ryvu agreed to contribute into the research collaboration its library
of compounds (SEL141 Library) to be screened for the purpose of identifying a DYRK1A/DYRK1B inhibitor, and to share structural data on
the compounds within its SEL 141 Program. Ryvu agreed to disclose two chemical scaffolds around which Ryvu has built a library of DYRK1A/B
kinase inhibitors. The parties further agreed that all medicinal and general chemistry work and analysis will be conducted in accordance
with the research pan by Ryvu in its laboratories in Krakow, Poland, including the determination of physicochemical properties, PK, and
appropriate
in vitro
and
in vivo
ADMET properties, and all of the biology work and analysis will be conducted in accordance
with the research plan by us in our laboratories in Cambridge or Watertown, Massachusetts or as otherwise located by us.
Funding
. We agreed to the following allocation
of funding obligations during the research collaboration term. All required payments by the Company under this agreement have been made
in a timely manner.
●
During
                                            Collaboration Period I, we must cover a certain percentage of our own internal and external
                                            costs and expenses incurred in connection with our activities under the research collaboration
                                            and a certain percentage of Ryvu's internal and external costs and expenses incurred
                                            in connection with its activities under the research collaboration. Ryvu must cover a certain
                                            percentage of its internal and external costs and expenses incurred in connection with its
                                            activities under the research collaboration. We agreed to pay Ryvu collectively up to a certain
                                            amount during Collaboration Period I to cover Ryvu's costs.
79
●
During
                                            Collaboration Period II, we were to cover a certain percentage of our own internal and external
                                            costs and expenses incurred in connection with our activities under the research collaboration
                                            and a certain percentage of Ryvu's internal and external costs and expenses incurred
                                            in connection with its activities under the research collaboration. Ryvu would not cover
                                            any costs of the research collaboration, unless Ryvu or both parties secured additional grant
                                            financing and mutually agreed to apply such funding to the research collaboration. We agreed
                                            to pay Ryvu up to a respective amount based on the actual cost and expenses of Ryvu during
                                            this period as evidenced and demonstrated by Ryvu. Because we terminated our collaboration
                                            with Ryvu at the end of Collaboration Period I and did not enter into Collaboration Period
                                            II, neither we nor Ryvu incurred any liabilities or obligations with respect to Collaboration
                                            Period II.
●
While
                                            covering its own internal and external costs and expenses incurred in connection with its
                                            activities under the research collaboration during this period, Ryvu will spend collectively
                                            up to a certain amount during Collaboration Period I.
License grants
. Both parties agreed to
grant each other for the research collaboration term a non-exclusive, royalty-free, fully-paid license in the treatment and remediation
of any human or veterinary oncologic disease, disorder or condition, or the Field, in the entire world, with the right to grant sublicenses
to affiliates and engaged persons solely as necessary or useful to conduct the activities under the research program. In addition, Ryvu
agreed to grant to us, for a period commencing upon the end of the research collaboration term and ending upon expiration of the option
period, a non-exclusive, royalty-free, fully-paid license in the Field in the entire world, with the right to grant sublicenses to its
affiliates and engaged persons solely as necessary or useful to undertake research and development of program compounds for the purpose
of evaluating such program compounds for a potential Option exercise.
Exclusivity
. Upon the effective date of
the agreement and for a further period of 25 years after the expiration (but not early termination) of the term of this agreement, Ryvu
shall not pursue, neither alone nor in collaboration with or through third parties, the research, development, manufacturing (for development
or commercialization), or commercialization of any compounds or therapeutic products selective against the target. In case of early termination
of this agreement by either party without the exercise of an option by Felicitex, Ryvu's exclusivity obligation shall also terminate
upon the effective date of any such early termination without any further applicable restrictions and limitations for Ryvu. During the
term of this agreement, Felicitex shall not undertake, neither alone nor in collaboration with or through third parties, any work on
medicinal chemistry for compounds selective against the target outside the scope of this agreement. In the event that we exercise our
option, our company shall be entitled to continue its work on medicinal chemistry for compounds selective against the target either by
itself or through an affiliate, engaged person, other sublicensee or other third party, in each case in accordance with the provisions
of this agreement, and such continuing work of our company shall not be considered a breach of this agreement.
Termination of the Ryvu research collaboration
and option agreement
. The Ryvu research collaboration and option agreement may be terminated (i) upon 60 days prior written notice
from us to Ryvu, (ii) upon 60 days prior written notice by either party is it deems that the research and development activities under
the research program are not progressing pursuant to the research plan and, in case that an adequate amendment of the research plan excess
the decision making authority of the JSC, the parties are unable to agree on an amendment of the research plan within 30 days following
the first notification of such assessment by the respective party to the JSC, (iii) by other material breaches of material obligations;
and (iv) by written notice immediately if the party becomes insolvent, bankrupt, or liquidated. Upon expiration or termination of the
agreement, the option period and all mutual licenses granted under this agreement shall terminate. A termination terminates all license
rights under this agreement, parties must wind down the research program, return materials owned by other party, and provide certain
other required information, documentation and materials.
Exclusive License Agreement
On December 31, 2018, we entered into an exclusive
license agreement with Ryvu, or Exclusive License Agreement. Pursuant to the Exclusive License Agreement, Ryvu agreed to grant us exclusive,
worldwide licenses for the purpose of facilitating our research, development, manufacturing, and commercialization activities on all
optioned compounds (FX-7742) and products against the target in the Field in the entire world. In consideration of the license grants,
we agreed to pay Ryvu certain milestones, royalties, and/or participation payments.
The one issued U.S. patent and pending patent applications
in certain other jurisdictions included in this license are based on WO2018/119039 and are expected to expire in December of 2037 worldwide,
except in Europe, where they are expected to expire in December 2036. The patent WO2018/119039 relates to our product candidate FX-7742.
80
Milestone, Participation and Royalty Payments
.
We agreed to make non-refundable, non-creditable development milestone payments and royalty payments to Ryvu in the course of internal
development, subject to adjustments in case that the Decreased Value Share (as defined in the agreement) or Adjusted Value Share (as
defined in the agreement) applies. We also agreed to make participation payments and royalty payments in course of external development.
Our agreement with Ryvu provides that milestone payments are to be made to Ryvu upon the achievement of certain liabilities the
first of which is participation in Phase II clinical trials.  To date, we have not achieved any of the milestones obligated by our
agreement and no milestone payments have been made to Ryvu.  The agreement with Ryvu does not provide for any payments to be received by
us from Ryvu. With respect to participation payments made to Ryvu, from inception in November 2014 through November 2017, we paid Ryvu
$461,727.16 in expense reimbursements. No other payments were made to Ryvu and no other contingent liability for payment exists as of
today.  Ryvu has not paid us any participation payments nor does it owe us any. Royalty rates under our agreement with Ryvu are
in the low single digits and will be payable only with respect to product sales in the countries where the patents are issued. 
As of the date hereof, patent applications in certain foreign jurisdictions are still pending and we have not paid, nor do we expect
to pay in the near future, any royalties to Ryvu. In the future, we may have milestone payments owed to Ryvu in an aggregate amount of
up to $11 million. The expiration date of these patents should they issue will vary by jurisdiction, and as indicated above, are expected
to expire in 2036 and 2037.
Term and Termination Provisions.
The term
of our license agreement with Ryvu continues in full force and effect until the expiration of all of our payment obligations under the
agreement. The agreement can be terminated earlier by either party if there is a material breach of the agreement by the other party
that has not been cured within 90 days after receipt by the breaching party of a notice of breach. Additionally, either party may terminate
the agreement immediately upon the insolvency of the other party.
Amendment No.1 to Exclusive Licensing Agreement
.
On April 19, 2019, we entered into the Amendment No.1 to Exclusive Licensing Agreement with Ryvu, pursuant to which the milestone payment
terms were amended. Under this amendment, development stage milestones payment amounts were increased for second and subsequent indications
by between forty and fifty percent and sales milestone payments were increased by forty percent.
Material Transfer Agreements
Under our material transfer agreement with Whitehead
Institute for Biomedical Research, or Whitehead, dated January 29, 2020, until the agreement is terminated, all results of research using
our materials are Whitehead's property. However, for inventions that represent a new use of our materials, such inventions will
become the property of Whitehead and we will receive a free non-exclusive license to use the materials for research, development, manufacturing
and commercialization. In addition, we may exercise an option for an exclusive license to inventions that represent new uses of our material
if we agree to pay the royalty option rates of $10,000 for initial exercise of the option, a $500,000 milestone payment upon NDA approval
of a covered invention, and 0.25% royalties on sales of the invention. During the option period and negotiation period, Felicitex will
reimburse Whitehead for costs of prosecuting patents per requests of Felicitex. Under this agreement, we have agreed to provide Whitehead
with an amount of our product candidate FX-9847. Whitehead is under no specific performance obligations under this agreement. This agreement
does not include specific agreement term and termination provisions however, it allows us to terminate Whitehead's right to use
our materials at any time.
Under our material transfer and royalty agreement
with Memorial Sloan Kettering Cancer Center, or MSK, dated December 4, 2020, MSK will own, and grant us a first option to license, inventions
or discoveries that are conceived and reduced to practice by MSK using our materials on the agreed-to research until the agreement is
terminated. Under this agreement, we have agreed to provide MSK with an amount of our product candidate FX 9847. MSK is under no specific
performance obligations under this agreement, but it has granted us the first right to negotiate any licenses to any MSK inventions utilizing
our material. This agreement terminates on December 4, 2022 unless earlier terminated by a party on 30 days prior written notice. This
agreement does not provide for any payments to us.
Under our material transfer agreement with Équilibre
Biopharmaceuticals, or Équilibre, dated February 15, 2021, Équilibre agreed to assign us its entire right and interest
in the inventions or discoveries that are conceived and reduced to practice by Équilibre using our materials on the agreed-to
research until the agreement is terminated. Under this agreement, we have agreed to provide Equilibre with amounts of our product candidates
FX-1610 and FX-9847. Equilibre is under no specific performance obligations under this agreement. This agreement does not include specific
agreement term and termination provisions, however, it allows us to terminate Equilibre's right to use our materials at any time.
This agreement does not provide for any payments to us.
Under our material transfer agreement with UAB
DolceRx Baltika, or DolceRx, dated May 15, 2021, DolceRx agreed to assign us its entire right and interest in the inventions or discoveries
that are conceived and reduced to practice by DolceRx using our materials on the agreed-to research until the agreement is terminated.
Under this agreement, we have agreed to provide DolceRx with amounts of our product candidates FX-1610 and FX-7742. DolceRx is under
no specific performance obligations under this agreement. This agreement does not include specific agreement term and termination provisions,
however, it allows us to terminate DolceRx's right to use our materials at any time. This agreement does not provide for any payments
to us.
Under our material transfer agreement with Barbara
Ann Karmanos Cancer Institute, or KCI, dated July 18, 2022, KCI agreed to assign us its entire right and interest in the inventions or
discoveries that are conceived and reduced to practice by KCI using our materials on the agreed-to research until the agreement is terminated.
Under this agreement, we have agreed to provide KCI with amounts of our product candidates to be specified by mutual agreement at a future
date. KCI is under no specific performance obligations under this agreement. This agreement does not include specific agreement term
and termination provisions, however, it allows us to terminate KCI's right to use our materials at any time. This agreement does
not provide for any payments to us.
81
Our Facilities
We are headquartered at 27 Strathmore Road, Natick,
MA 01760, with lab and office space of approximately 1,600 square feet. We lease this facility pursuant to a lease agreement entered
into with Kaufman Nir LLC and TarMeta Inc., dated March 15, 2017. Under the lease, we pay $10,500 basic monthly rent. The lease has a
24-month term and renews automatically for an additional 12-month term unless we give 90 days' notice of termination or terminate
immediately with three months' rent payments.
We have entered into a sublease agreement with
Quateris LLC, dated March 15, 2017, providing partial access
to our lab facilities for $2,500 per month. Felicitex does not receive or recognize any income from this sublease; it only reduces its
net monthly lease obligation by $2,500 dollars each month. Both the lease and sublease have a 24-month initial term and renew automatically
for additional 12-month terms unless we give 90 days' notice of termination, or we terminate immediately with three months'
rent payments.
Marketing
We have entered into several collaboration agreements
with certain international pharmaceutical firms to assist in the continued development of our therapeutic assets. Subject to successfully
filing Investigational New Drug Applications (INDs), business development efforts will focus on further fostering such collaborations
and positive relations with candidate collaborators who typically pay upfront fees, milestone payments, and a significant fraction of
the ongoing development costs as product candidates move through the regulatory process.
Subject to receiving marketing approvals, we
expect to embark, alongside our partners, with development and commercialization activities by selecting and training focused sales and
marketing organizations in each geography of interest. We expect collaborators will manage most of the marketing tasks in geographies
outside of the United States, while we expect to play a role in the marketing of our products in the United States alongside our selected
partner. The marketing partner in the United States will be chosen in part on its proven ability to communicate and serve the needs of
the leading cancer centers and our target community-oncologists who are the most critical decision-makers in treating the patients for
which our dormancy/acquired resistance product candidates are being developed. We expect to enter into distribution and other marketing
arrangements with third parties for any of our product candidates that obtain marketing approval.
In addition, for those products that obtain marketing
approval and are highly focused on a limited number of specific patients, we plan to build a limited mission-driven marketing and sales
management organization to create and implement marketing strategies for these selected products in the United States. We will oversee
and support our focused salesforce and assume marketing responsibilities with the assistance of contracted service organizations, including
developing educational initiatives concerning approved products and establishing relationships with key opinion leaders, researchers,
and practitioners in the relevant sub-specialties within oncology.
The area of negotiating
collaboration and licensing deals in the pharmaceutical industry and in oncology, in particular, is very competitive. We expect to encounter
substantial competition from many firms vying for the attention of established pharmaceutical firms active in the cancer therapeutics
market. Other forms of competition are discussed immediately below.
Competition
The biotechnology and pharmaceutical industries
are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. Our unique knowledge,
experience, and scientific resources provide us with competitive advantages. Nevertheless, the market for oncology products is very competitive,
changes rapidly, and welcomes the advent of new technology quickly.
82
There are many companies with ambitions to address
the unmet needs in cancer. Many of these potential and current competitors enjoy significantly greater financial, technical and human
resources to bring to their business implementations to market. Also, selected early-stage companies may prove to be significant competitors
in the future as they may be successful in establishing collaborative arrangements with large and established companies and pursuing
activities that permit them to discover, develop, license, or commercialize products that address the same unmet needs we are pursuing.
Competition also presents itself in the form of cost-effective generics and non-drug-based treatments.
Moreover, we are aware of several other drug
candidates developing potential treatments for some of the indications that we are targeting.
Specifically, our competitors include:
●
HiberCell, Inc.:
This
                                            company is developing oncology drug candidates targeting the same mechanism of action that
                                            we are targeting, dormant cancer cells;
●
Biosplice Therapeutics, Inc.
:
                                            This company also has an oncology drug candidate, Cirtuvivint (SM08502), which is DYRK1A
                                            inhibitor in Phase I clinical trials; and
●
Brickell Biotech, Inc.: This
                                            company has a diabetes drug candidate, BBI-02, which is a DYRK1A inhibitor ready for Phase
                                            I clinical trials.
Our commercial opportunity could be reduced or
eliminated if our competitors develop and commercialize drugs that are safer, more effective, more convenient, less expensive or with
a more favorable label than our current drug candidates or any other drug candidates that we may develop. Our competitors also may obtain
FDA or other regulatory approvals for their drug candidates more rapidly than we may obtain approval for our drug candidates, which could
result in our competitors establishing a strong market position before we are able to enter the market. Many of the companies against
which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Primary methods of treating
cancer patients include surgery, radiation, and drug therapy, including chemotherapy and hormone therapy. More recently, targeted drug
therapy has emerged as an important contributor to improved outcomes. Typically, a combination of approaches is deployed on a cancer
patient. If our product candidates are approved for marketing, they may compete with these approaches. To the extent our products, if
approved for marketing, work in combination, providing synergy with other products and creating opportunities for improved outcomes,
our products may be considered competitive.
Manufacturing
We do not own or operate, and currently have
no plans to establish, any manufacturing facilities. We expect to rely on third parties for the manufacture of our drug candidates undergoing
preclinical and clinical testing, as well as for manufacture of any drugs that we may commercialize.
Should our product candidates receive marketing
approval, we expect to rely on contracted commercial manufacturers with established track records for quality and compliance. All of
our drug candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry
appears amenable to scale up and does not currently require unusual equipment in the manufacturing process. We expect to continue to
develop product candidates that can be produced cost-effectively at contract manufacturing facilities. We generally expect to rely on
third parties to manufacture companion diagnostics for our products, which are assays or tests to identify an appropriate patient population.
83
Employees
As of March 31, 2022, we have two
full-time employees and one part-time employee.
None of our employees is represented by labor
unions, and we believe that we have an excellent relationship with our employees.
Legal Proceedings
From time to time, we may become involved in
various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties,
and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of
any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating
results.
Regulations
Government authorities in the United States at
the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture,
quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring
and reporting, marketing and export and import of drug products. Generally, before a new drug can be marketed, considerable data demonstrating
its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review,
and approved by the regulatory authority.
In the United States,
the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. Drugs also are
subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent
compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and
financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval
process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions,
the FDA's refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product
recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals
of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have
a material adverse effect on us.
84
Any of our future drug
candidates must be approved by the FDA through an NDA process before they may be legally marketed in the United States. The process generally
involves the following:
●
Completion
                                            of extensive preclinical studies in accordance with applicable regulations, including studies
                                            conducted in accordance with good laboratory practice, or GLP, requirements;
●
Submission
                                            to the FDA of an IND, which must become effective before human clinical trials may begin;
●
Approval
                                            by an independent institutional review board, or IRB, or ethics committee at each clinical
                                            trial site before each trial may be initiated;
●
Performance
                                            of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
                                            good clinical practice, or GCP, requirements and other clinical trial-related regulations
                                            to establish the safety and efficacy of the investigational product for each proposed indication;
●
Submission
                                            to the FDA of an NDA;
●
A
                                            determination by the FDA within 60 days of its receipt of an NDA to accept the filing for
                                            review;
●
Satisfactory
                                            completion of a FDA pre-approval inspection of the manufacturing facility or facilities where
                                            the drug will be produced to assess compliance with current good manufacturing practices,
                                            or cGMP, requirements to assure that the facilities, methods and controls are adequate to
                                            preserve the drug's identity, strength, quality and purity;
●
Potential
                                            FDA audit of the preclinical and/or clinical trial sites that generated the data in support
                                            of the NDA;
●
Payment
                                            of user fees and FDA review and approval of the NDA, including consideration of the views
                                            of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the
                                            United States; and
●
Compliance
                                            with any post-approval requirements, including the potential requirement to implement a Risk
                                            Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval
                                            studies.
The data required to
support an NDA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and
approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future
drug candidates will be granted on a timely basis, or at all.
Preclinical Studies
and IND
The preclinical developmental
stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity
in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with
manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as
part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become
effective before human clinical trials may begin. Preclinical studies include laboratory evaluation of product chemistry and formulation,
as well as
in vitro
and animal studies to assess the potential for adverse events and in some cases to establish a rationale
for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations
for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information,
analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of
an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after
the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises
concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may
not result in the FDA allowing clinical trials to commence.
85
Clinical Trials
The clinical stage of
development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified
investigators, generally physicians not employed by or under the trial sponsor's control, in accordance with GCP requirements,
which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial.
Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures,
subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol,
and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must
be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the
informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical
trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results
to public registries.
A sponsor who wishes
to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under
an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in
support of an NDA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial
was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary.
Clinical trials generally
are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap. In some cases, drug approvals may also
require a post-approval clinical study, referred to as a Phase 4 study.
●
Phase
                                            1 clinical trials generally involve a small number of healthy volunteers or disease-affected
                                            patients who are initially exposed to a single dose and then multiple doses of the drug candidate.
                                            The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action,
                                            side effect tolerability and safety of the drug candidate.
●
Phase
                                            2 clinical trials involve studies in disease-affected patients to determine the dose required
                                            to produce the desired benefits. At the same time, safety and further PK and PD information
                                            is collected, possible adverse effects and safety risks are identified, and a preliminary
                                            evaluation of efficacy is conducted.
●
Phase
                                            3 clinical trials generally involve a large number of patients at multiple sites and are
                                            designed to provide the data necessary to demonstrate the effectiveness of the product for
                                            its intended use, its safety in use and to establish the overall benefit/risk relationship
                                            of the product and provide an adequate basis for product approval. These trials may include
                                            comparisons with placebo and/or other comparator treatments. The duration of treatment is
                                            often extended to mimic the actual use of a product during marketing. Post-approval trials,
                                            sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing
                                            approval. These trials are used to gain additional experience from the treatment of patients
                                            in the intended therapeutic indication. In certain instances, the FDA may mandate the performance
                                            of Phase 4 clinical trials as a condition of approval of an NDA.
Progress reports detailing
the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports
must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting
a significant risk to humans exposed to the drug, findings from animal or
in vitro
testing that suggest a significant
risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in
the protocol or investigator brochure.
Clinical trials may
not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial
at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted
in accordance with the IRB's requirements or if the drug has been associated with unexpected serious harm to patients. Additionally,
some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data
safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points
based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies
and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process
for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable
of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity,
strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies
must be conducted to demonstrate that our drug candidates do not undergo unacceptable deterioration over their shelf life.
86
Breakthrough Therapy
Designation
Breakthrough therapy
designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and
for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically
significant endpoint(s).
To determine whether
the improvement over available therapy is substantial is a matter of judgment and depends on both the magnitude of the treatment effect,
which could include duration of the effect, and the importance of the observed clinical outcome. In general, the preliminary clinical
evidence should show a clear advantage over available therapy.
For purposes of breakthrough
therapy designation, clinically significant endpoint generally refers to an endpoint that measures an effect on irreversible morbidity
or mortality (IMM) or on symptoms that represent serious consequences of the disease. A clinically significant endpoint can also refer
to findings that suggest an effect on IMM or serious symptoms, including:
●
An
                                            effect on an established surrogate endpoint;
●
An
                                            effect on a surrogate endpoint or intermediate clinical endpoint considered reasonably likely
                                            to predict a clinical benefit (i.e., the accelerated approval standard);
●
An
                                            effect on a pharmacodynamic biomarker(s) that does not meet criteria for an acceptable surrogate
                                            endpoint, but strongly suggests the potential for a clinically meaningful effect on the underlying
                                            disease; or
●
A
                                            significantly improved safety profile compared to available therapy (e.g., less dose-limiting
                                            toxicity for an oncology agent), with evidence of similar efficacy.
A
drug that receives breakthrough therapy designation is eligible for the following:
●
More
                                            frequent meetings with FDA to discuss the drug's development plan and ensure collection
                                            of appropriate data needed to support drug approval;
●
More
                                            frequent written communication from FDA about such things as the design of the proposed clinical
                                            trials and use of biomarkers;
●
Eligibility
                                            for Accelerated Approval and Priority Review, if relevant criteria are met;
●
Rolling
                                            Review, which means that a drug company can submit completed sections of its Biologic License
                                            Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until
                                            every section of the NDA is completed before the entire application can be reviewed. BLA
                                            or NDA review usually does not begin until the drug company has submitted the entire application
                                            to the FDA;
●
Intensive
                                            guidance on an efficient drug development program, beginning as early as Phase 1; or
●
Organizational
                                            commitment involving senior managers.
We intend to request
breakthrough therapy designation for our drug candidates.
Ideally,
we would submit a breakthrough therapy designation request to the FDA no later than the end-of-phase-2 meetings if any of the features
of the designation are to be obtained. We expect that the FDA would respond to our breakthrough therapy designation requests within sixty
days of receipt of a request.
NDA Review Process
Following completion
of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated
use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed
labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA is a request for
approval to market the drug for one or more specified indications and must contain proof of safety and efficacy for a drug. The application
must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come
from company-sponsored clinical trials intended to test the safety and efficacy of a product's use or from a number of alternative
sources, including studies initiated by unaffiliated investigators. To support marketing approval, the data submitted must be sufficient
in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval
of an NDA must be obtained before a drug may be marketed in the United States.
Under the Prescription
Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a significant user fee. Fee waivers or reductions are available
in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally,
no user fees are assessed on NDAs for drug candidates designated as orphan drugs, unless the drug candidate also includes a non-orphan
drug indication.
87
In addition, under the
Pediatric Research Equity Act, an NDA or supplement to an NDA must contain data that are adequate to assess the safety and effectiveness
of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant
deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers
from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products
with orphan drug designation.
The FDA also may require
submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The
REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such
as restricted distribution methods, patient registries, or other risk minimization tools.
The FDA reviews all
submitted NDAs before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The
FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA
begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months,
from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six months
from the filing date of a new molecular entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates
for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.
Before approving an
NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether
they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities
are in compliance with cGMP requirements and adequate to ensure consistent production of the product within required specifications.
The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications
for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should
be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such
recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive
discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA, it will issue an approval letter
or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the drug with specific prescribing information
for specific indications. A CRL indicates that the review cycle of the application is complete, and the application will not be approved
in its present form. A CRL usually describes all of the specific deficiencies in the NDA identified by the FDA. The CRL may require additional
clinical data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical
trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies
identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA
does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data
differently than we interpret the same data.
Even if the FDA approves
a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included
in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug's
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential
market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing
studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing
changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.
Orphan Drugs
Under the Orphan Drug
Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease
or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States
and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for
this type of disease or condition will be recovered from sales of the product.
Orphan drug designation
must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its
potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration
of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives the first FDA approval
for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that
the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such
approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity by means
of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors,
however, may receive approval of either a different product for the same indication or the same product for a different indication but
that could be used off-label in the orphan drug indication. Orphan drug exclusivity also could block the approval of one of
our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same
indication we are seeking approval, or if a drug candidate is determined to be contained within the scope of the competitor's product
for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication
broader than that which is designated, it may not be entitled to orphan drug exclusivity.
88
In the European Union,
the European Medicines Agency's Committee for Orphan Medicinal Products grants orphan drug designation to promote the development
of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition
affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended
for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating, or serious and chronic condition when, without
incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing
the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method
exists, the medicine must be of significant benefit to those affected by the condition. In the European Union, orphan drug designation
entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following approval
for the approved therapeutic indication. This period may be reduced to six years if, at the end of the fifth year, the orphan drug designation
criteria are no longer met, including where it is shown that the drug is sufficiently profitable not to justify maintenance of market
exclusivity. In the European Union, a marketing authorization for an orphan drug designated product will not be granted if a similar
drug has been approved in the European Union for the same therapeutic indication, unless the applicant can establish that its product
is safer, more effective or otherwise clinically superior. A similar drug is a product containing a similar active substance or substances
as those contained in an already authorized product. Similar active substance is defined as an identical active substance, or an active
substance with the same principal molecular structural features (but not necessarily all of the same molecular features) and which acts
via the same mechanism.
Post-Approval
Requirements
Following
approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among
other things, monitoring and record-keeping requirements, requirements to report adverse experiences, and comply with promotion and advertising
requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (known as "off-label use")
and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs
for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted
to the FDA in conjunction with their first use. Further, if there are any modifications to the drug, including changes in indications,
labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or supplemental
NDA, or sNDA, which may require the development of additional data or preclinical studies and clinical trials.
The
FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to
assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe
use, such as restricted distribution methods, patient registries and other risk minimization tools.
Any
of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products.
Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.
The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to
the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks;
or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other
things:
●
Restrictions
                                            on the marketing or manufacturing of the product, complete withdrawal of the product from
                                            the market or product recalls;
89
●
Fines,
                                            warning letters or holds on post-approval clinical studies;
●
Refusal
                                            of the FDA to approve pending applications or supplements to approved applications;
●
Applications,
                                            or suspension or revocation of product license approvals;
●
Product
                                            seizure or detention, or refusal to permit the import or export of products; or
●
Injunctions
                                            or the imposition of civil or criminal penalties. The FDA strictly regulates marketing, labeling,
                                            advertising, and promotion of products that are placed on the market. Drugs may be promoted
                                            only for the approved indications and in accordance with the provisions of the approved label.
                                            The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion
                                            of off-label uses, and a company that is found to have improperly promoted off-label uses
                                            may be subject to significant liability.
Coverage,
Pricing and Reimbursement
Significant
uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In
the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale
will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such
products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health
insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be
separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for
the product. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might
not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price,
examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning
their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and
cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be
considered medically necessary or cost-effective. A payor's decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be approved. Further, one payor's determination to provide coverage for a product does not assure that
other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain
price levels sufficient to realize an appropriate return on our investment in product development.
Different
pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through
their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products
to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement
price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials
that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies
to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become
very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries,
cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.
The
marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has
increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement
rates may change at any time.
Even
if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable
coverage policies and reimbursement rates may be implemented in the future.
90
Healthcare
Reform
In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate
post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among
policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.
For
example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers.
Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise
described above, are the following:
●
created
                                            an annual, nondeductible fee on any entity that manufactures or imports certain specified
                                            branded prescription drugs and biologic agents apportioned among these entities according
                                            to their market share in some government healthcare programs that began in 2011;
●
increased
                                            the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program,
                                            retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most
                                            branded and generic drugs, respectively, and capped the total rebate amount for innovator
                                            drugs at 100% of the Average Manufacturer Price, or AMP;
●
created
                                            a new Medicare Part D coverage gap discount program, in which manufacturers must now agree
                                            to offer 70% point-of-sale discounts, off negotiated prices of applicable brand drugs to
                                            eligible beneficiaries during their coverage gap period, as a condition for the manufacturers'
                                            outpatient drugs to be covered under Medicare Part D;
●
extended
                                            manufacturers' Medicaid rebate liability to covered drugs dispensed to individuals
                                            who are enrolled in Medicaid managed care organizations; expanded eligibility criteria for
                                            Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional
                                            individuals and added new mandatory eligibility categories for individuals with income at
                                            or below 133% of the federal poverty level, thereby potentially increasing manufacturers'
                                            Medicaid rebate liability;
●
expanded
                                            of the list of entities eligible for discounts under the 340B Drug Discount Program;
●
created
                                            a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
                                            comparative clinical effectiveness research, along with funding for such research;
●
expanded
                                            healthcare fraud and abuse laws, including the Foreign Corrupt Practices Act, or the FCPA,
                                            and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties
                                            for noncompliance;
●
created
                                            a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
                                            are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;
●
required
                                            reporting of certain financial arrangements with physicians and teaching hospitals;
●
required
                                            annual reporting of certain information regarding drug samples that manufacturers and distributors
                                            provide to physicians;
●
established
                                            a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service
                                            delivery models to lower Medicare and Medicaid spending; and
●
created
                                            a licensure framework for follow on biologic products.
Since
its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and we expect there will
be additional challenges and amendments to the ACA in the future. Former President Trump signed several Executive Orders and other directives
designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance
mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA.
While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the
ACA have been enacted. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated the tax-based shared responsibility
payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, a process
that is commonly referred to as the "individual mandate." In addition, the Further Consolidated Appropriations Act, 2020
permanently eliminated, effective January 1, 2020, the ACA-mandated "Cadillac" tax on high-cost employer-sponsored health
coverage and medical device tax; and, effective January 1, 2021, it also eliminated the health insurance tax. On December 14, 2018, the
U.S. District Court for the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the
ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December
18, 2019, the U.S. Court of Appeals for the Fifth Circuit ruled that the individual mandate was unconstitutional and remanded the case
back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On June 17, 2021, the U.S. Supreme
Court reversed the ruling of the Fifth Circuit, holding that the challengers lacked standing to sue and otherwise abstaining from reaching
the merits of the case. Notwithstanding the resolution of this legal challenge, there may be other efforts to challenge, repeal, or replace
the ACA which may impact our business in the future.
91
President Joseph R. Biden, Jr. signed an Executive
Order on Strengthening Medicaid and the Affordable Care Act, stating his administration's intentions to reverse the actions of
his predecessor and strengthen the ACA. As part of this Executive Order, the Department of Health and Human Services, United States Treasury,
and the Department of Labor were directed to review all existing regulations, orders, guidance documents, policies, and agency actions
and to consider if they are consistent with ensuring coverage under the ACA making high-quality healthcare affordable and accessible
to Americans. We are unable to predict the likelihood of changes to the ACA or other healthcare laws which may negatively impact our
profitability.
President Biden intends, as his predecessor did,
to take action against drug prices which are considered "high." Such measures could be addressed in a legislative package
in 2022, including with the reauthorization of the Prescription Drug User Fee Act ("PDUFA"), or in the future. Drug pricing
continues to be a subject of debate at the executive and legislative levels of U.S. government, and we expect to see legislation focusing
on this in the coming years. The American Rescue Plan Act of 2021, signed into law by President Biden on March 14, 2021, included a provision
that will eliminate the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. With the elimination of
the rebate cap, manufacturers may be required to compensate states in an amount greater than what the state Medicaid programs pay for
the drug.
Further legislation or regulation could be passed
that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted
since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year,
effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030 with the exception of a temporary
suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2022, unless additional congressional
action is taken.
Moreover, there has recently been heightened
governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional
inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, to review
the relationship between pricing and manufacturer patient assistance programs, and to reform government program reimbursement methodologies
for pharmaceutical products. The Prescription Drug Pricing Reduction Act, or PDPRA, which was introduced in Congress in 2019, and again
in 2020, proposed to, among other things, penalize pharmaceutical manufacturers for raising prices on drugs covered by Medicare Parts
B and D faster than the rate of inflation, cap out-of-pocket expenses for Medicare Part D beneficiaries, and several changes to how drugs
are reimbursed in Medicare Part B. A similar drug pricing bill, the Elijah E. Cummings Lower Drug Costs Now Act, proposed to enable direct
price negotiations by the federal government for certain drugs (with the maximum price paid by Medicare capped based on an international
index), would require manufacturers to offer these negotiated prices to other payers, and would restrict manufacturers from raising prices
on drugs covered by Medicare Parts B and D. This Act passed in the House of Representatives when it was introduced in 2019, and it has
been introduced again in the 2021 term. A modified version of this Act was included in the Build Back Better proposed legislation in
late 2021, which also included a provision enabling government price negotiations. We cannot predict whether any proposed legislation
will become law and the effect of these possible changes on our business cannot be predicted at this time.
Further, the Centers for Medicare & Medicaid
Services ("CMS") has significant regulatory authority to promulgate regulations and impose other compliance requirements
that may increase our compliance costs and impact our ability to attain profitability and market our product candidates. CMS sets coverage
and reimbursement rates for Medicare and oversees the implementation of Medicaid at the state level. CMS could modify or impose coverage
restrictions or modify reimbursement rates on any of our product candidates in a manner that could adversely impact our business. For
example, on January 8, 2021, CMS approved Tennessee's Medicaid section 1115 demonstration application, granting the state the unprecedented
ability to implement a closed drug formulary without foregoing the state's entitlement to rebates under the Medicaid Drug Rebate
Program. Implementation of a closed formulary could mean that our products could be excluded from coverage under Medicaid. It is unclear
whether the Biden Administration will reverse or modify Tennessee's section 1115 demonstration approval.
Within CMS, the Center for Medicare and Medicaid
Innovation ("CMMI"), as established by the ACA, has broad authority to design, implement, and test new health care payment
models that could potentially lower health care spending while maintaining quality or increase quality without increasing spending. CMMI
has considered implementing models that could have a significant adverse effect on our business. For example, on November 27, 2020, CMMI
finalized a mandatory Medicare Part B drug payment model that would have aligned payment for drugs with international reference prices,
entitled the Most Favored Nation (MFN) Model. The MFN Model was enjoined by a Federal court on December 28, 2020 for failure to comply
with rulemaking procedural requirements and was ultimately withdrawn by the Biden Administration on December 29, 2021. It is unclear
whether the Biden Administration will propose and implement the same or a similar model in future rulemaking, and we cannot predict how
future regulatory actions by CMMI or any other component of CMS may impact our business.
Any reduction in reimbursement from Medicare
and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which
we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.
92
The
Foreign Corrupt Practices Act
The
FCPA prohibits any United States individual or business from paying, offering, or authorizing payment or offering of anything of value,
directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the
foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose
securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that
accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an
adequate system of internal accounting controls for international operations.
Environmental
Regulations
We
use certain plastic, glass, fabric, metal and other products in our business which may be harmful if released into the environment. In
view of the nature of our business, compliance with federal, state, and local laws regulating the discharge of materials into the environment,
or otherwise relating to the protection of the environment, has had no material effect upon our operations or earnings, and we do not
expect it to have a material impact in the foreseeable future.
Tax
Laws and Regulations
Changes
in tax laws or regulations in the jurisdictions in which we do business, including the United States, or changes in how the tax
laws are interpreted, could further impact our effective tax rate, further restrict our ability to repatriate undistributed offshore
earnings, or impose new restrictions, costs or prohibitions on our current practices and reduce our net income and adversely affect our
cash flows.
We
are also subject to tax audits in the United States and other jurisdictions and our tax positions may be challenged by tax authorities.
Although we believe that our current tax provisions are reasonable and appropriate, there can be no assurance that these items will be
settled for the amounts accrued, that additional tax exposures will not be identified in the future or that additional tax reserves will
not be necessary for any such exposures. Any increase in the amount of taxation incurred as a result of challenges to our tax filing
positions could result in a material adverse effect on our business, results of operations and financial condition.
Other
Regulations
We
are subject to international, federal, national, regional, state, local and other laws and regulations affecting our business, including
those promulgated under the Occupational Safety and Health Act, the Consumer Product Safety Act, the Flammable Fabrics Act, the Textile
Fiber Product Identification Act, the rules and regulations of the Consumer Products Safety Commission, the Food, Drug, and Cosmetic
Act, the Foreign Corrupt Practices Act of 1977 (FCPA), various securities laws and regulations including but not limited to the Securities
Exchange Act of 1934, the Securities Exchange Act of 1933, and the Nasdaq Stock Market LLC Rules, various labor, workplace and related
laws, and environmental laws and regulations. Failure to comply with such laws and regulations may expose us to potential liability and
have an adverse effect on our results of operations.
Other
U.S. Regulatory Matters
Research
and development activities prior to product approval and manufacturing, sales, promotion and other activities following product approval
are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers
for Medicare & Medicaid Services, other divisions of the Department of Health and Human Services, or HHS, the Department of
Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational
Safety & Health Administration, the Environmental Protection Agency and state and local governments.
93
For
example, in the United States, prescription drug manufacturers must comply with federal fraud and abuse, data privacy, transparency,
and other healthcare laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription
drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that
is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which
payment may be made under a federal healthcare program, such as Medicare or Medicaid. Moreover, the government may assert that a claim
including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the civil False Claims Act.
Federal
civil and criminal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower
and qui tam actions, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false
or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false
record or statement material to a false or fraudulent claim to the federal government. Pharmaceutical companies have been prosecuted
under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would
bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies'
marketing of the product for unapproved, and thus non-covered, uses.
Federal
civil and criminal statutes prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact
or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, healthcare benefits,
items or services.
Pricing
and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and more recent
requirements in the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010,
or collectively the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration,
additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention
Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection
and unfair competition laws.
Payments
made to institutions, physicians and other healthcare providers are subject to federal and state regulations, including the Physician
Payments Sunshine Act, or the Sunshine Act. The Sunshine Act requires certain manufacturers of drugs, devices, biologicals and medical
supplies, with certain exceptions, to report annually to CMS information related to payments and other transfers of value to physicians
and teaching hospitals and ownership and investment interests held by physicians and their immediate family members.
Personally
identifiable information, under certain conditions, is also subject to data privacy and security regulation by both federal and state
governments. The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) as amended by the Health Information Technology
for Economic and Clinical Health Act (HITECH), and their implementing regulations, imposes certain requirements relating to the privacy,
security and transmission of individually identifiable health information on covered entities and business associates that perform services
for covered entities that involve individually identifiable health information.
The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing,
storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.
Many
states have similar healthcare statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs,
or, in several states, apply regardless of the payor. Certain states require the posting of information relating to clinical studies,
pharmaceutical companies to implement a comprehensive compliance program that includes a limit on expenditures for, or payments to, individual
medical or health professionals and track and report gifts and other payments made to physicians and other healthcare providers, and
certain state and local jurisdictions require the registration of pharmaceutical sales representatives.
94
The
failure to comply with any of these laws or regulatory requirements may subject a pharmaceutical manufacturer to possible legal or regulatory
action. Depending on the circumstances, failure to comply with these laws can result in significant civil, criminal and administrative
penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare
and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, integrity oversight and reporting obligations,
and the curtailment or restructuring of operations. Any action against us for violation of these laws, even if we successfully defend
against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our
business.
Prohibitions
or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. Changes
in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:
(i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or
discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could
adversely affect the operation of our business.
In
addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and
other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated
by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could
be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that
continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these
laws may affect our future operations.
Overseas
Government Regulation
In
addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among
other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product,
we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials
or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the
submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example,
a clinical trial application must be submitted to each country's national health authority and an independent ethics committee,
much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country's requirements,
clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use
may be restricted in some countries.
The
requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to
country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the
ethical principles that have their origin in the Declaration of Helsinki.
To
obtain regulatory approval of an investigational drug under EU regulatory systems, we must submit a marketing authorization application.
The application used to file the NDA in the United States is similar to that required in the EU, with the exception of, among other things,
country-specific document requirements.
For
other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials
must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin
in the Declaration of Helsinki.
If
we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.
European
Union General Data Protection Regulation
In
addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU's General
Data Protection Regulation, or the GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data of persons
in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened
timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories
of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing
of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States
and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting
the processing of personal data, including genetic, biometric or health data.
The
GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal
data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements
of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to €20,000,000 or
up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties.
GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process, and we may be required
to put in place additional mechanisms to ensure compliance with the new data protection rules.
95
MANAGEMENT
Directors
and Executive Officers
Set
forth below is information regarding our directors and executive officers as of the date of this prospectus.
Name
Age
Position
Marc Duey
66
Chairman and Director
Maria Vilenchik
53
Chief Executive Officer and Director
Arthur Healey
61
Chief Financial Officer and Secretary
Alex Shlyankevich
61
Director
Yuriy Gankin
56
Director
Michael Frid
50
Director
Michael Kody
53
Director Nominee
(1)
Douglas T. Moore
66
Director Nominee
(1)
(1)
Appointed to our
                                            board of directors effective automatically upon the effectiveness of the registration statement
                                            of which this prospectus forms a part.
Marc Duey
has served as Executive
Chairman and Chairman of the Board of the Company since 2014. Mr. Duey has also served as the managing partner of Duce Management, LLC
since September 2012, and was Chairman of TarMeta from 2016 until we acquired it in December 2021. Mr. Duey brings more than two decades
of experience in the Pharmaceutical and Biotechnology fields to our Company. Mr. Duey has managed an investment portfolio of technology
companies, including Atrin Pharmaceuticals, Felicitex, and TarMeta. From March 1994 to March 2020, Mr. Duey was the founder and Chief
Executive Officer of ProMetrics, Inc., a healthcare advisory firm dedicated to serving the biopharmaceutical industry, where Mr. Duey
managed more than 100 consultants serving the patient-level data needs of dynamic pharmaceutical firms, including many oncology firms,
in their quest to launch and grow successful brands. Mr. Duey is also a director of Atrin Pharmaceuticals and Trustee of International
House Philadelphia. Since 2007, Mr. Duey has also taught as an adjunct professor at West Chester University in Pennsylvania for undergraduates
and graduates in its marketing and MBA programs, specializing in its Pharmaceutical Product Development Program. Mr. Duey's educational
background includes Bachelor and Master of Science degrees in Science, with a specialization in Toxicology from the University of Ottawa,
an MBA from The University of Western Ontario's Richard Ivey School of Business, and a Master's Degree in International Business
from University of Liège. Our board of directors believes that Mr. Duey is qualified to serve as a member of the board due to
his record of service as chairman of Felicitex's board for eight years and TarMeta's board for six years, as well as his
more than 20 years of experience in the pharmaceutical and biotechnology fields.
Maria Vilenchik
founded our company
and has served as our Chief Executive Officer since May 2012. Dr Vilenchik leads the Company and is responsible for all management functions,
including business development, fundraising, and intellectual property. Prior to her tenure at the Company, Dr. Vilenchik was a consultant
at Advanced Bio Design Inc. in the Oncology Drug Development Department. From 2004 to 2012, Dr. Vilenchik worked at Hoffman-La Roche
Inc. as a Principal Scientist in the Discovery Oncology division. At Hoffman-La Roche, Dr. Vilenchik was a project leader for all phases
of pre-clinical drug discovery, led multi-functional teams through discovery, led identification and optimization phases, and independently
planned and managed aggressive research and product development timelines. From 2004 to 2005, Dr. Vilenchik was a Business Development
Consultant with Keryx Biopharmaceuticals in New York. Dr. Vilenchik participated in post-doctoral training at Memorial Sloan Kettering
Cancer Center, Dr. Rosen lab, from 2001 to 2004. Dr. Vilenchik's education includes a Bachelor of Science from St. Petersburg Polytechnic
University in St. Petersburg, Russia, a Master of Science from Brandeis University in Waltham, Massachusetts, and a Master of Philosophy
and a PhD in Molecular Pharmacology from Columbia University in New York. Our board of directors believes that Dr. Vilenchik is qualified
to serve as a member of the board due to her experience as our chief executive officer since our founding in 2012, and her expertise
in oncology and drug development.
Arthur Healey
has been our Chief
Financial Officer and Secretary since April 2021. Mr. Healey had previously provided consulting services to the Company from November
2017. Since January 2017, Mr. Healey has been the owner and Chief Executive Officer of A.T. Healey, LLC, an outsourced finance and accounting
company. Mr. Healey has also been Chief Financial Officer of Viihealth, Inc. since January 2017; Chief Financial Officer to New View
Surgical, Inc. since October 2016 and advisor of other private companies. Mr. Healey provides finance, accounting, and tax services,
including CFO services, to early-stage technology companies and those in the venture capital industry. Mr. Healey's experience
also includes consulting companies on corporate reorganizations, mergers and acquisitions, and contract negotiations. Mr. Healey previously
served as a Senior Manager at EY (formerly Ernst & Young LLP), Manager at PWC (formerly Coopers & Lybrand) and Manager at KPMG.
Mr. Healey has a BS in Accounting from Villanova University and a JD from Villanova University School of Law.
96
Alex Shlyankevich
has been our
director since January 2017. In April 2015, Dr. Shylankevich became President and owner of MH Biomedical Investments, LLC, or MH, a healthcare
investment company. At MH, Dr. Shlyankevich creates portfolios of healthcare investment projects and manages their deal sourcing, due
diligence, negotiations, and corporate governance. Dr. Shlyankevich has also served as a director at NuPulseCV, Inc., GiveVision, and
Constant Therapeutics LLC. Dr. Shlyankevich has more than 25 years of experience in the pharmaceutical industry in a variety of both
technical and managerial capacities, along with more than six years of experience specifically in healthcare investments. Dr. Shlyankevich
has a thorough understanding of compliance, business and budgetary aspects of CMC operations. Additionally, Dr. Shlyankevich has a background
in brand and generic pharmaceutical, biotech, drug delivery, medical devices, services, contract pharmaceuticals, and startup companies.
Dr. Shlyankevich has experience at all stages of the biomedical startup process: cross-functional and international facilitation of product
development, program leadership, collaboration management, business presentation, and start up organization growth. Further, in the drug
pharmaceutical process, Dr. Shylankevich has worked with matters involving the submission, approval, and commercial stages of the regulatory
review process of the FDA and the Federal Institute for Drugs and Medical Devices, the medical regulatory body in Germany. His educational
background includes a Master of Science degree in Pharmacy from the Moscow Medical School and a PhD. in Pharmaceutical Analysis. Our
board of directors believes that Dr. Shlyankevich is qualified to serve as a member of the board due to his business and investment management
background and experience in the pharmaceutical industry in a variety of technical and managerial capacities.
Yuriy Gankin
has been our director
since 2012. Dr. Gankin contributes his experience in business development and operations, as well as life science expertise to the Company.
Dr. Gankin is a life sciences researcher, entrepreneur, and inventor with more than two decades of experience. Dr. Gankin's research
has been published in multiple scientific journals and Dr. Gankin holds several patents in the areas of mass spectrometry and cancer
therapy. Dr. Gankin's expertise is in research, database development, and modeling in chemistry and biology. Since December 2019,
Dr. Gankin has been founder and Chief Scientific Officer at Quantori, LLC, a developer of intelligent IT and data science solutions for
life science and healthcare organizations. From June 2014 to December 2019, Mr. Gankin served as the Chief Life Science Officer at EPAM
Systems. At EPAM Systems, a software development services company, Dr. Gankin developed and managed scientific strategy, client management,
and pre-sales support. Dr. Gankin holds a PhD in Analytical Chemistry from Tufts University and an MBA from MIT Sloan School of Management.
Our board of directors believes that Dr. Gankin is qualified to serve as a member of the board due to his experience in business development
and operations and his life science expertise.
Michael
Frid
has been our director since May 2012. Dr. Frid served as our Vice President for preclinical operations from May 2012 to
June 2018. Prior to that, Dr. Frid worked at Wolfe Laboratories leading drug discovery and development and CMC processes. Since January
2016, Dr. Frid has been Chief Scientific Officer for Manna Molecular Science LLC, a research and development company that focused on
the manufacturing of cannabis-infused products such as hemp-derived cannabidiol (CBD). In this position, Dr. Frid leads the research,
development and manufacturing process scale up for the dosage forms for different administration routes. Since June 2019, Dr. Frid has
also been Chief Product Officer at Vella Bioscience, Inc., a cosmetics company. At Vella Bioscience, Dr. Frid develops and tests new
products, selection of manufacturing sites and oversight, and intellectual property strategy and execution. Dr. Frid holds a PhD in Organic
Chemistry from Massachusetts Institute of Technology (Dr. Buchwald lab) and he graduated cum laude with a BS from New York University.
Dr. Frid is a member of the honor societies Phi Beta Kappa, Phi Lambda Upsilon and Sigma Xi. Our board of directors believes that Dr.
Frid is qualified to serve as a member of the board due to his long experience as our board member and former officer, and knowledge
of our research and development programs, intellectual property portfolio, and business strategy.
Michael Kody
will be a member of
our board of directors immediately upon the effectiveness of the registration statement of which this prospectus forms a part. Mr. Kody
is a certified public accountant excelling in financial planning, accounting and risk management, and business process administration.
Mr. Kody is heavily involved in the pharmaceutical drug industry. From 2021 to the present day, Mr. Kody was the Chief Financial Officer
of Pharmaceutical Associates, Inc., where he revises financial reporting processes and provides guidance to the company for strategic
initiatives that included mergers and acquisitions, investments, and new market opportunities. From 2019 to 2021, Mr. Kody worked for
Prasco Laboratories, LLC in Healthcare Service as the Divisional President. During his tenure, Mr. Kody developed a business plan for
Prasco to achieve its target valuation within five years. Further, Mr. Kody also has executive experience from his time at G&W Laboratories
Inc. from 2017 to 2019, he was the Lead Executive that managed the operations and sale of the generic drug division valued at $100 million.
From 2007 to 2017, Mr. Kody worked as the SVP at AmerisourceBergen Corp. (NYSE: ABC). Mr. Kody's financial and audit experience
comes from his 16 years, from 1991 to 2007, as a public accountant at PricewaterhouseCoopers LLP in the Detroit, Chicago, Dallas, and
Philadelphia offices. At PwC Mr. Kody was a Senior Director who performed financial audits, Sarbanes Oxley Compliance review, and prepared
financial statements. Mr. Kody holds a Bachelor of Arts in Economics from the University of Michigan and is currently a Certified Public
Accountant in the states of Michigan and Pennsylvania. Our board of directors believes Mr. Kody is qualified to serve on the board due
to his financial experience in accounting and his business development background with pharmaceutical companies.
Douglas T. Moore
will be a member
of our board of directors immediately upon the effectiveness of the registration statement of which this prospectus forms a part. Through
his more than 25 years of retail experience, Mr. Moore has developed an understanding of strategic and tactical business issues that
include store operations, merchandising, supply chain, sourcing, and human resource planning. He also possesses senior management, marketing,
risk assessment and retail knowledge. Mr. Moore has served on multiple company boards, including his present position as a director on
the Board of LL Flooring Holdings Inc., formerly Lumber Liquidators Flooring (NYSE: LL), one of the leading specialty retailers of hard-surface
flooring in North America, since April 2006. From August 2019 to September 2021, Mr. Moore was the Chief Executive Officer of 1847 Goedeker
Inc., (NYSE American: GOED) ("Goedeker's") a publicly traded company, where he spearheaded a $222 million dollar acquisition
of Appliance Connection, Inc. and grew the company's market cap over seven times its previous amount during the company's
2020 initial public offering. Prior to his tenure at Goedeker's, Mr. Moore was a Senior Vice President of in the division of Aging
in the Home Remodelers, which is a part of FirstSTREET for Boomers and Beyond, Inc., a leading direct marketer of products for baby boomers,
from August 2017 to August 2019. Further, Mr. Moore has experience organically growing sales, as Mr. Moore was also the President and
Chief Executive Officer of Med-Air Homecare, a home healthcare equipment and service provider, from November 2013 to May 2019. Additionally,
Mr. Moore has extensive experience with consumer facing retail businesses, as he was the Chief Merchandising and Marketing Officer of
H. H. Gregg, Inc., a consumer electronics retail chain, from February 2012 to June 2012; the Vice President of Operations for Safelite
Group, Inc., a provider of vehicle glass repairs and replacements and insurance claims management company, from 2011 to 2012; the Senior
Vice President of Merchandising at Sears Holdings Corporation from 2007 to 2010; and the EVP Chief Merchandising Officer at Circuit City
Stores, Inc. from 2004 to 2007. Mr. Moore received his undergraduate degree and M.B.A. from the University of Virginia. We believe Mr.
Moore is qualified to serve on our board of directors due to his extensive experience in the retail industry and public company board
experience.
97
Mr.
                                            Kody and Mr. Moore will be members of our board of directors automatically upon the effectiveness
                                            of the registration statement of which this prospectus forms a part.
Our
directors currently have terms which will end at our next annual meeting of the shareholders or until their successors are elected and
qualify, subject to their prior death, resignation or removal. Officers serve at the discretion of the board of directors. There is no
arrangement or understanding between any director or executive officer and any other person pursuant to which he was or is to be selected
as a director, nominee or officer.
Family
Relationships
There
are no family relationships among any of our officers or directors.
Involvement
in Certain Legal Proceedings
To
the best of our knowledge, except as described below, none of our directors or executive officers has, during the past ten years:
●
been
                                            convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding
                                            traffic violations and other minor offences);
●
had
                                            any bankruptcy petition filed by or against the business or property of the person, or of
                                            any partnership, corporation or business association of which he was a general partner or
                                            executive officer, either at the time of the bankruptcy filing or within two years prior
                                            to that time;
●
been
                                            subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
                                            of any court of competent jurisdiction or federal or state authority, permanently or temporarily
                                            enjoining, barring, suspending or otherwise limiting, his involvement in any type of business,
                                            securities, futures, commodities, investment, banking, savings and loan, or insurance activities,
                                            or to be associated with persons engaged in any such activity;
●
been
                                            found by a court of competent jurisdiction in a civil action or by the Securities and Exchange
                                            Commission or the Commodity Futures Trading Commission to have violated a federal or state
                                            securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
●
been
                                            the subject of, or a party to, any federal or state judicial or administrative order, judgment,
                                            decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement
                                            of a civil proceeding among private litigants), relating to an alleged violation of any federal
                                            or state securities or commodities law or regulation, any law or regulation respecting financial
                                            institutions or insurance companies including, but not limited to, a temporary or permanent
                                            injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent
                                            cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
                                            mail or wire fraud or fraud in connection with any business entity; or
●
been
                                            the subject of, or a party to, any sanction or order, not subsequently reversed, suspended
                                            or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange
                                            Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the
                                            Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity
                                            or organization that has disciplinary authority over its members or persons associated with
                                            a member.
Corporate
Governance
Governance
Structure
We
chose to appoint a separate Chairman of the Board who is not our Chief Executive Officer. Our board of directors has made this decision
based on their belief that an independent Chairman of the Board can act as a balance to the Chief Executive Officer, who also serves
as a non-independent director.
The
Board's Role in Risk Oversight
The
board of directors oversees that the assets of our company are properly safeguarded, that the appropriate financial and other controls
are maintained, and that our business is conducted wisely and in compliance with applicable laws and regulations and proper governance.
Included in these responsibilities is the board's oversight of the various risks facing our company. In this regard, our board
seeks to understand and oversee critical business risks. Our board does not view risk in isolation. Risks are considered in virtually
every business decision and as part of our business strategy. Our board recognizes that it is neither possible nor prudent to eliminate
all risk. Indeed, purposeful and appropriate risk-taking is essential for our company to be competitive on a global basis and to achieve
its objectives.
While
the board oversees risk management, company management is charged with managing risk. Management communicates routinely with the board
and individual directors on the significant risks identified and how they are being managed. Directors are free to, and indeed often
do, communicate directly with senior management.
Our
board administers its risk oversight function as a whole by making risk oversight a matter of collective consideration. Much of this
work has been delegated to committees, which will meet regularly and report back to the full board. The audit committee oversees risks
related to our financial statements, the financial reporting process, accounting and legal matters, the compensation committee evaluates
the risks and rewards associated with our compensation philosophy and programs, and the nominating and corporate governance committee
evaluates risk associated with management decisions and strategic direction.
98
Independent
Directors
Nasdaq's rules generally require that a majority
of an issuer's board of directors must consist of independent directors. Our board of directors currently consists of five (5)
directors, Maria Vilenchik, Marc Duey, Alex Shlyankevich, Yuriy Gankin, and Michael Frid. There are two (2) director nominees, Michael
Kody, and Douglas Moore, who will also be members of our board of directors immediately upon the effectiveness of the registration statement
of which this prospectus forms a part. Including the director nominees, there will be five (5) directors who will meet the definition
of "Independent Director" within the meaning of Nasdaq's listing rules. We will also enter into independent director
agreements with our current independent directors and the director nominees, the terms of which are described under "
Executive
Compensation - Director Agreements
". As a result of these board changes, our board of directors will consist of seven
(7) directors, five (5) of whom will be independent within the meaning of Nasdaq's rules.
Committees
of the Board of Directors
Our
board has established an audit committee, a compensation committee, and a nominating and corporate governance committee, each with its
own charter approved by the board. The committee charters have been filed as exhibits to the registration statement of which this prospectus
is a part. Upon completion of this offering, we intend to make each committee's charter available on our website at https://www.felicitex.com/.
In
addition, our board of directors may, from time to time, designate one or more additional committees, which shall have the duties and
powers granted to it by our board of directors.
Audit
Committee
Michael Kody, Douglas Moore and Yuriy Gankin,
each of whom satisfies the "independence" requirements of Rule 10A-3 under the Exchange Act and Nasdaq's rules,
will serve on our audit committee upon Michael Kody's and Douglas Moore's appointment to the board, with Mr. Kody serving
as the chairman. Our board has determined that Mr. Kody qualifies as an "audit committee financial expert." The audit committee
oversees our accounting and financial reporting processes and the audits of the financial statements of our company.
The
audit committee is responsible for, among other things: (i) retaining and overseeing our independent accountants; (ii) assisting the
board in its oversight of the integrity of our financial statements, the qualifications, independence and performance of our independent
auditors and our compliance with legal and regulatory requirements; (iii) reviewing and approving the plan and scope of the internal
and external audit; (iv) pre-approving any audit and non-audit services provided by our independent auditors; (v) approving the fees
to be paid to our independent auditors; (vi) reviewing with our chief executive officer and principal financial officer and independent
auditors the adequacy and effectiveness of our internal controls; (vii) reviewing hedging transactions; and (viii) reviewing and assessing
annually the audit committee's performance and the adequacy of its charter.
Compensation
Committee
Alex Shlyankevich, Yuriy Gankin,
and Michael Frid, each of whom satisfies the "independence" requirements of Rule 10C-1 under the Exchange Act and Nasdaq's
rules, will serve on our compensation committee, with Dr. Gankin serving as the chairman. The members of the compensation committee are
also "outside directors" as defined in Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code, and
"non-employee directors" within the meaning of Section 16 of the Exchange Act. The compensation committee assists the board
in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers.
The
compensation committee is responsible for, among other things: (i) reviewing and approving the remuneration of our executive officers;
(ii) making recommendations to the board regarding the compensation of our independent directors; (iii) making recommendations to the
board regarding equity-based and incentive compensation plans, policies and programs; and (iv) reviewing and assessing annually the compensation
committee's performance and the adequacy of its charter.
Nominating
and Corporate Governance Committee
Alex Shlyankevich, Douglas Moore,
and Michael Frid, each of whom satisfies the "independence" requirements of Nasdaq's rules, will serve on our nominating
and corporate governance committee upon Douglas Moore's appointment to the board, with Dr. Frid serving as the chairman. The nominating
and corporate governance committee assists the board of directors in selecting individuals qualified to become our directors and in determining
the composition of the board and its committees.
99
The
nominating and corporate governance committee will be responsible for, among other things: (i) identifying and evaluating individuals
qualified to become members of the board by reviewing nominees for election to the board submitted by shareholders and recommending to
the board director nominees for each annual meeting of shareholders and for election to fill any vacancies on the board; (ii) advising
the board with respect to board organization, desired qualifications of board members, the membership, function, operation, structure
and composition of committees (including any committee authority to delegate to subcommittees), and self-evaluation and policies; (iii)
advising on matters relating to corporate governance and monitoring developments in the law and practice of corporate governance; (iv)
overseeing compliance with the our code of ethics; and (v) approving any related party transactions.
The
nominating and corporate governance committee's methods for identifying candidates for election to our board of directors (other
than those proposed by our shareholders, as discussed below) will include the solicitation of ideas for possible candidates from a number
of sources - members of our board of directors, our executives, individuals personally known to the members of our board of directors,
and other research. The nominating and corporate governance committee may also, from time-to-time, retain one or more third-party search
firms to identify suitable candidates.
In
making director recommendations, the nominating and corporate governance committee may consider some or all of the following factors:
(i) the candidate's judgment, skill, experience with other organizations of comparable purpose, complexity and size, and subject
to similar legal restrictions and oversight; (ii) the interplay of the candidate's experience with the experience of other board
members; (iii) the extent to which the candidate would be a desirable addition to the board and any committee thereof; (iv) whether or
not the person has any relationships that might impair his or her independence; and (v) the candidate's ability to contribute to
the effective management of our company, taking into account the needs of our company and such factors as the individual's experience,
perspective, skills and knowledge of the industry in which we operate.
A
shareholder may nominate one or more persons for election as a director at an annual meeting of shareholders if the shareholder complies
with the notice and information provisions contained in our bylaws. Such notice must be in writing to our Company not later than the
close of business on the ninetieth (90th) day nor earlier than the close of business on the one-hundred-twentieth (120th) day prior to
the first anniversary of the preceding year's annual meeting; provided, however, that in the event that the date of the annual
meeting is advanced more than thirty (30) days prior to or delayed by more than thirty (30) days after the anniversary of the preceding
year's annual meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the
one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of the ninetieth
(90th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting
is first made or as otherwise required by the Exchange Act. In addition, shareholders furnishing such notice must be a holder of record
on both (i) the date of delivering such notice and (ii) the record date for the determination of shareholders entitled to vote
at such meeting.
Code
of Ethics
We
have adopted a code of ethics that applies to all of our directors, officers and employees, including our principal executive officer,
principal financial officer and principal accounting officer. Such code of ethics addresses, among other things, honesty and ethical
conduct, conflicts of interest, compliance with laws, regulations and policies, including disclosure requirements under the federal securities
laws, and reporting of violations of the code.
A
copy of the code of ethics has been filed as an exhibit to the registration statement of which this prospectus is a part. We are required
to disclose any amendment to, or waiver from, a provision of our code of ethics applicable to our principal executive officer, principal
financial officer, principal accounting officer, controller, or persons performing similar functions. We intend to use our website as
a method of disseminating this disclosure as well as by SEC filings, as permitted or required by applicable SEC rules. Any such disclosure
will be posted to our website within four (4) business days following the date of any such amendment to, or waiver from, a provision
of our code of ethics.
100
EXECUTIVE
COMPENSATION
Summary
Compensation Table - Years Ended December 31, 2021 and 2020
The
following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to all individuals
who served as the Company's principal executive officer or acting in similar capacity during the last two completed fiscal years,
regardless of compensation level, and other individuals as required by Item 402(m)(2) of Regulation S-K, during the noted periods.
Name
                                            and Principal Position
Year
Salary
($)
Bonus
($)
Stock
Awards
($)
Option
Awards
($)
All
                                            Other
Compensation
($)
Total
($)
Maria Vilenchik,
2021
160,000
-
-
308,610
-
468,610
President, Chief Executive Officer and Director
2020
160,000
-
-
38,316
-
198,316
(1)
Information for
                                            Arthur Healey, the Company's Chief Financial Officer, is not required to be presented
                                            in this table pursuant to the instructions to Item 402(m)(2) of Regulation S-K.
Executive
Employment Agreements
Dr.
Maria Vilenchik, Chief Executive Officer
We entered into an employment agreement with our
Chief Executive Officer, Dr. Maria Vilenchik, dated December 30, 2022 and effective as of January 1, 2022. This agreement was amended
and ratified by our board of directors on March 10, 2022. Dr. Vilenchik's employment is at will and may be terminated by either
party at any time, with or without cause or reason. Although Dr. Vilenchik will initially serve as our Chief Executive Officer, we may
appoint a new Chief Executive Officer during Dr. Vilenchik's term. In that case, she would report to the Chief Executive Officer
and have the duties and responsibilities commensurate with her new position as our board of directors may determine. Dr. Vilenchik's
compensation will not be reduced in that circumstance.
We will pay Dr. Vilenchik an base annual salary of
$160,000, payable in monthly installments, until the Company raises a minimum of $10,000,000 in an equity capital raise, at which time
her base salary will increase to $250,000. Dr. Vilenchik's base salary will begin to accrue on January 1, 2022 and will be subject
to annual review and adjustment, but not reduction, pursuant to the Company's employee compensation policies in effect from time
to time. Dr. Vilenchik will be eligible for the following bonus cash compensation: (i) an annual bonus for the achievement of milestones
established by the Compensation Committee of the Board of Directors of up to 30% of her base salary; and (ii) a cash bonus equal to 2%
of any "upfront payment" on any collaboration agreement reached with a pharmaceutical company, so long as the negotiations
were initiated during her employment with the Company.  Additionally, Dr. Vilenchik will receive the following equity compensation:
(i) a grant of nonqualified stock options exercisable for 220,265 shares of common stock that will vest quarterly at a rate 1/16 per
quarter over a period of four years; and (i) a grant of nonqualified stock options exercisable for 330,397 shares of common stock that
will vest upon the achievement of milestones including: (a) 16.67% upon each of the first, second and third FDA approval of a new drug
indication pursuant to a successful IND application by the Company; (b) 16.67% upon the first dosing of a patient in each of the Company's
first, second and third Phase IIb trials; and (c) nonqualified stock options exercisable for 22,027 shares of common stock upon a non-dilutive
research funding from any U.S agency. The options will have an exercise price no higher than the fair market value on the date of grant
and shall be exercisable on a cashless basis, at Dr. Vilenchik's option, in the event of an exit. Dr. Vilenchik will be provided
with any standard executive officer benefits, reimbursement for all reasonable business-related expenses, 25 days of paid time off per
year, and a monthly phone allowance of up to $100 per month.
If
we terminate Dr. Vilenchik without cause or she resigns for good reason, as provided under her employment agreement, then we must, for
the shorter of 12 months or the period before Dr. Vilenchik obtains gainful employment or self-employment, pay monthly severance payments
of her base salary and any unvested options granted under her employment agreement will continue to vest. Any additional payments or
benefits following termination other than previously accrued obligations will be subject to Dr. Vilenchik's execution of a general
release of claims. Dr. Vilenchik is also subject to standard exclusive employment, confidentiality, non-disparagement, non-solicitation,
assignment of inventions, and non-competition provisions.
101
Other
Key Employee Agreements
Alexei Belenky, Lead Scientist
Under our employment contract with Alexei Belenky,
dated December 30, 2021, we agreed that Dr. Belenky would begin permanent full-time employment as our Lead Scientist on December 30,
2021. Dr. Belenky's employment is at will and his employment may be terminated by either party at any time and with or without
cause or reason. We may modify Dr. Belenky's job title or duties, provided that such changes would be considered reasonable for
a similar position in our industry or business. His job title or duties may be changed by agreement and with both his and our approval
or after a notice period required under law. We will pay Dr. Belenky an annual salary of $160,000, payable in monthly installments. Dr.
Belenky will receive a grant of nonqualified stock options exercisable for 22,027 shares of common stock that will vest over four years.
We will reimburse Dr. Belenky for all reasonable expenses, in accordance with our lawful policies as in effect from time to time, including
but not limited to, any travel and entertainment expenses incurred by Dr. Belenky in connection with the business of the Company. He
will be entitled to four weeks of paid vacation each year during the term of the agreement, and upon termination of employment, we will
compensate Dr. Belenky for any accrued but unused vacation. Dr. Belenky will be entitled to only those additional benefits that are currently
available as described in the lawful provisions of our employment booklets, manuals, and policy documents or as required by law. Any
discretionary benefits are subject to change, without compensation, upon the Company providing Dr. Belenky with 60 days' written
notice of that change and providing that any change to those benefits is taken generally with respect to other employees and does not
single out Dr. Belenky. Dr. Belenky is also subject to standard exclusive employment, confidentiality, non-disparagement, non-solicitation,
non-competition, and assignment of inventions provisions.
Outstanding
Equity Awards at Fiscal Year-End
As
of December 31, 2021, the following named executive officers had the following unexercised options, stock that has not vested, and equity
incentive plan awards:
Name
Number of Securities Underlying Unexercised Options
    # Exercisable
#
Unexercisable
Incentive Plan Awards: Number of Securities Underlying
    Unexercised Options
Option Exercise Price
Option Expiration Date
Number of Shares or Units of Stock not Vested
Market Value of Shares or Units not Vested
Awards: Number of Unearned Shares, Units or Other
    Rights not Vested
Value of Unearned Shares, Units or Other Rights not
    Vested
Maria Vilenchik, Chief Executive Officer and
    Director
87,425
-
-
$
0.18
2/28/2023
-
-
-
-
152,295
-
-
$
2.36
6/14/2031
15,532
-
-
$
2.36
6/14/2031
-
-
-
-
22,027
-
-
$
2.36
6/14/2031
-
3,305
-
$
2.36
3/17/2031
-
-
-
-
110,133
-
-
$
2.36
11/1/2031
Director
Compensation
The
table below sets forth the compensation paid to our directors during the fiscal year ended December 31, 2021 other than compensation
disclosed above in a director's capacity as an executive officer.
Name
Fees
Earned or
Paid in
Cash
($)
Stock
Awards
($)
Option
Awards
($)
All
                                            Other
Compensation
($)
Total
($)
Marc Duey
-
-
5,784
-
5,784
Alexander Shlyankevich
-
-
5,784
-
5,784
Yuriy Gankin
-
-
5,784
-
5,784
Michael Frid
-
-
17,352
-
17,352
Valeria Povolotsky
(1)
-
-
5,784
-
5,784
(1)
Resigned from the board of directors effective February 10,
                                         2022.
No
other member of our board of directors received any compensation for his or her services as a director during the fiscal year ended December
31, 2021.
102
Director
Agreements
On July 23, 2021, we entered into agreements with
each of the members of our board of directors. Under these agreements, we have agreed to award each director a one-time grant of nonqualified
stock options under our 2012 Plan to purchase 3,304 shares of our common stock at an exercise price equal to the fair market value of
the stock on the option grant date, as determined in good faith by our board of directors.  These options will vest over three years
subject to continued service on the board of directors or as a consultant to the Company and will be subject to the terms and conditions
of the 2012 Plan and standard form of 2021 Plan stock option agreement. We will also reimburse each director for reasonable travel and
other business-related expenses incurred in in connection with the performance of the director's duties for us, subject to preapproval
if an expense is more than $300. These agreements have confidentiality, assignment of inventions, and other standard provisions. Separately,
we have entered into our standard form of indemnification agreement for officers and directors of the Company with each of our directors
and director nominees.
The current independent directors, Alex Shlyankevich, Yuriy Gankin,
and Michael Frid, and the director nominees, Douglas T. Moore and Michael Kody, will enter into new independent director agreements. These
agreements will supersede the previous director agreements with the current independent directors. Under their independent director agreements
with us, each independent director and director nominee will receive an annual cash fee and an initial award of equity upon either: (i)
the director nominee's appointment to our board of directors immediately upon effectiveness of the registration statement of which
this prospectus forms a part or (ii) the effective date of this registration statement for current directors. We will pay an annual cash
compensation fee and provide an annual equity award to each director and director nominee, both paid in four equal installments no later
than the fifth business day of each calendar quarter commencing in the quarter following the effective date of our registration statement.
The cash fee to be paid to each director nominee will be $[ ]. The annual equity award for each independent director and director nominee
will be [ ] [shares of common stock/options]. Under their agreements, [ ] [shares of common stock] [options] will be awarded to each director
nominee and independent director. The [shares of common stock] [options] will vest in four (4) equal quarterly installments commencing
in the quarter following the effective date of this registration statement. We will also reimburse each independent director and director
nominee for pre-approved reasonable business-related expenses incurred in good faith in connection with the performance of the independent
director or director nominee's duties for us. As also required under the independent director agreements, we have separately entered
into a standard indemnification agreement with each of our current independent directors and director nominees, the term of which for
the director nominees will begin on the date of the director nominee's appointment.
The
2012 Stock Option and Restrictive Stock Plan
On July 20, 2012, we adopted the Felicitex Therapeutics
Inc. 2012 Stock Option and Restricted Stock Plan, or the 2012 Plan. The purpose of the 2012 Plan is to grant restricted stock and stock
options to our officers, employees, directors, advisors and consultants. The maximum number of shares of common stock that may be issued
pursuant to awards granted under the 2012 Plan after the effect of the reverse stock-split, is 1,101,321 shares. As of the date of this
prospectus, options to purchase 1,018,146 shares of our common stock are outstanding. There were also 83,175 shares of restricted stock
awards granted under the 2012 Plan, all of which are fully vested and included in the number of shares of our common stock currently
outstanding. The 2012 Plan terminates on July 20, 2022.
The
following summary briefly describes the principal features of the 2012 Plan and is qualified in its entirety by reference to the full
text of the 2012 Plan.
Awards
that may be granted include: (a) Incentive Stock Options, (b) Non-qualified Stock Options, and (c) Restricted Stock.
These awards offer our officers, employees, consultants and directors the possibility of future value, depending on the long-term price
appreciation of our Common Stock and the award holder's continuing service with our company.
Stock
options give the option holder the right to acquire from us a designated number of shares of Common Stock at a purchase price that is
fixed upon the grant of the option. The exercise price will not be less than the market price of the Common Stock on the date of grant.
Stock options granted may be either tax-qualified stock options (so-called "incentive stock options") or non-qualified stock
options.
Restricted
Stock are shares of Common Stock awarded to participants at no cost. Restricted Stock represent issued and outstanding shares of our
Common Stock subject to vesting criteria, or restricted stock units, which represent the right to receive shares of our Common Stock
subject to satisfaction of the vesting criteria. Restricted shares are forfeitable and non-transferable until the shares vest. The
vesting date or dates and other conditions for vesting are established when the shares are awarded.
All
of the permissible types of awards under the 2012 Plan are described in more detail as follows:
Purposes
of 2012 Plan:
The purposes of the 2012 Plan are to secure the benefits arising from capital stock ownership by officers, employees,
directors, and advisors or consultants for our company who are expected to contribute to our Company's future growth and success.
Administration of the 2012 Plan:
The 2012 Plan is currently administered by our board of directors and will be administered by
our compensation committee once it is established (which we refer to as the administrator). Among other things, the administrator has
the authority to select persons who will receive awards, determine the types of awards and the number of shares to be covered by awards,
and to establish the terms, conditions, performance criteria, restrictions and other provisions of awards. The administrator has authority
to establish, amend and rescind rules and regulations relating to the 2012 Plan.
Eligible
Recipients:
Persons eligible to receive awards under the 2012 Plan will be those officers, employees, consultants, and directors
of our company and its subsidiaries who are selected by the administrator.
103
Shares Available Under the 2012 Plan:
The maximum number of shares of our Common Stock that may be delivered to participants under the 2012 Plan is 1,101,231 subject
to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to an award under the 2012 Plan
for which the award is canceled, forfeited or expires again become available for grants under the 2012 Plan. Shares subject to an award
that is settled in cash will not again be made available for grants under the 2012 Plan.
Stock
Options:
General.
Subject
to the provisions of the 2012 Plan, the administrator has the authority to determine all grants of stock options. That determination
will include: (i) the number of shares subject to any option; (ii) the exercise price per share; (iii) the expiration
date of the option; (iv) the manner, time and date of permitted exercise; (v) other restrictions, if any, on the option or
the shares underlying the option; and (vi) any other terms and conditions as the administrator may determine.
Option
Price
. The exercise price for stock options will be determined at the time of grant. Normally, the exercise price will not be less
than the fair market value on the date of grant. As a matter of tax law, the exercise price for any incentive stock option awarded may
not be less than the fair market value of the shares on the date of grant. However, incentive stock option grants to any person owning
more than 10% of our voting stock must have an exercise price of not less than 110% of the fair market value on the grant date.
Exercise
of Options.
An option may be exercised only in accordance with the terms and conditions for the option agreement as established by
the administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the administrator, by actual or constructive delivery of shares of Common Stock to
the holder of the option based upon the fair market value of the shares on the date of exercise.
Expiration
or Termination.
Options, if not previously exercised, will expire on the expiration date established by the administrator at the
time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders of more
than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date if the holder's
service with our company or a subsidiary terminates before the expiration date. The option may remain exercisable for specified periods
after certain terminations of employment, including terminations as a result of death, disability or retirement, with the precise period
during which the option may be exercised to be established by the administrator and reflected in the grant evidencing the award.
Incentive
and Non-Qualified Options.
As described elsewhere in this summary, an incentive stock option is an option that is intended
to qualify under certain provisions of the Code, for more favorable tax treatment than applies to non-qualified stock options. Any
option that does not qualify as an incentive stock option will be a non-qualified stock option. Under the Code, certain restrictions
apply to incentive stock options. For example, the exercise price for incentive stock options may not be less than the fair market value
of the shares on the grant date and the term of the option may not exceed ten years. In addition, an incentive stock option may not be
transferred, other than by will or the laws of descent and distribution, and is exercisable during the holder's lifetime only by
the holder. In addition, no incentive stock options may be granted to a holder that is first exercisable in a single year if that option,
together with all incentive stock options previously granted to the holder that also first become exercisable in that year, relate to
shares having an aggregate market value in excess of $100,000, measured at the grant date.
Stock
Awards:
Stock awards can also be granted under the 2012 Plan. A stock award is a grant of shares of Common Stock or of a right
to receive shares in the future. These awards will be subject to such conditions, restrictions and contingencies as the administrator
shall determine at the date of grant. Those may include requirements for continuous service and/or the achievement of specified performance
goals.
Section 162(m)
of the Code:
Section 162(m) of the Code limits publicly-held companies to an annual deduction for U.S. federal income
tax purposes of $1.0 million for compensation paid to each of their principal executive officer or principal financial officer and
their three highest compensated executive officers (other than the principal executive officer or principal financial officer) determined
at the end of each year, referred to as covered employees.
104
Other
Material Provisions:
Awards will be evidenced by a written agreement, in such form as may be approved by the administrator. In
the event of various changes to the capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations,
an appropriate adjustment will be made by the administrator to the number of shares covered by outstanding awards or to the exercise
price of such awards. The administrator is also permitted to include in the written agreement provisions that provide for certain changes
in the award in the event of a change of control of our company, including acceleration of vesting. Except as otherwise determined by
the administrator at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution.
Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.
Our board also has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend
the 2012 Plan or any outstanding award or may terminate the 2012 Plan as to further grants, provided that no amendment will, without
the approval of our stockholders, to the extent that such approval is required by law or the rules of an applicable exchange, increase
the number of shares available under the 2012 Plan, change the persons eligible for awards under the 2012 Plan, extend the time within
which awards may be made, or amend the provisions of the 2012 Plan related to amendments. No amendment that would adversely affect any
outstanding award made under the 2012 Plan can be made without the consent of the holder of such award.
The 2022 Equity Incentive Plan
On March 15, 2022, our Board of Directors approved,
and our majority shareholders ratified, the Felicitex Therapeutics, Inc. 2022 Equity Incentive Plan, or the 2022 Plan.
Purpose of the 2022 Plan
: The purpose
of the 2022 Plan is to advance our interests and the interests of our shareholders by providing an incentive to attract, retain and reward
persons performing services for us and by motivating such persons to contribute to our growth and profitability. The maximum number of
shares of common stock that may be issued pursuant to awards granted under the 2022 Plan is 825,992 shares. Cancelled and forfeited stock
options and stock awards may again become available for grant under the 2022 Plan. As of the date of this prospectus, we have granted
options to purchase 96,117 shares of our common stock under the 2022 Plan and 729,874 shares remain available for issuance under the
2022 Plan. We intend that awards granted under the 2022 Plan be exempt from or comply with Section 409A of the Internal Revenue
Code, or the Code (including any amendments or replacements of such section), and the 2022 Plan shall be so construed.
The following summary briefly describes the principal
features of the 2022 Plan and is qualified in its entirety by reference to the full text of the 2022 Plan.
Awards that may be granted include: (a) Incentive
Stock Options, or ISO, (b) Nonstatutory Stock Options, (c) Stock Appreciation Rights, (d) Restricted Stock, (e) Restricted Stock Units,
or RSUs, (f) Stock granted as a bonus or in lieu of another award, and (g) Performance Awards. These awards offer us and our shareholders
the possibility of future value, depending on the long-term price appreciation of our common stock and the award holder's continuing
service with us.
Stock options give the option holder the right
to acquire from us a designated number of shares of our common stock at a purchase price that is fixed at the time of the grant of the
option. The exercise price will not be less than the market price of the common stock on the date of grant. Stock options granted may
be either incentive stock options or non-statutory stock options.
Stock appreciation rights, or SARs, which may
be granted alone or in tandem with options, have an economic value similar to that of options. When an SAR for a particular number of
shares is exercised, the holder receives a payment equal to the difference between the market price of the shares on the date of exercise
and the exercise price of the shares under the SAR. Again, the exercise price for SARs normally is the market price of the shares on
the date the SAR is granted. Under the 2022 Plan, holders of SARs may receive this payment - the appreciation value - either
in cash or shares of common stock valued at the fair market value on the date of exercise. The form of payment will be determined by
us.
Restricted stock are awards of a right to receive
shares of our common stock on a future date. Restricted Stock Unit Awards are evidenced by award agreements in such form as our board
of directors shall from time to time establish. Restricted stock shares can take the form of awards of restricted stock, which represent
issued and outstanding shares of our common stock subject to vesting criteria, or restricted stock units, which represent the right to
receive shares of our common stock subject to satisfaction of the vesting criteria. Restricted shares are forfeitable and non-transferable
until the shares vest. The vesting date or dates and other conditions for vesting are established when the shares are awarded.
105
Our board of directors may grant common stock
to any eligible recipient as a bonus, or to grant stock or other awards in lieu of obligations to pay cash or deliver other property
under the 2022 Plan or under other plans or compensatory arrangements.
The 2022 Plan also provides for performance awards,
representing the right to receive a payment, which may be in the form of cash, shares of common stock, or a combination, based on the
attainment of pre-established goals.
All of the permissible types of awards under
the 2022 Plan are described in more detail below.
Administration of the 2022 Plan:
The
2022 Plan is currently administered by our board of directors. All questions of interpretation of the 2022 Plan, of any award agreement
or of any other form of agreement or other document employed by us in the administration of the 2022 Plan or of any award shall be determined
by the Board, and such determinations shall be final, binding and conclusive upon all persons having an interest in the 2022 Plan or
such award, unless fraudulent or made in bad faith. Any and all actions, decisions and determinations taken or made by the board of directors.
in the exercise of its discretion pursuant to the 2022 Plan or award agreement or other agreement thereunder (other than determining
questions of interpretation pursuant to the preceding sentence) shall be final, binding and conclusive upon all persons having an interest
therein.
Eligible Recipients:
Persons
eligible to receive awards under the 2022 Plan will be those employees, consultants and directors of us or of any of our subsidiaries.
Shares Available Under the 2022 Plan:
The maximum aggregate number of shares of common stock that may be issued under the 2022 Plan shall be 825,992 shares and shall consist
of authorized but unissued or reacquired shares of common stock or any combination thereof, subject to adjustment for certain corporate
changes affecting the shares, such as stock splits, merger, consolidation, reorganization, reincorporation, recapitalization, reclassification,
stock dividend. Shares subject to an award under the 2022 Plan for which the award is canceled, forfeited, or expires again become available
for grants under the 2022 Plan.
Stock Options and Stock Appreciation Rights:
General.
Stock options and SARs shall
be evidenced by award agreements specifying the number of shares of common stock covered thereby, in such form as the board of directors
shall from time to time establish. Each Stock option grant will identify the option as an ISO or Nonstatutory Stock Option. Subject to
the provisions of the 2022 Plan, the administrator has the authority to determine all grants of stock options. That determination will
include: (i) the number of shares subject to any option; (ii) the exercise price per share; (iii) the expiration date of the option;
(iv) the manner, time and date of permitted exercise; (v) other restrictions, if any, on the option or the shares underlying the option;
and (vi) any other terms and conditions as the administrator may determine.
Option Price
. The exercise price for each
stock option or SAR shall be established in the discretion of the board of directors; provided, however, that the exercise price per
share for the stock option or SAR shall be not less than the fair market value of a share of common stock on the effective date of grant
of the stock option or SAR. Notwithstanding the foregoing, a stock option or SAR may be granted with an exercise price lower than the
minimum exercise price set forth above if such stock option or SAR is granted pursuant to an assumption or substitution for another option
in a manner qualifying under the provisions of Section 424(a) of the Code.
Exercise of Options.
Stock options
may be immediately exercisable but subject to repurchase or may be exercisable at such time or times, or upon such event or events, and
subject to such terms, conditions, performance criteria and restrictions as shall be determined by the board of directors and set forth
in the award agreement evidencing such stock option. No stock option or SAR shall be exercisable after the expiration of ten (10) years
after the effective date of grant of such stock option or SAR. Subject to the foregoing, unless otherwise specified by the board of directors
in the grant of a stock option or SAR, any stock option or SAR granted hereunder shall terminate ten (10) years after the effective date
of grant of the stock option or SAR, unless earlier terminated in accordance with its provisions. The board of directors may set a reasonable
minimum number of shares of common stock that may be exercised at any one time.
Expiration or Termination.
Options,
if not previously exercised, will expire on the expiration date established by the administrator at the time of grant. In the case of
incentive stock options, such term cannot exceed ten years provided that in the case of holders of more than 10% of our total combined
voting stock, such term cannot exceed five years. Options will terminate before their expiration date if the holder's service with
our company or a subsidiary terminates before the expiration date. The option may remain exercisable for specified periods after certain
terminations of employment, including terminations as a result of death, disability or retirement, with the precise period during which
the option may be exercised to be established by the administrator and reflected in the grant evidencing the award.
106
Incentive Stock Options.
Stock options
intending to qualify as ISOs may only be granted to employees, as determined by the board of directors. No ISO shall be granted to any
person if immediately after the grant of such award, such person would own common stock, including common stock subject to outstanding
awards held by him or her under the 2022 Plan or any other plan established by the Company, amounting to more than ten percent (10%)
of the total combined voting power or value of all classes of stock of the Company. To the extent that the award agreement specifies
that an Option is intended to be treated as an ISO, the Option is intended to qualify to the greatest extent possible as an "incentive
stock option" within the meaning of Section 422 of the Code, and shall be so construed; provided, however, that any such designation
shall not be interpreted as a representation, guarantee or other undertaking on the part of the Company that the Option is or will be
determined to qualify as an ISO. If and to the extent that any shares of Stock are issued under a portion of any Option that exceeds
the $100,000 limitation of Section 422 of the Code, such shares of common stock shall not be treated as issued under an ISO notwithstanding
any designation otherwise.
Restricted Stock Awards:
Stock
awards can also be granted under the 2022 Plan. A stock award is a grant of shares of common stock or of a right to receive shares in
the future. These awards will be subject to such conditions, restrictions and contingencies as the administrator shall determine at the
date of grant. Those may include requirements for continuous service and/or the achievement of specified performance goals.
Restricted Stock Units
: RSU
Awards shall be evidenced by award agreements in such form as the board of directors shall from time to time establish. The purchase
price for shares of Stock issuable under each RSU Award shall be established by the board of directors in its discretion. Except as may
be required by Applicable Law or established by the board of directors, no monetary payment (other than applicable tax withholding) shall
be required as a condition of receiving a RSU Award. Shares issued pursuant to any RSU Award may (but need not) be made subject to vesting
conditions based upon the satisfaction of such Service requirements, conditions, restrictions or Performance Criteria, as shall be established
by the Board and set forth in the award agreement evidencing such award.
Performance Criteria
:
Under
the 2022 Plan, Performance Criteria means business criteria including, but not limited to: revenue; revenue growth; earnings before interest
and taxes; earnings before interest, taxes, depreciation and amortization; earnings per share; operating income; pre-or after-tax income;
net operating profit after taxes; economic value added (or an equivalent metric); ratio of operating earnings to capital spending; cash
flow (before or after dividends); cash-flow per share (before or after dividends); net earnings; net sales; sales growth; share price
performance; return on assets or net assets; return on equity; return on capital (including return on total capital or return on invested
capital); cash flow return on investment; total shareholder return; improvement in or attainment of expense levels; and improvement in
or attainment of working capital levels or Performance Criteria. Any Performance Criteria may be used to measure the Company's
performance as a whole or any of the Company's business units and may be measured relative to a peer group or index.
Performance Awards.
Performance
awards shall be evidenced by award agreements in such form as the board of directors shall from time to time establish. Each performance
sward shall entitle the participant to a payment in cash or common stock upon the attainment of Performance Criteria and other terms
and conditions specified by the board of directors. Notwithstanding the satisfaction of any Performance Criteria, the amount to be paid
under a performance award may be adjusted by the board of directors on the basis of such further consideration as the board of directors
in its sole discretion shall determine. The board of directors may, in its discretion, substitute actual common stock for the cash payment
otherwise required to be made to a participant pursuant to a performance award.
Bonus Stock and Awards in Lieu of Obligations.
The
board of directors may grant common stock to any eligible recipient as a bonus, or to grant common stock or other awards in lieu of obligations
to pay cash or deliver other property under the 2022 Plan or under other plans or compensatory arrangements, provided that, in the case
of participants subject to Section 16 of the Exchange Act, the amount of such grants remains within the discretion of the board of directors
to the extent necessary to ensure that acquisitions of common stock or other awards are exempt from liability under Section 16(b) of
the Exchange Act. common stock or awards granted hereunder shall be subject to such other terms as shall be determined by the board of
directors.
Other Material Provisions:
Awards
will be evidenced by a written agreement, in such form as may be approved by the administrator. In the event of various changes to the
capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate adjustment will be
made by the administrator to the number of shares covered by outstanding awards or to the exercise price of such awards. The administrator
is also permitted to include in the written agreement provisions that provide for certain changes in the award in the event of a change
of control of our company, including acceleration of vesting. Except as otherwise determined by the administrator at the date of grant,
awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution, we are
permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. Our board of directors also
has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend the 2022 Plan
or any outstanding award or may terminate the 2022 Plan as to further grants, provided that no amendment will, without the approval of
our stockholders, to the extent that such approval is required by law or the rules of an applicable exchange, increase the number of
shares available under the 2022 Plan, change the persons eligible for awards under the 2022 Plan, extend the time within which awards
may be made, or amend the provisions of the 2022 Plan related to amendments. No amendment that would adversely affect any outstanding
award made under the 2022 Plan can be made without the consent of the holder of such award.
107
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Transactions
with Related Persons
The following includes a summary of transactions
since the beginning of our 2019 fiscal year, or any currently proposed transaction, in which we were or are to be a participant and the
amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last
three completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation
described under "
Executive Compensation
" above). We believe the terms obtained or consideration that we paid or received,
as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid
or received, as applicable, in arm's-length transactions.
●
On January 16, 2018, Marc
                                            Duey, our Chairman, agreed to lend up to $550,000 to the Company on an unsecured basis, at
                                            an interest rate of 12% per year, payable on demand and convertible into shares of our common
                                            stock at Mr. Duey's option at a price per share of $2.29 On March 17, 2020, we issued
                                            238,612 shares of our common stock on Mr. Duey's conversion of $502,000 in principal
                                            and $45,000 of accrued interest on loans under the January 16, 2018 agreement. Mr. Duey also
                                            received warrants to purchase 47,722   additional shares of common stock as an
                                            incentive to convert these loans.
●
On March 31, 2020, Mr. Duey
                                            entered into an additional on-demand agreement to lend us up to $550,000 on an unsecured
                                            basis, at an interest rate of 12% per year, payable on demand and convertible into shares
                                            of our common stock at Mr. Duey's option at a price per share of $2.29. On March 17,
                                            2021, we issued 232,473 shares of common stock to Mr. Duey on conversion of $521,000 in principal
                                            and $27,823 of accrued interest on loans under the March 31, 2020 agreement. Additionally,
                                            the Company issued warrants that are exercisable into 46,495 shares of common stock within
                                            five years at an exercise price of $2.36 per share as an incentive to convert these loans.
●
Through
                                            December 31, 2020, Duce Consulting, Inc., a company owned by Marc Duey, provided management
                                            consulting services to TarMeta valued at $48,000. This amount was recorded as a capital contribution
                                            by TarMeta.
●
An outsourced accounting
                                            and finance firm that is owned by our Chief Financial Officer provided accounting, bookkeeping,
                                            finance and other services to us. For the three months ended March 31, 2022, total fees for
                                            services were $91,083. For the years ended December 31, 2021 and 2020, total fees for these
                                            services were $96,000 and $41,000, respectively. The cost of these services was recorded
                                            as a General and Administrative expense. For the year ended December 31, 2021, $60,000 of
                                            accounts payable owed to our Chief Financial Officer was converted into options to purchase
                                            25,416 shares of our common stock.
●
On March 31, 2021, Mr. Duey
                                            entered into an additional on-demand agreement to lend us up to $550,000 on an unsecured
                                            basis, at an interest rate of 12% per year, payable on demand and convertible into shares
                                            of our common stock at Mr. Duey's option at a price per share of $2.29. On November
                                            2, 2021, we issued 147,586 shares of our common stock to Mr. Duey on conversion of $348,420
                                            in principal on loans under the March 31, 2021 agreement. Additionally, the Company issued
                                            warrants that are exercisable into 29,518 shares of common stock within five years at an
                                            exercise price of $2.36 per share as an incentive to convert these loans.
●
On December 30, 2021, we
                                            completed the acquisition of TarMeta Biosciences, LLC pursuant to an Agreement and Plan of
                                            Merger with TarMeta. In consideration of the acquisition of TarMeta, we issued a total of
                                            635,378 shares of our common stock to the members of TarMeta in exchange for their TarMeta
                                            membership interests. We issued 607,845 of these shares to Mr. Duey, who was a member of
                                            TarMeta and one of the designees of its shares.
●
During
                                            the year ended December 31, 2020, our Chief Executive Officer provided scientific advisory
                                            services to TarMeta totaling $30,000.
●
As
                                            of March 15, 2022, the total liability owed to our Chairman, Marc Duey, for loans Mr. Duey
                                            made to us was $541,180 in principle plus $54,564 in accrued interest.  On March 16,
                                            2022, our board of directors authorized the conversion of the combined liability in
                                            the amount of $595,744 into 192,977 shares of our common stock, effective as of March 16,
                                            2022.  The conversion price valuation was determined using an independent 409A
                                            valuation.
●
From
                                            January 1, 2022 through March 15, 2022, our Chairman and principal investor made additional
                                            advances to the Company in the amount of $335,000.
●
On March 16, 2022, we entered into a convertible grid note with the
Chairman with respect to additional advances that the Chairman has made and expects to make to us for general working capital purposes
from now until additional funds are raised from investors. The grid note carries interest at the rate of 12% per year payable in one lump
sum on the maturity date, matures on the one-year anniversary of the issuance date and may be prepaid at any time, in whole or in part,
without penalty. As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has loaned
to us an additional $408,000 under the grid note.
●
Anna
                                            Vilenchik, the mother of our CEO, was compensated $10,000 for research services rendered
                                            during the year ended December 31, 2021, and $8,300 during the three months ended March 31,
                                            2022, as an independent contractor.
Promoters
and Certain Control Persons
Each of Maria Vilenchik, our co-founder and Chief
Executive Officer, and Michael Frid, Valeria Povolotsky, and Yuriy Gankin, each co-founders, may be deemed a "promoter" as
defined by Rule 405 of the Securities Act. For information regarding compensation, including items of value, that have been provided
or that may be provided to these individuals, please refer to "
Executive Compensation
" above.
108
PRINCIPAL
SHAREHOLDERS
The following table sets forth certain information
with respect to the beneficial ownership of our common stock as of the date of this prospectus for (i) each of our named executive officers,
directors, and director nominees; (ii) all of our named executive officers and directors as a group; and (iii) each other shareholder
known by us to be the beneficial owner of more than 5% of our outstanding common stock.
The
following table assumes that the underwriters have not exercised the over-allotment option.
Beneficial
ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. For
purposes of this table, a person or group of persons is deemed to have "beneficial ownership" of any shares of common stock
that such person or any member of such group has the right to acquire within sixty (60) days of the date of this prospectus. For purposes
of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares
that such person or persons has the right to acquire within sixty (60) days of the date of this prospectus are deemed to be outstanding
for such person, but not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion
herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership by any person.
Unless
otherwise indicated, the address of each beneficial owner listed in the table below is c/o our company, Felicitex Therapeutics Inc.,
27 Strathmore Road, Natick, MA 01760.
Common
Stock
Beneficially
Owned Prior
to this Offering
(1)(2)
Common
    Stock
Beneficially Owned After
this Offering
(2)(3)
Name of Beneficial Owner
Shares
%
Shares
%
Marc Duey
(5) (6)
3,167,447
66.0
3,167,447
43.5
%
Maria Vilenchik
(4) (5) (7)
1,124,625
22.8
1,124,625
15.2
%
Alex Shlyankevich
(5) (8)
1,653
*
1,653
*
Yuriy Gankin
(5) (9)
174,033
3.9
174,033
2.5
%
Michael Frid
(5) (10)
178,706
3.9
178,706
2.5
%
Michael Kody, Director Nominee
(11)
—
—
—
—
Douglas T. Moore, Director Nominee
(12)
—
—
—
—
All executive officers and directors** (7 persons)
4,556,850
88.4
%
4,556,850
59.4
%
Norma Investments Limited
(14)
436,373
9.8
%
436,373
6.3
%
*
Less
                                            than 1%
**
Arthur Healey is
                                            not a named executive officer and is therefore not included.
(1)
Based on 4,455,999 shares of common stock issued and outstanding as
of August 10, 2022.
(2)
Beneficial
                                            ownership is determined in accordance with the rules of the SEC and generally includes voting
                                            or investment power with respect to securities. Except as disclosed in the following footnotes,
                                            each of the beneficial owners listed above has direct ownership of and sole voting and investment
                                            power to the shares of the Company's common stock.
(3)
Based
                                            on 6,978,518 shares of common stock issued and outstanding after this offering.
(4)
Named
                                            Executive Officer.
(5)
Director.
109
(6)
Consists of (i) 2,864,975 shares of common stock held directly, (ii)
fully vested nonqualified stock options exercisable into 1,468 shares, (iii) nonqualified stock options exercisable into 184 shares within
60 days of the date of this prospectus, (iv) 177,086 shares of common stock issuable upon the conversion of a convertible promissory note
as of the date of this prospectus, and (v) warrants to purchase 123,734 shares of common stock. Does not include 1,652 shares issuable
upon the exercise of options not vesting within 60 days.
(7)
Consists of (i) 694,264 shares of common stock, (ii) nonqualified stock
options exercisable into 13,950 shares within 60 days of the date of this prospectus, and (iii) fully vested non-qualified stock options
to purchase 416,411 shares of common stock. Does not include (iv) 192,730 shares of common stock issuable upon the exercise of nonqualified
options, subject to vesting, (v) 1,652 shares issuable upon the exercise of options not vesting within 60 days, and (vi) 330,397 shares
of common stock issuable upon the exercise of nonqualified options, subject to certain milestones.
(8)
Consists of (i) fully vested non-qualified stock options exercisable
into 1,468 shares and (ii) non-qualified stock options exercisable into 184 shares within 60 days of the date of this prospectus. Does
not include 1,652 shares issuable upon the exercise of options not vesting within 60 days of the date of this prospectus.
(9)
Consists of (i) 164,887 shares of common stock, (ii) fully vested non-qualified
stock option to purchase 8,778 shares of common stock, and (iii) non-qualified stock options exercisable into 184 shares within 60 days
of the date of this prospectus. Does not include 1,652 shares issuable upon the exercise of options not vesting within 60 days.
(10)
Consists of (i) 133,639 shares of common stock, (ii) a fully vested
non-qualified stock option to purchase 44,699 shares of common stock, and (iii) non-qualified stock options exercisable into 184 shares
within 60 days of the date of this prospectus. Does not include 1,652 shares issuable upon the exercise of options not vesting within
60 days.
(11)
Under
                                            the independent director agreement between Michael Kody and the Company, Mr. Kody will receive
                                            (i) an initial award of [ ] shares of common stock, which will vest in four (4) equal quarterly
                                            installments commencing in the quarter following the date of his appointment immediately
                                            upon the effectiveness of the registration statement of which this prospectus forms a part
                                            and (ii) an annual amount of equity compensation of [ ] shares of common stock.
(12)
Under the independent
                                            director agreement between Douglas T. Moore and the Company, Mr. Moore will receive (i) an
                                            initial award of [ ] shares of common stock, which will vest in four (4) equal quarterly
                                            installments commencing in the quarter following the date of his appointment immediately
                                            upon the effectiveness of the registration statement of which this prospectus forms a part
                                            and (ii) an annual amount of equity compensation of [ ] shares of common stock.
(13)
Includes the
                                            shares of common stock beneficially owned by Arthur Healey, our Chief Financial Officer.
                                            Mr. Healey owns a fully vested non-qualified stock option to purchase 25,416 shares of common
                                            stock.
(14)
[  ]
                                            has voting and dispositive control over Norma Investments Limited. Norma Investments Limited's
                                            business address is Coastal Building, Wickham's Cay II, P.O. Box 2221, Road Town, Tortola,
                                            British Virgin Islands.
We
do not currently have any arrangements which if consummated may result in a change of control of our company.
110
DESCRIPTION
OF SECURITIES
General
Our
authorized capital stock currently consists of 100,000,000 shares, consisting of 100,000,000 shares of common stock, par value $0.0001
per share.
The
following description summarizes important terms of the classes of our capital stock following the filing of our articles of incorporation.
This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of incorporation and
our bylaws which have been filed as exhibits to the registration statement of which this prospectus is a part.
As of the date of this prospectus, there were
4,455,999 shares of common stock issued and outstanding held by eleven (11) stockholders of record.
Common
Stock
Voting
Rights
.
The holders of common stock are entitled to one vote for each share held of record on all matters submitted to
a vote of the shareholders. Under our articles of incorporation and bylaws, any corporate action to be taken by vote of shareholders
other than for election of directors shall be authorized by the affirmative vote of the majority of votes cast. Directors are elected
by a plurality of votes. Shareholders do not have cumulative voting rights.
Dividend
Rights
. Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled
to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.
Liquidation
Rights
. In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably
in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities and
the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.
Other
Rights
. Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking
fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to,
and may be adversely affected by, the rights of the holders of shares of any series of preferred stock.
Units
Each
unit being offered in this offering consists of one share of common stock and a warrant to purchase one share of common stock. The share
of common stock and warrant that are part of the units are immediately separable and will be issued separately in this offering, although
they will have been purchased together in this offering.
Warrants
Included in the Units
Form
.
The warrants will be issued under a warrant agent agreement between us and [  ], as warrant agent. The material terms and provisions
of the warrants offered hereby are summarized below. The following description is subject to, and qualified in its entirety by, the form
of warrant agent agreement and accompanying form of warrant, which is filed as an exhibit to the registration statement of which this
prospectus is a part. You should review a copy of the form of warrant agent agreement and accompanying form of warrant for a complete
description of the terms and conditions applicable to the warrants.
Exercisability
.
The warrants are exercisable immediately upon issuance and will thereafter remain exercisable at any time up to five (5) years from the
date of original issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a
duly executed exercise notice accompanied by payment in full for the number of shares purchased upon such exercise (except in the case
of a cashless exercise as discussed below).
Exercise
Price
. Each warrant represents the right to purchase one share of common stock at an exercise price of $[  ] per share
(equal to 100% of the public offering price). The exercise price is subject to appropriate adjustment in the event of certain share dividends
and distributions, stock splits, stock combinations, reclassifications or similar events affecting our shares of common stock and also
upon any distributions of assets, including cash, stock or other property to our shareholders.
111
The warrant exercise price is also subject to
the following anti-dilution adjustments: Subject to certain exemptions outlined in the warrants, for a period until the later of: (i)
two years from the date of issuance of the warrants, or (ii) on the date no Qualified Buyer holds any warrants, if the Company shall
sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter into an agreement to sell, or grant any right
to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any
shares of its common stock or convertible security, at an effective price per share less than the exercise price of the warrant then
in effect, or a dilutive issuance, the exercise price of the warrant shall be reduced to equal the effective price per share in such
dilutive issuance; provided, however, that in no event shall the exercise price of the warrant be reduced to an exercise price lower
than 50% of the public offering price per unit in this offering, or the floor price. On the date that is 90 calendar days immediately
following the initial issuance date of the warrants, the exercise price of the warrants will adjust to be equal to the Reset Price, provided
that such value is less than the exercise price in effect on that date. The Reset Price is equal to the greater of (a) the floor price
and (b) 100% of the lowest volume weighted average price per share of our common stock occurring during the 90 calendar days following
the issuance date of the warrants. The lowest Reset Price is the same as the floor price, or $3.125, which is 50% of the offering price,
based on an assumed public offering price of $6.25 per unit, the midpoint of the price range of the units, per share. Separately, the
Company may choose to lower the exercise price of the warrants at its option at any time during the life of the warrants.
Cashless
Exercise
. If, at any time during the term of the warrants, the issuance of shares of common stock upon exercise of the warrants
is not covered by an effective registration statement, the holder is permitted to effect a cashless exercise of the warrants (in whole
or in part) by having the holder deliver to us a duly executed exercise notice, canceling a portion of the warrant in payment of the
purchase price payable in respect of the number of shares of common stock purchased upon such exercise.
Additional Warrants
. Additionally,
in the event of any adjustment under the dilutive issuance provision of the warrants that results in a reduction of the exercise price,
in aggregate, to 50% of the Initial Exercise Price, then in connection with such adjustment, each Qualified Buyer shall receive two Additional
Warrants for each one warrant held by such holder on the date of adjustment. The maximum number of warrants subject to such adjustment
by a given Qualified Buyer will be limited to the number of warrants purchased by such Qualified Buyer in this offering. Qualified Buyers
will also receive Additional Warrants as a result of the Reset Price being set at the floor price. Such Additional Warrants shall be
on substantially the same terms as the warrant; provided, however, that the term of the Additional Warrants shall be five (5) years from
the issuance date and such Additional Warrants will not be tradable warrants.
Failure to Timely Deliver Shares
.
If we fail for any reason to deliver to the holder the shares subject to an
exercise within the timeframe specified in the warrant, we will be required pay to the holder cash liquidated damages. In addition, if
the holder or its broker has to purchase shares to deliver in satisfaction of a sale by the holder, then we shall be required to pay
to the holder a certain cash amount as specified in the warrant.
Exercise Limitation.
A holder will
not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially own in excess
of 4.99% (or, upon election by the holder prior to the issuance of any warrants, 9.99%) of the number of shares of our common
stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the
terms of the warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided
that any increase in such percentage shall not be effective until 61 days following notice from the holder to us.
Forced Exercise
. The warrants (including
the Additional Warrants) will be subject to forced exercise commencing six months from issuance subject to the condition that the volume
weighted average price of our common stock exceeds 200% of the Initial Exercise Price for ten consecutive trading days and subject to
certain other conditions set forth in the warrants.
Rights
as a Shareholder
. Except as otherwise provided in the warrants or by virtue of such holder's ownership of our shares of
common stock, the holder of a warrant does not have the rights or privileges of a holder of our shares of common stock, including any
voting rights, until the holder exercises the warrant.
Warrant Agent; Global Certificate
.
The
warrants will be issued in registered form under the warrant agent agreement between the warrant
agent and us. The warrants shall initially be represented only by one or more global warrants deposited with the warrant agent, as custodian
on behalf of The Depository Trust Company (DTC) and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed
by DTC. Our transfer agent, VStock Transfer, LLC, will serve as the warrant agent.
112
Governing
Law and Jurisdiction
. The warrant agent agreement and warrant provide that the validity, interpretation, and performance of the
warrant agent agreement and the warrants will be governed by the laws of the State of New York, without giving effect to conflicts of
law principles that would result in the application of the substantive laws of another jurisdiction. In addition, the warrant agent agreement
and warrant provide that any action, proceeding or claim against any party arising out of or relating to the warrant agent agreement
or the warrants must be brought and enforced in the state and federal courts sitting in the Borough of Manhattan in the State of New
York. Investors in this offering will be bound by these provisions. However, we do not intend that the foregoing provisions would apply
to actions arising under the Securities Act or the Exchange Act.
Representative's
Warrants
Upon
the closing of this offering, there will be up to [198,400] shares of common stock issuable upon exercise of the representative's
warrants. See "
Underwriting-Representative's Warrants
" below for a description of the representative's
warrants.
Warrants
Issued to Marc Duey
On March 17, 2020, March 17, 2021 and November
2, 2021, we issued warrants to purchase 47,722, 46,495 and 29,518 shares of our common stock, respectively, to Marc Duey, our Chairman.
These warrants are exercisable at $2.36 per share. The March 2020 warrants have a term of six years while the March 2021 and the November
2021 warrants each have five-year terms.
Options
On July 20, 2012, we adopted the Felicitex Therapeutics
Inc. 2012 Stock Option and Restricted Stock Plan, or the 2012 Plan. The purpose of the 2012 Plan is to grant restricted stock and stock
options to our officers, employees, directors, advisors and consultants. The maximum number of shares of common stock that may be issued
pursuant to awards granted under the 2012 Plan is 1,101,321 shares. Cancelled and forfeited stock options and stock awards may again
become available for grant under the Plan. As of the date of this prospectus, unexercised options to purchase 1,018,146 shares of our
common stock are outstanding under the 2012 Plan. There were also 83,175 shares of restricted stock awards granted under the 2012 Plan,
all of which are fully vested and are included in number of shares of our common stock currently outstanding. The 2012 Plan expires on
July 20, 2022.
On March 15, 2022, we adopted the Felicitex Therapeutics
Inc. 2022 Equity Incentive Stock Plan, or the 2022 Plan. The purpose of the 2022 Plan is to grant restricted stock and stock options
to our officers, employees, directors, advisors and consultants. The maximum number of shares of common stock that may be issued pursuant
to awards granted under the 2022 Plan is 825,992 shares. Cancelled and forfeited stock options and stock awards may again become available
for grant under the Plan. As of the date of this prospectus, unexercised options to purchase 96,117 shares of our common stock are outstanding
under the 2022 Plan. The 2022 Plan expires on March 15, 2032.
Anti-Takeover
Provisions
Provisions
of the Delaware Revised Statutes, our articles of incorporation and our bylaws could have the effect of delaying or preventing
a third-party from acquiring us, even if the acquisition would benefit our stockholders. Such provisions of the Delaware Revised
Statutes, our articles of incorporation and our bylaws are intended to enhance the likelihood of continuity and stability in the composition
of our board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that
may involve an actual or threatened change of control of our company. These provisions are designed to reduce our vulnerability to an
unsolicited proposal for a takeover that does not contemplate the acquisition of all of our outstanding shares, or an unsolicited proposal
for the restructuring or sale of all or part of our company.
113
Bylaws
In
addition, various provisions of our bylaws may have an anti-takeover effect. These provisions may delay, defer or prevent a tender offer
or takeover attempt of the company that a stockholder might consider in his or her best interest, including attempts that might result
in a premium over the market price for the shares held by our stockholders. Our bylaws may be adopted, amended or repealed by the affirmative
vote of the holders of at least a majority of our outstanding shares of capital stock entitled to vote for the election of directors,
and except as provided by Delaware law, our board of directors shall have the power to adopt, amend or repeal the bylaws by
a vote of not less than a majority of our directors. Any bylaw provision adopted by the board of directors may be amended or repealed
by the holders of a majority of the outstanding shares of capital stock entitled to vote for the election of directors. Our bylaws also
contain limitations as to who may call special meetings as well as require advance notice of stockholder matters to be brought at a meeting.
Additionally, our bylaws also provide that no director may be removed by less than a two-thirds vote of the issued and outstanding shares
entitled to vote on the removal. Our bylaws also permit the board of directors to establish the number of directors and fill any vacancies
and newly created directorships. These provisions will prevent a shareholder from increasing the size of our board of directors and gaining
control of our board of directors by filling the resulting vacancies with its own nominees.
Our
bylaws establish an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including
proposed nominations of persons for election to the board of directors. Shareholders at an annual meeting will only be able to consider
proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors
or by a shareholder who was a shareholder of record on the record date for the meeting, who is entitled to vote at the meeting and who
has given us timely written notice, in proper form, of the shareholder's intention to bring that business before the meeting. Although
our bylaws do not give the board of directors the power to approve or disapprove shareholder nominations of candidates or proposals regarding
other business to be conducted at a special or annual meeting, our bylaws may have the effect of precluding the conduct of certain business
at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation
of proxies to elect its own slate of directors or otherwise attempting to obtain control of our company.
Authorized
but Unissued Shares
Our
authorized but unissued shares of common stock are available for our board of directors to issue without stockholder approval. We may
use these additional shares for a variety of corporate purposes, including raising additional capital, corporate acquisitions and employee
stock plans. The existence of our authorized but unissued shares of common stock could render it more difficult or discourage an attempt
to obtain control of the company by means of a proxy context, tender offer, merger or other transaction since our board of directors
can issue large amounts of capital stock as part of a defense to a take-over challenge.
Supermajority
Voting Provisions
Delaware Law
provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation's
articles of incorporation or bylaws, unless a corporation's articles of incorporation or bylaws, as the case may be, require a
greater percentage. Although our articles of incorporation and bylaws do not currently provide for such a supermajority vote on any matters,
our board of directors can amend our bylaws and we can, with the approval of our stockholders, amend our articles of incorporation to
provide for such a super-majority voting provision.
Cumulative
Voting
Furthermore,
the holders of our common stock do not have cumulative voting rights in the election of our directors. The combination of the present
ownership by a few shareholders of a significant portion of our issued and outstanding common stock and lack of cumulative voting makes
it more difficult for other shareholders to replace our board of directors or for a third party to obtain control of our company by replacing
its board of directors.
Exchange
Listing
We
intend to file an application to list our shares of common stock on the Nasdaq Capital Market under the symbol "FLCT" and
the warrants offered in this offering on the Nasdaq Capital Market under the symbol "FLCTW." We will not consummate and close
this offering without a listing approval letter from the Nasdaq Capital Market. Our receipt of a listing approval letter is not the same
as an actual listing on the Nasdaq Capital Market. The listing approval letter will serve only to confirm that, if we sell a number of
units in this firm commitment offering sufficient to satisfy applicable listing criteria, our common stock and warrants will in fact
be listed.
If our shares of common stock and warrants are
listed on the Nasdaq Capital Market, we will be subject to continued listing requirements and corporate governance standards of the Nasdaq
Capital Market. We expect these new rules and regulations to significantly increase our legal, accounting and financial compliance costs.
Transfer
Agent and Registrar
We have appointed VStock Transfer, LLC, 18 Lafayette
Place, Woodmere, NY 1159, (212) 828-8436, as the transfer agent for our common stock.
114
SHARES
ELIGIBLE FOR FUTURE SALE
Before
this offering, there has not been a public market for shares of our common stock. Future sales of substantial amounts of shares of our
common stock, including shares issued upon the conversion of convertible notes, the exercise of outstanding options and warrants, in
the public market after this offering, or the possibility of these sales occurring, could cause the prevailing market price for our common
stock to fall or impair our ability to raise equity capital in the future.
Immediately
following the closing of this offering, we will have [   ] shares of common stock issued and outstanding, assuming no
exercise of the warrants being offered in this offering. In the event the underwriters exercise the over-allotment option to purchase
additional shares of common stock and/or warrants in full, we will have [   ] shares of common stock issued and outstanding.
The common stock sold in this offering will be freely tradable without restriction or further registration or qualification under the
Securities Act.
Previously
issued shares of common stock that were not offered and sold in this offering, as well as shares issuable upon the exercise of warrants
and subject to employee stock options, are or will be upon issuance, "restricted securities," as that term is defined in
Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if such public resale is registered
under the Securities Act or if the resale qualifies for an exemption from registration under Rule 144 or Rule 701 under the Securities
Act, which are summarized below.
Rule
144
In
general, a person who has beneficially owned restricted shares of our common stock for at least twelve months, or at least six months
in the event we have been a reporting company under the Exchange Act for at least ninety (90) days before the sale, would be entitled
to sell such securities, provided that such person is not deemed to be an affiliate of ours at the time of sale or to have been an affiliate
of ours at any time during the ninety (90) days preceding the sale. A person who is an affiliate of ours at such time would be subject
to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of shares that
does not exceed the greater of the following:
●
1%
                                            of the number of shares of our common stock then outstanding; or
●
1%
                                            of the average weekly trading volume of our common stock during the four calendar weeks preceding
                                            the filing by such person of a notice on Form 144 with respect to the sale;
provided
that, in each case, we are subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule
144 trades must also comply with the manner of sale, notice and other provisions of Rule 144, to the extent applicable.
Rule
701
In
general, Rule 701 allows a shareholder who purchased shares of our capital stock pursuant to a written compensatory plan or contract
and who is not deemed to have been an affiliate of ours during the immediately preceding 90 days to sell those shares in reliance upon
Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of
Rule 144. All holders of Rule 701 shares, however, are required to wait until ninety (90) days after the date of this prospectus before
selling shares pursuant to Rule 701.
Lock-Up
Agreements
We,
all of our directors and officers and our shareholders holding at least 10% of the outstanding shares of our common stock have agreed
with the underwriters, subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our common
stock or securities convertible into or exercisable or exchangeable for our common stock for a period of six months after the closing
of this offering. See "
Underwriting-Lock-Up - No Sales of Securities
."
115
UNDERWRITING
We are offering the shares of common stock and
warrants described in this prospectus through Aegis Capital Corp., who is acting as the representative of the underwriters
of this offering (the "Representative"). The underwriting agreement that we intend to enter into with the Representative
(the "Underwriting Agreement") will provide that the obligations of the underwriters are subject to representations, warranties
and conditions contained therein. The underwriters will agree to buy, subject to the terms of the Underwriting Agreement, the number
of shares of common stock and warrants listed opposite their names below. Pursuant to the Underwriting Agreement, the underwriters will
be committed to purchase and pay for all of the shares and warrants if any are purchased, other than those shares and accompanying warrants
covered by the over-allotment option described below.
Underwriters
Number
                                            of
Shares
Number
                                            of
Accompanying
Warrants
Aegis Capital Corp.
[         ]
Total
The shares of common stock and warrants sold
by the underwriters to the public will initially be offered at the initial public offering price range set forth on the cover page of
this prospectus. The per unit purchase price of our common stock and warrants in this offering has been arbitrarily determined by us
and the Representative without regard to an independent valuation of the common stock or warrants included in the units
being offered in this offering. Although we completed an independent valuation of our common stock as of a November 5, 2021 valuation
date, we have not obtained an independent appraisal opinion on the valuation of our units as of the date of this offering and
we did not rely on the November 5, 2021 valuation in determining the pricing for this offering. Accordingly, our units may have a value
significantly less than the offering price, and our common stock and warrants included in the units may never obtain a value equal to
or greater than the offering price.
Any shares of common stock sold by the underwriters to securities dealers
may be sold at a discount from the initial public offering price not to exceed $[  ] per share. If all of the shares are not sold at the
initial offering price, the representative may change the offering price and the other selling terms. The representative has advised us
that the underwriters do not intend to make sales to discretionary accounts.
We have granted to the representative an
option, exercisable for 45 days from the date of this prospectus, to purchase up to [   ] additional shares of common stock and/or
warrants at the public offering price less the underwriting discount, constituting 15% of the total number of shares of common stock
to be offered in this offering (excluding shares and/or warrants subject to this option). This offering is being conducted on a firm
commitment basis.  Any shares of common stock and/or warrants issued or sold under the option will be issued and sold on the
same terms and conditions as the other shares of common stock and warrants that are the subject of this offering.
In
connection with the offering, the underwriters may purchase and sell shares in the open market. Purchases and sales in the open market
may include short sales, purchases to cover short positions, which may include purchases pursuant to the over-allotment option, and stabilizing
purchases.
●
Short
                                            sales involve secondary market sales by an underwriter of a greater number of shares than
                                            they are required to purchase in the offering.
●
"Covered"
                                            short sales are sales of shares in an amount up to the number of shares represented by the
                                            over-allotment option.
●
"Naked"
                                            short sales are sales of shares in an amount in excess of the number of shares represented
                                            by the over-allotment option.
●
Covering
                                            transactions involve purchases of shares either pursuant to the over-allotment option or
                                            in the open market after the distribution has been completed in order to cover short positions.
●
To
                                            close a naked short position, an underwriter must purchase shares in the open market after
                                            the distribution has been completed.  A naked short position is more likely to
                                            be created if an underwriter is concerned that there may be downward pressure on the price
                                            of the shares in the open market after pricing that could adversely affect investors who
                                            purchase in the offering.
●
To
                                            close a covered short position, an underwriter must purchase shares in the open market after
                                            the distribution has been completed or must exercise the over-allotment option. In determining
                                            the source of shares to close the covered short position, the underwriters will consider,
                                            among other things, the price of shares available for purchase in the open market as compared
                                            to the price at which they may purchase shares through the over-allotment option.
●
Stabilizing
                                            transactions involve bids to purchase shares so long as the stabilizing bids do not exceed
                                            a specified maximum.
116
Purchases
to cover short positions and stabilizing purchases, as well as other purchases by an underwriter for its own account, may have the effect
of preventing or retarding a decline in the market price of the shares of common stock. They may also cause the price of the shares of
common stock to be higher than the price that would otherwise exist in the open market in the absence of these transactions. The underwriters
may conduct these transactions in the over-the-counter market or otherwise. If the underwriters commence any of these transactions, they
may discontinue them at any time.
Discounts
and Expenses
The following table shows the underwriting discounts
payable to the underwriters by us in connection with this offering (assuming both the exercise and non-exercise of the over-allotment
option that we have granted to the representative), based on the assumed initial public offering price of $6.25 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus:
Per
Share
Without Option
With
Option
Public offering price
$
$
$
Underwriting discounts and commissions (8%)
Proceeds, before expenses, to us
$
$
$
We
have agreed to pay the underwriters a cash fee equal to eight percent (8%) of the aggregate gross proceeds of received by the Company
from the securities sold in this offering (excluding shares that may be issued under the over-allotment option). We have further agreed
to pay a non-accountable expense allowance to the representative of the underwriters equal to 1.0% of the gross proceeds received by
the Company at the closing of the offering.
Representative's
Warrants
We have agreed to issue warrants to the representative to purchase
a number of shares of common stock equal to 8% of the total number of shares sold in this offering (excluding shares that may be issued
under the over-allotment option) at an exercise price equal to 125% of the public offering price of the shares sold in this offering (excluding
shares that may be issued under the over-allotment option). The underwriters' warrants will be exercisable commencing six months
from the closing of this initial public offering and terminating on the fifth anniversary of the commencement date of sales in this offering,
and will have a cashless exercise provision. The underwriters' warrants are not exercisable or convertible for more than five years
from the commencement date of sales in this offering. The underwriters' warrants also provide for customary anti-dilution provisions,
a one-time demand registration right and immediate "piggyback" registration rights with respect to the registration of the
shares of common stock underlying the warrants. We have registered the underwriters' warrants and the shares underlying the underwriters'
warrants in this offering.
The
underwriters' warrant and the underlying shares may be deemed to be compensation by FINRA, and therefore will be subject to FINRA
Rule 5110(e)(1). In accordance with FINRA Rule 5110(e)(1), neither the underwriters' warrant nor any of our shares of common stock
issued upon exercise of the underwriters' warrants may be sold, transferred, assigned, pledged or hypothecated, or be the subject
of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities
by any person, for a period of 180 days immediately following the commencement date of sales in this offering, subject to certain exceptions.
The underwriters' warrant to be received by the Representative and related persons in connection with this offering: (i) fully
comply with lock-up restrictions pursuant to FINRA Rule 5110(e)(1); and (ii) fully comply with transfer restrictions pursuant to FINRA
Rule 5110(e)(2). In the event of written notice of a registration trigger event, as defined in the underwriter's warrant, the parties
shall negotiate in good faith a single demand registration right as outlined in the underwriter's warrant.
Other
Compensation
In addition, we have agreed to issue to the underwriters warrants to
purchase a number of shares of common stock and warrants equal to 8.0% of the aggregate number of shares of common stock sold in the offering
(including shares of common stock sold upon exercise of the over-allotment option), excluding shares underlying the Warrants. The underwriters'
warrants will be exercisable at any time and from time to time, in whole or in part, during the five-year period commencing six months
from the date of commencement of the sales of the shares of common stock and warrants in connection with this offering, at a price per
share equal to $[7.8125] which is 125% of the initial public offering price per share and accompanying Warrant. Such underwriter's
warrants are exercisable on a cash basis. The warrants will provide for registration rights (including a one-time demand registration
right and unlimited piggyback rights).
117
We estimate that our total expenses of this offering, excluding underwriting
discounts, will be approximately $653,000 which includes a maximum of $125,000 of out of pocket expenses for "road show,"
diligence, and reasonable legal fees and disbursements for underwriters' counsel, subject to a maximum of $62,500 in the event that
this offering is not consummated. We have also agreed to reimburse the underwriters, subject to compliance with FINRA Rule 5110(g).
Indemnification
Pursuant
to the Underwriting Agreement, we also intend to agree to indemnify the underwriters against certain liabilities, including civil liabilities
under the Securities Act, or to contribute to payments that the underwriters may be required to make in respect of those liabilities.
Determination
of Offering Price
In
determining the initial public offering price, we and the representative have considered a number of factors, including:
●
the
                                            information set forth in this prospectus and otherwise available to the representative;
●
our
                                            prospects and the history and prospects for the industry in which we compete;
●
an
                                            assessment of our management;
●
our
                                            prospects for future revenue and earnings;
●
the
                                            general condition of the securities markets at the time of this offering;
●
the
                                            recent market prices of, and demand for, publicly traded securities of generally comparable
                                            companies; and
●
other
                                            factors deemed relevant by the Representative and us.
The
estimated initial public offering price set forth on the cover page of this preliminary prospectus is subject to change as a result of
market conditions and other factors. Neither we nor the representative can assure investors that an active trading market will develop
for our shares of common stock, or that the shares will trade in the public market at or above the initial public offering price.
We
have agreed to indemnify the representative and the other underwriters against certain liabilities, including liabilities under the Securities
Act. If we are unable to provide this indemnification, we will contribute to payments that the representative and the other underwriters
may be required to make for these liabilities.
Right
of First Refusal
We
have granted the Representative a right of first refusal, for a period of twelve (12) months from the closing of the offering, to act
as sole investment banker, sole book-runner, and/or sole placement agent, at the Representative's sole discretion, for each and
every future public and private equity and debt offering, including all equity linked financings, subject to certain exceptions (each,
a "subject transaction"), during such twelve (12) month period, of the Company, or any successor to or subsidiary of the
Company, on terms and conditions customary to the Representative for such subject transactions.
Tail
Rights
In
the event that the Representative does not consummate the offering, the Representative shall be entitled to a cash fee equal to eight
percent (8.0%) of the gross proceeds received by the Company from the sale of the securities to any investor actually introduced by the
Representative to the Company during the engagement period (the "Tail Financing"), and such Tail Financing is consummated
at any time during the engagement period or within the twelve (12) month period following the expiration of the engagement period, provided
that such financing is by a party actually introduced to the Company in an offering in which the Company has direct knowledge of such
party's participation and not a party that the Company can demonstrate was already known to the Company. In addition, unless (x)
the Company terminates the underwriting agreement for cause, or (y) the Representative fails to provide the underwriting services
provided in the underwriting agreement, upon termination of such agreement, if the Company subsequently completes a public or private
financing with any investors introduced to the Company by the Representative during the twelve (12) month period following such termination,
the Representative shall be entitled to receive the same compensation to be paid to the Representative in connection with this offering.
118
Lock-Up
- No Sales of Securities
The Company, on behalf of itself and any successor
entity, will agree in the Underwriting Agreement that, without the prior written consent of the Representative or unless excluded from
Lock-Up restrictions in the Underwriting Agreement, it will not, for a period of 180 days after the date of the Underwriting Agreement
(the "Lock-Up Period"), offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or
file with the Commission a registration statement under the Securities Act relating to, any Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock, or publicly disclose the intention to make any offer, sale, pledge, disposition
or filing, or (y) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of the Common Stock or any such other securities, whether any such transaction described in clause (x) or (y) above is to be settled
by delivery of Common Stock or such other securities, in cash or otherwise.
In
addition, each of our directors, officers and stockholders holding at least ten percent (10%) of the outstanding shares of common stock
of the Company has agreed that for a period of 180 days after the date of this prospectus, without the prior written consent of the Representative,
and subject to certain exceptions, they will not, directly or indirectly, (i) offer, pledge, sell, contract to sell, grant,
lend, or otherwise transfer or dispose of, directly or indirectly, any common stock of the Company or any securities convertible into
or exercisable or exchangeable for the common stock of the Company, whether now owned or hereafter acquired by such person or with respect
to which such person has or hereafter acquires the power of disposition; (ii) enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of such securities; (iii) make any demand for or
exercise any right with respect to the registration of any such securities; or (iv) publicly disclose the intention to make any
offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any such securities.
Price
Stabilization, Short Positions and Penalty Bids
To
facilitate this offering, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of our securities
during and after the offering. Specifically, the underwriters may over-allot or otherwise create a short position in our securities for
their own account by selling more securities than we have sold to the underwriters. The underwriters may close out any short position
by either exercising its option to purchase additional securities or purchasing securities in the open market.
In
addition, the underwriters may stabilize or maintain the price of our securities by bidding for or purchasing securities in the open
market and may impose penalty bids. If penalty bids are imposed, selling concessions allowed to broker-dealers participating in this
offering are reclaimed if securities previously distributed in this offering are repurchased, whether in connection with stabilization
transactions or otherwise. The effect of these transactions may be to stabilize or maintain the market price of our securities at a level
above that which might otherwise prevail in the open market. The imposition of a penalty bid may also affect the price of our securities
to the extent that it discourages resales of our securities. The magnitude or effect of any stabilization or other transactions is uncertain.
These transactions may be effected on the Nasdaq Capital Market or otherwise and, if commenced, may be discontinued at any time.
In
connection with this offering, the underwriters and selling group members, if any, may also engage in passive market making transactions
in our securities on the Nasdaq Capital Market. Passive market making consists of displaying bids on the Nasdaq Capital Market by the
prices of independent market makers and effecting purchases limited by those prices in response to order flow. Rule 103 of Regulation
M promulgated by the SEC limits the amount of net purchases that each passive market maker may make and the displayed size of each bid.
Passive market making may stabilize the market price of our securities at a level above that which might otherwise prevail in the open
market and, if commenced, may be discontinued at any time.
Neither
we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described
above may have on the price of our securities. In addition, neither we nor the underwriters make any representation that the underwriters
will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice.
119
Affiliations
Each
underwriter and its respective affiliates are full-service financial institutions engaged in various activities, which may include securities
trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. The underwriters may in the future engage in investment banking and other commercial dealings in
the ordinary course of business with us or our affiliates. The underwriters may in the future receive customary fees and commissions
for these transactions. We have not engaged the underwriters to perform any services for us in the previous 180 days, nor do we have
any agreement to engage the underwriters to perform any services for us in the future, subject to the right to act as an advisor as described
above.
In
the ordinary course of its various business activities, each underwriter and its respective affiliates may make or hold a broad array
of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including
bank loans) for its own account and for the accounts of its customers, and such investment and securities activities may involve securities
and/or instruments of the issuer. Each underwriter and its respective affiliates may also make investment recommendations and/or publish
or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients
that they acquire, long and/or short positions in such securities and instruments.
Electronic
Offer, Sale and Distribution
In
connection with this offering, the underwriters or certain of the securities dealers may distribute prospectuses by electronic means,
such as e-mail.
Selling
Restrictions
No
action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the shares of common stock,
or the possession, circulation or distribution of this prospectus or any other material relating to us or the shares of common stock,
where action for that purpose is required. Accordingly, the shares of common stock may not be offered or sold, directly or indirectly,
and neither this prospectus nor any other offering material or advertisements in connection with the shares of common stock may be distributed
or published, in or from any country or jurisdiction except in compliance with any applicable rules and regulations of any such country
or jurisdiction.
Offer
Restrictions Outside the United States
Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.
120
LEGAL
MATTERS
Bevilacqua
PLLC and IP Supra, PLLC have acted as our counsel in connection with the preparation of this prospectus. The underwriters have been represented
in connection with this offering by Alston & Bird LLP.
EXPERTS
The consolidated and combined financial statements
of Felicitex Therapeutics Inc. as of December 31, 2021 and 2020 and for the years then ended included in the registration statement of
which this prospectus forms a part have been so included in reliance on the report of Friedman LLP, an independent registered public
accounting firm (the report on the financial statements contains an explanatory paragraph regarding the Company's ability to continue
as a going concern) appearing elsewhere herein, given on the authority of said firm as experts in auditing and accounting.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities we are offering
by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information
about us and our securities, you should refer to the registration statement and the exhibits and schedules filed with the registration
statement. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are materially
complete but may not include a description of all aspects of such contracts, agreements or other documents, and you should refer to the
exhibits attached to the registration statement for copies of the actual contract, agreement or other document.
Upon
completion of this offering, we will be subject to the information requirements of the Exchange Act and will file annual, quarterly and
current event reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration
statement, over the Internet at the SEC's website at www.sec.gov.
121
FINANCIAL
STATEMENTS
Page
Reviewed
    Condensed Consolidated and Combined Financial Statements (unaudited)
Condensed
    Consolidated Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021
F-2
Condensed
    Consolidated and Combined Statements of Operations and Comprehensive Loss (unaudited) for the three months ended March 31, 2022 and
    2021
F-3
Condensed
    Consolidated and Combined Statements of Stockholders' Deficit (unaudited) for the three months ended March 31, 2022 and 2021
F-4
Condensed
    Consolidated and Combined Statements of Cash Flows (unaudited) for the three months ended March 31, 2022 and 2021
F-5
Notes
    to Condensed Consolidated and Combined Financial Statements (unaudited)
F-6-F-18
Audited
    Consolidated and Combined  Financial Statements for the Years Ended December 31, 2021 and 2020
Report
    of Independent Registered Public Accounting Firm (PCAOB Firm ID 711)
F-19
Consolidated
    and Combined  Balance Sheets as of December 31, 2021 and 2020
F-20
Consolidated
    and Combined  Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021 and 2020
F-21
Consolidated
    and Combined  Statements of Stockholders' Deficit for the Years Ended December 31, 2021 and 2020
F-22
Consolidated
    and Combined  Statements of Cash Flows for the Years Ended December 31, 2021 and 2020
F-23
Notes
    to Consolidated and Combined Financial Statements
F-24
F-
1
FELICITEX THERAPEUTICS,
INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
March 31,
2022
December 31,
(unaudited)
2021
Assets
Current assets:
Cash
$
32,023
$
10,362
Prepaid Expenses
11,250
-
Total current assets
43,273
10,362
Deposits
3,500
3,500
Property and equipment, net
1,801
1,960
Total assets
$
48,574
$
15,822
Liabilities and Deficit
Current liabilities:
Accounts payable
$
353,393
$
232,842
Accrued expenses and other current liabilities
40,781
47,171
Due to related party
120,203
48,652
Convertible note payable - related party
128,224
206,180
Warrant liability
276,708
276,708
Total current liabilities
919,309
811,553
Total liabilities
919,309
811,553
Common Stock: Par value of $0.0001 per share, 100,000,000 shares authorized;
    4,455,999 and 4,263,022 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.
446
426
Additional paid-in capital
6,199,324
5,566,727
Accumulated deficit
(7,070,505
)
(6,362,884
)
Total deficit
(870,735
)
(795,731
)
Total liabilities and deficit
$
48,574
$
15,822
The accompanying notes are
an integral part of these unaudited condensed consolidated financial statements.
F-
2
FELICITEX
THERAPEUTICS, INC.
CONDENSED CONSOLIDATED
AND COMBINED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
Three Months Ended
March 31,
2022
2021
Operating expenses:
Research and development
$
164,935
$
133,846
General and administrative expenses
519,747
153,058
Total operating expenses
684,682
286,904
Operating loss
(684,682
)
(286,904
)
Other income (expense):
Other income
-
10,298
Interest expense
(22,939
)
(7,601
)
Inducement loss
-
(80,972
)
Total other expense, net
(22,939
)
(78,275
)
Net loss before provision for income tax
(707,621
)
(365,179
)
Income tax expense (benefit)
-
-
Net loss and comprehensive loss
(707,621
)
(365,179
)
Less: Net loss of TarMeta Biosciences, LLC prior to acquisition by Felicitex
    Therapeutics, Inc.
-
(70,148
)
Net loss attributable to Felicitex Therapeutics, Inc.
$
(707,621
)
$
(295,031
)
Net loss per share attributable to Felicitex Therapeutics, Inc.-basic and
    diluted
$
(0.16
)
$
(0.09
)
Weighted average common shares outstanding attributable to Felicitex Therapeutics,
    Inc.-basic and diluted
4,295,189
3,283,747
The accompanying notes are
an integral part of these unaudited condensed consolidated and combined financial statements.
F-
3
FELICITEX
THERAPEUTICS, INC.
CONDENSED CONSOLIDATED
AND COMBINED STATEMENTS OF CHANGES IN DEFICIT (UNAUDITED)
Additional
Common Stock
Paid-In
Accumulated
Total
Shares
Amount
Capital
Deficit
Deficit
Balances at January 1, 2021
3,247,585
$
325
$
5,881,728
$
(6,640,657
)
$
(758,604
)
Stock options issued for settlement of deferred compensation
-
-
36,667
-
36,667
Stock options issued for settlement of accounts payable
-
-
22,246
-
22,246
Stock compensation expense
-
-
75,355
-
75,355
Common stock issued in connection with settlement of convertible
    note payable - related party
232,473
23
548,800
-
548,823
Contributions
-
-
49,643
-
49,643
Net loss and comprehensive loss
-
-
-
(365,179
)
(365,179
)
Balances at March 31, 2021
3,480,058
$
348
$
6,614,439
$
(7,005,836
)
$
(391,049
)
Balances at January 1, 2022
4,263,022
$
426
$
5,566,727
$
(6,362,884
)
$
(795,731
)
Common stock issued in connection with settlement of convertible
    note payable - related party
192,977
20
595,724
-
595,744
Stock compensation expense
-
-
36,873
-
36,873
Net loss and comprehensive loss
-
-
-
(707,621
)
(707,621
)
Balances at March 31, 2022
4,455,999
$
446
$
6,199,324
$
(7,070,505
)
$
(870,735
)
The accompanying notes are an integral
part of these unaudited condensed consolidated and combined financial statements.
F-
4
FELICITEX THERAPEUTICS,
INC.
CONDENSED CONSOLIDATED AND COMBINED STATEMENTS
OF CASH FLOWS (UNAUDITED)
Three Months Ended
March 31,
2022
2021
Cash flows from operating activities
Net loss
$
(707,621
)
$
(365,179
)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization
159
768
Loss on extinguishment of debt
-
80,972
Stock based compensation
36,873
75,355
Forgiveness of PPP loan Payable
-
(10,298
)
Changes in operating assets and liabilities:
Accounts payable
186,500
1,577
Accrued expenses
53,776
32,703
Other current assets
(11,250
)
-
Net cash flows used in operating activities
(441,563
)
(184,102
)
Cash flows from financing activities
Proceeds from convertible note payable
463,224
105,000
Equity contributions - related party
-
49,643
Net cash flows provided by financing activities
463,224
154,643
Net change in cash
21,661
(29,459
)
Cash, beginning of period-
10,362
38,355
Cash, end of period
$
32,023
$
8,896
Supplementary cash flows information
Cash paid during the year for interest
-
-
Cash paid during the year for taxes
-
-
Non-cash investing and financing activities
Conversion of convertible note payable into common stock
$
595,744
$
548,823
Conversion of deferred compensation into stock options
-
$
36,667
Conversion of accounts payable into stock options
-
$
22,246
The accompanying notes are an integral
part of these unaudited condensed consolidated and combined financial statements.
F-
5
FELICITEX
THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED
AND COMBINED FINANCIAL STATEMENTS (UNAUDITED)
1.
Nature
                                            of the Business and Basis of Presentation
Felicitex Therapeutics,
Inc. ("Felicitex") was incorporated in Delaware on May 4, 2012. Felicitex is an early-stage drug development company developing
treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term outcomes for the deadliest and
most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.
The
Company has established a drug discovery platform focused on cellular dormancy to identify novel targets and corresponding small molecule
inhibitors and has developed seven advanced clinical drug candidates thus far. It has an expanding IP position that includes two fundamental
composition of matter patents, three methods of use patents, and a companion diagnostics patent. The research and development activities
of the Company are currently in the pre-clinical phase of development. The company has retroactively applied impacts for the reverse
stock split of 1 to 9.08, which was approved by the Board of Directors on May 23, 2022. All references to the number of shares in the
footnotes have been retroactively updated.
Basis
of Presentation and Principles of Consolidation and Combination
The
accompanying unaudited condensed consolidated and combined financial statements have been prepared in accordance with accounting principles
generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions for
Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed financial statements reflect
all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results. Interim
operating results are not necessarily indicative of results that may be expected for the full year ending December 31, 2022 or for any
subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements
and notes thereto of the Company which are included in the accompanying Form S-1/A.
On
July 23, 2021, the Company incorporated Felicitex Therapeutics UAB ("UAB"), a Lithuania Corporation, for the purpose of applying
for grants. The Company intends to use the grant proceeds, if awarded, in pre-clinical studies to be conducted in Europe to assess the
potential of conducting clinical trials on its molecule in the future. The Company's CEO is necessarily the sole owner of UAB in
order to comply with the funding requirements of the government grant programs in Lithuania and the European Union. As discussed in Note
14, UAB is deemed to be a Variable Interest Entity ("VIE"), and is therefore required to be included in the consolidated
and combined financial statements of the Company.
As
discussed in Note 11, on December 30, 2021, the Company acquired TarMeta BioSciences, LLC ("TarMeta"), an early-stage drug
discovery platform company with deep expertise in analytical chemistry whose mission is to identify and commercialize novel small molecule
therapeutics for difficult to treat cancers. The Company determined the TarMeta acquisition to be a common control transaction under
ASC Topic 805, Business Combinations, and accounted for this transaction at the carrying amount of the net assets acquired. As a result
of the TarMeta acquisition, the financial statements for the three months ended March 31, 2021 has been adjusted to include the financial
information of TarMeta for the period. TarMeta ceased to exist as a separate legal entity on December 31, 2021 and is therefore not included
in the financial statements for the three months ended March 31, 2022.
The
consolidated and combined financial statements include the accounts of Felicitex, UAB and TarMeta (collectively, the "Company").
All intercompany transactions and balances have been eliminated in consolidation and combination. There is no difference between net
loss and comprehensive loss in these consolidated and combined financial statements.
Liquidity
and Going Concern
The
Company is in the development stage and has incurred losses and negative cash flows from operations. The Company had a net loss of approximately
$0.7 million and negative cash flows from operations of approximately $0.4 million for the three months ended March 31, 2022. Further,
the Company has an accumulated deficit of $7.0 million, as of March 31, 2022. Based on the current development plans for the Company's
drug candidates and other operating requirements, existing cash is not sufficient to fund operations for the twelve months following
the financial statement filing date. These factors raise substantial doubt about the Company's ability to continue as a going concern.
F-
6
A
significant amount of additional capital will be necessary to advance the development of our products to the point at which they may
become commercially viable. The Company plans to raise additional capital from various potential sources, including equity and/or debt
financings, grant funding, and strategic relationships. In addition, the Company has an active equity purchase agreement with Aegis Capital
to sell $15 million of Company common stock in an initial public offering, which amount, if fully accessible, would be sufficient to
fund the Company's operations beyond one year from the filing date of these statements. However, there can be no guarantee that
the Company will be able to close on the financing. Should such financing be unsuccessful, the Company would be required to delay, scale
back or eliminate some or all of its research and development programs, which would likely have a material adverse effect on the Company
and its consolidated and combined financial statements.
The
accompanying consolidated and combined financial statements do not include any adjustments relating to the recoverability and classification
of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described
above.
Other
Uncertainties
Generally,
the industry in which the Company operates subjects the Company to a number of other risks and uncertainties that can affect its operating
results and financial condition. Such factors include, but are not limited to: the timing, costs and results of clinical trials and other
development activities versus expectations; the ability to obtain regulatory approval to market product candidates; the ability to manufacture
products successfully; competition from products sold or being developed by other companies; the price of, and demand for, Company products
once approved; the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products.
The
Company faces the ongoing risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company's
research and pre-clinical studies. The effects of the ongoing coronavirus pandemic may also increase non-research related costs such
as insurance premiums, increase the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact
our key pre-clinical trial vendors and suppliers of our pharmaceutical ingredients. The full extent to which the COVID-19 pandemic could
impact drug development and research, or impact the Company's suppliers and other commercial partners, will depend on future developments
that cannot be predicted. We assessed certain accounting matters that generally require consideration of forecasted financial information
in context with the information reasonably available to us and the unknown future impacts COVID-19 as of March 31, 2022, and through
the date of this report.
2.
Summary
                                            of Significant Accounting Policies
Cash
The
Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company
had no cash equivalents at March 31, 2022 and year ended December 31, 2021, respectively. At times, the Company's cash balances
may exceed the current insured amounts under the Federal Deposit Insurance Corporation ("FDIC"). On March 31, 2022 and December
31, 2021, the Company did not exceed FDIC insurance limits. Unrealized gain or loss are included in the interest income and are immaterial
to the consolidated and combined financial statements.
Use
of Estimates
The
preparation of consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at
the date of the consolidated and combined financial statements as well as the reported amounts of revenues and expenses during the reporting
period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical
experience, risk of loss, general economic conditions and trends and the assessment of the probable future outcome. Subjective and significant
estimates include, but are not limited to, the valuation of stock-based compensation, valuation of issued warrants, expense recognition
and accruals associated with third party providers supporting pre-clinical studies and other research and development, and income tax
asset realization. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects
of changes, if any, are reflected in the consolidated and combined statements of operations in the period that they are determined.
F-
7
Segment
Information
The
Company determined its operating segment after considering the Company's organizational structure and the information regularly
reviewed and evaluated by the Company's chief operating decision maker ("CODM") in deciding how to allocate resources
and assess performance. The Company has determined that its CODM is its Chief Executive Officer. Effective January 1, 2022, the financial
accounts of both TarMeta and Felicitex are integrated into a single report to be reviewed by the CODM. Previously, the CODM reviewed
the financial information of Felicitex and TarMeta independently for the purpose of evaluating financial performance and allocating resources.
On the basis of these factors, the Company has determined that it operates and manages its business as one segment for the three months
ended March 31, 2022, and two operating segments for the three months ended March 31, 2021.
Substantially
all the Company's long-lived assets are held in the United States. Segment considerations are further discussed in Note 12.
Property
and Equipment, Net
Property
and equipment are stated at cost less accumulated depreciation and amortization. Expenditures for repairs and maintenance are expensed
as incurred. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets
as follows:
Estimated Useful Life
Equipment
3 years
Leasehold improvements
Shorter of remaining life of lease or useful life
Patent Costs
All
patent-related costs are expensed as incurred due to uncertainty with respect to the Company's ability to commercialize the patents.
Amounts incurred are classified as general and administrative expenses.
Leases
Lease
agreements are evaluated to determine whether they are capital or operating leases in accordance with Financial Accounting Standards
Board ("FASB") Accounting Standards Codification ("ASC") Topic 840, Leases ("ASC 840"). When any
one of the four test criteria in ASC 840 is met, the lease then qualifies as a capital lease. Capital leases are capitalized at the lower
of the net present value of the total amount payable under the leasing agreement (excluding finance charges) or the fair market value
of the leased asset. Capital lease assets are depreciated on a straight-line basis, over a period consistent with the Company's
normal depreciation policy for tangible fixed assets. The Company allocates each lease payment between a reduction of the lease obligation
and interest expense using the effective interest method. Rent expense for operating leases, which may include free rent or fixed escalation
amounts in addition to minimum lease payments, is recognized on a straight-line basis over the duration of the lease term. The Company
had no capital leases related to equipment as of March 31, 2022 and December 31, 2021.
Collaborative
Arrangements
The
Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties
that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope
of FASB ASC Topic 808, Collaborative Arrangements ("ASC 808"). For collaborative arrangements that contain multiple elements,
the Company determines which units of account are deemed to be within the scope of ASC 808 and which units of account are more reflective
of a vendor-customer relationship, and therefore are within the scope of ASC 606. For units of account that are accounted for pursuant
to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature
or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of ASC 808, the Company
evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple
units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result
of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded
as increases or decreases to Research and Development Expense or General and Administrative Expense, as appropriate. Milestone payments
are considered contingent liabilities and are recognized when the Company deems the milestone event to be probable.
F-
8
Fair
Value Measurements
FASB
ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value, and expands
disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset
or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly
transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy
has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable
inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would
use in pricing the asset or liability based on market data obtained from sources independent of the Company.
Unobservable
inputs reflect the Company's assumption about the inputs that market participants would use in pricing the asset or liability developed
based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the
inputs, as follows:
●
Level
                                            1 - Valuations based on quoted prices for identical instruments in active markets.
                                            Since valuations are based on quoted prices that are readily and regularly available in an
                                            active market, valuation of these instruments does not entail a significant degree of judgment.
●
Level
                                            2 - Valuations based on observable inputs other than quoted prices included in Level
                                            1, such as quoted prices for either similar instruments in active markets, identical or similar
                                            instruments in markets that are not active, or model-derived valuations whose inputs or significant
                                            value drivers are observable or can be corroborated by observable market data.
●
Level
                                            3 - Valuations based on inputs that are unobservable. These valuations require significant
                                            judgment.
The
availability of valuation techniques and observable inputs can vary and is affected by a wide variety of factors, including the type
of asset or liability, whether the asset or liability is new and not yet established in the marketplace, and other characteristics particular
to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market,
the determination of fair value requires more judgment. Those estimated values do not necessarily represent the amounts that may be ultimately
realized due to the occurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of valuations,
those estimated values may be materially higher or lower than the values that would have been used had a ready market for the assets
or liabilities existed.
As
of March 31, 2022, the Company's assets and liabilities measured at fair value on a recurring basis were categorized as follows
within the fair value hierarchy:
Level
    1
Level
    2
Level
    3
Total
Liabilities
Warrant liability
$
-
$
-
$
276,708
$
276,708
Total liabilities
$
-
$
-
$
276,708
$
276,708
As of December 31,
2021, the Company's assets and liabilities measured at fair value on a recurring basis were categorized as follows within the fair
value hierarchy:
Level
    1
Level
    2
Level
    3
Total
Liabilities
Warrant liability
$
-
$
-
$
276,708
$
276,708
Total liabilities
$
-
$
-
$
276,708
$
276,708
The
value of cash, prepaid expenses, accounts payable, accrued expenses, PPP loan payable, amounts due to related parties and convertible
notes payable - related party approximate fair value to due to the short-term nature of these assets and liabilities.
The
Company estimated the fair value of the warrant liability classified as Level 3 liabilities using the Black-Scholes option pricing model
utilizing certain weighted average assumptions such as expected stock price volatility, expected term of the warrants, and risk-free
interest rates.
F-
9
The
following table summarizes the activity for the Company's Level 3 liabilities measured at fair value on a recurring basis:
Amount
Balance as of January 1, 2021
$
78,823
Issuance
151,497
Changes in fair value
46,388
Balance as of December 31, 2021
$
276,708
Issuance
-
Changes in fair value
-
Balance as of March 31, 2022
$
276,708
During
the three months ended March 31, 2022 and the year ended December 31, 2021, there were no transfers between Level 1 and Level 2, nor
into and out of Level 3.
Research
and Development
Costs
and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC
730-10. Research and development costs are charged to expense as incurred and include the cost of wages, equipment, materials, and laboratory
fees paid in conducting scientific research on potential drug candidates. Research and development costs were $0.2 million and $0.1 million
for the three months ended March 31, 2022, and 2021, respectively.
Stock-Based
Compensation
The
Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of FASB ASC Topic 718,
Compensation - Stock Based Compensation. The Company expenses stock-based compensation to employees and non-employees over the requisite
service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of options granted using
the Black Scholes Merton model. The Company estimates when and if performance-based awards will be earned. If an award is not considered
probable of being earned, no amount of equity-based compensation expense is recognized. If the award is deemed probable of being earned,
related equity-based compensation expense is recorded. The fair value of an award ultimately expected to vest is recognized as an expense,
net of forfeitures, over the requisite service, which is generally the vesting period of the award. Options forfeitures are recorded
as they occur.
The
Black Scholes Merton model requires the input of certain subjective assumptions and the application of judgment in dete
rmining
the fair value of the awards. The most significant assumptions and judgments include the following:
●
Expected
                                            volatility - The expected price volatility is based on the historical volatilities
                                            of peer group companies as the Company does not have a sufficient trading history. Industry
                                            peers consist of several public companies in the bio-tech industry similar in size, stage
                                            of life cycle, and capital structure. The Company also blends in historical data on the volatility
                                            of its own equity, increasing in proportion as the period of historical data on the Company's
                                            data becomes more representative.
●
Risk-free
                                            interest rate - The risk-free rate was determined based on yields of U.S. Treasury
                                            Bonds of comparable terms.
●
Expected
                                            dividend yield - The Company has not previously issued dividends and do not anticipate
                                            paying dividends in the foreseeable future. Therefore, we used a dividend rate of zero based
                                            on our expectation of additional dividends.
●
Expected
                                            term -The expected term of the options was estimated using the simplified method.
Common shares issued
to third parties for services provided are valued at fair value of the Company's shares.
Warrant
Liability
Warrants
are accounted for in accordance with the guidance contained in ASC 815-40-15-7D and 7F, under which the warrants do not meet the criteria
for equity treatment and must be recorded as liabilities. Accordingly, the Company classifies warrants as liabilities at their fair value
and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date
until exercised, and any change in fair value is recognized in the consolidated and combined statement of operations and comprehensive
loss. The warrants are valued using a Black Scholes model.
F-
10
Income
Taxes
ASC Topic
740, Income Taxes ("ASC 740") sets forth standards for financial presentation and disclosure of income tax liabilities and
expense. The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
A
valuation allowance is established to reduce net deferred tax assets to the amount expected to be realized. The Company recognizes the
effect of income tax positions only if those positions are more likely than not of being sustained. Changes in recognition and measurement
are reflected in the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included
in income tax expense.
The
Company provides reserves for potential payments of taxes to various tax authorities related to uncertain tax positions. Amounts recognized
are based on a determination of whether a tax benefit previously taken by the Company on filed tax returns or a position expected to
be taken on future tax returns is more likely than not sustaining a challenge from the local tax authorities. The tax benefit recognized
is equal to the largest amount that is more than 50% likely to be sustained. Interest and penalties associated with uncertain tax positions
are recorded as a component of income tax expense.
Prior
to its acquisition by the Company on December 30, 2021, TarMeta was a limited liability company. As a limited liability company, the
Company elected to treat TarMeta as a partnership for federal and state income tax reporting purposes. Accordingly, for federal and certain
state income tax purposes, TarMeta's income was included in the income tax returns of its members. In most jurisdictions, income
tax liabilities and/or tax benefits are passed through to the individual members.
Basic
and Diluted Loss per Share
Basic
and diluted loss per share is computed based on the weighted-average outstanding shares of common stock, which are all voting shares.
Diluted net loss per share is computed giving effect to all proportional shares of common stock, including stock options and warrants
to the extent dilutive. Basic net loss per share was the same as diluted net loss per share for the three months ended March 31, 2022
and 2021, respectively, as the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following
potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
March
    31,
2022
March
    31,
2021
Stock options
    excluded
1,114,264
409,926
Stock warrants excluded
123,735
94,217
Stock
    convertible under outstanding notes payable excluded
42,519
28,044
Total
    potentially dilutive securities
1,280,518
532,187
Emerging
Growth Company Status
The
Company anticipates that it will qualify as an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012
(the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued
subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company will elect to
use this extended transition period for complying with new or revised accounting standards that have different effective dates for public
and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably
opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated and combined financial statements
may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
F-
11
Recently
Adopted Accounting Pronouncements
In
November 2018, the FASB issued Accounting Standard Update ("ASU") No. 2018-18, Collaborative Arrangements (Topic 808) ("ASU
No. 2018-18"). This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative
Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. The Company early adopted ASU No.
2018-18 as of January 1, 2020. The adoption of this update did not have a material effect on the Company's consolidated and combined
financial statements, as there were no collaborative arrangements that had identified performance obligations to customers.
In
August 2020, the FASB issued ASU No. 2020-06,
Debt - Debt with Conversion and Other Options
(Subtopic 470-20) and
Derivatives and Hedging - Contracts in Entity's Own Equity
(Subtopic 815-40) ("ASU No. 2020-06"). ASU No. 2020-06 was issued to address issues identified as a result of the complexity
associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities
and equity. For convertible instruments, the FASB decided to reduce the number of accounting models for convertible debt instruments
and convertible preferred stock. In addition to eliminating certain accounting models, the FASB also decided to enhance information transparency
by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. This update is effective
for public business entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal year. For all
other entities, this update is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal
years. Early adoption is permitted, but no earlier than fiscal years beginning after December 31, 2020. The Company has adopted ASU No.
2021-04 and believes it will have no material effect on its consolidated and combined financial statements.
In
May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock
Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting
for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options ("ASU 2021-04"). The amendments
in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding
equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The update
is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
The adoption of ASU No. 2021-04 did not have a material effect on the condensed consolidated and combined financial statements.
Recent
Accounting Pronouncements Not Yet Adopted
In
February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) as subsequently amended ("ASU No. 2016-02"). ASU No. 2016-02
was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance
sheet and disclosing key information about leasing arrangements. The amendments in this update are effective for fiscal years beginning
after December 15, 2018, including interim periods within those fiscal years, for public business entities, not-for-profit entities that
has issued securities that are traded, listed or quoted on an exchange or an over-the-counter market, and employee benefit plans that
file financial statements with the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that
the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial statements.
In
December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"),
as part as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining
or improving the usefulness of the information provided to users of financial statements. Amendments include removal of certain exceptions
to the general principles of ASC 740 and simplification in several other areas such as accounting for a franchise tax (or similar tax)
that is partially based on income. The update is effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that
the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial statements.
F-
12
3.
Property
                                            and Equipment, Net
Property and equipment,
net consisted of the following as of March 31, 2022 and the year ended December 31, 2021, respectively:
March
    31,
2022
December 31,
2021
Equipment
$
21,525
$
21,525
Less: Accumulated depreciation
(19,724
)
(19,565
)
Property and equipment, net
$
1,801
$
1,960
4.
Paycheck
                                            Protection Program Loan
During
the year ended December 31, 2020, the Company received loan proceeds in the amount of $10 thousand under the Paycheck Protection Program
("PPP") which was established as part of the Coronavirus Aid, Relief and Economic Security Act ("CARES Act")
administered through the Small Business Administration ("SBA"). The PPP provides loans to qualifying businesses in amounts
up to 2.5 times their average monthly payroll expenses and was designed to provide a direct financial incentive for qualifying businesses
to keep their workforce employed during the Coronavirus crisis. PPP loans are uncollateralized and guaranteed by the SBA and are forgivable
after a "covered period" (eight or twenty-four weeks) as long as the borrower maintains its payroll levels and uses the loan
proceeds for eligible expenses, including payroll, benefits, mortgage interest, rent and utilities. The forgiveness amount will be reduced
if the borrower terminates employees or reduces salaries and wages more than 25% during the covered period. Any unforgiven portion is
payable over 2 years if issued before, or 5 years if issued after, June 5, 2020 at an interest rate of 1% with payments deferred until
the SBA remits the borrower's loan forgiveness amount to the lender, or, if the borrower does not apply for forgiveness, ten months
after the end of the covered period. PPP loan terms provide for customary events of default, including payment defaults, breaches of
representations and warranties, and insolvency events and may be accelerated upon the occurrence of one or more of these events of default.
Additionally, PPP loan terms do not include prepayment penalties. On February 24, 2021, the Company's PPP loan in the amount of
$10 thousand was forgiven.
5.
Convertible
                                            Note Payable - Related Party
The
Chairman of the Board ("Principal Investor") has substantial control of the voting power of the Company. During the three
months ended March 31, 2022 and 2021, the Company issued convertible notes payable to the Principal Investor for cash advances made to
the Company. The notes payable outstanding as of March 31, 2022 are convertible to common stock at a price of $3.09 per share.
On
March 17, 2021, the Company issued 232,473 shares of common stock to the Principal Investor as consideration for the conversion of a
$521 thousand shareholder loan and $27 thousand in accrued interest. In addition, the Company issued warrants exercisable into 46,495
shares of common stock within five years at an exercise price of $2.36  per share as an incentive for converting the loan receivable
into shares of common stock.
On
March 31, 2021, the Company entered into a loan agreement with principal investor to lend up to $550 thousand. The note is convertible
at $2.29 per share and accrues interest at 12% with no maturity date.
On
November 2, 2021, the Company issued 147,586 shares of common stock to its principal investor as consideration for the conversion of
a $348 thousand convertible note payable. In addition, the Company issued warrants exercisable into 29,518 shares of common stock within
five years at an exercise price of $2.36 per share to the shareholder as an incentive for converting the loan receivable into shares
of common stock.
On
March 16, 2022, the Company issued 192,977 shares of common stock to its principal investor as consideration for the conversion of $596
thousand loan payable pursuant to a debt cancellation and exchange agreement,
On
March 16, 2022, we entered into a convertible grid note with Mr. Duey with respect to additional advances that Mr. Duey has made and
expects to make to us for general working capital purposes until additional funds are raised from investors. The grid note carries interest
at the rate of 12% per year payable in one lump sum on the maturity date, matures on the one-year anniversary of the issuance date and
may be prepaid at any time, in whole or in part, without penalty. It may also be converted at any time, in the sum of any advances and
accrued interest at a price per share of $3.09. As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since
April 1, 2022, Mr. Duey has loaned to us an additional $408,000 under the grid note.
The
warrants above do not meet criteria for equity treatment and are recorded as liabilities based on the guidance in ASC 815-40-15-7D and
7F. Refer to Note 2.
As
                                            of March 31, 2022 and December 31, 2021, the Company had $128 thousand and $206 thousand,
                                            respectively, in outstanding convertible note payables related to the Principal Investor.
                                            The notes bear an interest rate of 12% with no maturity date. Accrued interest related to
                                            the advances from the Principal Investor was $3 thousand and $36 thousand at the three months
                                            ended March 31, 2022 and December 31, 2021, respectively. Interest expense related to the
                                            advances from the Principal Investor was $23 thousand and $8 thousand for the three months
                                            ended March 31, 2022 and March 31, 2021, respectively.
F-
13
6.
Deficit
Common Stock
Each holder of Company common
stock is entitled to one vote for each share thereof held by such holder at all meetings of stockholders (and written action in lieu
of meetings). Common stockholders are not entitled to receive dividends, unless declared by the board of directors. In the event of the
liquidation, dissolution, or winding-up of the Company, holders of Company common stock will be entitled to receive all assets of the
Company available for distribution to its stockholders.
On March 17, 2021, the Company
issued 232,473 shares of common stock to the Principal Investor as consideration for the conversion of a $548 thousand convertible note.
See Note 5 for further details.
On November 2, 2021, the
Company issued 147,586 shares of common stock to the Principal Investor as consideration for the conversion of a $348 thousand convertible
note. See Note 5 for further details.
On December 30, 2021, the
Company issued 635,378 shares of common stock as consideration for the acquisition of the assets owned by TarMeta BioSciences, LLC. See
Note 11 for further details.
On March 16, 2022, the Company
issued 192,977 shares of common stock to the principal investor for the consideration of $596 thousand convertible note. See Note 5 for
further details.
Stock Warrants
On March 17, 2021, the Company
issued warrants exercisable into 46,495 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the Principal
Investor as an incentive to convert a convertible note payable into shares of common stock.
On November 2, 2021, the
Company issued warrants exercisable into 29,518 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the
Principal Investor as an incentive to convert a convertible note payable into shares of common stock.
No warrants were exercised
or expired during the three months ended March 31, 2022 and the year ended December 31, 2021. The following table provides the activity
in warrants for the three months ended March 31, 2022 and the year ended December 31, 2021:
Total
Warrants
Weighted
Average
Remaining
Term (Years)
Weighted
Average
Exercise Price
Average
Intrinsic
Value
Outstanding January 1, 2021
47,722
4.21
2.36
-
Issued
76,013
4.45
2.36
0.73
Outstanding December 31, 2021
123,735
4.36
2.36
$
0.73
Issued
-
-
-
-
Outstanding March 31, 2022
123,735
3.72
$
2.36
$
0.73
The warrants issued in 2021
had a total fair value of $151 thousand at the time of issue, calculated using the Black Scholes model assuming an underlying security
value of $2.36 per share and volatility rate of 99.97%, a risk-free rate of .60%, and a term of 5.0 years. The fair value at issuance
was recorded in Inducement loss and changes in the fair value are recorded as Gain/(loss) on fair value of warrant liability.
F-
14
7.
Stock-Based
                                            Compensation
Stock Options
On
July 20, 2012, the Company adopted the 2012 Stock Option and Restricted Stock Plan, and the shareholders authorized the Board to make
grants restricted shares or options to purchase shares up to 242,291 shares of common stock.
On March 17, 2021, the Board
of Directors authorized the Company to grant 37,558 options to its CEO, of which 15,532 was payment in exchange for deferred compensation,
and 22,027 was payment for bonus. The Company issued 12,708 options to its CFO in exchange for its account payable. The Company also
issued 6,608 options to a Director for consulting services, and 19,824 options to Directors for services as Directors. All options granted
are exercisable at a price of $2.36 per share.
On November 2, 2021, the
Board authorized the Company to grant 110,133 options to its CEO as a discretionary bonus for achieving significant milestones during
the year and also granted 12,708 options exercisable at a price of $2.36 per share to the CFO as payment in full of $30,000 accounts
payable.
On December 21, 2021, the
shareholders approved an increase in the size of the stock option plan to 1,101,321 shares, which no shares remained available to grant
as of March 31, 2022.
On March 15, 2022, the Company
adopted the 2022 Equity Incentive Plan and authorized the Company to issue options which may be exercised for up to 825,992 shares of
the Company's common stock.
On March 15, 2022, the Company
granted options exercisable into 220,265 shares of common stock that vest over a four year period and 330,397 shares of common stock
that vest upon the achievement of milestones, awarded to its CEO, and 30,837 options excisable into 30,837 shares of common stock that
vest over four years to employees and consultants. As of March 31, 2022, 729,874 shares remained available to grant.
No
options were exercised or expired during the three months ended March 31, 2022, and the year ended December 31, 2021. The following tables
provide the stock option activity for the three months ended March 31, 2022, and the year ended December 31, 2021:
Total Options
Outstanding
Weighted
Average
Remaining
Term (Years)
Weighted
Average
Exercise Price
Weighted
Average Fair
Value at Issue
Outstanding January 1, 2021
333,229
6.61
$
1.18
$
1.36
Granted
199,537
10.00
2.36
2.54
Outstanding December 31, 2021
532,766
7.10
$
1.73
$
1.82
Granted
581,498
10.00
3.09
2.45
Outstanding March 31, 2022
1,114,264
8.99
$
2.37
$
2.14
Vested Options March 31, 2022
531,940
8.50
$
2.45
$
2.45
The intrinsic value of the
options at March 31, 2022 and December 31, 2021 was $734,000 and $734,000, respectively. The total fair value of instruments issued for
the three months ended March 31, 2022 and the three months ended March 31, 2021 was $1.3 million and $0.4 million, respectively.
As
of March 31, 2022 and December 31, 2021, unrecorded compensation expense was $1.3 million and $0, respectively.
F-
15
The
Company used the Black Scholes valuation model to determine the fair value of the options issued, using the following key assumptions
for the three months ended March 31, 2022 and 2021:
March 31,
2022
March 31,
2021
Fair Value per Share
$
3.09
$
2.36
Expected Term (Years)
5.00
5.00
Expected Dividend
-
-
Expected Volatility
102.48
%
99.97
%
Risk free rate
2.70
%
0.86
%
8.
Commitments
                                            and Contingencies
Commitments
On
October 1, 2014 the Company entered into a Research Collaboration and Option Agreement with Ryvu Therapeutics S.A. ("Ryvu"
and formerly "Selvita S.A.") for sole responsibility and discretion of developing and commercializing certain compounds and
products. On December 31, 2018, the Company entered into an Exclusive License Agreement with Ryvu. The milestone payments to be paid
to Ryvu under the agreement were amended by agreements dated December 31, 2018 and April 16, 2019. Under the terms of the agreement,
the Company is obligated to make contingent milestone payments to Ryvu up to $11 million on a product-by-product basis upon the achievement
of certain development and regulatory approval milestones related to a product. The Company has also agreed to pay Ryvu low single-digit
royalties on net sales of products sold by the Company up to $3 million per year. Royalties on each product are payable on a country-by-country
basis until the later of (i) a specified period of time after the first commercial sale, and (ii) the date of expiration of the last
valid claim in the last-to-expire of the issued patents covered by the license agreement with Ryvu. At any time during the term, the
Company has the right to terminate its royalty payment obligation by providing written notice to Ryvu and paying Ryvu a royalty termination
fee. There were no royalty or milestone payments due to Ryvu at March 31, 2022 and December 31, 2021.
On
May 5, 2014, the Company entered into a Collaboration and License Agreement with Eurobio Scientific, SA ("Eurobio" and formerly
"Diaxonhit") for the development and commercialization of certain compounds developed and owned by Eurobio. The terms were
amended by agreement on July 23, 2014. Under the agreement, the Company shall pay Eurobio a license fee of $100,000 per year for 12 years
plus contingent milestone payments to Eurobio up to $11.5 million on a product-by-product basis upon the achievement of certain development
and approval milestones related to a product. The Company has also agreed to pay Eurobio low single-digit royalties on net sales of products
sold by the Company. In addition, the Company is obligated to pay Eurobio a percentage of payments received from third parties under
sub-licensing agreements ranging from 5% to 10% as well as royalties ranging from 5% to 14% on net sales of products sold by third parties
under sub-licensing agreements. Royalties on each product are payable on a country-by-country basis until the later of (i) a specified
period of time after the first commercial sale, and (ii) the date of expiration of the last valid claim in the last-to-expire of the
issued patents covered by the license agreement with Eurobio. There were no royalty, milestone, or sub-license payments due to Eurobio
at March 31, 2022, and December 31, 2021.
Contingencies
The
Company believes that it has adequately accrued for the potential impact of loss contingencies that are probable and reasonably estimable.
The Company does not believe that the ultimate resolution of any matters to which it is presently a party will have a material effect
on the Company's results of operations, financial condition, or cash flows. However, the ultimate outcome is not known, and an
unfavorable resolution of one or more of these matters could have a material effect on the Company's financial condition, results
of operations or cash flows. There are no known claims or pending litigations against the company as of March 31, 2022, or December 31,
2021.
Employment
Agreement
On December 30, 2021, the
company entered into an employment agreement with its CEO subject to Board approval. Pursuant to the agreement, the CEO will receive
tiered compensation which increases in the event the Company raises a minimum of $10,000,000 in an equity capital raise. The compensation
will be payable in accordance with the Company's standard payroll practices for salaried employees. The CEO is also eligible for
an annual bonus for the achievement of milestones established by the Compensation Committee of the Board and is eligible to receive a
cash bonus equal to a percentage of any upfront payment on any collaboration agreement reached with a pharmaceutical company. The CEO
will also receive a grant of nonqualified stock options exercisable into 220,265 common shares that shall vest quarterly over a period
of four years, nonqualified stock options exercisable into 330,397 common shares that shall vest upon achievement of milestones and nonqualified
stock options exercisable for 22,027 shares of common stock upon a non-dilutive research funding from any U.S agency.
F-
16
Collaborative
Arrangements
The Company assessed the
Ryvu and Eurobio agreements summarized in Note 8 under Topic 808 to determine whether the license agreements or units of account within
the license agreements represent a collaborative arrangement based on the risk, rewards, and activities of the parties. The Company concluded
that neither Ryvu nor Eurobio represent a customer, as Ryvu and Eurobio are the entities that have performance conditions to the Company
and the Company records no revenue related to the transactions within the Ryvu and Eurobio agreements. There were no cash payments or
transactions in the Consolidated and Combined Statements of Operations and Comprehensive Loss related to the Ryvu agreement for the three
months ended March 31, 2022 and the three months ended March 31, 2021.
9.
Related-Party
                                            Transactions
Debt
As discussed in Note 5, during
the three months ended March 31, 2022, and the year ended December 31, 2021, the Company issued convertible notes payable to the Principal
Investor bearing an interest rate of 12%. The convertible note payable carries interest at the rate of 12% per year payable in one lump
sum on the maturity date, matures on the one year anniversary of the issuance date and may be prepaid at any time, in whole or in part,
without penalty. It may also be converted at any time, in the sum of any advances and accrued interest at a price per share of $3.09.
As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has loaned to us an additional
$408,000 under the grid note.
Consulting
and Management Services
The
Chief Financial Officer ("CFO") of the Company is the owner of an outsourced accounting and finance company that also employs
other accountants and bookkeepers. Total fees for accounting and finance services rendered during the three months ended March 31, 2022,
and 2021 were $91 thousand and $13 thousand, respectively. The cost of these services was recorded as a General and Administrative expense
and are reflected as a related party liability on the accompanying consolidated and combined balance sheet. As of March 31, 2022 and
December 31, 2021 the balance due to related party was $120 thousand and $49 thousand, respectively.
Anna
Vilenchik, the mother of our CEO, was compensated as an independent contractor $8,300 and $0 for research services rendered during the
three months ended March 31,2021 and 2021, respectively.
10.
Segment
                                            information
For
the three months ended March 31, 2022, the Company operated its business as one segment. For the three months ended March 31, 2021, the
Company managed its business activities in two reportable segments: Felicitex and TarMeta. The Company evaluated the performance
of its reportable segments based on Research and Development and General and Administrative expenses, which comprises the net operating
loss of each segment. Both Felicitex and TarMeta's operations are primarily within the United States. For the three months ended
March 31, 2021, TarMeta recognized $0 revenue. There are no inter-segment sales included in the amounts disclosed. Beginning January
1, 2022, the Company combined the activities of the segments into one operating segment.
Felicitex
This
reporting segment includes the development of treatments that target both dormant and proliferating cancers to improve the effectiveness
and long-term outcomes for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal,
osteosarcoma, glioblastoma, and lung. The Felicitex reporting segment consists of one operating segment.
F-
17
TarMeta
This
reporting segment includes the identification and commercialization of novel, small molecule therapeutics for difficult to treat cancers.
The TarMeta reporting segment consists of one operating segment.
Summarized
financial information concerning the Company's reportable segments is shown in the following tables:
Three Month Ended March 31, 2021
Felicitex
TarMeta
Total
Operating expenses:
Research and development
$
78,165
$
55,681
$
133,846
General and administrative expenses
138,591
14,467
153,058
Total operating expenses
216,756
70,148
286,904
Operating loss
$
(216,756
)
$
(70,148
)
$
(286,904
)
Year Ended December 31, 2021
Felicitex
TarMeta
Total
Assets
Current assets:
Cash
$
3,511
$
6,851
$
10,362
Total current assets
3,511
6,851
10,362
Deposits
-
3,500
3,500
Property and equipment, net
610
1,350
1,960
Total assets
$
4,121
$
11,701
$
15,822
11.
Business
                                            Combination
On
December 30, 2021, Felicitex acquired 100% of the ownership interests in the development stage drug discovery company TarMeta Biosciences,
LLC ("TarMeta") in exchange for 5,769,231 common shares of Felicitex ("TarMeta acquisition"). One individual
investor had a controlling interest in both Felicitex and TarMeta prior to the acquisition. The Company determined the TarMeta acquisition
to be a common control transaction under ASC Topic 805, Business Combinations, and accounted for this transaction at the carrying amount
of the net assets acquired. As a result of the TarMeta acquisition, the financial statement as of and for the year ended December 31,
2021 have been adjusted to include the financial information of TarMeta.
12.
Variable
                                            Interest Entity
On July 23, 2021, the Company's
CEO incorporated UAB Felicitex Therapeutics ("UAB"), a Lithuania Corporation, for the purpose of applying for research and
development grants in the European Union. The Company's CEO is the sole owner of UAB in order to comply with the funding requirements
of the targeted grant programs. Due to the Company's control over the operations of UAB, its power to direct activities that most
significantly impact its economic performance, and the fact that the Company has the obligation to absorb losses or the right to receive
benefits from UAB, UAB is considered a VIE in accordance with applicable GAAP. A company with an interest in a VIE must consolidate the
entity in its financial statements if it has both (1) the power to direct the economically significant activities of the entity and (2)
the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to the VIE.
As of March 31, 2022, no grants have been awarded to UAB, nor have any contracts to fund UAB or utilize UAB grant proceeds been finalized,
and its balances and the activity were de minimis. In accordance with applicable GAAP, UAB has been consolidated from its inception in
the consolidated and combined financial statements.
13.
Subsequent
                                            Events
The
Company has executed a reverse stock-split whereby each shareholder received one (1) share of Common Stock for every nine and eight hundredths
(9.08) shares of Common Stock held as of that date, and as such, all share numbers were retroactively adjusted to account for the reverse
split.
F-
18
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders of Felicitex Therapeutics, Inc.
Opinion on the Consolidated and Combined Financial
Statements
We have audited the accompanying consolidated
and combined balance sheets of Felicitex Therapeutics, Inc. (the "Company") as of December 31, 2021 and 2020, and the related
consolidated and combined statement of operations, changes in deficit, and cash flows for the years ended December 31, 2021 and 2020,
and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of
its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United
States of America.
Substantial Doubt about the Company's
Ability to Continue as a Going Concern
The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
has an accumulated deficit of approximately $6.4 million, and recurring losses since inception, which raise substantial doubt about its
ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding
those matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty. Our opinion is not modified with respect to that matter.
Basis for Opinion
These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the
standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards
require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material
misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial
reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial
reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Friedman LLP
We have served as the Company's
    auditor since 2021.
Marlton, New Jersey
March 22, 2022, except for Note 1 and Note 15, as to which the date is June
                                2, 2022
F-
19
FELICITEX THERAPEUTICS,
INC.
CONSOLIDATED AND COMBINED BALANCE SHEETS
Year Ended December 31,
2021
2020
Assets
Current assets:
Cash
$
10,362
$
38,355
Total current assets
10,362
38,355
Deposits
3,500
3,500
Property and equipment, net
1,960
4,952
Total assets
$
15,822
$
46,807
Liabilities and Deficit
Current liabilities:
Accounts payable
$
232,842
$
133,260
Accrued expenses and other current liabilities
47,171
29,348
Deferred compensation
-
36,667
Due to related party
48,652
35,915
PPP loan payable
-
10,298
Convertible note payable - related party
206,180
481,100
Warrant liability
276,708
78,823
Total current liabilities
811,553
805,411
Total liabilities
811,553
805,411
Commitments and contingencies (Note 9)
Deficit
Common Stock: Par value of $0.0001 per share, 100,000,000
    shares authorized; 4,263,022 and 3,247,585 shares issued and outstanding at December 31, 2021 and 2020, respectively.
426
325
Additional paid-in capital
5,566,727
5,881,728
Accumulated deficit
(6,362,884
)
(6,640,657
)
Total deficit
(795,731
)
(758,604
)
Total liabilities and deficit
$
15,822
$
46,807
The accompanying notes are an integral part of
these consolidated and combined financial statements.
F-
20
FELICITEX THERAPEUTICS,
INC.
CONSOLIDATED AND COMBINED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
Year Ended December 31,
2021
2020
Operating expenses:
Research and development
$
631,751
$
487,717
General and administrative expenses
777,940
648,550
Total operating expenses
1,409,691
1,136,267
Operating loss
(1,409,691
)
(1,136,267
)
Other income (expense):
Interest income
182
45
PPP Loan Forgiveness
10,298
-
Other income
12,064
-
Interest expense
(44,007
)
(39,123
)
Inducement loss
(151,497
)
(83,510
)
Gain (Loss) on change in fair value
    of warrant liability
(46,388
)
4,687
Total other expense, net
(219,348
)
(117,901
)
Net loss before provision for income tax
(1,629,039
)
(1,254,168
)
Income tax expense (benefit)
-
-
Net loss and comprehensive loss
(1,629,039
)
(1,254,168
)
Less: Net loss of TarMeta Biosciences,
    LLC prior to acquisition by Felicitex Therapeutics, Inc. (Note 13)
(277,526
)
(535,725
)
Net loss attributable to Felicitex
    Therapeutics, Inc.
$
(1,351,513
)
$
(718,443
)
Net loss per share attributable to
    Felicitex Therapeutics, Inc.-basic and diluted
$
(0.39
)
$
(0.22
)
Weighted average common shares outstanding
    attributable to Felicitex Therapeutics, Inc. basic and diluted
3,457,249
3,198,555
The accompanying notes are an integral part of
these consolidated and combined financial statements.
F-
21
FELICITEX THERAPEUTICS,
INC.
CONSOLIDATED AND COMBINED STATEMENTS OF CHANGES
IN DEFICIT
Additional
Common Stock
Paid-In
Accumulated
Total
Shares
Amount
Capital
Deficit
Deficit
Balance at January 1, 2020
3,008,973
$
301
$
4,305,148
$
(5,386,489
)
$
(1,081,040
)
Stock options issued for settlement of deferred compensation
-
-
399,250
-
399,250
Common stock issued in connection with settlement of convertible
    note payable - related party
238,612
24
546,780
-
546,804
Contributions
-
-
630,550
-
630,550
Net loss and comprehensive loss
-
-
-
(1,254,168
)
(1,254,168
)
Balance at December 31, 2020
3,247,585
$
325
$
5,881,728
$
(6,640,657
)
$
(758,604
)
Stock options issued for settlement of deferred compensation
-
-
36,667
-
36,667
Stock options issued for settlement of accounts payable
-
-
52,739
-
52,739
Stock compensation expense
-
-
339,620
-
339,620
Common stock issued in connection with settlement of convertible
    note payable - related party
380,059
37
897,206
-
897,243
Common stock issued in connection with acquisition of
    TarMeta
635,378
64
(1,906,876
)
1,906,812
-
Contributions
-
-
265,643
-
265,643
Net loss and comprehensive loss
-
-
-
(1,629,039
)
(1,629,039
)
Balance at December 31, 2021
4,263,022
$
426
$
5,566,727
$
(6,362,884
)
$
(795,731
)
The accompanying notes are an integral part of
these consolidated and combined financial statements.
F-
22
FELICITEX THERAPEUTICS,
INC.
CONSOLIDATED AND COMBINED STATEMENTS OF CASH
FLOWS
Year Ended December 31,
2021
2020
Cash flows from operating activities
Net loss
$
(1,629,039
)
$
(1,254,168
)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization
2,992
135,559
Loss on extinguishment of debt
151,497
83,510
Gain on change in fair value of warrant liability
46,388
(4,687
)
Stock based compensation
339,620
-
Forgiveness of paycheck protection loan payable
(10,298
)
-
Changes in operating assets and liabilities:
Increase (decrease) in liabilities:
Accounts payable
170,660
(81,907
)
Accrued expenses
49,903
(20,609
)
Deferred compensation
-
163,334
Other current liabilities
(9,961
)
487
Net cash flows used in operating activities
(888,238
)
(978,481
)
Cash flows from investing activities
Purchase of property and equipment
-
(957
)
Net cash flows used in investing activities
-
(957
)
Cash flows from financing activities
Payments of capital leases
-
(142,181
)
Proceeds from convertible note payable
594,602
511,600
Equity contributions - related party
265,643
630,550
Proceeds from PPP loan
-
10,298
Net cash flows provided by financing activities
860,245
1,010,267
Net change in cash
(27,993
)
30,829
Cash, beginning of year
38,355
7,526
Cash, end of year
$
10,362
$
38,355
Supplementary cash flows information
Cash paid during the year for interest
$
-
$
-
Cash paid during the year for taxes
$
-
$
-
Non-cash investing and financing activities
Conversion of convertible note payable into common stock
$
897,243
$
546,804
Conversion of deferred compensation into stock options
$
36,667
$
399,250
Conversion of accounts payable into stock options
$
52,739
$
-
Acquisition of Tarmeta Biosciences
$
1,907,389
$
-
The accompanying notes are an integral part of
these consolidated and combined financial statements.
F-
23
FELICITEX
THERAPEUTICS, INC.
NOTES TO CONSOLIDATED
AND COMBINED FINANCIAL STATEMENTS
1.
Nature of the Business and Basis of Presentation
Felicitex Therapeutics, Inc.
("Felicitex") was incorporated in Delaware on Mary 4, 2012. Felicitex is an early-stage drug development company developing
treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term outcomes for the deadliest and
most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.
The Company has established
a drug discovery platform focused on cellular dormancy to identify novel targets and corresponding small molecule inhibitors and has
developed two advanced drug candidates thus far that are all in the preclinical development stage. It has an expanding IP position that
includes two fundamental composition of matter patents and three methods of use patents. The research and development activities of the
Company are currently in the pre-clinical phase of development.
The company has retroactively
applied the impacts for the reverse stock split of 1 to 9.08, which was approved by the Board of Directors on May 23, 2022. All references
to the number of shares in the footnotes have been retroactively adjusted.
Basis of Presentation
and Principles of Consolidation and Combination
The accompanying consolidated
and combined financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America ("U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC"). On
July 23, 2021, the Company incorporated Felicitex Therapeutics UAB ("UAB"), a Lithuania Corporation, for the purpose of applying
for grants. The Company intends to use the grant proceeds, if awarded, in pre-clinical studies to be conducted in Europe to assess the
potential of conducting clinical trials on its molecule in the future. The Company's CEO is necessarily the sole owner of UAB in
order to comply with the funding requirements of the government grant programs in Lithuania and the European Union. As discussed in Note
14, UAB is deemed to be a Variable Interest Entity ("VIE"), and is therefore required to be included in the consolidated
and combined financial statements of the Company.
As discussed in Note 13,
on December 30, 2021, the Company acquired TarMeta BioSciences, LLC ("TarMeta"), an early-stage drug discovery platform company
with deep expertise in analytical chemistry whose mission is to identify and commercialize novel small molecule therapeutics for difficult
to treat cancers. The Company determined the TarMeta acquisition to be a common control transaction under ASC Topic 805, Business Combinations,
and accounted for this transaction at the carrying amount of the net assets acquired. As a result of the TarMeta acquisition, the financial
statements as of and for the years ended December 31, 2021 and 2020 have been adjusted to include the financial information of TarMeta
for the period. As a result of the business combination, TarMeta ceased to exist as a separate legal entity. The consolidated and combined
financial statements include the accounts of Felicitex, UAB and TarMeta (collectively, the "Company"). All intercompany transactions
and balances have been eliminated in combination. There is no difference between net loss and comprehensive loss in these consolidated
and combined financial statements.
Liquidity and Going
Concern
The
Company is in the development stage and has incurred losses and negative cash flows from operations. The Company had a net loss of approximately
$1.6 million and $1.3 million, and negative cash flows from operations of approximately $900 thousand and $1.0 million for the years
ended December 31, 2021, and 2020, respectively. Further, the Company has an accumulated deficit of $6,362,884
,
as
of December 31, 2021. Based on the current development plans for the Company's drug candidates and other operating requirements,
existing cash is not sufficient to fund operations for the twelve months following the financial statement filing date. These factors
raise substantial doubt about the Company's ability to continue as a going concern.
A significant amount of additional
capital will be necessary to advance the development of our products to the point at which they may become commercially viable. The Company
plans to raise additional capital from various potential sources, including equity and/or debt financings, grant funding, and strategic
relationships. In addition, the Company has an active equity purchase agreement with Aegis Capital to sell up to $15 million of Company
common stock in an initial public offering, which amount, if fully accessible, would be sufficient to fund the Company's operations
beyond one year from the filing date of these statements. However, there can be no guarantee that the Company will be able to close on
the financing. Should such financing be unsuccessful, the Company would be required to delay, scale back or eliminate some or all of
its research and development programs, which would likely have a material adverse effect on the Company and its consolidated and combined
financial statements.
F-
24
The accompanying consolidated
and combined financial statements do not include any adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Other Uncertainties
Generally, the industry in
which the Company operates subjects the Company to a number of other risks and uncertainties that can affect its operating results and
financial condition. Such factors include, but are not limited to: the timing, costs and results of clinical trials and other development
activities versus expectations; the ability to obtain regulatory approval to market product candidates; the ability to manufacture products
successfully; competition from products sold or being developed by other companies; the price of, and demand for, Company products once
approved; the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products.
The Company faces the ongoing
risk that the coronavirus pandemic may slow, for an unforeseeable period, the conduct of the Company's research and pre-clinical
studies. The effects of the ongoing coronavirus pandemic may also increase non-research related costs such as insurance premiums, increase
the demand for and cost of capital, increase loss of work time from key personnel, and negatively impact our key pre-clinical trial vendors
and suppliers of our pharmaceutical ingredients. The full extent to which the COVID-19 pandemic could impact drug development and research,
or impact the Company's suppliers and other commercial partners, will depend on future developments that cannot be predicted. We
assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information
reasonably available to us and the unknown future impacts COVID-19 as of December 31, 2021, and through the date of this report.
2.
Summary of Significant Accounting Policies
Cash
The Company considers all
highly liquid investments with original maturities of three months or less to be cash equivalents. The Company had no cash equivalents
at December 31, 2021 and 2020. At times, the Company's cash balances may exceed the current insured amounts under the Federal Deposit
Insurance Corporation ("FDIC"). On December 31, 2021 and 2020, the Company did not exceed FDIC insurance limits. Unrealized
gain or loss are included in the interest income and are immaterial to the consolidated and combined financial statements.
Use of Estimates
The
preparation of consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at
the date of the consolidated and combined financial statements as well as the reported amounts of revenues and expenses during the reporting
period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical
experience, risk of loss, general economic conditions and trends and the assessment of the probable future outcome. Subjective and significant
estimates include, but are not limited to, the valuation of stock-based compensation, valuation of issued warrants, expense recognition
and accruals associated with third party providers supporting pre-clinical studies and other research and development, and income tax
asset realization. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects
of changes, if any, are reflected in the consolidated and combined statements of operations in the period that they are determined.
Segment Information
The Company determined its
operating segment after considering the Company's organizational structure and the information regularly reviewed and evaluated
by the Company's chief operating decision maker ("CODM") in deciding how to allocate resources and assess performance.
The Company has determined that its CODM is its Chief Executive Officer. The CODM reviews the financial information of Felicitex and
TarMeta independently for the purpose of evaluating financial performance and allocating resources. On the basis of these factors, the
Company determined that it operates and manages its business as two operating segments and accordingly has two reportable segments for
financial reporting purposes. Substantially all the Company's long-lived assets are held in the United States. Segment considerations
are further discussed in Note 12.
F-
25
Property and Equipment,
Net
Property and equipment are
stated at cost less accumulated depreciation and amortization. Expenditures for repairs and maintenance are expensed as incurred. Depreciation
and amortization are computed using the straight-line method over the estimated useful lives of the assets as follows:
Estimated
                                            Useful Life
Equipment
3
                                            years
Leasehold improvements
Shorter of remaining
                                            life of lease or useful life
Patent Costs
All patent-related costs
are expensed as incurred due to uncertainty with respect to the Company's ability to commercialize the patents. Amounts incurred
are classified as general and administrative expenses.
Leases
Lease agreements are evaluated
to determine whether they are capital or operating leases in accordance with Financial Accounting Standards Board ("FASB")
Accounting Standards Codification ("ASC") Topic 840,
Leases
("ASC 840"). When any one of the four test
criteria in ASC 840 is met, the lease then qualifies as a capital lease. Capital leases are capitalized at the lower of the net present
value of the total amount payable under the leasing agreement (excluding finance charges) or the fair market value of the leased asset.
Capital lease assets are depreciated on a straight-line basis, over a period consistent with the Company's normal depreciation
policy for tangible fixed assets. The Company allocates each lease payment between a reduction of the lease obligation and interest expense
using the effective interest method. Rent expense for operating leases, which may include free rent or fixed escalation amounts in addition
to minimum lease payments, is recognized on a straight-line basis over the duration of the lease term. The Company had one capital lease
related to equipment as of January 1, 2020, that was fully paid off prior to December 31, 2020.
Collaborative Arrangements
The Company analyzes its
collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both
active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB ASC Topic
808,
Collaborative Arrangements
("ASC 808"). For collaborative arrangements that contain multiple elements, the Company
determines which units of account are deemed to be within the scope of ASC 808 and which units of account are more reflective of a vendor-customer
relationship, and therefore are within the scope of ASC 606. For units of account that are accounted for pursuant to ASC 808, an appropriate
recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable
accounting policy election. For collaborative arrangements that are within the scope of ASC 808, the Company evaluates the income statement
classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative
arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead
of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to Research
and Development Expense or General and Administrative Expense, as appropriate. Milestone payments are considered contingent liabilities
and are recognized when the Company deems the milestone event to be probable.
Fair Value Measurements
FASB ASC Topic 820,
Fair
Value Measurements and Disclosures
, defines fair value, establishes a framework for measuring fair value, and expands disclosures
about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset or paid
to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction
between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy has been
established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable
inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would
use in pricing the asset or liability based on market data obtained from sources independent of the Company.
F-
26
Unobservable inputs reflect
the Company's assumption about the inputs that market participants would use in pricing the asset or liability developed based
on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the inputs,
as follows:
●
Level 1 - Valuations
                                            based on quoted prices for identical instruments in active markets. Since valuations are
                                            based on quoted prices that are readily and regularly available in an active market, valuation
                                            of these instruments does not entail a significant degree of judgment.
●
Level 2 - Valuations
                                            based on observable inputs other than quoted prices included in Level 1, such as quoted prices
                                            for either similar instruments in active markets, identical or similar instruments in markets
                                            that are not active, or model-derived valuations whose inputs or significant value drivers
                                            are observable or can be corroborated by observable market data.
●
Level 3 - Valuations
                                            based on inputs that are unobservable. These valuations require significant judgment.
The availability of valuation
techniques and observable inputs can vary and is affected by a wide variety of factors, including the type of asset or liability, whether
the asset or liability is new and not yet established in the marketplace, and other characteristics particular to the transaction. To
the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair
value requires more judgment. Those estimated values do not necessarily represent the amounts that may be ultimately realized due to
the occurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of valuations, those
estimated values may be materially higher or lower than the values that would have been used had a ready market for the assets or liabilities
existed.
As of December 31, 2021, the Company's assets
and liabilities measured at fair value on a recurring basis were categorized as follows within the fair value hierarchy:
Level 1
Level 2
Level 3
Total
Liabilities
Warrant liability
$
-
$
-
$
276,708
$
276,708
Total liabilities
$
-
$
-
$
276,708
$
276,708
As of December 31, 2020, the Company's assets
and liabilities measured at fair value on a recurring basis were categorized as follows within the fair value hierarchy:
Level 1
Level 2
Level 3
Total
Liabilities
Warrant liability
$
-
$
-
$
78,823
$
78,823
Total liabilities
$
-
$
-
$
78,823
$
78,823
The value of cash, prepaid expenses, accounts
payable, accrued expenses, PPP loan payable, amounts due to related parties and convertible notes payable - related party approximate
fair value to due to the short-term nature of these assets and liabilities.
The Company estimated the
fair value of the warrant liability classified as Level 3 liabilities using the Black-Scholes option pricing model utilizing certain
weighted average assumptions such as expected stock price volatility, expected term of the warrants, and risk-free interest rates. The
following table summarizes the activity for the Company's Level 3 liabilities measured at fair value on a recurring basis:
Amount
Balance as of January 1, 2020
$
-
Issuance
83,510
Changes in fair value
(4,687
)
Balance as of January 1, 2021
$
78,823
Issuance
151,497
Changes in fair value
46,388
Balance as of December 31, 2021
$
276,708
During the year ended December
31, 2021, and 2020 there were no transfers between Level 1 and Level 2, nor into and out of Level 3.
F-
27
Research and Development
Costs and expenses that can
be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. Research and
development costs are charged to expense as incurred and include the cost of wages, equipment, materials, and laboratory fees paid in
conducting scientific research on potential drug candidates. Research and development costs were $632 thousand and $488 thousand for
the years ended December 31, 2021, and 2020, respectively.
Stock-Based Compensation
The Company accounts for
stock-based compensation to employees and non-employees in conformity with the provisions of FASB ASC Topic 718
, Compensation - Stock
Based Compensation
. The Company expenses stock-based compensation to employees and non-employees over the requisite service period
based on the estimated grant-date fair value of the awards. The Company estimates the fair value of options granted using the Black Scholes
Merton model. The Company estimates when and if performance-based awards will be earned. If an award is not considered probable of being
earned, no amount of equity-based compensation expense is recognized. If the award is deemed probable of being earned, related equity-based
compensation expense is recorded. The fair value of an award ultimately expected to vest is recognized as an expense, net of forfeitures,
over the requisite service, which is generally the vesting period of the award. Options forfeitures are recorded as they occur.
The Black Scholes Merton
model requires the input of certain subjective assumptions and the application of judgment in determining the fair value of the awards.
The most significant assumptions and judgments include the following:
●
Expected volatility -
                                            The expected price volatility is based on the historical volatilities of peer group companies
                                            as the Company does not have a sufficient trading history. Industry peers consist of several
                                            public companies in the bio-tech industry similar in size, stage of life cycle, and capital
                                            structure. The Company also blends in historical data on the volatility of its own equity,
                                            increasing in proportion as the period of historical data on the Company's data becomes
                                            more representative.
●
Risk-free interest rate -
                                            The risk-free rate was determined based on yields of U.S. Treasury Bonds of comparable terms.
●
Expected dividend yield -
                                            The Company has not previously issued dividends and do not anticipate paying dividends in
                                            the foreseeable future. Therefore, we used a dividend rate of zero based on our expectation
                                            of additional dividends.
●
Expected term -The expected
                                            term of the options was estimated using the simplified method.
Common shares issued to third
parties for services provided are valued at fair value of the Company's shares.
Warrant Liability
Warrants are accounted for
in accordance with the guidance contained in ASC 815-40-15-7D and 7F, under which the warrants do not meet the criteria for equity treatment
and must be recorded as liabilities. Accordingly, the Company classifies warrants as liabilities at their fair value and adjusts the
warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised,
and any change in fair value is recognized in the consolidated and combined statement of operations and comprehensive loss. The warrants
are valued using a Black Scholes model.
Income Taxes
ASC Topic 740,
Income
Taxes
("ASC 740") sets forth standards for financial presentation and disclosure of income tax liabilities and expense.
The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax basis and tax carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
A valuation allowance is
established to reduce net deferred tax assets to the amount expected to be realized. The Company recognizes the effect of income tax
positions only if those positions are more likely than not of being sustained. Changes in recognition and measurement are reflected in
the period in which the change in judgment occurs. Interest and penalties related to unrecognized tax benefits are included in income
tax expense.
F-
28
The Company provides reserves
for potential payments of taxes to various tax authorities related to uncertain tax positions. Amounts recognized are based on a determination
of whether a tax benefit previously taken by the Company on filed tax returns or a position expected to be taken on future tax returns
is more likely than not sustaining a challenge from the local tax authorities. The tax benefit recognized is equal to the largest amount
that is more than 50% likely to be sustained. Interest and penalties associated with uncertain tax positions are recorded as a component
of income tax expense.
Prior to its acquisition
by the Company on December 30, 2021, TarMeta was a limited liability company. As a limited liability company, the Company elected to
treat TarMeta as a partnership for federal and state income tax reporting purposes. Accordingly, for federal and certain state income
tax purposes, TarMeta's income was included in the income tax returns of its members. In most jurisdictions, income tax liabilities
and/or tax benefits are passed through to the individual members.
Basic and Diluted Loss
per Share
Basic and diluted loss per
share is computed based on the weighted-average outstanding shares of common stock, which are all voting shares. Diluted net loss per
share is computed giving effect to all proportional shares of common stock, including stock options and warrants to the extent dilutive.
Basic net loss per share was the same as diluted net loss per share for the year ended December 31, 2021, and 2020, respectively, as
the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following potentially dilutive securities
were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:
December 31,
2021
December 31,
2020
Stock options excluded
532,766
333,229
Stock warrants excluded
123,735
47,
722
Stock convertible under outstanding notes payable excluded
105,529
218,400
Total potentially dilutive securities
762,030
599,351
Emerging Growth Company
Status
The Company anticipates that
it will qualify as an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act").
Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS Act until such time as those standards apply to private companies. The Company will elect to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies until
the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended
transition period provided in the JOBS Act. As a result, these consolidated and combined financial statements may not be comparable to
companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently Adopted Accounting
Pronouncements
In November 2018, the FASB
issued Accounting Standard Update ("ASU") No. 2018-18,
Collaborative Arrangements (Topic 808)
("ASU No. 2018-18").
This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808)
including the alignment of unit of account guidance between the two topics. The Company early adopted ASU No. 2018-18 as of January 1,
2020. The adoption of this update did not have a material effect on the Company's consolidated and combined financial statements,
as there were no collaborative arrangements that had identified performance obligations to customers.
Recent Accounting Pronouncements
Not Yet Adopted
In February 2016, the FASB
issued ASU No. 2016-02,
Leases (Topic 842) as subsequently amended
("ASU No. 2016-02"). ASU No. 2016-02 was issued
to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet
and disclosing key information about leasing arrangements. The amendments in this update are effective for fiscal years beginning after
December 15, 2018, including interim periods within those fiscal years, for public business entities, not-for-profit entities that has
issued securities that are traded, listed or quoted on an exchange or an over-the-counter market, and employee benefit plans that file
financial statements with the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after
December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that the adoption
of ASU No. 2021-04 will have a material effect on its consolidated and combined financial statements.
F-
29
In December 2019, the FASB
issued ASU 2019-12,
Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
("ASU 2019-12"), as part
as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or
improving the usefulness of the information provided to users of financial statements. Amendments include removal of certain exceptions
to the general principles of ASC 740 and simplification in several other areas such as accounting for a franchise tax (or similar tax)
that is partially based on income. The update is effective for public business entities for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning
after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not believe that
the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial statements.
In May 2021, the FASB issued
ASU 2021-04,
Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation
(Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain
Modifications or Exchanges of Freestanding Equity-Classified Written Call Options
("ASU 2021-04"). The amendments in
ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding
equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The update
is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
The Company does not believe that the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial
statements.
In August 2020, the FASB
issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts
in Entity's Own Equity (Subtopic 815-40) ("ASU No. 2020-06"). ASU No. 2020-06 was issued to address issues identified
as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with
characteristics of liabilities and equity. For convertible instruments, the FASB decided to reduce the number of accounting models for
convertible debt instruments and convertible preferred stock. In addition to eliminating certain accounting models, the FASB also decided
to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share
guidance. This update is effective for public business entities for fiscal years beginning after December 15, 2021, and interim periods
within those fiscal year. For all other entities, this update is effective for fiscal years beginning after December 15, 2023, and interim
periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 31, 2020. The
Company does not believe that the adoption of ASU No. 2021-04 will have a material effect on its consolidated and combined financial
statements.
3.
Property and Equipment, Net
Property and equipment, net
consisted of the following as of December 31, 2021 and 2020, respectively:
December 31,
2021
December 31,
2020
Equipment
$
21,525
$
21,525
Less: Accumulated depreciation
(19,565
)
(16,573
)
Property and equipment, net
$
1,960
$
4,952
4.
Paycheck Protection Program Loan
During the year ended December
31, 2020, the Company received loan proceeds in the amount of $10 thousand under the Paycheck Protection Program ("PPP")
which was established as part of the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") administered through
the Small Business Administration ("SBA"). The PPP provides loans to qualifying businesses in amounts up to 2.5 times their
average monthly payroll expenses and was designed to provide a direct financial incentive for qualifying businesses to keep their workforce
employed during the Coronavirus crisis. PPP loans are uncollateralized and guaranteed by the SBA and are forgivable after a "covered
period" (eight or twenty-four weeks) as long as the borrower maintains its payroll levels and uses the loan proceeds for eligible
expenses, including payroll, benefits, mortgage interest, rent and utilities. The forgiveness amount will be reduced if the borrower
terminates employees or reduces salaries and wages more than 25% during the covered period. Any unforgiven portion is payable over 2
years if issued before, or 5 years if issued after, June 5, 2020 at an interest rate of 1% with payments deferred until the SBA remits
the borrower's loan forgiveness amount to the lender, or, if the borrower does not apply for forgiveness, ten months after the
end of the covered period. PPP loan terms provide for customary events of default, including payment defaults, breaches of representations
and warranties, and insolvency events and may be accelerated upon the occurrence of one or more of these events of default. Additionally,
PPP loan terms do not include prepayment penalties. On February 24, 2021, the Company's PPP loan in the amount of $10 thousand
was forgiven.
F-
30
5.
Convertible Note Payable - Related Party
The Chairman of the Board
("Principal Investor") has substantial control of the voting power of the Company. During the years ended December 31, 2021
and 2020, the Company issued convertible notes payable to the Principal Investor in lieu of paying cash compensation. The notes payable
are convertible to common stock at a price of $2.27.
On March 17, 2020, the Principal
Investor agreed to accept 238,612 shares of common stock at a price of $2.36 per share as payment in full of $502 thousand of principal
and $45 thousand of accrued interest on outstanding loans. In addition, the Principal Investor received warrants to purchase 47,722 additional
shares of common stock as an incentive to convert the note. The conversion was accounted for as a general conversion with the fair value
of the warrants recognized as an expense in Inducement loss and included as an adjustment to reconcile net loss to net cash provided
by (used in) operating activities in our consolidated and combined statements of cash flows. Inducement expense recorded for the year
ended December 31, 2020 was $84 thousand. The common stock consideration issued under the original terms of the notes payable was accounted
for under general conversion accounting guidance, with a net carrying amount of $547 thousand recorded in additional paid in capital
and as a non-cash transaction excluded from cash activities on the consolidated and combined statements of cash flows.
As of December 31, 2020,
the Company had $481 thousand in outstanding convertible note payables related to the Principal Investor. The notes bear an interest
rate of 12% with no maturity date. Interest expense related to the advances from the Principal Investor was $29 thousand for the year
ended December 31, 2020.
On March 17, 2021, the Company
issued 232,473 shares of common stock to the Principal Investor as consideration for the conversion of a $521 thousand shareholder loan
and $27 thousand in accrued interest. In addition, the Company issued warrants exercisable into 46,495 shares of common stock within
five years at an exercise price of $2.36 per share   as an incentive for converting the loan receivable into shares of common
stock.
On March 31, 2021, the Company
entered into a loan agreement with principal investor to lend up to $550 thousand. The note is convertible at $2.29 per share and accrues
interest at 12% with no maturity date.
On November 2, 2021, the
Company issued 147,586 shares of common stock to an existing shareholder as consideration for the conversion of a $348 thousand convertible
note payable. In addition, the Company issued warrants exercisable into 29,518 shares of common stock within five years at an exercise
price of $2.36 per share   to the shareholder as an incentive for converting the loan receivable into shares of common stock.
On March 16, 2022, we entered
into a convertible grid note with Mr. Duey with respect to additional advances that Mr. Duey has made and expects to make to us for general
working capital purposes until additional funds are raised from investors. The grid note carries interest at the rate of 12% per year
payable in one lump sum on the maturity date, matures on the one-year anniversary of the issuance date and may be prepaid at any time,
in whole or in part, without penalty. It may also be converted at any time, in the sum of any advances and accrued interest at a price
per share of $3.09. As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has
loaned to us an additional $408,000 under the grid note.
The warrants above do not
meet criteria for equity treatment and are recorded as liabilities based on the guidance in ASC 815-40-15-7D and 7F. Refer to Note 2.
As of December 31, 2021,
the Company had $206 thousand in outstanding convertible note payables related to the Principal Investor. The notes bear an interest
rate of 12% with no maturity date. Accrued interest related to the advances from the Principal Investor was $36 thousand for the year
ended December 31, 2021.
6.
Deficit
Common Stock
Each holder of Company common
stock is entitled to one vote for each share thereof held by such holder at all meetings of stockholders (and written action in lieu
of meetings). Common stockholders are not entitled to receive dividends, unless declared by the board of directors. In the event of the
liquidation, dissolution, or winding-up of the Company, holders of Company common stock will be entitled to receive all assets of the
Company available for distribution to its stockholders.
On March 17, 2020, the Company
issued 238,612 shares of common stock to the Principal Investor as consideration for the conversion of a $502 thousand convertible note
plus $45 thousand in accrued interest. See Note 5 for further details.
F-
31
On March 17, 2021, the Company
issued 232,473 shares of common stock to the Principal Investor as consideration for the conversion of a $548 thousand convertible note.
See Note 5 for further details.
On November 2, 2021, the
Company issued 147,586 shares of common stock to the Principal Investor as consideration for the conversion of a $348 thousand convertible
note. See Note 5 for further details.
On December 30, 2021, the
Company issued 635,378 shares of common stock as consideration for the acquisition of the assets owned by TarMeta BioSciences, LLC. See
Note 13 for further details.
Stock Warrants
On March 17, 2020, the Company
issued warrants exercisable into 47,722 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the Principal
Investor as an incentive to convert a convertible note payable into shares of common stock.
On March 17, 2021, the Company
issued warrants exercisable into 46,495 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the Principal
Investor as an incentive to convert a convertible note payable into shares of common stock.
On November 2, 2021, the
Company issued warrants exercisable into 29,518 shares of common stock within 5.0 years at an exercise price of $2.36 per share to the
Principal Investor as an incentive to convert a convertible note payable into shares of common stock.
No warrants were exercised
or expired during the year ended December 31, 2021 or December 31, 2020. The following table provides the activity in warrants for the
year ended December 31, 2021 and 2020:
Total Warrants
Weighted Average Remaining Term (Years)
Weighted Average Exercise Price
Average Intrinsic Value
Outstanding January 1, 2020
-
-
-
-
Issued
47,722
5.00
2.36
-
Outstanding January 1, 2021
47,722
4.21
2.36
-
Issued
76,013
5.00
2.36
0.08
Outstanding December 31, 2021
123,735
4.40
$
2.36
$
0.08
The warrants issued in 2020
had a total fair value of $84 thousand at time of issue, calculated using the Black Scholes model assuming an underlying security value
of $2.36 per share and volatility rate of 99.90%, a risk-free rate of 1.21%, and a term of 5.0 years. The warrants issued in 2021 had
a total fair value of $151 thousand at the time of issue, calculated using the Black Scholes model 6assuming an underlying security value
of 2.36 per share and volatility rate of 99.97%, a risk-free rate of .60%, and a term of 5.0 years. The fair value at issuance was recorded
in Inducement loss and changes in the fair value are recorded as Gain/(loss) on fair value of warrant liability.
7.
Stock-Based Compensation
Stock Options
On July 20, 2012, the Company
adopted the 2012 Stock Option and Restricted Stock Plan and the shareholders authorized the Board to make grants restricted shares or
options to purchase shares up to 242,291 shares of common stock.
On March 17, 2020, the
Board authorized the Company to grant 174,114 options exercisable at a price of $2.36 per share to employees as payment in full of the
$334 thousand deferred compensation payable plus $65 thousand bonus.
F-
32
On March 17, 2021, the Board
of Directors authorized the Company to grant 37,558 options to its CEO, of which 15,532 was payment in exchange for deferred compensation,
and 22,027 was payment for bonus. The Company issued 12,708 options to its CFO in exchange for its account payable. The Company also
issued 6,608 options to a Director for consulting services, and 19,824 options to Directors for services as Directors. All options granted
are exercisable at a price of $2.36 per share.
On November 2, 2021, the
Board authorized the Company to grant 110,133 options to its CEO as a discretionary bonus for achieving significant milestones during
the year and also granted 12,708 options exercisable at a price of $2.36 per share to the CFO as payment in full of $30,000 accounts
payable.
On December 21, 2021, the
shareholders approved an increase in the size of the stock option plan to 1,101,321 shares, which 568,556 shares remained available to
grant as of December 31, 2021.
No options were exercised
or expired during the years ended December 31, 2021 and 2020. The following tables provide the stock option activity for the year ended
December 31, 2021 and 2020:
Total Options Outstanding
Weighted Average Remaining Term (Years)
Weighted Average
Exercise
Price
Weighted
Average Fair
Value at
Issue
Outstanding January 1, 2020
159,115
3.40
$
1.63
$
8.26
Granted
174,114
10.00
2.69
1.98
Outstanding December 31, 2020
333,229
6.61
$
1.18
$
1.36
Granted
199,537
10.00
2.36
2.54
Outstanding December 31, 2021
532,766
7.10
1.73
1.82
All options were fully vested
on grant date. The intrinsic value of the options as of December 31, 2021 and 2020 was $734 thousand and $347 thousand, respectively.
The total compensation for instruments issued for the years ended December 31, 2021 and 2020 was $376 thousand and $-0-, respectively.
There was no unrecognized
compensation expense as of December 31, 2021 or 2020.
The Company used the Black
Scholes valuation model to determine the fair value of the options issued, using the following key assumptions for the year ended December
31, 2021 and December 31, 2020:
December 31,
2021
December 31,
2020
Fair Value per Share
$
2.36
$
2.36
Expected Term (Years)
5.00
5.00
Expected Dividend
-
-
Expected Volatility
99.97
%
99.90
%
Risk free rate
0.86
%
1.42
%
8.
Income Taxes
The difference between the
income tax provision and income taxes computed using the U. S. federal income tax rate of 21% consisted of the following for the year
ended December 31, 2021 and 2020:
Year Ended
December 31,
2021
Year Ended
December 31,
2020
Provision at statutory rate
21.00
%
21.00
%
State taxes, net of federal benefit
6.43
%
3.98
%
Permanent differences
-11.31
%
-8.21
%
Change in valuation allowance
-16.12
%
-16.76
%
Total
0.00
%
0.00
%
F-
33
Deferred Tax Assets
Deferred income taxes reflect
the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and
amounts used for income tax purposes. Significant components of the Company's deferred taxes as of December 31, 2021 and 2020 are
as follows:
Year Ended
December 31,
2021
Year Ended
December 31,
2020
Deferred tax assets:
Fixed assets and intangibles
$
113,552
$
110,608
Stock compensation
230,189
131,699
Net operating loss carryforwards
824,326
602,379
Total deferred tax assets
1,168,067
844,687
Less: Valuation allowance
(1,168,067
)
(844,687
)
Net deferred tax assets (liability)
$
-
$
-
During the years ended December
31, 2021 and 2020 the Company recorded a valuation allowance equal to its net deferred tax assets. The Company determined that due to
a recent history of net losses, that at this time, sufficient uncertainty exists regarding the future realization of these deferred tax
assets through future taxable income. If, in the future, the Company believes that it is more likely than not that these deferred tax
benefits will be realized, the valuation allowances will be reduced or eliminated. With a full valuation allowance, any change in the
deferred tax asset or liability is fully offset by a corresponding change in the valuation allowance. For the years ended December 31,
2021 and 2020, the valuation allowance on the Company's net deferred tax assets increased by $191 thousand and $287 thousand, respectively.
The
Company has federal net operating losses ("NOLs") of approximately $3.0 million, of which $600 thousand begin to expire in
2037 and $2.4 million may be carried forward indefinitely. The Company has state net operating losses of $2.4 million which begin to
expire in 2038. Pursuant to Section 382 of the Internal Revenue Code, use of the Company's NOLs and credit carry forwards may be
limited if the Company experiences a cumulative change in ownership of greater than 50% in a moving three-year period.
The Company also has federal
credits that begin to expire 2031 and state tax credits that may be carried forward indefinitely.
The Company has not recorded
any liabilities related to uncertain tax positions in its consolidated and combined financial statements as of December 31, 2021 or 2020.
To the extent the Company
has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal
Revenue Service and state and local tax authorities to the extent utilized in a future period. As of December 31, 2021, the tax years
from 2018 to present remain open to examination by relevant taxing jurisdictions to which the Company is subject. However, to the extent
the Company utilizes net operating losses from years prior to 2018, the statute remains open to the extent of the net operating losses
or other credits that are utilized.
9.
Commitments and Contingencies
Commitments
On October 1, 2014 the Company
entered into a Research Collaboration and Option Agreement with Ryvu Therapeutics S.A. ("Ryvu" and formerly "Selvita
S.A.") for sole responsibility and discretion of developing and commercializing certain compounds and products. On December 31,
2018, the Company entered into an Exclusive License Agreement with Ryvu. The milestone payments to be paid to Ryvu under the agreement
were amended by agreements dated December 31, 2018 and April 16, 2019. Under the terms of the agreement, the Company is obligated to
make contingent milestone payments to Ryvu up to $11 million on a product-by-product basis upon the achievement of certain development
and regulatory approval milestones related to a product. The Company has also agreed to pay Ryvu low single-digit royalties on net sales
of products sold by the Company up to $3 million per year. Royalties on each product are payable on a country-by-country basis until
the later of (i) a specified period of time after the first commercial sale, and (ii) the date of expiration of the last valid claim
in the last-to-expire of the issued patents covered by the license agreement with Ryvu. At any time during the term, the Company has
the right to terminate its royalty payment obligation by providing written notice to Ryvu and paying Ryvu a royalty termination fee.
There were no royalty or milestone payments made to Ryvu during the years ended December 31, 2021 and 2020.
F-
34
On May 5, 2014, the Company
entered into a Collaboration and License Agreement with Eurobio Scientific, SA ("Eurobio" and formerly "Diaxonhit")
for the development and commercialization of certain compounds developed and owned by Eurobio. The terms were amended by agreement on
July 23, 2014. Under the agreement, the Company shall pay Eurobio a license fee of $100,000 per year for 12 years plus contingent milestone
payments to Eurobio up to $11.5 million on a product-by-product basis upon the achievement of certain development and approval milestones
related to a product. The Company has also agreed to pay Eurobio low single-digit royalties on net sales of products sold by the Company.
In addition, the Company is obligated to pay Eurobio a percentage of payments received from third parties under sub-licensing agreements
ranging from 5% to 10% as well as royalties ranging from 5% to 14% on net sales of products sold by third parties under sub-licensing
agreements. Royalties on each product are payable on a country-by-country basis until the later of (i) a specified period of time after
the first commercial sale, and (ii) the date of expiration of the last valid claim in the last-to-expire of the issued patents covered
by the license agreement with Eurobio. There were no royalty, milestone, or sub-license payments made to Diaxonhit during the years ended
December 31, 2021 or 2020.
Contingencies
The Company believes that
it has adequately accrued for the potential impact of loss contingencies that are probable and reasonably estimable. The Company does
not believe that the ultimate resolution of any matters to which it is presently a party will have a material effect on the Company's
results of operations, financial condition, or cash flows. However, the ultimate outcome is not known, and an unfavorable resolution
of one or more of these matters could have a material effect on the Company's financial condition, results of operations or cash
flows. There are no known claims or pending litigations against the company as of December 31, 2021 or 2020.
Employment Agreement
On December 30, 2021 the
company entered into an employment agreement with its CEO subject to Board approval. Pursuant to the agreement, the CEO will receive
tiered compensation which increases in the event the Company raises a minimum of $10,000,000 in an equity capital raise. The compensation
will be payable in accordance with the Company's standard payroll practices for salaried employees. The CEO is also eligible for
an annual bonus for the achievement of milestones established by the Compensation Committee of the Board and is eligible to receive a
cash bonus equal to a percentage of any upfront payment on any collaboration agreement reached with a pharmaceutical company. The CEO
will also receive a grant of nonqualified stock options exercisable into 220,265 common shares that shall vest quarterly over a period
of four years, nonqualified stock options exercisable into 330,397 common shares that shall vest upon achievement of milestones and nonqualified
stock options exercisable for 22,027 shares of common stock upon a non-dilutive research funding from any U.S agency
10.
Collaborative Arrangements
The Company assessed the
Ryvu and Eurobio agreements summarized in Note 9 under Topic 808 to determine whether the license agreements or units of account within
the license agreements represent a collaborative arrangement based on the risk, rewards, and activities of the parties. The Company concluded
that neither Ryvu nor Eurobio represent a customer, as Ryvu and Eurobio are the entities that have performance conditions to the Company
and the Company records no revenue related to the transactions within the Ryvu and Eurobio agreements. There were no cash payments or
transactions in the Consolidated and Combined Statements of Operations and Comprehensive Loss related to the Ryvu agreement for the years
ended December 31, 2021 or 2020. The $100 thousand annual license fee payable to Eurobio in 2021 and 2020 was recorded as general and
administrative expense.
11.
Related-Party Transactions
Debt
As discussed in Note 5, during
the years ended December 31, 2021 and 2021, the Company issued convertible notes payable to the Principal Investor bearing an interest
rate of 12%. It may also be converted at any time, in the sum of any advances and accrued interest at a price per share of $3.09. As
of March 31, 2022, Mr. Duey had loaned to us $128,224 under the grid note entered into on March 16, 2022. Since April 1, 2022, Mr. Duey
has loaned to us an additional $408,000 under the grid note.
F-
35
Consulting and Management
Services
The family office of the
Principal Investor provided management services to TarMeta during the years ended December 31, 2021 and 2020 totaling $0 and $48 thousand
respectively, which represents the fair value of the services provided. The cost of these services was recorded as a capital contribution
on the books of TarMeta.
In addition, the Chief Financial
Officer ("CFO") of the Company is the owner of an outsourced accounting and finance company that also employs other accountants
and bookkeepers. Total fees for accounting and finance services rendered during the years ended December 31, 2021 and 2020 were $49 thousand
and $36 thousand, respectively. The cost of these services was recorded as a General and Administrative expense and are reflected as
a related party liability on the accompanying consolidated and combined balance sheet.
The Chief Executive Officer
("CEO") of the Company provided scientific advisory services to TarMeta during the years ended December 31, 2021 and 2020,
totaling $0 thousand and $30 thousand, respectively. The cost of these services was recorded as research and development expense on the
accompanying consolidated and combined statements of operations.
Anna Vilenchik, the mother
of our CEO, was compensated $10,000 for research services rendered during the year ended December 31, 2021, as an independent contractor.
12.
Segment information
The Company manages its business
activities in two reportable segments: Felicitex and TarMeta. The Company evaluates the performance of its reportable segments
based on Research and Development and General and Administrative expenses, which comprises the net operating loss of each segment. Both
Felicitex and TarMeta's operations are primarily within the United States. For the years ended December 31, 2021 or 2020 TarMeta
recognized $12 thousand and $0 revenue, respectively, which was recorded as Other Revenue on the Statement of Operations. There are no
inter-segment sales included in the amounts disclosed.
Felicitex
This reporting segment includes
the development of treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term outcomes
for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma,
and lung. The Felicitex reporting segment consists of one operating segment.
TarMeta
This reporting segment includes
the identification and commercialization of novel, small molecule therapeutics for difficult to treat cancers. The TarMeta reporting
segment consists of one operating segment.
Summarized financial information
concerning the Company's reportable segments is shown in the following tables:
Year Ended December 31, 2020
Felicitex
TarMeta
Total
Operating expenses:
Research and development
$
212,440
$
275,277
$
487,717
General and administrative expenses
398,022
250,528
648,550
Total operating expenses
610,462
525,805
1,136,267
Operating loss
$
(610,462
)
$
(525,805
)
$
(1,136,267
)
F-
36
Year Ended December 31, 2020
Felicitex
TarMeta
Total
Assets
Current assets:
Cash
11,282
27,073
38,355
Total current assets
11,282
27,073
38,355
Deposits
-
3,500
3,500
Property and equipment, net
849
4,103
4,952
Total assets
12,131
34,676
46,807
Year
                                            Ended December 31, 2020
Felicitex
TarMeta
Total
Depreciation expense
106
135,453
135,559
Year
                                            Ended December 31, 2021
Felicitex
TarMeta
Total
Operating expenses:
Research and development
$
402,382
$
229,369
$
631,751
General and administrative expenses
717,720
60,220
777,940
Total operating expenses
1,120,102
289,589
1,409,691
Operating loss
$
(1,120,102
)
$
(289,589
)
$
(1,409,691
)
Year Ended December 31, 2021
Felicitex
TarMeta
Total
Assets
Current assets:
Cash
3,511
6,851
10,362
Total current assets
3,511
6,851
10,362
Deposits
-
3,500
3,500
Property and equipment, net
610
1,350
1,960
Total assets
4,121
11,701
15,822
Year
                                            Ended December 31, 2021
Felicitex
TarMeta
Total
Depreciation expense
239
2,753
2,992
13.
Business Combination
On December 30, 2021, Felicitex
acquired 100% of the ownership interests in the development stage drug discovery company TarMeta Biosciences, LLC ("TarMeta")
in exchange for 635,378 common shares of Felicitex ("TarMeta acquisition"). One individual investor had a controlling interest
in both Felicitex and TarMeta prior to the acquisition. The Company determined the TarMeta acquisition to be a common control transaction
under ASC Topic 805,
Business Combinations
, and accounted for this transaction at the carrying amount of the net assets acquired.
As a result of the TarMeta acquisition, the financial statements as of and for the years ended December 31, 2021 and 2020 have been adjusted
to include the financial information of TarMeta.
F-
37
14.
Variable Interest Entity
On July 23, 2021, the Company's
CEO incorporated UAB Felicitex Therapeutics ("UAB"), a Lithuania Corporation, for the purpose of applying for research and
development grants in the European Union. The Company's CEO is the sole owner of UAB in order to comply with the funding requirements
of the targeted grant programs. Due to the Company's control over the operations of UAB, its power to direct activities that most
significantly impact its economic performance, and the fact that the Company has the obligation to absorb losses or the right to receive
benefits from UAB, UAB is considered a VIE in accordance with applicable GAAP. A company with an interest in a VIE must consolidate the
entity in its financial statements if it has both (1) the power to direct the economically significant activities of the entity and (2)
the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to the VIE.
As of December 31, 2021, no grants have been awarded to UAB, nor have any contracts to fund UAB or utilize UAB grant proceeds been finalized,
and its balances and the activity were de minimis. In accordance with applicable GAAP, UAB has been consolidated and combined from its
inception in the consolidated and combined financial statements.
15.
Subsequent Events
On March 10, 2022, the Company
modified its employment agreement with its CEO. Under the modified agreement, The CEO will receive tiered compensation which increases
in the event the Company raises a minimum of $10,000,000 in an equity capital raise. The compensation will be payable in accordance with
the Company's standard payroll practices for salaried employees. The CEO is also eligible for an annual bonus for the achievement
of milestones established by the Compensation Committee of the Board and is eligible to receive a cash bonus equal to a percentage of
any upfront payment on any collaboration agreement reached with a pharmaceutical company. The CEO will also receive a grant of nonqualified
stock options exercisable into 220,265 shares of common stock that will vest quarterly over a period of four years, and nonqualified
stock options exercisable into 330,397 shares of common stock that will vest upon achievement of milestones. The CEO is also eligible
for a grant of 22,027 options in the event the Company secures grant funding from a U.S. Agency.
On March 15, 2022, the Board
of Directors ratified the modified employment agreement with the Company's CEO, and ratified the employment agreement of its lead
scientist, and a consulting agreement with a key scientific advisor. The board also authorized the grant of options exercisable into
220,265 shares of common stock that will vest quarterly over a period of four years, and nonqualified stock options exercisable into
330,397 shares of common stock that will vest upon achievement of milestones and the grant of options exercisable into 22,027 shares
of common stock to the lead scientist and 8,811 shares of common stock to the scientific advisor. Of the 550,662 options awarded to the
CEO, 454,545 options were awarded from the 2012 Stock Option and Restricted Stock Plan and 96,117 options were awarded from the 2022
Equity Incentive Plan.
From January 1, 2022 through
March 15, 2022, our Chairman and principal investor made additional advances to the Company in the amount of $335,000. The total liability
due to the Chairman as of March 15, 2022 was $541,180 in principle plus $54,564 in accrued interest. On March 16, 2022, the Board of
Directors of the Company authorized the conversion of the combined liability in the amount of $595,744 into 192,977 shares of common
stock, to be effective March 16, 2022. The conversion price valuation was determined using an independent 409A valuation. The Company
has also entered into a convertible grid note with the Chairman with respect to additional advances that the Chairman expects to make
to the Company for general working capital purposes from now until additional funds are raised from investors.
On March 15, 2022, the majority
shareholders of the Company approved the 2022 Equity Incentive Plan and authorized the Company to issue options which may be exercised
for up to 825,992 shares of the Company's common stock. On March 16, 2022, we entered into a convertible grid note with Mr. Duey
with respect to additional advances that Mr. Duey has made and expects to make to us for general working capital purposes until additional
funds are raised from investors. The grid note carries interest at the rate of 12% per year payable in one lump sum on the maturity date,
matures on the one-year anniversary of the issuance date and may be prepaid at any time, in whole or in part, without penalty. It may
also be converted at any time, in the sum of any advances and accrued interest at a price per share of $3.09. As of March 31, 2022, Mr.
Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr. Duey has loaned to us an additional $408,000 under the
grid note.
The company has retroactively
applied the impacts for the reverse stock split of 1 to 9.08, which was approved by the Board of Directors on May 23, 2022. All references
to the number of shares in the footnotes have been retroactively adjusted.
F-
38
[    ]
Units
Felicitex Therapeutics Inc.
PRELIMINARY PROSPECTUS
______________, 2022
Until       ,
2022 (25 days after the date of this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not participating
in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus
when acting as underwriters and with respect to their unsold allotments or subscriptions.
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution
The following table sets forth the costs and
expenses, other than underwriting discounts and commissions, payable by us in connection with the sale of common stock being registered.
All amounts, other than the SEC registration fee, Nasdaq listing fee and FINRA filing fee, are estimates. We will pay all these expenses.
Amount
SEC registration fee
$
[  ]
Nasdaq listing fee
*
FINRA filing fee
[  ]
Accounting fees and expenses
*
Legal fees and expenses
*
Transfer agent fees and expenses
*
Printing and related fees
*
Miscellaneous
*
Total
$
*
*
To be filed by amendment.
Item 14. Indemnification of Directors and Officers
We are a Delaware corporation. The Delaware Revised
Statutes and certain provisions of our bylaws under certain circumstances provide for indemnification of our officers, directors and
controlling persons against liabilities which they may incur in such capacities. A summary of the circumstances in which such indemnification
is provided for is contained herein, but this description is qualified in its entirety by reference to our bylaws and to the statutory
provisions.
In general, any officer, director, employee or
agent may be indemnified against expenses, fines, settlements or judgments arising in connection with a legal proceeding to which such
person is a party, if that person's actions were in good faith, were believed to be in our best interest, and were not unlawful.
Unless such person is successful upon the merits in such an action, indemnification may be awarded only after a determination by independent
decision of our board of directors, by legal counsel, or by a vote of our stockholders, that the applicable standard of conduct was met
by the person to be indemnified.
The circumstances under which indemnification
is granted in connection with an action brought on our behalf is generally the same as those set forth above; however, with respect to
such actions, indemnification is granted only with respect to expenses actually incurred in connection with the defense or settlement
of the action. In such actions, the person to be indemnified must have acted in good faith and in a manner believed to have been in our
best interest, and have not been adjudged liable for negligence or misconduct.
Indemnification may also be granted pursuant
to the terms of agreements which may be entered in the future or pursuant to a vote of stockholders or directors. The Delaware Revised
Statutes also grant us the power to purchase and maintain insurance which protects our officers and directors against any liabilities
incurred in connection with their service in such a position, and such a policy may be obtained by us.
To the maximum extent permitted by law, our articles
of incorporation eliminate or limit the liability of our directors to us or our shareholders for monetary damages for breach of a director's
fiduciary duty as a director.
We intend to enter into separate indemnification
agreements with our directors and officers. Each indemnification agreement will provide, among other things, for indemnification to the
fullest extent permitted by law and our articles of incorporation and bylaws against any and all expenses, judgments, fines, penalties
and amounts paid in settlement of any claim. The indemnification agreements will provide for the advancement or payment of all expenses
to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable
law and our articles of incorporation and bylaws.
We are in the process of obtaining standard policies
of insurance under which coverage is provided (a) to our directors and officers against loss rising from claims made by reason of
breach of duty or other wrongful act, and (b) to us with respect to payments which we may make to such officers and directors pursuant
to the above indemnification provision or otherwise as a matter of law.
The underwriting agreement, filed as Exhibit 1.1
to this registration statement, will provide for indemnification, under certain circumstances, by the underwriter of us and our
officers and directors for certain liabilities arising under the Securities Act or otherwise.
Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us under the foregoing provisions, we have been
informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore
unenforceable.
II-
1
Item 15. Recent Sales of Unregistered Securities
During the past three years, we issued the following
securities, which were not registered under the Securities Act.
On January 16, 2018, Marc Duey, our Chairman,
agreed to lend up to $550,000 to the Company on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey's option at a price per share of $2.29. On March 17, 2020, we issued 238,612 shares
of our common stock on Mr. Duey's conversion of $502,000 in principal and $45,000 of accrued interest on loans under the January
16, 2018 agreement. Mr. Duey also received warrants to purchase 47,722 additional shares of common stock as an incentive to convert these
loans.
On March 17, 2020, we granted an option to purchase
152,295 shares of our common stock to Dr. Vilenchik under the 2012 Plan, at an exercise price of $2.36 per share, as payment of the discretionary
bonus that we awarded to Dr. Vilenchik for achieving significant milestones, in the amount of $50,000, and deferred compensation owed
to Dr. Vilenchik, in the amount of $299,000, for Dr. Vilenchik's services to the Company since May 20, 2018.
On March 17, 2020, we granted an option to purchase
21,819 shares of our common stock to Dr. Frid under the 2012 Plan, at an exercise price of $2.36 per share, as payment of the discretionary
bonus that we awarded to Dr. Frid for achieving significant milestones, in the amount of $15,000, and deferred compensation owed to Dr.
Frid, in the amount of $35,000, for Dr. Frid's services to the Company in 2018
.
On March 31, 2020, Mr. Duey entered into an additional
on-demand agreement to lend us up to $550,000 on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey's option at a price per share of $2.29. On March 17, 2021, we issued 232,473 shares
of common stock to Mr. Duey on conversion of $521,000 in principal and $27,823 of accrued interest on loans under the March 31, 2020
agreement. Additionally, the Company issued warrants that are exercisable into 46,495 shares of common stock within five years at an
exercise price of $2.36 per share as an incentive to convert these loans
On March 17, 2021, we granted (i) an option to
purchase 15,532 shares of our common stock to Dr. Vilenchik under the 2012 Plan, at an exercise price of $2.36 per share, as payment
of the deferred compensation owed in the amount of $36,667, and (ii) an option to purchase 22,027 shares of our common stock under the
2012 Plan, at an exercise price of $2.36 per share, as payment of the discretionary bonus that we awarded to her for achieving significant
milestones in 2020, in the approximate fair value amount of $50,000
.
On March 17, 2021, we granted an option to purchase
6,608 shares of our common stock to Dr. Frid under the 2012 Plan, at an exercise price of $2.36 per share, as payment of his support
to the Company without compensation during 2020.
On March 17, 2021, we granted an option to purchase
12,708 shares of our common stock to Arthur Healey under the 2012 Plan, as payment of $30,000 of accounts payable due to him for services
rendered since May 31, 2019.
On March 17, 2021, we granted an option to purchase
3,304 shares of our common stock to each of our directors under the 2012 Plan, which vests in three equal installments over three years,
at an exercise price equal to the fair market value of that stock on the option grant date, as compensation for the directors'
services on the board of directors of the Company.
On March 31, 2021, Mr. Duey entered into an additional
on-demand agreement to lend us up to $550,000 on an unsecured basis, at an interest rate of 12% per year, payable on demand and convertible
into shares of our common stock at Mr. Duey's option at a price per share of $2.29. On November 2, 2021, we issued 147,586 shares
of our common stock to Mr. Duey on conversion of $348,420 in principal on loans under the March 31, 2021 agreement. Additionally, the
Company issued warrants that are exercisable into 29,518 shares of common stock within five years at an exercise price of $2.36 per share
as an incentive to convert these loans
.
On November 2, 2021, we granted an option to
purchase 110,133 shares of our common stock to Dr. Vilenchik under the 2012 Plan, at an exercise price of $2.36 per share, as a bonus
for achieving significant milestones in 2021.
On March 17, 2021, we granted an option to purchase
12,708 shares of our common stock to Arthur Healey under the 2012 Plan, at an exercise price of $2.36 per share, as payment of $30,000
of accounts payable due to him for services rendered since May 1, 2021.
On December 30, 2021, we completed the acquisition
of TarMeta Biosciences, LLC by entering into an Agreement and Plan of Merger with TarMeta. In consideration of the acquisition of TarMeta,
we issued a total of 635,378 shares of our common stock to the members of TarMeta, including the issuance of 607,845 shares of our common
stock to our Chairman, Marc Duey, (i) 22,027 shares of our common stock to Felix Chapovsky, and (iii) 5,507 shares to Alexei Belenky.
We also issued a non-qualified stock option to purchase 8,811 shares of our common stock to Felix Chapovsky. We have entered an employment
agreement with Alexei Belenky on December 30, 2021 granting him a nonqualified stock option to purchase 22,027 shares in our common stock,
vesting over four years.
On March 10, 2022, we entered into an employment
agreement with our CEO, Maria Vilenchik. Under the agreement, we agreed to grant Dr. Vilenchik nonqualified stock options exercisable
for 220,265 shares of common stock that will vest quarterly at a rate 1/16 per quarter over a period of four years. In addition, Dr.
Vilenchik will receive a grant of nonqualified stock options exercisable into 352,423 shares of common stock upon the achievement of
milestones related to approval of drug research, patient trials and non-dilutive research funding. The exercise price of such options,
once vested, shall be at a price per share that does not exceed the fair market value of such shares of Company common stock on the date
of the grant.
II-
2
On March 15, 2022, our board of directors ratified
the granting of options to purchase 22,027 shares of our common stock to our lead scientist and 8,811 shares of our common stock to our
scientific advisor.
From January 1, 2022 through March 15, 2022,
our Chairman and principal investor made additional advances to the Company in the amount of $335,000. The total liability due to the
Chairman as of March 15, 2022 was $541,180 in principle plus $54,564 in accrued interest.  On March 16, 2022, the Board of Directors
of the Company authorized the conversion of the combined liability in the amount of $595,744 into 192,977 shares of common stock,
effective March 16, 2022.  The conversion price valuation was determined using an independent 409A valuation.
On March 16, 2022, the Company has also entered
into a convertible grid note with the Chairman with respect to additional advances that the Chairman expects to make to the Company for
general working capital purposes from now until additional funds are raised from investors. The grid note carries interest at the rate
of 12% per year payable in one lump sum on the maturity date, matures on the one-year anniversary of the issuance date and may be prepaid
at any time, in whole or in part, without penalty. It may also be converted at any time, in the sum of any advances and accrued interest
at a price per share of $3.09. As of March 31, 2022, Mr. Duey had loaned to us $128,224 under this grid note. Since April 1, 2022, Mr.
Duey has loaned to us an additional $408,000 under the grid note.
The issuance of these securities was made in
reliance upon the exemption from the registration requirements of Section 5 of the Securities Act provided by Section 4(a)(2) of the
Securities Act. The Company has reason to believe that all of the foregoing purchasers were familiar with or had access to information
concerning the operations and financial conditions of the Company, and all of those individuals' purchasing securities represented
that they were accredited investors, acquiring the shares for investment and without a view to the distribution thereof. At the time
of issuance, all of the foregoing securities were deemed to be restricted securities for purposes of the Securities Act and the certificates
representing such securities bore legends to that effect.
Item 16. Exhibits.
(a) Exhibits.
Exhibit No.
Description
1.1**
Form of Underwriting Agreement
3.1*
Certificate of Incorporation of Felicitex Therapeutics Inc.
3.2*
Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc.
3.3*
Second Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc.
3.4*
Certificate of Amendment of Felicitex Therapeutics Inc.
3.5*
Second Certificate of Amendment of Felicitex Therapeutics Inc.
3.6*
Third Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc.
3.7**
Certificate of Amendment to Third Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc.
3.8*
Bylaws of Felicitex Therapeutics Inc.
3.9*
Certificate of Merger of TarMeta Biosciences, LLC and Felicitex Therapeutics Inc., dated December 30, 2021
4.1**
Form of Representative's Warrant (included in Exhibit 1.1)
4.2**
Form of Warrant Agent Agreement
4.3**
Form of Investor Warrant
4.4**
Form of Investor Additional Warrant
4.5*
Warrant to Purchase Common Shares between Felicitex Therapeutics Inc. and Marc Duey, dated March 17, 2020
4.6*
Warrant to Purchase Common Shares between Felicitex Therapeutics Inc. and Marc Duey, dated March 17, 2021
4.7*
Warrant to Purchase Common Shares between Felicitex Therapeutics, Inc and Marc Duey, dated November 2, 2021
5.1**
Opinion of
Bevilacqua PLLC
10.1*
Agreement and Plan of Merger between Felicitex Therapeutics Inc. and TarMeta Biosciences, LLC, dated December 30, 2021
10.2*
License and Collaboration Agreement between Felicitex Therapeutics Inc. and Diaxonhit, dated April 16, 2014***
10.3*
Amendment No. 1 to License and Collaboration Agreement between Felicitex Therapeutics Inc. and Diaxonhit, dated July 21, 2014***
10.4*
Amendment No. 2 to License and Collaboration Agreement between Felicitex Therapeutics Inc. and Eurobio Scientific SA (formerly Diaxonhit), dated February 14, 2022***
10.5*
Research Collaboration and Licensing Option Agreement between Felicitex Therapeutics Inc. and Selvita S.A., dated November 6, 2014***
10.6*
Notice of Option Exercise under the Research Collaboration and Option Agreement dated October 1, 2014, dated August 30, 2018***
10.7*
Exclusive License Agreement between Felicitex Therapeutics Inc. and Selvita S.A., dated December 31, 2018***
10.8*
Amendment No. 1 to Exclusive Licensing Agreement between Felicitex Therapeutics Inc. and Selvita S.A., dated April 16, 2019***
10.9*
Material Transfer and Royalty Agreement between Felicitex Therapeutics Inc. and Memorial Sloan Kettering Cancer Center, dated December 4, 2020***
10.10*
Material Transfer Agreement between Felicitex Therapeutics Inc. and Équilibre Biopharmaceuticals, dated February 15, 2021***
10.11*
Material Transfer Agreement between Felicitex Therapeutics Inc. and Whitehead Institute for Biomedical Research, dated January 29, 2020***
10.12†*
Employment Agreement between Felicitex Therapeutics Inc. and Maria Vilenchik dated March 10, 2022
10.13†*
Employment Contract between Felicitex Therapeutics and Alexei Belenky dated December 30, 2021
10.14†*
Form of Independent Director Agreement between Felicitex Therapeutics Inc. and each independent director and each director nominee
II-
3
10.15†*
Form of Indemnification Agreement between Felicitex Therapeutics Inc. and each independent director and each director nominee
10.16†*
Felicitex Therapeutics Inc. 2012 Stock Option and Restricted Stock Plan
10.17†*
Felicitex Therapeutics Non-Statutory Stock Option Agreement with Valeria Povolotsky, dated March 1, 2013
10.18†*
Felicitex Therapeutics Non-Statutory Stock Option Agreement with Yuriy Gankin dated March 1, 2013
10.19†*
Felicitex Therapeutics Non-Statutory Stock Option Agreement with Michael Frid dated March 1, 2013
10.20†*
Felicitex Therapeutics Non-Statutory Stock Option Agreement with Maria Vilenchik dated March 1, 2013
10.21†*
Felicitex Therapeutics Inc. 2022 Equity Incentive Plan
10.22†*
Shareholder Loan Agreement between Marc Duey and Felicitex Therapeutics Inc., dated January 16, 2018
10.23†*
Shareholder Loan Agreement between Marc Duey and Felicitex Therapeutics Inc., dated March 31, 2020
10.24*
Grid Note between Marc Duey and Felicitex Therapeutics dated March 16, 2022
10.25*
Grant Agreement from Massachusetts Life Sciences Center dated July 15, 2015
10.26†*
Consulting Agreement between Felicitex Therapeutics Inc. and Michael Frid, dated July 20, 2012***
10.27*
Consulting Agreement between Felicitex Therapeutics Inc. and Valeria Povolotsky, Ph.D., dated July 20, 2012***
10.28*
Lease between Felicitex Therapeutics Inc., TarMeta Biosciences, LLC and Kaufman Nir LLC, dated March 15, 2017
10.29**
Sublease between Felicitex Therapeutics Inc. and Quateris, LLC, dated March 15, 2017
10.30†*
Board of Directors Agreement between Felicitex Therapeutics Inc. and Yuriy Gankin, dated July 23, 2021
10.31†*
Board of Directors Agreement between Felicitex Therapeutics Inc. and Valeria Povolotsky, dated July 23, 2021
10.32†*
Board of Directors Agreement between Felicitex Therapeutics Inc. and Michael Frid, dated July 23, 2021
10.33†*
Board of Directors Agreement between Felicitex Therapeutics Inc. and Alex Shlyankevich, dated July 23, 2021
10.34†*
Board of Directors Agreement between Felicitex Therapeutics Inc. and Marc Duey, dated July 23, 2021
10.35†*
Board of Directors Agreement between Felicitex Therapeutics Inc. and Maria Vilenchik, dated July 23, 2021
10.36*
Material Transfer and Agreement between Felicitex Therapeutics Inc. and UAB DolceRx Baltika, dated May 15, 2021***
10.37*
Material Transfer and Agreement between Felicitex Therapeutics Inc. and Barbara Ann Karmanos Cancer Institute, dated July 18, 2022***
14.1*
Code of Ethics and Business Conduct
21.1*
List of Subsidiaries
23.1*
Consent of Friedman LLP
23.2**
Consent of
Bevilacqua PLLC
(included in Exhibit 5.1)
24.1*
Power of Attorney (included on the signature page of this registration statement)
99.1*
Audit Committee Charter
99.2*
Compensation Committee Charter
99.3*
Nominating and Corporate Governance Committee Charter
99.4**
Consent of Michael Kody to be named as a director nominee
99.5*
Consent of Douglas T. Moore to be named as a director nominee
107*
Filing Fees Table
*
Filed
herewith.
**
To be filed by amendment.
***
Portions of this exhibit have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv)
                                                    because the Registrant has determined that the information is not material and is the type that the Registrant treats as private or
                                                    confidential.
†
Executive compensation plan or arrangement.
(b) Financial Statement Schedules.
All financial statement schedules are omitted
because the information called for is not required or is shown either in the financial statements or in the notes thereto.
Item 17. Undertakings
The undersigned registrant hereby undertakes
to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered
in such names as required by the underwriters to permit prompt delivery to each purchaser.
Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.
(a) The undersigned registrant hereby undertakes:
(1)
To file, during
                                            any period in which offers or sales are being made, a post-effective amendment to this registration
                                            statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities
    Act of 1933 (the "Act");
II-
4
(ii)
To reflect in the prospectus any facts or events arising after the
    effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the
    aggregate, represent a fundamental change in the information set forth in this registration statement; and
(iii)
To include any material information with respect to the plan of distribution
    not previously disclosed in this registration statement or any material change to such information in this registration statement.
(2)
That, for the purpose of determining any liability under the Act, each
    such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the
    offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment
    any of the securities being registered which remain unsold at the termination of the offering.
(4)
That,
                                            for the purpose of determining liability under the Securities Act of 1933 to any purchaser,
                                            each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
                                            to an offering, other than registration statements relying on Rule 430B or other than prospectuses
                                            filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
                                            statement as of the date it is first used after effectiveness. Provided, however, that no
                                            statement made in a registration statement or prospectus that is part of the registration
                                            statement or made in a document incorporated or deemed incorporated by reference into the
                                            registration statement or prospectus that is part of the registration statement will, as
                                            to a purchaser with a time of contract of sale prior to such first use, supersede or modify
                                            any statement that was made in the registration statement or prospectus that was part of
                                            the registration statement or made in any such document immediately prior to such date of
                                            first use.
(5)
That,
                                            for the purpose of determining liability of the registrant under the Securities
                                            Act of 1933 to any purchaser in the initial distribution of the securities,
                                            the undersigned registrant undertakes that in a primary offering of securities
                                            of the undersigned registrant pursuant to this registration statement, regardless
                                            of the underwriting method used to sell the securities to the purchaser, if the
                                            securities are offered or sold to such purchaser by means of any of the following communications,
                                            the undersigned registrant will be a seller to the purchaser and will be considered
                                            to offer or sell such securities to such purchaser:
(i)
Any
                                            preliminary prospectus or prospectus of the undersigned registrant relating to
                                            the offering required to be filed pursuant to Rule 424;
(ii)
Any
                                            free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or
                                            used or referred to by the undersigned registrant;
(iii)
The portion
                                            of any other free writing prospectus relating to the offering containing material information
                                            about the undersigned registrant or its securities provided by or on behalf of
                                            the undersigned registrant; and
(iv)
Any other communication
                                            that is an offer in the offering made by the undersigned registrant to the purchaser.
(b) Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.
(c) The undersigned registrant hereby undertakes
that:
(i)
For purposes
                                            of determining any liability under the Securities Act, the information omitted from the form
                                            of prospectus filed as part of this registration statement in reliance upon Rule 430A and
                                            contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)
                                            or 497(h) under the Securities Act shall be deemed to be part of this registration statement
                                            as of the time it was declared effective.
(ii)
For purposes
                                            of determining any liability under the Securities Act, each post-effective amendment that
                                            contains a form of prospectus shall be deemed to be a new registration statement relating
                                            to the securities offered therein, and the offering of such securities at that time shall
                                            be deemed to be the initial bona fide offering thereof.
II-
5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Natick,
State of Massachusetts, on August 10, 2022.
Felicitex Therapeutics Inc.
By:
/s/ Maria Vilenchik
Maria Vilenchik
Chief Executive Officer
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints
each of Maria Vilenchik and Marc Duey as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution,
for him and his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments)
to this registration statement and to file a new registration statement under Rule 461, and to file the same, with all exhibits thereto,
and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents
full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the foregoing,
as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
SIGNATURE
TITLE
DATE
/s/
    María Vilenchik
Chief Executive
    Officer and Director
August
    10, 2022
Maria Vilenchik
(principal executive officer)
/s/
    Arthur Healey
Chief Financial
    Officer
August
    10, 2022
Arthur Healey
(principal financial and accounting
    officer)
/s/
    Marc Duey
Executive
    Chairman
August
    10, 2022
Marc Duey
/s/
    Alex Shlyankevich
Director
August
    10, 2022
Alex Shlyankevich
/s/
Yuriy Gankin
Director
August
    10, 2022
Yuriy Gankin
/s/
    Michael Frid
Director
August
    10, 2022
Michael
    Frid
II-6